{"19c0f49928b1aec1565fbd42b46f47af9ba7ec79": [["RSPH CommentaryFrom evidence into action -Using the planning system to promote healthy weight environments Obesity is a modern day public health challenge that cannot be met by a traditional biomedical science approach alone.", [["Obesity", "DISEASE", 107, 114], ["the planning system", "TREATMENT", 48, 67], ["Obesity", "PROBLEM", 107, 114]]], ["Tackling obesity levels in England requires action by national and local government, health and social care, non-governmental agencies, communities and individuals -a whole system approach.RSPH CommentaryTraditionally public discussion and campaigns targeted individual level behaviour change and treatment.", [["obesity", "DISEASE", 9, 16], ["Tackling obesity levels", "PROBLEM", 0, 23], ["treatment", "TREATMENT", 297, 306]]], ["This does not address the environment in which we live, that influences the decisions and actions that we make; things such as what we eat, whether we exercise, how we travel to work, how we interact within the community and if we have access to and use open spaces.RSPH CommentaryLocal authorities are in a unique position to improve the quality of the environment by actively promoting walking and cycling, enabling easier access to healthier food and drink options and supporting a diverse and healthy high street retail offer.", [["open spaces", "TREATMENT", 254, 265]]], ["By doing so, local authorities can help promote a healthy weight and reduce inequalities associated with obesity prevalence.RSPH CommentaryA healthy weight environment can support people with healthier food and drink options and opportunities to increase their physical activity through the way a place is designed and the variety of uses provided.", [["obesity", "DISEASE", 105, 112], ["people", "ORGANISM", 180, 186], ["people", "SPECIES", 180, 186], ["obesity prevalence", "PROBLEM", 105, 123]]], ["To further encourage and support local authorities Public Health England has published guidance to provide strategic information on the use of the planning system to promote local healthy weight environments, in particular to focus on the healthier food and active environments.", [["the planning system", "TREATMENT", 143, 162]]], ["PHE has provided a template 'Healthy Weight Environments Supplementary Planning document' which can be used as a starting point for local public health teams to liaise with planning officers and other local authority teams, including environmental health, licensing, transport, and leisure.", [["PHE", "CHEMICAL", 0, 3], ["PHE", "CHEMICAL", 0, 3], ["a template 'Healthy Weight Environments", "TREATMENT", 17, 56]]], ["This guidance provides practical support to those local authorities looking to develop policies and approaches to promote a healthy weight environment.RSPH CommentaryThe drive to use the planning system to promote healthy weight environments has been highly influenced by the Government Office for Science's Foresight report of 2007 Tackling Obesities: Future Choices (1), which recognised the role of the planning system in tackling obesity.", [["obesity", "DISEASE", 434, 441], ["practical support", "TREATMENT", 23, 40], ["the planning system", "TREATMENT", 183, 202], ["tackling obesity", "PROBLEM", 425, 441], ["obesity", "OBSERVATION", 434, 441]]], ["Many local authorities are already including healthy weight environment elements into local planning policy and practice.", [["local", "OBSERVATION_MODIFIER", 5, 10], ["authorities", "OBSERVATION", 11, 22]]], ["The Local Government Association (LGA) has published case studies of councils using planning to take a holistic approach to the challenge of obesity (3) including Gateshead Council's innovative SPD approach which is featured as a PHE case study (4) .RSPH CommentaryThe use of planning policy and development management is a clear example of an intervention to tackle obesity which is not yet consistently applied across the Country.", [["obesity", "DISEASE", 141, 148], ["obesity", "DISEASE", 367, 374], ["a holistic approach", "TREATMENT", 101, 120], ["obesity", "PROBLEM", 141, 148], ["Gateshead Council's innovative SPD approach", "TREATMENT", 163, 206], ["a PHE case study", "TEST", 228, 244], ["planning policy", "TREATMENT", 276, 291], ["development management", "TREATMENT", 296, 318], ["an intervention", "TREATMENT", 341, 356], ["tackle obesity", "PROBLEM", 360, 374], ["obesity", "OBSERVATION", 141, 148], ["obesity", "OBSERVATION", 367, 374]]], ["PHE wants to support consistent whole system approaches, including the use of the planning system.", [["PHE", "CHEMICAL", 0, 3], ["PHE", "CHEMICAL", 0, 3], ["the planning system", "TREATMENT", 78, 97]]], ["This policy to implementation lag has to be seen in the context of an increasing obesity challenge (See Figure 2 ) facing society.", [["obesity", "DISEASE", 81, 88], ["an increasing obesity challenge", "PROBLEM", 67, 98], ["increasing", "OBSERVATION_MODIFIER", 70, 80], ["obesity", "OBSERVATION", 81, 88]]], ["This context can be understood both in terms of prevalence in certain age groups such as children, and concentration of obesogenic environments in certain neighbourhoods which are helping to widen health inequalities.", [["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97]]], ["This was recognised within the Childhood Obesity; a plan for action Chapter 2.", [["Obesity", "DISEASE", 41, 48], ["Obesity", "OBSERVATION", 41, 48]]], ["The challenges it identified, included the proliferation of fast food outlets, less active travel, limited access to green spaces and physical activity; and these factors create an environment that makes it harder for children and their families to make healthy choices, particularly in some of our most deprived areas.", [["children", "ORGANISM", 218, 226], ["children", "SPECIES", 218, 226], ["less", "OBSERVATION_MODIFIER", 79, 83], ["active", "OBSERVATION_MODIFIER", 84, 90]]], ["The Childhood Obesity plan confirmed that local authorities have a key role in tackling this challenge and pledged support;RSPH Commentary\u2022 to make sure that all local authorities are empowered and confident in finding what works for them, and \u2022 to develop resources that support local authorities who want to use their powers and provide up to date guidance and training for planning inspectors.RSPH CommentaryIn response, Public Health England (PHE) published its latest guidance (Using the planning system to promote healthy weight environments.", [["Obesity", "DISEASE", 14, 21], ["The Childhood Obesity", "PROBLEM", 0, 21], ["the planning system", "TREATMENT", 489, 508], ["Obesity", "OBSERVATION", 14, 21]]], ["Specifically, can the local food environment influence diet and obesity? \u2022 How can the planning regime be used to promote healthy weight environments?RSPH CommentaryThe publication Identifies the background work necessary in order to comply with planning policy development, where the key is the use of local evidence and consultation.", [["obesity", "DISEASE", 64, 71], ["obesity", "PROBLEM", 64, 71], ["obesity", "OBSERVATION", 64, 71]]], ["It specifically provides guidance on the use of the 400m exclusion zone for hot food takeaways, features of the built environment and building design that promotes physical activity, use of green space, allotments and neighbourhood design.RSPH CommentaryThere remain challenges to promoting a healthy food environment, for example the impact from the rise of industrial kitchens for food delivery must be monitored.", [["food delivery", "TREATMENT", 383, 396]]], ["Work must continue to influence the energy and compositional content of other food options and build our homes and neighbourhood to allow people to more active.", [["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144]]], ["These challenges become even more acute as society, policies and systems grapple with the practicalities and long term implications of policy changes necessitated by the recent Covid-19 national emergency, namely permitting all food businesses to temporarily operate as takeaways (6) .RSPH CommentaryActions to promote a healthy weight environment should form part of a wider, long term systems approach to promoting a healthier weight in the local area, which can be supported by PHE guidance on whole systems approach to obesity (7) .", [["PHE", "CHEMICAL", 481, 484], ["obesity", "DISEASE", 523, 530], ["long term systems approach", "TREATMENT", 377, 403], ["whole systems approach", "TREATMENT", 497, 519], ["obesity", "PROBLEM", 523, 530], ["acute", "OBSERVATION_MODIFIER", 34, 39]]], ["Other examples of integrated place-based approaches include the NHS England Healthy New Towns (8) and the Childhood Obesity Trailblazers (9) programmes.", [["Obesity Trailblazers", "DISEASE", 116, 136], ["the Childhood Obesity Trailblazers", "TREATMENT", 102, 136], ["Obesity", "OBSERVATION", 116, 123]]]], "PMC6162912": [["BackgroundIt has long been recognised that \u201cdiseases know no borders\u201d and have the potential to spread across vast geographic spaces, particularly in regions where similar epidemiological profiles, socio-economic drivers, and frequent movements of people or animal carriers facilitate disease transmission and persistence.", [["people", "ORGANISM", 248, 254], ["people", "SPECIES", 248, 254], ["animal carriers facilitate disease transmission", "PROBLEM", 258, 305]]], ["The Ebola epidemic in West Africa (2013\u20132016) is a prime example of a regional health crisis, exacerbated by the mobility of infected patients across the porous borders of Guinea, Liberia, and Sierra Leone [1, 2].", [["Ebola", "DISEASE", 4, 9], ["Ebola", "ORGANISM", 4, 9], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["a regional health crisis", "PROBLEM", 68, 92], ["Ebola", "OBSERVATION_MODIFIER", 4, 9], ["regional", "OBSERVATION_MODIFIER", 70, 78], ["health crisis", "OBSERVATION", 79, 92]]], ["Other examples of diseases which present a strong cross-border dimension include malaria and artemisinin-resistant malaria in Southeast Asia [3, 4], cholera in Sub-Saharan Africa [5], Zika in Latin America [6], avian influenza in Southeast Asia [7] and diseases that receive less global health attention such as onchocerciasis [8] and Japanese encephalitis [9].", [["malaria", "DISEASE", 81, 88], ["artemisinin", "CHEMICAL", 93, 104], ["malaria", "DISEASE", 115, 122], ["cholera", "DISEASE", 149, 156], ["avian influenza", "DISEASE", 211, 226], ["onchocerciasis", "DISEASE", 312, 326], ["Japanese encephalitis", "DISEASE", 335, 356], ["artemisinin", "CHEMICAL", 93, 104], ["artemisinin", "SIMPLE_CHEMICAL", 93, 104], ["avian influenza", "SPECIES", 211, 226], ["diseases", "PROBLEM", 18, 26], ["malaria", "PROBLEM", 81, 88], ["artemisinin", "PROBLEM", 93, 104], ["resistant malaria", "PROBLEM", 105, 122], ["diseases", "PROBLEM", 253, 261], ["Japanese encephalitis", "PROBLEM", 335, 356], ["diseases", "OBSERVATION", 18, 26], ["malaria", "OBSERVATION", 81, 88], ["resistant", "OBSERVATION_MODIFIER", 105, 114], ["malaria", "OBSERVATION", 115, 122]]], ["In such contexts, the development of effective communication channels between health authorities and other stakeholders within and between countries is thought to be crucial to enable effective responses in emergency situations as well as routine surveillance of endemic diseases, sustain progress towards disease elimination, and inform policy development through the exchange of data, information and expertise [8, 10].", [["endemic diseases", "PROBLEM", 263, 279], ["effective", "OBSERVATION_MODIFIER", 37, 46]]], ["In Europe, disease surveillance networks have been in operation since the 1980s and are currently integrated and managed under The European Surveillance System (TESSy), a web-based technical platform which collects and disseminates national surveillance data from all European Union (EU) and European Economic Area (EEA) countries using standardized formats [13].", [["disease", "OBSERVATION", 11, 18]]], ["From the 1990s, bilateral and regional public health networks or programmes have also been established in low- and middle-income contexts, including in Africa [14], Southeast Asia [15\u201317], the Middle East [18, 19], and South America [20].", [["bilateral", "ANATOMY_MODIFIER", 16, 25]]], ["While good practices and outcomes have been reported [15, 19, 22], studies informed by political and institutional perspectives have identified constraints to the achievement of meaningful and effective cooperation, given the divisive force of state politics and interests, gaps in domestic capacities, and weaknesses in institutional frameworks to support collective action amongst regional partners [23\u201325].", [["gaps in domestic capacities", "PROBLEM", 274, 301], ["weaknesses in institutional frameworks", "PROBLEM", 307, 345], ["domestic capacities", "OBSERVATION", 282, 301]]], ["A number of qualitative studies of health data sharing have been conducted [28\u201330], but these have focused on researchers and research data, not on health officers, implementers and data from national health information systems.BackgroundConsidering this gap in knowledge, we present and analyse here findings from an exploratory qualitative study of regional health cooperation in Southeast Asia, with a focus on issues and challenges that may influence health data and information sharing.", [["qualitative studies", "TEST", 12, 31], ["an exploratory qualitative study", "TEST", 315, 347]]], ["In the wake of recent regional health emergencies, such as avian influenza H5N1, severe acute respiratory syndrome (SARS), and artemisinin-resistant malaria, several programmes have been developed in the region to share epidemiological data and expertise between national health authorities and practitioners, and develop an integrated approach to address common health problems.", [["influenza H5N1", "DISEASE", 65, 79], ["acute respiratory syndrome", "DISEASE", 88, 114], ["SARS", "DISEASE", 116, 120], ["artemisinin", "CHEMICAL", 127, 138], ["malaria", "DISEASE", 149, 156], ["artemisinin", "CHEMICAL", 127, 138], ["avian influenza H5N1", "ORGANISM", 59, 79], ["artemisinin", "SIMPLE_CHEMICAL", 127, 138], ["avian influenza H5N1", "SPECIES", 59, 79], ["recent regional health emergencies", "PROBLEM", 15, 49], ["avian influenza H5N1", "PROBLEM", 59, 79], ["severe acute respiratory syndrome", "PROBLEM", 81, 114], ["SARS", "PROBLEM", 116, 120], ["artemisinin-resistant malaria", "PROBLEM", 127, 156], ["common health problems", "PROBLEM", 356, 378], ["wake", "OBSERVATION_MODIFIER", 7, 11], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory syndrome", "OBSERVATION", 94, 114], ["resistant", "OBSERVATION_MODIFIER", 139, 148], ["malaria", "OBSERVATION", 149, 156]]], ["The collection of views and experiences from participants who have been involved in these initiatives provides a unique insight to better understand the practice of South-South health data sharing in a context characterized by imbalances between more and less resourced countries.", [["participants", "SPECIES", 45, 57]]], ["Early developments date back to the 1990s, when the relaxation of international tensions in the region, combined with concerns about endemic and emerging infections which spread across and beyond regional borders, attracted considerable donor investments to support regional initiatives for disease prevention and control [32].", [["infections", "DISEASE", 154, 164], ["endemic", "PROBLEM", 133, 140], ["emerging infections", "PROBLEM", 145, 164], ["regional initiatives", "TREATMENT", 266, 286], ["disease prevention", "TREATMENT", 291, 309], ["infections", "OBSERVATION", 154, 164]]], ["Some initiatives have been horizontal in scope; others have focused on specific diseases including malaria [33], HIV [34], and avian influenza [35].", [["malaria", "DISEASE", 99, 106], ["avian influenza", "DISEASE", 127, 142], ["HIV", "ORGANISM", 113, 116], ["avian influenza", "ORGANISM", 127, 142], ["HIV", "SPECIES", 113, 116], ["avian influenza", "SPECIES", 127, 142], ["HIV", "SPECIES", 113, 116], ["specific diseases", "PROBLEM", 71, 88], ["malaria", "PROBLEM", 99, 106], ["HIV", "PROBLEM", 113, 116], ["avian influenza", "PROBLEM", 127, 142], ["horizontal", "OBSERVATION_MODIFIER", 27, 37]]], ["In keeping with the global health agenda, and in recognition of the regional dimension of the problem, substantive efforts have been made to strengthen regional malaria initiatives, within the wider context of the Strategy for Malaria Elimination in the Greater Mekong Subregion (2015\u20132030) and the Emergency Response to Artemisinin Resistance [36].", [["malaria", "DISEASE", 161, 168], ["Malaria", "DISEASE", 227, 234], ["Artemisinin", "CHEMICAL", 321, 332], ["Artemisinin", "CHEMICAL", 321, 332], ["strengthen regional malaria initiatives", "PROBLEM", 141, 180], ["Malaria Elimination", "PROBLEM", 227, 246], ["Artemisinin Resistance", "TEST", 321, 343], ["malaria", "OBSERVATION", 161, 168], ["Malaria", "OBSERVATION", 227, 234], ["Greater", "OBSERVATION_MODIFIER", 254, 261]]], ["The consolidation of organisations for political and/or economic cooperation in Southeast Asia has also provided institutional frameworks to support regional public health networks and programmes [37].", [["consolidation", "OBSERVATION", 4, 17]]], ["To different degrees, the prevention and control of infectious diseases has been on the agenda of the Association of Southeast Asian Nations (ASEAN), the Asian Development Bank (ADB), and the Asia-Pacific Economic Cooperation (APEC), in joint action with the WHO South East Asia (SEARO) and Western Pacific Regional Offices (WPRO).", [["infectious diseases", "DISEASE", 52, 71], ["infectious diseases", "PROBLEM", 52, 71], ["different degrees", "OBSERVATION_MODIFIER", 3, 20], ["infectious", "OBSERVATION", 52, 62], ["joint", "ANATOMY", 237, 242]]], ["For example, between 2004 and 2008, the ASEAN Secretariat managed an Emerging Infectious Disease (EID) programme aimed to strengthen public health capacities regionally through joint training courses, seminars and workshops, links between human and animal health sectors, and exchanges of staff between laboratories in the region [37].Study context ::: MethodsThe sharing of data, information, and expertise between country partners has been a key feature in most initiatives.", [["Infectious Disease", "DISEASE", 78, 96], ["human", "ORGANISM", 239, 244], ["human", "SPECIES", 239, 244], ["human", "SPECIES", 239, 244], ["joint training courses", "TREATMENT", 177, 199], ["Methods", "TREATMENT", 353, 360], ["Infectious", "OBSERVATION", 78, 88], ["joint", "ANATOMY", 177, 182]]], ["Sub-regional networks such as the ADB-sponsored Greater Mekong Subregion Communicable Disease Control project (GMS-CDC) or the Mekong Basin Disease Surveillance (MBDS) network have appointed contact persons at selected border provinces, who are required to e-mail standard forms to their counterparts in the neighbouring country, including information on cumulative number of cases and deaths, outbreak location, and presumptive causes of disease outbreaks.", [["deaths", "DISEASE", 386, 392], ["persons", "SPECIES", 199, 206], ["disease outbreaks", "PROBLEM", 439, 456], ["disease", "OBSERVATION", 439, 446]]], ["In both networks, data sharing schedules are tailored to different epidemiological and risk profiles: outbreaks of emergency diseases such as H5N1, cholera and SARS must be communicated to the WHO and the neighbouring province within 24 h, while the data sharing schedule for endemic diseases such as malaria, TB, or HIV is more relaxed (i.e. monthly or quarterly).", [["H5N1", "DISEASE", 142, 146], ["cholera", "DISEASE", 148, 155], ["SARS", "DISEASE", 160, 164], ["malaria", "DISEASE", 301, 308], ["TB", "DISEASE", 310, 312], ["HIV", "DISEASE", 317, 320], ["H5N1", "SPECIES", 142, 146], ["HIV", "SPECIES", 317, 320], ["HIV", "SPECIES", 317, 320], ["emergency diseases", "PROBLEM", 115, 133], ["H5N1", "PROBLEM", 142, 146], ["cholera", "PROBLEM", 148, 155], ["endemic diseases", "PROBLEM", 276, 292], ["malaria", "PROBLEM", 301, 308], ["TB", "PROBLEM", 310, 312], ["HIV", "PROBLEM", 317, 320]]], ["Data sharing activities have also been included in vertical programmes for disease control.", [["disease control", "TREATMENT", 75, 90]]], ["From the 1990s, various efforts to build a regional malaria database have been made [38] and revived as part of the current strategy of malaria elimination in the GMS.", [["malaria", "DISEASE", 52, 59], ["malaria", "DISEASE", 136, 143], ["a regional malaria database", "PROBLEM", 41, 68], ["malaria elimination", "PROBLEM", 136, 155], ["malaria", "OBSERVATION", 136, 143]]], ["Another example is the AIDS Data Hub, based in Bangkok, which collects and publishes HIV/AIDS regional data by scanning published literature and web sites, and receiving data from a network of country partners [39].Data collection and analysis ::: MethodsData collection for this project primarily involved key informant interviews, conducted in Cambodia and Vietnam, between January and April 2016, to capture diversity and similarities in health and surveillance systems, while relying on strong professional links between the researchers and stakeholders in the two countries.", [["AIDS", "DISEASE", 23, 27], ["AIDS", "DISEASE", 89, 93], ["HIV", "SPECIES", 85, 88], ["MethodsData collection", "TREATMENT", 248, 270], ["surveillance systems", "TEST", 452, 472]]], ["Key informants were identified amongst those who were involved in active or recently completed regional programmes and data sharing activities (or could provide expert information and views), after preliminary consultations with local partners; additional participants were identified through snowball sampling.", [["participants", "SPECIES", 256, 268], ["snowball sampling", "TEST", 293, 310]]], ["In order to account for different perspectives, we aimed to recruit participants from ministries of health and other government bodies (both at the central and provincial level), managers of vertical programmes and departments of communicable disease control, data management officers, and experts at international organisations.", [["participants", "SPECIES", 68, 80], ["communicable disease control", "TREATMENT", 230, 258]]], ["The researchers (ML, ST, SML) contacted individuals or offices by phone or email to request participation in the study.", [["the study", "TEST", 109, 118]]], ["Prior to each interview, participants were provided an information sheet with details about the project aim and methods and a tentative list of topics to be covered during the meeting.", [["participants", "SPECIES", 25, 37]]], ["Given the exploratory nature of this study, we prioritised a grounded approach [40], rather than using a predetermined analytical framework.", [["this study", "TEST", 32, 42]]], ["Thus, the interview schedule was tailored to the role and expertise of informants and lightly structured to elicit views and experiences about their involvement in regional data and information sharing activities, both in the event of disease outbreak and for routine surveillance of endemic diseases.", [["disease outbreak", "PROBLEM", 235, 251], ["endemic diseases", "PROBLEM", 284, 300], ["disease", "OBSERVATION", 235, 242]]], ["Further, participants were asked to comment on the value of data and information sharing and to discuss factors and challenges that may affect the transfer, exchange, and use of health data and expertise across borders.", [["participants", "SPECIES", 9, 21]]], ["All interviews were conducted face-to-face by ML, alone or together with either ST or LMS.", [["LMS", "ANATOMY", 86, 89]]], ["Relevant documents (such as reports and published papers) were also collected and reviewed at different stages to clarify points or triangulate information.Data collection and analysis ::: MethodsThe analysis of qualitative data was structured around three categories mapped across the dataset, representing different yet interlinked elements in data and information sharing processes: (1) the nature of shared data and information; (2) the nature of communication channels; and (3) how information flow may be affected by the local, regional, and global system of rules and arrangements.", [["Methods", "TREATMENT", 189, 196], ["The analysis", "TEST", 196, 208], ["qualitative data", "TEST", 212, 228]]], ["Preliminary findings were presented at two international workshops in Cambodia and Vietnam, both held in March 2017, where feedback from stakeholders was obtained and provided additional insights into the process of analysis.Data comparability ::: The nature of shared data and information ::: ResultsOne important area of concern was the extent to which shared data from different countries can be used to produce a regional mapping of disease burden, given gaps in national information systems and imbalances in their ability to provide an estimate of the true disease incidence.", [["disease burden", "PROBLEM", 437, 451], ["the true disease incidence", "PROBLEM", 554, 580], ["important", "OBSERVATION_MODIFIER", 305, 314], ["area", "OBSERVATION_MODIFIER", 315, 319], ["disease", "OBSERVATION", 437, 444]]], ["As one international expert in Cambodia noted, the comparison of raw data could lead to wrong epidemiological conclusions and potentially affect resource allocation in biased ways:\u201cIf one country is saying they have 30 cases and another country 50\u2026 it seems that the problem in the second country is worse than in the first country, but it may just be that the other country was not able to detect many cases\u2026\u201d (CAM-20).Data comparability ::: The nature of shared data and information ::: ResultsTwo informants at the Ministry of Health in Cambodia further highlighted a conflict between a single reporting system for cross-border activities and the fragmentation of the disease information systems in the country (CAM-14, CAM-17).", [["CAM", "TEST", 412, 415], ["CAM", "TEST", 715, 718], ["CAM", "TEST", 723, 726]]], ["Similarly, one malaria epidemiologist remarked:\"What is Cambodia sharing?", [["malaria", "DISEASE", 15, 22], ["one", "OBSERVATION_MODIFIER", 11, 14], ["malaria", "OBSERVATION", 15, 22]]], ["Data from the village malaria workers programme that go to the CNM [the National Malaria Centre] or data from the NHIS [the National Health Information System]\u2026 the two systems are not well integrated\u2026\" (CAM-29).Inconsistencies in case definitions ::: The nature of shared data and information ::: ResultsThe use of differing case definitions and formats in data collection and reporting was identified as another barrier to data comparability (VIET19, VIET26).", [["malaria", "DISEASE", 22, 29], ["Malaria", "DISEASE", 81, 88], ["CAM", "TEST", 204, 207], ["formats in data collection", "TEST", 347, 373]]], ["Some informants recognised it would be useful to have a regional analysis of imported malaria or dengue cases since this would enable better understanding of the role of population mobility in disease transmission.", [["malaria", "DISEASE", 86, 93], ["dengue", "DISEASE", 97, 103], ["dengue", "SPECIES", 97, 103], ["imported malaria", "PROBLEM", 77, 93], ["dengue cases", "PROBLEM", 97, 109]]], ["However, one data manager at the MoH in Cambodia pointed out that comparative analysis of such data is problematic due to inconsistencies in the definition of imported cases across countries in the region, depending on whether internal or international mobility is seen as the main driver of disease transmission and other variables.", [["comparative analysis", "TEST", 66, 86], ["such data", "TEST", 90, 99], ["disease transmission and other variables", "PROBLEM", 292, 332], ["disease", "OBSERVATION", 292, 299]]], ["Similar issues were noted by HIV experts in Vietnam:\u201cThere is no standard methodology for at risk populations, like IDU [injecting drug users], MSM [men who have sex with men] and sex workers\u2026 many methods have been tried\u2026 but there are no regional guidelines\u2026 there have been many pilot studies, using different approaches\u2026 but then it is difficult to integrate different datasets and not really cost-effective\u2026\u201d (VIET19).Inconsistencies in case definitions ::: The nature of shared data and information ::: ResultsThe case of the regional malaria database further illustrates challenges resulting from discrepancies in data collection methods and formats.", [["IDU", "CHEMICAL", 116, 119], ["malaria", "DISEASE", 541, 548], ["men", "ORGANISM", 149, 152], ["men", "ORGANISM", 171, 174], ["men", "SPECIES", 149, 152], ["men", "SPECIES", 171, 174], ["HIV", "SPECIES", 29, 32], ["pilot studies", "TEST", 282, 295], ["the regional malaria database", "PROBLEM", 528, 557], ["discrepancies in data collection methods", "TEST", 604, 644], ["no", "UNCERTAINTY", 237, 239], ["many", "OBSERVATION_MODIFIER", 277, 281], ["pilot", "OBSERVATION_MODIFIER", 282, 287]]], ["As part of the regional strategy for malaria elimination in the Greater Mekong Subregion, national stakeholders and international actors agreed to develop a regional database with data on malaria cases from all countries in the region.", [["malaria", "DISEASE", 37, 44], ["malaria", "DISEASE", 188, 195], ["malaria elimination", "PROBLEM", 37, 56], ["malaria cases", "PROBLEM", 188, 201], ["malaria", "OBSERVATION", 37, 44]]], ["However, discrepancies in data collection systems emerged as a major barrier to project implementation, requiring a laborious process of negotiations on common indicators.", [["discrepancies in data collection systems", "PROBLEM", 9, 49], ["a laborious process", "TREATMENT", 114, 133]]], ["Two informants in Cambodia explained:\u201cWe had several meetings to establish a regional database\u2026 But the main problem is the type of data\u2026 that are very different in each country\u2026 so at the meeting, we decided to share basic indicators\u2026 Another problem is the unit of data collection, which can vary considerably from township, to provinces to operational districts, to communes\u2026\u201d (CAM-22).\u201cWe are developing a web-based regional database.", [["data collection", "TEST", 267, 282], ["main", "OBSERVATION_MODIFIER", 104, 108], ["problem", "OBSERVATION", 109, 116]]], ["It took about three days to get countries to agree on indicators\u2026 whether it should be at the commune level, at the provincial level, or at the country level (\u2026) eventually we agreed on confirmed cases disaggregated by species, number of person tested, depending on the capacities; admitted malaria cases, including data from the private sector if available; severe malaria cases; malaria deaths; and completeness of health facility report\u201d (CAM-24).Inconsistencies in case definitions ::: The nature of shared data and information ::: ResultsThe second informant also noted that completeness of reporting \u2013 defined as the proportion of health facilities that are actually reporting out of the total proportion of facilities that are expected to report \u2013 is a key variable in the development of the regional database: \u201cthis point is very important as missing data can be incorporated into the modelling exercise so that we can have an estimate of real figures\u201d (CAM-24).Reliability of information systems and trustworthiness of shared information ::: The nature of shared data and information ::: ResultsAnother area of concern was that perceptions about the reliability of the information source can affect the credibility of international communications.", [["malaria", "DISEASE", 291, 298], ["malaria", "DISEASE", 366, 373], ["malaria", "DISEASE", 381, 388], ["deaths", "DISEASE", 389, 395], ["person", "SPECIES", 238, 244], ["severe malaria cases", "PROBLEM", 359, 379], ["malaria deaths", "PROBLEM", 381, 395], ["severe", "OBSERVATION_MODIFIER", 359, 365], ["malaria", "OBSERVATION", 366, 373]]], ["One health sector manager at the central level in Cambodia, who was involved in several regional initiatives, explained that \u201cdistrict hospital in some countries can do many testing\u2026. when they report pneumonia, it is really pneumonia\u2026 they tell everything; but when we report cases, it is only based on clinical symptoms\u2026 they say it is not reliable\u201d (CAM-18).Reliability of information systems and trustworthiness of shared information ::: The nature of shared data and information ::: ResultsFurther, a few participants noted that asymmetries in capacities to detect outbreaks may result in different risk perceptions, undermining the potential for collective action.", [["pneumonia", "DISEASE", 201, 210], ["pneumonia", "DISEASE", 225, 234], ["participants", "SPECIES", 510, 522], ["pneumonia", "PROBLEM", 201, 210], ["pneumonia", "PROBLEM", 225, 234], ["clinical symptoms", "PROBLEM", 304, 321], ["asymmetries in capacities", "PROBLEM", 534, 559], ["outbreaks", "PROBLEM", 570, 579], ["pneumonia", "OBSERVATION", 201, 210], ["pneumonia", "OBSERVATION", 225, 234]]], ["While informants in both Cambodia and Vietnam reported examples of joint outbreak investigations conducted in recent years, one quarantine officer in Vietnam explained:\u201cIn 2013, we had some suspected cases of [cross-border] cholera and we wanted to do a joint outbreak investigation with Cambodia but at that time most suspected cases were identified only in Vietnam so the priorities were different.\u201d", [["cholera", "DISEASE", 224, 231], ["a joint outbreak investigation", "TEST", 252, 282], ["joint", "ANATOMY", 67, 72], ["joint", "ANATOMY", 254, 259]]], ["(VIET-01).The politics of participation at cross-border and regional meetings ::: Communication channels and information flows ::: ResultsDespite positive views about the value of regional meetings, some narratives illustrate that meetings can be a locus where imbalances in capacities are reflected, influencing the dynamics of data and information sharing in undesirable ways.", [["a locus where imbalances in capacities", "PROBLEM", 247, 285]]], ["In particular, two international experts reported that different levels of technical proficiency and ownership of data and data collection systems impacted on the ability of country partners to share data and speak confidently:\u201cWhen a country owns and is confident of their data\u2026.", [["data collection systems", "TEST", 123, 146]]], ["Despite improvements in IT and network access, in both Cambodia and Vietnam routine surveillance data are still collected on paper forms in many health facilities, particularly at the community level.", [["Vietnam routine surveillance data", "TEST", 68, 101]]], ["The supervisor at the provincial level collects and checks data from all operational districts every two months.", [["checks data", "TEST", 52, 63]]], ["The national supervisor then visits each provincial health department quarterly to get the provincial report\u201d (CAM-11).Information flow and data collection systems ::: Communication channels and information flows ::: ResultsAnother informant in Cambodia explained:\u201cSometimes our reporting is not timely and complete \u2013 especially because it is difficult to have all data from other programs (\u2026) as they are under other staff, and sometimes the national programme for malaria or HIV do not have all data every week\u201d (CAM-16).Language ::: Communication channels and information flows ::: ResultsMany participants pointed out that language was an important variable affecting the exchange of information and access to shared data resources.", [["malaria", "DISEASE", 466, 473], ["HIV", "SPECIES", 477, 480], ["participants", "SPECIES", 597, 609], ["HIV", "SPECIES", 477, 480], ["malaria", "PROBLEM", 466, 473]]], ["In other contexts, however, language was identified a major barrier to cross-border cooperation or the use of regional data (CAM-06, CAM-14, CAM-21), as the following excerpts illustrate:\u201cEmail exchange are in English\u2026 but there are language limitations so we cannot explain well the full situation.", [["regional data", "TEST", 110, 123], ["CAM", "TEST", 125, 128], ["CAM", "TEST", 133, 136], ["CAM", "TEST", 141, 144]]], ["Due to language problems, it is difficult to explain effectively\u2026 even if we have translators during the meetings\u2026\u201d (VIET-17).\u201cIn the past, the regional website was only available in English, so many people could not access the information well.", [["people", "ORGANISM", 200, 206], ["people", "SPECIES", 200, 206], ["language problems", "PROBLEM", 7, 24]]], ["Now we use it more because it has recently been translated in Vietnamese\u201d (VIET16).National regulations and norms ::: Institutional and organisational arrangements ::: ResultsThe analysis of interviews showed that local rules and arrangements shaped the ability of local stakeholders to share data in variable ways, resulting in potential asymmetries in data exchange between partners even when informal agreements exist to promote international communications.", [["The analysis of interviews", "TEST", 175, 201]]], ["As reported by several informants, this norm may enhance high-level coordination and national stewardship in the event of emergencies, but constrains the ability of local managers to engage in cross-border collaborations:\u201cIf we need information from other countries, it is always the central level - because this is government\u2026 I think they work with the WHO and other countries\u2026 If we need information from other countries, they will do\u2026\u201d (VIET05).Regional governance ::: Institutional and organisational arrangements ::: ResultsIn both countries, there was a consensus amongst participants that the IHR 2005 were an effective instrument to mandate the global notification of health emergencies of international concern; however, the lack of a clear legal framework to support regional programmes (usually based on \u201csoft law\u201d agreements such as memoranda of understanding) was seen as a barrier to the establishment of direct communication across borders.", [["participants", "SPECIES", 579, 591], ["governance", "OBSERVATION", 458, 468]]], ["Similarly, another informant in Vietnam stressed that the lack of agreed standard operating procedures was a barrier to the implementation of joint responses to cross-border disease outbreaks (VIET-26).", [["joint", "MULTI-TISSUE_STRUCTURE", 142, 147], ["standard operating procedures", "TREATMENT", 73, 102], ["cross-border disease outbreaks", "PROBLEM", 161, 191], ["joint", "ANATOMY", 142, 147]]], ["On another note, one informant in Cambodia lamented the proliferation of bilateral and multilateral public health agreements, suggesting that ASEAN should be the overarching framework to coordinate regional public health initiatives (CAM-08).Sustainability of donor-funded initiatives ::: Institutional and organisational arrangements ::: ResultsFinancing arrangements and the sustainability of public health programmes emerged as another important structural issue affecting dynamics of regional data sharing.", [["public health programmes", "TREATMENT", 395, 419], ["bilateral", "ANATOMY_MODIFIER", 73, 82]]], ["Over the past two decades, the development and maintenance of regional public health networks has been financed predominantly by non-regional donors through various forms of \u201ctriangular\u201d cooperation, an arrangement in which one or more donors provide financial support and technical input to promote South-South cooperation [43].", [["donors", "ORGANISM", 236, 242], ["financial support", "TREATMENT", 251, 268]]], ["However, donor funding for regional initiatives has decreased recently due to changing donor priorities and expectations that participating countries would sustain cross-border partnerships with their own resources.", [["changing donor priorities", "TREATMENT", 78, 103]]], ["In our interviews, we found that more resourced regional partners, particularly Thailand and, to a lesser extent, Vietnam, have provided increasing support to neighbouring countries (CAM-02, VIET-30, VIET-32), especially in cross-border areas where population movement is seen as a major driver of disease transmission, such as the Thailand-Myanmar border.", [["VIET-30, VIET-32", "CHEMICAL", 191, 207], ["VIET-32", "CELL", 200, 207], ["increasing support", "TREATMENT", 137, 155], ["CAM-02", "TREATMENT", 183, 189], ["disease transmission", "PROBLEM", 298, 318], ["population movement", "OBSERVATION", 249, 268], ["disease", "OBSERVATION", 298, 305]]], ["However, South-South financing has tended to prioritise training and capacity building, and has not been able to match the level of funding from international donors.", [["donors", "ORGANISM", 159, 165]]], ["We still have the phone, but no funding to use it and it is more expensive than a normal phone (\u2026)\u201d (CAM-21).\u201cIn the past they [the programme] also provided funds for local staff, but now they give only a small contribution to pay internet expenses\u2026 about US $10-15 a month\u2026 it\u2019s not enough\u201d (CAM-01).Study limitations and suggestions for further research ::: DiscussionThis study Is based on a unique collection of stakeholders\u2019 views about public health data and information sharing across borders in a developing context.", [["Study limitations", "TEST", 301, 318]]], ["To the best of our knowledge, this is the first study of this kind and, hopefully, our analysis can be useful to inform and encourage further research on these issues.", [["our analysis", "TEST", 83, 95]]], ["In our study, whenever possible, we tried to encourage personal and critical engagement with the given topics.", [["our study", "TEST", 3, 12]]], ["Second, given the exploratory nature of this study, we could generate insights on the socio-technical complexity of health data and information sharing, but in-depth exploration of emerging issues would require additional work and specific methodologies.", [["this study", "TEST", 40, 50]]], ["For example, network analysis could be used to chart structural patterns in the flow of data and information within and across countries, including centrality of nodes, reciprocity in information exchange, clustering, and, importantly, brokerage dynamics.", [["network analysis", "TEST", 13, 29], ["nodes", "OBSERVATION", 162, 167]]], ["Lastly, this study was conducted in a particular geopolitical and public health context of regional cooperation.", [["this study", "TEST", 8, 18], ["regional cooperation", "OBSERVATION", 91, 111]]], ["As noted earlier, the focus on Southeast Asia provides strategic opportunities to explore different aspects of the phenomenon investigated here.", [["the phenomenon", "PROBLEM", 111, 125]]], ["However, future research work could be conducted in other areas to enable comparative case study analysis and provide stronger evidential bases for theory development and generalisation.ConclusionsOur study documents ways in which imbalances between national health systems and capacities may affect the practice of cross-border data and information sharing, suggesting that best practices require significant involvement of an independent third-party brokering organisation or office, which can redress gaps between country partners at different levels in the data sharing process, create meaningful communication channels and make the most of shared information and data sets.", [["comparative case study analysis", "TEST", 74, 105], ["theory development", "PROBLEM", 148, 166], ["generalisation", "PROBLEM", 171, 185], ["Our study", "TEST", 197, 206]]], ["By way of conclusion, we can extend this argument a step further and speculate that data and information sharing works better if supported by strong multilateral arrangements, since these typically involve a third\u2013party organisation with responsibilities for budget administration, data management, and overall coordination.", [["budget administration", "TREATMENT", 259, 280], ["data management", "TREATMENT", 282, 297]]], ["By contrast, a bilateral cooperation agreement is likely to have a weaker brokering orientation and is generally thought to be a less effective mechanisms to address collective good problems, as documented in studies of aid relationships [64]; this is even more apparent in contexts where transnational issues have a wide regional dimension and require harmonisation, coordination, and integration between more than two parties.", [["a weaker brokering orientation", "PROBLEM", 65, 95], ["bilateral", "ANATOMY_MODIFIER", 15, 24], ["more apparent", "OBSERVATION_MODIFIER", 257, 270]]], ["In the past few years, political developments in Europe and the United States have coincided with a crisis of multilateralism and regional cooperation - two foundations of the global order from the postwar to the present [65].", [["a crisis of multilateralism", "PROBLEM", 98, 125]]]], "02cb66c571aff5637cfd471c464354cad440c2c3": [["INTRODUCTIONThe relatively new concept of immunizing a fetus offers a number of interesting challenges and opens many avenues for basic as well as applied research.", [["fetus", "ANATOMY", 55, 60], ["fetus", "ORGAN", 55, 60], ["new", "OBSERVATION_MODIFIER", 27, 30]]], ["Ten years ago the immunologic capabilities of a bovine fetus were unknown.", [["fetus", "ANATOMY", 55, 60], ["bovine", "ORGANISM", 48, 54], ["fetus", "ORGAN", 55, 60], ["bovine", "SPECIES", 48, 54], ["bovine", "SPECIES", 48, 54], ["a bovine fetus", "PROBLEM", 46, 60]]], ["Today, knowledge concerning in utero vaccination of the bovine fetus has advanced to the point that such a procedure is conceivably practical for prevention of colibacillosis in neonatal calves.INTRODUCTIONMichigan State University (1, 2, 5, 6, 7, 8) has been one of the pioneers in vaccination of the bovine fetus.", [["fetus", "ANATOMY", 63, 68], ["fetus", "ANATOMY", 309, 314], ["colibacillosis", "DISEASE", 160, 174], ["utero", "ORGANISM", 31, 36], ["bovine", "ORGANISM", 56, 62], ["fetus", "ORGAN", 63, 68], ["calves", "ORGANISM", 187, 193], ["bovine", "ORGANISM", 302, 308], ["fetus", "DEVELOPING_ANATOMICAL_STRUCTURE", 309, 314], ["bovine", "SPECIES", 56, 62], ["calves", "SPECIES", 187, 193], ["bovine", "SPECIES", 302, 308], ["bovine", "SPECIES", 56, 62], ["bovine", "SPECIES", 302, 308], ["the bovine fetus", "TREATMENT", 52, 68], ["a procedure", "TREATMENT", 105, 116], ["colibacillosis in neonatal calves", "PROBLEM", 160, 193], ["colibacillosis", "OBSERVATION", 160, 174], ["neonatal calves", "ANATOMY", 178, 193], ["bovine fetus", "OBSERVATION", 302, 314]]], ["This along with work in Australia (3, 4) constitute much of the early work on immunity of the bovine fetus to Escbericbia coll.", [["fetus", "ANATOMY", 101, 106], ["bovine", "ORGANISM", 94, 100], ["fetus", "DEVELOPING_ANATOMICAL_STRUCTURE", 101, 106], ["bovine", "SPECIES", 94, 100]]], ["Since the cost of research with pregnant cattle is high, there have been limitations on the number of studies.", [["cattle", "ORGANISM", 41, 47], ["cattle", "SPECIES", 41, 47], ["cattle", "SPECIES", 41, 47], ["studies", "TEST", 102, 109], ["high", "OBSERVATION_MODIFIER", 51, 55]]], ["Consequently, questions are unanswered and potential uses of prenatal immunization have not been realized fully.", [["prenatal immunization", "TREATMENT", 61, 82]]], ["For example, the degree of heterogenetic protection resulting from in utero injection of a single type of organism, the fetal response to organisms other than E. coli and reovirus, or the effect of antigenically stimulating a prenatally vaccinated calf are but a few of the important questions.ABILITY OF THE FETUS TO DEVELOP IMMUNITY (ANTIBODY)Ovine fetuses were used first in our immunization studies wherein unborn lambs, when injected intracardially with Brucella organisms from mid-gestation (80 days prenatally) up to near gestation, responded by producing humoral antibodies (5, 6) .", [["fetal", "ANATOMY", 120, 125], ["fetuses", "ANATOMY", 351, 358], ["fetal", "ANATOMICAL_SYSTEM", 120, 125], ["E. coli", "ORGANISM", 159, 166], ["reovirus", "ORGANISM", 171, 179], ["calf", "ORGANISM", 248, 252], ["Ovine", "ORGANISM", 345, 350], ["fetuses", "ORGANISM", 351, 358], ["lambs", "ORGANISM", 418, 423], ["humoral antibodies", "PROTEIN", 563, 581], ["E. coli", "SPECIES", 159, 166], ["calf", "SPECIES", 248, 252], ["lambs", "SPECIES", 418, 423], ["E. coli", "SPECIES", 159, 166], ["heterogenetic protection", "TREATMENT", 27, 51], ["organism", "PROBLEM", 106, 114], ["the fetal response to organisms", "PROBLEM", 116, 147], ["E. coli", "PROBLEM", 159, 166], ["reovirus", "PROBLEM", 171, 179], ["antigenically stimulating a prenatally vaccinated calf", "TREATMENT", 198, 252], ["Ovine fetuses", "PROBLEM", 345, 358], ["our immunization studies", "TEST", 378, 402], ["Brucella organisms", "PROBLEM", 459, 477], ["degree", "OBSERVATION_MODIFIER", 17, 23], ["heterogenetic protection", "OBSERVATION", 27, 51], ["humoral antibodies", "OBSERVATION", 563, 581]]], ["If the unborn lambs were given a second antigenic stimulus (Brucella organisms) in utero, they developed serum antibody concentrations as high as those attained when adult sheep were given primary and secondary stimulation.", [["serum", "ANATOMY", 105, 110], ["lambs", "ORGANISM", 14, 19], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["sheep", "ORGANISM", 172, 177], ["serum antibody", "PROTEIN", 105, 119], ["lambs", "SPECIES", 14, 19], ["sheep", "SPECIES", 172, 177], ["sheep", "SPECIES", 172, 177], ["the unborn lambs", "PROBLEM", 3, 19], ["a second antigenic stimulus", "TREATMENT", 31, 58], ["Brucella organisms", "PROBLEM", 60, 78], ["serum antibody concentrations", "TEST", 105, 134], ["adult sheep", "TREATMENT", 166, 177]]], ["When secondarily stimulated at birth, neonatal lambs responded rapidly with high levels of antibody (5ORAL VACCINATION OF THE FETUSFollowing the aforementioned preliminary studies, a finding of great practical importance was that the unborn lamb produced antibodies against Brucella organisms when antigen was deposited in amniotic fluid (7) .", [["amniotic fluid", "ANATOMY", 323, 337], ["lambs", "ORGANISM", 47, 52], ["lamb", "ORGANISM", 241, 245], ["Brucella organisms", "ORGANISM", 274, 292], ["amniotic fluid", "ORGANISM_SUBSTANCE", 323, 337], ["antibodies", "PROTEIN", 255, 265], ["lambs", "SPECIES", 47, 52], ["lamb", "SPECIES", 241, 245], ["lamb", "SPECIES", 241, 245], ["high levels of antibody", "PROBLEM", 76, 99], ["the unborn lamb produced antibodies", "TEST", 230, 265], ["Brucella organisms", "PROBLEM", 274, 292], ["antigen", "PROBLEM", 298, 305], ["amniotic fluid", "TEST", 323, 337], ["amniotic fluid", "OBSERVATION", 323, 337]]], ["This was an oral vaccination since amniotic fluid is being swal-lowed constantly by the fetus.", [["oral", "ANATOMY", 12, 16], ["amniotic fluid", "ANATOMY", 35, 49], ["fetus", "ANATOMY", 88, 93], ["oral", "ORGANISM_SUBDIVISION", 12, 16], ["amniotic fluid", "ORGANISM_SUBSTANCE", 35, 49], ["fetus", "ORGAN", 88, 93], ["an oral vaccination", "TREATMENT", 9, 28], ["amniotic fluid", "PROBLEM", 35, 49], ["fluid", "OBSERVATION", 44, 49], ["fetus", "ANATOMY", 88, 93]]], ["Furthermore, secondary responses were elicited in fetal lambs when a booster vaccination was administered intra-amniotically following a primary intraamniotic vaccination.ORAL VACCINATION OF THE FETUSThe unborn calf is also capable of mounting an antibody response when vaccinated orally (amniotic fluid) with an E. coli organism (1).", [["fetal lambs", "ANATOMY", 50, 61], ["intraamniotic", "ANATOMY", 145, 158], ["amniotic fluid", "ANATOMY", 289, 303], ["fetal lambs", "ORGAN", 50, 61], ["calf", "ORGANISM", 211, 215], ["amniotic fluid", "ORGANISM_SUBSTANCE", 289, 303], ["E. coli", "ORGANISM", 313, 320], ["lambs", "SPECIES", 56, 61], ["calf", "SPECIES", 211, 215], ["E. coli", "SPECIES", 313, 320], ["E. coli", "SPECIES", 313, 320], ["secondary responses", "PROBLEM", 13, 32], ["a booster vaccination", "TREATMENT", 67, 88], ["a primary intraamniotic vaccination", "TREATMENT", 135, 170], ["an antibody response", "TEST", 244, 264], ["amniotic fluid", "TEST", 289, 303], ["an E. coli organism", "PROBLEM", 310, 329], ["E. coli organism", "OBSERVATION", 313, 329]]], ["Not only did fetal calves have antibodies against E. coli but fetal lambs responded to E. coli antigen in a similar manner.ORAL VACCINATION OF THE FETUSGay (3, 4) also has demonstrated that calves vaccinated prenatally with E. coli (some were vaccinated intramuscularly, some intra-amniotically) had antibodies against E. coli at birth.PROTECTI ON AT BIRTHThe presence of humoral antibodies at birth is only significant if the newborn is protected against a challenge exposure.", [["fetal calves", "ANATOMY", 13, 25], ["fetal lambs", "ANATOMY", 62, 73], ["fetal calves", "ORGAN", 13, 25], ["E. coli", "ORGANISM", 50, 57], ["fetal lambs", "ORGANISM", 62, 73], ["E. coli", "ORGANISM", 87, 94], ["antigen", "GENE_OR_GENE_PRODUCT", 95, 102], ["calves", "ORGANISM", 190, 196], ["E. coli", "ORGANISM", 224, 231], ["E. coli", "ORGANISM", 319, 326], ["newborn", "ORGANISM", 427, 434], ["antibodies", "PROTEIN", 31, 41], ["E. coli antigen", "PROTEIN", 87, 102], ["antibodies", "PROTEIN", 300, 310], ["humoral antibodies", "PROTEIN", 372, 390], ["calves", "SPECIES", 19, 25], ["E. coli", "SPECIES", 50, 57], ["lambs", "SPECIES", 68, 73], ["E. coli", "SPECIES", 87, 94], ["calves", "SPECIES", 190, 196], ["E. coli", "SPECIES", 224, 231], ["E. coli", "SPECIES", 319, 326], ["E. coli", "SPECIES", 50, 57], ["E. coli", "SPECIES", 87, 94], ["E. coli", "SPECIES", 224, 231], ["E. coli", "SPECIES", 319, 326], ["fetal calves", "PROBLEM", 13, 25], ["antibodies", "PROBLEM", 31, 41], ["E. coli", "PROBLEM", 50, 57], ["fetal lambs", "PROBLEM", 62, 73], ["E. coli antigen", "PROBLEM", 87, 102], ["calves vaccinated prenatally", "PROBLEM", 190, 218], ["E. coli", "PROBLEM", 224, 231], ["antibodies", "PROBLEM", 300, 310], ["E. coli", "PROBLEM", 319, 326], ["humoral antibodies", "PROBLEM", 372, 390], ["E. coli", "OBSERVATION", 87, 94], ["coli", "OBSERVATION", 322, 326], ["humoral antibodies", "OBSERVATION", 372, 390]]], ["Calves prenatally vaccinated (amniotic fluid) with E. coti were protected against an oral challenge dose of live E. coli organisms (homologous strain) given at birth (1) ( Table 1) .", [["amniotic fluid", "ANATOMY", 30, 44], ["oral", "ANATOMY", 85, 89], ["Calves", "ORGANISM", 0, 6], ["amniotic fluid", "ORGANISM_SUBSTANCE", 30, 44], ["E. coti", "ORGANISM", 51, 58], ["oral", "ORGANISM_SUBDIVISION", 85, 89], ["E. coli organisms", "ORGANISM", 113, 130], ["Calves", "SPECIES", 0, 6], ["E. coti", "SPECIES", 51, 58], ["E. coli", "SPECIES", 113, 120], ["E. coti", "SPECIES", 51, 58], ["E. coli", "SPECIES", 113, 120], ["amniotic fluid", "TEST", 30, 44], ["E. coti", "TREATMENT", 51, 58], ["an oral challenge dose", "TREATMENT", 82, 104], ["live E. coli organisms", "PROBLEM", 108, 130], ["homologous strain)", "TREATMENT", 132, 150], ["coli organisms", "OBSERVATION", 116, 130]]], ["Although totally deprived of colostrum, these calves were normal, healthy animals during the 6-wk observation.", [["colostrum", "ANATOMY", 29, 38], ["colostrum", "ORGANISM_SUBSTANCE", 29, 38], ["calves", "ORGANISM", 46, 52], ["calves", "SPECIES", 46, 52], ["normal", "OBSERVATION", 58, 64]]], ["The same dose of oral challenge organisms given to five calves that were not vaccinated in utero resuited in death within 2 to 10 days.", [["oral", "ANATOMY", 17, 21], ["death", "DISEASE", 109, 114], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["calves", "ORGANISM", 56, 62], ["calves", "SPECIES", 56, 62], ["oral challenge organisms", "TREATMENT", 17, 41]]], ["The foregoing challenge procedure was used in prenatally vaccinated lambs (1) with results similar to those for calves.BREADTH OF PROTECTIONGay (3, 4) has reported heterogenetic antibody or protection.", [["lambs", "ORGANISM", 68, 73], ["calves", "ORGANISM", 112, 118], ["heterogenetic antibody", "PROTEIN", 164, 186], ["lambs", "SPECIES", 68, 73], ["calves", "SPECIES", 112, 118], ["The foregoing challenge procedure", "TREATMENT", 0, 33], ["prenatally vaccinated lambs", "TREATMENT", 46, 73], ["heterogenetic antibody", "TREATMENT", 164, 186]]], ["In his first report (3) calves had antibodies against several serotypes of E. coli even though a single serotype was used in the prenatal immunizing inoculum.", [["calves", "ORGANISM", 24, 30], ["E. coli", "ORGANISM", 75, 82], ["antibodies", "PROTEIN", 35, 45], ["calves", "SPECIES", 24, 30], ["E. coli", "SPECIES", 75, 82], ["E. coli", "SPECIES", 75, 82], ["antibodies", "TREATMENT", 35, 45], ["E. coli", "PROBLEM", 75, 82], ["a single serotype", "PROBLEM", 95, 112], ["the prenatal immunizing inoculum", "TREATMENT", 125, 157], ["E. coli", "OBSERVATION", 75, 82], ["immunizing inoculum", "OBSERVATION", 138, 157]]], ["One such calf (vaccinated for the longest period before birth) had antibodies against a Salmonella organism.", [["calf", "ORGANISM", 9, 13], ["antibodies", "PROTEIN", 67, 77], ["calf", "SPECIES", 9, 13], ["Salmonella", "SPECIES", 88, 98], ["antibodies", "PROBLEM", 67, 77], ["a Salmonella organism", "PROBLEM", 86, 107], ["calf", "ANATOMY", 9, 13], ["Salmonella organism", "OBSERVATION", 88, 107]]], ["The second study (4) , in which challenge exposures were used, indicated that in utero vaccination with a single serotype of E. coli could result in heterogenetic protection against neonatal colisepticemia.BREADTH OF PROTECTIONThe fact that a fetus responds to an antigenic stimulus by production of a broad spectrum antibody is probably significant.", [["fetus", "ANATOMY", 243, 248], ["colisepticemia", "DISEASE", 191, 205], ["utero", "ORGANISM", 81, 86], ["E. coli", "ORGANISM", 125, 132], ["fetus", "ORGANISM", 243, 248], ["broad spectrum antibody", "PROTEIN", 302, 325], ["E. coli", "SPECIES", 125, 132], ["E. coli", "SPECIES", 125, 132], ["The second study", "TEST", 0, 16], ["utero vaccination", "PROBLEM", 81, 98], ["E. coli", "PROBLEM", 125, 132], ["heterogenetic protection", "TREATMENT", 149, 173], ["neonatal colisepticemia", "PROBLEM", 182, 205], ["a fetus", "PROBLEM", 241, 248], ["an antigenic stimulus", "TREATMENT", 261, 282], ["a broad spectrum antibody", "PROBLEM", 300, 325], ["colisepticemia", "OBSERVATION", 191, 205], ["PROTECTION", "OBSERVATION", 217, 227], ["probably", "UNCERTAINTY", 329, 337], ["significant", "OBSERVATION_MODIFIER", 338, 349]]], ["The 4 Scourvax-reo, Norden Laboratories, Lincoln, NE. breadth of protection resulting from vaccination with a single type of organism has not been determined by challenge exposure.", [["NE", "PROTEIN", 50, 52], ["vaccination", "TREATMENT", 91, 102], ["a single type of organism", "PROBLEM", 108, 133], ["protection", "OBSERVATION", 65, 75]]], ["The effect of using two immunizing organisms is unknown.LOCAL IMMUNITYCalves vaccinated prenatally had protection against challenge exposures even though some had no detectable humoral antibodies (1) .", [["humoral antibodies", "PROTEIN", 177, 195], ["two immunizing organisms", "PROBLEM", 20, 44], ["LOCAL IMMUNITYCalves vaccinated", "TREATMENT", 56, 87], ["detectable humoral antibodies", "PROBLEM", 166, 195]]], ["To define the protective mechanisms, immunofluorescent antibody examinations were made on 14 calves vaccinated in utero with E. coIi or sterile saline (8) ( Table 2 ).", [["calves", "ORGANISM", 93, 99], ["calves", "SPECIES", 93, 99], ["E. coIi", "SPECIES", 125, 132], ["immunofluorescent antibody examinations", "TEST", 37, 76], ["E. coIi", "TREATMENT", 125, 132], ["sterile saline", "TREATMENT", 136, 150]]], ["At birth, calves vaccinated prenatally with E. coli had antibody-producing ceils (IgG, IgM, and anti-E. toll) in the mucosa of the duodenum, jejunum, ileum, and in the jejunal lymph node.", [["mucosa", "ANATOMY", 117, 123], ["duodenum", "ANATOMY", 131, 139], ["jejunum", "ANATOMY", 141, 148], ["ileum", "ANATOMY", 150, 155], ["jejunal lymph node", "ANATOMY", 168, 186], ["calves", "ORGANISM", 10, 16], ["E. coli", "ORGANISM", 44, 51], ["ceils", "ORGANISM", 75, 80], ["IgG", "GENE_OR_GENE_PRODUCT", 82, 85], ["IgM", "GENE_OR_GENE_PRODUCT", 87, 90], ["mucosa", "MULTI-TISSUE_STRUCTURE", 117, 123], ["duodenum", "MULTI-TISSUE_STRUCTURE", 131, 139], ["jejunum", "MULTI-TISSUE_STRUCTURE", 141, 148], ["ileum", "MULTI-TISSUE_STRUCTURE", 150, 155], ["jejunal lymph node", "MULTI-TISSUE_STRUCTURE", 168, 186], ["antibody-producing ceils", "PROTEIN", 56, 80], ["IgG", "PROTEIN", 82, 85], ["IgM", "PROTEIN", 87, 90], ["anti-E. toll", "PROTEIN", 96, 108], ["calves", "SPECIES", 10, 16], ["E. coli", "SPECIES", 44, 51], ["E. coli", "SPECIES", 44, 51], ["E. coli", "PROBLEM", 44, 51], ["antibody", "TEST", 56, 64], ["ceils", "TEST", 75, 80], ["IgG", "TEST", 82, 85], ["IgM", "TEST", 87, 90], ["mucosa", "ANATOMY", 117, 123], ["duodenum", "ANATOMY", 131, 139], ["jejunum", "ANATOMY", 141, 148], ["ileum", "ANATOMY", 150, 155], ["jejunal", "ANATOMY", 168, 175], ["lymph node", "OBSERVATION", 176, 186]]], ["This local cellular immunity may explain protection in the absence of humoral antibody.", [["cellular", "ANATOMY", 11, 19], ["cellular", "CELL", 11, 19], ["humoral antibody", "PROTEIN", 70, 86], ["This local cellular immunity", "TREATMENT", 0, 28], ["humoral antibody", "PROBLEM", 70, 86], ["humoral antibody", "OBSERVATION", 70, 86]]], ["The one calf given an oral dose of antigen at birth had more immune-producing cells (also in the spleen) than calves not receiving a booster at birth.", [["oral", "ANATOMY", 22, 26], ["immune-producing cells", "ANATOMY", 61, 83], ["spleen", "ANATOMY", 97, 103], ["calf", "ORGANISM_SUBDIVISION", 8, 12], ["oral", "ORGANISM_SUBDIVISION", 22, 26], ["cells", "CELL", 78, 83], ["spleen", "ORGAN", 97, 103], ["calves", "ORGANISM", 110, 116], ["immune-producing cells", "CELL_TYPE", 61, 83], ["calf", "SPECIES", 8, 12], ["calves", "SPECIES", 110, 116], ["an oral dose of antigen", "TREATMENT", 19, 42], ["calf", "ANATOMY", 8, 12], ["spleen", "ANATOMY", 97, 103]]], ["The heterogenicity of the antibodies produced at the local cellular level is not known.NEONATAL RESPONSE TO REOVIRUSSince reovirus is marketed 4 as a preventative for enteritis in newborn calves, the response of the fetus to this virus was of interest.", [["cellular", "ANATOMY", 59, 67], ["fetus", "ANATOMY", 216, 221], ["enteritis", "DISEASE", 167, 176], ["cellular", "CELL", 59, 67], ["reovirus", "ORGANISM", 122, 130], ["calves", "ORGANISM", 188, 194], ["fetus", "ORGANISM", 216, 221], ["antibodies", "PROTEIN", 26, 36], ["calves", "SPECIES", 188, 194], ["The heterogenicity of the antibodies", "PROBLEM", 0, 36], ["REOVIRUSSince reovirus", "TREATMENT", 108, 130], ["enteritis in newborn calves", "PROBLEM", 167, 194], ["this virus", "PROBLEM", 225, 235], ["antibodies", "OBSERVATION", 26, 36], ["not known", "UNCERTAINTY", 77, 86], ["enteritis", "OBSERVATION", 167, 176]]], ["Recent studies in which calves were vaccinated prenatally with the commercial reovirus vaccine 4 or a combination of this and E. coli, showed that there were serum antibodies against reovirus at birth (2) .", [["serum", "ANATOMY", 158, 163], ["calves", "ORGANISM", 24, 30], ["reovirus", "ORGANISM", 78, 86], ["E. coli", "ORGANISM", 126, 133], ["serum", "ORGANISM_SUBSTANCE", 158, 163], ["reovirus", "ORGANISM", 183, 191], ["serum antibodies", "PROTEIN", 158, 174], ["calves", "SPECIES", 24, 30], ["E. coli", "SPECIES", 126, 133], ["calves", "SPECIES", 24, 30], ["E. coli", "SPECIES", 126, 133], ["Recent studies", "TEST", 0, 14], ["the commercial reovirus vaccine", "TREATMENT", 63, 94], ["E. coli", "PROBLEM", 126, 133], ["serum antibodies", "TEST", 158, 174], ["reovirus", "PROBLEM", 183, 191]]], ["Although this was a pilot study involving six animals, results indicated that the fetus produced antibodies within 8 days after vaccination.", [["fetus", "ANATOMY", 82, 87], ["fetus", "ORGANISM", 82, 87], ["antibodies", "PROTEIN", 97, 107], ["a pilot study", "TEST", 18, 31], ["the fetus produced antibodies", "PROBLEM", 78, 107], ["vaccination", "TREATMENT", 128, 139]]], ["There was also evidence that E. coli in the immunizing inoculum augmented the production of antibody against reovirus.FIELD STUDIESSeveral Michigan veterinary practitioners have performed in utero vaccination (E. coli) in herds where calfhood enteritis was a problem.", [["calfhood enteritis", "DISEASE", 234, 252], ["E. coli", "ORGANISM", 29, 36], ["reovirus", "ORGANISM", 109, 117], ["utero", "ORGANISM", 191, 196], ["E. coli", "ORGANISM", 210, 217], ["E. coli", "SPECIES", 29, 36], ["E. coli", "SPECIES", 210, 217], ["E. coli", "SPECIES", 29, 36], ["E. coli", "SPECIES", 210, 217], ["E. coli", "PROBLEM", 29, 36], ["the immunizing inoculum", "PROBLEM", 40, 63], ["antibody", "PROBLEM", 92, 100], ["reovirus", "PROBLEM", 109, 117], ["utero vaccination", "TREATMENT", 191, 208], ["E. coli", "PROBLEM", 210, 217], ["calfhood enteritis", "PROBLEM", 234, 252], ["E. coli", "OBSERVATION", 29, 36], ["immunizing inoculum", "OBSERVATION", 44, 63], ["enteritis", "OBSERVATION", 243, 252]]], ["For unknown reasons, an unexpected number of abortions occurred within 2 to 4 days after the vaccination.", [["abortions", "DISEASE", 45, 54], ["the vaccination", "TREATMENT", 89, 104]]], ["Aborted fetuses that lived and calves that were full-term appeared to be protected against enteritis.", [["fetuses", "ANATOMY", 8, 15], ["enteritis", "DISEASE", 91, 100], ["fetuses", "ORGANISM", 8, 15], ["calves", "ORGANISM", 31, 37], ["calves", "SPECIES", 31, 37], ["Aborted fetuses", "PROBLEM", 0, 15], ["enteritis", "PROBLEM", 91, 100], ["fetuses", "OBSERVATION", 8, 15]]], ["The occurrence ofVACCINATION PROCEDUREThe ovine fetus requires 15 days following injection of Brucella to achieve maximum antibodies (6) .", [["fetus", "ANATOMY", 48, 53], ["ovine", "ORGANISM", 42, 47], ["fetus", "ORGAN", 48, 53], ["Brucella", "TREATMENT", 94, 102], ["maximum antibodies", "TEST", 114, 132]]], ["A similar time is required for maximums in lambs stimulated at birth.", [["lambs", "ORGANISM", 43, 48]]], ["Antibody which was protective against colisepticemia appeared in the serum of colostrumdeprived calves at 10 to 14 days after birth (3).", [["serum", "ANATOMY", 69, 74], ["colisepticemia", "SIMPLE_CHEMICAL", 38, 52], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["calves", "ORGANISM", 96, 102], ["calves", "SPECIES", 96, 102], ["Antibody", "TEST", 0, 8], ["colisepticemia", "PROBLEM", 38, 52]]], ["Based upon these two reports, the bovine fetus should be vaccinated at least 14 days prenatally for maximum antibody protection at birth.", [["fetus", "ANATOMY", 41, 46], ["bovine", "ORGANISM", 34, 40], ["fetus", "ORGANISM", 41, 46], ["bovine", "SPECIES", 34, 40], ["bovine", "SPECIES", 34, 40], ["the bovine fetus", "TREATMENT", 30, 46], ["maximum antibody protection", "TREATMENT", 100, 127]]], ["Since parturition dates in cows may be variable, we advocate fetal vaccinations 3 to 4 wk before anticipated date of birth.", [["fetal", "ANATOMY", 61, 66], ["cows", "ORGANISM", 27, 31], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 61, 66], ["fetal vaccinations", "TREATMENT", 61, 79]]], ["While the fetus is capable of mounting antibody responses considerably earlier than 4 wk before birth, antibody at birth may be lower if antigenic stimulation occurs too early in the gestation period (5) .VACCINATION PROCEDUREThe fetus is vaccinated orally by injection through the dam's right flank.", [["fetus", "ANATOMY", 10, 15], ["fetus", "ANATOMY", 230, 235], ["right flank", "ANATOMY", 288, 299], ["fetus", "ORGANISM", 10, 15], ["fetus", "ORGANISM", 230, 235], ["flank", "ORGANISM_SUBDIVISION", 294, 299], ["mounting antibody responses", "PROBLEM", 30, 57], ["antibody", "TREATMENT", 103, 111], ["antigenic stimulation", "PROBLEM", 137, 158], ["VACCINATION PROCEDUREThe fetus", "TREATMENT", 205, 235], ["right", "ANATOMY_MODIFIER", 288, 293], ["flank", "ANATOMY", 294, 299]]], ["Injection site is where the fetus is closest to the abdominal wall as determined by ballottment, care being taken to avoid abomasal or duodenal areas.", [["fetus", "ANATOMY", 28, 33], ["abdominal wall", "ANATOMY", 52, 66], ["abomasal", "ANATOMY", 123, 131], ["duodenal areas", "ANATOMY", 135, 149], ["fetus", "ORGANISM", 28, 33], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 52, 66], ["abomasal", "ORGANISM_SUBDIVISION", 123, 131], ["duodenal", "PATHOLOGICAL_FORMATION", 135, 143], ["Injection site", "TREATMENT", 0, 14], ["care", "TREATMENT", 97, 101], ["abomasal or duodenal areas", "PROBLEM", 123, 149], ["fetus", "OBSERVATION", 28, 33], ["abdominal wall", "ANATOMY", 52, 66], ["abomasal", "ANATOMY", 123, 131], ["duodenal", "ANATOMY", 135, 143]]], ["Following clipping of hair and scrubbing the skin with a surgical antiseptic, local anesthetic is infiltrated into subcutaneous tissue, abdominal muscles, and peritoneum at the proposed injection site.", [["hair", "ANATOMY", 22, 26], ["skin", "ANATOMY", 45, 49], ["subcutaneous tissue", "ANATOMY", 115, 134], ["abdominal muscles", "ANATOMY", 136, 153], ["peritoneum", "ANATOMY", 159, 169], ["hair", "ORGAN", 22, 26], ["skin", "ORGAN", 45, 49], ["subcutaneous tissue", "TISSUE", 115, 134], ["abdominal muscles", "TISSUE", 136, 153], ["peritoneum", "MULTI-TISSUE_STRUCTURE", 159, 169], ["clipping of hair", "TREATMENT", 10, 26], ["scrubbing the skin", "PROBLEM", 31, 49], ["a surgical antiseptic", "TREATMENT", 55, 76], ["local anesthetic", "TREATMENT", 78, 94], ["clipping", "OBSERVATION", 10, 18], ["hair", "OBSERVATION_MODIFIER", 22, 26], ["scrubbing", "OBSERVATION", 31, 40], ["skin", "ANATOMY", 45, 49], ["subcutaneous tissue", "ANATOMY", 115, 134], ["abdominal muscles", "ANATOMY", 136, 153], ["peritoneum", "ANATOMY", 159, 169]]], ["A 12 gauge hypodermic needle, 5 cm long, is inserted into the peritoneal cavity via a stab incision in the skin.", [["peritoneal cavity", "ANATOMY", 62, 79], ["skin", "ANATOMY", 107, 111], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 62, 79], ["skin", "ORGAN", 107, 111], ["A 12 gauge hypodermic needle", "TREATMENT", 0, 28], ["a stab incision", "TREATMENT", 84, 99], ["12 gauge", "OBSERVATION_MODIFIER", 2, 10], ["hypodermic needle", "OBSERVATION", 11, 28], ["5 cm", "OBSERVATION_MODIFIER", 30, 34], ["peritoneal", "ANATOMY", 62, 72], ["cavity", "ANATOMY_MODIFIER", 73, 79], ["stab", "OBSERVATION_MODIFIER", 86, 90], ["incision", "OBSERVATION", 91, 99], ["skin", "ANATOMY", 107, 111]]], ["This short needle serves as a cannula for passage of a 25 or 30 cm 16 gauge needle which is directed toward the uterus and gently pushed through the uterine wall and fetal membranes until the fetus is touched, but not pierced.", [["uterus", "ANATOMY", 112, 118], ["uterine wall", "ANATOMY", 149, 161], ["fetal membranes", "ANATOMY", 166, 181], ["fetus", "ANATOMY", 192, 197], ["uterus", "ORGAN", 112, 118], ["uterine wall", "MULTI-TISSUE_STRUCTURE", 149, 161], ["fetal membranes", "MULTI-TISSUE_STRUCTURE", 166, 181], ["fetus", "ORGAN", 192, 197], ["a cannula", "TREATMENT", 28, 37], ["a 25 or 30 cm 16 gauge needle", "TREATMENT", 53, 82], ["uterus", "ANATOMY", 112, 118], ["uterine wall", "ANATOMY", 149, 161], ["fetal membranes", "OBSERVATION", 166, 181]]], ["Presence of the needle in the amniotic cavity is confirmed by aspirating amniotic fluid prior to the injection; however, on rare occasions fluid can not be aspirated.", [["amniotic cavity", "ANATOMY", 30, 45], ["amniotic fluid", "ANATOMY", 73, 87], ["amniotic cavity", "MULTI-TISSUE_STRUCTURE", 30, 45], ["amniotic fluid", "ORGANISM_SUBSTANCE", 73, 87], ["the needle in the amniotic cavity", "PROBLEM", 12, 45], ["aspirating amniotic fluid", "PROBLEM", 62, 87], ["the injection", "TREATMENT", 97, 110], ["rare occasions fluid", "PROBLEM", 124, 144], ["needle", "OBSERVATION", 16, 22], ["amniotic cavity", "ANATOMY", 30, 45], ["amniotic fluid", "OBSERVATION", 73, 87], ["fluid", "OBSERVATION", 139, 144]]], ["The volume of bacterial antigen injected is 2 to 3 ml containing approximately 2 \u00d7 101\u00b0 cells S Department of Microbiology and Public Health, G. R. Carter. per ml.", [["cells", "ANATOMY", 88, 93], ["bacterial antigen", "PROTEIN", 14, 31], ["bacterial antigen", "PROBLEM", 14, 31], ["volume", "OBSERVATION_MODIFIER", 4, 10], ["bacterial", "OBSERVATION_MODIFIER", 14, 23]]], ["Aseptic techniques are used throughout the vaccination procedure.", [["Aseptic techniques", "TREATMENT", 0, 18], ["the vaccination procedure", "TREATMENT", 39, 64]]], ["With one assistant, the vaccination can be performed in 5 min.VACCINATION PROCEDUREThe immunizing inoculum, E. coli, 026:K60, was prepared at the University. s The organism was seeded on bottles of trypticase soy agar and incubated 20 to 24 h at 37 C. The growth was washed twice with sterile saline solution and examined by bacteriologic culture technique to determine purity.", [["E. coli", "ORGANISM", 108, 115], ["E. coli", "SPECIES", 108, 115], ["E. coli", "SPECIES", 108, 115], ["the vaccination", "TREATMENT", 20, 35], ["trypticase soy agar", "TREATMENT", 198, 217], ["sterile saline solution", "TREATMENT", 285, 308], ["bacteriologic culture technique", "TEST", 325, 356]]], ["To kill the cells, .4% formalin was added, and the suspension was incubated in a shaking water bath (37 C) for 18 to 24 h.", [["cells", "ANATOMY", 12, 17], ["formalin", "CHEMICAL", 23, 31], ["formalin", "CHEMICAL", 23, 31], ["cells", "CELL", 12, 17], ["formalin", "SIMPLE_CHEMICAL", 23, 31], [".4% formalin", "TREATMENT", 19, 31], ["the suspension", "TREATMENT", 47, 61], ["a shaking water bath", "TREATMENT", 79, 99]]], ["The formalin-killed cells were then washed twice with sterile saline and a cell count was obtained.", [["cells", "ANATOMY", 20, 25], ["cell", "ANATOMY", 75, 79], ["formalin", "CHEMICAL", 4, 12], ["formalin", "CHEMICAL", 4, 12], ["formalin", "SIMPLE_CHEMICAL", 4, 12], ["cells", "CELL", 20, 25], ["saline", "SIMPLE_CHEMICAL", 62, 68], ["cell", "CELL", 75, 79], ["formalin-killed cells", "CELL_LINE", 4, 25], ["The formalin-killed cells", "TREATMENT", 0, 25], ["sterile saline", "TREATMENT", 54, 68], ["a cell count", "TEST", 73, 85]]], ["The suspension was then diluted with sterile saline containing .002% thimerosal to a desired concentration, approximately 1.5 or 2 x 1010 ceUs/ml, stored at 4 C and used within 20 days.POSSIBLE APPLICATION OF IN UTERO VACCINATIONThe potentially useful applications of prenatal vaccination are dependent upon expanded research efforts.", [["thimerosal", "CHEMICAL", 69, 79], ["thimerosal", "CHEMICAL", 69, 79], ["saline", "SIMPLE_CHEMICAL", 45, 51], ["thimerosal", "SIMPLE_CHEMICAL", 69, 79], ["The suspension", "TREATMENT", 0, 14], ["sterile saline", "TREATMENT", 37, 51], ["UTERO VACCINATION", "TREATMENT", 212, 229], ["prenatal vaccination", "TREATMENT", 268, 288], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["However, it appears feasible that such a procedure could provide protection against diseases for which there are inadequate or unsatisfactory immunization procedures after birth.", [["a procedure", "TREATMENT", 39, 50], ["diseases", "PROBLEM", 84, 92], ["unsatisfactory immunization procedures", "TREATMENT", 127, 165]]], ["For example, viral diseases such as bovine viral diarrhea (BVD) or infectious bovine rhinotracheitis (IBR) might be prevented by fetal vaccination.", [["fetal", "ANATOMY", 129, 134], ["viral diseases", "DISEASE", 13, 27], ["bovine viral diarrhea", "DISEASE", 36, 57], ["BVD", "DISEASE", 59, 62], ["infectious bovine rhinotracheitis", "DISEASE", 67, 100], ["IBR", "DISEASE", 102, 105], ["bovine", "ORGANISM", 36, 42], ["bovine rhinotracheitis", "ORGANISM", 78, 100], ["fetal", "ANATOMICAL_SYSTEM", 129, 134], ["bovine", "SPECIES", 36, 42], ["bovine", "SPECIES", 78, 84], ["rhinotracheitis", "SPECIES", 85, 100], ["BVD", "SPECIES", 59, 62], ["bovine rhinotracheitis", "SPECIES", 78, 100], ["viral diseases", "PROBLEM", 13, 27], ["bovine viral diarrhea", "PROBLEM", 36, 57], ["BVD", "PROBLEM", 59, 62], ["infectious bovine rhinotracheitis", "PROBLEM", 67, 100], ["fetal vaccination", "PROBLEM", 129, 146], ["viral diseases", "OBSERVATION", 13, 27], ["bovine", "OBSERVATION_MODIFIER", 36, 42], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["diarrhea", "OBSERVATION", 49, 57], ["infectious", "OBSERVATION_MODIFIER", 67, 77], ["bovine rhinotracheitis", "OBSERVATION", 78, 100]]], ["Postnatal vaccination for these diseases is not always effective and, if given at the wrong time, results in abortions and fetal aberrations.", [["fetal", "ANATOMY", 123, 128], ["abortions", "DISEASE", 109, 118], ["fetal aberrations", "DISEASE", 123, 140], ["fetal", "ANATOMICAL_SYSTEM", 123, 128], ["Postnatal vaccination", "TREATMENT", 0, 21], ["these diseases", "PROBLEM", 26, 40], ["abortions", "PROBLEM", 109, 118], ["fetal aberrations", "PROBLEM", 123, 140], ["fetal aberrations", "OBSERVATION", 123, 140]]], ["There are at least two viruses (reovirus, coronavirus) responsible for enteric disorders of the newborn calf.", [["enteric disorders", "DISEASE", 71, 88], ["reovirus, coronavirus", "ORGANISM", 32, 53], ["calf", "ORGANISM_SUBDIVISION", 104, 108], ["calf", "SPECIES", 104, 108], ["two viruses (reovirus", "PROBLEM", 19, 40], ["coronavirus", "PROBLEM", 42, 53], ["enteric disorders of the newborn calf", "PROBLEM", 71, 108], ["at least", "OBSERVATION_MODIFIER", 10, 18], ["two", "OBSERVATION_MODIFIER", 19, 22], ["viruses", "OBSERVATION", 23, 30], ["newborn calf", "ANATOMY", 96, 108]]], ["Although it may be possible to immunize the neonatal calf against these diseases, prenatal vaccination conceivably could provide the newborn with a more effective immunization, because protective antibodies would be present at birth.POSSIBLE APPLICATION OF IN UTERO VACCINATIONAn application of importance is protection of calves against colibacillosis, an enteric disease that kills many calves before 10 days of age.", [["colibacillosis", "DISEASE", 338, 352], ["enteric disease", "DISEASE", 357, 372], ["calf", "ORGANISM", 53, 57], ["calves", "ORGANISM", 323, 329], ["calves", "ORGANISM", 389, 395], ["protective antibodies", "PROTEIN", 185, 206], ["calf", "SPECIES", 53, 57], ["calves", "SPECIES", 323, 329], ["calves", "SPECIES", 389, 395], ["calves", "SPECIES", 323, 329], ["these diseases", "PROBLEM", 66, 80], ["prenatal vaccination", "TREATMENT", 82, 102], ["a more effective immunization", "TREATMENT", 146, 175], ["protective antibodies", "TREATMENT", 185, 206], ["UTERO VACCINATIONAn application", "TREATMENT", 260, 291], ["colibacillosis", "PROBLEM", 338, 352], ["an enteric disease", "PROBLEM", 354, 372], ["may be possible", "UNCERTAINTY", 12, 27], ["enteric", "ANATOMY", 357, 364], ["disease", "OBSERVATION", 365, 372]]], ["Since this disease affects calves before they develop their own defensive mechanisms, protection at the time of birth is of great value.POSSIBLE APPLICATION OF IN UTERO VACCINATIONIf there is heterogenetic protection, as has been reported in calves vaccinated prenatally, this phenomenon would increase interest in and significance of the technique.", [["calves", "ORGANISM", 27, 33], ["calves", "ORGANISM", 242, 248], ["calves", "SPECIES", 27, 33], ["calves", "SPECIES", 242, 248], ["calves", "SPECIES", 242, 248], ["this disease affects calves", "PROBLEM", 6, 33], ["heterogenetic protection", "TREATMENT", 192, 216], ["this phenomenon", "PROBLEM", 272, 287], ["disease", "OBSERVATION", 11, 18], ["heterogenetic protection", "OBSERVATION", 192, 216]]]], "PMC5563143": [["IntroductionCoronaviruses are single\u2010stranded, positive\u2010sense, enveloped RNA viruses that infect both humans and animals.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["humans", "ORGANISM", 102, 108], ["humans", "SPECIES", 102, 108], ["humans", "SPECIES", 102, 108], ["enveloped RNA viruses", "PROBLEM", 63, 84], ["RNA viruses", "OBSERVATION", 73, 84]]], ["Coronavirus infections have a range of severity and include upper and lower respiratory symptoms, with a low frequency of acute lung injury and acute respiratory distress syndrome.1 Acute gastrointestinal, hepatic, and neurological symptoms have also been observed.2 Since 2002, the human coronaviruses (CoVs) have emerged as significant public health threats.", [["respiratory", "ANATOMY", 76, 87], ["lung", "ANATOMY", 128, 132], ["respiratory", "ANATOMY", 150, 161], ["gastrointestinal", "ANATOMY", 188, 204], ["hepatic", "ANATOMY", 206, 213], ["neurological", "ANATOMY", 219, 231], ["Coronavirus infections", "DISEASE", 0, 22], ["acute lung injury", "DISEASE", 122, 139], ["acute respiratory distress syndrome", "DISEASE", 144, 179], ["Acute gastrointestinal, hepatic, and neurological symptoms", "DISEASE", 182, 240], ["upper", "ORGANISM_SUBDIVISION", 60, 65], ["lung", "ORGAN", 128, 132], ["gastrointestinal", "ORGAN", 188, 204], ["hepatic", "ORGAN", 206, 213], ["human", "ORGANISM", 283, 288], ["coronaviruses", "ORGANISM", 289, 302], ["CoVs", "CANCER", 304, 308], ["human", "SPECIES", 283, 288], ["human coronaviruses", "SPECIES", 283, 302], ["Coronavirus infections", "PROBLEM", 0, 22], ["upper and lower respiratory symptoms", "PROBLEM", 60, 96], ["acute lung injury", "PROBLEM", 122, 139], ["acute respiratory distress syndrome", "PROBLEM", 144, 179], ["Acute gastrointestinal, hepatic, and neurological symptoms", "PROBLEM", 182, 240], ["infections", "OBSERVATION", 12, 22], ["upper", "ANATOMY_MODIFIER", 60, 65], ["lower", "ANATOMY_MODIFIER", 70, 75], ["respiratory", "ANATOMY", 76, 87], ["symptoms", "OBSERVATION", 88, 96], ["low frequency", "OBSERVATION_MODIFIER", 105, 118], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["lung", "ANATOMY", 128, 132], ["injury", "OBSERVATION", 133, 139], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory distress", "OBSERVATION", 150, 170], ["syndrome", "OBSERVATION", 171, 179], ["Acute", "OBSERVATION_MODIFIER", 182, 187], ["gastrointestinal", "ANATOMY", 188, 204], ["hepatic", "ANATOMY", 206, 213]]], ["The severe acute respiratory syndrome (SARS) virus is the etiological agent of the 2003\u20132005 pandemic that affected more than 30 countries.3 In 2012, the Middle East respiratory syndrome (MERS) virus emerged in the Middle East, followed by the spread of the virus to other countries (e.g., the UK, South Korea).", [["acute respiratory syndrome (SARS) virus", "DISEASE", 11, 50], ["Middle East respiratory syndrome", "DISEASE", 154, 186], ["Middle East respiratory", "ORGANISM", 154, 177], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 4, 50], ["Middle East respiratory syndrome (MERS) virus", "SPECIES", 154, 199], ["The severe acute respiratory syndrome", "PROBLEM", 0, 37], ["SARS) virus", "PROBLEM", 39, 50], ["the Middle East respiratory syndrome (MERS) virus", "PROBLEM", 150, 199], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory syndrome", "OBSERVATION", 17, 37], ["Middle", "ANATOMY_MODIFIER", 154, 160], ["respiratory syndrome", "OBSERVATION", 166, 186], ["Middle", "ANATOMY_MODIFIER", 215, 221]]], ["As of 2016, there had been 1728 confirmed cases of MERS affecting persons in 27 countries.4 Prior to these outbreaks, CoVs were known to be responsible for mild upper and lower respiratory infections.", [["respiratory", "ANATOMY", 177, 188], ["MERS", "DISEASE", 51, 55], ["respiratory infections", "DISEASE", 177, 199], ["persons", "ORGANISM", 66, 73], ["CoVs", "GENE_OR_GENE_PRODUCT", 118, 122], ["upper", "ORGANISM_SUBDIVISION", 161, 166], ["persons", "SPECIES", 66, 73], ["CoVs", "PROBLEM", 118, 122], ["mild upper and lower respiratory infections", "PROBLEM", 156, 199], ["mild", "OBSERVATION_MODIFIER", 156, 160], ["upper", "ANATOMY_MODIFIER", 161, 166], ["lower", "ANATOMY_MODIFIER", 171, 176], ["respiratory", "ANATOMY", 177, 188], ["infections", "OBSERVATION", 189, 199]]], ["For example, human CoV 229E and OC43 cause a minority of respiratory tract infections.2 Based on phylogenetic and serological analyses, the International Committee for Taxonomy of Viruses has placed the CoVs in four genera, namely the Alphacoronaviruses, Betacoronaviruses, Gammacoronaviruses and Deltacoronaviruses.5 Under this classification, the betacoronavirus genus has been divided into groups a to d, whereby the SARS\u2010like CoVs are found in group B and MERS\u2010like CoVs in group C. The group D so far has been detected only in bats.6", [["respiratory tract", "ANATOMY", 57, 74], ["respiratory tract infections", "DISEASE", 57, 85], ["SARS", "DISEASE", 420, 424], ["human CoV 229E", "ORGANISM", 13, 27], ["OC43", "GENE_OR_GENE_PRODUCT", 32, 36], ["respiratory tract", "ORGANISM_SUBDIVISION", 57, 74], ["CoVs", "GENE_OR_GENE_PRODUCT", 203, 207], ["Betacoronaviruses", "GENE_OR_GENE_PRODUCT", 255, 272], ["betacoronavirus genus", "ORGANISM", 349, 370], ["CoVs", "GENE_OR_GENE_PRODUCT", 430, 434], ["CoVs", "DNA", 203, 207], ["SARS\u2010like CoVs", "DNA", 420, 434], ["human", "SPECIES", 13, 18], ["human CoV 229E", "SPECIES", 13, 27], ["human CoV 229E", "PROBLEM", 13, 27], ["OC43", "PROBLEM", 32, 36], ["respiratory tract infections", "PROBLEM", 57, 85], ["serological analyses", "TEST", 114, 134], ["Taxonomy of Viruses", "PROBLEM", 168, 187], ["the CoVs in four genera", "TREATMENT", 199, 222], ["the Alphacoronaviruses", "TREATMENT", 231, 253], ["Betacoronaviruses", "TREATMENT", 255, 272], ["Gammacoronaviruses", "TREATMENT", 274, 292], ["Deltacoronaviruses", "TREATMENT", 297, 315], ["the SARS\u2010like CoVs", "PROBLEM", 416, 434], ["respiratory tract", "ANATOMY", 57, 74], ["infections", "OBSERVATION", 75, 85], ["Viruses", "OBSERVATION", 180, 187]]]], "f65412fb7f1e59c915c5998dd8b2b5d97c4ec498": [["BACKGROUNDThere is a robust pipeline of SARS-CoV-2 vaccine candidates in various stages of preclinical and clinical development.", [["SARS", "PROBLEM", 40, 44], ["CoV-2 vaccine", "TREATMENT", 45, 58]]], ["1, 2 While the challenges of developing a vaccine at an accelerated timeline for this newlyemerged pathogen have been well described, 2 less attention has been given to the challenges of vaccine deployment and delivery.", [["a vaccine", "TREATMENT", 40, 49], ["this newlyemerged pathogen", "PROBLEM", 81, 107], ["vaccine deployment", "TREATMENT", 187, 205], ["delivery", "TREATMENT", 210, 218]]], ["Lessons from the 2009 H1N1 pandemic vaccine deployment may be instructive for the current situation.", [["H1N1 pandemic vaccine deployment", "TREATMENT", 22, 54]]], ["In a survey about the 2009 H1N1 pandemic response published in 2013, WHO African Region (subsequently called \"African Region\") countries reported 62% overall utilization of the 32,096,290 deployed H1N1 vaccine doses, 3, 4 covering approximately 1% of the region's population.", [["H1N1", "DISEASE", 197, 201], ["H1N1 vaccine doses", "TREATMENT", 197, 215]]], ["4 Most of these vaccine doses arrived after June 2010, despite the fact that H1N1 vaccines were prequalified by WHO for procurement beginning November 2009.", [["H1N1", "ORGANISM", 77, 81], ["these vaccine doses", "TREATMENT", 10, 29], ["H1N1 vaccines", "TREATMENT", 77, 90]]], ["3 This delay, largely due to obstacles in vaccine deployment and delivery, resulted in many preventable illnesses.BACKGROUNDThe SARS-CoV-2 pandemic has already caused more severe health impact than the 2009 influenza pandemic, 5 and national governments, and technical and partner agencies should aspire to higher goals than the population coverage achieved during the prior pandemic.", [["SARS", "DISEASE", 128, 132], ["influenza pandemic", "DISEASE", 207, 225], ["SARS-CoV-2", "ORGANISM", 128, 138], ["This delay", "PROBLEM", 2, 12], ["vaccine deployment", "TREATMENT", 42, 60], ["delivery", "TREATMENT", 65, 73], ["many preventable illnesses", "PROBLEM", 87, 113], ["the population coverage", "TREATMENT", 325, 348], ["many", "OBSERVATION_MODIFIER", 87, 91], ["preventable", "OBSERVATION_MODIFIER", 92, 103], ["illnesses", "OBSERVATION", 104, 113], ["severe", "OBSERVATION_MODIFIER", 172, 178]]], ["4 A WHO report following the 2009 pandemic concluded that existing health systems, immunization infrastructures, and deployment training played key roles during the vaccine response.", [["immunization infrastructures", "TREATMENT", 83, 111], ["deployment training", "TREATMENT", 117, 136]]], ["6 Critical to immunization infrastructure is the cold chain, defined as the series of actions and equipment necessary to maintain a vaccine within a specific low temperature range from production to the point of administration.", [["Critical to immunization infrastructure", "TREATMENT", 2, 41], ["a vaccine", "TREATMENT", 130, 139], ["cold chain", "OBSERVATION_MODIFIER", 49, 59]]], ["While the number of deployed H1N1 vaccine doses covered only a fraction of at-risk populations identified, 29% of countries of the WHO African Region reported having insufficient cold chain and logistics capacity for a comprehensive H1N1 response.", [["H1N1", "DISEASE", 233, 237], ["deployed H1N1 vaccine doses", "TREATMENT", 20, 47], ["insufficient cold chain", "PROBLEM", 166, 189], ["logistics capacity", "TEST", 194, 212]]], ["4 Since 2014, a concerted global effort has improved cold chain infrastructure in developing countries, 7, 8 which may facilitate a more rapid, widespread, and equitable SARS-CoV-2 vaccine response.", [["CoV-2", "ORGANISM", 175, 180], ["cold chain infrastructure", "PROBLEM", 53, 78], ["equitable SARS", "PROBLEM", 160, 174], ["CoV", "TEST", 175, 178], ["global effort", "OBSERVATION", 26, 39], ["improved", "OBSERVATION_MODIFIER", 44, 52], ["cold", "OBSERVATION_MODIFIER", 53, 57], ["chain infrastructure", "OBSERVATION", 58, 78]]], ["We undertook this study to investigate the impact SARS-CoV-2 vaccination programs would have on vaccine .", [["SARS-CoV", "SPECIES", 50, 58], ["this study", "TEST", 13, 23], ["the impact SARS", "PROBLEM", 39, 54], ["CoV-2 vaccination programs", "TREATMENT", 55, 81], ["vaccine", "TREATMENT", 96, 103]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.13.20147595 doi: medRxiv preprint delivery and storage systems in the WHO African Region.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprint delivery", "TREATMENT", 322, 347], ["storage systems", "TREATMENT", 352, 367], ["med", "ANATOMY", 99, 102]]], ["Our goal was to assess the operational feasibility of mass vaccination programs targeting SARS-CoV-2 risk groups.METHODSThis analysis is similar to cold chain capacity assessments that are performed routinely by countries in preparation for new vaccine introductions.", [["SARS", "DISEASE", 90, 94], ["SARS-CoV", "SPECIES", 90, 98], ["mass vaccination programs", "TREATMENT", 54, 79], ["SARS", "TEST", 90, 94], ["METHODSThis analysis", "TEST", 113, 133], ["cold chain capacity assessments", "TEST", 148, 179], ["new vaccine introductions", "TREATMENT", 241, 266], ["mass", "OBSERVATION", 54, 58]]], ["10 We compared the number of doses and vaccine storage volumes required for routine immunization alone and with SARS-CoV-2 mass vaccination campaigns.", [["SARS-CoV", "SPECIES", 112, 120], ["vaccine storage volumes", "TREATMENT", 39, 62], ["routine immunization", "TREATMENT", 76, 96], ["SARS", "PROBLEM", 112, 116], ["CoV", "TEST", 117, 120], ["2 mass vaccination campaigns", "TREATMENT", 121, 149]]], ["We then compared the required vaccine storage volumes for both scenarios to available cold storage capacities from countries in the African Region.", [["vaccine storage volumes", "TREATMENT", 30, 53], ["cold storage capacities", "PROBLEM", 86, 109]]], ["Our outcomes of interest included the monthly percentage increases in vaccine doses to be administered, doses administered per vaccinator, and cold storage volume requirements for SARS-CoV-2 mass vaccination campaigns compared to routine immunization baselines.Immunization strategiesWe used a standard routine immunization schedule for the simulated country based on current WHO policy recommendations (Supplemental Table 1 ).", [["SARS", "DISEASE", 180, 184], ["the monthly percentage increases in vaccine doses", "TREATMENT", 34, 83], ["cold storage volume requirements", "TREATMENT", 143, 175], ["SARS", "PROBLEM", 180, 184], ["CoV", "PROBLEM", 185, 188], ["2 mass vaccination campaigns", "TREATMENT", 189, 217], ["routine immunization baselines", "TREATMENT", 230, 260], ["Immunization strategies", "TREATMENT", 261, 284], ["a standard routine immunization schedule", "TREATMENT", 292, 332]]], ["11 We then adopted a SARS-CoV-2 vaccination campaign strategy targeting the following risk groups: persons agedVaccine storageWe identified WHO prequalified routine vaccine products, 15 and we recorded the cold storage volumes required per dose in multi-dose vials for the standard routine immunization schedule (Supplemental Table 1 ).", [["persons", "ORGANISM", 99, 106], ["persons", "SPECIES", 99, 106], ["a SARS-CoV-2 vaccination campaign strategy", "TREATMENT", 19, 61], ["routine vaccine products", "TREATMENT", 157, 181], ["the cold storage volumes", "TREATMENT", 202, 226], ["multi-dose vials", "TREATMENT", 248, 264], ["the standard routine immunization schedule", "TREATMENT", 269, 311]]], ["As no licensed SARS-CoV-2 vaccines are available, we adopted a proxy of cold storage volumes required for WHO prequalified influenza vaccines in multi-dose vials (10 doses per vial).", [["influenza", "DISEASE", 123, 132], ["SARS-CoV-2", "ORGANISM", 15, 25], ["licensed SARS", "PROBLEM", 6, 19], ["CoV-2 vaccines", "TREATMENT", 20, 34], ["cold storage volumes", "TREATMENT", 72, 92], ["WHO prequalified influenza vaccines", "TREATMENT", 106, 141], ["multi-dose vials", "TREATMENT", 145, 161]]], ["15 Cold storage volume is the total volume of vaccines maintained at refrigerated temperatures throughout storage and transport.", [["Cold storage volume", "TREATMENT", 3, 22], ["the total volume of vaccines", "TREATMENT", 26, 54]]], ["Cold storage in countries is organized by levels, with the national level being where procured vaccines are received and stored before distribution to subnational levels (region, district, and health facility).", [["procured vaccines", "TREATMENT", 86, 103]]], ["Vaccines (and diluents, for reconstituted products) are produced by the manufacturer in vials or other primary packaging that are then packed together in labeled boxes called \"secondary packaging\".", [["Vaccines", "TREATMENT", 0, 8], ["diluents", "TREATMENT", 14, 22], ["other primary packaging", "TREATMENT", 97, 120]]], ["15 Products in secondary packaging are packed in cartons called \"tertiary packaging\".", [["secondary packaging", "TREATMENT", 15, 34], ["secondary packaging", "OBSERVATION", 15, 34], ["packed", "OBSERVATION_MODIFIER", 39, 45]]], ["15 Vaccines are typically maintained in tertiary packaging at the national level.", [["Vaccines", "TREATMENT", 3, 11], ["tertiary packaging", "TREATMENT", 40, 58], ["tertiary packaging", "OBSERVATION", 40, 58]]], ["16 Tertiary packaging volumes per dose are often ten times the secondary packaging volumes per dose due to additional insulation and thermal packing materials.", [["Tertiary packaging volumes", "TREATMENT", 3, 29], ["additional insulation and thermal packing materials", "TREATMENT", 107, 158], ["thermal packing", "OBSERVATION_MODIFIER", 133, 148]]], ["At subnational levels, packaging materials are removed and vaccines are stored in their secondary packaging.", [["packaging materials", "TREATMENT", 23, 42], ["vaccines", "TREATMENT", 59, 67], ["packaging materials", "OBSERVATION", 23, 42]]], ["16, 17 Cold storage temperature for routine vaccines is typically 2\u00b0 to 8\u00b0C, although some more thermostable products are becoming available.", [["Cold storage temperature", "TREATMENT", 7, 31], ["routine vaccines", "TREATMENT", 36, 52]]], ["15 Vaccine vials used in most developing countries carry individual thermo-chemical temperature monitors that indicate when a vial has been outside of the recommended storage temperature range and should be discarded.", [["15 Vaccine vials", "TREATMENT", 0, 16]]], ["18,19Vaccine deliveryWe estimated vaccine storage volumes using WHO tools and guidance.", [["Vaccine", "TREATMENT", 5, 12]]], ["9, 15, 17, 18, 20 We compared routine immunization to SARS-CoV-2 vaccination campaigns according to evidence-based assumptions about vaccine wastage (doses that are damaged or unused), 21 reserve stock (excess supply in case of increased demand or stock outs), 9, 18, 22 and resupply intervals (Supplemental Table 2 ).", [["SARS", "DISEASE", 54, 58], ["SARS-CoV", "SPECIES", 54, 62], ["routine immunization", "TREATMENT", 30, 50], ["SARS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["2 vaccination campaigns", "TREATMENT", 63, 86], ["vaccine wastage", "TREATMENT", 133, 148]]], ["20 In the case of SARS-CoV-2 vaccines, we assumed 7.5% wastage, 0% reserve stock and monthly resupply intervals given high global demand and limited supply.", [["SARS", "DISEASE", 18, 22], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22], ["CoV-2 vaccines", "TREATMENT", 23, 37], ["0% reserve stock", "TREATMENT", 64, 80]]], ["We received summary cold storage capacity data from Gavi, the Vaccine .", [["the Vaccine", "TREATMENT", 58, 69]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Vaccine deliveryThe copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["Vaccine delivery", "TREATMENT", 196, 212], ["The copyright holder", "TREATMENT", 212, 232], ["med", "ANATOMY", 99, 102]]], ["13.20147595 doi: medRxiv preprint Alliance, for African Region countries that are eligible to receive Gavi support.", [["African Region countries", "TREATMENT", 48, 72], ["Gavi support", "TREATMENT", 102, 114]]], ["For comparisons, capacity data were standardized by dividing the total cold storage capacity by the population of children aged < 2 years in each country.AnalysisWe calculated the monthly doses and cold storage volumes required for routine immunization programs and SARS-CoV-2 vaccination campaigns to reach 90% of target populations.", [["children", "ORGANISM", 114, 122], ["children", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 266, 274], ["capacity data", "TEST", 17, 30], ["AnalysisWe", "TREATMENT", 154, 164], ["cold storage volumes", "TREATMENT", 198, 218], ["routine immunization programs", "TREATMENT", 232, 261], ["SARS", "TEST", 266, 270], ["CoV-2 vaccination campaigns", "TREATMENT", 271, 298]]], ["17 We developed a vaccine flow-down schematic ( Figure 1 ) to depict the quantity of routine vaccine doses maintained at each immunization system level by month under normal circumstances and used this to calculate the total quantity of vaccine doses and their storage volumes at each level.", [["a vaccine flow", "TEST", 16, 30], ["routine vaccine doses", "TREATMENT", 85, 106], ["the total quantity of vaccine doses", "TREATMENT", 215, 250]]], ["To assess the feasibility of storing SARS-CoV-2 vaccines, we compared the anticipated vaccine volumes for routine immunization and SARS-CoV-2 vaccination campaigns to actual vaccine cold storage capacities at national and subnational levels under normal circumstances.", [["SARS", "DISEASE", 37, 41], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 131, 139], ["storing SARS", "PROBLEM", 29, 41], ["CoV-2 vaccines", "TREATMENT", 42, 56], ["the anticipated vaccine volumes", "TREATMENT", 70, 101], ["routine immunization", "TREATMENT", 106, 126], ["SARS", "TEST", 131, 135], ["CoV-2 vaccination campaigns", "TREATMENT", 136, 163]]], ["We defined \"immunization program workloads\" as the doses delivered per vaccinator.", [["immunization program workloads", "TREATMENT", 12, 42]]], ["We calculated the median nurse density per capita from African Region countries (7.48 per 10,000 population) multiplied by the proportion of nurses estimated to provide immunization services (43%).", [["immunization services", "TREATMENT", 169, 190], ["density", "OBSERVATION", 31, 38]]], ["14, 23 We assumed baseline 3% nurse absenteeism and an additional 8% absenteeism for the SARS-CoV-2 pandemic months.", [["SARS", "DISEASE", 89, 93], ["the SARS", "PROBLEM", 85, 93]]], ["For the monthly comparisons and time series, we assumed constant routine immunization demand throughout the year and constant SARS-CoV-2 immunization demand during a mass vaccination campaign of four months duration.", [["constant routine immunization demand", "TREATMENT", 56, 92], ["constant SARS", "PROBLEM", 117, 130], ["CoV-2 immunization demand", "TREATMENT", 131, 156], ["a mass vaccination campaign", "TREATMENT", 164, 191]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)AnalysisThe copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.13.20147595 doi: medRxiv preprint (Microsoft Corp, Redmond, WA, US).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["26 As there was no involvement of human participants or personal identifiable information, institutional review board approval was not required.Role of the funding sourceThis work had no specific funding support.Description of population and vaccination target groupsWe simulated a country of 20 million people in the WHO African Region ( Table 1 ).", [["human", "ORGANISM", 34, 39], ["people", "ORGANISM", 304, 310], ["human", "SPECIES", 34, 39], ["participants", "SPECIES", 40, 52], ["people", "SPECIES", 304, 310], ["human", "SPECIES", 34, 39], ["vaccination target groups", "TREATMENT", 242, 267], ["no", "UNCERTAINTY", 16, 18]]], ["The percentage of the total population within each risk group was 3.1% for persons \u2265 65 years, 10.4% for persons with chronic diseases, 0.1% for HCWs, and 11.8% for all risk groups combined.Vaccine dosesAs in most developing countries, all routine vaccination services in the simulated country would be received by children aged <5 years and 9 through 14 years.", [["chronic diseases", "DISEASE", 118, 134], ["persons", "ORGANISM", 105, 112], ["children", "ORGANISM", 315, 323], ["persons", "SPECIES", 75, 82], ["persons", "SPECIES", 105, 112], ["children", "SPECIES", 315, 323], ["chronic diseases", "PROBLEM", 118, 134], ["HCWs", "TEST", 145, 149], ["Vaccine dosesAs", "TREATMENT", 190, 205], ["all routine vaccination services", "TREATMENT", 236, 268], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["total", "OBSERVATION_MODIFIER", 22, 27], ["chronic", "OBSERVATION_MODIFIER", 118, 125], ["diseases", "OBSERVATION", 126, 134]]], ["Assuming systems would also be in place to provide immunization services to HCWs, established routine immunization platforms reached 31.0% of the national population.", [["immunization services", "TREATMENT", 51, 72], ["routine immunization platforms", "TEST", 94, 124]]], ["A total of 921,695 routine vaccine doses would be given each month.", [["routine vaccine doses", "TREATMENT", 19, 40]]], ["Targeting SARS-CoV-2 vaccination of risk groups would therefore increase monthly doses administered over the routine immunization baseline by 29.9% for persons \u2265 65 years, 101.5% for persons with chronic diseases, 1.2% for HCWs, and 114.8% for all risk groups combined.Immunization workloadThere were an estimated 13,800 nurses in the simulated country, of which an estimated 5,934 (43%) provide vaccination services.", [["SARS", "DISEASE", 10, 14], ["chronic diseases", "DISEASE", 196, 212], ["SARS-CoV-2", "ORGANISM", 10, 20], ["persons", "ORGANISM", 152, 159], ["persons", "ORGANISM", 183, 190], ["persons", "SPECIES", 152, 159], ["persons", "SPECIES", 183, 190], ["SARS", "TEST", 10, 14], ["CoV", "TEST", 15, 18], ["risk groups", "PROBLEM", 36, 47], ["chronic diseases", "PROBLEM", 196, 212], ["HCWs", "TEST", 223, 227], ["Immunization workload", "TREATMENT", 269, 290], ["vaccination services", "TREATMENT", 396, 416], ["SARS", "OBSERVATION", 10, 14]]], ["Accounting for baseline and pandemic absenteeism, one vaccinator would .", [["baseline and pandemic absenteeism", "PROBLEM", 15, 48]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Immunization workloadThe copyright holder for this preprint this version posted August 14, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 217, 237], ["med", "ANATOMY", 99, 102]]], ["Repeating the analysis using nurse density estimates from other WHO Regions, the immunization program workload would be 26.8% using estimates from the Americas, 36.5% using estimates from the Eastern Mediterranean, 10.4% using estimates from Europe, 42.1% using estimates from South-East Asia, 19.8% using estimates from the Western Pacific, and 24.2% using global estimates (with the relative proportions being the same regardless of risk group) (Supplemental Table 4 and Figure 3 ).Routine vaccine storageWe applied standardized African Region vaccine storage capacity range and quartiles to the simulated country.", [["the analysis", "TEST", 10, 22], ["global estimates", "TEST", 358, 374], ["Routine vaccine storageWe", "TREATMENT", 484, 509], ["standardized African Region vaccine", "TREATMENT", 518, 553]]], ["The total vaccine storage capacity would range from 38,403 L to 1,605,826 L, and national level storage capacity would range from 12,534 L to 524,141 L (Table 3) .", [["The total vaccine storage capacity", "TEST", 0, 34], ["national level storage capacity", "TEST", 81, 112]]], ["We assessed the storage capacity during the month with the highest vaccine volumes.", [["the highest vaccine volumes", "TREATMENT", 55, 82]]], ["Using the vaccine flow-down schematic and adding the SARS-CoV-2 vaccination campaign during months 9 to 12, the maximum vaccine volumes were during month 10 for the national level and month 11 for the subnational levels (Supplemental Figures 1 and 2 ).", [["SARS-CoV", "SPECIES", 53, 61], ["the vaccine flow", "TEST", 6, 22], ["the SARS", "TEST", 49, 57], ["CoV-2 vaccination campaign", "TREATMENT", 58, 84], ["the maximum vaccine volumes", "TREATMENT", 108, 135], ["the subnational levels", "TEST", 197, 219]]], ["We found that the maximum monthly routine vaccine volumes for the national level would be 244,963 L and for the aggregate subnational levels would be 28,793 L. At the national level, only the country with the highest value capacity has sufficient cold storage capacity to accommodate all routine vaccines according to our vaccine storage assumptions.", [["the maximum monthly routine vaccine volumes", "TREATMENT", 14, 57], ["the national level", "TEST", 62, 80], ["the aggregate subnational levels", "TEST", 108, 140], ["the highest value capacity", "PROBLEM", 205, 231], ["cold storage capacity", "PROBLEM", 247, 268], ["all routine vaccines", "TREATMENT", 284, 304], ["our vaccine storage assumptions", "TREATMENT", 318, 349]]], ["Routine vaccine volumes exceeded that available .", [["Routine vaccine volumes", "TREATMENT", 0, 23]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . at the national level for more than 75% of African Region country storage capacities (Figure 4 ).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["At subnational levels, substantial excess available space existed at the 25th percentile or higher of African Region country storage capacities, but not for the lower 25% ( Figure 5 ).SARS-CoV-2 vaccine storageWe estimated the volume required to store SARS-CoV-2 vaccines in tertiary packaging at the national level and in secondary packaging at subnational levels (Supplemental Figures 1 and 2) .", [["SARS", "DISEASE", 184, 188], ["SARS", "DISEASE", 252, 256], ["SARS-CoV-2", "ORGANISM", 184, 194], ["substantial excess available space", "PROBLEM", 23, 57], ["SARS", "TEST", 184, 188], ["CoV-2 vaccine storageWe", "TREATMENT", 189, 212], ["CoV-2 vaccines", "TREATMENT", 257, 271], ["tertiary packaging", "TREATMENT", 275, 293], ["substantial", "OBSERVATION_MODIFIER", 23, 34], ["excess", "OBSERVATION_MODIFIER", 35, 41]]], ["At the national level, monthly SARS-CoV-2 vaccines would occupy 3,809 L for persons \u2265 65 years, 12,948 L for persons with chronic diseases, 159 L for HCWs, and 14,645 L for all risk groups combined (Table 3) .", [["SARS", "DISEASE", 31, 35], ["chronic diseases", "DISEASE", 122, 138], ["persons", "ORGANISM", 76, 83], ["persons", "ORGANISM", 109, 116], ["persons", "SPECIES", 76, 83], ["persons", "SPECIES", 109, 116], ["SARS-CoV", "SPECIES", 31, 39], ["CoV-2 vaccines", "TREATMENT", 36, 50], ["chronic diseases", "PROBLEM", 122, 138], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["diseases", "OBSERVATION", 130, 138]]], ["Excluding the lowest range value for country capacity, the percentage of total national level stores displaced by these vaccines by quartile of African Region country capacities ranged from 0.7%-6.7% for persons \u2265 65 years, 2.5% to 22.9% for persons with chronic diseases, <0.01% to 0.3% for HCWs, and 2.8% to 25.9% for all risk groups combined (Table 3 and Figure 4 ).", [["chronic diseases", "DISEASE", 255, 271], ["persons", "SPECIES", 204, 211], ["persons", "SPECIES", 242, 249], ["country capacity", "TEST", 37, 53], ["total national level stores", "PROBLEM", 73, 100], ["these vaccines", "TREATMENT", 114, 128], ["capacities", "TEST", 167, 177], ["chronic diseases", "PROBLEM", 255, 271], ["chronic", "OBSERVATION_MODIFIER", 255, 262], ["diseases", "OBSERVATION", 263, 271]]], ["At the subnational levels, monthly SARS-CoV-2 vaccines targeting risk groups would occupy 1,533 L for persons \u2265 65 years, 5,211 L for persons with chronic diseases, 64 L for HCWs, and 5,894 L for all risk groups combined.", [["chronic diseases", "DISEASE", 147, 163], ["persons", "ORGANISM", 102, 109], ["persons", "ORGANISM", 134, 141], ["persons", "SPECIES", 102, 109], ["persons", "SPECIES", 134, 141], ["monthly SARS", "TEST", 27, 39], ["CoV-2 vaccines", "TREATMENT", 40, 54], ["chronic diseases", "PROBLEM", 147, 163], ["chronic", "OBSERVATION_MODIFIER", 147, 154], ["diseases", "OBSERVATION", 155, 163]]], ["The percentage of subnational level stores displaced by these vaccines by quartile of African Region country storage capacity ranged from 0.1% to 5.9% for persons \u2265 65 years, 0.5% to 20.1% for persons with chronic diseases, <0.01% to 0.2% for HCWs, and 0.5% to 22.8% for all risk groups combined (Table 3 and Figure 5 ).DISCUSSIONWe used WHO tools and guidelines to estimate the operational impact of a SARS-CoV-2 vaccination campaign in the WHO African Region.", [["chronic diseases", "DISEASE", 206, 222], ["SARS", "DISEASE", 403, 407], ["persons", "SPECIES", 155, 162], ["persons", "SPECIES", 193, 200], ["subnational level stores", "PROBLEM", 18, 42], ["these vaccines", "TREATMENT", 56, 70], ["storage capacity", "TEST", 109, 125], ["chronic diseases", "PROBLEM", 206, 222], ["a SARS", "PROBLEM", 401, 407], ["CoV-2 vaccination campaign", "TREATMENT", 408, 434], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["chronic", "OBSERVATION_MODIFIER", 206, 213], ["diseases", "OBSERVATION", 214, 222]]], ["15,20 While we simulated a country of 20 million population for this analysis, we used actual immunization, population, healthcare worker density, and cold storage capacity data available for the region.", [["15,20", "CHEMICAL", 0, 5], ["this analysis", "TEST", 64, 77], ["actual immunization", "TREATMENT", 87, 106], ["cold storage capacity data", "TEST", 151, 177]]], ["As no SARS-CoV-2 vaccines are currently licensed, 1 we assumed a two dose vaccine series, multidose vials, and vaccine storage and volume characteristics similar to influenza vaccines.DISCUSSION. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. .0Our analysis revealed that the national level storage capacity would be insufficient to accommodate additional SARS-CoV-2 vaccines for a vaccination campaign targeting risk groups as large as persons \u2265 65 years (3.1% of the population) in at least 75% of African Region countries.", [["influenza", "DISEASE", 165, 174], ["CC", "CHEMICAL", 196, 198], ["SARS", "DISEASE", 580, 584], ["SARS-CoV-2", "ORGANISM", 6, 16], ["persons", "SPECIES", 661, 668], ["SARS-CoV", "SPECIES", 6, 14], ["SARS", "PROBLEM", 6, 10], ["CoV-2 vaccines", "TREATMENT", 11, 25], ["a two dose vaccine series", "TREATMENT", 63, 88], ["multidose vials", "TREATMENT", 90, 105], ["vaccine storage", "TREATMENT", 111, 126], ["volume characteristics", "PROBLEM", 131, 153], ["influenza vaccines", "TREATMENT", 165, 183], ["CC", "TEST", 196, 198], ["The copyright holder", "TREATMENT", 391, 411], ["Our analysis", "TEST", 469, 481], ["the national level storage capacity", "PROBLEM", 496, 531], ["CoV-2 vaccines", "TREATMENT", 585, 599], ["a vaccination campaign", "TREATMENT", 604, 626], ["med", "ANATOMY", 295, 298], ["large", "OBSERVATION_MODIFIER", 652, 657]]], ["However, all African Region countries likely have sufficient subnational levels storage capacity to accommodate SARS-CoV-2 vaccines for mass vaccination campaigns.", [["SARS", "DISEASE", 112, 116], ["CoV-2", "ORGANISM", 117, 122], ["SARS-CoV", "SPECIES", 112, 120], ["sufficient subnational levels storage capacity", "PROBLEM", 50, 96], ["SARS", "TEST", 112, 116], ["CoV-2 vaccines", "TREATMENT", 117, 131], ["mass vaccination campaigns", "TREATMENT", 136, 162]]], ["This means that there is insufficient excess cold storage capacity at the national level, whereas once vaccines are distributed to subnational levels in the health system there should be adequate storage capacity.", [["insufficient excess cold storage capacity", "PROBLEM", 25, 66], ["vaccines", "TREATMENT", 103, 111]]], ["This bottleneck in the vaccine cold chain at the national level can be addressed in advance by decreasing reserve stocks, shortening supply intervals, removing products from tertiary packaging earlier in the chain, distributing vaccines to the subnational levels, and/or installing more refrigeration capacity.", [["This bottleneck in the vaccine cold chain", "TREATMENT", 0, 41], ["decreasing reserve stocks", "TREATMENT", 95, 120], ["removing products", "TREATMENT", 151, 168], ["tertiary packaging", "TREATMENT", 174, 192]]], ["However, implementation of SARS-CoV-2 vaccination campaigns will also require increases in accompanying dry goods, such as syringes, safety boxes, cotton, alcohol, and personal protective equipment, necessitating additional planning and budget for operations and waste management.", [["SARS", "DISEASE", 27, 31], ["alcohol", "CHEMICAL", 155, 162], ["alcohol", "CHEMICAL", 155, 162], ["CoV-2", "ORGANISM", 32, 37], ["alcohol", "SIMPLE_CHEMICAL", 155, 162], ["SARS", "PROBLEM", 27, 31], ["CoV-2 vaccination campaigns", "TREATMENT", 32, 59], ["personal protective equipment", "TREATMENT", 168, 197], ["operations", "TREATMENT", 248, 258], ["waste management", "TREATMENT", 263, 279]]], ["More in-country vaccine shipments will be required to distribute routine and SARS-CoV-2 vaccines if transportation capacities are not increased, adding costs and logistical challenges.", [["SARS-CoV", "SPECIES", 77, 85], ["SARS", "TEST", 77, 81], ["CoV-2 vaccines", "TREATMENT", 82, 96], ["transportation capacities", "PROBLEM", 100, 125], ["logistical challenges", "TREATMENT", 162, 183]]], ["Care should be taken not to disrupt routine vaccine supply and distribution, as stockouts of routine vaccines will exacerbate national immunization programs already impacted by the pandemic.0While we found that the aggregate subnational level storage capacities are adequate for SARS-CoV-2 vaccines, with very large margins expected for a majority of countries, it should be noted that it is not possible nor practical to fill all available subnational level storage capacity.", [["SARS-CoV", "SPECIES", 279, 287], ["routine vaccine supply", "TREATMENT", 36, 58], ["routine vaccines", "TREATMENT", 93, 109], ["national immunization programs", "TREATMENT", 126, 156], ["the aggregate subnational level storage capacities", "PROBLEM", 211, 261], ["SARS", "PROBLEM", 279, 283], ["CoV-2 vaccines", "TREATMENT", 284, 298], ["large", "OBSERVATION_MODIFIER", 310, 315], ["margins", "OBSERVATION", 316, 323]]], ["For example, at the health facility level, standard vaccine refrigerators may have multiple times the capacity needed for vaccines used at that facility, but that excess capacity cannot be easily used to store vaccines for other facilities.0The logistics of maximizing available storage capacity at the lower levels of the cold chain makes it impractical.", [["standard vaccine refrigerators", "TREATMENT", 43, 73], ["vaccines", "TREATMENT", 122, 130], ["excess capacity", "PROBLEM", 163, 178], ["maximizing available storage capacity", "PROBLEM", 258, 295], ["lower", "ANATOMY_MODIFIER", 303, 308], ["cold chain", "ANATOMY", 323, 333]]], ["Nevertheless, our findings show that there is ample vaccine storage capacity available at subnational levels, and creative management of both routine and campaign vaccines could leverage some of that excess capacity during the SARS-CoV-2 vaccination campaign period.0.", [["SARS", "DISEASE", 227, 231], ["ample vaccine storage capacity", "PROBLEM", 46, 76], ["creative management", "TREATMENT", 114, 133], ["both routine and campaign vaccines", "TREATMENT", 137, 171], ["excess capacity", "PROBLEM", 200, 215], ["the SARS", "TEST", 223, 231]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. .1Another major obstacle for SARS-CoV-2 vaccine delivery in the African Region will be the availability of qualified vaccinators.", [["CC", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 300, 304], ["SARS-CoV-2", "ORGANISM", 300, 310], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["SARS", "PROBLEM", 300, 304], ["CoV-2 vaccine delivery", "TREATMENT", 305, 327], ["med", "ANATOMY", 99, 102]]], ["The African Region has the smallest health workforce of any WHO Region, 14 and the workload required to vaccinate risk groups would increase by 32.5% for persons \u2265 65 years and 110.4% for persons with chronic diseases, compared to routine immunization baselines.", [["chronic diseases", "DISEASE", 201, 217], ["persons", "SPECIES", 154, 161], ["persons", "SPECIES", 188, 195], ["chronic diseases", "PROBLEM", 201, 217], ["routine immunization baselines", "TEST", 231, 261], ["smallest", "OBSERVATION_MODIFIER", 27, 35], ["chronic", "OBSERVATION_MODIFIER", 201, 208], ["diseases", "OBSERVATION", 209, 217]]], ["SARS-CoV-2 vaccination activities targeting HCWs will require less additional workload given their small population size and ease of access to vaccination services.", [["SARS", "DISEASE", 0, 4], ["CoV-2", "ORGANISM", 5, 10], ["SARS", "TEST", 0, 4], ["CoV-2 vaccination activities", "TREATMENT", 5, 33], ["vaccination services", "TREATMENT", 143, 163], ["small", "OBSERVATION_MODIFIER", 99, 104], ["size", "OBSERVATION_MODIFIER", 116, 120]]], ["Our analysis highlights the need for significant planning, and investment in equipment, training, and logistics for SARS-CoV-2 vaccine deployment.1There is reason for optimism that the African Region SARS-CoV-2 vaccination response will be much While a one dose vaccine would be ideal, initial Phase 1 data indicate that two doses will likely be needed.", [["SARS", "DISEASE", 116, 120], ["SARS", "DISEASE", 200, 204], ["CoV-2", "ORGANISM", 121, 126], ["CoV-2", "ORGANISM", 205, 210], ["Our analysis", "TEST", 0, 12], ["SARS", "PROBLEM", 116, 120], ["CoV-2 vaccine deployment", "TREATMENT", 121, 145], ["the African Region SARS", "PROBLEM", 181, 204], ["CoV-2 vaccination response", "TREATMENT", 205, 231], ["a one dose vaccine", "TREATMENT", 251, 269]]], ["2 Nasal spray or transdermal patch vaccines that could be administered by trained lay persons would free skilled health workers to provide other essential services, but no such vaccines are currently in human trials.", [["Nasal", "ANATOMY", 2, 7], ["persons", "ORGANISM", 86, 93], ["human", "ORGANISM", 203, 208], ["persons", "SPECIES", 86, 93], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 203, 208], ["2 Nasal spray", "TREATMENT", 0, 13], ["transdermal patch vaccines", "TREATMENT", 17, 43], ["such vaccines", "TREATMENT", 172, 185]]], ["1 While single dose vial vaccine presentations limit vaccine wastage, 4,18 and prefilled syringe presentations limit wastage and greatly simplify administration, 18 their cold storage volumes per dose make them highly problematic for use in mass vaccination campaigns in the African Region.", [["single dose vial vaccine", "TREATMENT", 8, 32], ["their cold storage volumes", "TREATMENT", 165, 191], ["mass vaccination campaigns", "TREATMENT", 241, 267]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["Our study should be interpreted in light of its strengths and limitations.", [["Our study", "TEST", 0, 9]]], ["Our use of real-world data inputs and WHO tools and guidance strengthen the generalizability of the results and comparability to other cold chain capacity assessments.", [["other cold chain capacity assessments", "TEST", 129, 166]]], ["Since there is no currently licensed SARS-CoV-2 vaccine, we used the characteristics of influenza vaccines as proxies.", [["influenza", "DISEASE", 88, 97], ["SARS-CoV-2", "ORGANISM", 37, 47], ["influenza", "ORGANISM", 88, 97], ["CoV-2 vaccine", "TREATMENT", 42, 55], ["influenza vaccines", "TREATMENT", 88, 106], ["no", "UNCERTAINTY", 15, 17]]], ["If a SARS-CoV-2 vaccine requiring only one dose for protection is eventually licensed, the estimated doses and storage volumes required could substantially decrease.", [["SARS", "DISEASE", 5, 9], ["SARS-CoV-2", "ORGANISM", 5, 15], ["a SARS-CoV-2 vaccine", "TREATMENT", 3, 23], ["protection", "TREATMENT", 52, 62], ["the estimated doses and storage volumes", "TREATMENT", 87, 126], ["decrease", "OBSERVATION_MODIFIER", 156, 164]]], ["Conversely, if only products requiring ultra-cold chain or extra effort and training to administer .", [["ultra-cold chain", "PROTEIN", 39, 55], ["ultra-cold chain", "TREATMENT", 39, 55]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.13.20147595 doi: medRxiv preprint are licensed, the operational feasibility of mass vaccination campaigns for developing countries would be very limited.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprint", "TREATMENT", 322, 338], ["mass vaccination campaigns", "TREATMENT", 384, 410], ["med", "ANATOMY", 99, 102], ["mass", "OBSERVATION", 384, 388]]], ["We applied WHO recommended routine vaccination schedules and product characteristics, 15,30 however, as of 2017, some of the routine vaccines we assumed for the simulated country had limited adoption in African Region countries (Supplemental Table 3 ).", [["routine vaccination schedules", "TREATMENT", 27, 56], ["the routine vaccines", "TREATMENT", 121, 141]]], ["If we overestimated routine vaccine volumes, then there would be even more available capacity for SARS-CoV-2 vaccines.(which was not certified by peer review)The development of candidate SARS-CoV-2 vaccines must take operational realities and suitability in developing countries into account.", [["CoV-2", "ORGANISM", 103, 108], ["SARS-CoV-2", "ORGANISM", 187, 197], ["SARS-CoV", "SPECIES", 187, 195], ["routine vaccine volumes", "TREATMENT", 20, 43], ["SARS", "TEST", 98, 102], ["CoV-2 vaccines", "TREATMENT", 103, 117], ["SARS", "PROBLEM", 187, 191], ["CoV-2 vaccines", "TREATMENT", 192, 206]]], ["While we believe that African Region countries currently have sufficient overall cold chain capacity to accommodate SARS-CoV-2 mass vaccination campaigns, our study highlights the limitations in cold storage capacity at national levels and in workforce availability to administer these vaccines.", [["SARS", "DISEASE", 116, 120], ["sufficient overall cold chain capacity", "PROBLEM", 62, 100], ["SARS", "PROBLEM", 116, 120], ["CoV", "TEST", 121, 124], ["2 mass vaccination campaigns", "TREATMENT", 125, 153], ["our study", "TEST", 155, 164], ["these vaccines", "TREATMENT", 280, 294]]], ["Vaccination of risk groups with SARS-CoV-2 vaccines is possible with sufficient planning and infrastructure strengthening, but we anticipate risks to routine immunization and significant logistical challenges.", [["SARS-CoV-2", "ORGANISM", 32, 42], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36], ["CoV-2 vaccines", "TREATMENT", 37, 51], ["routine immunization", "TREATMENT", 150, 170], ["significant logistical challenges", "TREATMENT", 175, 208]]], ["Further, the development of products that are not programmatically suitable for use in developing country contexts will result in massive inequities, and concerted global efforts are urgently required to ensure that preventive interventions are made available to all who need them globally.", [["preventive interventions", "TREATMENT", 216, 240]]], ["We believe that resources must be mobilized urgently to ensure that infrastructures and training are in place to maximize the impact of future SARS-CoV-2 vaccines in the African Region and other developing country settings.(which was not certified by peer review).", [["SARS", "DISEASE", 143, 147], ["SARS-CoV-2", "ORGANISM", 143, 153], ["CoV-2 vaccines", "TREATMENT", 148, 162]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. .ACKNOWLEDGMENTS: The work of two authors (JR and JSH) was supported by the Bill & MelindaGates Foundation (OPP1177124).", [["CC", "CHEMICAL", 0, 2], ["OPP1177124", "CHEMICAL", 379, 389], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["The work of one author (AJD) was supported by National Institute of Allergy and Infectious Diseases at National Institutes of Health (T32AI007524).ACKNOWLEDGMENTS: The work of two authors (JR and JSH) was supported by the Bill & Melinda.", [["Infectious Diseases", "DISEASE", 80, 99], ["Infectious", "OBSERVATION_MODIFIER", 80, 90]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["The copyright holder", "TREATMENT", 407, 427], ["med", "ANATOMY", 99, 102], ["med", "ANATOMY", 311, 314]]], ["13.20147595 doi: medRxiv preprint 2 0 Table 2Age group Routine immunization b (doses)\u2265 Notes: a.", [["medRxiv preprint", "TREATMENT", 17, 33], ["Routine immunization b (doses)", "TREATMENT", 55, 85]]], ["Analysis assumes 90% coverage of target groups and a two-dose series for SARS-CoV-2 vaccines b.", [["SARS", "DISEASE", 73, 77], ["SARS-CoV-2", "ORGANISM", 73, 83], ["SARS-CoV", "SPECIES", 73, 81], ["Analysis", "TEST", 0, 8], ["a two-dose series", "TREATMENT", 51, 68], ["SARS", "PROBLEM", 73, 77], ["CoV-2 vaccines", "TREATMENT", 78, 92]]], ["We assumed that both HPV doses were delivered to girls at 9 years of age. c.", [["HPV", "ORGANISM", 21, 24], ["girls", "SPECIES", 49, 54], ["both HPV doses", "TREATMENT", 16, 30]]], ["Vaccinators = nurse density per capita (6.9 per 10,000) x country population (20,000,000) x %nurses that provide immunization services (43%).", [["immunization services", "TREATMENT", 113, 134]]], ["Adjustments account for 3% absenteeism (baseline) and an additional 8% absenteeism (during pandemic).", [["3% absenteeism", "PROBLEM", 24, 38], ["an additional 8% absenteeism", "PROBLEM", 54, 82]]], ["24, 25 .CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint Notes: a.", [["med", "ANATOMY", 106, 109]]], ["We developed a vaccine flow-down schematic ( Figure 1 ) to depict the routine vaccine doses maintained at each immunization system level by month and used it to calculate the total monthly vaccine doses and volumes stored throughout the immunization system.", [["a vaccine flow", "TEST", 13, 27], ["the routine vaccine doses", "TREATMENT", 66, 91], ["the total monthly vaccine doses", "TREATMENT", 171, 202], ["the immunization system", "TREATMENT", 233, 256]]], ["The range and quintiles of these values were calculated and then applied to the simulated African country.", [["range", "OBSERVATION_MODIFIER", 4, 9]]], ["We used the median percentage of national level stores to total stores (32.6%) and health facility stores to total stores (34.9%) from the same data set for our analyses.(which was not certified by peer review)c.", [["total stores", "TEST", 109, 121], ["our analyses", "TEST", 157, 169]]], ["Vaccine coverage, reserve stock, resupply, and wastage assumptions are in Supplemental Table 2 .(which was not certified by peer review).CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint Notes: a.", [["CC", "CHEMICAL", 137, 139], ["Vaccine coverage", "TREATMENT", 0, 16], ["CC", "TEST", 137, 139], ["reserve stock", "OBSERVATION", 18, 31], ["med", "ANATOMY", 235, 238]]], ["Each color represents a supply shipment as it moves through the immunization system. b.", [["a supply shipment", "TREATMENT", 22, 39], ["the immunization system", "TREATMENT", 60, 83], ["supply shipment", "OBSERVATION", 24, 39]]], ["Each box represents routine vaccine doses to immunize the target population in one month, except reserve stock boxes at the health facility level which represent routine vaccine doses for 0.5 months. c.", [["Each box", "TREATMENT", 0, 8], ["routine vaccine doses", "TREATMENT", 20, 41], ["routine vaccine doses", "TREATMENT", 162, 183]]], ["Vaccines stored at the national level use tertiary packaging volumes while vaccines stored at subnational levels use secondary packaging volumes. f.", [["f.", "SPECIES", 146, 148], ["Vaccines", "TREATMENT", 0, 8], ["tertiary packaging volumes", "TREATMENT", 42, 68], ["vaccines", "TREATMENT", 75, 83]]], ["This schematic does not depict stock rotations which would preferentially use vaccines received earlier.(which was not certified by peer review).", [["vaccines", "TREATMENT", 78, 86]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint c.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["For illustrative purposes only, the mass vaccination campaign is conducted during months 9 through 12.(which was not certified by peer review)d.", [["the mass vaccination campaign", "TREATMENT", 32, 61], ["mass", "OBSERVATION", 36, 40]]], ["HCWs target group removed because volume contribution was too small to depict in the figure.(which was not certified by peer review).", [["volume contribution", "PROBLEM", 34, 53], ["too small to depict", "OBSERVATION_MODIFIER", 58, 77]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.13.20147595 doi: medRxiv preprintFigure 3.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprintFigure", "TREATMENT", 322, 344], ["med", "ANATOMY", 99, 102]]], ["Monthly routine and SARS-CoV-2 campaign vaccine doses per vaccinator, by WHO Region estimated nurse densityNotes:Figure 3.", [["SARS-CoV", "SPECIES", 20, 28]]], ["Monthly routine and SARS-CoV-2 campaign vaccine doses per vaccinator, by WHO Region estimated nurse densitya.", [["SARS-CoV", "SPECIES", 20, 28]]], ["Data points represent the total monthly vaccines delivered divided by the total number of vaccinators in a country.", [["the total monthly vaccines", "TREATMENT", 22, 48]]], ["Vaccinators = nurse density per capita x country population (20,000,000) x %nurses that provide immunization services (43%). b.", [["immunization services", "TREATMENT", 96, 117]]], ["Routine immunization programs account for 3% absenteeism (baseline).", [["Routine immunization programs", "TREATMENT", 0, 29]]], ["SARS-CoV-2 vaccination programs account for 3% absenteeism (baseline) and an additional 8% absenteeism (during pandemic). d.", [["SARS", "DISEASE", 0, 4], ["CoV-2", "ORGANISM", 5, 10], ["SARS", "TEST", 0, 4], ["CoV-2 vaccination programs", "TREATMENT", 5, 31], ["3% absenteeism", "PROBLEM", 44, 58], ["an additional 8% absenteeism", "PROBLEM", 74, 102]]], ["HCWs target group removed because volume contribution was too small to depict in the figure.Figure 3.", [["volume contribution", "PROBLEM", 34, 53], ["too small to depict", "OBSERVATION_MODIFIER", 58, 77]]], ["Monthly routine and SARS-CoV-2 campaign vaccine doses per vaccinator, by WHO Region estimated nurse density.", [["SARS-CoV", "SPECIES", 20, 28], ["density", "OBSERVATION", 100, 107]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.13.20147595 doi: medRxiv preprintFigure 4.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprintFigure", "TREATMENT", 322, 344], ["med", "ANATOMY", 99, 102]]], ["Maximum national level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacityNotes:Figure 4.", [["SARS-CoV", "SPECIES", 43, 51], ["SARS", "TEST", 43, 47], ["CoV-2 vaccine volumes", "TREATMENT", 48, 69]]], ["Maximum national level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacity1.", [["SARS-CoV", "SPECIES", 43, 51], ["SARS", "TEST", 43, 47], ["CoV-2 vaccine volumes", "TREATMENT", 48, 69]]], ["Based on the maximum monthly national level vaccine storage volume (month 10) of the vaccine flowdown schematic (Figure 1 ).", [["the maximum monthly national level vaccine storage volume", "TREATMENT", 9, 66], ["the vaccine", "TREATMENT", 81, 92]]], ["HCWs target group removed because volume contribution was too small to depict in the figure.Figure 4.", [["volume contribution", "PROBLEM", 34, 53], ["too small to depict", "OBSERVATION_MODIFIER", 58, 77]]], ["Maximum national level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacity3.", [["SARS-CoV", "SPECIES", 43, 51], ["SARS", "TEST", 43, 47], ["CoV-2 vaccine volumes", "TREATMENT", 48, 69]]], ["Lower range capacity category excluded from figure .", [["Lower range capacity category", "PROBLEM", 0, 29]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.13.20147595 doi: medRxiv preprintFigure 5.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprintFigure", "TREATMENT", 322, 344], ["med", "ANATOMY", 99, 102]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacityNotes:Figure 5.", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacity1.", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72]]], ["Based on the maximum monthly subnational vaccine storage volume (month 11) of the vaccine flow-down schematic (Figure 1 ).", [["the vaccine flow", "TEST", 78, 94]]], ["HCWs target group removed because volume contribution was too small to depict in the figure.Figure 5.", [["volume contribution", "PROBLEM", 34, 53], ["too small to depict", "OBSERVATION_MODIFIER", 58, 77]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacity3.", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72]]], ["Lower range capacity category excluded from figure .", [["Lower range capacity category", "PROBLEM", 0, 29]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Figure 5.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacityThe copyright holder for this preprint this version posted August 14, 2020. .", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72], ["The copyright holder", "TREATMENT", 170, 190]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Figure 5.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacityThe copyright holder for this preprint this version posted August 14, 2020.", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72], ["The copyright holder", "TREATMENT", 170, 190]]], ["Chronic diseases (SARS-CoV-2) All risk groups (SARS-CoV-2)Figure 5.", [["Chronic diseases", "DISEASE", 0, 16], ["SARS", "DISEASE", 18, 22], ["Chronic diseases (SARS", "PROBLEM", 0, 22], ["diseases", "OBSERVATION", 8, 16]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacity.", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Figure 5.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacityThe copyright holder for this preprint this version posted August 14, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Figure 5.", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72], ["The copyright holder", "TREATMENT", 170, 190], ["med", "ANATOMY", 284, 287]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacityThe copyright holder for this preprint this version posted August 14, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Figure 5.", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72], ["The copyright holder", "TREATMENT", 170, 190], ["med", "ANATOMY", 284, 287]]], ["Maximum subnational level monthly routine and SARS-CoV-2 vaccine volumes as a proportion of total country capacity, by quartile of African Region country storage capacityThe copyright holder for this preprint this version posted August 14, 2020. . https://doi.org/10.1101/2020.08.13.20147595 doi: medRxiv preprint", [["SARS-CoV", "SPECIES", 46, 54], ["Maximum subnational level", "TEST", 0, 25], ["SARS", "TEST", 46, 50], ["CoV-2 vaccine volumes", "TREATMENT", 51, 72], ["The copyright holder", "TREATMENT", 170, 190], ["medRxiv", "TREATMENT", 297, 304]]]], "667cc2dbcca90dc76330786e59f3f27cf1ff2ee6": [["IntroductionCanine infectious respiratory disease (CIRD) is a highly contagious disease, especially in dogs housed in groups in rehoming centers and boarding or training kennels.", [["respiratory", "ANATOMY", 30, 41], ["infectious respiratory disease", "DISEASE", 19, 49], ["CIRD", "DISEASE", 51, 55], ["dogs", "ORGANISM", 103, 107], ["dogs", "SPECIES", 103, 107], ["IntroductionCanine infectious respiratory disease", "PROBLEM", 0, 49], ["a highly contagious disease", "PROBLEM", 60, 87], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["respiratory disease", "OBSERVATION", 30, 49], ["highly", "OBSERVATION_MODIFIER", 62, 68], ["contagious", "OBSERVATION_MODIFIER", 69, 79], ["disease", "OBSERVATION", 80, 87]]], ["Many dogs suffer from a mild cough and recover after a short time; however, in some cases a severe bronchopneumonia can develop (Appel and Binn, 1987) .", [["cough", "DISEASE", 29, 34], ["bronchopneumonia", "DISEASE", 99, 115], ["dogs", "ORGANISM", 5, 9], ["dogs", "SPECIES", 5, 9], ["a mild cough", "PROBLEM", 22, 34], ["a severe bronchopneumonia", "PROBLEM", 90, 115], ["mild", "OBSERVATION_MODIFIER", 24, 28], ["cough", "OBSERVATION", 29, 34], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["bronchopneumonia", "OBSERVATION", 99, 115]]], ["In addition to causing distress to the dogs, CIRD also delays rehoming at rescue centers and causes disruption of schedules in training kennels as well as incurring considerable treatment costs.IntroductionCIRD is considered to be a multifactorial disease because it usually occurs when dogs from different origins are brought together, a situation that exposes the dogs to a variety of different microorganisms as well as an unfamiliar environment.", [["CIRD", "DISEASE", 45, 49], ["IntroductionCIRD", "DISEASE", 194, 210], ["dogs", "ORGANISM", 39, 43], ["dogs", "ORGANISM", 287, 291], ["dogs", "ORGANISM", 366, 370], ["dogs", "SPECIES", 39, 43], ["dogs", "SPECIES", 287, 291], ["distress", "PROBLEM", 23, 31], ["training kennels", "TREATMENT", 127, 143], ["considerable treatment costs", "TREATMENT", 165, 193], ["a multifactorial disease", "PROBLEM", 231, 255], ["different microorganisms", "PROBLEM", 387, 411], ["distress", "OBSERVATION", 23, 31], ["considered to be", "UNCERTAINTY", 214, 230], ["multifactorial", "OBSERVATION_MODIFIER", 233, 247], ["disease", "OBSERVATION", 248, 255]]], ["The infectious agents that have been considered the major causative pathogens involved are canine parainfluenzavirus (CPIV) (Binn et al., 1967) , canine ade-novirus type 2 (CAV-2) (Ditchfield et al., 1962) , and the bacterium Bordetella bronchiseptica (Bemis et al., 1977a; Keil et al., 1998) .", [["Bordetella bronchiseptica", "DISEASE", 226, 251], ["canine parainfluenzavirus", "ORGANISM", 91, 116], ["canine ade-novirus type 2", "ORGANISM", 146, 171], ["CAV-2", "CELL", 173, 178], ["Bordetella bronchiseptica", "ORGANISM", 226, 251], ["canine", "SPECIES", 91, 97], ["canine", "SPECIES", 146, 152], ["Bordetella bronchiseptica", "SPECIES", 226, 251], ["canine", "SPECIES", 91, 97], ["CPIV", "SPECIES", 118, 122], ["canine ade-novirus type 2 (CAV-2)", "SPECIES", 146, 179], ["Bordetella bronchiseptica", "SPECIES", 226, 251], ["The infectious agents", "TREATMENT", 0, 21], ["the major causative pathogens", "PROBLEM", 48, 77], ["the bacterium Bordetella bronchiseptica", "PROBLEM", 212, 251], ["infectious", "OBSERVATION", 4, 14]]], ["Also, canine herpesvirus, human reovirus, and mycoplasma species have been isolated from dogs with symptoms of CIRD (Karpas et al., 1968; Lou and Wenner, 1963; Randolph et al., 1993) .", [["CIRD", "DISEASE", 111, 115], ["canine herpesvirus", "ORGANISM", 6, 24], ["human", "ORGANISM", 26, 31], ["reovirus", "ORGANISM", 32, 40], ["mycoplasma species", "ORGANISM", 46, 64], ["dogs", "ORGANISM", 89, 93], ["canine herpesvirus", "SPECIES", 6, 24], ["human", "SPECIES", 26, 31], ["reovirus", "SPECIES", 32, 40], ["dogs", "SPECIES", 89, 93], ["canine herpesvirus", "SPECIES", 6, 24], ["human reovirus", "SPECIES", 26, 40], ["canine herpesvirus", "PROBLEM", 6, 24], ["human reovirus", "PROBLEM", 26, 40], ["mycoplasma species", "PROBLEM", 46, 64], ["symptoms", "PROBLEM", 99, 107], ["canine herpesvirus", "OBSERVATION", 6, 24], ["human reovirus", "OBSERVATION", 26, 40], ["mycoplasma species", "OBSERVATION", 46, 64]]], ["Experimental infection of dogs with single infectious agents has been shown to cause only mild respiratory symptoms but failed to reproduce the severe disease that can be seen in natural outbreaks, supporting the theory that the pathogenesis of CIRD is multifactorial (Appel and Percy, 1970; Karpas et al., 1968; Bemis et al., 1977b) .IntroductionVaccines are available against some of the infectious agents that have been found to be associated with this disease, namely, Bordetella bronchiseptica as well as CPIV and CAV-2.", [["respiratory", "ANATOMY", 95, 106], ["infection", "DISEASE", 13, 22], ["respiratory symptoms", "DISEASE", 95, 115], ["CIRD", "DISEASE", 245, 249], ["Bordetella bronchiseptica", "DISEASE", 473, 498], ["dogs", "ORGANISM", 26, 30], ["Bordetella bronchiseptica", "ORGANISM", 473, 498], ["CAV-2", "GENE_OR_GENE_PRODUCT", 519, 524], ["dogs", "SPECIES", 26, 30], ["Bordetella bronchiseptica", "SPECIES", 473, 498], ["Bordetella bronchiseptica", "SPECIES", 473, 498], ["CPIV", "SPECIES", 510, 514], ["Experimental infection of dogs", "PROBLEM", 0, 30], ["single infectious agents", "TREATMENT", 36, 60], ["mild respiratory symptoms", "PROBLEM", 90, 115], ["the severe disease", "PROBLEM", 140, 158], ["IntroductionVaccines", "TREATMENT", 335, 355], ["the infectious agents", "TREATMENT", 386, 407], ["this disease", "PROBLEM", 451, 463], ["Bordetella bronchiseptica", "PROBLEM", 473, 498], ["infection", "OBSERVATION", 13, 22], ["mild", "OBSERVATION_MODIFIER", 90, 94], ["respiratory", "ANATOMY", 95, 106], ["symptoms", "OBSERVATION", 107, 115], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["disease", "OBSERVATION", 151, 158], ["CAV", "OBSERVATION", 519, 522]]], ["Despite the use of these vaccines, CIRD is still prevalent in kennels worldwide, suggesting that additional viruses or bacteria may be involved in the disease.IntroductionMembers of the family Coronaviridae are enveloped viruses, 80 -160 nm in diameter, containing a linear positive-stranded RNA genome.", [["CIRD", "DISEASE", 35, 39], ["kennels", "DISEASE", 62, 69], ["kennels", "CANCER", 62, 69], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 193, 206], ["linear positive-stranded RNA genome", "DNA", 267, 302], ["these vaccines", "TREATMENT", 19, 33], ["CIRD", "TREATMENT", 35, 39], ["additional viruses", "PROBLEM", 97, 115], ["bacteria", "PROBLEM", 119, 127], ["the disease", "PROBLEM", 147, 158], ["a linear positive-stranded RNA genome", "PROBLEM", 265, 302], ["viruses", "OBSERVATION", 108, 115], ["disease", "OBSERVATION", 151, 158], ["linear", "OBSERVATION_MODIFIER", 267, 273], ["positive", "OBSERVATION", 274, 282], ["stranded RNA genome", "OBSERVATION", 283, 302]]], ["The structural proteins of coronaviruses are the spike glycoprotein, the membrane glycoprotein, and the nucleocapsid protein.", [["membrane", "ANATOMY", 73, 81], ["coronaviruses", "ORGANISM", 27, 40], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["structural proteins", "PROTEIN", 4, 23], ["spike glycoprotein", "PROTEIN", 49, 67], ["membrane glycoprotein", "PROTEIN", 73, 94], ["nucleocapsid protein", "PROTEIN", 104, 124], ["coronaviruses", "PROBLEM", 27, 40], ["the spike glycoprotein", "PROBLEM", 45, 67], ["the membrane glycoprotein", "TREATMENT", 69, 94], ["the nucleocapsid protein", "PROBLEM", 100, 124], ["coronaviruses", "OBSERVATION", 27, 40]]], ["The hemagglutinin/ esterase glycoprotein is found only on the surface of group 2 coronaviruses (e.g., bovine coronavirus and murine hepatitis virus) (Spaan et al., 1988) .IntroductionThe polymerase gene of coronaviruses is known to be highly conserved.", [["surface", "ANATOMY", 62, 69], ["bovine coronavirus and murine hepatitis virus", "DISEASE", 102, 147], ["hemagglutinin/ esterase glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 40], ["surface", "CELLULAR_COMPONENT", 62, 69], ["2 coronaviruses", "ORGANISM", 79, 94], ["bovine coronavirus", "ORGANISM", 102, 120], ["murine hepatitis virus", "ORGANISM", 125, 147], ["coronaviruses", "ORGANISM", 206, 219], ["hemagglutinin/ esterase glycoprotein", "PROTEIN", 4, 40], ["polymerase gene", "DNA", 187, 202], ["bovine", "SPECIES", 102, 108], ["coronavirus", "SPECIES", 109, 120], ["murine", "SPECIES", 125, 131], ["hepatitis virus", "SPECIES", 132, 147], ["bovine coronavirus", "SPECIES", 102, 120], ["murine hepatitis virus", "SPECIES", 125, 147], ["The hemagglutinin/ esterase glycoprotein", "TREATMENT", 0, 40], ["bovine coronavirus and murine hepatitis virus", "PROBLEM", 102, 147], ["coronaviruses", "PROBLEM", 206, 219], ["coronaviruses", "OBSERVATION", 206, 219]]], ["It has therefore previously been used for phylogenetic analysis of this virus family (Stephensen et al., 1999) .", [["phylogenetic analysis", "TEST", 42, 63]]], ["A possible role of Coronaviridae in the pathogenesis of CIRD was investigated in this study because members of this family are known to cause respiratory disease in humans as well as cattle, swine, and poultry (M\u00e4kel\u00e4 et al., 1998; Pensaert et al., 1986; Ignjatovic and Sapats, 2000) .", [["respiratory", "ANATOMY", 142, 153], ["Coronaviridae", "CHEMICAL", 19, 32], ["CIRD", "DISEASE", 56, 60], ["respiratory disease", "DISEASE", 142, 161], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 19, 32], ["CIRD", "CANCER", 56, 60], ["humans", "ORGANISM", 165, 171], ["cattle", "ORGANISM", 183, 189], ["humans", "SPECIES", 165, 171], ["cattle", "SPECIES", 183, 189], ["swine", "SPECIES", 191, 196], ["humans", "SPECIES", 165, 171], ["cattle", "SPECIES", 183, 189], ["swine", "SPECIES", 191, 196], ["Coronaviridae", "TREATMENT", 19, 32], ["this study", "TEST", 81, 91], ["respiratory disease in humans", "PROBLEM", 142, 171], ["possible", "UNCERTAINTY", 2, 10], ["disease", "OBSERVATION", 154, 161]]], ["In cattle, bovine respiratory coronavirus is associated with shipping fever, a multifactorial respiratory disease similar to CIRD (Storz et al., 2000) .", [["respiratory", "ANATOMY", 94, 105], ["respiratory coronavirus", "DISEASE", 18, 41], ["shipping fever", "DISEASE", 61, 75], ["respiratory disease", "DISEASE", 94, 113], ["CIRD", "DISEASE", 125, 129], ["cattle", "ORGANISM", 3, 9], ["bovine", "ORGANISM", 11, 17], ["respiratory coronavirus", "ORGANISM", 18, 41], ["cattle", "SPECIES", 3, 9], ["bovine", "SPECIES", 11, 17], ["respiratory coronavirus", "SPECIES", 18, 41], ["cattle", "SPECIES", 3, 9], ["bovine respiratory coronavirus", "SPECIES", 11, 41], ["bovine respiratory coronavirus", "PROBLEM", 11, 41], ["shipping fever", "PROBLEM", 61, 75], ["a multifactorial respiratory disease", "PROBLEM", 77, 113], ["respiratory coronavirus", "OBSERVATION", 18, 41], ["multifactorial", "OBSERVATION_MODIFIER", 79, 93], ["respiratory disease", "OBSERVATION", 94, 113]]], ["Canine coronaviruses are reported to cause acute diarrhea mainly in young dogs (Tennant et al., 1993) .", [["Canine coronaviruses", "DISEASE", 0, 20], ["diarrhea", "DISEASE", 49, 57], ["Canine coronaviruses", "ORGANISM", 0, 20], ["dogs", "ORGANISM", 74, 78], ["Canine", "SPECIES", 0, 6], ["dogs", "SPECIES", 74, 78], ["Canine coronaviruses", "SPECIES", 0, 20], ["Canine coronaviruses", "PROBLEM", 0, 20], ["acute diarrhea", "PROBLEM", 43, 57], ["coronaviruses", "OBSERVATION", 7, 20], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["diarrhea", "OBSERVATION", 49, 57]]], ["However, one study reports the detection of canine coronavirus in dogs with respiratory disease and describes the isolation of the virus from one lung sample and three intestinal samples (Binn et al., 1979) .IntroductionThis investigation sought to detect coronaviruses associated with CIRD in a large kenneled dog population with a history of endemic respiratory disease, using virus culture and PCR techniques as well as serology on paired serum samples.PCR using consensus primers for the coronavirus RNA polymerase geneUsing the primers Conscoro5 and Conscoro6, we analyzed the cDNA obtained from 40 tracheal samples by RT-PCR.", [["respiratory", "ANATOMY", 76, 87], ["lung sample", "ANATOMY", 146, 157], ["intestinal samples", "ANATOMY", 168, 186], ["respiratory", "ANATOMY", 352, 363], ["serum samples", "ANATOMY", 442, 455], ["tracheal samples", "ANATOMY", 604, 620], ["canine coronavirus", "DISEASE", 44, 62], ["respiratory disease", "DISEASE", 76, 95], ["CIRD", "DISEASE", 286, 290], ["respiratory disease", "DISEASE", 352, 371], ["canine coronavirus", "ORGANISM", 44, 62], ["dogs", "ORGANISM", 66, 70], ["lung", "ORGAN", 146, 150], ["intestinal samples", "CANCER", 168, 186], ["coronaviruses", "ORGANISM", 256, 269], ["dog", "ORGANISM", 311, 314], ["serum samples", "ORGANISM_SUBSTANCE", 442, 455], ["coronavirus", "ORGANISM", 492, 503], ["Conscoro5", "GENE_OR_GENE_PRODUCT", 541, 550], ["Conscoro6", "GENE_OR_GENE_PRODUCT", 555, 564], ["tracheal samples", "TISSUE", 604, 620], ["consensus primers", "DNA", 466, 483], ["coronavirus RNA polymerase geneUsing the primers Conscoro5", "DNA", 492, 550], ["Conscoro6", "DNA", 555, 564], ["cDNA", "DNA", 582, 586], ["canine coronavirus", "SPECIES", 44, 62], ["dogs", "SPECIES", 66, 70], ["dog", "SPECIES", 311, 314], ["coronavirus", "SPECIES", 492, 503], ["canine coronavirus", "SPECIES", 44, 62], ["coronavirus", "SPECIES", 492, 503], ["one study", "TEST", 9, 18], ["canine coronavirus in dogs", "PROBLEM", 44, 70], ["respiratory disease", "PROBLEM", 76, 95], ["the virus", "PROBLEM", 127, 136], ["This investigation", "TEST", 220, 238], ["coronaviruses", "PROBLEM", 256, 269], ["endemic respiratory disease", "PROBLEM", 344, 371], ["virus culture", "TEST", 379, 392], ["PCR techniques", "TEST", 397, 411], ["serology on paired serum samples", "TEST", 423, 455], ["PCR", "TEST", 456, 459], ["consensus primers", "TREATMENT", 466, 483], ["the coronavirus RNA polymerase", "TREATMENT", 488, 518], ["the cDNA", "TEST", 578, 586], ["PCR", "TEST", 627, 630], ["canine coronavirus", "OBSERVATION", 44, 62], ["respiratory disease", "OBSERVATION", 76, 95], ["lung", "ANATOMY", 146, 150], ["intestinal", "ANATOMY", 168, 178], ["large", "OBSERVATION_MODIFIER", 296, 301], ["endemic", "OBSERVATION_MODIFIER", 344, 351], ["respiratory disease", "OBSERVATION", 352, 371], ["tracheal", "ANATOMY", 604, 612]]], ["Of these, 7 were found to be positive by PCR and subsequent hybridization (17.5%).", [["PCR", "TEST", 41, 44], ["subsequent hybridization", "TEST", 49, 73], ["positive", "OBSERVATION", 29, 37]]], ["The PCR products were cloned and sequenced and the sequence data were compared to available viral sequences using the FASTA similarity search program (Pearson, 1990) .PCR using consensus primers for the coronavirus RNA polymerase geneComparison of the coronavirus cDNA polymerase sequence obtained from four of the canine tracheal samples to other coronavirus sequences revealed that they were most similar to sequence data from bovine coronavirus (GenBank Accession No.", [["tracheal samples", "ANATOMY", 322, 338], ["coronavirus", "ORGANISM", 203, 214], ["coronavirus", "ORGANISM", 252, 263], ["canine", "ORGANISM", 315, 321], ["tracheal samples", "CANCER", 322, 338], ["coronavirus", "ORGANISM", 348, 359], ["bovine coronavirus", "ORGANISM", 429, 447], ["PCR products", "DNA", 4, 16], ["viral sequences", "DNA", 92, 107], ["consensus primers", "DNA", 177, 194], ["coronavirus RNA polymerase", "PROTEIN", 203, 229], ["coronavirus cDNA polymerase sequence", "DNA", 252, 288], ["coronavirus sequences", "DNA", 348, 369], ["coronavirus", "SPECIES", 203, 214], ["coronavirus", "SPECIES", 252, 263], ["canine", "SPECIES", 315, 321], ["bovine", "SPECIES", 429, 435], ["coronavirus", "SPECIES", 436, 447], ["coronavirus", "SPECIES", 203, 214], ["canine", "SPECIES", 315, 321], ["bovine coronavirus", "SPECIES", 429, 447], ["The PCR products", "TREATMENT", 0, 16], ["the sequence data", "TEST", 47, 64], ["PCR", "TEST", 167, 170], ["consensus primers", "TREATMENT", 177, 194], ["the coronavirus RNA polymerase", "TEST", 199, 229], ["the coronavirus cDNA polymerase sequence", "TEST", 248, 288], ["the canine tracheal samples", "TEST", 311, 338], ["other coronavirus sequences", "TEST", 342, 369], ["sequence data", "TEST", 410, 423], ["bovine coronavirus", "PROBLEM", 429, 447], ["tracheal", "ANATOMY", 322, 330]]], ["AF 220295) and human coronavirus strain OC 43 (GenBank Accession No.", [["AF 220295", "CHEMICAL", 0, 9], ["OC", "CHEMICAL", 40, 42], ["human", "ORGANISM", 15, 20], ["coronavirus strain OC 43", "ORGANISM", 21, 45], ["human", "SPECIES", 15, 20], ["coronavirus", "SPECIES", 21, 32], ["human coronavirus strain OC 43", "SPECIES", 15, 45], ["AF", "PROBLEM", 0, 2], ["human coronavirus strain OC", "PROBLEM", 15, 42]]], ["AF 124989).", [["AF 124989", "CHEMICAL", 0, 9], ["AF 124989", "CHEMICAL", 0, 9]]], ["The identity in the analyzed 251-bp sequence was 98.8% for the bovine and 98.4% for the human coronavirus polymerase gene, whereas it was only 68.53% for canine coronavirus (strain 1-71).PCR using consensus primers for the coronavirus RNA polymerase geneAn alignment of the novel sequence with the corresponding sequences of 11 coronaviruses and phylogenetic analysis using the maximum parsimony method resulted in the consensus tree shown in Fig. 1 .", [["canine coronavirus", "DISEASE", 154, 172], ["bovine", "ORGANISM", 63, 69], ["human", "ORGANISM", 88, 93], ["coronavirus polymerase", "GENE_OR_GENE_PRODUCT", 94, 116], ["canine coronavirus", "ORGANISM", 154, 172], ["251-bp sequence", "DNA", 29, 44], ["human coronavirus polymerase gene", "DNA", 88, 121], ["consensus primers", "DNA", 197, 214], ["bovine", "SPECIES", 63, 69], ["human", "SPECIES", 88, 93], ["coronavirus", "SPECIES", 94, 105], ["canine coronavirus", "SPECIES", 154, 172], ["human coronavirus", "SPECIES", 88, 105], ["canine coronavirus", "SPECIES", 154, 172], ["coronavirus", "SPECIES", 223, 234], ["bp sequence", "TEST", 33, 44], ["the bovine", "TEST", 59, 69], ["the human coronavirus polymerase gene", "TEST", 84, 121], ["canine coronavirus", "PROBLEM", 154, 172], ["PCR", "TEST", 187, 190], ["consensus primers", "TEST", 197, 214], ["the coronavirus RNA polymerase", "TEST", 219, 249], ["the corresponding sequences", "TEST", 294, 321], ["phylogenetic analysis", "TEST", 346, 367], ["the maximum parsimony method", "TEST", 374, 402]]], ["The cDNA sequence obtained from a tracheal sample (T101) was found on a common branch with bovine coronavirus, human coronavirus-OC43, and hemagglutinating encephalomyelitis virus.PCR using consensus primers for the coronavirus RNA polymerase geneThe virus was provisionally called canine respiratory coronavirus (CRCV).Sequencing of the spike geneFor further analysis of the RNA sequence of CRCV, an alignment of the RNA for the spike gene of the bovine coronavirus LY 138 strain and the human coronavirus OC43 strain was performed.", [["tracheal sample", "ANATOMY", 34, 49], ["T101", "ANATOMY", 51, 55], ["hemagglutinating encephalomyelitis", "DISEASE", 139, 173], ["canine respiratory coronavirus", "DISEASE", 282, 312], ["LY 138", "CHEMICAL", 467, 473], ["tracheal sample", "CANCER", 34, 49], ["T101", "CANCER", 51, 55], ["bovine", "ORGANISM", 91, 97], ["coronavirus", "ORGANISM", 98, 109], ["human", "ORGANISM", 111, 116], ["coronavirus-OC43", "ORGANISM", 117, 133], ["hemagglutinating encephalomyelitis virus", "ORGANISM", 139, 179], ["canine respiratory coronavirus", "ORGANISM", 282, 312], ["CRCV", "CANCER", 314, 318], ["CRCV", "CANCER", 392, 396], ["bovine", "ORGANISM", 448, 454], ["coronavirus LY 138 strain", "ORGANISM", 455, 480], ["human", "ORGANISM", 489, 494], ["coronavirus OC43", "ORGANISM", 495, 511], ["cDNA sequence", "DNA", 4, 17], ["consensus primers", "DNA", 190, 207], ["coronavirus RNA polymerase gene", "DNA", 216, 247], ["spike gene", "DNA", 338, 348], ["RNA sequence", "DNA", 376, 388], ["CRCV", "DNA", 392, 396], ["spike gene", "DNA", 430, 440], ["bovine", "SPECIES", 91, 97], ["coronavirus", "SPECIES", 98, 109], ["human", "SPECIES", 111, 116], ["coronavirus", "SPECIES", 117, 128], ["hemagglutinating encephalomyelitis virus", "SPECIES", 139, 179], ["coronavirus", "SPECIES", 216, 227], ["canine respiratory coronavirus", "SPECIES", 282, 312], ["bovine", "SPECIES", 448, 454], ["coronavirus", "SPECIES", 455, 466], ["human", "SPECIES", 489, 494], ["coronavirus", "SPECIES", 495, 506], ["bovine coronavirus", "SPECIES", 91, 109], ["human coronavirus-OC43", "SPECIES", 111, 133], ["hemagglutinating encephalomyelitis virus", "SPECIES", 139, 179], ["canine respiratory coronavirus", "SPECIES", 282, 312], ["CRCV", "SPECIES", 314, 318], ["CRCV", "SPECIES", 392, 396], ["bovine coronavirus LY 138", "SPECIES", 448, 473], ["human coronavirus", "SPECIES", 489, 506], ["The cDNA sequence", "TEST", 0, 17], ["a tracheal sample", "TEST", 32, 49], ["bovine coronavirus", "PROBLEM", 91, 109], ["human coronavirus", "TEST", 111, 128], ["OC43", "PROBLEM", 129, 133], ["hemagglutinating encephalomyelitis virus", "PROBLEM", 139, 179], ["PCR", "TEST", 180, 183], ["consensus primers", "TREATMENT", 190, 207], ["the coronavirus RNA polymerase gene", "TREATMENT", 212, 247], ["The virus", "PROBLEM", 247, 256], ["further analysis", "TEST", 352, 368], ["the RNA sequence", "TEST", 372, 388], ["CRCV", "TEST", 392, 396], ["the bovine coronavirus LY", "TEST", 444, 469], ["the human coronavirus OC43 strain", "TEST", 485, 518], ["tracheal", "ANATOMY", 34, 42], ["common branch", "ANATOMY", 72, 85], ["bovine coronavirus", "OBSERVATION", 91, 109], ["hemagglutinating encephalomyelitis virus", "OBSERVATION", 139, 179], ["virus", "OBSERVATION", 251, 256], ["respiratory coronavirus", "OBSERVATION", 289, 312]]], ["Consensus regions were chosen for the selection of four primer pairs amplifying the complete spike gene in four overlapping fragments; the primer sequences are shown in Table 1 .", [["fragments", "ANATOMY", 124, 133], ["primer pairs", "DNA", 56, 68], ["spike gene", "DNA", 93, 103], ["primer sequences", "DNA", 139, 155], ["four primer pairs", "PROBLEM", 51, 68], ["the complete spike gene in four overlapping fragments", "PROBLEM", 80, 133], ["the primer sequences", "TEST", 135, 155], ["overlapping", "OBSERVATION_MODIFIER", 112, 123], ["fragments", "OBSERVATION", 124, 133]]], ["The cDNA obtained from tracheal sample T101 was used to perform RT-PCR and subsequent sequencing of the obtained spike fragments.", [["tracheal sample", "ANATOMY", 23, 38], ["fragments", "ANATOMY", 119, 128], ["cDNA", "DNA", 4, 8], ["spike fragments", "DNA", 113, 128], ["The cDNA", "TEST", 0, 8], ["tracheal sample T101", "TEST", 23, 43], ["RT-PCR", "TEST", 64, 70], ["subsequent sequencing", "TEST", 75, 96], ["the obtained spike fragments", "PROBLEM", 100, 128], ["tracheal", "ANATOMY", 23, 31]]], ["The analysis of the sequencing data showed that the spike gene of CRCV is 4092 nucleotides long, corresponding to 1093 amino acids.", [["amino acids", "CHEMICAL", 119, 130], ["nucleotides", "CHEMICAL", 79, 90], ["amino acids", "CHEMICAL", 119, 130], ["CRCV", "GENE_OR_GENE_PRODUCT", 66, 70], ["amino acids", "AMINO_ACID", 119, 130], ["spike gene", "DNA", 52, 62], ["CRCV", "DNA", 66, 70], ["The analysis", "TEST", 0, 12], ["the sequencing data", "TEST", 16, 35], ["the spike gene of CRCV", "PROBLEM", 48, 70], ["amino acids", "TEST", 119, 130]]], ["It was determined that the cDNA sequence obtained from tracheal sample T101 had a 97.312% nucleotide identity with the spike gene of bovine coronavirus strain LY138 (GenBank Accession No.", [["tracheal sample", "ANATOMY", 55, 70], ["nucleotide", "CHEMICAL", 90, 100], ["tracheal sample T101", "CANCER", 55, 75], ["bovine", "ORGANISM", 133, 139], ["coronavirus strain", "ORGANISM", 140, 158], ["LY138", "ORGANISM", 159, 164], ["cDNA sequence", "DNA", 27, 40], ["spike gene", "DNA", 119, 129], ["bovine", "SPECIES", 133, 139], ["coronavirus", "SPECIES", 140, 151], ["bovine coronavirus", "SPECIES", 133, 151], ["the cDNA sequence", "TEST", 23, 40], ["tracheal sample", "TEST", 55, 70], ["nucleotide identity", "TEST", 90, 109], ["bovine coronavirus strain", "PROBLEM", 133, 158], ["tracheal", "ANATOMY", 55, 63], ["bovine coronavirus", "OBSERVATION", 133, 151]]], ["AF058942) and 96.921% identity with that of human coronavirus strain OC43 (GenBank Accession No.", [["AF058942", "CHEMICAL", 0, 8], ["human", "ORGANISM", 44, 49], ["coronavirus strain OC43", "ORGANISM", 50, 73], ["human", "SPECIES", 44, 49], ["coronavirus", "SPECIES", 50, 61], ["human coronavirus", "SPECIES", 44, 61], ["human coronavirus strain OC43", "PROBLEM", 44, 73]]], ["Z32768) in an overlap of 4092 nucleotides.", [["Z32768", "CHEMICAL", 0, 6], ["Z32768", "CHEMICAL", 0, 6], ["nucleotides", "CHEMICAL", 30, 41]]], ["When comparing the amino acid sequence obtained by translation of the cDNA sequence from T101 to the amino acid sequence of the BCV, HCV-OC43, and canine enteric coronavirus spike proteins the identities were 96, 95.2, and 21.2%.PCR using primers for the hemagglutinin/esterase geneBovine coronavirus and other group 2 coronaviruses contain an additional structural protein, the hemagglutinin/ esterase (HE).", [["amino acid", "CHEMICAL", 19, 29], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "CHEMICAL", 19, 29], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "AMINO_ACID", 19, 29], ["amino acid", "AMINO_ACID", 101, 111], ["BCV", "GENE_OR_GENE_PRODUCT", 128, 131], ["HCV-OC43", "ORGANISM", 133, 141], ["canine enteric coronavirus", "ORGANISM", 147, 173], ["esterase geneBovine coronavirus", "ORGANISM", 269, 300], ["coronaviruses", "ORGANISM", 319, 332], ["esterase", "GENE_OR_GENE_PRODUCT", 394, 402], ["cDNA sequence", "DNA", 70, 83], ["T101", "DNA", 89, 93], ["amino acid sequence", "PROTEIN", 101, 120], ["OC43", "PROTEIN", 137, 141], ["canine enteric coronavirus spike proteins", "PROTEIN", 147, 188], ["hemagglutinin", "PROTEIN", 255, 268], ["esterase", "PROTEIN", 269, 277], ["structural protein", "PROTEIN", 355, 373], ["hemagglutinin", "PROTEIN", 379, 392], ["esterase", "PROTEIN", 394, 402], ["HE", "PROTEIN", 404, 406], ["canine enteric coronavirus", "SPECIES", 147, 173], ["geneBovine coronavirus", "SPECIES", 278, 300], ["group 2 coronaviruses", "SPECIES", 311, 332], ["HCV-OC43", "SPECIES", 133, 141], ["canine enteric coronavirus", "SPECIES", 147, 173], ["geneBovine coronavirus", "SPECIES", 278, 300], ["the amino acid sequence", "TEST", 15, 38], ["the cDNA sequence", "TEST", 66, 83], ["the amino acid sequence", "TEST", 97, 120], ["the BCV", "TEST", 124, 131], ["HCV", "TEST", 133, 136], ["OC43", "TEST", 137, 141], ["canine enteric coronavirus spike proteins", "TEST", 147, 188], ["the identities", "TEST", 189, 203], ["PCR", "TEST", 229, 232], ["primers", "TEST", 239, 246], ["the hemagglutinin/esterase", "TEST", 251, 277], ["coronavirus", "PROBLEM", 289, 300], ["other group 2 coronaviruses", "PROBLEM", 305, 332], ["the hemagglutinin/ esterase", "TEST", 375, 402], ["BCV", "ANATOMY", 128, 131], ["coronavirus spike", "OBSERVATION", 162, 179]]], ["Because of the high similarity of CRCV with BCV, we analyzed the presence of a HE gene in CRCV.PCR using primers for the hemagglutinin/esterase geneAn alignment of the HE gene sequences of BCV and HCV OC43 was used to design the primers HE1 and HE2 (Table 2 ).", [["CRCV", "ANATOMY", 90, 94], ["CRCV", "CANCER", 34, 38], ["HE", "GENE_OR_GENE_PRODUCT", 79, 81], ["CRCV", "CANCER", 90, 94], ["esterase geneAn", "GENE_OR_GENE_PRODUCT", 135, 150], ["HE", "GENE_OR_GENE_PRODUCT", 168, 170], ["BCV", "ORGANISM", 189, 192], ["HCV", "ORGANISM", 197, 200], ["OC43", "ORGANISM", 201, 205], ["HE gene", "DNA", 79, 86], ["hemagglutinin/esterase geneAn alignment", "DNA", 121, 160], ["HE gene sequences", "DNA", 168, 185], ["primers HE1", "DNA", 229, 240], ["HE2", "DNA", 245, 248], ["CRCV", "SPECIES", 34, 38], ["BCV", "SPECIES", 44, 47], ["CRCV", "SPECIES", 90, 94], ["BCV", "SPECIES", 189, 192], ["HCV", "SPECIES", 197, 200], ["BCV", "TREATMENT", 44, 47], ["PCR", "TEST", 95, 98], ["primers", "TREATMENT", 105, 112], ["the hemagglutinin/esterase", "TEST", 117, 143], ["BCV", "TEST", 189, 192], ["HCV OC43", "PROBLEM", 197, 205], ["BCV", "ANATOMY", 189, 192]]], ["Four tracheal samples that had previously been identified as positive for coronavirus RNA by RT-PCR with primers for the spike gene were tested by RT-PCR with the primer set for the HE gene.", [["tracheal samples", "ANATOMY", 5, 21], ["tracheal samples", "CANCER", 5, 21], ["coronavirus", "ORGANISM", 74, 85], ["HE", "GENE_OR_GENE_PRODUCT", 182, 184], ["coronavirus RNA", "RNA", 74, 89], ["spike gene", "DNA", 121, 131], ["HE gene", "DNA", 182, 189], ["coronavirus", "SPECIES", 74, 85], ["Four tracheal samples", "TEST", 0, 21], ["coronavirus RNA", "PROBLEM", 74, 89], ["PCR", "TEST", 96, 99], ["primers", "TREATMENT", 105, 112], ["the spike gene", "PROBLEM", 117, 131], ["PCR", "TEST", 150, 153], ["the primer", "TEST", 159, 169], ["tracheal", "ANATOMY", 5, 13]]], ["All four samples showed a PCR band of the expected size (Fig. 2) .Detection of CRCV in tissue samples by RT-PCR and association of PCR-positive samples with respiratory signsUsing a nested set of primers for the spike gene (Sp1-2 and Sp3-4), tracheal and lung samples from 119 dogs were analyzed for CRCV.", [["samples", "ANATOMY", 9, 16], ["tissue samples", "ANATOMY", 87, 101], ["samples", "ANATOMY", 144, 151], ["respiratory", "ANATOMY", 157, 168], ["tracheal", "ANATOMY", 242, 250], ["lung samples", "ANATOMY", 255, 267], ["respiratory signs", "DISEASE", 157, 174], ["CRCV", "CANCER", 79, 83], ["tissue samples", "TISSUE", 87, 101], ["Sp1-2", "GENE_OR_GENE_PRODUCT", 224, 229], ["Sp3-4", "GENE_OR_GENE_PRODUCT", 234, 239], ["tracheal", "MULTI-TISSUE_STRUCTURE", 242, 250], ["lung samples", "CANCER", 255, 267], ["dogs", "ORGANISM", 277, 281], ["CRCV", "DNA", 79, 83], ["spike gene", "DNA", 212, 222], ["Sp1", "DNA", 224, 227], ["Sp3-4", "DNA", 234, 239], ["dogs", "SPECIES", 277, 281], ["CRCV", "SPECIES", 79, 83], ["CRCV", "SPECIES", 300, 304], ["All four samples", "TEST", 0, 16], ["a PCR band", "TEST", 24, 34], ["CRCV in tissue samples", "PROBLEM", 79, 101], ["RT", "TEST", 105, 107], ["PCR", "TEST", 108, 111], ["PCR", "TEST", 131, 134], ["positive samples", "PROBLEM", 135, 151], ["respiratory signs", "TEST", 157, 174], ["a nested set of primers", "TREATMENT", 180, 203], ["the spike gene", "TEST", 208, 222], ["Sp1", "TEST", 224, 227], ["Sp3", "TEST", 234, 237], ["tracheal and lung samples", "TEST", 242, 267], ["CRCV", "TEST", 300, 304], ["size", "OBSERVATION_MODIFIER", 51, 55], ["Fig", "OBSERVATION_MODIFIER", 57, 60], ["tracheal", "ANATOMY", 242, 250], ["lung", "ANATOMY", 255, 259]]], ["Of these, 42 were from dogs with no respiratory signs (grade 1), 18 dogs had shown mild respiratory signs (grade 2), 46 had shown moderate (grade 3), and 13 severe respiratory signs (grades 4 and 5).", [["respiratory", "ANATOMY", 36, 47], ["respiratory", "ANATOMY", 88, 99], ["respiratory", "ANATOMY", 164, 175], ["respiratory signs", "DISEASE", 36, 53], ["respiratory signs", "DISEASE", 88, 105], ["respiratory signs", "DISEASE", 164, 181], ["dogs", "ORGANISM", 23, 27], ["dogs", "ORGANISM", 68, 72], ["dogs", "SPECIES", 23, 27], ["dogs", "SPECIES", 68, 72], ["respiratory signs", "PROBLEM", 36, 53], ["mild respiratory signs", "PROBLEM", 83, 105], ["moderate (grade 3), and 13 severe respiratory signs", "PROBLEM", 130, 181], ["no", "UNCERTAINTY", 33, 35], ["respiratory", "ANATOMY", 36, 47], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["respiratory signs", "OBSERVATION", 88, 105], ["moderate", "OBSERVATION_MODIFIER", 130, 138], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["respiratory signs", "OBSERVATION", 164, 181]]], ["Grades 4 and 5 were merged due to the low case numbers in these groups.Detection of CRCV in tissue samples by RT-PCR and association of PCR-positive samples with respiratory signsIn total 32 tracheal samples (26.9%) and 20 lung samples (16.8%) were found positive by nested RT-PCR.", [["tissue samples", "ANATOMY", 92, 106], ["samples", "ANATOMY", 149, 156], ["respiratory", "ANATOMY", 162, 173], ["tracheal samples", "ANATOMY", 191, 207], ["lung samples", "ANATOMY", 223, 235], ["respiratory signs", "DISEASE", 162, 179], ["CRCV", "CANCER", 84, 88], ["tissue samples", "TISSUE", 92, 106], ["tracheal samples", "CANCER", 191, 207], ["lung samples", "CANCER", 223, 235], ["CRCV", "DNA", 84, 88], ["CRCV", "SPECIES", 84, 88], ["CRCV in tissue samples", "PROBLEM", 84, 106], ["RT", "TEST", 110, 112], ["PCR", "TEST", 113, 116], ["PCR", "TEST", 136, 139], ["positive samples", "PROBLEM", 140, 156], ["respiratory signs", "TEST", 162, 179], ["tracheal samples", "TEST", 191, 207], ["20 lung samples", "TEST", 220, 235], ["nested RT-PCR", "TEST", 267, 280], ["tracheal", "ANATOMY", 191, 199], ["lung", "ANATOMY", 223, 227]]], ["For eight dogs a positive PCR result was obtained for both trachea and lung.", [["trachea", "ANATOMY", 59, 66], ["lung", "ANATOMY", 71, 75], ["dogs", "ORGANISM", 10, 14], ["trachea", "MULTI-TISSUE_STRUCTURE", 59, 66], ["lung", "ORGAN", 71, 75], ["dogs", "SPECIES", 10, 14], ["a positive PCR", "TEST", 15, 29], ["trachea", "ANATOMY", 59, 66], ["lung", "ANATOMY", 71, 75]]], ["Table 3 shows the PCR results for coronavirus in dogs with different grades of respiratory disease.Detection of CRCV in tissue samples by RT-PCR and association of PCR-positive samples with respiratory signsSequence analysis of the nested PCR products obtained from tracheal tissues of six different dogs showed identical DNA sequences for all six cDNA samples.Establishment of a serological assay for CRCVBecause of the homology of the spike gene region of CRCV to the spike region of bovine coronavirus, an ELISA antigen for BCV was used for serological analysis.Establishment of a serological assay for CRCVSera from 5 dogs with no history of infectious respiratory disease that had not been housed in the investigated kennel were tested.", [["respiratory", "ANATOMY", 79, 90], ["tissue samples", "ANATOMY", 120, 134], ["samples", "ANATOMY", 177, 184], ["respiratory", "ANATOMY", 190, 201], ["tracheal tissues", "ANATOMY", 266, 282], ["samples", "ANATOMY", 353, 360], ["respiratory", "ANATOMY", 657, 668], ["coronavirus", "DISEASE", 34, 45], ["respiratory disease", "DISEASE", 79, 98], ["respiratory signs", "DISEASE", 190, 207], ["infectious respiratory disease", "DISEASE", 646, 676], ["coronavirus", "ORGANISM", 34, 45], ["dogs", "ORGANISM", 49, 53], ["CRCV", "CANCER", 112, 116], ["tissue samples", "TISSUE", 120, 134], ["tracheal tissues", "MULTI-TISSUE_STRUCTURE", 266, 282], ["dogs", "ORGANISM", 300, 304], ["DNA", "CELLULAR_COMPONENT", 322, 325], ["CRCV", "GENE_OR_GENE_PRODUCT", 458, 462], ["bovine", "ORGANISM", 486, 492], ["coronavirus", "ORGANISM", 493, 504], ["BCV", "ORGANISM", 527, 530], ["dogs", "ORGANISM", 622, 626], ["CRCV", "DNA", 112, 116], ["DNA sequences", "DNA", 322, 335], ["spike gene region", "DNA", 437, 454], ["CRCV", "DNA", 458, 462], ["dogs", "SPECIES", 49, 53], ["dogs", "SPECIES", 300, 304], ["bovine", "SPECIES", 486, 492], ["coronavirus", "SPECIES", 493, 504], ["dogs", "SPECIES", 622, 626], ["CRCV", "SPECIES", 112, 116], ["CRCV", "SPECIES", 458, 462], ["bovine coronavirus", "SPECIES", 486, 504], ["BCV", "SPECIES", 527, 530], ["the PCR", "TEST", 14, 21], ["coronavirus", "PROBLEM", 34, 45], ["respiratory disease", "PROBLEM", 79, 98], ["CRCV in tissue samples", "PROBLEM", 112, 134], ["RT", "TEST", 138, 140], ["PCR", "TEST", 141, 144], ["PCR", "TEST", 164, 167], ["positive samples", "PROBLEM", 168, 184], ["respiratory signs", "TEST", 190, 207], ["Sequence analysis", "TEST", 207, 224], ["the nested PCR products", "TEST", 228, 251], ["identical DNA sequences", "TEST", 312, 335], ["all six cDNA samples", "TEST", 340, 360], ["a serological assay", "TEST", 378, 397], ["bovine coronavirus", "PROBLEM", 486, 504], ["an ELISA antigen", "TEST", 506, 522], ["BCV", "PROBLEM", 527, 530], ["serological analysis", "TEST", 544, 564], ["a serological assay", "TEST", 582, 601], ["CRCVSera", "PROBLEM", 606, 614], ["infectious respiratory disease", "PROBLEM", 646, 676], ["respiratory disease", "OBSERVATION", 79, 98], ["tracheal", "ANATOMY", 266, 274], ["bovine coronavirus", "OBSERVATION", 486, 504], ["infectious", "OBSERVATION_MODIFIER", 646, 656], ["respiratory disease", "OBSERVATION", 657, 676]]], ["The OD values ranged from \u03ea0.013 to 0.39, with an average OD value of 0.154.", [["The OD values", "TEST", 0, 13], ["an average OD value", "TEST", 47, 66]]], ["Furthermore, sera from 30 dogs admitted to a veterinary clinic for various reasons were tested for antibodies to coronavirus.", [["sera", "ANATOMY", 13, 17], ["coronavirus", "DISEASE", 113, 124], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["dogs", "ORGANISM", 26, 30], ["coronavirus", "ORGANISM", 113, 124], ["antibodies", "PROTEIN", 99, 109], ["dogs", "SPECIES", 26, 30], ["antibodies", "PROBLEM", 99, 109], ["coronavirus", "PROBLEM", 113, 124]]], ["Of these, 20 samples showed an OD of \u03fd0.4 (\u03ea0.46 to 0.396) and 10 samples showed an OD of \u03fe1.0 (1.012 to 1.949).", [["samples", "ANATOMY", 13, 20], ["an OD", "TEST", 28, 33], ["an OD", "TEST", 81, 86]]], ["Samples with an OD of 0.6 or above were subsequently considered positive.Comparison of the immune response to CRCV of dogs with and without respiratory diseaseThe BCV antigen ELISA was performed using paired sera of 111 dogs from the study kennel.", [["Samples", "ANATOMY", 0, 7], ["respiratory", "ANATOMY", 140, 151], ["sera", "ANATOMY", 208, 212], ["respiratory disease", "DISEASE", 140, 159], ["CRCV", "CANCER", 110, 114], ["dogs", "ORGANISM", 118, 122], ["BCV antigen", "GENE_OR_GENE_PRODUCT", 163, 174], ["sera", "ORGANISM_SUBSTANCE", 208, 212], ["dogs", "ORGANISM", 220, 224], ["dogs", "SPECIES", 118, 122], ["dogs", "SPECIES", 220, 224], ["CRCV", "SPECIES", 110, 114], ["BCV", "SPECIES", 163, 166], ["Samples", "TEST", 0, 7], ["an OD", "TEST", 13, 18], ["respiratory disease", "PROBLEM", 140, 159], ["The BCV antigen ELISA", "TEST", 159, 180], ["paired sera", "TEST", 201, 212], ["positive", "OBSERVATION", 64, 72], ["without", "UNCERTAINTY", 132, 139], ["respiratory disease", "OBSERVATION", 140, 159], ["BCV", "ANATOMY", 163, 166]]], ["Of these, 81 dogs had shown symptoms of respiratory disease during a period of 21 days and 30 had remained healthy.Comparison of the immune response to CRCV of dogs with and without respiratory diseaseOf the group of dogs which developed respiratory disease, 17 were positive for antibodies to CRCV on the day of entry into the kennel and 64 were negative.Comparison of the immune response to CRCV of dogs with and without respiratory diseaseOf the 64 dogs in this group which had no detectable antibodies to CRCV on day 1, 63 tested positive on day 21.", [["respiratory", "ANATOMY", 40, 51], ["respiratory", "ANATOMY", 238, 249], ["respiratory disease", "DISEASE", 40, 59], ["respiratory diseaseOf", "DISEASE", 182, 203], ["respiratory disease", "DISEASE", 238, 257], ["respiratory diseaseOf", "DISEASE", 423, 444], ["dogs", "ORGANISM", 13, 17], ["CRCV", "CANCER", 152, 156], ["dogs", "ORGANISM", 160, 164], ["dogs", "ORGANISM", 217, 221], ["CRCV", "CANCER", 294, 298], ["CRCV", "CANCER", 393, 397], ["dogs", "ORGANISM", 401, 405], ["dogs", "ORGANISM", 452, 456], ["antibodies", "PROTEIN", 280, 290], ["CRCV", "PROTEIN", 294, 298], ["antibodies", "PROTEIN", 495, 505], ["CRCV", "PROTEIN", 509, 513], ["dogs", "SPECIES", 13, 17], ["dogs", "SPECIES", 160, 164], ["dogs", "SPECIES", 217, 221], ["dogs", "SPECIES", 401, 405], ["dogs", "SPECIES", 452, 456], ["CRCV", "SPECIES", 152, 156], ["CRCV", "SPECIES", 294, 298], ["CRCV", "SPECIES", 393, 397], ["CRCV", "SPECIES", 509, 513], ["symptoms", "PROBLEM", 28, 36], ["respiratory disease", "PROBLEM", 40, 59], ["respiratory disease", "PROBLEM", 238, 257], ["antibodies", "PROBLEM", 280, 290], ["CRCV", "TEST", 294, 298], ["detectable antibodies", "PROBLEM", 484, 505], ["respiratory disease", "OBSERVATION", 40, 59], ["respiratory disease", "OBSERVATION", 238, 257]]], ["All 46 dogs of these 63 for which a sample on day 7 was available tested negative on day 7.", [["sample", "ANATOMY", 36, 42], ["dogs", "ORGANISM", 7, 11], ["dogs", "SPECIES", 7, 11]]], ["Therefore 63 dogs showed a seroconversion during the study period, whereas only 1 dog remained negative.Comparison of the immune response to CRCV of dogs with and without respiratory diseaseOf the 30 dogs that had remained healthy, 17 had antibodies to CRCV on the day of entry.", [["respiratory", "ANATOMY", 171, 182], ["respiratory diseaseOf", "DISEASE", 171, 192], ["dogs", "ORGANISM", 13, 17], ["dog", "ORGANISM", 82, 85], ["CRCV", "CANCER", 141, 145], ["dogs", "ORGANISM", 149, 153], ["dogs", "ORGANISM", 200, 204], ["CRCV", "CANCER", 253, 257], ["antibodies", "PROTEIN", 239, 249], ["CRCV", "PROTEIN", 253, 257], ["dogs", "SPECIES", 13, 17], ["dog", "SPECIES", 82, 85], ["dogs", "SPECIES", 149, 153], ["dogs", "SPECIES", 200, 204], ["CRCV", "SPECIES", 141, 145], ["CRCV", "SPECIES", 253, 257], ["a seroconversion", "PROBLEM", 25, 41], ["the study", "TEST", 49, 58], ["respiratory diseaseOf the 30 dogs", "PROBLEM", 171, 204], ["negative", "OBSERVATION", 95, 103]]], ["All of the 13 dogs that were negative on day 1 tested negative on day 7 but showed a seroconversion until day 21.Comparison of the immune response to CRCV of dogs with and without respiratory diseaseThus, of 34 dogs that were positive for antibodies to CRCV on arrival in the kennel, 17 developed respiratory disease (50%), whereas of 77 dogs that were negative on arrival, 64 developed respiratory signs during the study period (83.1%) (Fig. 3) .Comparison of the immune response to CRCV of dogs with and without respiratory diseaseTherefore dogs that had no antibodies to CRCV on entry into the kennel had an increased probability of developing respiratory disease (P \u03fd 0.001).Comparison of the immune response to CRCV of dogs with and without respiratory diseaseOnly 1 of the 77 dogs that were negative on arrival remained negative during the study period of 21 days, whereas 76 dogs showed a seroconversion.Serology using canine enteric coronavirus (CECV) antigenAn ELISA assay using a canine coronavirus antigen was performed to investigate whether CRCV showed a serological cross-reaction to canine enteric coronavirus.", [["respiratory", "ANATOMY", 180, 191], ["respiratory", "ANATOMY", 297, 308], ["respiratory", "ANATOMY", 387, 398], ["respiratory", "ANATOMY", 514, 525], ["respiratory", "ANATOMY", 647, 658], ["respiratory diseaseThus", "DISEASE", 180, 203], ["respiratory disease", "DISEASE", 297, 316], ["respiratory signs", "DISEASE", 387, 404], ["respiratory disease", "DISEASE", 514, 533], ["respiratory disease", "DISEASE", 647, 666], ["respiratory diseaseOnly", "DISEASE", 746, 769], ["enteric coronavirus", "DISEASE", 1105, 1124], ["dogs", "ORGANISM", 14, 18], ["CRCV", "CANCER", 150, 154], ["dogs", "ORGANISM", 158, 162], ["dogs", "ORGANISM", 211, 215], ["dogs", "ORGANISM", 338, 342], ["CRCV", "CANCER", 484, 488], ["dogs", "ORGANISM", 492, 496], ["dogs", "ORGANISM", 543, 547], ["CRCV", "CANCER", 716, 720], ["dogs", "ORGANISM", 724, 728], ["dogs", "ORGANISM", 782, 786], ["dogs", "ORGANISM", 882, 886], ["canine enteric coronavirus", "ORGANISM", 926, 952], ["CECV", "ORGANISM", 954, 958], ["canine coronavirus", "ORGANISM", 990, 1008], ["canine enteric coronavirus", "ORGANISM", 1098, 1124], ["antibodies", "PROTEIN", 239, 249], ["CRCV", "PROTEIN", 253, 257], ["antibodies", "PROTEIN", 560, 570], ["canine coronavirus antigen", "PROTEIN", 990, 1016], ["dogs", "SPECIES", 14, 18], ["dogs", "SPECIES", 158, 162], ["dogs", "SPECIES", 211, 215], ["dogs", "SPECIES", 338, 342], ["dogs", "SPECIES", 492, 496], ["dogs", "SPECIES", 543, 547], ["dogs", "SPECIES", 724, 728], ["dogs", "SPECIES", 782, 786], ["dogs", "SPECIES", 882, 886], ["canine enteric coronavirus", "SPECIES", 926, 952], ["canine coronavirus", "SPECIES", 990, 1008], ["canine enteric coronavirus", "SPECIES", 1098, 1124], ["CRCV", "SPECIES", 150, 154], ["CRCV", "SPECIES", 253, 257], ["CRCV", "SPECIES", 484, 488], ["CRCV", "SPECIES", 574, 578], ["CRCV", "SPECIES", 716, 720], ["canine enteric coronavirus", "SPECIES", 926, 952], ["CECV", "SPECIES", 954, 958], ["canine coronavirus", "SPECIES", 990, 1008], ["CRCV", "SPECIES", 1054, 1058], ["canine enteric coronavirus", "SPECIES", 1098, 1124], ["respiratory diseaseThus", "PROBLEM", 180, 203], ["34 dogs", "PROBLEM", 208, 215], ["antibodies", "PROBLEM", 239, 249], ["respiratory disease", "PROBLEM", 297, 316], ["respiratory signs", "PROBLEM", 387, 404], ["the study", "TEST", 412, 421], ["respiratory disease", "PROBLEM", 514, 533], ["antibodies", "PROBLEM", 560, 570], ["developing respiratory disease", "PROBLEM", 636, 666], ["respiratory diseaseOnly", "TEST", 746, 769], ["a seroconversion", "PROBLEM", 894, 910], ["Serology", "TEST", 911, 919], ["ELISA assay", "TEST", 970, 981], ["a canine coronavirus antigen", "TEST", 988, 1016], ["CRCV", "TEST", 1054, 1058], ["a serological cross-reaction to canine enteric coronavirus", "PROBLEM", 1066, 1124], ["respiratory disease", "OBSERVATION", 297, 316], ["without", "UNCERTAINTY", 506, 513], ["respiratory disease", "OBSERVATION", 514, 533], ["increased", "OBSERVATION_MODIFIER", 611, 620], ["respiratory disease", "OBSERVATION", 647, 666], ["seroconversion", "OBSERVATION", 896, 910]]], ["Sera from 27 dogs, previously tested for antibodies to CRCV using the BCV antigen, were selected.Serology using canine enteric coronavirus (CECV) antigenIt was found that 8 dogs had antibodies to CECV on the day of entry into the kennel; of these 4 also had antibodies to CRCV.", [["Sera", "ANATOMY", 0, 4], ["CECV", "CHEMICAL", 196, 200], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["dogs", "ORGANISM", 13, 17], ["CRCV", "CANCER", 55, 59], ["BCV", "ORGANISM", 70, 73], ["canine enteric coronavirus", "ORGANISM", 112, 138], ["CECV", "ORGANISM", 140, 144], ["dogs", "ORGANISM", 173, 177], ["CRCV", "CANCER", 272, 276], ["antibodies", "PROTEIN", 41, 51], ["CRCV", "PROTEIN", 55, 59], ["BCV antigen", "PROTEIN", 70, 81], ["canine enteric coronavirus (CECV) antigen", "PROTEIN", 112, 153], ["antibodies", "PROTEIN", 182, 192], ["antibodies", "PROTEIN", 258, 268], ["CRCV", "PROTEIN", 272, 276], ["dogs", "SPECIES", 13, 17], ["canine enteric coronavirus", "SPECIES", 112, 138], ["dogs", "SPECIES", 173, 177], ["CRCV", "SPECIES", 55, 59], ["BCV", "SPECIES", 70, 73], ["canine enteric coronavirus", "SPECIES", 112, 138], ["CECV", "SPECIES", 140, 144], ["CRCV", "SPECIES", 272, 276], ["Sera", "TEST", 0, 4], ["antibodies", "PROBLEM", 41, 51], ["the BCV antigen", "TEST", 66, 81], ["Serology", "TEST", 97, 105], ["canine enteric coronavirus (CECV) antigen", "TEST", 112, 153], ["antibodies", "TREATMENT", 182, 192], ["antibodies to CRCV", "TREATMENT", 258, 276], ["enteric coronavirus", "ANATOMY", 119, 138]]], ["Nineteen dogs were found to be negative for CECV on day 1; 17 of these were also negative for CRCV.", [["dogs", "ORGANISM", 9, 13], ["dogs", "SPECIES", 9, 13], ["CRCV", "SPECIES", 94, 98], ["CECV", "TEST", 44, 48], ["CRCV", "PROBLEM", 94, 98]]], ["Of the 19 negative dogs, 5 showed a seroconversion to CECV during the 21-day period of the investigation and 17 showed a seroconversion to CRCV.Serology using canine enteric coronavirus (CECV) antigenAnalysis of the prevalence of respiratory disease in this group showed that 6 of the 8 dogs (75%) that were positive for antibodies to CECV on day 1 developed respiratory disease.", [["respiratory", "ANATOMY", 230, 241], ["respiratory", "ANATOMY", 359, 370], ["CECV", "CHEMICAL", 54, 58], ["CRCV", "DISEASE", 139, 143], ["respiratory disease", "DISEASE", 230, 249], ["CECV", "CHEMICAL", 335, 339], ["respiratory disease", "DISEASE", 359, 378], ["dogs", "ORGANISM", 19, 23], ["CRCV", "CANCER", 139, 143], ["canine enteric coronavirus", "ORGANISM", 159, 185], ["dogs", "ORGANISM", 287, 291], ["antibodies", "PROTEIN", 321, 331], ["dogs", "SPECIES", 19, 23], ["canine enteric coronavirus", "SPECIES", 159, 185], ["dogs", "SPECIES", 287, 291], ["CECV", "SPECIES", 54, 58], ["CRCV", "SPECIES", 139, 143], ["canine enteric coronavirus", "SPECIES", 159, 185], ["CECV", "SPECIES", 187, 191], ["CECV", "SPECIES", 335, 339], ["the investigation", "TEST", 87, 104], ["a seroconversion to CRCV", "TREATMENT", 119, 143], ["Serology", "TEST", 144, 152], ["respiratory disease", "PROBLEM", 230, 249], ["antibodies to CECV", "PROBLEM", 321, 339], ["respiratory disease", "PROBLEM", 359, 378], ["enteric coronavirus", "ANATOMY", 166, 185], ["respiratory disease", "OBSERVATION", 230, 249], ["respiratory disease", "OBSERVATION", 359, 378]]], ["Of the group of 19 dogs that had no detectable antibodies to CECV on day 1, 15 showed signs of respiratory disease (78.9%) (P \u03ed 0.594).Virus isolationTracheal tissue samples from five dogs that had been identified as positive for coronavirus RNA by RT-PCR were inoculated on cell cultures of canine adult lung fibro-blasts and MDCK cells.", [["respiratory", "ANATOMY", 95, 106], ["Tracheal tissue samples", "ANATOMY", 150, 173], ["cell cultures", "ANATOMY", 275, 288], ["lung fibro-blasts", "ANATOMY", 305, 322], ["MDCK cells", "ANATOMY", 327, 337], ["respiratory disease", "DISEASE", 95, 114], ["dogs", "ORGANISM", 19, 23], ["Virus", "ORGANISM", 135, 140], ["Tracheal tissue samples", "CANCER", 150, 173], ["dogs", "ORGANISM", 184, 188], ["coronavirus", "ORGANISM", 230, 241], ["cell cultures", "CELL", 275, 288], ["canine", "ORGANISM", 292, 298], ["adult lung fibro-blasts", "CELL", 299, 322], ["MDCK cells", "CELL", 327, 337], ["antibodies", "PROTEIN", 47, 57], ["coronavirus RNA", "RNA", 230, 245], ["cell cultures", "CELL_LINE", 275, 288], ["canine adult lung fibro-blasts", "CELL_TYPE", 292, 322], ["MDCK cells", "CELL_LINE", 327, 337], ["dogs", "SPECIES", 19, 23], ["dogs", "SPECIES", 184, 188], ["canine", "SPECIES", 292, 298], ["coronavirus", "SPECIES", 230, 241], ["canine", "SPECIES", 292, 298], ["respiratory disease", "PROBLEM", 95, 114], ["P", "TEST", 124, 125], ["Virus isolation", "TREATMENT", 135, 150], ["Tracheal tissue samples", "TEST", 150, 173], ["five dogs", "TEST", 179, 188], ["coronavirus RNA", "PROBLEM", 230, 245], ["RT-PCR", "TEST", 249, 255], ["cell cultures", "TEST", 275, 288], ["canine adult lung fibro", "TEST", 292, 315], ["blasts", "PROBLEM", 316, 322], ["MDCK cells", "PROBLEM", 327, 337], ["respiratory disease", "OBSERVATION", 95, 114], ["Tracheal tissue", "ANATOMY", 150, 165], ["lung", "ANATOMY", 305, 309], ["MDCK cells", "OBSERVATION", 327, 337]]], ["For three samples virus isolation was also attempted on A72 cells.", [["A72 cells", "ANATOMY", 56, 65], ["A72 cells", "CELL", 56, 65], ["A72 cells", "CELL_LINE", 56, 65], ["three samples virus isolation", "TREATMENT", 4, 33]]], ["The cultures showed no signs of a cytopathic effect during three passages.", [["cultures", "ANATOMY", 4, 12], ["The cultures", "TEST", 0, 12], ["a cytopathic effect", "PROBLEM", 32, 51], ["no signs of", "UNCERTAINTY", 20, 31], ["cytopathic effect", "OBSERVATION", 34, 51]]], ["After the third passage, RNA was extracted from the cultures and found to be negative for coronavirus by RT-PCR.DiscussionThis study reports the detection of a canine coronavirus, provisionally called CRCV, in kenneled dogs with respiratory disease.DiscussionCoronaviruses have been reported to cause respiratory disease of man, cattle, swine, and poultry, but their presence in the respiratory tract of dogs and a possible association with CIRD has not been determined.", [["cultures", "ANATOMY", 52, 60], ["respiratory", "ANATOMY", 229, 240], ["respiratory", "ANATOMY", 301, 312], ["respiratory tract", "ANATOMY", 383, 400], ["canine coronavirus", "DISEASE", 160, 178], ["respiratory disease", "DISEASE", 229, 248], ["respiratory disease", "DISEASE", 301, 320], ["CIRD", "DISEASE", 441, 445], ["coronavirus", "ORGANISM", 90, 101], ["canine coronavirus", "ORGANISM", 160, 178], ["CRCV", "CANCER", 201, 205], ["dogs", "ORGANISM", 219, 223], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 259, 272], ["man", "ORGANISM", 324, 327], ["respiratory tract", "ORGANISM_SUBDIVISION", 383, 400], ["dogs", "ORGANISM", 404, 408], ["canine coronavirus", "SPECIES", 160, 178], ["dogs", "SPECIES", 219, 223], ["man", "SPECIES", 324, 327], ["cattle", "SPECIES", 329, 335], ["swine", "SPECIES", 337, 342], ["dogs", "SPECIES", 404, 408], ["canine coronavirus", "SPECIES", 160, 178], ["CRCV", "SPECIES", 201, 205], ["cattle", "SPECIES", 329, 335], ["swine", "SPECIES", 337, 342], ["the cultures", "TEST", 48, 60], ["coronavirus", "PROBLEM", 90, 101], ["PCR", "TEST", 108, 111], ["This study", "TEST", 122, 132], ["a canine coronavirus", "PROBLEM", 158, 178], ["respiratory disease", "PROBLEM", 229, 248], ["Coronaviruses", "PROBLEM", 259, 272], ["respiratory disease", "PROBLEM", 301, 320], ["CIRD", "TREATMENT", 441, 445], ["respiratory disease", "OBSERVATION", 229, 248], ["respiratory tract", "ANATOMY", 383, 400]]], ["Only one study has mentioned the isolation of canine coronavirus from four dogs with symptoms of respiratory disease (Binn et al., 1979) .", [["respiratory", "ANATOMY", 97, 108], ["canine coronavirus", "DISEASE", 46, 64], ["respiratory disease", "DISEASE", 97, 116], ["canine coronavirus", "ORGANISM", 46, 64], ["dogs", "ORGANISM", 75, 79], ["canine coronavirus", "SPECIES", 46, 64], ["dogs", "SPECIES", 75, 79], ["canine coronavirus", "SPECIES", 46, 64], ["one study", "TEST", 5, 14], ["canine coronavirus", "PROBLEM", 46, 64], ["symptoms", "PROBLEM", 85, 93], ["respiratory disease", "PROBLEM", 97, 116], ["respiratory disease", "OBSERVATION", 97, 116]]], ["Therefore it was investigated in this study whether coronaviruses could be detected in dogs from a kennel with a high prevalence of CIRD.", [["CIRD", "DISEASE", 132, 136], ["coronaviruses", "ORGANISM", 52, 65], ["dogs", "ORGANISM", 87, 91], ["dogs", "SPECIES", 87, 91], ["this study", "TEST", 33, 43], ["coronaviruses", "PROBLEM", 52, 65]]], ["The disease was endemic in this kennel and could not be controlled by the use of vaccines recommended against \"kennel cough,\" strongly suggesting that additional agents were contributing to the disease syndrome observed.", [["kennel cough", "DISEASE", 111, 123], ["The disease", "PROBLEM", 0, 11], ["endemic", "PROBLEM", 16, 23], ["vaccines", "TREATMENT", 81, 89], ["kennel cough", "PROBLEM", 111, 123], ["the disease syndrome", "PROBLEM", 190, 210], ["disease", "OBSERVATION", 4, 11], ["endemic", "OBSERVATION_MODIFIER", 16, 23]]], ["Samples taken from the respiratory tract of these dogs were examined using RT-PCR primers directed to the conserved polymerase gene of coronaviruses (Stephensen et al., 1999) .", [["Samples", "ANATOMY", 0, 7], ["respiratory tract", "ANATOMY", 23, 40], ["respiratory tract", "ORGANISM_SUBDIVISION", 23, 40], ["dogs", "ORGANISM", 50, 54], ["coronaviruses", "ORGANISM", 135, 148], ["conserved polymerase gene", "DNA", 106, 131], ["dogs", "SPECIES", 50, 54], ["Samples", "TEST", 0, 7], ["RT-PCR primers", "TREATMENT", 75, 89], ["coronaviruses", "PROBLEM", 135, 148], ["respiratory tract", "ANATOMY", 23, 40]]], ["Analysis of the cDNA sequences obtained from the canine samples revealed that CRCV had the highest similarity with the polymerase gene of bovine coronavirus (98.8%) and human coronavirus OC43 (98.4%) but only a very low similarity to the polymerase gene of the enteric canine coronavirus (strain 1-71, 68.53% similarity).DiscussionPhylogenetic analysis of the polymerase sequences of 11 coronaviruses showed CRCV to be located on a common branch with 3 group 2 viruses: bovine coronavirus (BCV), human coronavirus strain OC43 (HCV-OC43), and hemagglutinating encephalomyelitis virus.", [["samples", "ANATOMY", 56, 63], ["enteric canine coronavirus", "DISEASE", 261, 287], ["bovine coronavirus", "DISEASE", 470, 488], ["hemagglutinating encephalomyelitis", "DISEASE", 542, 576], ["canine", "ORGANISM", 49, 55], ["CRCV", "GENE_OR_GENE_PRODUCT", 78, 82], ["bovine coronavirus", "ORGANISM", 138, 156], ["human", "ORGANISM", 169, 174], ["coronavirus OC43", "ORGANISM", 175, 191], ["enteric canine coronavirus", "ORGANISM", 261, 287], ["coronaviruses", "ORGANISM", 387, 400], ["CRCV", "CANCER", 408, 412], ["bovine coronavirus", "ORGANISM", 470, 488], ["BCV", "ORGANISM", 490, 493], ["human", "ORGANISM", 496, 501], ["coronavirus strain OC43", "ORGANISM", 502, 525], ["HCV-OC43", "ORGANISM", 527, 535], ["hemagglutinating encephalomyelitis virus", "ORGANISM", 542, 582], ["cDNA sequences", "DNA", 16, 30], ["CRCV", "DNA", 78, 82], ["polymerase gene", "DNA", 119, 134], ["polymerase gene", "DNA", 238, 253], ["polymerase sequences", "DNA", 360, 380], ["canine", "SPECIES", 49, 55], ["bovine", "SPECIES", 138, 144], ["coronavirus", "SPECIES", 145, 156], ["human", "SPECIES", 169, 174], ["coronavirus OC43", "SPECIES", 175, 191], ["canine coronavirus", "SPECIES", 269, 287], ["bovine", "SPECIES", 470, 476], ["coronavirus", "SPECIES", 477, 488], ["human", "SPECIES", 496, 501], ["coronavirus", "SPECIES", 502, 513], ["hemagglutinating encephalomyelitis virus", "SPECIES", 542, 582], ["canine", "SPECIES", 49, 55], ["CRCV", "SPECIES", 78, 82], ["bovine coronavirus", "SPECIES", 138, 156], ["human coronavirus OC43", "SPECIES", 169, 191], ["canine coronavirus", "SPECIES", 269, 287], ["CRCV", "SPECIES", 408, 412], ["bovine coronavirus", "SPECIES", 470, 488], ["BCV", "SPECIES", 490, 493], ["human coronavirus strain OC43 (HCV-OC43", "SPECIES", 496, 535], ["hemagglutinating encephalomyelitis virus", "SPECIES", 542, 582], ["the cDNA sequences", "TEST", 12, 30], ["the canine samples", "TEST", 45, 63], ["CRCV", "TEST", 78, 82], ["bovine coronavirus", "PROBLEM", 138, 156], ["human coronavirus OC43", "TEST", 169, 191], ["a very low similarity", "PROBLEM", 209, 230], ["DiscussionPhylogenetic analysis", "TEST", 321, 352], ["the polymerase sequences", "TEST", 356, 380], ["coronaviruses", "PROBLEM", 387, 400], ["CRCV", "PROBLEM", 408, 412], ["bovine coronavirus", "PROBLEM", 470, 488], ["human coronavirus strain OC43", "PROBLEM", 496, 525], ["HCV", "TEST", 527, 530], ["hemagglutinating encephalomyelitis virus", "PROBLEM", 542, 582], ["enteric canine coronavirus", "ANATOMY", 261, 287], ["common branch", "ANATOMY", 432, 445], ["bovine coronavirus", "OBSERVATION", 470, 488], ["hemagglutinating encephalomyelitis virus", "OBSERVATION", 542, 582]]], ["However, canine enteric coronavirus, a group 1 coronavirus, was shown to be only distantly related.DiscussionCanine respiratory coronavirus therefore is a novel coronavirus of dogs that is most closely related to BCV and HCV-OC43, both of which are known to cause respiratory disease.DiscussionSequence analysis of the spike gene confirmed the high similarity of CRCV with BCV and HCV-OC43, both of which are members of the group 2 of the Coronaviridae family.", [["respiratory", "ANATOMY", 264, 275], ["enteric coronavirus", "DISEASE", 16, 35], ["respiratory coronavirus", "DISEASE", 116, 139], ["respiratory disease", "DISEASE", 264, 283], ["canine enteric coronavirus", "ORGANISM", 9, 35], ["Canine respiratory coronavirus", "ORGANISM", 109, 139], ["coronavirus", "ORGANISM", 161, 172], ["dogs", "ORGANISM", 176, 180], ["BCV", "ORGANISM", 213, 216], ["HCV-OC43", "ORGANISM", 221, 229], ["CRCV", "CANCER", 363, 367], ["BCV", "ORGANISM", 373, 376], ["HCV-OC43", "ORGANISM", 381, 389], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 439, 452], ["spike gene", "DNA", 319, 329], ["canine enteric coronavirus", "SPECIES", 9, 35], ["group 1 coronavirus", "SPECIES", 39, 58], ["Canine respiratory coronavirus", "SPECIES", 109, 139], ["dogs", "SPECIES", 176, 180], ["canine enteric coronavirus", "SPECIES", 9, 35], ["Canine respiratory coronavirus", "SPECIES", 109, 139], ["BCV", "SPECIES", 213, 216], ["HCV-OC43", "SPECIES", 221, 229], ["CRCV", "SPECIES", 363, 367], ["BCV", "SPECIES", 373, 376], ["HCV-OC43", "SPECIES", 381, 389], ["canine enteric coronavirus", "PROBLEM", 9, 35], ["a group 1 coronavirus", "PROBLEM", 37, 58], ["Canine respiratory coronavirus", "PROBLEM", 109, 139], ["a novel coronavirus of dogs", "PROBLEM", 153, 180], ["BCV", "TEST", 213, 216], ["HCV", "PROBLEM", 221, 224], ["OC43", "PROBLEM", 225, 229], ["respiratory disease", "PROBLEM", 264, 283], ["Sequence analysis", "TEST", 294, 311], ["the spike gene", "TEST", 315, 329], ["BCV", "TEST", 373, 376], ["HCV", "PROBLEM", 381, 384], ["enteric coronavirus", "ANATOMY", 16, 35], ["respiratory coronavirus", "OBSERVATION", 116, 139], ["HCV", "OBSERVATION", 221, 224], ["known to cause", "UNCERTAINTY", 249, 263], ["respiratory disease", "OBSERVATION", 264, 283]]], ["Group 2 coronaviruses contain an additional structural protein, HE.", [["coronaviruses", "ORGANISM", 8, 21], ["structural protein", "PROTEIN", 44, 62], ["HE", "PROTEIN", 64, 66], ["structural protein", "OBSERVATION", 44, 62]]], ["We were able to demonstrate the presence of a HE gene in the cDNA obtained from canine tracheal samples by PCR.", [["tracheal samples", "ANATOMY", 87, 103], ["HE", "GENE_OR_GENE_PRODUCT", 46, 48], ["canine", "ORGANISM", 80, 86], ["tracheal samples", "TISSUE", 87, 103], ["HE gene", "DNA", 46, 53], ["cDNA", "DNA", 61, 65], ["canine", "SPECIES", 80, 86], ["the cDNA", "TEST", 57, 65], ["tracheal", "ANATOMY", 87, 95]]], ["CRCV therefore has a HE gene and belongs to group 2 of the coronavirus family.DiscussionAttempts to isolate CRCV from tissue of the respiratory tract, using either canine lung fibroblasts or a kidney epithelial cell line, have been unsuccessful so far.", [["tissue", "ANATOMY", 118, 124], ["respiratory tract", "ANATOMY", 132, 149], ["lung fibroblasts", "ANATOMY", 171, 187], ["kidney epithelial cell line", "ANATOMY", 193, 220], ["CRCV", "GENE_OR_GENE_PRODUCT", 0, 4], ["coronavirus", "ORGANISM", 59, 70], ["CRCV", "CANCER", 108, 112], ["tissue", "TISSUE", 118, 124], ["respiratory tract", "ORGANISM_SUBDIVISION", 132, 149], ["canine", "ORGANISM", 164, 170], ["lung fibroblasts", "CELL", 171, 187], ["kidney epithelial cell line", "CELL", 193, 220], ["CRCV", "DNA", 0, 4], ["HE gene", "DNA", 21, 28], ["CRCV", "PROTEIN", 108, 112], ["canine lung fibroblasts", "CELL_TYPE", 164, 187], ["kidney epithelial cell line", "CELL_LINE", 193, 220], ["coronavirus", "SPECIES", 59, 70], ["canine", "SPECIES", 164, 170], ["CRCV", "SPECIES", 0, 4], ["CRCV", "SPECIES", 108, 112], ["canine", "SPECIES", 164, 170], ["canine lung fibroblasts", "TREATMENT", 164, 187], ["a kidney epithelial cell line", "TREATMENT", 191, 220], ["respiratory tract", "ANATOMY", 132, 149], ["lung", "ANATOMY", 171, 175], ["fibroblasts", "OBSERVATION", 176, 187], ["kidney", "ANATOMY", 193, 199], ["epithelial cell line", "OBSERVATION", 200, 220]]], ["However, the isolation of CRCV may require the use of fetal canine cells or tracheal organ culture.", [["fetal canine cells", "ANATOMY", 54, 72], ["tracheal organ culture", "ANATOMY", 76, 98], ["CRCV", "CANCER", 26, 30], ["fetal canine cells", "CELL", 54, 72], ["tracheal organ culture", "CELL", 76, 98], ["fetal canine cells", "CELL_TYPE", 54, 72], ["CRCV", "SPECIES", 26, 30], ["canine", "SPECIES", 60, 66], ["the isolation of CRCV", "PROBLEM", 9, 30], ["fetal canine cells", "TREATMENT", 54, 72], ["tracheal organ culture", "TEST", 76, 98], ["tracheal organ", "ANATOMY", 76, 90]]], ["Also it is possible that the virus was inactivated during storage or due to freezing and thawing.DiscussionBy PCR, CRCV was detected in tracheal and lung tissue and therefore appears to infect the upper and lower respiratory tracts of dogs.", [["tracheal", "ANATOMY", 136, 144], ["lung tissue", "ANATOMY", 149, 160], ["upper", "ANATOMY", 197, 202], ["lower respiratory tracts", "ANATOMY", 207, 231], ["tracheal", "TISSUE", 136, 144], ["lung tissue", "TISSUE", 149, 160], ["upper", "ORGANISM_SUBDIVISION", 197, 202], ["lower respiratory", "ORGANISM_SUBDIVISION", 207, 224], ["dogs", "ORGANISM", 235, 239], ["CRCV", "DNA", 115, 119], ["dogs", "SPECIES", 235, 239], ["CRCV", "SPECIES", 115, 119], ["the virus", "PROBLEM", 25, 34], ["freezing", "PROBLEM", 76, 84], ["PCR", "TEST", 110, 113], ["CRCV", "TEST", 115, 119], ["the upper and lower respiratory tracts of dogs", "PROBLEM", 193, 239], ["is possible", "UNCERTAINTY", 8, 19], ["virus", "OBSERVATION", 29, 34], ["tracheal", "ANATOMY", 136, 144], ["lung tissue", "ANATOMY", 149, 160], ["appears to", "UNCERTAINTY", 175, 185], ["infect", "OBSERVATION", 186, 192], ["upper", "ANATOMY_MODIFIER", 197, 202], ["lower", "ANATOMY_MODIFIER", 207, 212], ["respiratory tracts", "ANATOMY", 213, 231], ["dogs", "OBSERVATION", 235, 239]]], ["The possible presence of viral RNA in other tissues needs to be analyzed in further studies and the target cells of CRCV have to be identified using in situ hybridization or immunohistochemistry.DiscussionThe presence of antibodies to CRCV was analyzed using an ELISA based on a BCV antigen because of the high sequence similarity of the two viruses in the spike gene and because CRCV antigen could not be obtained by virus culture.", [["tissues", "ANATOMY", 44, 51], ["cells", "ANATOMY", 107, 112], ["CRCV", "ANATOMY", 116, 120], ["tissues", "TISSUE", 44, 51], ["cells", "CELL", 107, 112], ["CRCV", "CANCER", 116, 120], ["CRCV", "CANCER", 235, 239], ["BCV", "ORGANISM", 279, 282], ["CRCV antigen", "GENE_OR_GENE_PRODUCT", 380, 392], ["viral RNA", "RNA", 25, 34], ["antibodies", "PROTEIN", 221, 231], ["CRCV", "PROTEIN", 235, 239], ["BCV antigen", "PROTEIN", 279, 290], ["spike gene", "DNA", 357, 367], ["CRCV antigen", "PROTEIN", 380, 392], ["CRCV", "SPECIES", 116, 120], ["CRCV", "SPECIES", 235, 239], ["BCV", "SPECIES", 279, 282], ["CRCV", "SPECIES", 380, 384], ["viral RNA in other tissues", "PROBLEM", 25, 51], ["further studies", "TEST", 76, 91], ["antibodies to CRCV", "TREATMENT", 221, 239], ["an ELISA", "TEST", 259, 267], ["a BCV antigen", "TEST", 277, 290], ["the high sequence similarity", "PROBLEM", 302, 330], ["the two viruses", "PROBLEM", 334, 349], ["CRCV antigen", "PROBLEM", 380, 392], ["virus culture", "TEST", 418, 431], ["possible presence of", "UNCERTAINTY", 4, 24], ["viral RNA", "OBSERVATION", 25, 34], ["viruses", "OBSERVATION", 342, 349]]], ["The ELISA results confirmed the presence of a virus similar to BCV in the study population.DiscussionThe prevalence of antibodies was 30% at the time of entry into the kennel and 99% after 21 days.", [["BCV", "ORGANISM", 63, 66], ["antibodies", "PROTEIN", 119, 129], ["BCV", "SPECIES", 63, 66], ["The ELISA", "TEST", 0, 9], ["a virus", "PROBLEM", 44, 51], ["antibodies", "TEST", 119, 129], ["virus", "OBSERVATION", 46, 51]]], ["Almost all dogs negative on the day of entry into the kennel showed a seroconversion to CRCV within 3 weeks, indicating that the virus is highly contagious.DiscussionSerology using an antigen for CECV showed a much lower prevalence of antibodies to CECV on day 21.", [["CRCV", "DISEASE", 88, 92], ["dogs", "ORGANISM", 11, 15], ["CRCV", "CANCER", 88, 92], ["antibodies", "PROTEIN", 235, 245], ["CECV", "PROTEIN", 249, 253], ["dogs", "SPECIES", 11, 15], ["CRCV", "SPECIES", 88, 92], ["CECV", "SPECIES", 196, 200], ["CECV", "SPECIES", 249, 253], ["the virus", "PROBLEM", 125, 134], ["an antigen", "TEST", 181, 191], ["CECV", "TEST", 196, 200], ["virus", "OBSERVATION", 129, 134], ["highly", "OBSERVATION_MODIFIER", 138, 144], ["contagious", "OBSERVATION", 145, 155]]], ["Therefore the BCV ELISA results did not reflect an infection with canine enteric coronavirus and the cross-reactivity between the two antigens seems to be low.", [["infection", "DISEASE", 51, 60], ["enteric coronavirus", "DISEASE", 73, 92], ["BCV", "ORGANISM", 14, 17], ["canine enteric coronavirus", "ORGANISM", 66, 92], ["canine enteric coronavirus", "SPECIES", 66, 92], ["BCV", "SPECIES", 14, 17], ["canine enteric coronavirus", "SPECIES", 66, 92], ["the BCV ELISA", "TEST", 10, 23], ["an infection", "PROBLEM", 48, 60], ["canine enteric coronavirus", "PROBLEM", 66, 92], ["infection", "OBSERVATION", 51, 60], ["coronavirus", "OBSERVATION", 81, 92], ["low", "OBSERVATION_MODIFIER", 155, 158]]], ["Serum antibodies to CRCV were present in about 30% of dogs of various origins, including dogs entering a rehoming kennel as well as pet dogs.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["CRCV", "GENE_OR_GENE_PRODUCT", 20, 24], ["dogs", "ORGANISM", 54, 58], ["dogs", "ORGANISM", 89, 93], ["Serum antibodies", "PROTEIN", 0, 16], ["CRCV", "PROTEIN", 20, 24], ["dogs", "SPECIES", 54, 58], ["dogs", "SPECIES", 89, 93], ["dogs", "SPECIES", 136, 140], ["CRCV", "SPECIES", 20, 24], ["Serum antibodies", "TEST", 0, 16], ["CRCV", "TEST", 20, 24], ["pet dogs", "TREATMENT", 132, 140]]], ["The presence of CRCV is therefore not limited to the investigated kennel and the virus seems to be established in the dog population.DiscussionWithin the kenneled population, CRCV RNA was detected in 27.3% of dogs with all grades of respiratory disease as well as in 26.2% of dogs that were apparently healthy at the time of euthanasia.", [["respiratory", "ANATOMY", 233, 244], ["respiratory disease", "DISEASE", 233, 252], ["CRCV", "CANCER", 16, 20], ["dog", "ORGANISM", 118, 121], ["CRCV", "ORGANISM", 175, 179], ["dogs", "ORGANISM", 209, 213], ["dogs", "ORGANISM", 276, 280], ["CRCV RNA", "RNA", 175, 183], ["dogs", "SPECIES", 209, 213], ["dogs", "SPECIES", 276, 280], ["CRCV", "SPECIES", 16, 20], ["CRCV", "SPECIES", 175, 179], ["the virus", "PROBLEM", 77, 86], ["CRCV RNA", "PROBLEM", 175, 183], ["respiratory disease", "PROBLEM", 233, 252], ["euthanasia", "PROBLEM", 325, 335], ["CRCV", "OBSERVATION", 16, 20], ["respiratory disease", "OBSERVATION", 233, 252], ["euthanasia", "OBSERVATION", 325, 335]]], ["However, CRCV RNA was most frequently found in the trachea of dogs with mild cough (55%).", [["trachea", "ANATOMY", 51, 58], ["cough", "DISEASE", 77, 82], ["CRCV", "GENE_OR_GENE_PRODUCT", 9, 13], ["trachea", "ORGAN", 51, 58], ["dogs", "ORGANISM", 62, 66], ["CRCV RNA", "RNA", 9, 17], ["dogs", "SPECIES", 62, 66], ["CRCV", "SPECIES", 9, 13], ["CRCV RNA", "PROBLEM", 9, 17], ["mild cough", "PROBLEM", 72, 82], ["trachea", "ANATOMY", 51, 58], ["mild", "OBSERVATION_MODIFIER", 72, 76], ["cough", "OBSERVATION", 77, 82]]], ["Studies using the human coronavirus strain 229E have shown that coronaviruses can cause disruption of the respiratory epithelium and ciliary dyskinesia (Chilvers et al., 2001) .", [["respiratory epithelium", "ANATOMY", 106, 128], ["ciliary", "ANATOMY", 133, 140], ["ciliary dyskinesia", "DISEASE", 133, 151], ["human", "ORGANISM", 18, 23], ["coronavirus strain 229E", "ORGANISM", 24, 47], ["coronaviruses", "ORGANISM", 64, 77], ["respiratory epithelium", "TISSUE", 106, 128], ["human", "SPECIES", 18, 23], ["coronavirus", "SPECIES", 24, 35], ["human coronavirus", "SPECIES", 18, 35], ["Studies", "TEST", 0, 7], ["the human coronavirus strain", "TEST", 14, 42], ["coronaviruses", "PROBLEM", 64, 77], ["the respiratory epithelium", "PROBLEM", 102, 128], ["ciliary dyskinesia", "PROBLEM", 133, 151], ["coronaviruses", "OBSERVATION", 64, 77], ["respiratory epithelium", "ANATOMY", 106, 128], ["ciliary dyskinesia", "OBSERVATION", 133, 151]]], ["If one supposes that an infection with CRCV may have a similar effect then the virus could play an important role in the early stages of the pathogenesis of CIRD.", [["infection", "DISEASE", 24, 33], ["CIRD", "DISEASE", 157, 161], ["CRCV", "CANCER", 39, 43], ["CIRD", "CANCER", 157, 161], ["CRCV", "SPECIES", 39, 43], ["an infection with CRCV", "PROBLEM", 21, 43], ["the virus", "PROBLEM", 75, 84], ["infection", "OBSERVATION", 24, 33]]], ["By damage of the respiratory epithelium and disruption of the ciliary clearance CRCV could facilitate the entry of other viral or bacterial pathogens causing the more severe respiratory symptoms.", [["respiratory epithelium", "ANATOMY", 17, 39], ["ciliary", "ANATOMY", 62, 69], ["respiratory", "ANATOMY", 174, 185], ["respiratory symptoms", "DISEASE", 174, 194], ["respiratory epithelium", "TISSUE", 17, 39], ["ciliary", "MULTI-TISSUE_STRUCTURE", 62, 69], ["CRCV", "GENE_OR_GENE_PRODUCT", 80, 84], ["the respiratory epithelium", "PROBLEM", 13, 39], ["the ciliary clearance CRCV", "PROBLEM", 58, 84], ["other viral or bacterial pathogens", "PROBLEM", 115, 149], ["the more severe respiratory symptoms", "PROBLEM", 158, 194], ["damage", "OBSERVATION", 3, 9], ["respiratory epithelium", "OBSERVATION", 17, 39], ["bacterial pathogens", "OBSERVATION", 130, 149], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["respiratory symptoms", "OBSERVATION", 174, 194]]], ["The less frequent detection of CRCV in tissue samples from dogs with more severe disease may be explained by the destruction of the respiratory epithelium by other microorganisms in the advanced stages of CIRD.", [["tissue samples", "ANATOMY", 39, 53], ["respiratory epithelium", "ANATOMY", 132, 154], ["CIRD", "DISEASE", 205, 209], ["CRCV", "CANCER", 31, 35], ["tissue samples", "TISSUE", 39, 53], ["dogs", "ORGANISM", 59, 63], ["respiratory epithelium", "TISSUE", 132, 154], ["CRCV", "PROTEIN", 31, 35], ["dogs", "SPECIES", 59, 63], ["CRCV", "SPECIES", 31, 35], ["CRCV in tissue samples", "PROBLEM", 31, 53], ["dogs", "PROBLEM", 59, 63], ["more severe disease", "PROBLEM", 69, 88], ["the destruction of the respiratory epithelium", "PROBLEM", 109, 154], ["other microorganisms", "PROBLEM", 158, 178], ["less", "OBSERVATION_MODIFIER", 4, 8], ["frequent", "OBSERVATION_MODIFIER", 9, 17], ["tissue", "ANATOMY", 39, 45], ["more severe", "OBSERVATION_MODIFIER", 69, 80], ["disease", "OBSERVATION", 81, 88], ["may be explained", "UNCERTAINTY", 89, 105], ["destruction", "OBSERVATION", 113, 124], ["respiratory epithelium", "ANATOMY", 132, 154], ["microorganisms", "OBSERVATION", 164, 178]]], ["At the same time it is likely that the immune response that is induced by CRCV in almost all dogs would help to clear the infection, causing the prevalence of CRCV RNA to be lower in later stages of the disease.DiscussionFurthermore, serological analysis revealed that dogs with antibodies to CRCV on the day of entry into the kennel developed respiratory disease less frequently than dogs RT-PCR results from tracheal and lung samples of 119 dogs with different respiratory signs (none to severe) using a nested PCR directed against the coronavirus spike gene.", [["respiratory", "ANATOMY", 344, 355], ["tracheal", "ANATOMY", 410, 418], ["lung samples", "ANATOMY", 423, 435], ["respiratory", "ANATOMY", 463, 474], ["infection", "DISEASE", 122, 131], ["respiratory disease", "DISEASE", 344, 363], ["respiratory signs", "DISEASE", 463, 480], ["CRCV", "GENE_OR_GENE_PRODUCT", 74, 78], ["dogs", "ORGANISM", 93, 97], ["CRCV", "GENE_OR_GENE_PRODUCT", 159, 163], ["dogs", "ORGANISM", 269, 273], ["tracheal", "MULTI-TISSUE_STRUCTURE", 410, 418], ["lung samples", "MULTI-TISSUE_STRUCTURE", 423, 435], ["dogs", "ORGANISM", 443, 447], ["coronavirus", "ORGANISM", 538, 549], ["CRCV RNA", "RNA", 159, 167], ["antibodies", "PROTEIN", 279, 289], ["CRCV", "PROTEIN", 293, 297], ["coronavirus spike gene", "DNA", 538, 560], ["dogs", "SPECIES", 93, 97], ["dogs", "SPECIES", 269, 273], ["dogs", "SPECIES", 385, 389], ["dogs", "SPECIES", 443, 447], ["CRCV", "SPECIES", 74, 78], ["CRCV", "SPECIES", 159, 163], ["CRCV", "SPECIES", 293, 297], ["the infection", "PROBLEM", 118, 131], ["CRCV RNA", "PROBLEM", 159, 167], ["the disease", "PROBLEM", 199, 210], ["serological analysis", "TEST", 234, 254], ["antibodies", "TREATMENT", 279, 289], ["respiratory disease", "PROBLEM", 344, 363], ["dogs RT-PCR", "TEST", 385, 396], ["tracheal and lung samples", "TEST", 410, 435], ["different respiratory signs", "PROBLEM", 453, 480], ["a nested PCR", "TREATMENT", 504, 516], ["the coronavirus spike gene", "PROBLEM", 534, 560], ["is likely", "UNCERTAINTY", 20, 29], ["immune response", "OBSERVATION", 39, 54], ["infection", "OBSERVATION", 122, 131], ["CRCV RNA", "OBSERVATION", 159, 167], ["lower", "OBSERVATION_MODIFIER", 174, 179], ["disease", "OBSERVATION", 203, 210], ["respiratory disease", "OBSERVATION", 344, 363], ["tracheal", "ANATOMY", 410, 418], ["lung", "ANATOMY", 423, 427]]], ["The table shows the number of positive samples out of total sample number and the percentage of positive samples in parentheses.", [["samples", "ANATOMY", 39, 46], ["sample", "ANATOMY", 60, 66], ["samples", "ANATOMY", 105, 112], ["positive samples in parentheses", "PROBLEM", 96, 127], ["positive", "OBSERVATION", 30, 38]]], ["Comparison of the prevalence of respiratory disease in two groups of dogs: Dogs in group 1 were positive for serum antibodies to respiratory coronavirus on the day of entry into the kennel; dogs in group 2 were negative.", [["respiratory", "ANATOMY", 32, 43], ["serum", "ANATOMY", 109, 114], ["respiratory disease", "DISEASE", 32, 51], ["respiratory coronavirus", "DISEASE", 129, 152], ["dogs", "ORGANISM", 69, 73], ["Dogs", "ORGANISM", 75, 79], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["respiratory coronavirus", "ORGANISM", 129, 152], ["dogs", "ORGANISM", 190, 194], ["serum antibodies", "PROTEIN", 109, 125], ["dogs", "SPECIES", 69, 73], ["dogs", "SPECIES", 190, 194], ["respiratory coronavirus", "SPECIES", 129, 152], ["respiratory disease", "PROBLEM", 32, 51], ["Dogs in group 1", "TEST", 75, 90], ["serum antibodies", "TEST", 109, 125], ["respiratory coronavirus", "PROBLEM", 129, 152], ["respiratory disease", "OBSERVATION", 32, 51], ["respiratory coronavirus", "OBSERVATION", 129, 152]]], ["The graph shows the percentage of dogs developing respiratory disease in group 1 compared to group 2 (P \u03fd 0.001).", [["respiratory", "ANATOMY", 50, 61], ["respiratory disease", "DISEASE", 50, 69], ["dogs", "ORGANISM", 34, 38], ["dogs", "SPECIES", 34, 38], ["The graph", "TEST", 0, 9], ["respiratory disease in group 1", "PROBLEM", 50, 80], ["percentage", "OBSERVATION_MODIFIER", 20, 30], ["respiratory disease", "OBSERVATION", 50, 69]]], ["N is the total number of dogs in each group. without antibodies (P \u03fd 0.001).", [["dogs", "ORGANISM", 25, 29], ["antibodies", "PROTEIN", 53, 63], ["dogs", "SPECIES", 25, 29], ["antibodies", "PROBLEM", 53, 63]]], ["Therefore the presence of antibodies to CRCV had a protective effect against respiratory disease in this population, indicating a possible role of the virus in the pathogenesis of CIRD.", [["respiratory", "ANATOMY", 77, 88], ["CRCV", "CHEMICAL", 40, 44], ["respiratory disease", "DISEASE", 77, 96], ["CIRD", "DISEASE", 180, 184], ["CRCV", "GENE_OR_GENE_PRODUCT", 40, 44], ["CIRD", "CANCER", 180, 184], ["antibodies", "PROTEIN", 26, 36], ["CRCV", "SPECIES", 40, 44], ["antibodies to CRCV", "PROBLEM", 26, 44], ["respiratory disease", "PROBLEM", 77, 96], ["the virus", "PROBLEM", 147, 156], ["virus", "OBSERVATION", 151, 156]]], ["However 50% of the dogs that were seropositive for CRCV on day 1 still developed respiratory disease.", [["respiratory", "ANATOMY", 81, 92], ["CRCV", "DISEASE", 51, 55], ["respiratory disease", "DISEASE", 81, 100], ["dogs", "ORGANISM", 19, 23], ["dogs", "SPECIES", 19, 23], ["CRCV", "SPECIES", 51, 55], ["CRCV", "TEST", 51, 55], ["respiratory disease", "PROBLEM", 81, 100], ["respiratory disease", "OBSERVATION", 81, 100]]], ["It was not determined if dogs which developed disease had lower antibody titers than those that stayed healthy as the ELISA was performed using a single serum dilution.", [["serum", "ANATOMY", 153, 158], ["dogs", "ORGANISM", 25, 29], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["dogs", "SPECIES", 25, 29], ["dogs", "PROBLEM", 25, 29], ["disease", "PROBLEM", 46, 53], ["lower antibody titers", "PROBLEM", 58, 79], ["the ELISA", "TEST", 114, 123], ["a single serum dilution", "TREATMENT", 144, 167]]], ["Alternatively, the disease in seropositive dogs may well have been caused by other respiratory pathogens present in this population.", [["dogs", "ORGANISM", 43, 47], ["dogs", "SPECIES", 43, 47], ["the disease in seropositive dogs", "PROBLEM", 15, 47], ["other respiratory pathogens", "PROBLEM", 77, 104], ["disease", "OBSERVATION", 19, 26], ["seropositive dogs", "OBSERVATION", 30, 47], ["respiratory", "OBSERVATION_MODIFIER", 83, 94], ["pathogens", "OBSERVATION", 95, 104]]], ["Studies determining the prevalence of other pathogens are currently under way.DiscussionAs CIRD is a complex disease involving a variety of microorganisms, further epidemiological studies are required to determine the exact role of CRCV in this syndrome.", [["CRCV", "CANCER", 232, 236], ["CRCV", "SPECIES", 232, 236], ["Studies", "TEST", 0, 7], ["other pathogens", "PROBLEM", 38, 53], ["a complex disease", "PROBLEM", 99, 116], ["microorganisms", "PROBLEM", 140, 154], ["further epidemiological studies", "TEST", 156, 187], ["this syndrome", "PROBLEM", 240, 253], ["pathogens", "OBSERVATION", 44, 53]]], ["It is likely that infections with CRCV alone may cause only subclinical or mild respiratory symptoms but in conjunction with other pathogenic agents severe respiratory disease may occur.", [["respiratory", "ANATOMY", 80, 91], ["respiratory", "ANATOMY", 156, 167], ["infections", "DISEASE", 18, 28], ["CRCV", "CHEMICAL", 34, 38], ["respiratory symptoms", "DISEASE", 80, 100], ["respiratory disease", "DISEASE", 156, 175], ["CRCV", "SPECIES", 34, 38], ["infections", "PROBLEM", 18, 28], ["CRCV", "TREATMENT", 34, 38], ["subclinical or mild respiratory symptoms", "PROBLEM", 60, 100], ["other pathogenic agents severe respiratory disease", "PROBLEM", 125, 175], ["is likely", "UNCERTAINTY", 3, 12], ["infections", "OBSERVATION", 18, 28], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["respiratory symptoms", "OBSERVATION", 80, 100], ["respiratory disease", "OBSERVATION", 156, 175]]], ["Alternatively, the presence of CRCV may exacerbate disease caused by other agents.DiscussionThis study describes the detection of a canine respiratory coronavirus in dogs with CIRD, which is genetically and antigenically distinct from the previously described enteric coronavirus.", [["CRCV", "CHEMICAL", 31, 35], ["respiratory coronavirus", "DISEASE", 139, 162], ["CIRD", "DISEASE", 176, 180], ["enteric coronavirus", "DISEASE", 260, 279], ["CRCV", "GENE_OR_GENE_PRODUCT", 31, 35], ["canine respiratory coronavirus", "ORGANISM", 132, 162], ["dogs", "ORGANISM", 166, 170], ["enteric coronavirus", "ORGANISM", 260, 279], ["canine respiratory coronavirus", "SPECIES", 132, 162], ["dogs", "SPECIES", 166, 170], ["CRCV", "SPECIES", 31, 35], ["canine respiratory coronavirus", "SPECIES", 132, 162], ["CRCV", "PROBLEM", 31, 35], ["disease", "PROBLEM", 51, 58], ["This study", "TEST", 92, 102], ["a canine respiratory coronavirus in dogs", "PROBLEM", 130, 170], ["CIRD", "TREATMENT", 176, 180], ["the previously described enteric coronavirus", "PROBLEM", 235, 279], ["respiratory coronavirus", "OBSERVATION", 139, 162], ["enteric coronavirus", "OBSERVATION", 260, 279]]], ["The pathogenesis of \"kennel cough\" has not been thoroughly investigated since the 1970s, when B. bronchiseptica, canine adenovirus type 2, and canine parainfluenza were determined to be the main causes of the disease.", [["cough", "DISEASE", 28, 33], ["parainfluenza", "DISEASE", 150, 163], ["B. bronchiseptica", "ORGANISM", 94, 111], ["canine adenovirus type 2", "ORGANISM", 113, 137], ["canine parainfluenza", "ORGANISM", 143, 163], ["B. bronchiseptica", "SPECIES", 94, 111], ["canine", "SPECIES", 113, 119], ["canine", "SPECIES", 143, 149], ["parainfluenza", "SPECIES", 150, 163], ["B. bronchiseptica", "SPECIES", 94, 111], ["canine adenovirus type 2", "SPECIES", 113, 137], ["canine parainfluenza", "SPECIES", 143, 163], ["\"kennel cough", "PROBLEM", 20, 33], ["B. bronchiseptica", "PROBLEM", 94, 111], ["canine adenovirus type 2", "PROBLEM", 113, 137], ["canine parainfluenza", "PROBLEM", 143, 163], ["the disease", "PROBLEM", 205, 216], ["disease", "OBSERVATION", 209, 216]]], ["However, the vaccination of all dogs against CPIV, CAV-2, and distemper virus did not help to control the disease in this kennel despite evidence that the majority of dogs responded to the vaccine within 21 days (data not shown).", [["dogs", "ORGANISM", 32, 36], ["CAV-2", "ORGANISM", 51, 56], ["distemper virus", "ORGANISM", 62, 77], ["dogs", "ORGANISM", 167, 171], ["dogs", "SPECIES", 32, 36], ["distemper virus", "SPECIES", 62, 77], ["dogs", "SPECIES", 167, 171], ["CPIV", "SPECIES", 45, 49], ["CAV-2", "SPECIES", 51, 56], ["distemper virus", "SPECIES", 62, 77], ["all dogs", "TREATMENT", 28, 36], ["CPIV", "PROBLEM", 45, 49], ["CAV", "TEST", 51, 54], ["distemper virus", "PROBLEM", 62, 77], ["the disease", "PROBLEM", 102, 113], ["the vaccine", "TREATMENT", 185, 196], ["CAV", "ANATOMY", 51, 54], ["disease", "OBSERVATION", 106, 113]]], ["A B. bronchiseptica vaccine had been used in the past prior to this study but was discontinued because it failed to protect against respiratory disease.", [["respiratory", "ANATOMY", 132, 143], ["respiratory disease", "DISEASE", 132, 151], ["B. bronchiseptica", "ORGANISM", 2, 19], ["B. bronchiseptica vaccine", "SPECIES", 2, 27], ["B. bronchiseptica", "SPECIES", 2, 19], ["A B. bronchiseptica vaccine", "TREATMENT", 0, 27], ["this study", "TEST", 63, 73], ["respiratory disease", "PROBLEM", 132, 151]]], ["Most rehoming and training kennels frequently have to deal with outbreaks of CIRD despite regular vaccination of all dogs.", [["CIRD", "DISEASE", 77, 81], ["CIRD", "CANCER", 77, 81], ["dogs", "ORGANISM", 117, 121], ["dogs", "SPECIES", 117, 121], ["CIRD", "TREATMENT", 77, 81], ["all dogs", "TREATMENT", 113, 121]]], ["The aetiology of CIRD therefore needs to be reevaluated and the role of novel microorganisms or microorganisms previously not associated with the disease should be established.Study populationDogs from a well-established rehoming kennel with a history of endemic respiratory disease were monitored for this study.", [["respiratory", "ANATOMY", 263, 274], ["CIRD", "DISEASE", 17, 21], ["respiratory disease", "DISEASE", 263, 282], ["novel microorganisms", "PROBLEM", 72, 92], ["microorganisms", "PROBLEM", 96, 110], ["the disease", "PROBLEM", 142, 153], ["Study populationDogs", "TEST", 176, 196], ["endemic respiratory disease", "PROBLEM", 255, 282], ["this study", "TEST", 302, 312], ["disease", "OBSERVATION", 146, 153], ["endemic", "OBSERVATION_MODIFIER", 255, 262], ["respiratory disease", "OBSERVATION", 263, 282]]], ["On entry into the kennel, all dogs were vaccinated with KAVAK DA 2 PiP69 (Fort Dodge), a live attenuated vaccine for distemper virus, canine adenovirus type 2, canine parainfluenzavirus, and canine parvovirus.", [["KAVAK DA 2 PiP69", "CHEMICAL", 56, 72], ["distemper virus", "DISEASE", 117, 132], ["canine parvovirus", "DISEASE", 191, 208], ["dogs", "ORGANISM", 30, 34], ["distemper virus", "ORGANISM", 117, 132], ["canine adenovirus type 2", "ORGANISM", 134, 158], ["canine", "ORGANISM", 160, 166], ["parainfluenzavirus", "ORGANISM", 167, 185], ["canine parvovirus", "ORGANISM", 191, 208], ["dogs", "SPECIES", 30, 34], ["distemper virus", "SPECIES", 117, 132], ["canine adenovirus", "SPECIES", 134, 151], ["canine", "SPECIES", 160, 166], ["canine parvovirus", "SPECIES", 191, 208], ["distemper virus", "SPECIES", 117, 132], ["canine adenovirus type 2", "SPECIES", 134, 158], ["canine", "SPECIES", 160, 166], ["canine parvovirus", "SPECIES", 191, 208], ["KAVAK DA", "TREATMENT", 56, 64], ["a live attenuated vaccine", "TREATMENT", 87, 112], ["distemper virus", "PROBLEM", 117, 132], ["canine parainfluenzavirus", "TREATMENT", 160, 185], ["canine parvovirus", "PROBLEM", 191, 208]]], ["Also, a killed leptospirosis vaccine was used (Fort Dodge).", [["leptospirosis", "DISEASE", 15, 28], ["a killed leptospirosis vaccine", "TREATMENT", 6, 36]]], ["The health status of each dog was assessed twice a day by a veterinary clinician and the respiratory signs were graded as follows: (1) no respiratory signs, (2) mild cough, (3) cough and nasal discharge, (4) cough, nasal discharge, and inappetence, (5) evidence of bronchopneumonia.", [["respiratory", "ANATOMY", 89, 100], ["respiratory", "ANATOMY", 138, 149], ["nasal", "ANATOMY", 187, 192], ["nasal", "ANATOMY", 215, 220], ["cough", "DISEASE", 166, 171], ["cough", "DISEASE", 177, 182], ["cough", "DISEASE", 208, 213], ["inappetence", "DISEASE", 236, 247], ["bronchopneumonia", "DISEASE", 265, 281], ["dog", "ORGANISM", 26, 29], ["nasal", "ORGANISM_SUBDIVISION", 187, 192], ["nasal", "ORGANISM_SUBDIVISION", 215, 220], ["dog", "SPECIES", 26, 29], ["dog", "SPECIES", 26, 29], ["the respiratory signs", "TEST", 85, 106], ["respiratory signs", "PROBLEM", 138, 155], ["mild cough", "PROBLEM", 161, 171], ["cough", "PROBLEM", 177, 182], ["nasal discharge", "PROBLEM", 187, 202], ["cough", "PROBLEM", 208, 213], ["nasal discharge", "PROBLEM", 215, 230], ["inappetence", "PROBLEM", 236, 247], ["bronchopneumonia", "PROBLEM", 265, 281], ["mild", "OBSERVATION_MODIFIER", 161, 165], ["cough", "OBSERVATION", 166, 171], ["nasal", "ANATOMY", 187, 192], ["nasal", "ANATOMY", 215, 220], ["bronchopneumonia", "OBSERVATION", 265, 281]]], ["The overall health status of the dogs was graded as follows: (1) good health, (2) poor health, (3) very poor health.", [["dogs", "ORGANISM", 33, 37], ["dogs", "SPECIES", 33, 37]]], ["The age, breed, and sex of the dogs were recorded.Study populationOne hundred and nineteen dogs from the kennel population were euthanased for welfare reasons, ranging from behavioral problems to signs of severe respiratory disease For these dogs, a full postmortem examination was performed.", [["respiratory", "ANATOMY", 212, 223], ["respiratory disease", "DISEASE", 212, 231], ["dogs", "ORGANISM", 31, 35], ["dogs", "ORGANISM", 91, 95], ["dogs", "ORGANISM", 242, 246], ["dogs", "SPECIES", 31, 35], ["dogs", "SPECIES", 91, 95], ["dogs", "SPECIES", 242, 246], ["Study population", "TEST", 50, 66], ["behavioral problems", "PROBLEM", 173, 192], ["severe respiratory disease", "PROBLEM", 205, 231], ["a full postmortem examination", "TEST", 248, 277], ["severe", "OBSERVATION_MODIFIER", 205, 211], ["respiratory disease", "OBSERVATION", 212, 231]]], ["The tissue samples were stored at \u03ea70\u00b0C until further use.Study populationSerum samples were collected from 111 dogs on the day of entry into the rehoming kennel.", [["tissue samples", "ANATOMY", 4, 18], ["populationSerum samples", "ANATOMY", 64, 87], ["tissue samples", "CANCER", 4, 18], ["populationSerum samples", "CANCER", 64, 87], ["dogs", "ORGANISM", 112, 116], ["dogs", "SPECIES", 112, 116], ["The tissue samples", "TEST", 0, 18], ["Study populationSerum samples", "TEST", 58, 87]]], ["For 81 dogs a follow-up serum was available on day 7 and for 111 dogs a serum was available on day 21 after entry.", [["serum", "ANATOMY", 24, 29], ["serum", "ANATOMY", 72, 77], ["dogs", "ORGANISM", 7, 11], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["dogs", "ORGANISM", 65, 69], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["dogs", "SPECIES", 7, 11], ["dogs", "SPECIES", 65, 69], ["a follow-up serum", "TEST", 12, 29], ["a serum", "TEST", 70, 77]]], ["Of the 111 dogs, 30 remained healthy during the 21 days between the first and the last serum samples, whereas 81 dogs developed respiratory disease.Study populationSera from 35 dogs housed elsewhere were obtained from the diagnostic service of the Royal Veterinary College.", [["serum samples", "ANATOMY", 87, 100], ["respiratory", "ANATOMY", 128, 139], ["respiratory disease", "DISEASE", 128, 147], ["dogs", "ORGANISM", 11, 15], ["serum samples", "ORGANISM_SUBSTANCE", 87, 100], ["dogs", "ORGANISM", 113, 117], ["dogs", "ORGANISM", 177, 181], ["dogs", "SPECIES", 11, 15], ["dogs", "SPECIES", 113, 117], ["dogs", "SPECIES", 177, 181], ["the last serum samples", "TEST", 78, 100], ["respiratory disease", "PROBLEM", 128, 147], ["Study populationSera", "TEST", 148, 168], ["respiratory disease", "OBSERVATION", 128, 147]]], ["These sera had been submitted for biochemical analysis for various reasons.", [["sera", "ANATOMY", 6, 10], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["biochemical analysis", "TEST", 34, 54]]], ["Five of these sera were from 18-month-old beagles with no history of respiratory disease.", [["sera", "ANATOMY", 14, 18], ["respiratory", "ANATOMY", 69, 80], ["respiratory disease", "DISEASE", 69, 88], ["sera", "ORGANISM_SUBSTANCE", 14, 18], ["beagles", "ORGANISM", 42, 49], ["these sera", "TEST", 8, 18], ["respiratory disease", "PROBLEM", 69, 88], ["no", "UNCERTAINTY", 55, 57], ["respiratory disease", "OBSERVATION", 69, 88]]], ["Sera were routinely stored at \u03ea20\u00b0C.RNA extraction and RT-PCRRNA was extracted from tracheal and lung tissue of 119 dogs using TriReagent (Sigma).", [["Sera", "ANATOMY", 0, 4], ["tracheal", "ANATOMY", 84, 92], ["lung tissue", "ANATOMY", 97, 108], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["tracheal", "TISSUE", 84, 92], ["lung tissue", "TISSUE", 97, 108], ["dogs", "ORGANISM", 116, 120], ["PCRRNA", "PROTEIN", 58, 64], ["dogs", "SPECIES", 116, 120], ["RNA extraction", "TREATMENT", 36, 50], ["RT-PCRRNA", "TREATMENT", 55, 64], ["PCRRNA", "ANATOMY", 58, 64], ["tracheal", "ANATOMY", 84, 92], ["lung", "ANATOMY", 97, 101], ["tissue", "ANATOMY_MODIFIER", 102, 108]]], ["Approximately 25-50 mg of homogenized tissue was used and RNA was extracted as recommended by the manufacturer.RNA extraction and RT-PCRSynthesis of cDNA was performed using Random Hexameres (Roche) and ImPromII reverse transcriptase (Promega).RNA extraction and RT-PCRFor the detection of coronaviruses a modification of the primers 2Bp and 4Bm directed against the polymerase gene as described by Stephensen et al. (1999) were used (Con-scoro5, 5\u0408-ACT-CAR-ATG-AAT-TTG-AAA-TAT-GC; Con-scoro6, 5\u0408-TCA-CAC-TTA-GGA-TAR-TCC-CA).RNA extraction and RT-PCRPCR was performed using Taq polymerase (Promega) in the provided reaction buffer containing a final concentration of 2.5 mM MgCl 2 and 0.5 M primers.", [["tissue", "ANATOMY", 38, 44], ["MgCl", "CHEMICAL", 674, 678], ["tissue", "TISSUE", 38, 44], ["ImPromII reverse transcriptase", "GENE_OR_GENE_PRODUCT", 203, 233], ["coronaviruses", "ORGANISM", 290, 303], ["2Bp", "GENE_OR_GENE_PRODUCT", 334, 337], ["4Bm", "GENE_OR_GENE_PRODUCT", 342, 345], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 574, 588], ["cDNA", "DNA", 149, 153], ["Random Hexameres", "DNA", 174, 190], ["ImPromII reverse transcriptase", "PROTEIN", 203, 233], ["primers 2Bp", "DNA", 326, 337], ["4Bm", "DNA", 342, 345], ["polymerase gene", "DNA", 367, 382], ["CAR", "DNA", 454, 457], ["ATG", "DNA", 458, 461], ["AAT", "DNA", 462, 465], ["AAA", "DNA", 470, 473], ["TAT", "DNA", 474, 477], ["Con-scoro6", "DNA", 482, 492], ["5\u0408", "DNA", 494, 496], ["TCA-", "DNA", 497, 501], ["TTA", "DNA", 505, 508], ["GGA", "DNA", 509, 512], ["TAR", "DNA", 513, 516], ["TCC", "DNA", 517, 520], ["CA", "DNA", 521, 523], ["Taq polymerase", "PROTEIN", 574, 588], ["RNA", "TREATMENT", 58, 61], ["RNA extraction", "TEST", 111, 125], ["RT-PCRSynthesis of cDNA", "TREATMENT", 130, 153], ["Random Hexameres (Roche)", "TREATMENT", 174, 198], ["ImPromII reverse transcriptase (Promega)", "TREATMENT", 203, 243], ["RNA extraction", "TREATMENT", 244, 258], ["RT", "TREATMENT", 263, 265], ["coronaviruses", "PROBLEM", 290, 303], ["the primers 2Bp", "TREATMENT", 322, 337], ["4Bm", "TREATMENT", 342, 345], ["Con-scoro5", "TEST", 435, 445], ["ACT", "TEST", 450, 453], ["CAR", "TEST", 454, 457], ["ATG", "TEST", 458, 461], ["AAT", "TEST", 462, 465], ["TTG", "TEST", 466, 469], ["AAA", "TEST", 470, 473], ["TAT", "TEST", 474, 477], ["GC", "TEST", 478, 480], ["Con-scoro6", "TEST", 482, 492], ["CAC", "TEST", 501, 504], ["TTA", "TEST", 505, 508], ["GGA", "TEST", 509, 512], ["RNA extraction", "TREATMENT", 525, 539], ["RT-PCRPCR", "TEST", 544, 553], ["Taq polymerase (Promega)", "TREATMENT", 574, 598], ["a final concentration of 2.5 mM MgCl", "TREATMENT", 642, 678], ["coronaviruses", "OBSERVATION", 290, 303], ["AAA", "ANATOMY", 470, 473]]], ["For PCR with the primers Conscoro5 and Conscoro6 the following temperature profile was used: After denaturation at 95\u00b0C for 5 min, 10 cycles were carried out at 95\u00b0C for 1 min, annealing at 37\u00b0C for 1 min, and extension at 72\u00b0C for 1 min.", [["primers Conscoro5", "DNA", 17, 34], ["Conscoro6", "DNA", 39, 48], ["PCR", "TEST", 4, 7]]], ["This was followed by 10 cycles using an annealing temperature of 45\u00b0C, 10 cycles at an annealing temperature of 50\u00b0C, and 10 cycles at an annealing temperature of 53\u00b0C, followed by a final extension at 72\u00b0C for 10 min.RNA extraction and RT-PCRA 20-l fraction of the PCR product was analyzed on a 1.5% agarose gel and blotted onto a nylon membrane after electrophoresis.", [["nylon membrane", "ANATOMY", 332, 346], ["agarose", "SIMPLE_CHEMICAL", 301, 308], ["membrane", "CELLULAR_COMPONENT", 338, 346], ["an annealing temperature", "TREATMENT", 37, 61], ["an annealing temperature", "TREATMENT", 84, 108], ["an annealing temperature", "TEST", 135, 159], ["RNA extraction", "TEST", 218, 232], ["RT", "TEST", 237, 239], ["PCRA", "TEST", 240, 244], ["the PCR product", "TREATMENT", 262, 277], ["a 1.5% agarose gel", "TREATMENT", 294, 312], ["a nylon membrane", "TREATMENT", 330, 346]]], ["The nylon membrane was hybridized with an oligonucleotide probe specific for the PCR product at 37\u00b0C overnight (Probe Conscoro, AAG-TTT-TAT-GGY-GGY-TGG-GA).", [["nylon membrane", "ANATOMY", 4, 18], ["nylon membrane", "CELLULAR_COMPONENT", 4, 18], ["Probe Conscoro, AAG-TTT-TAT", "DNA", 112, 139], ["GGY", "DNA", 140, 143], ["GGY", "DNA", 144, 147], ["The nylon membrane", "TREATMENT", 0, 18], ["an oligonucleotide probe", "TREATMENT", 39, 63], ["the PCR product", "TREATMENT", 77, 92], ["Conscoro", "TEST", 118, 126], ["AAG", "TEST", 128, 131], ["TTT", "TEST", 132, 135], ["TAT", "TEST", 136, 139], ["GGY", "TEST", 140, 143], ["nylon membrane", "OBSERVATION", 4, 18]]], ["The probe was 3\u0408A-tailed with digoxi-genin-dUTP and was detected using anti-digoxigenin conjugate and CSPD chemoluminescent substrate (Roche).RNA extraction and RT-PCRPrimers for the HE gene were chosen using an alignment of the HE genes of BCV strain LY-138 (GenBank Accession No.", [["digoxi-genin-dUTP", "CHEMICAL", 30, 47], ["LY-138", "CHEMICAL", 252, 258], ["digoxi-genin", "CHEMICAL", 30, 42], ["dUTP", "CHEMICAL", 43, 47], ["anti-digoxigenin", "CHEMICAL", 71, 87], ["digoxi-genin", "SIMPLE_CHEMICAL", 30, 42], ["dUTP", "SIMPLE_CHEMICAL", 43, 47], ["anti-digoxigenin conjugate", "SIMPLE_CHEMICAL", 71, 97], ["CSPD", "SIMPLE_CHEMICAL", 102, 106], ["HE", "GENE_OR_GENE_PRODUCT", 183, 185], ["HE", "GENE_OR_GENE_PRODUCT", 229, 231], ["BCV", "ORGANISM", 241, 244], ["3\u0408A", "DNA", 14, 17], ["anti-digoxigenin conjugate", "PROTEIN", 71, 97], ["RT-PCRPrimers", "DNA", 161, 174], ["HE gene", "DNA", 183, 190], ["HE genes", "DNA", 229, 237], ["BCV strain LY-138", "SPECIES", 241, 258], ["The probe", "TREATMENT", 0, 9], ["digoxi-genin", "TREATMENT", 30, 42], ["dUTP", "TREATMENT", 43, 47], ["anti-digoxigenin conjugate", "TREATMENT", 71, 97], ["CSPD chemoluminescent substrate", "TREATMENT", 102, 133], ["RNA extraction", "TREATMENT", 142, 156], ["RT-PCRPrimers", "TREATMENT", 161, 174], ["the HE gene", "TREATMENT", 179, 190], ["BCV strain LY", "TEST", 241, 254]]], ["M84486) and HCV strain OC43 (GenBank Accession No.", [["M84486", "CHEMICAL", 0, 6], ["HCV", "SPECIES", 12, 15], ["OC43", "SPECIES", 23, 27], ["HCV strain OC43", "PROBLEM", 12, 27]]], ["M76373).", [["M76373", "CHEMICAL", 0, 6], ["M76373", "CHEMICAL", 0, 6]]], ["The following temperature profile was used for the PCR: denaturation at 95\u00b0C for 5 min, followed by 35 cycles of 95\u00b0C for 1 min, 50\u00b0C for 40 s, and 72\u00b0C for 1 min, followed by a final extension at 72\u00b0C for 10 min.", [["The following temperature profile", "TEST", 0, 33], ["the PCR", "TEST", 47, 54], ["denaturation", "PROBLEM", 56, 68]]], ["The expected size of the PCR product was 497 bp.RNA extraction and RT-PCRPrimer sequences specific for the spike gene were derived from an alignment of the spike region of bovine coronavirus strain LY-138 (GenBank Accession No.", [["LY-138", "CHEMICAL", 198, 204], ["bovine", "ORGANISM", 172, 178], ["coronavirus strain LY-138", "ORGANISM", 179, 204], ["RT-PCRPrimer sequences", "DNA", 67, 89], ["spike gene", "DNA", 107, 117], ["spike region", "DNA", 156, 168], ["bovine", "SPECIES", 172, 178], ["coronavirus", "SPECIES", 179, 190], ["bovine coronavirus strain LY-138", "SPECIES", 172, 204], ["the PCR product", "TEST", 21, 36], ["bp", "TEST", 45, 47], ["RNA extraction", "TREATMENT", 48, 62], ["RT-PCRPrimer sequences", "TEST", 67, 89], ["the spike gene", "PROBLEM", 103, 117], ["bovine coronavirus strain LY", "PROBLEM", 172, 200], ["size", "OBSERVATION_MODIFIER", 13, 17], ["bovine coronavirus", "OBSERVATION", 172, 190]]], ["AF 058942) and human coronavirus strain OC43 (GenBank Accession No.", [["AF 058942", "CHEMICAL", 0, 9], ["human", "ORGANISM", 15, 20], ["coronavirus strain OC43", "ORGANISM", 21, 44], ["human", "SPECIES", 15, 20], ["coronavirus", "SPECIES", 21, 32], ["human coronavirus", "SPECIES", 15, 32], ["AF", "PROBLEM", 0, 2], ["human coronavirus strain OC43", "PROBLEM", 15, 44]]], ["L14643).RNA extraction and RT-PCRFor sequencing of the complete spike gene the primers Sp1-Sp8, SpF, and SpR were designed.", [["L14643", "CHEMICAL", 0, 6], ["L14643", "CHEMICAL", 0, 6], ["Sp1", "GENE_OR_GENE_PRODUCT", 87, 90], ["Sp8", "GENE_OR_GENE_PRODUCT", 91, 94], ["SpF", "GENE_OR_GENE_PRODUCT", 96, 99], ["SpR", "GENE_OR_GENE_PRODUCT", 105, 108], ["spike gene", "DNA", 64, 74], ["Sp1", "PROTEIN", 87, 90], ["Sp8", "DNA", 91, 94], ["SpF", "DNA", 96, 99], ["SpR", "DNA", 105, 108], ["RNA extraction", "TREATMENT", 8, 22], ["RT-PCRFor sequencing", "TEST", 27, 47], ["the primers Sp1", "TEST", 75, 90], ["SpF", "TEST", 96, 99]]], ["Table 1 shows the primer sequences.", [["primer sequences", "DNA", 18, 34], ["the primer sequences", "TEST", 14, 34]]], ["A PCR was performed using Pfu polymerase (Promega) and the following temperature profile: denaturation at 95\u00b0C for 5 min, followed by 35 cycles of 95\u00b0C for 1 min, 50\u00b0C for 40 s, and 72\u00b0C for 3 min.", [["Pfu polymerase", "PROTEIN", 26, 40], ["A PCR", "TEST", 0, 5], ["denaturation", "PROBLEM", 90, 102]]], ["The final extension was performed at 72\u00b0C for 10 min.RNA extraction and RT-PCRThe PCR products were separated on an agarose gel and purified using the Qiaquick gel purification kit (Qiagen).", [["agarose", "SIMPLE_CHEMICAL", 116, 123], ["RNA extraction", "TREATMENT", 53, 67], ["RT-PCRThe PCR products", "TREATMENT", 72, 94], ["an agarose gel", "TREATMENT", 113, 127], ["the Qiaquick gel purification kit", "TREATMENT", 147, 180]]], ["PCR products were cloned into the pT7blue2 blunt vector (Novagen) and sequenced using the Thermo sequenase fluorescent labeled primer cycle sequencing kit with 7-deaza-dGTP (Amersham Pharmacia) using Cy5-labeled primers.RNA extraction and RT-PCRFor the detection of coronavirus RNA in tissue samples, the cDNA was tested by PCR with the primers Sp1 and Sp2, followed by a nested PCR using the primers Sp3 and Sp4 and 2 l of the product of the first amplification.RNA extraction and RT-PCRThe temperature profile used was denaturation at 95\u00b0C for 5 min, followed by 35 cycles of 95\u00b0C for 1 min, 55\u00b0C for 40 s, and 72\u00b0C for 1 min.", [["tissue samples", "ANATOMY", 285, 299], ["7-deaza-dGTP", "CHEMICAL", 160, 172], ["7-deaza-dGTP", "CHEMICAL", 160, 172], ["Novagen", "GENE_OR_GENE_PRODUCT", 57, 64], ["7-deaza-dGTP", "SIMPLE_CHEMICAL", 160, 172], ["Cy5", "SIMPLE_CHEMICAL", 200, 203], ["coronavirus", "ORGANISM", 266, 277], ["tissue samples", "CANCER", 285, 299], ["Sp1", "GENE_OR_GENE_PRODUCT", 345, 348], ["Sp2", "GENE_OR_GENE_PRODUCT", 353, 356], ["Sp3", "GENE_OR_GENE_PRODUCT", 401, 404], ["PCR products", "DNA", 0, 12], ["pT7blue2 blunt vector", "DNA", 34, 55], ["Novagen", "DNA", 57, 64], ["Cy5-labeled primers", "DNA", 200, 219], ["coronavirus RNA", "RNA", 266, 281], ["cDNA", "DNA", 305, 309], ["Sp1", "PROTEIN", 345, 348], ["Sp2", "DNA", 353, 356], ["Sp3", "PROTEIN", 401, 404], ["Sp4", "PROTEIN", 409, 412], ["coronavirus", "SPECIES", 266, 277], ["PCR products", "TREATMENT", 0, 12], ["the Thermo sequenase fluorescent", "TREATMENT", 86, 118], ["sequencing kit", "TEST", 140, 154], ["dGTP (Amersham Pharmacia", "TREATMENT", 168, 192], ["Cy5-labeled primers", "TREATMENT", 200, 219], ["RNA extraction", "TREATMENT", 220, 234], ["RT", "TREATMENT", 239, 241], ["coronavirus RNA in tissue samples", "PROBLEM", 266, 299], ["the cDNA", "TEST", 301, 309], ["the primers Sp1", "TEST", 333, 348], ["a nested PCR", "TEST", 370, 382], ["the primers Sp3", "TEST", 389, 404], ["Sp4", "TEST", 409, 412], ["the first amplification", "TREATMENT", 439, 462], ["RNA extraction", "TREATMENT", 463, 477], ["RT-PCRThe temperature profile", "TREATMENT", 482, 511], ["denaturation", "PROBLEM", 521, 533], ["coronavirus RNA", "OBSERVATION", 266, 281]]], ["The nested PCR produced a 442-bp fragment.Phylogenetic analysisNucleic acid similarity searches were performed using FASTA (Pearson, 1990) , with a gap open penalty of 16 and a gap extension penalty of 4.", [["analysisNucleic acid", "SIMPLE_CHEMICAL", 55, 75], ["442-bp fragment", "DNA", 26, 41], ["The nested PCR", "TEST", 0, 14], ["a 442-bp fragment", "TREATMENT", 24, 41], ["Phylogenetic analysisNucleic acid similarity searches", "TEST", 42, 95], ["a gap open penalty", "TEST", 146, 164], ["a gap extension penalty", "TEST", 175, 198], ["fragment", "OBSERVATION_MODIFIER", 33, 41]]], ["Protein similarities were determined using FASTA or GCG (Genetics Computer Group, Wisconsin, USA) with a gap open penalty of 8 and a gap extension penalty of 2.Phylogenetic analysisSequence alignments were performed using ClustalX (Thompson et al., 1997) .Phylogenetic analysisThe phylogenetic relationship to known coronaviruses was analyzed using the Phylip 3.6 package (Felsenstein, 1989) .", [["coronaviruses", "ORGANISM", 316, 329], ["Protein similarities", "TEST", 0, 20], ["a gap open penalty", "TEST", 103, 121], ["a gap extension penalty", "TEST", 131, 154], ["Phylogenetic analysisSequence alignments", "TEST", 160, 200], ["Phylogenetic analysis", "TEST", 256, 277], ["known coronaviruses", "PROBLEM", 310, 329], ["coronaviruses", "OBSERVATION", 316, 329]]], ["The alignments were followed by a bootstrap analysis using the Seqboot program.", [["a bootstrap analysis", "TEST", 32, 52], ["the Seqboot program", "TREATMENT", 59, 78]]], ["The data sets obtained were used for a maximum parsimony analysis using the DNApars program and a consensus tree was calculated using Con-sense.", [["a maximum parsimony analysis", "TEST", 37, 65], ["the DNApars program", "TREATMENT", 72, 91]]], ["The resulting trees were drawn using the Treeview program (Page, 1996) .GenBank Accession numbersThe CRCV polymerase partial sequence has been assigned GenBank Accession No.", [["CRCV", "GENE_OR_GENE_PRODUCT", 101, 105], ["CRCV polymerase partial sequence", "DNA", 101, 133], ["CRCV", "SPECIES", 101, 105], ["The CRCV polymerase partial sequence", "PROBLEM", 97, 133]]], ["AY150273; the CRCV spike gene sequence has been assigned GenBank Accession No.", [["AY150273", "CHEMICAL", 0, 8], ["AY150273", "GENE_OR_GENE_PRODUCT", 0, 8], ["CRCV", "GENE_OR_GENE_PRODUCT", 14, 18], ["CRCV spike gene sequence", "DNA", 14, 38], ["the CRCV spike gene sequence", "PROBLEM", 10, 38]]], ["AY150272.ELISAELISA antigen for bovine coronavirus or canine coronavirus (Churchill Applied Biosciences, Huntingdon, UK) was resuspended in PBS at the concentration recommended by the manufacturer and incubated on 96-well plates (Falcon) overnight at 37\u00b0C. The plates were washed with PBS and blocked with PBS containing 5% skimmed milk powder for 30 min.", [["milk", "ANATOMY", 332, 336], ["AY150272", "CHEMICAL", 0, 8], ["AY150272", "CHEMICAL", 0, 8], ["AY150272", "SIMPLE_CHEMICAL", 0, 8], ["bovine", "ORGANISM", 32, 38], ["coronavirus", "ORGANISM", 39, 50], ["canine coronavirus", "ORGANISM", 54, 72], ["milk", "ORGANISM_SUBSTANCE", 332, 336], ["ELISAELISA antigen", "PROTEIN", 9, 27], ["bovine", "SPECIES", 32, 38], ["coronavirus", "SPECIES", 39, 50], ["canine coronavirus", "SPECIES", 54, 72], ["bovine coronavirus", "SPECIES", 32, 50], ["canine coronavirus", "SPECIES", 54, 72], ["ELISAELISA antigen", "TEST", 9, 27], ["bovine coronavirus", "PROBLEM", 32, 50], ["canine coronavirus", "PROBLEM", 54, 72], ["The plates", "TREATMENT", 257, 267], ["PBS", "TREATMENT", 285, 288], ["PBS", "TREATMENT", 306, 309], ["5% skimmed milk powder", "TREATMENT", 321, 343], ["plates", "OBSERVATION_MODIFIER", 261, 267]]], ["The sera were diluted 1:100 in blocking buffer and incubated on the plates for 1 h.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["The sera", "TREATMENT", 0, 8], ["blocking buffer", "TREATMENT", 31, 46]]], ["After washing with PBS/0.05% Tween 20 (Sigma), a peroxidase-labeled rabbit anti-dog IgG conjugate (Sigma) was added (1:5000 in PBS/ 0.05% Tween 20) for 1 h.", [["Tween 20", "CHEMICAL", 29, 37], ["Tween 20", "CHEMICAL", 138, 146], ["Tween 20", "SIMPLE_CHEMICAL", 29, 37], ["Sigma", "SIMPLE_CHEMICAL", 39, 44], ["peroxidase", "SIMPLE_CHEMICAL", 49, 59], ["rabbit", "ORGANISM", 68, 74], ["anti-dog IgG conjugate", "SIMPLE_CHEMICAL", 75, 97], ["Sigma", "SIMPLE_CHEMICAL", 99, 104], ["peroxidase-labeled rabbit anti-dog IgG conjugate", "PROTEIN", 49, 97], ["rabbit", "SPECIES", 68, 74], ["rabbit", "SPECIES", 68, 74], ["PBS", "TREATMENT", 19, 22], ["a peroxidase-labeled rabbit anti-dog IgG conjugate", "TREATMENT", 47, 97]]], ["The plates were incubated with color substrate (OPD, Sigma) for 10 min and the reaction was stopped by adding 2 M H 2 SO 4 .", [["H 2 SO 4", "CHEMICAL", 114, 122], ["the reaction", "PROBLEM", 75, 87]]], ["The adsorption was determined in an ELISA photometer at 492 nm.Virus cultureVirus isolation was attempted on canine adult lung fibroblasts (passages 3 to 7) and MDCK and A72 cells.", [["adult lung fibroblasts", "ANATOMY", 116, 138], ["MDCK", "ANATOMY", 161, 165], ["A72 cells", "ANATOMY", 170, 179], ["Virus", "ORGANISM", 63, 68], ["canine", "ORGANISM", 109, 115], ["adult lung fibroblasts", "CELL", 116, 138], ["MDCK", "CELL", 161, 165], ["A72 cells", "CELL", 170, 179], ["canine adult lung fibroblasts", "CELL_TYPE", 109, 138], ["MDCK", "CELL_LINE", 161, 165], ["A72 cells", "CELL_LINE", 170, 179], ["canine", "SPECIES", 109, 115], ["canine", "SPECIES", 109, 115], ["an ELISA photometer", "TEST", 33, 52], ["Virus cultureVirus isolation", "TEST", 63, 91], ["canine adult lung fibroblasts", "PROBLEM", 109, 138], ["MDCK", "TEST", 161, 165], ["lung", "ANATOMY", 122, 126], ["fibroblasts", "OBSERVATION", 127, 138]]], ["The lung fibroblasts were maintained in MEM with 20% fetal calf serum (FCS); MDCK and A72 cells were maintained in MEM with 5% FCS.", [["lung fibroblasts", "ANATOMY", 4, 20], ["fetal calf serum", "ANATOMY", 53, 69], ["MDCK", "ANATOMY", 77, 81], ["A72 cells", "ANATOMY", 86, 95], ["lung fibroblasts", "CELL", 4, 20], ["fetal calf", "ORGANISM_SUBSTANCE", 53, 63], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["FCS", "ORGANISM_SUBSTANCE", 71, 74], ["MDCK", "CELL", 77, 81], ["A72 cells", "CELL", 86, 95], ["lung fibroblasts", "CELL_TYPE", 4, 20], ["MDCK", "CELL_LINE", 77, 81], ["A72 cells", "CELL_LINE", 86, 95], ["calf", "SPECIES", 59, 63], ["The lung fibroblasts", "PROBLEM", 0, 20], ["20% fetal calf serum", "TEST", 49, 69], ["FCS", "TEST", 71, 74], ["MDCK and A72 cells", "TEST", 77, 95], ["lung", "ANATOMY", 4, 8], ["fibroblasts", "OBSERVATION", 9, 20], ["calf", "ANATOMY", 59, 63]]], ["Tracheal tissue samples (approx 25 mg) were homogenized using a scalpel and mixed vigorously in 1 ml of MEM containing penicillin (100 U/ml), streptomycin (0.1 mg/ml), amphotericin B (2.5 g/ml), and trypsin (1 g/ml).", [["Tracheal tissue samples", "ANATOMY", 0, 23], ["MEM", "CHEMICAL", 104, 107], ["penicillin", "CHEMICAL", 119, 129], ["streptomycin", "CHEMICAL", 142, 154], ["amphotericin B", "CHEMICAL", 168, 182], ["penicillin", "CHEMICAL", 119, 129], ["streptomycin", "CHEMICAL", 142, 154], ["amphotericin B", "CHEMICAL", 168, 182], ["Tracheal tissue samples", "TISSUE", 0, 23], ["penicillin", "SIMPLE_CHEMICAL", 119, 129], ["streptomycin", "SIMPLE_CHEMICAL", 142, 154], ["amphotericin B", "SIMPLE_CHEMICAL", 168, 182], ["trypsin", "SIMPLE_CHEMICAL", 199, 206], ["trypsin", "PROTEIN", 199, 206], ["Tracheal tissue samples", "TREATMENT", 0, 23], ["a scalpel", "TREATMENT", 62, 71], ["MEM containing penicillin", "TREATMENT", 104, 129], ["streptomycin", "TREATMENT", 142, 154], ["amphotericin B", "TREATMENT", 168, 182], ["trypsin", "TREATMENT", 199, 206], ["tissue", "ANATOMY", 9, 15]]], ["The samples were centrifuged at 13,000 rpm for 10 min and the supernatant was used to inoculate cell cultures.", [["samples", "ANATOMY", 4, 11], ["supernatant", "ANATOMY", 62, 73], ["cell cultures", "ANATOMY", 96, 109], ["cell cultures", "CELL", 96, 109], ["cell cultures", "CELL_LINE", 96, 109], ["The samples", "TEST", 0, 11], ["the supernatant", "TREATMENT", 58, 73], ["cell cultures", "TEST", 96, 109]]], ["After 30 min at 37\u00b0C the supernatant was removed and maintenance medium was added to the cultures.", [["supernatant", "ANATOMY", 25, 36], ["the supernatant", "TREATMENT", 21, 36], ["maintenance medium", "TREATMENT", 53, 71], ["the cultures", "TEST", 85, 97]]], ["The cultures were passaged three times in the absence of a cytopathic effect.", [["cultures", "ANATOMY", 4, 12], ["The cultures", "TEST", 0, 12], ["a cytopathic effect", "PROBLEM", 57, 76], ["cytopathic effect", "OBSERVATION", 59, 76]]], ["Then, RNA was extracted from the cells and RT-PCR for coronavirus was performed using the nested PCR for the spike gene.Statistical analysisThe data were analysed using the 2 test or Fisher's exact test and P values below 0.05 were considered statistically significant. and guidance.", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["coronavirus", "ORGANISM", 54, 65], ["spike gene", "DNA", 109, 119], ["RT-PCR", "TEST", 43, 49], ["coronavirus", "PROBLEM", 54, 65], ["the nested PCR", "TEST", 86, 100], ["Statistical analysis", "TEST", 120, 140], ["The data", "TEST", 140, 148], ["the 2 test", "TEST", 169, 179], ["Fisher's exact test", "TEST", 183, 202], ["P values", "TEST", 207, 215]]], ["We also thank Dr. V. Chalker and Dr. M. Collins for critical reading of the manuscript and S. Oliver for providing a control sample for bovine coronavirus.", [["bovine coronavirus", "DISEASE", 136, 154], ["bovine", "ORGANISM", 136, 142], ["coronavirus", "ORGANISM", 143, 154], ["bovine", "SPECIES", 136, 142], ["bovine coronavirus", "SPECIES", 136, 154], ["a control sample", "TREATMENT", 115, 131], ["bovine coronavirus", "PROBLEM", 136, 154]]]], "959619fe79ff33c9982720c4c91bd59699d3b060": [["IntroductionCoronavirus disease 2019 (COVID-19), resulting from an infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a serious threat to global public health [1, 2] .", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["infection", "DISEASE", 67, 76], ["acute respiratory syndrome coronavirus", "DISEASE", 93, 131], ["SARS-CoV-2", "CHEMICAL", 135, 145], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 86, 133], ["SARS-CoV-2", "ORGANISM", 135, 145], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 86, 131], ["SARS-CoV-2", "SPECIES", 135, 145], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["an infection", "PROBLEM", 64, 76], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 82, 131], ["infection", "OBSERVATION", 67, 76], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome", "OBSERVATION", 99, 119]]], ["The SARS-CoV-2, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) are responsible for severe and potentially lethal acute respiratory syndromes in humans.", [["respiratory", "ANATOMY", 190, 201], ["acute respiratory syndrome coronavirus", "DISEASE", 23, 61], ["SARS-CoV)", "DISEASE", 63, 72], ["Middle East respiratory syndrome coronavirus", "DISEASE", 78, 122], ["acute respiratory syndromes", "DISEASE", 184, 211], ["SARS-CoV-2", "ORGANISM", 4, 14], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 16, 61], ["SARS-CoV", "ORGANISM", 63, 71], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 78, 122], ["MERS-CoV", "ORGANISM", 124, 132], ["humans", "ORGANISM", 215, 221], ["humans", "SPECIES", 215, 221], ["SARS-CoV", "SPECIES", 4, 12], ["severe acute respiratory syndrome coronavirus", "SPECIES", 16, 61], ["SARS-CoV", "SPECIES", 63, 71], ["Middle East respiratory syndrome coronavirus", "SPECIES", 78, 122], ["MERS-CoV", "SPECIES", 124, 132], ["humans", "SPECIES", 215, 221], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 16, 61], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 78, 122], ["potentially lethal acute respiratory syndromes in humans", "PROBLEM", 165, 221], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome coronavirus", "OBSERVATION", 29, 61], ["Middle", "ANATOMY_MODIFIER", 78, 84], ["respiratory syndrome", "OBSERVATION", 90, 110], ["lethal", "OBSERVATION_MODIFIER", 177, 183], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["respiratory syndromes", "OBSERVATION", 190, 211]]], ["Unfortunately, to date, there are no specific/targeted drugs, or vaccines, and the number of SARS-CoV-2-positive patients is growing in various parts of the world.IntroductionIn spite of the rising number of confirmed cases, the epidemiological studies involving COVID-19 are insufficient, especially those focusing on asymptomatic patients, patients with mild symptoms, or the areas surrounding the COVID-19 hotspots [4] .", [["SARS", "DISEASE", 93, 97], ["SARS-CoV-2", "ORGANISM", 93, 103], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 332, 340], ["patients", "ORGANISM", 342, 350], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 332, 340], ["patients", "SPECIES", 342, 350], ["SARS-CoV", "SPECIES", 93, 101], ["vaccines", "TREATMENT", 65, 73], ["SARS", "TEST", 93, 97], ["CoV", "TEST", 98, 101], ["the epidemiological studies", "TEST", 225, 252], ["COVID", "TEST", 263, 268], ["mild symptoms", "PROBLEM", 356, 369], ["the COVID", "TEST", 396, 405], ["growing", "OBSERVATION_MODIFIER", 125, 132], ["mild", "OBSERVATION_MODIFIER", 356, 360], ["symptoms", "OBSERVATION", 361, 369]]], ["It is worth mentioning that around 30-60% of COVID-19 patients either are asymptomatic or have mild Wan-Qiang Huang, Man-Ling Liu, Si-Ceng Lin, Xiao-Zhou Zhang, Yan Zhang, Xiao-Qing He and Jun-Lin Liu contributed equally to this work.IntroductionThis article is part of the Topical Collection on Covid-19 * Na He ylhena@163.com * Qin-Qin Yan yanqinqin699@163.com * Man Mi a17742321665@163.com disease, but this does not result in their decreased ability to spread the virus.", [["Na", "CHEMICAL", 307, 309], ["Na", "CHEMICAL", 307, 309], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["Yan yanqinqin699@163.com * Man Mi a17742321665@163.com", "SPECIES", 338, 392], ["COVID", "TEST", 45, 50], ["asymptomatic", "PROBLEM", 74, 86], ["mild Wan-Qiang Huang", "PROBLEM", 95, 115], ["Covid", "TEST", 296, 301], ["disease", "PROBLEM", 393, 400], ["their decreased ability", "PROBLEM", 430, 453], ["the virus", "PROBLEM", 464, 473], ["mild", "OBSERVATION_MODIFIER", 95, 99], ["disease", "OBSERVATION", 393, 400]]], ["Thus, these patients may trigger a new wave of COVID-19 outbreak [5] .", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["COVID", "TEST", 47, 52]]], ["Moreover, the attention received by the COVID-19 hotspots often exceeds the areas around them, which may result in a surge in the number of patients.", [["patients", "ORGANISM", 140, 148], ["COVID-19 hotspots", "DNA", 40, 57], ["patients", "SPECIES", 140, 148]]], ["In a study by Lu et al., multivariate Cox regression analysis revealed that the patient's age and C reactive protein (CRP) levels are independent risk factors for predicting the death [6] .", [["death", "DISEASE", 178, 183], ["patient", "ORGANISM", 80, 87], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 98, 116], ["CRP", "GENE_OR_GENE_PRODUCT", 118, 121], ["C reactive protein", "PROTEIN", 98, 116], ["CRP", "PROTEIN", 118, 121], ["patient", "SPECIES", 80, 87], ["a study", "TEST", 3, 10], ["multivariate Cox regression analysis", "TEST", 25, 61], ["the patient's age", "TEST", 76, 93], ["C reactive protein (CRP) levels", "PROBLEM", 98, 129], ["the death", "PROBLEM", 174, 183]]], ["But the studies exploring the relationship between age, CRP levels, and the severity of COVID-19, especially by the means of smooth curve fitting, are lacking.", [["CRP", "GENE_OR_GENE_PRODUCT", 56, 59], ["CRP", "PROTEIN", 56, 59], ["the studies", "TEST", 4, 15], ["CRP levels", "TEST", 56, 66], ["COVID", "TEST", 88, 93], ["smooth curve fitting", "TREATMENT", 125, 145]]], ["Thus, we describe the clinical characteristics as well as laboratory findings of COVID-19 patients residing in Xiaogan City, so as to have an insight regarding the prevention as well as treatment of COVID-19, and simultaneously explore the relationship between age, CRP levels, and the severity of COVID-19, thereby exploring the indicators for predicting the severity of COVID-19.Data SourcesThis was a retrospective study involving the confirmed COVID-19 cases, diagnosed between February 1 and March 1, 2020, and residing in Xiaogan City.", [["COVID-19", "CHEMICAL", 372, 380], ["patients", "ORGANISM", 90, 98], ["CRP", "GENE_OR_GENE_PRODUCT", 266, 269], ["CRP", "PROTEIN", 266, 269], ["patients", "SPECIES", 90, 98], ["COVID", "TEST", 81, 86], ["COVID", "TEST", 199, 204], ["CRP levels", "TEST", 266, 276], ["COVID", "TEST", 298, 303], ["COVID", "TEST", 372, 377], ["a retrospective study", "TEST", 402, 423], ["COVID", "TEST", 448, 453]]], ["Since the break out of COVID-19, stringent preventive measures were followed in Hubei Province, including the introduction of fever clinics that catered specifically to the suspected COVID-19 patients, defined as the presence of fever, dry cough, or any respiratory signs, and particularly those with a history of travel to Wuhan or direct exposure to confirmed COVID-19 patients within 2 weeks prior to the beginning of disease.", [["respiratory", "ANATOMY", 254, 265], ["fever", "DISEASE", 126, 131], ["COVID", "DISEASE", 183, 188], ["fever", "DISEASE", 229, 234], ["dry cough", "DISEASE", 236, 245], ["respiratory signs", "DISEASE", 254, 271], ["patients", "ORGANISM", 192, 200], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 192, 200], ["patients", "SPECIES", 371, 379], ["COVID", "TEST", 23, 28], ["stringent preventive measures", "TREATMENT", 33, 62], ["fever", "PROBLEM", 126, 131], ["fever", "PROBLEM", 229, 234], ["dry cough", "PROBLEM", 236, 245], ["any respiratory signs", "PROBLEM", 250, 271], ["disease", "PROBLEM", 421, 428], ["fever", "OBSERVATION", 229, 234], ["disease", "OBSERVATION", 421, 428]]], ["A confirmed case of COVID-19 was defined in accordance with the criteria given by the World Health Organization (WHO) [7] .", [["COVID-19", "DNA", 20, 28], ["COVID", "TEST", 20, 25]]], ["Only the laboratory confirmed COVID-19 patients were included in the study.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["COVID", "TEST", 30, 35], ["the study", "TEST", 65, 74]]], ["We gathered the information of 134 laboratory confirmed COVID-19 patients admitted in 3 hospitals of Xiaogan City.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73]]], ["The incubation period was defined as the duration between direct exposure and the onset of symptoms, estimated amongst the patients providing a reliable date of close contact with confirmed or suspected COVID-19 patients from Wuhan.", [["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 212, 220], ["symptoms", "PROBLEM", 91, 99]]], ["The epidemiological information was gathered through short interviews involving each patient.Data SourcesThe medical records of patients were fetched and sent out to the data collection center located in Xiaogan.", [["patient", "ORGANISM", 85, 92], ["patients", "ORGANISM", 128, 136], ["patient", "SPECIES", 85, 92], ["patients", "SPECIES", 128, 136]]], ["The data was gathered and evaluated by a group of physicians directly involved in the treatment of COVID-19 patients.", [["COVID", "DISEASE", 99, 104], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116]]], ["This study was approved by the ethics committee of the Xiaogan Central Hospital in Hubei Province.", [["This study", "TEST", 0, 10]]], ["Written informed consent was obtained from each participant.Laboratory Confirmation and TreatmentAt admission, sputum specimens and throat swabs were collected from all the patients.", [["sputum specimens", "ANATOMY", 111, 127], ["throat swabs", "ANATOMY", 132, 144], ["throat swabs", "ORGANISM_SUBSTANCE", 132, 144], ["patients", "ORGANISM", 173, 181], ["participant", "SPECIES", 48, 59], ["patients", "SPECIES", 173, 181], ["Laboratory Confirmation", "TEST", 60, 83], ["sputum specimens", "TEST", 111, 127], ["throat swabs", "TEST", 132, 144], ["throat", "ANATOMY", 132, 138]]], ["The presence of virus was confirmed by subjecting the samples to real-time polymerase chain reaction (rt-PCR) for SARS-CoV-2 RNA within 3 h. rt-PCR was repeated twice every 24 h.Laboratory Confirmation and TreatmentOther laboratory tests included a complete blood count, serum biochemistry, and recognition of other respiratory pathogens including influenza A virus (H1N1, H3N2, H7N9), influenza B virus, respiratory syncytial virus, and others.", [["samples", "ANATOMY", 54, 61], ["blood", "ANATOMY", 258, 263], ["serum", "ANATOMY", 271, 276], ["respiratory pathogens", "DISEASE", 316, 337], ["influenza A virus", "DISEASE", 348, 365], ["influenza B", "DISEASE", 386, 397], ["respiratory syncytial virus", "DISEASE", 405, 432], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 114, 124], ["blood", "ORGANISM_SUBSTANCE", 258, 263], ["serum", "ORGANISM_SUBSTANCE", 271, 276], ["influenza A virus", "ORGANISM", 348, 365], ["H1N1, H3N2, H7N9", "ORGANISM", 367, 383], ["influenza B virus", "ORGANISM", 386, 403], ["respiratory syncytial virus", "ORGANISM", 405, 432], ["SARS-CoV-2 RNA", "RNA", 114, 128], ["influenza A virus", "SPECIES", 348, 365], ["influenza B virus", "SPECIES", 386, 403], ["respiratory syncytial virus", "SPECIES", 405, 432], ["SARS-CoV", "SPECIES", 114, 122], ["influenza A virus", "SPECIES", 348, 365], ["H7N9", "SPECIES", 379, 383], ["influenza B virus", "SPECIES", 386, 403], ["respiratory syncytial virus", "SPECIES", 405, 432], ["virus", "PROBLEM", 16, 21], ["the samples", "TEST", 50, 61], ["polymerase chain reaction", "PROBLEM", 75, 100], ["rt-PCR", "TEST", 102, 108], ["SARS", "PROBLEM", 114, 118], ["CoV", "TEST", 119, 122], ["h. rt-PCR", "TEST", 138, 147], ["TreatmentOther laboratory tests", "TEST", 206, 237], ["a complete blood count", "TEST", 247, 269], ["serum biochemistry", "TEST", 271, 289], ["other respiratory pathogens", "PROBLEM", 310, 337], ["influenza A virus", "PROBLEM", 348, 365], ["H1N1", "PROBLEM", 367, 371], ["H3N2", "PROBLEM", 373, 377], ["H7N9", "PROBLEM", 379, 383], ["influenza B virus", "PROBLEM", 386, 403], ["respiratory syncytial virus", "PROBLEM", 405, 432], ["virus", "OBSERVATION", 16, 21], ["respiratory pathogens", "OBSERVATION", 316, 337], ["respiratory syncytial virus", "OBSERVATION", 405, 432]]], ["The majority of the patients received antiviral treatment.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["antiviral treatment", "TREATMENT", 38, 57], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["antiviral treatment", "OBSERVATION", 38, 57]]], ["Similarly, many patients received probiotics.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["probiotics", "TREATMENT", 34, 44]]], ["Moreover, the patients with resting respiratory rate > 30 per minute, oxygen saturation < 93% on room air, or > 50% progression of illness involving numerous pulmonary lobes on two consecutive days on chest computed tomography (CT) received corticosteroid (40-80 mg/day) and gamma globulin (15-20 g/day) for 3-5 days.", [["pulmonary lobes", "ANATOMY", 158, 173], ["oxygen", "CHEMICAL", 70, 76], ["illness", "DISEASE", 131, 138], ["gamma globulin", "CHEMICAL", 275, 289], ["oxygen", "CHEMICAL", 70, 76], ["patients", "ORGANISM", 14, 22], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["pulmonary lobes", "MULTI-TISSUE_STRUCTURE", 158, 173], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 275, 289], ["gamma globulin", "PROTEIN", 275, 289], ["patients", "SPECIES", 14, 22], ["resting respiratory rate", "TEST", 28, 52], ["oxygen saturation", "TEST", 70, 87], ["illness", "PROBLEM", 131, 138], ["numerous pulmonary lobes", "PROBLEM", 149, 173], ["chest computed tomography", "TEST", 201, 226], ["CT", "TEST", 228, 230], ["corticosteroid", "TREATMENT", 241, 255], ["gamma globulin", "TREATMENT", 275, 289], ["pulmonary lobes", "ANATOMY", 158, 173], ["chest", "ANATOMY", 201, 206]]], ["Antibiotics such as quinolones and 2ndgeneration beta-lactams were used, if the fever lasted for > 7 days or the levels of CRP were \u2265 30 mg/L (normal range 0-8 mg/L).", [["quinolones", "CHEMICAL", 20, 30], ["2ndgeneration beta-lactams", "CHEMICAL", 35, 61], ["fever", "DISEASE", 80, 85], ["quinolones", "CHEMICAL", 20, 30], ["2ndgeneration beta-lactams", "CHEMICAL", 35, 61], ["quinolones", "SIMPLE_CHEMICAL", 20, 30], ["2ndgeneration beta-lactams", "SIMPLE_CHEMICAL", 35, 61], ["CRP", "GENE_OR_GENE_PRODUCT", 123, 126], ["CRP", "PROTEIN", 123, 126], ["Antibiotics", "TREATMENT", 0, 11], ["quinolones", "TREATMENT", 20, 30], ["2ndgeneration beta-lactams", "TREATMENT", 35, 61], ["the fever", "PROBLEM", 76, 85], ["CRP", "TEST", 123, 126]]], ["COVID-19 patients were considered as cured and subsequently discharged from the hospital, if the outcomes of 2 successive rt-PCR, performed 24 h apart, were negative.Logistic Regression Models and Smooth Curve FittingIn order to explore the association between age, CRP levels, and severity of COVID-19, we used the methods of multiple regression equation and curve fitting.", [["patients", "ORGANISM", 9, 17], ["CRP", "GENE_OR_GENE_PRODUCT", 266, 269], ["CRP", "PROTEIN", 266, 269], ["patients", "SPECIES", 9, 17], ["successive rt-PCR", "TEST", 111, 128], ["CRP levels", "TEST", 266, 276], ["COVID", "TEST", 294, 299], ["multiple regression equation", "TREATMENT", 327, 355], ["curve fitting", "TREATMENT", 360, 373], ["negative", "OBSERVATION", 157, 165]]], ["The multiple regression equation included crude and adjusted (I, II, and III) models and were used to remove the influence of confounding factors and find independent quantitative effect values [8] .", [["The multiple regression equation", "TEST", 0, 32], ["confounding factors", "PROBLEM", 126, 145], ["multiple", "OBSERVATION_MODIFIER", 4, 12]]], ["In order to intuitively reflect the relationship of disease severity with age and CRP levels, we used the method of smooth curve fitting [9] .Statistical AnalysisOn admission, based on the American Thoracic Society guideline, the study cohort was divided into severe and non-severe cases [10] .", [["CRP", "GENE_OR_GENE_PRODUCT", 82, 85], ["CRP", "PROTEIN", 82, 85], ["disease severity", "PROBLEM", 52, 68], ["CRP levels", "TEST", 82, 92], ["the method of smooth curve fitting", "TREATMENT", 102, 136], ["the study", "TEST", 226, 235], ["severe and non-severe cases", "PROBLEM", 260, 287], ["disease", "OBSERVATION", 52, 59], ["Thoracic", "ANATOMY", 198, 206]]], ["The continuous variables were described as either means and standard deviations or medians with interquartile ranges, while the categorical variables were described as percentages.", [["standard deviations or medians with interquartile ranges", "PROBLEM", 60, 116]]], ["Differences in the laboratory values were assessed by the Student's t test or the Mann-Whitney U test (for normally or not normally distributed continuous variables, respectively).", [["the laboratory values", "TEST", 15, 36], ["the Mann-Whitney U test", "TEST", 78, 101]]], ["A P value of < 0.05 was considered as statistically significant and analysis was performed by SPSS version 22.0 (SPSS, Chicago, IL, USA) for Windows and R3.3.1 (R Advancement Core Group, http://www.r-project.org).Epidemiological FeaturesThe median age of 134 confirmed COVID-19 patients was 45 (33-56) years.", [["COVID", "DISEASE", 269, 274], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 278, 286], ["A P value", "TEST", 0, 9], ["analysis", "TEST", 68, 76], ["SPSS version", "TEST", 94, 106], ["Windows", "TEST", 141, 148], ["Epidemiological Features", "PROBLEM", 213, 237], ["COVID", "TEST", 269, 274]]], ["Over half of all the patients were women (51.5%).", [["patients", "ORGANISM", 21, 29], ["women", "ORGANISM", 35, 40], ["patients", "SPECIES", 21, 29], ["women", "SPECIES", 35, 40]]], ["A history of contact with wildlife, recent travel to Wuhan, and close contact with people from Wuhan was observed in 21.1%, 39.1%, and 39.1% of patients, respectively.", [["people", "ORGANISM", 83, 89], ["patients", "ORGANISM", 144, 152], ["people", "SPECIES", 83, 89], ["patients", "SPECIES", 144, 152]]], ["Moreover, 2 patients were local residents of Wuhan (Table 1) .Epidemiological FeaturesAmongst the 134 patients, there were only 12 (8.9%) patients with severe illness, of which 5 (3.7%) received care in intensive care units (ICU) and 2 patients died.Clinical CharacteristicsAmongst the patients with coexisting conditions, 14 (10.4%) had hypertension, 12 (8.9%) had diabetes, and only 1 (0.7%) had cerebrovascular disease.", [["cerebrovascular", "ANATOMY", 398, 413], ["illness", "DISEASE", 159, 166], ["hypertension", "DISEASE", 338, 350], ["diabetes", "DISEASE", 366, 374], ["cerebrovascular disease", "DISEASE", 398, 421], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 236, 244], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 286, 294], ["severe illness", "PROBLEM", 152, 166], ["coexisting conditions", "PROBLEM", 300, 321], ["hypertension", "PROBLEM", 338, 350], ["diabetes", "PROBLEM", 366, 374], ["cerebrovascular disease", "PROBLEM", 398, 421], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["illness", "OBSERVATION", 159, 166], ["hypertension", "OBSERVATION", 338, 350], ["cerebrovascular", "ANATOMY", 398, 413], ["disease", "OBSERVATION", 414, 421]]], ["The median duration from the beginning of symptoms to hospital admission was 2.0 (1.0-4.0) days.", [["symptoms", "PROBLEM", 42, 50], ["median duration", "OBSERVATION_MODIFIER", 4, 19]]], ["The most common symptoms reported at the disease onset were fever (66.4%), cough (33.6%), sore throat (14.7%), myalgia or fatigue (7.0%), shortness of breath (4.2), nausea and vomiting (2.8), diarrhea (2.1), and chest pain (0.7%) ( Table 1) .Laboratory and Radiographic Findings in COVID-19 PatientsIn order to explore the relationship between the severity of COVID-19 and CRP, the laboratory data was collected in detail, and the data was then divided into severe and nonsevere group, as well as ICU and non-ICU groups ( Table 2) .", [["chest", "ANATOMY", 212, 217], ["fever", "DISEASE", 60, 65], ["cough", "DISEASE", 75, 80], ["sore throat", "DISEASE", 90, 101], ["myalgia", "DISEASE", 111, 118], ["fatigue", "DISEASE", 122, 129], ["shortness of breath", "DISEASE", 138, 157], ["nausea", "DISEASE", 165, 171], ["vomiting", "DISEASE", 176, 184], ["diarrhea", "DISEASE", 192, 200], ["chest pain", "DISEASE", 212, 222], ["Patients", "ORGANISM", 291, 299], ["CRP", "GENE_OR_GENE_PRODUCT", 373, 376], ["CRP", "PROTEIN", 373, 376], ["Patients", "SPECIES", 291, 299], ["The most common symptoms", "PROBLEM", 0, 24], ["fever", "PROBLEM", 60, 65], ["cough", "PROBLEM", 75, 80], ["sore throat", "PROBLEM", 90, 101], ["myalgia", "PROBLEM", 111, 118], ["fatigue", "PROBLEM", 122, 129], ["shortness of breath", "PROBLEM", 138, 157], ["nausea", "PROBLEM", 165, 171], ["vomiting", "PROBLEM", 176, 184], ["diarrhea", "PROBLEM", 192, 200], ["chest pain", "PROBLEM", 212, 222], ["COVID", "TEST", 282, 287], ["COVID", "TEST", 360, 365], ["CRP", "TEST", 373, 376], ["the laboratory data", "TEST", 378, 397], ["sore throat", "ANATOMY", 90, 101], ["chest", "ANATOMY", 212, 217]]], ["Compared with non-severe patients, the severe patients had significantly higher median blood levels of white blood cell (WBC) count, neutrophil count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), potassium, blood urea nitrogen (BUN), fasting glucose, CRP, and lactate dehydrogenase (LDH) and significantly lower median blood levels of lymphocyte count, albumin, and sodium (all P values < 0.05).Laboratory and Radiographic Findings in COVID-19 PatientsSimilarly, compared with non-ICU patients, ICU patients had significantly higher median blood levels of AST, potassium, fasting glucose, CRP, creatinine, and LDH and significantly lower median blood levels of lymphocyte count, sodium, and albumin (all P values < 0.05).", [["blood", "ANATOMY", 87, 92], ["white blood cell", "ANATOMY", 103, 119], ["WBC", "ANATOMY", 121, 124], ["neutrophil", "ANATOMY", 133, 143], ["blood", "ANATOMY", 228, 233], ["blood", "ANATOMY", 340, 345], ["lymphocyte", "ANATOMY", 356, 366], ["blood", "ANATOMY", 561, 566], ["blood", "ANATOMY", 666, 671], ["lymphocyte", "ANATOMY", 682, 692], ["alanine", "CHEMICAL", 151, 158], ["aspartate", "CHEMICAL", 183, 192], ["potassium", "CHEMICAL", 217, 226], ["blood urea nitrogen", "CHEMICAL", 228, 247], ["lactate", "CHEMICAL", 281, 288], ["sodium", "CHEMICAL", 387, 393], ["potassium", "CHEMICAL", 582, 591], ["creatinine", "CHEMICAL", 615, 625], ["sodium", "CHEMICAL", 700, 706], ["alanine", "CHEMICAL", 151, 158], ["aspartate", "CHEMICAL", 183, 192], ["potassium", "CHEMICAL", 217, 226], ["urea", "CHEMICAL", 234, 238], ["nitrogen", "CHEMICAL", 239, 247], ["glucose", "CHEMICAL", 263, 270], ["lactate", "CHEMICAL", 281, 288], ["sodium", "CHEMICAL", 387, 393], ["potassium", "CHEMICAL", 582, 591], ["glucose", "CHEMICAL", 601, 608], ["creatinine", "CHEMICAL", 615, 625], ["sodium", "CHEMICAL", 700, 706], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 46, 54], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["white blood cell", "CELL", 103, 119], ["WBC", "CELL", 121, 124], ["neutrophil", "CELL", 133, 143], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 151, 175], ["ALT", "SIMPLE_CHEMICAL", 177, 180], ["aspartate aminotransferase", "SIMPLE_CHEMICAL", 183, 209], ["AST", "SIMPLE_CHEMICAL", 211, 214], ["potassium", "SIMPLE_CHEMICAL", 217, 226], ["blood", "ORGANISM_SUBSTANCE", 228, 233], ["urea nitrogen", "SIMPLE_CHEMICAL", 234, 247], ["BUN", "SIMPLE_CHEMICAL", 249, 252], ["fasting", "SIMPLE_CHEMICAL", 255, 262], ["glucose", "SIMPLE_CHEMICAL", 263, 270], ["CRP", "GENE_OR_GENE_PRODUCT", 272, 275], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 281, 302], ["LDH", "GENE_OR_GENE_PRODUCT", 304, 307], ["blood", "ORGANISM_SUBSTANCE", 340, 345], ["lymphocyte", "CELL", 356, 366], ["albumin", "GENE_OR_GENE_PRODUCT", 374, 381], ["sodium", "SIMPLE_CHEMICAL", 387, 393], ["patients", "ORGANISM", 506, 514], ["patients", "ORGANISM", 520, 528], ["blood", "ORGANISM_SUBSTANCE", 561, 566], ["AST", "SIMPLE_CHEMICAL", 577, 580], ["potassium", "SIMPLE_CHEMICAL", 582, 591], ["fasting", "SIMPLE_CHEMICAL", 593, 600], ["glucose", "SIMPLE_CHEMICAL", 601, 608], ["CRP", "GENE_OR_GENE_PRODUCT", 610, 613], ["creatinine", "SIMPLE_CHEMICAL", 615, 625], ["LDH", "GENE_OR_GENE_PRODUCT", 631, 634], ["blood", "ORGANISM_SUBSTANCE", 666, 671], ["lymphocyte", "CELL", 682, 692], ["sodium", "SIMPLE_CHEMICAL", 700, 706], ["albumin", "GENE_OR_GENE_PRODUCT", 712, 719], ["alanine aminotransferase", "PROTEIN", 151, 175], ["ALT", "PROTEIN", 177, 180], ["aspartate aminotransferase", "PROTEIN", 183, 209], ["AST", "PROTEIN", 211, 214], ["CRP", "PROTEIN", 272, 275], ["lactate dehydrogenase", "PROTEIN", 281, 302], ["LDH", "PROTEIN", 304, 307], ["albumin", "PROTEIN", 374, 381], ["AST", "PROTEIN", 577, 580], ["CRP", "PROTEIN", 610, 613], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 506, 514], ["patients", "SPECIES", 520, 528], ["significantly higher median blood levels", "PROBLEM", 59, 99], ["white blood cell", "TEST", 103, 119], ["WBC) count", "TEST", 121, 131], ["neutrophil count", "TEST", 133, 149], ["alanine aminotransferase", "TEST", 151, 175], ["ALT", "TEST", 177, 180], ["aspartate aminotransferase", "TEST", 183, 209], ["AST", "TEST", 211, 214], ["potassium", "TEST", 217, 226], ["blood urea nitrogen", "TEST", 228, 247], ["BUN", "TEST", 249, 252], ["fasting glucose", "TEST", 255, 270], ["CRP", "TEST", 272, 275], ["lactate dehydrogenase", "TEST", 281, 302], ["LDH", "TEST", 304, 307], ["significantly lower median blood levels", "PROBLEM", 313, 352], ["lymphocyte count", "TEST", 356, 372], ["albumin", "TEST", 374, 381], ["sodium", "TEST", 387, 393], ["all P values", "TEST", 395, 407], ["COVID", "TEST", 456, 461], ["AST", "TEST", 577, 580], ["potassium", "TEST", 582, 591], ["fasting glucose", "TEST", 593, 608], ["CRP", "TEST", 610, 613], ["creatinine", "TEST", 615, 625], ["LDH", "TEST", 631, 634], ["significantly lower median blood levels", "PROBLEM", 639, 678], ["lymphocyte count", "TEST", 682, 698], ["sodium", "TEST", 700, 706], ["albumin", "TEST", 712, 719], ["all P values", "TEST", 721, 733], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["neutrophil count", "OBSERVATION", 133, 149], ["lymphocyte count", "OBSERVATION", 356, 372], ["lymphocyte count", "OBSERVATION", 682, 698]]], ["Amongst 134 patients who underwent chest CT on admission, the most common patterns were ground-glass opacity (50.0%) and bilateral patchy shadows (43.3%).", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["chest CT", "TEST", 35, 43], ["ground-glass opacity", "PROBLEM", 88, 108], ["bilateral patchy shadows", "PROBLEM", 121, 145], ["chest", "ANATOMY", 35, 40], ["ground", "OBSERVATION_MODIFIER", 88, 94], ["glass opacity", "OBSERVATION", 95, 108], ["bilateral", "ANATOMY_MODIFIER", 121, 130], ["patchy", "OBSERVATION_MODIFIER", 131, 137], ["shadows", "OBSERVATION_MODIFIER", 138, 145]]], ["Severe patients yielded more prominent radiologic abnormalities on than non-severe patients (all P values < 0.05).Complications and TreatmentAmongst all the patients with COVID-19, the most common complications were acute respiratory distress syndrome (ARDS, 2.1%), cardiac arrhythmias (2.1%), myocardial injury (2.1%), ventilator-associated pneumonia (VAP, 1.4), and acute kidney injury (0.7%).Complications and TreatmentOverall, in terms of medication, intravenous antibiotics, antifungal agents, antiviral agents, corticosteroid, immunoglobulin, and Chinese medicine were administered in 23.8%, 0.7%, 92.3%, 2.1%, 11.2%, and 89.5% respectively.Complications and TreatmentSimultaneously, oxygen inhalation, invasive, and noninvasive mechanical ventilation were initiated in 36.4%, 3.5%, and 2.1% patients respectively ( Table 3) .Relationship of Severity of COVID-19 with Age and CRP LevelsThe relationship between severity of COVID-19 and age was assessed by the methods of multiple regression equation and smooth curve fitting.", [["respiratory", "ANATOMY", 222, 233], ["cardiac", "ANATOMY", 266, 273], ["myocardial", "ANATOMY", 294, 304], ["kidney", "ANATOMY", 374, 380], ["intravenous", "ANATOMY", 455, 466], ["acute respiratory distress syndrome", "DISEASE", 216, 251], ["ARDS", "DISEASE", 253, 257], ["cardiac arrhythmias", "DISEASE", 266, 285], ["myocardial injury", "DISEASE", 294, 311], ["ventilator-associated pneumonia", "DISEASE", 320, 351], ["VAP", "DISEASE", 353, 356], ["acute kidney injury", "DISEASE", 368, 387], ["oxygen", "CHEMICAL", 690, 696], ["oxygen", "CHEMICAL", 690, 696], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 157, 165], ["cardiac", "ORGAN", 266, 273], ["myocardial", "MULTI-TISSUE_STRUCTURE", 294, 304], ["kidney", "ORGAN", 374, 380], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 455, 466], ["corticosteroid", "SIMPLE_CHEMICAL", 517, 531], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 533, 547], ["oxygen", "SIMPLE_CHEMICAL", 690, 696], ["patients", "ORGANISM", 798, 806], ["CRP", "GENE_OR_GENE_PRODUCT", 882, 885], ["immunoglobulin", "PROTEIN", 533, 547], ["CRP", "PROTEIN", 882, 885], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 798, 806], ["more prominent radiologic abnormalities", "PROBLEM", 24, 63], ["all P values", "TEST", 93, 105], ["Treatment", "TREATMENT", 132, 141], ["COVID", "TEST", 171, 176], ["acute respiratory distress syndrome", "PROBLEM", 216, 251], ["ARDS", "PROBLEM", 253, 257], ["cardiac arrhythmias", "PROBLEM", 266, 285], ["myocardial injury", "PROBLEM", 294, 311], ["ventilator-associated pneumonia", "PROBLEM", 320, 351], ["VAP", "PROBLEM", 353, 356], ["acute kidney injury", "PROBLEM", 368, 387], ["TreatmentOverall", "TREATMENT", 413, 429], ["medication", "TREATMENT", 443, 453], ["intravenous antibiotics", "TREATMENT", 455, 478], ["antifungal agents", "TREATMENT", 480, 497], ["antiviral agents", "TREATMENT", 499, 515], ["corticosteroid", "TREATMENT", 517, 531], ["immunoglobulin", "TREATMENT", 533, 547], ["Chinese medicine", "TREATMENT", 553, 569], ["Treatment", "TREATMENT", 665, 674], ["oxygen inhalation", "TREATMENT", 690, 707], ["noninvasive mechanical ventilation", "TREATMENT", 723, 757], ["COVID", "TEST", 860, 865], ["CRP Levels", "TEST", 882, 892], ["COVID", "TEST", 929, 934], ["multiple regression equation", "TREATMENT", 977, 1005], ["smooth curve fitting", "TREATMENT", 1010, 1030], ["more", "OBSERVATION_MODIFIER", 24, 28], ["prominent", "OBSERVATION_MODIFIER", 29, 38], ["radiologic", "OBSERVATION_MODIFIER", 39, 49], ["abnormalities", "OBSERVATION", 50, 63], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["respiratory distress syndrome", "OBSERVATION", 222, 251], ["cardiac", "ANATOMY", 266, 273], ["arrhythmias", "OBSERVATION", 274, 285], ["myocardial", "ANATOMY", 294, 304], ["injury", "OBSERVATION", 305, 311], ["pneumonia", "OBSERVATION", 342, 351], ["acute", "OBSERVATION_MODIFIER", 368, 373], ["kidney", "ANATOMY", 374, 380], ["injury", "OBSERVATION", 381, 387]]], ["In the crude mode, the severity of COVID-19 was associated with age (odds ratio (OR) = 1.060, 95% CI 1.017-1.104).", [["COVID", "TEST", 35, 40], ["CI", "TEST", 98, 100]]], ["Additionally, this relationship was also evident through adjusted I model (OR = 1.057, 95% CI 1.016-1.100), adjusted II model (OR = 1.056, 95% CI 1.005-1.109), and adjusted III model (OR = 1.065, 95% CI 1.009-1.125) ( Table 4 ).", [["CI", "TEST", 91, 93], ["CI", "TEST", 143, 145], ["CI", "TEST", 200, 202]]], ["The smooth curve fitting graph also reflected that the severity of COVID-19 was positively correlated with age (Fig. 1) .", [["COVID-19", "CHEMICAL", 67, 75], ["COVID-19", "GENE_OR_GENE_PRODUCT", 67, 75], ["COVID", "PROTEIN", 67, 72], ["COVID", "TEST", 67, 72], ["smooth", "OBSERVATION_MODIFIER", 4, 10], ["curve", "OBSERVATION_MODIFIER", 11, 16]]], ["Similarly, the crude mode revealed an association between the severity of COVID-19 and CRP levels (OR = 1.035, 95% CI 1.013-1.158).", [["COVID-19", "GENE_OR_GENE_PRODUCT", 74, 82], ["CRP", "GENE_OR_GENE_PRODUCT", 87, 90], ["CRP", "PROTEIN", 87, 90], ["the crude mode", "TEST", 11, 25], ["COVID", "TEST", 74, 79], ["CRP levels", "TEST", 87, 97], ["CI", "TEST", 115, 117]]], ["Additionally, this relationship was also evident through adjusted I model (OR = 1.028, 95% CI 1.004-1.152), adjusted II model (OR = 1.044, 95% CI 1.009-1.1080), and adjusted III model (OR = 1.044, 95% CI 1.006-1.083) ( Table 5 ).", [["CI", "TEST", 91, 93], ["CI", "TEST", 143, 145], ["CI", "TEST", 201, 203]]], ["The smooth curve fitting graph also reflected that the severity of COVID-19 was positively correlated with CRP levels (Fig. 2 ).DiscussionCompared with the initial COVID-19 patients observed in Wuhan, in terms of disease symptoms and severity, the patients from Xiaogan City, in our study, were relatively moderate, but we could not neglect asymptomatic or mild patients.", [["COVID-19", "CHEMICAL", 67, 75], ["COVID-19", "GENE_OR_GENE_PRODUCT", 67, 75], ["CRP", "GENE_OR_GENE_PRODUCT", 107, 110], ["patients", "ORGANISM", 173, 181], ["patients", "ORGANISM", 248, 256], ["patients", "ORGANISM", 362, 370], ["COVID", "PROTEIN", 67, 72], ["CRP", "PROTEIN", 107, 110], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 248, 256], ["patients", "SPECIES", 362, 370], ["COVID", "TEST", 67, 72], ["CRP levels", "TEST", 107, 117], ["disease symptoms", "PROBLEM", 213, 229], ["severity", "PROBLEM", 234, 242], ["our study", "TEST", 279, 288], ["smooth", "OBSERVATION_MODIFIER", 4, 10], ["curve", "OBSERVATION_MODIFIER", 11, 16], ["moderate", "OBSERVATION_MODIFIER", 306, 314], ["mild", "OBSERVATION_MODIFIER", 357, 361]]], ["According to Michael Osterholm, Director of the Center for infectious Disease Research and Policy, University of Minnesota, knowing the proportion of asymptomatic or mild patients is crucial to understand the reasons behind a particular epidemic [5] .", [["infectious Disease", "DISEASE", 59, 77], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["infectious", "OBSERVATION", 59, 69], ["mild", "OBSERVATION_MODIFIER", 166, 170]]], ["A study investigated Japanese citizens (N = 565) evacuated from Wuhan in early February.", [["A study", "TEST", 0, 7]]], ["All these individuals were monitored for the symptoms and repeatedly tested for SARS-CoV-2.", [["individuals", "ORGANISM", 10, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 90], ["SARS-CoV", "SPECIES", 80, 88], ["the symptoms", "PROBLEM", 41, 53], ["SARS", "TEST", 80, 84], ["CoV", "TEST", 85, 88]]], ["It was reported that only 13 of the 565 evacuees were infected, of which 4 (31%) never developed any symptom [11] .", [["any symptom", "PROBLEM", 97, 108], ["infected", "OBSERVATION", 54, 62]]], ["A Shanghai Children's Medical Center study involving more than 700 SARS-CoV-2 infected children across the country found that 56% of the children were asymptomatic or had mild form of COVID-19 [12] .", [["SARS-CoV-2 infected", "DISEASE", 67, 86], ["SARS-CoV-2", "ORGANISM", 67, 77], ["children", "ORGANISM", 87, 95], ["children", "ORGANISM", 137, 145], ["Children", "SPECIES", 11, 19], ["CoV-", "SPECIES", 72, 76], ["children", "SPECIES", 87, 95], ["children", "SPECIES", 137, 145], ["asymptomatic", "PROBLEM", 151, 163], ["COVID", "TEST", 184, 189]]], ["Thus, the only way to prevent the spread of these asymptomatic cases is the use of social isolation measures including closing the schools, cancelling public gatherings, and keeping people at home and away from public places.DiscussionIn terms of medication, following the antiviral agents, Chinese herbal medicines were most widely used.", [["people", "ORGANISM", 182, 188], ["people", "SPECIES", 182, 188], ["social isolation measures", "TREATMENT", 83, 108], ["medication", "TREATMENT", 247, 257], ["the antiviral agents", "TREATMENT", 269, 289], ["Chinese herbal medicines", "TREATMENT", 291, 315]]], ["Amongst the confirmed COVID-19 Chinese patients, 91.5% used Chinese herbal medicine, of which 90.6% resided in Hubei Province [13] .", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["COVID", "TEST", 22, 27], ["Chinese herbal medicine", "TREATMENT", 60, 83]]], ["Clinical observations have revealed that the cure rate with traditional Chinese medicine (TCM) has reached over 90% [13] .", [["Clinical observations", "TEST", 0, 21], ["traditional Chinese medicine", "TREATMENT", 60, 88]]], ["The TCMs have been found to effectively alleviate the symptoms, contain the progress of the disease, improve the cure rate, reduce the mortality rate, and promote the recovery from COVID-19 [14, 15] .DiscussionAs per our analysis, the severity of COVID-19 was found to be positively correlated with the age and CRP levels.", [["COVID-19", "CHEMICAL", 181, 189], ["COVID-19", "CHEMICAL", 247, 255], ["TCMs", "CANCER", 4, 8], ["COVID-19", "GENE_OR_GENE_PRODUCT", 247, 255], ["CRP", "GENE_OR_GENE_PRODUCT", 311, 314], ["CRP", "PROTEIN", 311, 314], ["the symptoms", "PROBLEM", 50, 62], ["the disease", "PROBLEM", 88, 99], ["the mortality rate", "TEST", 131, 149], ["COVID", "TEST", 181, 186], ["our analysis", "TEST", 217, 229], ["COVID", "TEST", 247, 252], ["CRP levels", "TEST", 311, 321], ["disease", "OBSERVATION", 92, 99]]], ["Firstly, the CRP levels were significantly elevated amongst the severe patients and those admitted in ICU (all P value < 0.05), as compared with non-severe and non-ICU patients, respectively.", [["CRP", "GENE_OR_GENE_PRODUCT", 13, 16], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 168, 176], ["CRP", "PROTEIN", 13, 16], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 168, 176], ["the CRP levels", "TEST", 9, 23], ["significantly elevated", "PROBLEM", 29, 51], ["severe", "OBSERVATION_MODIFIER", 64, 70]]], ["Secondly, in both the crude and adjusted (I to III) models, the value of OR was > 1 (all P value < 0.05).", [["the value", "TEST", 60, 69]]], ["Finally, as per the smooth curve fitting, the severity of COVID increases with increase in the age and CRP levels (all P value < 0.05).", [["CRP", "GENE_OR_GENE_PRODUCT", 103, 106], ["CRP", "PROTEIN", 103, 106], ["COVID increases", "PROBLEM", 58, 73], ["CRP levels", "TEST", 103, 113], ["all P value", "TEST", 115, 126], ["increases", "OBSERVATION_MODIFIER", 64, 73], ["increase", "OBSERVATION_MODIFIER", 79, 87]]], ["This study has some limitations.", [["This study", "TEST", 0, 10]]], ["The sample size was insufficient, especially the severe cases.", [["sample", "ANATOMY", 4, 10], ["The sample size", "TEST", 0, 15], ["the severe cases", "PROBLEM", 45, 61], ["size", "OBSERVATION_MODIFIER", 11, 15], ["severe", "OBSERVATION_MODIFIER", 49, 55]]], ["When the data was collected, most of the patients were still hospitalized, so we were unable to estimate either the case fatality rate or the predictors of fatality.ConclusionCompared with the patients primarily infected with SARS-CoV-2 in Wuhan, the signs and symptoms of patients in Xiaogan City were fairly moderate.", [["SARS", "DISEASE", 226, 230], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 193, 201], ["SARS-CoV-2", "ORGANISM", 226, 236], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 273, 281], ["SARS-CoV", "SPECIES", 226, 234], ["SARS", "PROBLEM", 226, 230], ["the signs", "TEST", 247, 256], ["symptoms", "PROBLEM", 261, 269], ["infected", "OBSERVATION", 212, 220], ["moderate", "OBSERVATION_MODIFIER", 310, 318]]], ["To prevent another wave of COVID-19 outbreaks, these asymptomatic or mild patients should not be ignored.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["COVID", "TEST", 27, 32], ["these asymptomatic", "PROBLEM", 47, 65], ["mild", "OBSERVATION_MODIFIER", 69, 73]]], ["The TCMs were widely used and could play a significant role in the treatment of COVID-19 patients.", [["TCMs", "ANATOMY", 4, 8], ["COVID", "DISEASE", 80, 85], ["TCMs", "SIMPLE_CHEMICAL", 4, 8], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["COVID", "TEST", 80, 85]]], ["The severity of COVID-19 was positively correlated with the age and CRP levels.", [["COVID-19", "CHEMICAL", 16, 24], ["COVID-19", "GENE_OR_GENE_PRODUCT", 16, 24], ["CRP", "GENE_OR_GENE_PRODUCT", 68, 71], ["COVID", "PROTEIN", 16, 21], ["CRP", "PROTEIN", 68, 71], ["COVID", "TEST", 16, 21], ["CRP levels", "TEST", 68, 78]]], ["Thus, in clinical practice, to prevent worsening of the disease, the treating physicians should pay special attention to elderly COVID-19 patients and those with high CRP levels.ConclusionFunding Information This work was supported by grants from the epidemic prevention and control project of Shaanxi Institute of Higher Education(XGH20043), the Social Science Foundation of Shaanxi Province (2019G017), and Chang'an University graduate student scientific research practice project (300103703068).ConclusionCompliance with Ethical Standards This study was approved by the ethics committee of the Xiaogan Central Hospital in Hubei Province.", [["patients", "ORGANISM", 138, 146], ["CRP", "GENE_OR_GENE_PRODUCT", 167, 170], ["CRP", "PROTEIN", 167, 170], ["patients", "SPECIES", 138, 146], ["the disease", "PROBLEM", 52, 63], ["high CRP levels", "TEST", 162, 177], ["Ethical Standards", "TREATMENT", 524, 541], ["This study", "TEST", 542, 552], ["worsening", "OBSERVATION_MODIFIER", 39, 48], ["disease", "OBSERVATION", 56, 63]]], ["Written informed consent was obtained from each participant.", [["participant", "SPECIES", 48, 59]]]], "8c1c3b1f8dedc265986178cbd90213cd0f6b73cb": [["IntroductionRespiratory syncytial virus (RSV) infection is a leading cause of serious viral lower respiratory tract illness in both infants and the elderly worldwide.", [["lower respiratory tract", "ANATOMY", 92, 115], ["IntroductionRespiratory syncytial virus (RSV) infection", "DISEASE", 0, 55], ["viral lower respiratory tract illness", "DISEASE", 86, 123], ["IntroductionRespiratory syncytial virus", "ORGANISM", 0, 39], ["RSV", "ORGANISM", 41, 44], ["tract", "ORGANISM_SUBDIVISION", 110, 115], ["infants", "ORGANISM", 132, 139], ["syncytial virus (RSV", "SPECIES", 24, 44], ["infants", "SPECIES", 132, 139], ["IntroductionRespiratory syncytial virus", "SPECIES", 0, 39], ["RSV", "SPECIES", 41, 44], ["IntroductionRespiratory syncytial virus (RSV) infection", "PROBLEM", 0, 55], ["serious viral lower respiratory tract illness", "PROBLEM", 78, 123], ["syncytial virus", "OBSERVATION", 24, 39], ["serious", "OBSERVATION_MODIFIER", 78, 85], ["viral", "OBSERVATION_MODIFIER", 86, 91], ["lower", "OBSERVATION_MODIFIER", 92, 97], ["respiratory tract illness", "OBSERVATION", 98, 123]]], ["RSV is a member of the Paramyxoviridae family and belongs to the Pneumovirinae subfamily.", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 23, 38], ["Pneumovirinae", "GENE_OR_GENE_PRODUCT", 65, 78], ["Paramyxoviridae family", "PROTEIN", 23, 45], ["Pneumovirinae subfamily", "PROTEIN", 65, 88], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3]]], ["The RSV genome consists of a single-stranded, negative-sense RNA molecule that encodes 11 proteins.", [["RSV", "ORGANISM", 4, 7], ["RSV genome", "DNA", 4, 14], ["negative-sense RNA molecule", "PROTEIN", 46, 73], ["RSV", "SPECIES", 4, 7], ["The RSV genome", "TEST", 0, 14], ["a single-stranded, negative-sense RNA molecule", "PROBLEM", 27, 73], ["RSV genome", "OBSERVATION", 4, 14]]], ["The viral nucleoprotein (N), phosphoprotein (P), and the large polymerase protein (L) make up the ribonucleoprotein complex that is necessary for viral transcription and replication.", [["large polymerase protein (L)", "GENE_OR_GENE_PRODUCT", 57, 85], ["viral nucleoprotein (N), phosphoprotein (P)", "PROTEIN", 4, 47], ["large polymerase protein", "PROTEIN", 57, 81], ["L", "PROTEIN", 83, 84], ["ribonucleoprotein complex", "PROTEIN", 98, 123], ["The viral nucleoprotein", "TEST", 0, 23], ["phosphoprotein (P)", "TREATMENT", 29, 47], ["the large polymerase protein", "TEST", 53, 81], ["the ribonucleoprotein complex", "PROBLEM", 94, 123], ["viral transcription", "TREATMENT", 146, 165], ["viral nucleoprotein", "OBSERVATION", 4, 23], ["ribonucleoprotein complex", "OBSERVATION_MODIFIER", 98, 123]]], ["Each of these replication complex proteins is found, along with genomic viral RNA, in discrete cytoplasmic granules often termed viral inclusion bodies (Garcia et al., 1993; Carromeu et al., 2007; Lindquist et al., 2010) .", [["cytoplasmic granules", "ANATOMY", 95, 115], ["cytoplasmic granules", "CELLULAR_COMPONENT", 95, 115], ["replication complex proteins", "PROTEIN", 14, 42], ["genomic viral RNA", "RNA", 64, 81], ["these replication complex proteins", "PROBLEM", 8, 42], ["genomic viral RNA", "PROBLEM", 64, 81], ["viral RNA", "OBSERVATION", 72, 81], ["discrete", "OBSERVATION_MODIFIER", 86, 94], ["cytoplasmic granules", "OBSERVATION", 95, 115], ["viral inclusion", "OBSERVATION", 129, 144]]], ["These inclusion bodies are thought to represent sites of viral replication.", [["viral replication", "PROBLEM", 57, 74], ["thought to represent", "UNCERTAINTY", 27, 47], ["viral replication", "OBSERVATION", 57, 74]]], ["While transcription of viral proteins likely occurs immediately after entry into host cells, detectable replication of the viral genome appears to begin several hours after inoculation.", [["cells", "ANATOMY", 86, 91], ["cells", "CELL", 86, 91], ["viral proteins", "PROTEIN", 23, 37], ["host cells", "CELL_TYPE", 81, 91], ["viral genome", "DNA", 123, 135], ["viral proteins", "PROBLEM", 23, 37], ["the viral genome", "PROBLEM", 119, 135], ["inoculation", "PROBLEM", 173, 184], ["viral proteins", "OBSERVATION", 23, 37], ["viral genome", "OBSERVATION", 123, 135]]], ["Following accumulation of sufficient amounts of viral proteins, a transition occurs in the RSV replication program from one dominated by transcription of viral genes to one in which replication of the full-length genome predominates.", [["RSV", "ORGANISM", 91, 94], ["viral proteins", "PROTEIN", 48, 62], ["viral genes", "DNA", 154, 165], ["full-length genome", "DNA", 201, 219], ["RSV", "SPECIES", 91, 94], ["viral proteins", "PROBLEM", 48, 62], ["the RSV replication program", "TREATMENT", 87, 114], ["viral genes", "TREATMENT", 154, 165], ["sufficient", "OBSERVATION_MODIFIER", 26, 36], ["amounts", "OBSERVATION_MODIFIER", 37, 44], ["viral proteins", "OBSERVATION", 48, 62], ["RSV replication", "OBSERVATION", 91, 106], ["viral genes", "OBSERVATION", 154, 165]]], ["As is the case for all negative-sense single-stranded RNA viruses, for replication to occur, the virus must first make a full-length antigenome intermediate RNA, which then serves as template for the production of new RNA genomes (Cowton et al., 2006) .", [["full-length antigenome intermediate RNA", "RNA", 121, 160], ["RNA genomes", "DNA", 218, 229], ["sense single-stranded RNA viruses", "PROBLEM", 32, 65], ["replication", "TREATMENT", 71, 82], ["the virus", "PROBLEM", 93, 102], ["new RNA genomes", "PROBLEM", 214, 229]]], ["PKR is activated by double-stranded RNA (dsRNA) during viral infection and often is associated with antiviral host cell responses.", [["cell", "ANATOMY", 115, 119], ["viral infection", "DISEASE", 55, 70], ["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["host cell", "CELL", 110, 119], ["PKR", "PROTEIN", 0, 3], ["double-stranded RNA", "RNA", 20, 39], ["PKR", "TEST", 0, 3], ["double-stranded RNA (dsRNA", "TREATMENT", 20, 46], ["viral infection", "PROBLEM", 55, 70], ["stranded RNA", "OBSERVATION_MODIFIER", 27, 39], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["infection", "OBSERVATION", 61, 70]]], ["Upon binding to dsRNA, PKR dimerizes and is autophosphorylated, resulting in activation of the protein.", [["PKR", "GENE_OR_GENE_PRODUCT", 23, 26], ["PKR", "PROTEIN", 23, 26], ["dsRNA", "PROBLEM", 16, 21], ["PKR dimerizes", "TEST", 23, 36], ["autophosphorylated", "PROBLEM", 44, 62], ["activation of the protein", "PROBLEM", 77, 102]]], ["Phosphorylated PKR is one of the four known kinases that regulates the activation of the translation initiation factor eukaryotic initiation factor 2 (eIF2\u03b1), which also include PKR-like ER-localized eIF2\u03b1 kinase (PERK), heme-regulated inhibitor (HRI) kinase, and general control nonrepressed 2 (GCN2) kinase.", [["PKR", "GENE_OR_GENE_PRODUCT", 15, 18], ["eukaryotic initiation factor 2", "GENE_OR_GENE_PRODUCT", 119, 149], ["eIF2", "GENE_OR_GENE_PRODUCT", 151, 155], ["\u03b1", "GENE_OR_GENE_PRODUCT", 155, 156], ["PKR", "GENE_OR_GENE_PRODUCT", 178, 181], ["ER", "GENE_OR_GENE_PRODUCT", 187, 189], ["eIF2\u03b1 kinase", "GENE_OR_GENE_PRODUCT", 200, 212], ["PERK", "GENE_OR_GENE_PRODUCT", 214, 218], ["heme-regulated inhibitor", "GENE_OR_GENE_PRODUCT", 221, 245], ["HRI", "GENE_OR_GENE_PRODUCT", 247, 250], ["general control nonrepressed 2", "GENE_OR_GENE_PRODUCT", 264, 294], ["GCN2", "GENE_OR_GENE_PRODUCT", 296, 300], ["Phosphorylated PKR", "PROTEIN", 0, 18], ["kinases", "PROTEIN", 44, 51], ["translation initiation factor eukaryotic initiation factor 2", "PROTEIN", 89, 149], ["eIF2\u03b1", "PROTEIN", 151, 156], ["PKR", "PROTEIN", 178, 181], ["ER", "PROTEIN", 187, 189], ["eIF2\u03b1 kinase", "PROTEIN", 200, 212], ["PERK", "PROTEIN", 214, 218], ["heme-regulated inhibitor (HRI) kinase", "PROTEIN", 221, 258], ["nonrepressed 2 (GCN2) kinase", "PROTEIN", 280, 308], ["Phosphorylated PKR", "TEST", 0, 18], ["PKR", "TEST", 178, 181], ["heme", "TEST", 221, 225], ["kinase", "TEST", 252, 258]]], ["Upon binding to eIF2\u03b1, activated PKR phosphorylates eIF2\u03b1 at serine 51.", [["serine", "CHEMICAL", 61, 67], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 16, 21], ["PKR", "GENE_OR_GENE_PRODUCT", 33, 36], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 52, 57], ["serine 51", "AMINO_ACID", 61, 70], ["eIF2\u03b1", "PROTEIN", 16, 21], ["PKR", "PROTEIN", 33, 36], ["eIF2\u03b1", "PROTEIN", 52, 57], ["activated PKR phosphorylates eIF2", "TREATMENT", 23, 56]]], ["Phosphorylated eIF2\u03b1 is incapable of delivering initiator Met-tRNA to host translation complexes, resulting in a reduction of protein synthesis in virus-infected cells. eIF2\u03b1 phosphorylation also leads to the formation of host stress granules, which are host RNA cytoplasmic granules that contain mRNA, translation factors, and mRNA-binding proteins.", [["cells", "ANATOMY", 162, 167], ["stress granules", "ANATOMY", 227, 242], ["cytoplasmic granules", "ANATOMY", 263, 283], ["Met", "CHEMICAL", 58, 61], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 15, 20], ["Met", "GENE_OR_GENE_PRODUCT", 58, 61], ["cells", "CELL", 162, 167], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 169, 174], ["stress granules", "CELLULAR_COMPONENT", 227, 242], ["cytoplasmic granules", "CELLULAR_COMPONENT", 263, 283], ["mRNA-binding proteins", "GENE_OR_GENE_PRODUCT", 328, 349], ["Phosphorylated eIF2\u03b1", "PROTEIN", 0, 20], ["initiator Met-tRNA", "PROTEIN", 48, 66], ["host translation complexes", "PROTEIN", 70, 96], ["virus-infected cells", "CELL_TYPE", 147, 167], ["eIF2\u03b1", "PROTEIN", 169, 174], ["mRNA", "RNA", 297, 301], ["translation factors", "PROTEIN", 303, 322], ["mRNA", "RNA", 328, 332], ["binding proteins", "PROTEIN", 333, 349], ["Phosphorylated eIF2", "TREATMENT", 0, 19], ["a reduction of protein synthesis in virus", "PROBLEM", 111, 152], ["infected cells", "PROBLEM", 153, 167], ["eIF2\u03b1 phosphorylation", "TREATMENT", 169, 190], ["host stress granules", "PROBLEM", 222, 242], ["host RNA cytoplasmic granules", "PROBLEM", 254, 283], ["translation factors", "PROBLEM", 303, 322], ["mRNA-binding proteins", "PROBLEM", 328, 349], ["protein synthesis", "OBSERVATION", 126, 143], ["infected cells", "OBSERVATION", 153, 167], ["host stress granules", "OBSERVATION", 222, 242], ["host RNA", "OBSERVATION", 254, 262], ["cytoplasmic granules", "OBSERVATION", 263, 283]]], ["In addition to activating eIF2\u03b1, PKR also functions in the activation of other proteins such as STAT1, p53, and NF\u03baB (Garcia et al., 2007) .IntroductionMany viruses deploy mechanisms to prevent PKR activation, presumably to inhibit the type I interferon response or to ensure that the host translation machinery remains sufficiently active for viral protein synthesis.", [["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 26, 31], ["PKR", "GENE_OR_GENE_PRODUCT", 33, 36], ["STAT1", "GENE_OR_GENE_PRODUCT", 96, 101], ["p53", "GENE_OR_GENE_PRODUCT", 103, 106], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 112, 116], ["PKR", "GENE_OR_GENE_PRODUCT", 194, 197], ["type I interferon", "GENE_OR_GENE_PRODUCT", 236, 253], ["eIF2\u03b1", "PROTEIN", 26, 31], ["PKR", "PROTEIN", 33, 36], ["STAT1", "PROTEIN", 96, 101], ["p53", "PROTEIN", 103, 106], ["NF\u03baB", "PROTEIN", 112, 116], ["PKR", "PROTEIN", 194, 197], ["type I interferon", "PROTEIN", 236, 253], ["viral protein", "PROTEIN", 344, 357], ["PKR", "TREATMENT", 33, 36], ["STAT1", "TEST", 96, 101], ["p53", "TEST", 103, 106], ["PKR activation", "PROBLEM", 194, 208], ["viral protein synthesis", "PROBLEM", 344, 367], ["PKR", "OBSERVATION", 194, 197]]], ["Viral strategies to prevent PKR activation include expression of viral products that interact directly with PKR and prevent activation, expression of viral proteins that bind and sequester dsRNA, or activation of host proteins that inhibit or counteract PKR activation (Garcia et al., 2007) .", [["PKR", "GENE_OR_GENE_PRODUCT", 28, 31], ["PKR", "GENE_OR_GENE_PRODUCT", 108, 111], ["PKR", "GENE_OR_GENE_PRODUCT", 254, 257], ["PKR", "PROTEIN", 28, 31], ["viral products", "PROTEIN", 65, 79], ["PKR", "PROTEIN", 108, 111], ["viral proteins", "PROTEIN", 150, 164], ["host proteins", "PROTEIN", 213, 226], ["PKR", "PROTEIN", 254, 257], ["Viral strategies", "TREATMENT", 0, 16], ["PKR activation", "PROBLEM", 28, 42], ["viral products", "TREATMENT", 65, 79], ["PKR", "TREATMENT", 108, 111], ["viral proteins", "PROBLEM", 150, 164], ["sequester dsRNA", "PROBLEM", 179, 194], ["host proteins", "PROBLEM", 213, 226]]], ["In virtually every case studied to date, the activation of PKR in virus-infected cells is associated with induction of an antiviral state.", [["cells", "ANATOMY", 81, 86], ["PKR", "GENE_OR_GENE_PRODUCT", 59, 62], ["cells", "CELL", 81, 86], ["PKR", "PROTEIN", 59, 62], ["virus-infected cells", "CELL_TYPE", 66, 86], ["PKR in virus", "PROBLEM", 59, 71], ["infected cells", "PROBLEM", 72, 86], ["an antiviral state", "PROBLEM", 119, 137], ["infected cells", "OBSERVATION", 72, 86], ["antiviral", "OBSERVATION", 122, 131]]], ["However, activation of PKR during hepatitis C virus (HCV) infection may enhance viral replication because of the resulting lack of synthesis of specific antiviral interferon-stimulated gene products during infection (Garaigorta and Chisari, 2009) .IntroductionRSV infection leads to increased levels of total PKR in cells during infection (Groskreutz et al., 2006) .", [["cells", "ANATOMY", 316, 321], ["hepatitis C virus (HCV) infection", "DISEASE", 34, 67], ["infection", "DISEASE", 206, 215], ["infection", "DISEASE", 264, 273], ["infection", "DISEASE", 329, 338], ["PKR", "GENE_OR_GENE_PRODUCT", 23, 26], ["hepatitis C virus", "ORGANISM", 34, 51], ["HCV", "ORGANISM", 53, 56], ["PKR", "GENE_OR_GENE_PRODUCT", 309, 312], ["cells", "CELL", 316, 321], ["PKR", "PROTEIN", 23, 26], ["antiviral interferon-stimulated gene products", "PROTEIN", 153, 198], ["PKR", "PROTEIN", 309, 312], ["hepatitis C virus", "SPECIES", 34, 51], ["hepatitis C virus", "SPECIES", 34, 51], ["HCV", "SPECIES", 53, 56], ["PKR", "PROBLEM", 23, 26], ["hepatitis C virus (HCV) infection", "PROBLEM", 34, 67], ["viral replication", "TREATMENT", 80, 97], ["specific antiviral interferon", "TREATMENT", 144, 173], ["stimulated gene products", "TREATMENT", 174, 198], ["infection", "PROBLEM", 206, 215], ["IntroductionRSV infection", "PROBLEM", 248, 273], ["increased levels", "PROBLEM", 283, 299], ["total PKR in cells", "PROBLEM", 303, 321], ["infection", "PROBLEM", 329, 338], ["PKR", "OBSERVATION", 23, 26], ["antiviral interferon", "OBSERVATION", 153, 173], ["infection", "OBSERVATION", 264, 273], ["increased", "OBSERVATION_MODIFIER", 283, 292], ["levels", "OBSERVATION_MODIFIER", 293, 299], ["total PKR", "OBSERVATION_MODIFIER", 303, 312]]], ["RSV infection also can induce the phosphorylation and activation of PKR (Groskreutz et al., 2010) .", [["RSV infection", "DISEASE", 0, 13], ["RSV", "ORGANISM", 0, 3], ["PKR", "GENE_OR_GENE_PRODUCT", 68, 71], ["PKR", "PROTEIN", 68, 71], ["RSV", "SPECIES", 0, 3], ["RSV infection", "PROBLEM", 0, 13], ["PKR", "PROBLEM", 68, 71], ["infection", "OBSERVATION", 4, 13]]], ["These studies suggest a direct interaction between PKR and the RSV nucleoprotein (N).IntroductionIn the current study, we sought to determine the functional role of PKR expression and activation in response to RSV infection using two well-established methods of PKR inhibition.", [["RSV infection", "DISEASE", 210, 223], ["PKR", "GENE_OR_GENE_PRODUCT", 51, 54], ["RSV", "ORGANISM", 63, 66], ["PKR", "GENE_OR_GENE_PRODUCT", 165, 168], ["RSV", "ORGANISM", 210, 213], ["PKR", "GENE_OR_GENE_PRODUCT", 262, 265], ["PKR", "PROTEIN", 51, 54], ["RSV nucleoprotein", "PROTEIN", 63, 80], ["PKR", "PROTEIN", 165, 168], ["PKR", "PROTEIN", 262, 265], ["RSV", "SPECIES", 63, 66], ["RSV", "SPECIES", 210, 213], ["These studies", "TEST", 0, 13], ["PKR", "TEST", 51, 54], ["the current study", "TEST", 100, 117], ["PKR expression", "TREATMENT", 165, 179], ["RSV infection", "PROBLEM", 210, 223], ["PKR inhibition", "TREATMENT", 262, 276], ["RSV infection", "OBSERVATION", 210, 223]]], ["The data reveal that 2-aminopurine (2-AP), a previously defined PKR chemical inhibitor, reduced RSV replication.", [["2-aminopurine", "CHEMICAL", 21, 34], ["2-AP", "CHEMICAL", 36, 40], ["2-aminopurine", "CHEMICAL", 21, 34], ["2-AP", "CHEMICAL", 36, 40], ["2-aminopurine", "SIMPLE_CHEMICAL", 21, 34], ["2-AP", "SIMPLE_CHEMICAL", 36, 40], ["PKR", "GENE_OR_GENE_PRODUCT", 64, 67], ["RSV", "ORGANISM", 96, 99], ["PKR", "PROTEIN", 64, 67], ["RSV", "SPECIES", 96, 99], ["The data", "TEST", 0, 8], ["aminopurine", "TEST", 23, 34], ["PKR chemical inhibitor", "TREATMENT", 64, 86], ["reduced RSV replication", "TREATMENT", 88, 111], ["RSV replication", "OBSERVATION", 96, 111]]], ["Unexpectedly PKR protein knockdown by shRNA did not affect RSV replication.", [["PKR", "GENE_OR_GENE_PRODUCT", 13, 16], ["RSV", "ORGANISM", 59, 62], ["PKR", "PROTEIN", 13, 16], ["RSV", "SPECIES", 59, 62], ["PKR protein knockdown", "TREATMENT", 13, 34], ["RSV replication", "PROBLEM", 59, 74], ["protein knockdown", "OBSERVATION", 17, 34]]], ["However, we did observe a drastic decrease in stress granule formation in PKRknockdown cells.", [["stress granule", "ANATOMY", 46, 60], ["PKRknockdown cells", "ANATOMY", 74, 92], ["stress granule", "CELLULAR_COMPONENT", 46, 60], ["PKRknockdown cells", "CELL", 74, 92], ["PKRknockdown cells", "CELL_LINE", 74, 92], ["a drastic decrease", "PROBLEM", 24, 42], ["stress granule formation in PKRknockdown cells", "PROBLEM", 46, 92], ["drastic", "OBSERVATION_MODIFIER", 26, 33], ["decrease", "OBSERVATION_MODIFIER", 34, 42], ["stress granule formation", "OBSERVATION", 46, 70], ["PKRknockdown cells", "OBSERVATION", 74, 92]]], ["These results suggest that PKR expression and activation have little effect on RSV replication in cultured cells, and that the PKR inhibitor 2-AP likely inhibits RSV replication in a manner independent of PKR.RSV induces the activation of PKR and eIF2\u03b1RSV infection potently induces stress granule formation (Lindquist et al., 2010) .", [["cells", "ANATOMY", 107, 112], ["stress granule", "ANATOMY", 283, 297], ["2-AP", "CHEMICAL", 141, 145], ["RSV infection", "DISEASE", 252, 265], ["2-AP", "CHEMICAL", 141, 145], ["PKR", "GENE_OR_GENE_PRODUCT", 27, 30], ["RSV", "ORGANISM", 79, 82], ["cells", "CELL", 107, 112], ["PKR", "GENE_OR_GENE_PRODUCT", 127, 130], ["2-AP", "GENE_OR_GENE_PRODUCT", 141, 145], ["RSV", "ORGANISM", 162, 165], ["PKR", "GENE_OR_GENE_PRODUCT", 205, 208], ["RSV", "ORGANISM", 209, 212], ["PKR", "GENE_OR_GENE_PRODUCT", 239, 242], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 247, 252], ["RSV", "ORGANISM", 252, 255], ["stress granule", "CELLULAR_COMPONENT", 283, 297], ["PKR", "PROTEIN", 27, 30], ["cultured cells", "CELL_LINE", 98, 112], ["PKR", "PROTEIN", 127, 130], ["PKR", "PROTEIN", 205, 208], ["PKR", "PROTEIN", 239, 242], ["eIF2", "PROTEIN", 247, 251], ["RSV", "SPECIES", 79, 82], ["RSV", "SPECIES", 162, 165], ["RSV", "SPECIES", 209, 212], ["RSV", "SPECIES", 252, 255], ["PKR expression", "PROBLEM", 27, 41], ["RSV replication in cultured cells", "PROBLEM", 79, 112], ["the PKR inhibitor", "TEST", 123, 140], ["RSV replication", "PROBLEM", 162, 177], ["RSV", "PROBLEM", 209, 212], ["PKR", "PROBLEM", 239, 242], ["RSV infection", "PROBLEM", 252, 265], ["stress granule formation", "PROBLEM", 283, 307], ["PKR", "OBSERVATION", 27, 30], ["RSV replication", "OBSERVATION", 162, 177], ["infection", "OBSERVATION", 256, 265], ["stress granule", "OBSERVATION", 283, 297]]], ["PKR and eIF2\u03b1 are phosphorylated during RSV infection.", [["RSV infection", "DISEASE", 40, 53], ["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 8, 13], ["RSV", "ORGANISM", 40, 43], ["PKR", "PROTEIN", 0, 3], ["eIF2\u03b1", "PROTEIN", 8, 13], ["RSV", "SPECIES", 40, 43], ["PKR", "TEST", 0, 3], ["eIF2", "TEST", 8, 12], ["phosphorylated", "PROBLEM", 18, 32], ["RSV infection", "PROBLEM", 40, 53], ["RSV infection", "OBSERVATION", 40, 53]]], ["(A) HEp-2 cells were infected with RSV (MOI = 1.0 pfu/cell) for the indicated times, fixed, and processed for immunofluorescence.", [["HEp-2 cells", "ANATOMY", 4, 15], ["cell", "ANATOMY", 54, 58], ["HEp-2 cells", "CELL", 4, 15], ["RSV", "ORGANISM", 35, 38], ["cell", "CELL", 54, 58], ["HEp-2 cells", "CELL_LINE", 4, 15], ["RSV", "SPECIES", 35, 38], ["HEp-2 cells", "TREATMENT", 4, 15], ["RSV", "PROBLEM", 35, 38], ["MOI", "TEST", 40, 43], ["immunofluorescence", "TEST", 110, 128], ["HEp", "ANATOMY", 4, 7]]], ["Anti-RSV P monoclonal antibody was used to localize viral protein and appears green in the merge panel.", [["P monoclonal antibody", "PROTEIN", 9, 30], ["viral protein", "PROTEIN", 52, 65], ["Anti-RSV", "SPECIES", 0, 8], ["P monoclonal antibody", "TEST", 9, 30], ["viral protein", "TEST", 52, 65], ["viral protein", "OBSERVATION", 52, 65]]], ["Anti-TIA-1 antibody was used to detect stress granule formation and appears red in the merge panel.", [["stress granule", "ANATOMY", 39, 53], ["TIA-1 antibody", "GENE_OR_GENE_PRODUCT", 5, 19], ["stress granule", "CELLULAR_COMPONENT", 39, 53], ["Anti-TIA-1 antibody", "PROTEIN", 0, 19], ["Anti-TIA-1 antibody", "TEST", 0, 19], ["stress granule formation", "PROBLEM", 39, 63], ["stress granule formation", "OBSERVATION", 39, 63]]], ["Phosphorylated eIF2\u03b1 (peIF2\u03b1) appears blue in the merge panel.", [["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 15, 20], ["peIF2\u03b1", "GENE_OR_GENE_PRODUCT", 22, 28], ["Phosphorylated eIF2\u03b1", "PROTEIN", 0, 20], ["peIF2\u03b1", "PROTEIN", 22, 28], ["Phosphorylated eIF2\u03b1 (peIF2\u03b1)", "TREATMENT", 0, 29]]], ["(B) HEp-2 cells were mock-inoculated or inoculated with RSV (MOI = 1.0 pfu/cell) for 24 h.", [["HEp-2 cells", "ANATOMY", 4, 15], ["cell", "ANATOMY", 75, 79], ["B) HEp-2 cells", "CELL", 1, 15], ["RSV", "ORGANISM", 56, 59], ["cell", "CELL", 75, 79], ["HEp-2 cells", "CELL_LINE", 4, 15], ["RSV", "SPECIES", 56, 59], ["B) HEp-2 cells", "TEST", 1, 15], ["RSV", "PROBLEM", 56, 59], ["MOI", "TEST", 61, 64], ["HEp", "ANATOMY", 4, 7]]], ["Cell lysates were analyzed by immunoblots for GAPDH, RSV P, phosphorylated PKR, or total PKR.", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["GAPDH", "GENE_OR_GENE_PRODUCT", 46, 51], ["RSV", "ORGANISM", 53, 56], ["PKR", "GENE_OR_GENE_PRODUCT", 75, 78], ["PKR", "GENE_OR_GENE_PRODUCT", 89, 92], ["GAPDH", "PROTEIN", 46, 51], ["RSV P", "PROTEIN", 53, 58], ["phosphorylated PKR", "PROTEIN", 60, 78], ["PKR", "PROTEIN", 89, 92], ["RSV", "SPECIES", 53, 56], ["Cell lysates", "TEST", 0, 12], ["immunoblots", "TEST", 30, 41], ["GAPDH", "TEST", 46, 51], ["RSV P", "TEST", 53, 58], ["phosphorylated PKR", "TEST", 60, 78], ["total PKR", "TEST", 83, 92]]], ["Relative protein densities comparing RSV-infected cells to mock-infected cells were quantified using Li-Cor Odyssey imaging software.", [["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 73, 78], ["RSV", "ORGANISM", 37, 40], ["cells", "CELL", 50, 55], ["cells", "CELL", 73, 78], ["RSV-infected cells", "CELL_TYPE", 37, 55], ["mock-infected cells", "CELL_TYPE", 59, 78], ["RSV", "SPECIES", 37, 40], ["Relative protein densities", "PROBLEM", 0, 26], ["RSV", "PROBLEM", 37, 40], ["infected cells", "PROBLEM", 64, 78], ["protein densities", "OBSERVATION", 9, 26], ["infected cells", "OBSERVATION", 41, 55], ["infected cells", "OBSERVATION", 64, 78]]], ["RSV initiates this process.", [["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3]]], ["Typically, stress granules form following induction of one of many types of stress-related pathways that result in a common downstream event, phosphorylation of the translation initiation factor, eIF2\u03b1 (Kedersha and Anderson, 2007) .", [["stress granules", "ANATOMY", 11, 26], ["stress granules", "CELLULAR_COMPONENT", 11, 26], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 196, 201], ["translation initiation factor", "PROTEIN", 165, 194], ["eIF2\u03b1", "PROTEIN", 196, 201], ["stress granules", "PROBLEM", 11, 26], ["stress-related pathways", "PROBLEM", 76, 99], ["a common downstream event", "PROBLEM", 115, 140], ["stress granules", "OBSERVATION", 11, 26]]], ["Therefore, we examined cells inoculated with RSV (MOI = 1.0 pfu/cell) for the presence of phosphorylated eIF2\u03b1 using indirect immunofluorescence.", [["cells", "ANATOMY", 23, 28], ["cell", "ANATOMY", 64, 68], ["cells", "CELL", 23, 28], ["RSV", "ORGANISM", 45, 48], ["cell", "CELL", 64, 68], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 105, 110], ["phosphorylated eIF2\u03b1", "PROTEIN", 90, 110], ["RSV", "SPECIES", 45, 48], ["RSV", "PROBLEM", 45, 48], ["MOI", "TEST", 50, 53], ["phosphorylated eIF2", "TREATMENT", 90, 109], ["indirect immunofluorescence", "TEST", 117, 144]]], ["We observed a striking increase in eIF2\u03b1 phosphorylation beginning 12 h post-inoculation that was concomitant with the appearance of stress granules and continued throughout infection (Fig. 1A) .RSV induces the activation of PKR and eIF2\u03b1We next sought to determine the mechanism by which RSV mediates the phosphorylation of eIF2\u03b1.", [["stress granules", "ANATOMY", 133, 148], ["infection", "DISEASE", 174, 183], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["stress granules", "CELLULAR_COMPONENT", 133, 148], ["RSV", "ORGANISM", 195, 198], ["PKR", "GENE_OR_GENE_PRODUCT", 225, 228], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 233, 238], ["RSV", "ORGANISM", 289, 292], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 325, 330], ["eIF2\u03b1", "PROTEIN", 35, 40], ["PKR", "PROTEIN", 225, 228], ["eIF2", "PROTEIN", 233, 237], ["eIF2\u03b1", "PROTEIN", 325, 330], ["RSV", "SPECIES", 195, 198], ["RSV", "SPECIES", 289, 292], ["eIF2\u03b1 phosphorylation", "TREATMENT", 35, 56], ["stress granules", "PROBLEM", 133, 148], ["RSV", "PROBLEM", 195, 198], ["PKR", "PROBLEM", 225, 228], ["striking", "OBSERVATION_MODIFIER", 14, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["eIF2\u03b1", "OBSERVATION", 35, 40], ["stress granules", "OBSERVATION", 133, 148], ["infection", "OBSERVATION", 174, 183]]], ["There are four well-defined kinases capable of eIF2\u03b1 phosphorylation: protein kinase RNA (PKR), a kinase activated by double-stranded RNA; PKR-like ER-localized eIF2\u03b1 kinase (PERK); general control nonrepressed 2 (GCN2); and heme-regulated inhibitor kinase (HRI) (Proud, 2005) .", [["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 47, 52], ["protein kinase RNA", "GENE_OR_GENE_PRODUCT", 70, 88], ["PKR", "GENE_OR_GENE_PRODUCT", 90, 93], ["PKR", "GENE_OR_GENE_PRODUCT", 139, 142], ["ER", "GENE_OR_GENE_PRODUCT", 148, 150], ["eIF2\u03b1 kinase", "GENE_OR_GENE_PRODUCT", 161, 173], ["PERK", "GENE_OR_GENE_PRODUCT", 175, 179], ["general control nonrepressed 2", "GENE_OR_GENE_PRODUCT", 182, 212], ["GCN2", "GENE_OR_GENE_PRODUCT", 214, 218], ["heme-regulated inhibitor kinase", "GENE_OR_GENE_PRODUCT", 225, 256], ["HRI", "GENE_OR_GENE_PRODUCT", 258, 261], ["kinases", "PROTEIN", 28, 35], ["eIF2\u03b1", "PROTEIN", 47, 52], ["protein kinase RNA", "PROTEIN", 70, 88], ["PKR", "PROTEIN", 90, 93], ["kinase", "PROTEIN", 98, 104], ["PKR", "PROTEIN", 139, 142], ["ER", "PROTEIN", 148, 150], ["eIF2\u03b1 kinase", "PROTEIN", 161, 173], ["PERK", "PROTEIN", 175, 179], ["nonrepressed 2", "PROTEIN", 198, 212], ["GCN2", "PROTEIN", 214, 218], ["heme-regulated inhibitor kinase", "PROTEIN", 225, 256], ["HRI", "PROTEIN", 258, 261], ["eIF2\u03b1 phosphorylation", "TEST", 47, 68], ["protein kinase RNA", "TEST", 70, 88], ["PKR", "TEST", 90, 93], ["a kinase", "TEST", 96, 104], ["double-stranded RNA", "TEST", 118, 137], ["PKR", "TEST", 139, 142], ["heme", "TEST", 225, 229]]], ["We reasoned that PKR was likely responsible for eIF2\u03b1 phosphorylation during RSV infection, as it is known that RSV infection activates PKR (Groskreutz et al., 2010) .", [["RSV infection", "DISEASE", 77, 90], ["RSV infection", "DISEASE", 112, 125], ["PKR", "GENE_OR_GENE_PRODUCT", 17, 20], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 48, 53], ["RSV", "ORGANISM", 77, 80], ["RSV", "ORGANISM", 112, 115], ["PKR", "GENE_OR_GENE_PRODUCT", 136, 139], ["PKR", "PROTEIN", 17, 20], ["eIF2\u03b1", "PROTEIN", 48, 53], ["PKR", "PROTEIN", 136, 139], ["RSV", "SPECIES", 77, 80], ["RSV", "SPECIES", 112, 115], ["PKR", "TEST", 17, 20], ["eIF2\u03b1 phosphorylation", "TREATMENT", 48, 69], ["RSV infection", "PROBLEM", 77, 90], ["RSV infection", "PROBLEM", 112, 125], ["likely responsible for", "UNCERTAINTY", 25, 47], ["infection", "OBSERVATION", 81, 90], ["RSV", "OBSERVATION_MODIFIER", 112, 115], ["infection", "OBSERVATION", 116, 125]]], ["In cells inoculated with RSV (MOI = 1.0 pfu/cell) for 24 h, we observed phosphorylated PKR and higher expression of total PKR in comparison to mock-inoculated cells (Fig. 1B) , consistent with previous reports.Knockdown of PKR expression does not affect RSV replicationWe investigated what effects inhibition of PKR signaling might have on RSV replication.", [["cells", "ANATOMY", 3, 8], ["cell", "ANATOMY", 44, 48], ["cells", "ANATOMY", 159, 164], ["cells", "CELL", 3, 8], ["RSV", "ORGANISM", 25, 28], ["cell", "CELL", 44, 48], ["PKR", "GENE_OR_GENE_PRODUCT", 87, 90], ["PKR", "GENE_OR_GENE_PRODUCT", 122, 125], ["cells", "CELL", 159, 164], ["Fig. 1B", "CELL", 166, 173], ["PKR", "GENE_OR_GENE_PRODUCT", 223, 226], ["RSV", "ORGANISM", 254, 257], ["PKR", "GENE_OR_GENE_PRODUCT", 312, 315], ["RSV", "ORGANISM", 340, 343], ["phosphorylated PKR", "PROTEIN", 72, 90], ["PKR", "PROTEIN", 122, 125], ["mock-inoculated cells", "CELL_LINE", 143, 164], ["PKR", "PROTEIN", 223, 226], ["PKR", "PROTEIN", 312, 315], ["RSV", "SPECIES", 25, 28], ["RSV", "SPECIES", 254, 257], ["RSV", "SPECIES", 340, 343], ["RSV", "PROBLEM", 25, 28], ["MOI", "TEST", 30, 33], ["phosphorylated PKR", "TEST", 72, 90], ["total PKR", "TEST", 116, 125], ["mock", "TEST", 143, 147], ["PKR expression", "PROBLEM", 223, 237], ["RSV replicationWe", "TREATMENT", 254, 271], ["PKR signaling", "PROBLEM", 312, 325], ["RSV replication", "TREATMENT", 340, 355], ["consistent with", "UNCERTAINTY", 177, 192], ["PKR", "OBSERVATION", 223, 226]]], ["HEp-2 cells were transduced with shRNA lentiviral constructs specific for PKR or a non-targeting shRNA control.", [["HEp-2 cells", "ANATOMY", 0, 11], ["HEp-2 cells", "CELL", 0, 11], ["PKR", "GENE_OR_GENE_PRODUCT", 74, 77], ["HEp-2 cells", "CELL_LINE", 0, 11], ["shRNA lentiviral constructs", "DNA", 33, 60], ["PKR", "PROTEIN", 74, 77], ["HEp-2 cells", "TREATMENT", 0, 11], ["shRNA lentiviral constructs", "TREATMENT", 33, 60], ["PKR", "PROBLEM", 74, 77], ["a non-targeting shRNA control", "TREATMENT", 81, 110]]], ["We selected for cells stably expressing the shRNA constructs and we compared PKR levels by immunoblotting in wild-type cells that were not transduced or cells transduced with PKR-targeting or nontargeting shRNA.", [["cells", "ANATOMY", 16, 21], ["wild-type cells", "ANATOMY", 109, 124], ["cells", "ANATOMY", 153, 158], ["cells", "CELL", 16, 21], ["PKR", "GENE_OR_GENE_PRODUCT", 77, 80], ["cells", "CELL", 119, 124], ["cells", "CELL", 153, 158], ["PKR", "GENE_OR_GENE_PRODUCT", 175, 178], ["shRNA constructs", "DNA", 44, 60], ["PKR", "PROTEIN", 77, 80], ["wild-type cells", "CELL_TYPE", 109, 124], ["PKR", "PROTEIN", 175, 178], ["nontargeting shRNA", "DNA", 192, 210], ["cells", "PROBLEM", 16, 21], ["the shRNA constructs", "PROBLEM", 40, 60], ["PKR levels", "TEST", 77, 87], ["immunoblotting", "TEST", 91, 105], ["type cells", "PROBLEM", 114, 124], ["PKR", "TEST", 175, 178], ["nontargeting shRNA", "PROBLEM", 192, 210]]], ["Cells expressing the PKR shRNA construct exhibited an approximate 90% decrease in total PKR protein levels ( Fig. 2A ) in comparison to wild-type cells or those expressing a non-targeting shRNA.", [["Cells", "ANATOMY", 0, 5], ["wild-type cells", "ANATOMY", 136, 151], ["Cells", "CELL", 0, 5], ["PKR", "GENE_OR_GENE_PRODUCT", 21, 24], ["PKR", "GENE_OR_GENE_PRODUCT", 88, 91], ["cells", "CELL", 146, 151], ["PKR shRNA construct", "DNA", 21, 40], ["PKR", "PROTEIN", 88, 91], ["wild-type cells", "CELL_TYPE", 136, 151], ["the PKR shRNA construct", "TEST", 17, 40], ["total PKR protein levels", "TEST", 82, 106], ["decrease", "OBSERVATION_MODIFIER", 70, 78]]], ["Wild-type, non-targeting, or PKR-knockdown cells were inoculated with RSV (MOI = 1.0 pfu/cell) and incubated for 24 h.Knockdown of PKR expression does not affect RSV replicationImmunoblot analysis of cell lysates did not demonstrate an increase in PKR phosphorylation in the RSV-inoculated PKR-knockdown cells in comparison to wild-type or non-targeting shRNA cells.", [["cells", "ANATOMY", 43, 48], ["cell", "ANATOMY", 89, 93], ["cell lysates", "ANATOMY", 200, 212], ["cells", "ANATOMY", 304, 309], ["cells", "ANATOMY", 360, 365], ["PKR", "GENE_OR_GENE_PRODUCT", 29, 32], ["cells", "CELL", 43, 48], ["RSV", "ORGANISM", 70, 73], ["cell", "CELL", 89, 93], ["PKR", "GENE_OR_GENE_PRODUCT", 131, 134], ["RSV", "ORGANISM", 162, 165], ["cell", "CELL", 200, 204], ["PKR", "GENE_OR_GENE_PRODUCT", 248, 251], ["RSV", "ORGANISM", 275, 278], ["PKR", "GENE_OR_GENE_PRODUCT", 290, 293], ["cells", "CELL", 304, 309], ["cells", "CELL", 360, 365], ["Wild-type, non-targeting, or PKR-knockdown cells", "CELL_LINE", 0, 48], ["PKR", "PROTEIN", 131, 134], ["PKR", "PROTEIN", 248, 251], ["PKR", "PROTEIN", 290, 293], ["non-targeting shRNA cells", "CELL_LINE", 340, 365], ["RSV", "SPECIES", 70, 73], ["RSV", "SPECIES", 162, 165], ["RSV", "SPECIES", 275, 278], ["PKR", "TEST", 29, 32], ["knockdown cells", "PROBLEM", 33, 48], ["RSV", "PROBLEM", 70, 73], ["MOI", "TEST", 75, 78], ["PKR expression", "TEST", 131, 145], ["RSV replication", "TEST", 162, 177], ["Immunoblot analysis", "TEST", 177, 196], ["cell lysates", "TEST", 200, 212], ["an increase in PKR phosphorylation", "PROBLEM", 233, 267], ["the RSV", "TEST", 271, 278], ["knockdown cells", "PROBLEM", 294, 309], ["non-targeting shRNA cells", "PROBLEM", 340, 365], ["increase", "OBSERVATION_MODIFIER", 236, 244], ["PKR phosphorylation", "OBSERVATION", 248, 267], ["RSV", "ANATOMY", 275, 278], ["inoculated PKR", "OBSERVATION", 279, 293], ["knockdown cells", "OBSERVATION", 294, 309], ["shRNA cells", "OBSERVATION", 354, 365]]], ["We next quantified the viral titers over a time course for each cell type.", [["cell", "ANATOMY", 64, 68], ["cell type", "CELL", 64, 73], ["the viral titers", "PROBLEM", 19, 35], ["viral titers", "OBSERVATION", 23, 35], ["cell type", "OBSERVATION", 64, 73]]], ["Cells were inoculated with RSV (MOI = 0.1 pfu/cell) and incubated for 0-4 days.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 46, 50], ["Cells", "CELL", 0, 5], ["RSV", "ORGANISM", 27, 30], ["cell", "CELL", 46, 50], ["RSV", "SPECIES", 27, 30], ["Cells", "TEST", 0, 5], ["RSV", "TEST", 27, 30], ["MOI", "TEST", 32, 35]]], ["Cell-associated virus was harvested for each time point, and titers were determined by plaque assay.", [["Cell", "ANATOMY", 0, 4], ["plaque", "ANATOMY", 87, 93], ["Cell", "CELL", 0, 4], ["Cell-associated virus", "PROBLEM", 0, 21], ["titers", "TEST", 61, 67], ["plaque assay", "TEST", 87, 99], ["virus", "OBSERVATION", 16, 21], ["plaque", "OBSERVATION", 87, 93]]], ["Viral titers in the PKRknockdown cells did not differ significantly from those in either wildtype cells or non-targeting shRNA-expressing cells (Fig. 2B) .", [["PKRknockdown cells", "ANATOMY", 20, 38], ["cells", "ANATOMY", 98, 103], ["cells", "ANATOMY", 138, 143], ["Viral", "ORGANISM", 0, 5], ["PKRknockdown cells", "CELL", 20, 38], ["cells", "CELL", 98, 103], ["cells", "CELL", 138, 143], ["Fig. 2B", "CELL", 145, 152], ["PKRknockdown cells", "CELL_LINE", 20, 38], ["wildtype cells", "CELL_LINE", 89, 103], ["non-targeting shRNA-expressing cells", "CELL_LINE", 107, 143], ["Viral titers", "TEST", 0, 12], ["the PKRknockdown cells", "TEST", 16, 38], ["non-targeting shRNA", "PROBLEM", 107, 126], ["expressing cells", "PROBLEM", 127, 143], ["titers", "OBSERVATION", 6, 12]]], ["These results indicate that inhibition of PKR activation does not affect RSV replication.Knockdown of PKR prevents formation of RSV-induced stress granules during infectionWe next determined whether PKR is the kinase responsible for stress granule formation during RSV infection.", [["stress granules", "ANATOMY", 140, 155], ["stress granule", "ANATOMY", 233, 247], ["RSV infection", "DISEASE", 265, 278], ["PKR", "GENE_OR_GENE_PRODUCT", 42, 45], ["RSV", "ORGANISM", 73, 76], ["PKR", "GENE_OR_GENE_PRODUCT", 102, 105], ["RSV", "ORGANISM", 128, 131], ["stress granules", "CELLULAR_COMPONENT", 140, 155], ["PKR", "GENE_OR_GENE_PRODUCT", 199, 202], ["stress granule", "CELLULAR_COMPONENT", 233, 247], ["RSV", "ORGANISM", 265, 268], ["PKR", "PROTEIN", 42, 45], ["PKR", "PROTEIN", 102, 105], ["PKR", "PROTEIN", 199, 202], ["RSV", "SPECIES", 73, 76], ["RSV", "SPECIES", 128, 131], ["RSV", "SPECIES", 265, 268], ["inhibition of PKR activation", "PROBLEM", 28, 56], ["RSV replication", "PROBLEM", 73, 88], ["PKR", "PROBLEM", 102, 105], ["RSV", "PROBLEM", 128, 131], ["stress granules", "PROBLEM", 140, 155], ["PKR", "PROBLEM", 199, 202], ["the kinase", "TEST", 206, 216], ["stress granule formation", "PROBLEM", 233, 257], ["RSV infection", "PROBLEM", 265, 278], ["PKR", "OBSERVATION", 42, 45], ["PKR", "OBSERVATION", 102, 105], ["RSV", "OBSERVATION", 128, 131], ["stress granules", "OBSERVATION", 140, 155], ["granule formation", "OBSERVATION", 240, 257], ["RSV infection", "OBSERVATION", 265, 278]]], ["We infected wild-type, shRNA non-targeting, or PKR-knockdown cells with RSV for 48 h (MOI = 5.0 pfu/cell).", [["cells", "ANATOMY", 61, 66], ["cell", "ANATOMY", 100, 104], ["PKR", "GENE_OR_GENE_PRODUCT", 47, 50], ["cells", "CELL", 61, 66], ["RSV", "ORGANISM", 72, 75], ["cell", "CELL", 100, 104], ["PKR-knockdown cells", "CELL_LINE", 47, 66], ["RSV", "SPECIES", 72, 75], ["PKR", "TEST", 47, 50], ["knockdown cells", "PROBLEM", 51, 66], ["RSV", "PROBLEM", 72, 75], ["MOI", "TEST", 86, 89], ["knockdown cells", "OBSERVATION", 51, 66]]], ["We then examined cells for the presence of stress granules using indirect immunofluorescence (Fig. 3A) .", [["cells", "ANATOMY", 17, 22], ["stress granules", "ANATOMY", 43, 58], ["cells", "CELL", 17, 22], ["stress granules", "CELLULAR_COMPONENT", 43, 58], ["stress granules", "PROBLEM", 43, 58], ["indirect immunofluorescence", "TEST", 65, 92], ["stress granules", "OBSERVATION", 43, 58]]], ["In wildtype and shRNA non-targeting cells, we observed robust stress granule formation in infected cells.", [["cells", "ANATOMY", 36, 41], ["stress granule", "ANATOMY", 62, 76], ["cells", "ANATOMY", 99, 104], ["cells", "CELL", 36, 41], ["stress granule", "CELLULAR_COMPONENT", 62, 76], ["cells", "CELL", 99, 104], ["wildtype and shRNA non-targeting cells", "CELL_LINE", 3, 41], ["infected cells", "CELL_TYPE", 90, 104], ["wildtype and shRNA non-targeting cells", "PROBLEM", 3, 41], ["robust stress granule formation in infected cells", "PROBLEM", 55, 104], ["robust", "OBSERVATION_MODIFIER", 55, 61], ["stress granule formation", "OBSERVATION", 62, 86], ["infected cells", "OBSERVATION", 90, 104]]], ["However, in PKR-knockdown cells, stress granule formation was substantially diminished.", [["cells", "ANATOMY", 26, 31], ["stress granule", "ANATOMY", 33, 47], ["PKR", "GENE_OR_GENE_PRODUCT", 12, 15], ["cells", "CELL", 26, 31], ["stress granule", "CELLULAR_COMPONENT", 33, 47], ["PKR", "PROTEIN", 12, 15], ["PKR", "TEST", 12, 15], ["stress granule formation", "PROBLEM", 33, 57], ["substantially diminished", "PROBLEM", 62, 86], ["knockdown cells", "OBSERVATION", 16, 31], ["stress granule formation", "OBSERVATION", 33, 57], ["substantially", "OBSERVATION_MODIFIER", 62, 75], ["diminished", "OBSERVATION_MODIFIER", 76, 86]]], ["We quantified the number of RSV-infected cells that formed stress granules for each cell type.", [["cells", "ANATOMY", 41, 46], ["stress granules", "ANATOMY", 59, 74], ["cell", "ANATOMY", 84, 88], ["RSV", "ORGANISM", 28, 31], ["cells", "CELL", 41, 46], ["stress granules", "CELLULAR_COMPONENT", 59, 74], ["cell type", "CELL", 84, 93], ["RSV-infected cells", "CELL_TYPE", 28, 46], ["RSV", "SPECIES", 28, 31], ["RSV", "PROBLEM", 28, 31], ["infected cells", "PROBLEM", 32, 46], ["stress granules", "PROBLEM", 59, 74], ["RSV", "OBSERVATION", 28, 31], ["infected cells", "OBSERVATION", 32, 46], ["stress granules", "OBSERVATION", 59, 74], ["for each cell type", "OBSERVATION", 75, 93]]], ["Our results show that while approximately 25-30% of infected wild-type and shRNA non-targeting cells form stress granules, stress granules form in only 2% of infected PKRknockdown cells (Fig. 3B ).", [["cells", "ANATOMY", 95, 100], ["stress granules", "ANATOMY", 106, 121], ["stress granules", "ANATOMY", 123, 138], ["PKRknockdown cells", "ANATOMY", 167, 185], ["cells", "CELL", 95, 100], ["stress granules", "CELLULAR_COMPONENT", 106, 121], ["stress granules", "CELLULAR_COMPONENT", 123, 138], ["PKRknockdown cells", "CELL", 167, 185], ["Fig. 3B", "CELL", 187, 194], ["shRNA non-targeting cells", "CELL_LINE", 75, 100], ["PKRknockdown cells", "CELL_LINE", 167, 185], ["infected wild-type and shRNA non-targeting cells", "PROBLEM", 52, 100], ["stress granules", "PROBLEM", 106, 121], ["stress granules", "PROBLEM", 123, 138], ["infected PKRknockdown cells", "PROBLEM", 158, 185], ["stress granules", "OBSERVATION", 106, 121], ["stress granules", "OBSERVATION", 123, 138], ["infected", "OBSERVATION_MODIFIER", 158, 166], ["PKRknockdown cells", "OBSERVATION", 167, 185]]], ["When each cell type was treated with sodium arsenite, a drug that induces stress granules via HRI kinase rather than PKR, we observed an equivalent frequency of stress granule formation (data not shown).", [["cell", "ANATOMY", 10, 14], ["stress granules", "ANATOMY", 74, 89], ["stress granule", "ANATOMY", 161, 175], ["sodium arsenite", "CHEMICAL", 37, 52], ["sodium arsenite", "CHEMICAL", 37, 52], ["cell type", "CELL", 10, 19], ["sodium arsenite", "SIMPLE_CHEMICAL", 37, 52], ["stress granules", "CELLULAR_COMPONENT", 74, 89], ["HRI", "GENE_OR_GENE_PRODUCT", 94, 97], ["PKR", "GENE_OR_GENE_PRODUCT", 117, 120], ["stress granule", "CELLULAR_COMPONENT", 161, 175], ["HRI kinase", "PROTEIN", 94, 104], ["PKR", "PROTEIN", 117, 120], ["sodium arsenite", "TREATMENT", 37, 52], ["stress granules via HRI kinase", "PROBLEM", 74, 104], ["PKR", "TEST", 117, 120], ["stress granule formation", "PROBLEM", 161, 185], ["stress granule formation", "OBSERVATION", 161, 185]]], ["These results confirm that PKR is required for stress granule formation following RSV infection.The chemical inhibitor 2-AP prevents PKR signaling and reduces RSV infectionTo confirm that PKR activation is dispensable for RSV replication, we sought another method to inhibit activation of the kinase.", [["stress granule", "ANATOMY", 47, 61], ["RSV infection", "DISEASE", 82, 95], ["2-AP", "CHEMICAL", 119, 123], ["RSV infection", "DISEASE", 159, 172], ["2-AP", "CHEMICAL", 119, 123], ["PKR", "GENE_OR_GENE_PRODUCT", 27, 30], ["stress granule", "CELLULAR_COMPONENT", 47, 61], ["RSV", "ORGANISM", 82, 85], ["2-AP", "SIMPLE_CHEMICAL", 119, 123], ["PKR", "GENE_OR_GENE_PRODUCT", 133, 136], ["RSV", "ORGANISM", 159, 162], ["PKR", "GENE_OR_GENE_PRODUCT", 188, 191], ["RSV", "ORGANISM", 222, 225], ["PKR", "PROTEIN", 27, 30], ["PKR", "PROTEIN", 133, 136], ["PKR", "PROTEIN", 188, 191], ["kinase", "PROTEIN", 293, 299], ["RSV", "SPECIES", 82, 85], ["RSV", "SPECIES", 159, 162], ["RSV", "SPECIES", 222, 225], ["PKR", "PROBLEM", 27, 30], ["stress granule formation", "PROBLEM", 47, 71], ["RSV infection", "PROBLEM", 82, 95], ["The chemical inhibitor", "TREATMENT", 96, 118], ["RSV infection", "PROBLEM", 159, 172], ["PKR activation", "PROBLEM", 188, 202], ["RSV replication", "TREATMENT", 222, 237], ["PKR", "OBSERVATION", 27, 30], ["granule formation", "OBSERVATION", 54, 71], ["RSV infection", "OBSERVATION", 82, 95], ["RSV infection", "OBSERVATION", 159, 172]]], ["The nucleotide analog 2-AP prevents PKR activation (Hu and Conway, 1993) .", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["2-AP", "CHEMICAL", 22, 26], ["2-AP", "SIMPLE_CHEMICAL", 22, 26], ["PKR", "GENE_OR_GENE_PRODUCT", 36, 39], ["PKR", "PROTEIN", 36, 39], ["The nucleotide analog", "TREATMENT", 0, 21]]], ["We first tested whether 2-AP treatment alters RSV-mediated PKR activation.", [["2-AP", "CHEMICAL", 24, 28], ["2-AP", "CHEMICAL", 24, 28], ["2-AP", "SIMPLE_CHEMICAL", 24, 28], ["RSV", "ORGANISM", 46, 49], ["PKR", "GENE_OR_GENE_PRODUCT", 59, 62], ["PKR", "PROTEIN", 59, 62], ["RSV", "SPECIES", 46, 49], ["AP treatment", "TREATMENT", 26, 38], ["RSV", "PROBLEM", 46, 49], ["PKR", "OBSERVATION", 59, 62]]], ["HEp-2 epithelial cells were pretreated with 10 mM 2-AP or vehicle for 2 h.", [["HEp-2 epithelial cells", "ANATOMY", 0, 22], ["2-AP", "CHEMICAL", 50, 54], ["2-AP", "CHEMICAL", 50, 54], ["HEp-2 epithelial cells", "CELL", 0, 22], ["2-AP", "SIMPLE_CHEMICAL", 50, 54], ["HEp-2 epithelial cells", "CELL_LINE", 0, 22], ["HEp-2 epithelial cells", "TREATMENT", 0, 22], ["epithelial cells", "ANATOMY", 6, 22]]], ["We then inoculated cells with RSV (MOI = 1.0 pfu/cell) in the presence of 2-AP or vehicle control for 1 h.", [["cells", "ANATOMY", 19, 24], ["cell", "ANATOMY", 49, 53], ["2-AP", "CHEMICAL", 74, 78], ["2-AP", "CHEMICAL", 74, 78], ["cells", "CELL", 19, 24], ["RSV", "ORGANISM", 30, 33], ["cell", "CELL", 49, 53], ["2-AP", "SIMPLE_CHEMICAL", 74, 78], ["RSV", "SPECIES", 30, 33], ["RSV", "PROBLEM", 30, 33], ["MOI", "TEST", 35, 38], ["inoculated cells", "OBSERVATION", 8, 24]]], ["The inoculum was removed and replaced with medium containing 2-AP or vehicle, and the infection was allowed to proceed for 24 h.", [["2-AP", "CHEMICAL", 61, 65], ["infection", "DISEASE", 86, 95], ["2-AP", "SIMPLE_CHEMICAL", 61, 65], ["The inoculum", "TREATMENT", 0, 12], ["the infection", "PROBLEM", 82, 95], ["inoculum", "OBSERVATION", 4, 12], ["infection", "OBSERVATION", 86, 95]]], ["Cell lysates were harvested for immunoblotting to assess the level of total or phosphorylated PKR.", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "CELL", 0, 12], ["PKR", "GENE_OR_GENE_PRODUCT", 94, 97], ["phosphorylated PKR", "PROTEIN", 79, 97], ["Cell lysates", "TREATMENT", 0, 12], ["immunoblotting", "TEST", 32, 46], ["phosphorylated PKR", "TREATMENT", 79, 97]]], ["The phosphorylation of PKR in RSV-infected cells treated with 2-AP was greatly reduced in comparison to vehicletreated cells (Fig. 4A ).", [["cells", "ANATOMY", 43, 48], ["cells", "ANATOMY", 119, 124], ["2-AP", "CHEMICAL", 62, 66], ["2-AP", "CHEMICAL", 62, 66], ["PKR", "GENE_OR_GENE_PRODUCT", 23, 26], ["RSV", "ORGANISM", 30, 33], ["cells", "CELL", 43, 48], ["2-AP", "SIMPLE_CHEMICAL", 62, 66], ["cells", "CELL", 119, 124], ["PKR", "PROTEIN", 23, 26], ["RSV-infected cells", "CELL_LINE", 30, 48], ["vehicletreated cells", "CELL_LINE", 104, 124], ["RSV", "SPECIES", 30, 33], ["PKR", "TEST", 23, 26], ["RSV", "PROBLEM", 30, 33], ["infected cells", "PROBLEM", 34, 48], ["infected cells", "OBSERVATION", 34, 48], ["reduced", "OBSERVATION_MODIFIER", 79, 86]]], ["In addition, we did not observe an increase in total PKR levels in the presence of 2-AP that occurs during RSV infection following virus inoculation.", [["RSV infection", "DISEASE", 107, 120], ["PKR", "GENE_OR_GENE_PRODUCT", 53, 56], ["2-AP", "GENE_OR_GENE_PRODUCT", 83, 87], ["RSV", "ORGANISM", 107, 110], ["PKR", "PROTEIN", 53, 56], ["RSV", "SPECIES", 107, 110], ["an increase in total PKR levels", "PROBLEM", 32, 63], ["RSV infection", "PROBLEM", 107, 120], ["virus inoculation", "TREATMENT", 131, 148], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["total PKR", "OBSERVATION_MODIFIER", 47, 56], ["RSV infection", "OBSERVATION", 107, 120]]], ["As a control, we compared 2-APtreated and vehicle-treated cells in the absence of infection and found no changes in the levels of PKR or phosphorylated PKR.", [["cells", "ANATOMY", 58, 63], ["infection", "DISEASE", 82, 91], ["2-APtreated", "CHEMICAL", 26, 37], ["2-APtreated", "SIMPLE_CHEMICAL", 26, 37], ["cells", "CELL", 58, 63], ["PKR", "GENE_OR_GENE_PRODUCT", 130, 133], ["PKR", "GENE_OR_GENE_PRODUCT", 152, 155], ["APtreated and vehicle-treated cells", "CELL_LINE", 28, 63], ["PKR", "PROTEIN", 130, 133], ["phosphorylated PKR", "PROTEIN", 137, 155], ["infection", "PROBLEM", 82, 91], ["changes in the levels of PKR", "PROBLEM", 105, 133], ["phosphorylated PKR", "TREATMENT", 137, 155], ["infection", "OBSERVATION", 82, 91]]], ["These results indicate that 2-AP inhibits PKR activation during RSV infection.", [["2-AP", "CHEMICAL", 28, 32], ["RSV infection", "DISEASE", 64, 77], ["2-AP", "CHEMICAL", 28, 32], ["2-AP", "SIMPLE_CHEMICAL", 28, 32], ["PKR", "GENE_OR_GENE_PRODUCT", 42, 45], ["RSV", "ORGANISM", 64, 67], ["PKR", "PROTEIN", 42, 45], ["RSV", "SPECIES", 64, 67], ["AP inhibits PKR activation", "PROBLEM", 30, 56], ["RSV infection", "PROBLEM", 64, 77], ["RSV infection", "OBSERVATION", 64, 77]]], ["We next assessed the effect of 2-AP treatment on viral protein expression using an immunoblotting assay for RSV P protein as a surrogate marker.", [["2-AP", "CHEMICAL", 31, 35], ["2-AP", "CHEMICAL", 31, 35], ["2-AP", "SIMPLE_CHEMICAL", 31, 35], ["RSV", "ORGANISM", 108, 111], ["RSV P protein", "PROTEIN", 108, 121], ["RSV", "SPECIES", 108, 111], ["2-AP treatment", "TREATMENT", 31, 45], ["viral protein expression", "TREATMENT", 49, 73], ["an immunoblotting assay", "TEST", 80, 103], ["RSV P protein", "TREATMENT", 108, 121]]], ["Relative amounts of total PKR, phosphorylated PKR, RSV P, and GAPDH were quantified using Odyssey imaging analysis software.", [["PKR", "GENE_OR_GENE_PRODUCT", 26, 29], ["PKR", "GENE_OR_GENE_PRODUCT", 46, 49], ["RSV P", "GENE_OR_GENE_PRODUCT", 51, 56], ["GAPDH", "GENE_OR_GENE_PRODUCT", 62, 67], ["PKR", "PROTEIN", 26, 29], ["phosphorylated PKR", "PROTEIN", 31, 49], ["RSV P", "PROTEIN", 51, 56], ["GAPDH", "PROTEIN", 62, 67], ["RSV", "SPECIES", 51, 54], ["total PKR", "TEST", 20, 29], ["phosphorylated PKR", "TEST", 31, 49], ["RSV P", "TEST", 51, 56], ["GAPDH", "TEST", 62, 67], ["Odyssey imaging analysis software", "TEST", 90, 123], ["amounts", "OBSERVATION_MODIFIER", 9, 16], ["total PKR", "OBSERVATION", 20, 29]]], ["Interestingly, we observed a 70% decrease in the amount of RSV P protein in 2-AP-treated cells in comparison to vehicle-treated cells.", [["cells", "ANATOMY", 89, 94], ["cells", "ANATOMY", 128, 133], ["2-AP", "CHEMICAL", 76, 80], ["2-AP", "CHEMICAL", 76, 80], ["RSV", "ORGANISM", 59, 62], ["2-AP", "SIMPLE_CHEMICAL", 76, 80], ["cells", "CELL", 89, 94], ["cells", "CELL", 128, 133], ["RSV P protein", "PROTEIN", 59, 72], ["2-AP-treated cells", "CELL_LINE", 76, 94], ["vehicle-treated cells", "CELL_LINE", 112, 133], ["RSV", "SPECIES", 59, 62], ["a 70% decrease", "PROBLEM", 27, 41], ["RSV P protein", "TEST", 59, 72], ["vehicle-treated cells", "TREATMENT", 112, 133], ["decrease", "OBSERVATION_MODIFIER", 33, 41], ["RSV", "OBSERVATION", 59, 62]]], ["This result suggests that treatment with 2-AP inhibits viral protein synthesis.The chemical inhibitor 2-AP prevents PKR signaling and reduces RSV infectionTo directly determine the effect of 2-AP treatment on RSV infection, we used indirect immunofluorescence to detect viral proteins in infected cells.", [["cells", "ANATOMY", 297, 302], ["2-AP", "CHEMICAL", 41, 45], ["2-AP", "CHEMICAL", 102, 106], ["RSV infection", "DISEASE", 142, 155], ["2-AP", "CHEMICAL", 191, 195], ["RSV infection", "DISEASE", 209, 222], ["2-AP", "CHEMICAL", 41, 45], ["2-AP", "CHEMICAL", 102, 106], ["2-AP", "CHEMICAL", 191, 195], ["2-AP", "SIMPLE_CHEMICAL", 41, 45], ["2-AP", "SIMPLE_CHEMICAL", 102, 106], ["PKR", "GENE_OR_GENE_PRODUCT", 116, 119], ["RSV", "ORGANISM", 142, 145], ["2-AP", "SIMPLE_CHEMICAL", 191, 195], ["RSV", "ORGANISM", 209, 212], ["cells", "CELL", 297, 302], ["viral protein", "PROTEIN", 55, 68], ["PKR", "PROTEIN", 116, 119], ["viral proteins", "PROTEIN", 270, 284], ["infected cells", "CELL_TYPE", 288, 302], ["RSV", "SPECIES", 142, 145], ["RSV", "SPECIES", 209, 212], ["AP inhibits viral protein synthesis", "PROBLEM", 43, 78], ["The chemical inhibitor", "TREATMENT", 79, 101], ["RSV infection", "PROBLEM", 142, 155], ["2-AP treatment", "TREATMENT", 191, 205], ["RSV infection", "PROBLEM", 209, 222], ["indirect immunofluorescence", "TEST", 232, 259], ["viral proteins in infected cells", "PROBLEM", 270, 302], ["protein synthesis", "OBSERVATION", 61, 78], ["RSV infection", "OBSERVATION", 142, 155], ["RSV", "ANATOMY", 209, 212], ["infection", "OBSERVATION", 213, 222], ["infected cells", "OBSERVATION", 288, 302]]], ["Cells were pretreated with 2-AP or vehicle and inoculated with RSV (MOI = 1.0 pfu/cell).", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 82, 86], ["2-AP", "CHEMICAL", 27, 31], ["Cells", "CELL", 0, 5], ["2-AP", "SIMPLE_CHEMICAL", 27, 31], ["RSV", "ORGANISM", 63, 66], ["cell", "CELL", 82, 86], ["RSV", "SPECIES", 63, 66], ["Cells", "TEST", 0, 5], ["RSV", "TEST", 63, 66], ["MOI", "TEST", 68, 71]]], ["After 24 h, cells were fixed and stained for the RSV F protein as a marker for infection.", [["cells", "ANATOMY", 12, 17], ["infection", "DISEASE", 79, 88], ["cells", "CELL", 12, 17], ["RSV F", "GENE_OR_GENE_PRODUCT", 49, 54], ["RSV F protein", "PROTEIN", 49, 62], ["RSV", "SPECIES", 49, 52], ["infection", "PROBLEM", 79, 88], ["infection", "OBSERVATION", 79, 88]]], ["RSVinfected cells per high-powered field (HPF) were quantified for each treatment.", [["RSVinfected cells", "ANATOMY", 0, 17], ["RSVinfected cells", "CELL", 0, 17], ["RSVinfected cells", "CELL_LINE", 0, 17], ["RSVinfected cells", "PROBLEM", 0, 17], ["each treatment", "TREATMENT", 67, 81]]], ["We observed an approximately 80% decrease in the percent of cells that stained positively for RSV F protein following 2-AP treatment ( Fig. 4B and C) .", [["cells", "ANATOMY", 60, 65], ["2-AP", "CHEMICAL", 118, 122], ["2-AP", "CHEMICAL", 118, 122], ["cells", "CELL", 60, 65], ["RSV F", "GENE_OR_GENE_PRODUCT", 94, 99], ["2-AP", "SIMPLE_CHEMICAL", 118, 122], ["RSV F protein", "PROTEIN", 94, 107], ["RSV", "SPECIES", 94, 97], ["an approximately 80% decrease in the percent of cells", "PROBLEM", 12, 65], ["RSV F protein", "TEST", 94, 107], ["2-AP treatment", "TREATMENT", 118, 132], ["approximately", "OBSERVATION_MODIFIER", 15, 28], ["80%", "OBSERVATION_MODIFIER", 29, 32], ["decrease", "OBSERVATION_MODIFIER", 33, 41]]], ["Thus, 2-AP treatment diminishes RSV infectivity.The chemical inhibitor 2-AP prevents PKR signaling and reduces RSV infectionTo determine the effects of 2-AP treatment on the capacity of RSV to complete an infectious cycle, cells were pretreated with vehicle or 2-AP and inoculated with RSV (MOI=0.1 pfu/cell).", [["cells", "ANATOMY", 223, 228], ["cell", "ANATOMY", 303, 307], ["2-AP", "CHEMICAL", 6, 10], ["2-AP", "CHEMICAL", 71, 75], ["2-AP", "CHEMICAL", 152, 156], ["2-AP", "CHEMICAL", 261, 265], ["2-AP", "CHEMICAL", 6, 10], ["2-AP", "CHEMICAL", 71, 75], ["2-AP", "CHEMICAL", 152, 156], ["2-AP", "SIMPLE_CHEMICAL", 6, 10], ["RSV", "ORGANISM", 32, 35], ["2-AP", "SIMPLE_CHEMICAL", 71, 75], ["PKR", "GENE_OR_GENE_PRODUCT", 85, 88], ["RSV", "ORGANISM", 111, 114], ["2-AP", "SIMPLE_CHEMICAL", 152, 156], ["RSV", "ORGANISM", 186, 189], ["cells", "CELL", 223, 228], ["2-AP", "SIMPLE_CHEMICAL", 261, 265], ["RSV", "ORGANISM", 286, 289], ["cell", "CELL", 303, 307], ["PKR", "PROTEIN", 85, 88], ["RSV", "SPECIES", 32, 35], ["RSV", "SPECIES", 111, 114], ["RSV", "SPECIES", 186, 189], ["RSV", "SPECIES", 286, 289], ["RSV infectivity", "PROBLEM", 32, 47], ["The chemical inhibitor", "TREATMENT", 48, 70], ["RSV infectionTo", "PROBLEM", 111, 126], ["2-AP treatment", "TREATMENT", 152, 166], ["RSV", "PROBLEM", 186, 189], ["RSV", "PROBLEM", 286, 289], ["MOI", "TEST", 291, 294], ["RSV infectivity", "OBSERVATION", 32, 47], ["infectious", "OBSERVATION", 205, 215]]], ["After a 1h adsorption, the inoculum was replaced with medium containing vehicle or 2-AP.", [["2-AP", "SIMPLE_CHEMICAL", 83, 87], ["a 1h adsorption", "TREATMENT", 6, 21], ["the inoculum", "TREATMENT", 23, 35]]], ["Titers of cell-associated virus were determined at 24h intervals for 0-4 days.", [["cell", "ANATOMY", 10, 14], ["cell", "CELL", 10, 14], ["cell-associated virus", "PROBLEM", 10, 31]]], ["The results show that 2-AP treatment mediated an approximately 1000-fold decrease in viral titer throughout the time course of infection (Fig. 5A) .", [["2-AP", "CHEMICAL", 22, 26], ["infection", "DISEASE", 127, 136], ["2-AP", "CHEMICAL", 22, 26], ["2-AP", "SIMPLE_CHEMICAL", 22, 26], ["2-AP treatment", "TREATMENT", 22, 36], ["viral titer", "PROBLEM", 85, 96], ["infection", "PROBLEM", 127, 136], ["-fold", "OBSERVATION_MODIFIER", 67, 72], ["decrease", "OBSERVATION_MODIFIER", 73, 81], ["viral titer", "OBSERVATION", 85, 96], ["infection", "OBSERVATION", 127, 136]]], ["To determine if 2-AP treatment affects viral entry, cells were pretreated with 2-AP and then inoculated with RSV (MOI = 0.1 pfu/cell).", [["cells", "ANATOMY", 52, 57], ["cell", "ANATOMY", 128, 132], ["2-AP", "CHEMICAL", 16, 20], ["2-AP", "CHEMICAL", 79, 83], ["2-AP", "CHEMICAL", 16, 20], ["2-AP", "SIMPLE_CHEMICAL", 16, 20], ["cells", "CELL", 52, 57], ["2-AP", "SIMPLE_CHEMICAL", 79, 83], ["RSV", "ORGANISM", 109, 112], ["cell", "CELL", 128, 132], ["RSV", "SPECIES", 109, 112], ["RSV", "TEST", 109, 112], ["MOI", "TEST", 114, 117]]], ["The inoculum then was replaced with medium containing vehicle control only and incubated for 0-4 days.", [["The inoculum", "TREATMENT", 0, 12], ["medium containing vehicle control", "TREATMENT", 36, 69], ["inoculum", "OBSERVATION", 4, 12]]], ["In contrast to cells incubated with 2-AP throughout infection, cells that had only been pretreated with 2-AP exhibited no change in viral titer when compared to vehicle-treated cells.", [["cells", "ANATOMY", 15, 20], ["cells", "ANATOMY", 63, 68], ["cells", "ANATOMY", 177, 182], ["infection", "DISEASE", 52, 61], ["cells", "CELL", 15, 20], ["2-AP", "SIMPLE_CHEMICAL", 36, 40], ["cells", "CELL", 63, 68], ["2-AP", "SIMPLE_CHEMICAL", 104, 108], ["cells", "CELL", 177, 182], ["vehicle-treated cells", "CELL_LINE", 161, 182], ["AP throughout infection", "PROBLEM", 38, 61], ["change in viral titer", "PROBLEM", 122, 143], ["infection", "OBSERVATION", 52, 61], ["viral titer", "OBSERVATION", 132, 143]]], ["These results suggest that 2-AP does not affect viral entry but rather a later step in the viral life cycle.", [["2-AP", "CHEMICAL", 27, 31], ["2-AP", "CHEMICAL", 27, 31], ["2-AP", "SIMPLE_CHEMICAL", 27, 31], ["viral entry", "PROBLEM", 48, 59]]], ["To determine whether the effects of 2-AP treatment on RSV were virus-specific, we performed a similar experiment using reovirus.", [["2-AP", "CHEMICAL", 36, 40], ["2-AP", "CHEMICAL", 36, 40], ["2-AP", "SIMPLE_CHEMICAL", 36, 40], ["RSV", "ORGANISM", 54, 57], ["reovirus", "ORGANISM", 119, 127], ["RSV", "SPECIES", 54, 57], ["2-AP treatment", "TREATMENT", 36, 50], ["RSV", "PROBLEM", 54, 57], ["virus", "PROBLEM", 63, 68], ["reovirus", "TREATMENT", 119, 127]]], ["Reovirus replication is unaffected by PKR knockdown (Zhang and Samuel, 2007) .", [["Reovirus", "GENE_OR_GENE_PRODUCT", 0, 8], ["PKR", "GENE_OR_GENE_PRODUCT", 38, 41], ["PKR", "PROTEIN", 38, 41], ["Reovirus replication", "TREATMENT", 0, 20], ["PKR knockdown", "OBSERVATION", 38, 51]]], ["In addition, the reovirus \u03c33 protein inhibits PKR activation by competitively binding dsRNA targets (Sherry, 2009) .", [["reovirus", "ORGANISM", 17, 25], ["\u03c33", "GENE_OR_GENE_PRODUCT", 26, 28], ["PKR", "GENE_OR_GENE_PRODUCT", 46, 49], ["reovirus \u03c33 protein", "PROTEIN", 17, 36], ["PKR", "PROTEIN", 46, 49], ["the reovirus", "TREATMENT", 13, 25]]], ["In contrast to our results with RSV, 2-AP treatment only affected reovirus replication during the first 24 h after infection.", [["2-AP", "CHEMICAL", 37, 41], ["infection", "DISEASE", 115, 124], ["2-AP", "CHEMICAL", 37, 41], ["RSV", "ORGANISM", 32, 35], ["2-AP", "SIMPLE_CHEMICAL", 37, 41], ["reovirus", "ORGANISM", 66, 74], ["RSV", "SPECIES", 32, 35], ["RSV", "PROBLEM", 32, 35], ["2-AP treatment", "TREATMENT", 37, 51], ["reovirus replication", "TREATMENT", 66, 86], ["infection", "PROBLEM", 115, 124], ["reovirus replication", "OBSERVATION", 66, 86], ["infection", "OBSERVATION", 115, 124]]], ["After 24 h, we did not observe a significant difference in viral titers between 2-AP-treated or vehicle-treated cells, indicating that 2-AP treatment is much less inhibitory for reovirus replication in comparison to the effect on RSV (Fig. 5B ).2-AP inhibits RSV replication in the absence of PKRWe next tested whether the effect on viral replication observed following 2-AP treatment requires PKR.", [["cells", "ANATOMY", 112, 117], ["2-AP", "CHEMICAL", 80, 84], ["2-AP", "CHEMICAL", 135, 139], ["2-AP", "CHEMICAL", 370, 374], ["2-AP", "CHEMICAL", 80, 84], ["2-AP", "CHEMICAL", 135, 139], ["2-AP", "CHEMICAL", 370, 374], ["2-AP", "SIMPLE_CHEMICAL", 80, 84], ["vehicle", "SIMPLE_CHEMICAL", 96, 103], ["cells", "CELL", 112, 117], ["2-AP", "SIMPLE_CHEMICAL", 135, 139], ["reovirus", "ORGANISM", 178, 186], ["RSV", "ORGANISM", 230, 233], ["Fig. 5B", "ORGANISM", 235, 242], [".2-AP", "GENE_OR_GENE_PRODUCT", 244, 249], ["RSV", "ORGANISM", 259, 262], ["PKRWe", "GENE_OR_GENE_PRODUCT", 293, 298], ["2-AP", "SIMPLE_CHEMICAL", 370, 374], ["PKR", "GENE_OR_GENE_PRODUCT", 394, 397], ["vehicle-treated cells", "CELL_LINE", 96, 117], ["PKRWe", "PROTEIN", 293, 298], ["PKR", "PROTEIN", 394, 397], ["RSV", "SPECIES", 230, 233], ["RSV", "SPECIES", 259, 262], ["a significant difference in viral titers", "PROBLEM", 31, 71], ["vehicle-treated cells", "PROBLEM", 96, 117], ["AP treatment", "TREATMENT", 137, 149], ["reovirus replication", "TREATMENT", 178, 198], ["RSV (Fig. 5B", "TEST", 230, 242], ["AP inhibits RSV replication", "PROBLEM", 247, 274], ["viral replication", "TREATMENT", 333, 350], ["AP treatment", "TREATMENT", 372, 384], ["PKR", "PROBLEM", 394, 397], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["difference", "OBSERVATION", 45, 55], ["viral titers", "OBSERVATION", 59, 71]]], ["We quantified the effect on viral titers in RSV-inoculated wild-type, non-targeting shRNA, or PKRknockdown cells treated with 2-AP or vehicle.", [["PKRknockdown cells", "ANATOMY", 94, 112], ["2-AP", "CHEMICAL", 126, 130], ["2-AP", "CHEMICAL", 126, 130], ["RSV", "ORGANISM", 44, 47], ["PKRknockdown cells", "CELL", 94, 112], ["2-AP", "SIMPLE_CHEMICAL", 126, 130], ["non-targeting shRNA", "CELL_LINE", 70, 89], ["PKRknockdown cells", "CELL_LINE", 94, 112], ["RSV", "SPECIES", 44, 47], ["viral titers", "TEST", 28, 40], ["RSV", "PROBLEM", 44, 47], ["non-targeting shRNA", "PROBLEM", 70, 89], ["PKRknockdown cells", "PROBLEM", 94, 112], ["viral titers", "OBSERVATION", 28, 40]]], ["Cells were inoculated with RSV (MOI = 0.1 pfu/cell) and incubated for 0-4 days.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 46, 50], ["Cells", "CELL", 0, 5], ["RSV", "ORGANISM", 27, 30], ["cell", "CELL", 46, 50], ["RSV", "SPECIES", 27, 30], ["Cells", "TEST", 0, 5], ["RSV", "TEST", 27, 30], ["MOI", "TEST", 32, 35]]], ["Cells were collected for each time point, and titers of cell-associated virus were determined by plaque assay.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 56, 60], ["plaque", "ANATOMY", 97, 103], ["Cells", "CELL", 0, 5], ["cell", "CELL", 56, 60], ["Cells", "TEST", 0, 5], ["cell-associated virus", "PROBLEM", 56, 77], ["plaque assay", "TEST", 97, 109], ["plaque", "OBSERVATION", 97, 103]]], ["Treatment of cells with 2-AP once again mediated a 1000-fold reduction in viral titers throughout the time course (Fig. 6A) .", [["cells", "ANATOMY", 13, 18], ["2-AP", "CHEMICAL", 24, 28], ["cells", "CELL", 13, 18], ["2-AP", "SIMPLE_CHEMICAL", 24, 28], ["Treatment of cells", "TREATMENT", 0, 18], ["a 1000-fold reduction", "TREATMENT", 49, 70], ["viral titers", "PROBLEM", 74, 86], ["viral titers", "OBSERVATION", 74, 86]]], ["Remarkably, 2-AP inhibited RSV replication in each cell type regardless of whether PKR was expressed or induced.", [["cell", "ANATOMY", 51, 55], ["2-AP", "CHEMICAL", 12, 16], ["2-AP", "CHEMICAL", 12, 16], ["2-AP", "SIMPLE_CHEMICAL", 12, 16], ["RSV", "ORGANISM", 27, 30], ["cell type", "CELL", 51, 60], ["PKR", "GENE_OR_GENE_PRODUCT", 83, 86], ["PKR", "PROTEIN", 83, 86], ["RSV", "SPECIES", 27, 30], ["AP inhibited RSV replication", "TREATMENT", 14, 42], ["PKR", "PROBLEM", 83, 86], ["RSV replication", "OBSERVATION", 27, 42], ["each cell type", "OBSERVATION", 46, 60], ["PKR", "OBSERVATION", 83, 86]]], ["We next treated wild-type, non-targeting shRNA, or PKR-knockdown cells with 2-AP or vehicle and inoculated the cells with RSV (MOI = 1.0 pfu/cell).", [["cells", "ANATOMY", 65, 70], ["cells", "ANATOMY", 111, 116], ["cell", "ANATOMY", 141, 145], ["2-AP", "CHEMICAL", 76, 80], ["PKR", "GENE_OR_GENE_PRODUCT", 51, 54], ["cells", "CELL", 65, 70], ["2-AP", "SIMPLE_CHEMICAL", 76, 80], ["cells", "CELL", 111, 116], ["RSV", "ORGANISM", 122, 125], ["cell", "CELL", 141, 145], ["PKR-knockdown cells", "CELL_LINE", 51, 70], ["RSV", "SPECIES", 122, 125], ["non-targeting shRNA", "PROBLEM", 27, 46], ["PKR", "TEST", 51, 54], ["knockdown cells", "PROBLEM", 55, 70], ["RSV", "PROBLEM", 122, 125], ["MOI", "TEST", 127, 130], ["knockdown cells", "OBSERVATION", 55, 70]]], ["Following incubation for 24 h, we harvested the cell lysates and used immunoblots to detect total PKR, phosphorylated PKR, or RSV P. The results show that 2-AP inhibited RSV P production in each cell type, independent of PKR levels (Fig. 6B) .", [["cell lysates", "ANATOMY", 48, 60], ["cell", "ANATOMY", 195, 199], ["2-AP", "CHEMICAL", 155, 159], ["2-AP", "CHEMICAL", 155, 159], ["cell lysates", "ORGANISM_SUBSTANCE", 48, 60], ["PKR", "GENE_OR_GENE_PRODUCT", 98, 101], ["PKR", "GENE_OR_GENE_PRODUCT", 118, 121], ["RSV P.", "ORGANISM", 126, 132], ["2-AP", "SIMPLE_CHEMICAL", 155, 159], ["RSV", "ORGANISM", 170, 173], ["cell type", "CELL", 195, 204], ["PKR", "GENE_OR_GENE_PRODUCT", 221, 224], ["PKR", "PROTEIN", 98, 101], ["phosphorylated PKR", "PROTEIN", 103, 121], ["PKR", "PROTEIN", 221, 224], ["RSV", "SPECIES", 126, 129], ["RSV", "SPECIES", 170, 173], ["the cell lysates", "TEST", 44, 60], ["immunoblots", "TEST", 70, 81], ["total PKR", "TEST", 92, 101], ["phosphorylated PKR", "TEST", 103, 121], ["RSV P.", "TEST", 126, 132], ["AP inhibited RSV P production", "PROBLEM", 157, 186], ["PKR levels", "TEST", 221, 231], ["RSV", "OBSERVATION", 170, 173]]], ["Taken together, these data indicate that inhibition of PKR activation does not affect RSV replication.", [["PKR", "GENE_OR_GENE_PRODUCT", 55, 58], ["RSV", "ORGANISM", 86, 89], ["PKR", "PROTEIN", 55, 58], ["RSV", "SPECIES", 86, 89], ["these data", "TEST", 16, 26], ["inhibition of PKR activation", "PROBLEM", 41, 69], ["RSV replication", "PROBLEM", 86, 101], ["PKR", "OBSERVATION", 55, 58]]], ["Furthermore, the decrease in RSV replication by 2-AP appears to be mediated via a PKR-independent mechanism.DiscussionSince RSV induces the expression and activation of PKR, we hypothesized that activation of this dsRNA detector would mediate an antiviral effect during RSV infection.", [["RSV infection", "DISEASE", 270, 283], ["2-AP", "CHEMICAL", 48, 52], ["RSV", "ORGANISM", 29, 32], ["2-AP", "GENE_OR_GENE_PRODUCT", 48, 52], ["PKR", "GENE_OR_GENE_PRODUCT", 82, 85], ["RSV", "ORGANISM", 124, 127], ["PKR", "GENE_OR_GENE_PRODUCT", 169, 172], ["RSV", "ORGANISM", 270, 273], ["PKR", "PROTEIN", 82, 85], ["PKR", "PROTEIN", 169, 172], ["RSV", "SPECIES", 29, 32], ["RSV", "SPECIES", 124, 127], ["RSV", "SPECIES", 270, 273], ["RSV replication", "TREATMENT", 29, 44], ["PKR", "TREATMENT", 169, 172], ["this dsRNA detector", "TREATMENT", 209, 228], ["an antiviral effect", "PROBLEM", 243, 262], ["RSV infection", "PROBLEM", 270, 283], ["decrease", "OBSERVATION_MODIFIER", 17, 25], ["RSV replication", "OBSERVATION", 29, 44], ["PKR", "OBSERVATION", 82, 85], ["antiviral effect", "OBSERVATION", 246, 262], ["RSV infection", "OBSERVATION", 270, 283]]], ["Surprisingly, we found that knockdown of PKR protein levels does not affect RSV replication.", [["PKR", "GENE_OR_GENE_PRODUCT", 41, 44], ["RSV", "ORGANISM", 76, 79], ["PKR", "PROTEIN", 41, 44], ["RSV", "SPECIES", 76, 79], ["PKR protein levels", "TEST", 41, 59], ["RSV replication", "PROBLEM", 76, 91]]], ["However, treatment with the kinase inhibitor 2-AP (which inhibits PKR) effectively blocks RSV replication regardless of PKR expression.", [["2-AP", "CHEMICAL", 45, 49], ["2-AP", "CHEMICAL", 45, 49], ["2-AP", "SIMPLE_CHEMICAL", 45, 49], ["PKR", "GENE_OR_GENE_PRODUCT", 66, 69], ["RSV", "ORGANISM", 90, 93], ["PKR", "GENE_OR_GENE_PRODUCT", 120, 123], ["PKR", "PROTEIN", 66, 69], ["PKR", "PROTEIN", 120, 123], ["RSV", "SPECIES", 90, 93], ["the kinase inhibitor", "TREATMENT", 24, 44], ["PKR)", "TREATMENT", 66, 70], ["blocks RSV replication", "TREATMENT", 83, 105], ["PKR expression", "PROBLEM", 120, 134], ["PKR expression", "OBSERVATION", 120, 134]]], ["This PKR-independent effect on RSV replication suggests that induction of other PKR-like kinases, which are 2-AP sensitive, enhances RSV replication.", [["PKR", "GENE_OR_GENE_PRODUCT", 5, 8], ["RSV", "ORGANISM", 31, 34], ["PKR", "GENE_OR_GENE_PRODUCT", 80, 83], ["2-AP", "GENE_OR_GENE_PRODUCT", 108, 112], ["RSV", "ORGANISM", 133, 136], ["PKR", "PROTEIN", 5, 8], ["PKR-like kinases", "PROTEIN", 80, 96], ["RSV", "SPECIES", 31, 34], ["RSV", "SPECIES", 133, 136], ["This PKR", "TEST", 0, 8], ["RSV replication", "TREATMENT", 31, 46], ["other PKR", "TEST", 74, 83], ["kinases", "TEST", 89, 96], ["RSV replication", "OBSERVATION", 133, 148]]], ["The identity of such kinases is not known.DiscussionOur results are unexpected for two main reasons.", [["kinases", "PROTEIN", 21, 28], ["such kinases", "PROBLEM", 16, 28], ["not known", "UNCERTAINTY", 32, 41]]], ["First, PKR initiates a cascade of events resulting in phosphorylation of eIF2\u03b1 and stress granule formation.", [["stress granule", "ANATOMY", 83, 97], ["PKR", "GENE_OR_GENE_PRODUCT", 7, 10], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 73, 78], ["stress granule", "CELLULAR_COMPONENT", 83, 97], ["PKR", "PROTEIN", 7, 10], ["eIF2\u03b1", "PROTEIN", 73, 78], ["phosphorylation of eIF2", "TREATMENT", 54, 77], ["stress granule formation", "PROBLEM", 83, 107], ["stress granule formation", "OBSERVATION", 83, 107]]], ["These events are associated with stalled translation initiation complexes, which might be expected to diminish the capacity of host cells to support viral replication.", [["cells", "ANATOMY", 132, 137], ["host cells", "CELL", 127, 137], ["stalled translation initiation complexes", "PROTEIN", 33, 73], ["host cells", "CELL_TYPE", 127, 137], ["stalled translation initiation complexes", "PROBLEM", 33, 73], ["host cells", "TREATMENT", 127, 137], ["viral replication", "TREATMENT", 149, 166], ["host cells", "OBSERVATION", 127, 137]]], ["Second, induction of PKR is often associated with an antiviral state.", [["PKR", "GENE_OR_GENE_PRODUCT", 21, 24], ["PKR", "PROTEIN", 21, 24], ["PKR", "TREATMENT", 21, 24], ["an antiviral state", "PROBLEM", 50, 68], ["antiviral", "OBSERVATION", 53, 62]]], ["For example, both vesicular stomatitis virus and influenza virus replicate to higher titers in PKR\u2212/\u2212 mice in comparison to wild-type mice (Balachandran et al., 2000) .", [["vesicular stomatitis", "DISEASE", 18, 38], ["vesicular stomatitis virus", "ORGANISM", 18, 44], ["influenza virus", "ORGANISM", 49, 64], ["PKR\u2212", "GENE_OR_GENE_PRODUCT", 95, 99], ["mice", "ORGANISM", 134, 138], ["PKR\u2212", "PROTEIN", 95, 99], ["stomatitis virus and influenza virus", "SPECIES", 28, 64], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 134, 138], ["stomatitis virus", "SPECIES", 28, 44], ["influenza virus", "SPECIES", 49, 64], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 134, 138], ["both vesicular stomatitis virus", "PROBLEM", 13, 44], ["influenza virus", "PROBLEM", 49, 64], ["vesicular stomatitis virus", "OBSERVATION", 18, 44], ["influenza virus", "OBSERVATION", 49, 64]]], ["Similarly, PKR\u2212/\u2212 mice succumb to infection at a higher frequency when infected with Bunyamwera virus in comparison to wild-type mice (Streitenfeld et al., 2003) .", [["infection", "DISEASE", 34, 43], ["PKR\u2212", "GENE_OR_GENE_PRODUCT", 11, 15], ["Bunyamwera virus", "ORGANISM", 85, 101], ["mice", "ORGANISM", 129, 133], ["PKR\u2212", "PROTEIN", 11, 15], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 18, 22], ["Bunyamwera virus", "SPECIES", 85, 101], ["mice", "SPECIES", 129, 133], ["infection", "PROBLEM", 34, 43], ["Bunyamwera virus", "PROBLEM", 85, 101], ["infection", "OBSERVATION", 34, 43]]], ["However, there are cases, in which PKR has a minimal effect on viral replication.", [["PKR", "GENE_OR_GENE_PRODUCT", 35, 38], ["PKR", "PROTEIN", 35, 38], ["viral replication", "TREATMENT", 63, 80], ["minimal", "OBSERVATION_MODIFIER", 45, 52], ["effect", "OBSERVATION_MODIFIER", 53, 59], ["viral replication", "OBSERVATION", 63, 80]]], ["Severe acute respiratory syndrome coronavirus replication is Cell lysates were analyzed by immunoblots for GAPDH, RSV P, phosphorylated PKR, or total PKR.", [["Cell lysates", "ANATOMY", 61, 73], ["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["Cell lysates", "ORGANISM_SUBSTANCE", 61, 73], ["GAPDH", "GENE_OR_GENE_PRODUCT", 107, 112], ["RSV", "ORGANISM", 114, 117], ["PKR", "GENE_OR_GENE_PRODUCT", 136, 139], ["PKR", "GENE_OR_GENE_PRODUCT", 150, 153], ["GAPDH", "PROTEIN", 107, 112], ["RSV P", "PROTEIN", 114, 119], ["phosphorylated PKR", "PROTEIN", 121, 139], ["PKR", "PROTEIN", 150, 153], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["RSV", "SPECIES", 114, 117], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["coronavirus replication", "PROBLEM", 34, 57], ["Cell lysates", "TEST", 61, 73], ["immunoblots", "TEST", 91, 102], ["GAPDH", "TEST", 107, 112], ["RSV P", "TEST", 114, 119], ["phosphorylated PKR", "TEST", 121, 139], ["total PKR", "TEST", 144, 153], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["coronavirus replication", "OBSERVATION", 34, 57]]], ["Relative protein densities were quantified using Li-Cor Odyssey imaging software.", [["Relative protein densities", "PROBLEM", 0, 26], ["protein densities", "OBSERVATION", 9, 26]]], ["The relative amount of RSV P protein expression was quantified for cells infected with RSV and treated with either vehicle or 2-AP.", [["cells", "ANATOMY", 67, 72], ["RSV", "ORGANISM", 23, 26], ["cells", "CELL", 67, 72], ["RSV", "ORGANISM", 87, 90], ["2-AP", "SIMPLE_CHEMICAL", 126, 130], ["RSV P protein", "PROTEIN", 23, 36], ["RSV", "SPECIES", 23, 26], ["RSV", "SPECIES", 87, 90], ["RSV P protein expression", "PROBLEM", 23, 47], ["cells", "PROBLEM", 67, 72], ["RSV", "TREATMENT", 87, 90], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["RSV", "OBSERVATION", 23, 26]]], ["Protein levels were standardized to RSVinfected and vehicle-treated cells.", [["cells", "ANATOMY", 68, 73], ["cells", "CELL", 68, 73], ["RSVinfected and vehicle-treated cells", "CELL_LINE", 36, 73], ["Protein levels", "TEST", 0, 14], ["RSVinfected", "TEST", 36, 47]]], ["The relative expression of PKR and phosphorylated PKR were quantified for each condition and compared to that of mock-infected cells treated with vehicle.", [["cells", "ANATOMY", 127, 132], ["PKR", "GENE_OR_GENE_PRODUCT", 27, 30], ["PKR", "GENE_OR_GENE_PRODUCT", 50, 53], ["cells", "CELL", 127, 132], ["PKR", "PROTEIN", 27, 30], ["phosphorylated PKR", "PROTEIN", 35, 53], ["mock-infected cells", "CELL_LINE", 113, 132], ["PKR and phosphorylated PKR", "TREATMENT", 27, 53], ["vehicle", "TREATMENT", 146, 153], ["PKR", "OBSERVATION", 27, 30], ["infected cells", "OBSERVATION", 118, 132]]], ["(B) HEp-2 cells were pretreated with 2-AP or vehicle, inoculated with RSV (MOI = 1.0 pfu/cell) for 24 h in the presence of 2-AP or vehicle, and processed for immunofluorescence.", [["HEp-2 cells", "ANATOMY", 4, 15], ["cell", "ANATOMY", 89, 93], ["2-AP", "CHEMICAL", 37, 41], ["2-AP", "CHEMICAL", 123, 127], ["B) HEp-2 cells", "CELL", 1, 15], ["2-AP", "SIMPLE_CHEMICAL", 37, 41], ["RSV", "ORGANISM", 70, 73], ["cell", "CELL", 89, 93], ["2-AP", "SIMPLE_CHEMICAL", 123, 127], ["HEp-2 cells", "CELL_LINE", 4, 15], ["RSV", "SPECIES", 70, 73], ["HEp-2 cells", "TREATMENT", 4, 15], ["RSV", "PROBLEM", 70, 73], ["MOI", "TEST", 75, 78], ["immunofluorescence", "TEST", 158, 176], ["HEp", "ANATOMY", 4, 7]]], ["Anti-RSV F antibody was used to detect virus-infected cells.", [["cells", "ANATOMY", 54, 59], ["RSV", "ORGANISM", 5, 8], ["cells", "CELL", 54, 59], ["RSV F antibody", "PROTEIN", 5, 19], ["virus-infected cells", "CELL_TYPE", 39, 59], ["RSV", "SPECIES", 5, 8], ["Anti-RSV F antibody", "TEST", 0, 19], ["virus", "PROBLEM", 39, 44], ["infected cells", "PROBLEM", 45, 59], ["infected cells", "OBSERVATION", 45, 59]]], ["Differential interference contrast (DIC) was used to define the periphery of each cell.", [["cell", "ANATOMY", 82, 86], ["cell", "CELL", 82, 86], ["Differential interference contrast (DIC)", "TEST", 0, 40], ["periphery", "ANATOMY_MODIFIER", 64, 73], ["each cell", "OBSERVATION", 77, 86]]], ["(C) The percentage of cells per HPF that stained positively for RSV F protein in images from (B) was determined.", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["HPF", "CELL", 32, 35], ["RSV F", "GENE_OR_GENE_PRODUCT", 64, 69], ["RSV F protein", "PROTEIN", 64, 77], ["RSV", "SPECIES", 64, 67], ["HPF", "TEST", 32, 35], ["RSV F protein in images", "TEST", 64, 87]]], ["Error bars indicate SEM. unaffected in cells treated with phosphorodiamidate morpholino oligomers specific for PKR mRNA (Krahling et al., 2009) .", [["cells", "ANATOMY", 39, 44], ["phosphorodiamidate", "CHEMICAL", 58, 76], ["phosphorodiamidate", "CHEMICAL", 58, 76], ["cells", "CELL", 39, 44], ["phosphorodiamidate morpholino oligomers", "SIMPLE_CHEMICAL", 58, 97], ["PKR", "GENE_OR_GENE_PRODUCT", 111, 114], ["PKR mRNA", "RNA", 111, 119], ["unaffected in cells", "PROBLEM", 25, 44], ["phosphorodiamidate morpholino oligomers", "TREATMENT", 58, 97], ["PKR mRNA", "PROBLEM", 111, 119], ["SEM", "OBSERVATION", 20, 23]]], ["Similarly, treatment of cells with PKR siRNAs has little effect on adenovirus or reovirus replication (Zhang and Samuel, 2007) or rotavirus protein synthesis (Rojas et al., 2010) .", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29], ["PKR", "GENE_OR_GENE_PRODUCT", 35, 38], ["adenovirus", "ORGANISM", 67, 77], ["reovirus", "ORGANISM", 81, 89], ["PKR", "PROTEIN", 35, 38], ["rotavirus protein", "PROTEIN", 130, 147], ["rotavirus", "SPECIES", 130, 139], ["cells", "PROBLEM", 24, 29], ["PKR siRNAs", "TREATMENT", 35, 45], ["adenovirus", "PROBLEM", 67, 77], ["reovirus replication", "PROBLEM", 81, 101], ["rotavirus protein synthesis", "PROBLEM", 130, 157], ["PKR siRNAs", "OBSERVATION", 35, 45]]], ["Rift Valley fever virus replication is not altered in PKR\u2212/\u2212 mouse embryo fibroblast cells (Habjan et al., 2009 ).", [["embryo fibroblast cells", "ANATOMY", 67, 90], ["Rift Valley fever", "DISEASE", 0, 17], ["Rift Valley fever virus", "ORGANISM", 0, 23], ["mouse", "ORGANISM", 61, 66], ["embryo fibroblast cells", "CELL", 67, 90], ["PKR\u2212/\u2212 mouse embryo fibroblast cells", "CELL_LINE", 54, 90], ["Rift Valley fever virus", "SPECIES", 0, 23], ["mouse", "SPECIES", 61, 66], ["Rift Valley fever virus", "SPECIES", 0, 23], ["mouse", "SPECIES", 61, 66], ["Rift Valley fever virus replication", "PROBLEM", 0, 35], ["mouse embryo fibroblast cells", "PROBLEM", 61, 90], ["fibroblast cells", "OBSERVATION", 74, 90]]], ["However, PKR effects are not always antagonistic to viral infection.", [["viral infection", "DISEASE", 52, 67], ["PKR", "GENE_OR_GENE_PRODUCT", 9, 12], ["PKR", "PROTEIN", 9, 12], ["PKR effects", "PROBLEM", 9, 20], ["viral infection", "PROBLEM", 52, 67], ["infection", "OBSERVATION", 58, 67]]], ["Knockdown of PKR by shRNA results in significantly decreased HCV RNA levels in cells treated with exogenous interferon and infected with HCV (Garaigorta and Chisari, 2009) .", [["cells", "ANATOMY", 79, 84], ["PKR", "GENE_OR_GENE_PRODUCT", 13, 16], ["cells", "CELL", 79, 84], ["interferon", "GENE_OR_GENE_PRODUCT", 108, 118], ["HCV", "ORGANISM", 137, 140], ["PKR", "PROTEIN", 13, 16], ["HCV RNA", "RNA", 61, 68], ["exogenous interferon", "PROTEIN", 98, 118], ["HCV", "SPECIES", 61, 64], ["HCV", "SPECIES", 137, 140], ["PKR", "TEST", 13, 16], ["significantly decreased HCV RNA levels in cells", "PROBLEM", 37, 84], ["exogenous interferon", "TREATMENT", 98, 118], ["HCV", "PROBLEM", 137, 140], ["PKR", "OBSERVATION", 13, 16], ["significantly", "OBSERVATION_MODIFIER", 37, 50], ["decreased", "OBSERVATION_MODIFIER", 51, 60], ["HCV RNA", "OBSERVATION", 61, 68], ["HCV", "OBSERVATION", 137, 140]]], ["Interestingly, levels of other proteins involved in the antiviral response are increased, suggesting that HCV induces PKR activation to inhibit host translation and prevent the expression of interferon-stimulated genes.", [["HCV", "ORGANISM", 106, 109], ["PKR", "GENE_OR_GENE_PRODUCT", 118, 121], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 191, 218], ["PKR", "PROTEIN", 118, 121], ["interferon-stimulated genes", "DNA", 191, 218], ["HCV", "SPECIES", 106, 109], ["other proteins", "PROBLEM", 25, 39], ["HCV induces PKR activation", "PROBLEM", 106, 132], ["host translation", "TREATMENT", 144, 160], ["antiviral response", "OBSERVATION", 56, 74], ["HCV", "OBSERVATION", 106, 109]]], ["We predicted a similar function for PKR during RSV infection since previous reports have demonstrated that 2-AP treatment leads to a dose-dependent increase in IFN-\u03b1 production in RSV-infected cells (Hornung et al., 2004) .DiscussionAlthough RSV is a single-stranded RNA virus, it produces multiple dsRNA intermediates during replication that are capable of activating PKR.", [["cells", "ANATOMY", 193, 198], ["RSV infection", "DISEASE", 47, 60], ["2-AP", "CHEMICAL", 107, 111], ["RSV-infected", "DISEASE", 180, 192], ["2-AP", "CHEMICAL", 107, 111], ["PKR", "GENE_OR_GENE_PRODUCT", 36, 39], ["RSV", "ORGANISM", 47, 50], ["2-AP", "SIMPLE_CHEMICAL", 107, 111], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 160, 165], ["RSV", "ORGANISM", 180, 183], ["cells", "CELL", 193, 198], ["RSV", "ORGANISM", 242, 245], ["PKR", "GENE_OR_GENE_PRODUCT", 369, 372], ["PKR", "PROTEIN", 36, 39], ["IFN", "PROTEIN", 160, 163], ["\u03b1", "PROTEIN", 164, 165], ["RSV-infected cells", "CELL_TYPE", 180, 198], ["PKR", "PROTEIN", 369, 372], ["RSV", "SPECIES", 47, 50], ["RSV", "SPECIES", 180, 183], ["RSV", "SPECIES", 242, 245], ["PKR", "PROBLEM", 36, 39], ["RSV infection", "PROBLEM", 47, 60], ["AP treatment", "TREATMENT", 109, 121], ["dependent increase", "PROBLEM", 138, 156], ["IFN", "PROBLEM", 160, 163], ["RSV", "PROBLEM", 180, 183], ["infected cells", "PROBLEM", 184, 198], ["RSV", "PROBLEM", 242, 245], ["a single-stranded RNA virus", "PROBLEM", 249, 276], ["multiple dsRNA intermediates", "PROBLEM", 290, 318], ["activating PKR", "PROBLEM", 358, 372], ["infection", "OBSERVATION", 51, 60], ["dependent", "OBSERVATION_MODIFIER", 138, 147], ["increase", "OBSERVATION_MODIFIER", 148, 156], ["RSV", "ANATOMY", 180, 183], ["infected cells", "OBSERVATION", 184, 198], ["RSV", "OBSERVATION", 242, 245], ["multiple", "OBSERVATION_MODIFIER", 290, 298], ["dsRNA intermediates", "OBSERVATION", 299, 318]]], ["PKR activation is likely required for eIF2\u03b1 phosphorylation and subsequent stress granule formation during RSV infection (Lindquist et al., 2010; Hanley et al., 2010) .", [["stress granule", "ANATOMY", 75, 89], ["RSV infection", "DISEASE", 107, 120], ["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 38, 43], ["stress granule", "CELLULAR_COMPONENT", 75, 89], ["RSV", "ORGANISM", 107, 110], ["PKR", "PROTEIN", 0, 3], ["eIF2\u03b1", "PROTEIN", 38, 43], ["RSV", "SPECIES", 107, 110], ["PKR activation", "TEST", 0, 14], ["eIF2\u03b1 phosphorylation", "TREATMENT", 38, 59], ["subsequent stress granule formation", "PROBLEM", 64, 99], ["RSV infection", "PROBLEM", 107, 120], ["stress granule formation", "OBSERVATION", 75, 99], ["RSV infection", "OBSERVATION", 107, 120]]], ["Other studies have reported that RSV induces robust PKR activation during infection, but eIF2\u03b1 phosphorylation is limited (Groskreutz et al., 2010) .", [["infection", "DISEASE", 74, 83], ["RSV", "ORGANISM", 33, 36], ["PKR", "GENE_OR_GENE_PRODUCT", 52, 55], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 89, 94], ["PKR", "PROTEIN", 52, 55], ["eIF2\u03b1", "PROTEIN", 89, 94], ["RSV", "SPECIES", 33, 36], ["Other studies", "TEST", 0, 13], ["RSV", "PROBLEM", 33, 36], ["robust PKR activation during infection", "PROBLEM", 45, 83], ["eIF2\u03b1 phosphorylation", "TEST", 89, 110], ["RSV", "OBSERVATION", 33, 36], ["robust", "OBSERVATION_MODIFIER", 45, 51], ["PKR", "OBSERVATION", 52, 55], ["infection", "OBSERVATION", 74, 83]]], ["Phosphorylation of eIF2\u03b1 may have been dampened by increased activity of protein phosphatase 2A (PP2A) during infection.", [["infection", "DISEASE", 110, 119], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 19, 24], ["protein phosphatase 2A", "GENE_OR_GENE_PRODUCT", 73, 95], ["PP2A", "GENE_OR_GENE_PRODUCT", 97, 101], ["eIF2\u03b1", "PROTEIN", 19, 24], ["protein phosphatase 2A", "PROTEIN", 73, 95], ["PP2A", "PROTEIN", 97, 101], ["Phosphorylation of eIF2\u03b1", "TREATMENT", 0, 24], ["protein phosphatase", "TEST", 73, 92], ["infection", "PROBLEM", 110, 119], ["dampened", "OBSERVATION_MODIFIER", 39, 47], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["activity", "OBSERVATION_MODIFIER", 61, 69], ["infection", "OBSERVATION", 110, 119]]], ["In contrast, we observed extensive eIF2\u03b1 phosphorylation during RSV infection, predominantly in cells that had been infected with RSV and in which stress granules had formed (Fig. 1) .", [["cells", "ANATOMY", 96, 101], ["stress granules", "ANATOMY", 147, 162], ["RSV infection", "DISEASE", 64, 77], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["RSV", "ORGANISM", 64, 67], ["cells", "CELL", 96, 101], ["RSV", "ORGANISM", 130, 133], ["granules", "ORGANISM_SUBSTANCE", 154, 162], ["eIF2\u03b1", "PROTEIN", 35, 40], ["RSV", "SPECIES", 64, 67], ["RSV", "SPECIES", 130, 133], ["extensive eIF2\u03b1 phosphorylation", "TREATMENT", 25, 56], ["RSV infection", "PROBLEM", 64, 77], ["RSV", "PROBLEM", 130, 133], ["stress granules", "PROBLEM", 147, 162], ["extensive", "OBSERVATION_MODIFIER", 25, 34], ["eIF2\u03b1 phosphorylation", "OBSERVATION", 35, 56], ["RSV infection", "OBSERVATION", 64, 77], ["infected", "OBSERVATION_MODIFIER", 116, 124], ["RSV", "OBSERVATION", 130, 133]]], ["Since phosphorylation of eIF2\u03b1 frequently precedes stress granule formation (Kedersha and Anderson, 2007) , our results are not surprising given the extensive stress granule formation induced by RSV (Lindquist et al., 2010) .", [["stress granule", "ANATOMY", 51, 65], ["stress granule", "ANATOMY", 159, 173], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 25, 30], ["stress granule", "CELLULAR_COMPONENT", 51, 65], ["stress granule", "CELLULAR_COMPONENT", 159, 173], ["RSV", "ORGANISM", 195, 198], ["eIF2\u03b1", "PROTEIN", 25, 30], ["RSV", "SPECIES", 195, 198], ["phosphorylation of eIF2", "TREATMENT", 6, 29], ["stress granule formation", "PROBLEM", 51, 75], ["the extensive stress granule formation", "PROBLEM", 145, 183], ["granule formation", "OBSERVATION", 58, 75], ["extensive", "OBSERVATION_MODIFIER", 149, 158], ["stress granule formation", "OBSERVATION", 159, 183]]], ["It is possible that PP2A activity is not sufficient to reverse eIF2\u03b1 phosphorylation in RSV-infected cells that form stress granules.", [["cells", "ANATOMY", 101, 106], ["stress granules", "ANATOMY", 117, 132], ["PP2A", "GENE_OR_GENE_PRODUCT", 20, 24], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 63, 68], ["RSV", "ORGANISM", 88, 91], ["cells", "CELL", 101, 106], ["stress granules", "CELLULAR_COMPONENT", 117, 132], ["PP2A", "PROTEIN", 20, 24], ["eIF2\u03b1", "PROTEIN", 63, 68], ["RSV-infected cells", "CELL_TYPE", 88, 106], ["RSV", "SPECIES", 88, 91], ["PP2A activity", "PROBLEM", 20, 33], ["RSV", "PROBLEM", 88, 91], ["infected cells", "PROBLEM", 92, 106], ["stress granules", "PROBLEM", 117, 132], ["infected cells", "OBSERVATION", 92, 106], ["stress granules", "OBSERVATION", 117, 132]]], ["Further experiments are required to assess PP2A activity in such cells.DiscussionExperiments using PKR-knockout mice show that RSV RNA levels increase during infection, suggesting a classic role for PKR as an antiviral molecule.", [["cells", "ANATOMY", 65, 70], ["infection", "DISEASE", 158, 167], ["PP2A", "GENE_OR_GENE_PRODUCT", 43, 47], ["cells", "CELL", 65, 70], ["PKR", "GENE_OR_GENE_PRODUCT", 99, 102], ["mice", "ORGANISM", 112, 116], ["RSV", "ORGANISM", 127, 130], ["PKR", "GENE_OR_GENE_PRODUCT", 199, 202], ["PP2A", "PROTEIN", 43, 47], ["PKR", "PROTEIN", 99, 102], ["RSV RNA", "RNA", 127, 134], ["PKR", "PROTEIN", 199, 202], ["antiviral molecule", "PROTEIN", 209, 227], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 112, 116], ["RSV", "SPECIES", 127, 130], ["Further experiments", "TEST", 0, 19], ["PP2A activity in such cells", "PROBLEM", 43, 70], ["PKR", "TEST", 99, 102], ["RSV RNA levels", "PROBLEM", 127, 141], ["infection", "PROBLEM", 158, 167], ["PKR", "PROBLEM", 199, 202], ["an antiviral molecule", "PROBLEM", 206, 227], ["RSV", "OBSERVATION", 127, 130], ["infection", "OBSERVATION", 158, 167], ["antiviral molecule", "OBSERVATION", 209, 227]]], ["In PKR-knockout mice, RSV infection induces lower levels of several cytokines, including TNF-\u03b1, IFN-\u03b2, and RANTES, among others, in comparison to wild-type mice.", [["RSV infection", "DISEASE", 22, 35], ["PKR", "GENE_OR_GENE_PRODUCT", 3, 6], ["mice", "ORGANISM", 16, 20], ["RSV", "ORGANISM", 22, 25], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 89, 94], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 96, 101], ["RANTES", "GENE_OR_GENE_PRODUCT", 107, 113], ["mice", "ORGANISM", 156, 160], ["PKR", "PROTEIN", 3, 6], ["cytokines", "PROTEIN", 68, 77], ["TNF", "PROTEIN", 89, 92], ["IFN", "PROTEIN", 96, 99], ["\u03b2", "PROTEIN", 100, 101], ["RANTES", "PROTEIN", 107, 113], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 16, 20], ["RSV", "SPECIES", 22, 25], ["mice", "SPECIES", 156, 160], ["RSV infection", "PROBLEM", 22, 35], ["TNF", "TEST", 89, 92], ["RSV", "OBSERVATION_MODIFIER", 22, 25], ["infection", "OBSERVATION", 26, 35]]], ["These results, when combined with histological analysis of mouse lung tissue, suggest that functional PKR leads to enhanced pathogenesis in RSV-infected animals (Minor et al., 2010) .DiscussionOur previous data show that RSV replication is reduced in cells in which stress granule formation is inhibited by knockdown of the stress granule-related Ras-GAP SH3 domain-binding protein (G3BP) (Lindquist et al., 2010) .", [["lung tissue", "ANATOMY", 65, 76], ["cells", "ANATOMY", 251, 256], ["stress granule", "ANATOMY", 266, 280], ["stress granule", "ANATOMY", 324, 338], ["RSV-infected", "DISEASE", 140, 152], ["mouse", "ORGANISM", 59, 64], ["lung tissue", "TISSUE", 65, 76], ["PKR", "GENE_OR_GENE_PRODUCT", 102, 105], ["RSV", "ORGANISM", 140, 143], ["animals", "ORGANISM", 153, 160], ["RSV", "ORGANISM", 221, 224], ["cells", "CELL", 251, 256], ["stress granule", "CELLULAR_COMPONENT", 266, 280], ["stress granule", "CELLULAR_COMPONENT", 324, 338], ["Ras-GAP SH3 domain-binding protein", "GENE_OR_GENE_PRODUCT", 347, 381], ["PKR", "PROTEIN", 102, 105], ["Ras-GAP SH3 domain-binding protein", "PROTEIN", 347, 381], ["G3BP", "PROTEIN", 383, 387], ["mouse", "SPECIES", 59, 64], ["mouse", "SPECIES", 59, 64], ["RSV", "SPECIES", 140, 143], ["RSV", "SPECIES", 221, 224], ["histological analysis", "TEST", 34, 55], ["mouse lung tissue", "PROBLEM", 59, 76], ["functional PKR", "PROBLEM", 91, 105], ["RSV", "PROBLEM", 140, 143], ["Our previous data", "TEST", 193, 210], ["RSV replication", "PROBLEM", 221, 236], ["stress granule formation", "PROBLEM", 266, 290], ["the stress granule", "PROBLEM", 320, 338], ["lung", "ANATOMY", 65, 69], ["RSV", "OBSERVATION", 221, 224], ["reduced", "OBSERVATION_MODIFIER", 240, 247], ["stress granule formation", "OBSERVATION", 266, 290]]], ["In the current study, we found that RSV replication is unaffected in PKR-knockdown cells that similarly are deficient for stress granule formation.", [["cells", "ANATOMY", 83, 88], ["stress granule", "ANATOMY", 122, 136], ["RSV", "ORGANISM", 36, 39], ["PKR", "GENE_OR_GENE_PRODUCT", 69, 72], ["cells", "CELL", 83, 88], ["stress granule", "CELLULAR_COMPONENT", 122, 136], ["PKR-knockdown cells", "CELL_LINE", 69, 88], ["RSV", "SPECIES", 36, 39], ["the current study", "TEST", 3, 20], ["RSV replication", "PROBLEM", 36, 51], ["knockdown cells", "PROBLEM", 73, 88], ["stress granule formation", "PROBLEM", 122, 146], ["RSV replication", "OBSERVATION", 36, 51], ["knockdown cells", "OBSERVATION", 73, 88], ["stress granule formation", "OBSERVATION", 122, 146]]], ["One possible explanation for this discrepancy is that knockdown of G3BP has effects in addition to inhibiting stress granule formation.", [["stress granule", "ANATOMY", 110, 124], ["G3BP", "CHEMICAL", 67, 71], ["G3BP", "GENE_OR_GENE_PRODUCT", 67, 71], ["stress granule", "CELLULAR_COMPONENT", 110, 124], ["G3BP", "PROTEIN", 67, 71], ["this discrepancy", "PROBLEM", 29, 45], ["knockdown of G3BP", "PROBLEM", 54, 71], ["inhibiting stress granule formation", "PROBLEM", 99, 134], ["possible explanation for", "UNCERTAINTY", 4, 28], ["stress granule formation", "OBSERVATION", 110, 134]]], ["Thus, viral replication might be inhibited by an alternative effect of the G3BP knockdown.", [["G3BP", "GENE_OR_GENE_PRODUCT", 75, 79], ["G3BP", "PROTEIN", 75, 79], ["viral replication", "TREATMENT", 6, 23], ["the G3BP knockdown", "TREATMENT", 71, 89], ["viral replication", "OBSERVATION", 6, 23]]], ["Another possibility is that in PKR-knockdown cells, PKR signaling does not occur, preventing the activation of intrinsic antiviral responses to the virus.", [["cells", "ANATOMY", 45, 50], ["PKR", "GENE_OR_GENE_PRODUCT", 31, 34], ["cells", "CELL", 45, 50], ["PKR", "GENE_OR_GENE_PRODUCT", 52, 55], ["PKR", "PROTEIN", 31, 34], ["PKR", "PROTEIN", 52, 55], ["knockdown cells", "PROBLEM", 35, 50], ["PKR signaling", "PROBLEM", 52, 65], ["intrinsic antiviral responses", "TREATMENT", 111, 140], ["the virus", "PROBLEM", 144, 153], ["knockdown cells", "OBSERVATION", 35, 50]]], ["Thus, the potential pro-viral function for which stress granules may normally be required would not be necessary, allowing the virus to replicate efficiently.DiscussionThe drug 2-AP has been cited as a specific inhibitor of PKR activation (Hu and Conway, 1993; Loving et al., 2006; Silva et al., 2004) and used in a number of studies examining the role of PKR during viral infection.", [["stress granules", "ANATOMY", 49, 64], ["2-AP", "CHEMICAL", 177, 181], ["viral infection", "DISEASE", 367, 382], ["stress granules", "CELLULAR_COMPONENT", 49, 64], ["2-AP", "SIMPLE_CHEMICAL", 177, 181], ["PKR", "GENE_OR_GENE_PRODUCT", 224, 227], ["PKR", "GENE_OR_GENE_PRODUCT", 356, 359], ["PKR", "PROTEIN", 224, 227], ["PKR", "PROTEIN", 356, 359], ["the potential pro-viral function", "PROBLEM", 6, 38], ["stress granules", "PROBLEM", 49, 64], ["the virus", "PROBLEM", 123, 132], ["PKR", "TREATMENT", 356, 359], ["viral infection", "PROBLEM", 367, 382], ["viral", "OBSERVATION_MODIFIER", 367, 372], ["infection", "OBSERVATION", 373, 382]]], ["However, 2-AP also may inhibit activation of tumor suppressor p53 during genotoxic stress (Huang et al., 2003) , interfere with cell cycle progression (Andreassen and Margolis, 1994) , and inhibit mitogen-activated protein kinase activation (Thorburn et al., 1994) .", [["tumor", "ANATOMY", 45, 50], ["cell", "ANATOMY", 128, 132], ["2-AP", "CHEMICAL", 9, 13], ["tumor", "DISEASE", 45, 50], ["2-AP", "CHEMICAL", 9, 13], ["2-AP", "SIMPLE_CHEMICAL", 9, 13], ["tumor", "CANCER", 45, 50], ["p53", "GENE_OR_GENE_PRODUCT", 62, 65], ["cell", "CELL", 128, 132], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 197, 229], ["tumor suppressor p53", "PROTEIN", 45, 65], ["mitogen-activated protein kinase", "PROTEIN", 197, 229], ["tumor suppressor p53", "PROBLEM", 45, 65], ["genotoxic stress", "PROBLEM", 73, 89], ["cell cycle progression", "PROBLEM", 128, 150], ["tumor", "OBSERVATION", 45, 50]]], ["Although PKR activation has been implicated in each of these processes (Garcia et al., 2006) , it is possible that 2-AP inhibits multiple kinases.", [["2-AP", "CHEMICAL", 115, 119], ["PKR", "GENE_OR_GENE_PRODUCT", 9, 12], ["2-AP", "SIMPLE_CHEMICAL", 115, 119], ["PKR", "PROTEIN", 9, 12], ["multiple kinases", "PROTEIN", 129, 145], ["PKR activation", "PROBLEM", 9, 23], ["PKR", "OBSERVATION", 9, 12]]], ["Our results demonstrate that while 2-AP is efficient at blocking PKR activation during RSV infection, its inhibitory effect on RSV replication is PKRindependent.", [["RSV infection", "DISEASE", 87, 100], ["2-AP", "CHEMICAL", 35, 39], ["2-AP", "GENE_OR_GENE_PRODUCT", 35, 39], ["PKR", "GENE_OR_GENE_PRODUCT", 65, 68], ["RSV", "ORGANISM", 87, 90], ["RSV", "ORGANISM", 127, 130], ["PKR", "PROTEIN", 65, 68], ["RSV", "SPECIES", 87, 90], ["RSV", "SPECIES", 127, 130], ["blocking PKR activation", "TREATMENT", 56, 79], ["RSV infection", "PROBLEM", 87, 100], ["RSV replication", "TREATMENT", 127, 142], ["RSV infection", "OBSERVATION", 87, 100]]], ["Therefore, the reliability of 2-AP as a PKR-specific inhibitor is suspect, given that the drug mediates non-PKRdependent effects.", [["2-AP", "CHEMICAL", 30, 34], ["2-AP", "SIMPLE_CHEMICAL", 30, 34], ["PKR", "GENE_OR_GENE_PRODUCT", 40, 43], ["PKR", "PROTEIN", 40, 43], ["a PKR", "TEST", 38, 43]]], ["Defining the other targets of 2-AP might lend insight into the complex perturbations that occur in host gene function during RSV infection.", [["RSV infection", "DISEASE", 125, 138], ["2-AP", "GENE_OR_GENE_PRODUCT", 30, 34], ["RSV", "ORGANISM", 125, 128], ["RSV", "SPECIES", 125, 128], ["the complex perturbations", "PROBLEM", 59, 84], ["RSV infection", "PROBLEM", 125, 138], ["complex", "OBSERVATION_MODIFIER", 63, 70], ["perturbations", "OBSERVATION", 71, 84], ["RSV", "OBSERVATION_MODIFIER", 125, 128], ["infection", "OBSERVATION", 129, 138]]], ["Cell lysates were subjected to immunoblotting for RSV P protein and GAPDH.", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["RSV", "ORGANISM", 50, 53], ["GAPDH", "GENE_OR_GENE_PRODUCT", 68, 73], ["RSV P protein", "PROTEIN", 50, 63], ["GAPDH", "PROTEIN", 68, 73], ["RSV", "SPECIES", 50, 53], ["Cell lysates", "TEST", 0, 12], ["immunoblotting", "TEST", 31, 45], ["RSV P protein", "TEST", 50, 63], ["GAPDH", "PROBLEM", 68, 73]]], ["The relative amount of RSV P protein was quantified for each cell type and compared to that in wild-type cells treated with vehicle.", [["cell", "ANATOMY", 61, 65], ["wild-type cells", "ANATOMY", 95, 110], ["RSV", "ORGANISM", 23, 26], ["cell type", "CELL", 61, 70], ["cells", "CELL", 105, 110], ["RSV P protein", "PROTEIN", 23, 36], ["wild-type cells", "CELL_TYPE", 95, 110], ["RSV", "SPECIES", 23, 26], ["RSV P protein", "TEST", 23, 36], ["each cell type", "PROBLEM", 56, 70], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["RSV", "OBSERVATION", 23, 26]]], ["Error bars indicate standard deviations.CellsHEp-2 cells (ATCC CCL-23) were maintained in OPTI-MEM I medium (Invitrogen) containing 5% (v/v) fetal calf serum (Sigma), 2 mM L-glutamine (Mediatech), 2.5 \u03bcg/mL amphotericin B (Mediatech), 100 \u00b5g/mL streptomycin (Mediatech), and 100 I.U./mL penicillin (Mediatech).", [["CellsHEp-2 cells", "ANATOMY", 40, 56], ["ATCC CCL-23", "ANATOMY", 58, 69], ["fetal calf serum", "ANATOMY", 141, 157], ["L-glutamine", "CHEMICAL", 172, 183], ["Mediatech", "CHEMICAL", 185, 194], ["amphotericin B", "CHEMICAL", 207, 221], ["Mediatech", "CHEMICAL", 223, 232], ["streptomycin", "CHEMICAL", 245, 257], ["penicillin", "CHEMICAL", 287, 297], ["L-glutamine", "CHEMICAL", 172, 183], ["amphotericin B", "CHEMICAL", 207, 221], ["Mediatech", "CHEMICAL", 223, 232], ["streptomycin", "CHEMICAL", 245, 257], ["penicillin", "CHEMICAL", 287, 297], ["CellsHEp-2 cells", "CELL", 40, 56], ["ATCC CCL-23", "CELL", 58, 69], ["calf", "ORGANISM", 147, 151], ["serum", "ORGANISM_SUBSTANCE", 152, 157], ["Sigma", "SIMPLE_CHEMICAL", 159, 164], ["L-glutamine", "SIMPLE_CHEMICAL", 172, 183], ["Mediatech", "ORGANISM_SUBSTANCE", 185, 194], ["amphotericin B", "SIMPLE_CHEMICAL", 207, 221], ["streptomycin", "SIMPLE_CHEMICAL", 245, 257], ["penicillin", "SIMPLE_CHEMICAL", 287, 297], ["CellsHEp-2 cells", "CELL_LINE", 40, 56], ["ATCC CCL-23", "CELL_LINE", 58, 69], ["calf", "SPECIES", 147, 151], ["ATCC CCL-23", "SPECIES", 58, 69], ["standard deviations", "PROBLEM", 20, 39], ["CellsHEp", "TEST", 40, 48], ["ATCC CCL", "TEST", 58, 66], ["OPTI", "TEST", 90, 94], ["Invitrogen", "TEST", 109, 119], ["fetal calf serum", "TEST", 141, 157], ["2 mM L-glutamine (Mediatech)", "TREATMENT", 167, 195], ["amphotericin B (Mediatech)", "TREATMENT", 207, 233], ["streptomycin", "TREATMENT", 245, 257], ["penicillin", "TREATMENT", 287, 297], ["standard deviations", "OBSERVATION", 20, 39], ["fetal calf", "ANATOMY", 141, 151]]], ["L929 cells were grown in either suspension or monolayer cultures in Joklik's modified Eagles minimal essential medium (SMEM, Lonza) containing 5% (v/v) fetal bovine serum (FBS, Invitrogen), 2 mM L-glutamine (Invitrogen), 100 U/mL of penicillin, 100 mg/mL of streptomycin (Invitrogen), and 250 \u03bcg/mL amphotericin B (Sigma).VirusesA suspension of RSV wild-type strain A2 prepared in HEp-2 cells (1 \u00d7 10 6 pfu/mL) was used to infect HEp-2 cell monolayer cultures.", [["L929 cells", "ANATOMY", 0, 10], ["monolayer cultures", "ANATOMY", 46, 64], ["serum", "ANATOMY", 165, 170], ["FBS", "ANATOMY", 172, 175], ["HEp-2 cells", "ANATOMY", 381, 392], ["HEp-2 cell monolayer cultures", "ANATOMY", 430, 459], ["L-glutamine", "CHEMICAL", 195, 206], ["Invitrogen", "CHEMICAL", 208, 218], ["penicillin", "CHEMICAL", 233, 243], ["streptomycin", "CHEMICAL", 258, 270], ["amphotericin B", "CHEMICAL", 299, 313], ["L-glutamine", "CHEMICAL", 195, 206], ["penicillin", "CHEMICAL", 233, 243], ["streptomycin", "CHEMICAL", 258, 270], ["amphotericin B", "CHEMICAL", 299, 313], ["L929 cells", "CELL", 0, 10], ["monolayer cultures", "CELL", 46, 64], ["bovine", "ORGANISM", 158, 164], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["FBS", "ORGANISM_SUBSTANCE", 172, 175], ["Invitrogen", "SIMPLE_CHEMICAL", 177, 187], ["L-glutamine", "SIMPLE_CHEMICAL", 195, 206], ["Invitrogen", "SIMPLE_CHEMICAL", 208, 218], ["penicillin", "SIMPLE_CHEMICAL", 233, 243], ["streptomycin", "SIMPLE_CHEMICAL", 258, 270], ["Invitrogen", "SIMPLE_CHEMICAL", 272, 282], ["amphotericin B", "SIMPLE_CHEMICAL", 299, 313], ["Sigma", "SIMPLE_CHEMICAL", 315, 320], ["RSV wild-type strain A2", "ORGANISM", 345, 368], ["HEp-2 cells", "CELL", 381, 392], ["HEp-2 cell monolayer cultures", "CELL", 430, 459], ["L929 cells", "CELL_LINE", 0, 10], ["monolayer cultures", "CELL_LINE", 46, 64], ["HEp-2 cells", "CELL_LINE", 381, 392], ["HEp-2 cell monolayer cultures", "CELL_LINE", 430, 459], ["bovine", "SPECIES", 158, 164], ["bovine", "SPECIES", 158, 164], ["RSV wild-type strain A2", "SPECIES", 345, 368], ["L929 cells", "PROBLEM", 0, 10], ["monolayer cultures", "TEST", 46, 64], ["Joklik", "TEST", 68, 74], ["fetal bovine serum", "TEST", 152, 170], ["FBS", "TEST", 172, 175], ["Invitrogen", "TEST", 177, 187], ["2 mM L-glutamine (Invitrogen", "TREATMENT", 190, 218], ["penicillin", "TREATMENT", 233, 243], ["streptomycin (Invitrogen)", "TREATMENT", 258, 283], ["VirusesA suspension", "TREATMENT", 322, 341], ["RSV", "PROBLEM", 345, 348], ["type strain A2", "PROBLEM", 354, 368], ["HEp-2 cells", "TREATMENT", 381, 392], ["HEp", "TEST", 430, 433], ["cell monolayer cultures", "TEST", 436, 459], ["RSV wild", "OBSERVATION", 345, 353]]], ["Infectious virus was adsorbed to the cells for 1 h in a 37\u00b0C incubator in 5% CO 2 .", [["cells", "ANATOMY", 37, 42], ["CO 2", "CHEMICAL", 77, 81], ["cells", "CELL", 37, 42], ["Infectious virus", "SPECIES", 0, 16], ["Infectious virus", "PROBLEM", 0, 16], ["a 37\u00b0C incubator", "TREATMENT", 54, 70]]], ["Following adsorption, the inoculum was removed and fresh medium added.", [["the inoculum", "TREATMENT", 22, 34], ["fresh medium", "TREATMENT", 51, 63], ["inoculum", "OBSERVATION", 26, 34]]], ["Cells then were incubated at 37\u00b0C in 5% CO 2 for the duration of the infection period.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 69, 78], ["CO 2", "CHEMICAL", 40, 44], ["Cells", "CELL", 0, 5], ["the infection period", "PROBLEM", 65, 85], ["infection", "OBSERVATION", 69, 78]]], ["Reovirus strain T1L is a laboratory stock.Determination of viral titersFor RSV plaque assays, cell-associated virus was harvested at indicated times by scraping infected HEp-2 cell culture monolayers into 1.0 mL of medium.", [["cell", "ANATOMY", 94, 98], ["HEp-2 cell culture monolayers", "ANATOMY", 170, 199], ["RSV", "ORGANISM", 75, 78], ["cell", "CELL", 94, 98], ["HEp-2 cell culture monolayers", "CELL", 170, 199], ["HEp-2 cell culture monolayers", "CELL_LINE", 170, 199], ["RSV", "SPECIES", 75, 78], ["viral titers", "PROBLEM", 59, 71], ["RSV plaque assays", "PROBLEM", 75, 92], ["cell-associated virus", "PROBLEM", 94, 115], ["T1L", "OBSERVATION_MODIFIER", 16, 19], ["viral titers", "OBSERVATION", 59, 71]]], ["Virus then was released from harvested cells as described (Utley et al., 2008) .", [["cells", "ANATOMY", 39, 44], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 39, 44], ["harvested cells", "CELL_TYPE", 29, 44], ["Virus", "PROBLEM", 0, 5], ["harvested cells", "OBSERVATION", 29, 44]]], ["Viral titers were determined using plaque assays as described (Murphy et al., 1990) .", [["plaque", "ANATOMY", 35, 41], ["Viral", "ORGANISM", 0, 5], ["Viral titers", "TEST", 0, 12], ["plaque assays", "TEST", 35, 48]]], ["For reovirus, titers were determined by plaque assay using L929 cells.", [["plaque", "ANATOMY", 40, 46], ["L929 cells", "ANATOMY", 59, 69], ["reovirus", "ORGANISM", 4, 12], ["L929 cells", "CELL", 59, 69], ["L929 cells", "CELL_LINE", 59, 69], ["reovirus", "PROBLEM", 4, 12], ["titers", "TEST", 14, 20], ["plaque assay", "TEST", 40, 52]]], ["Reovirus-infected HEp-2 cells were scraped into the medium, frozen at \u221280\u00b0C and thawed at room temperature twice prior to determination of viral titer in the suspension by plaque assay (Virgin et al., 1988) .", [["HEp-2 cells", "ANATOMY", 18, 29], ["plaque", "ANATOMY", 172, 178], ["Reovirus", "CELL", 0, 8], ["HEp-2 cells", "CELL", 18, 29], ["C", "SIMPLE_CHEMICAL", 74, 75], ["Reovirus-infected HEp-2 cells", "CELL_LINE", 0, 29], ["Reovirus", "TEST", 0, 8], ["infected HEp-2 cells", "TREATMENT", 9, 29], ["viral titer", "PROBLEM", 139, 150], ["infected", "OBSERVATION_MODIFIER", 9, 17], ["HEp-2 cells", "OBSERVATION_MODIFIER", 18, 29], ["viral titer", "OBSERVATION", 139, 150], ["plaque", "OBSERVATION", 172, 178]]], ["Reovirus yields were calculated according to the following formula: log 10 yield t = log 10 (pfu/cell)t \u2212 log 10 (pfu/cell)t 0 , where t is the time postinfection and t 0 is the time at inoculation after absorption.2-Aminopurine (2-AP) treatmentWe generated a 150 mM stock solution of 2-AP (Sigma A3509) diluted in phosphate-buffered saline (PBS) and glacial acetic acid (Fisher A-38-500).", [["cell", "ANATOMY", 118, 122], ["2-Aminopurine", "CHEMICAL", 215, 228], ["2-AP", "CHEMICAL", 230, 234], ["2-AP", "CHEMICAL", 285, 289], ["phosphate", "CHEMICAL", 315, 324], ["glacial acetic acid", "CHEMICAL", 351, 370], ["Fisher A-38-500", "CHEMICAL", 372, 387], ["2-Aminopurine", "CHEMICAL", 215, 228], ["2-AP", "CHEMICAL", 230, 234], ["2-AP", "CHEMICAL", 285, 289], ["phosphate", "CHEMICAL", 315, 324], ["glacial acetic acid", "CHEMICAL", 351, 370], ["2-Aminopurine", "SIMPLE_CHEMICAL", 215, 228], ["2-AP", "SIMPLE_CHEMICAL", 230, 234], ["2-AP", "SIMPLE_CHEMICAL", 285, 289], ["Sigma A3509", "SIMPLE_CHEMICAL", 291, 302], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 315, 340], ["glacial acetic acid", "SIMPLE_CHEMICAL", 351, 370], ["log", "TEST", 85, 88], ["pfu/cell", "TEST", 93, 101], ["Aminopurine", "TREATMENT", 217, 228], ["a 150 mM stock solution", "TREATMENT", 258, 281], ["phosphate-buffered saline (PBS", "TREATMENT", 315, 345], ["glacial acetic acid", "TEST", 351, 370]]], ["Glacial acetic acid was diluted at a ratio of 1:200 in PBS.", [["acetic acid", "CHEMICAL", 8, 19], ["Glacial acetic acid", "CHEMICAL", 0, 19], ["acetic acid", "SIMPLE_CHEMICAL", 8, 19], ["Glacial acetic acid", "TREATMENT", 0, 19]]], ["For each use, the solution was incubated at 60\u00b0C for resuspension.", [["the solution", "TREATMENT", 14, 26], ["resuspension", "TREATMENT", 53, 65]]], ["HEp-2 cells were pretreated with 10 mM 2-AP diluted in medium or mock-treated with vehicle (glacial acetic acid in PBS).", [["HEp-2 cells", "ANATOMY", 0, 11], ["2-AP", "CHEMICAL", 39, 43], ["glacial acetic acid", "CHEMICAL", 92, 111], ["2-AP", "CHEMICAL", 39, 43], ["glacial acetic acid", "CHEMICAL", 92, 111], ["HEp-2 cells", "CELL", 0, 11], ["2-AP", "SIMPLE_CHEMICAL", 39, 43], ["glacial acetic acid", "SIMPLE_CHEMICAL", 92, 111], ["HEp-2 cells", "CELL_LINE", 0, 11], ["HEp-2 cells", "TREATMENT", 0, 11], ["vehicle (glacial acetic acid in PBS", "TREATMENT", 83, 118]]], ["Cells then were infected with RSV in the presence of 10 mM 2-AP or vehicle for 1 h.", [["Cells", "ANATOMY", 0, 5], ["2-AP", "CHEMICAL", 59, 63], ["2-AP", "CHEMICAL", 59, 63], ["Cells", "CELL", 0, 5], ["RSV", "ORGANISM", 30, 33], ["2-AP", "SIMPLE_CHEMICAL", 59, 63], ["RSV", "SPECIES", 30, 33], ["RSV", "PROBLEM", 30, 33], ["infected", "OBSERVATION", 16, 24], ["10 mM", "OBSERVATION_MODIFIER", 53, 58]]], ["Following infection, the inoculum was removed and replaced with fresh medium containing 10 mM 2-AP or vehicle and incubated for the duration of infection.Fixation and immunostainingCells were fixed with 3.7% (w/v) formaldehyde in PBS for 10 min at room temperature.", [["Cells", "ANATOMY", 181, 186], ["infection", "DISEASE", 10, 19], ["2-AP", "CHEMICAL", 94, 98], ["infection", "DISEASE", 144, 153], ["formaldehyde", "CHEMICAL", 214, 226], ["2-AP", "CHEMICAL", 94, 98], ["formaldehyde", "CHEMICAL", 214, 226], ["2-AP", "SIMPLE_CHEMICAL", 94, 98], ["Cells", "CELL", 181, 186], ["/v) formaldehyde", "SIMPLE_CHEMICAL", 210, 226], ["infection", "PROBLEM", 10, 19], ["the inoculum", "TREATMENT", 21, 33], ["infection", "PROBLEM", 144, 153], ["Fixation", "TREATMENT", 154, 162], ["immunostaining", "TEST", 167, 181], ["Cells", "TEST", 181, 186], ["w/v) formaldehyde in PBS", "TREATMENT", 209, 233], ["infection", "OBSERVATION", 10, 19], ["inoculum", "OBSERVATION_MODIFIER", 25, 33], ["infection", "OBSERVATION", 144, 153]]], ["Cells were permeabilized with 0.2% (w/v) Triton X-100 and 3.7% paraformaldehyde in PBS for 10 min at room temperature.", [["Cells", "ANATOMY", 0, 5], ["Triton X-100", "CHEMICAL", 41, 53], ["paraformaldehyde", "CHEMICAL", 63, 79], ["paraformaldehyde", "CHEMICAL", 63, 79], ["Cells", "CELL", 0, 5], ["Triton X-100", "SIMPLE_CHEMICAL", 41, 53], ["paraformaldehyde", "SIMPLE_CHEMICAL", 63, 79], ["Cells", "TEST", 0, 5], ["Triton", "TREATMENT", 41, 47]]], ["Following fixation, cells were blocked in 5% (w/v) BSA in PBS for 1 h followed by addition of primary antibody for 1 h.", [["cells", "ANATOMY", 20, 25], ["BSA", "CHEMICAL", 51, 54], ["cells", "CELL", 20, 25], ["BSA", "SIMPLE_CHEMICAL", 51, 54], ["primary antibody", "PROTEIN", 94, 110], ["fixation, cells", "TREATMENT", 10, 25], ["w/v) BSA in PBS", "TREATMENT", 46, 61], ["primary antibody", "TREATMENT", 94, 110], ["fixation", "OBSERVATION", 10, 18]]], ["Cells then were washed three times in PBS and species-specific IgG Alexa Fluor (Molecular Probes) was added at a dilution of 1:1000 in block solution for detection of primary antibodies.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["IgG", "ORGANISM", 63, 66], ["Alexa Fluor", "SIMPLE_CHEMICAL", 67, 78], ["Molecular Probes", "SIMPLE_CHEMICAL", 80, 96], ["IgG Alexa Fluor", "PROTEIN", 63, 78], ["Molecular Probes", "PROTEIN", 80, 96], ["primary antibodies", "PROTEIN", 167, 185], ["PBS", "TREATMENT", 38, 41], ["species", "TREATMENT", 46, 53], ["specific IgG Alexa Fluor (Molecular Probes", "TREATMENT", 54, 96], ["primary antibodies", "PROBLEM", 167, 185], ["primary antibodies", "OBSERVATION", 167, 185]]], ["Cells were washed 3 times in PBS and fixed on glass slides using Prolong Antifade kit (Molecular Probes).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Prolong Antifade kit (Molecular Probes", "TREATMENT", 65, 103]]], ["Images were obtained using a Zeiss inverted LSM510 confocal microscope equipped with a 40\u00d7 Plan-Neofluar oil objective lens.Fixation and immunostainingA polyclonal anti-TIA-1 (sc-1751) antibody was obtained from Santa Cruz and used for immunostaining.", [["sc-1751", "CHEMICAL", 176, 183], ["TIA-1", "GENE_OR_GENE_PRODUCT", 169, 174], ["sc-1751", "GENE_OR_GENE_PRODUCT", 176, 183], ["TIA-1 (sc-1751) antibody", "PROTEIN", 169, 193], ["Santa Cruz", "PROTEIN", 212, 222], ["Images", "TEST", 0, 6], ["Fixation", "TREATMENT", 124, 132], ["immunostaining", "TEST", 137, 151], ["A polyclonal anti-TIA", "TEST", 151, 172], ["antibody", "TEST", 185, 193], ["immunostaining", "TEST", 236, 250]]], ["Monoclonal anti-phosphorylated eIF2\u03b1 (1090-1) and anti-PKR (1511-1) antibodies were obtained from Epitomics.", [["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 31, 36], ["1090-1", "GENE_OR_GENE_PRODUCT", 38, 44], ["anti-PKR (1511-1", "GENE_OR_GENE_PRODUCT", 50, 66], ["Monoclonal anti-phosphorylated eIF2\u03b1 (1090-1", "PROTEIN", 0, 44], ["PKR (1511-1) antibodies", "PROTEIN", 55, 78], ["Monoclonal anti-phosphorylated eIF2\u03b1", "TREATMENT", 0, 36], ["anti-PKR", "TEST", 50, 58], ["antibodies", "TEST", 68, 78]]], ["An anti-RSV F protein humanized mouse monoclonal antibody (palivizumab; MedImmune) was used to identify RSV F protein.", [["palivizumab", "CHEMICAL", 59, 70], ["anti-RSV F", "GENE_OR_GENE_PRODUCT", 3, 13], ["mouse", "ORGANISM", 32, 37], ["RSV", "ORGANISM", 104, 107], ["anti-RSV F protein humanized mouse monoclonal antibody", "PROTEIN", 3, 57], ["MedImmune", "PROTEIN", 72, 81], ["RSV F protein", "PROTEIN", 104, 117], ["mouse", "SPECIES", 32, 37], ["anti-RSV", "SPECIES", 3, 11], ["mouse", "SPECIES", 32, 37], ["RSV", "SPECIES", 104, 107], ["An anti-RSV F protein humanized mouse monoclonal antibody (palivizumab", "TREATMENT", 0, 70]]], ["Anti-RSV P protein (clone 3_5) monoclonal antibody was a kind gift of Ewa Bjorling and Earling Norrby.Fixation and immunostainingshRNA reagents Lentiviral shRNA particles were obtained from Dharmacon for human GAPDH (S-001000-01), a non-targeting control (S-005000-01), and a set of three PKR SMARTvector shRNA constructs (SK-003527-00-10).", [["RSV", "ORGANISM", 5, 8], ["Lentiviral", "ORGANISM", 144, 154], ["human", "ORGANISM", 204, 209], ["GAPDH", "GENE_OR_GENE_PRODUCT", 210, 215], ["PKR", "GENE_OR_GENE_PRODUCT", 289, 292], ["Anti-RSV P protein", "PROTEIN", 0, 18], ["clone 3_5) monoclonal antibody", "PROTEIN", 20, 50], ["human GAPDH", "PROTEIN", 204, 215], ["S-001000-01", "PROTEIN", 217, 228], ["PKR SMARTvector shRNA constructs", "DNA", 289, 321], ["SK-003527-00-10", "DNA", 323, 338], ["human", "SPECIES", 204, 209], ["RSV", "SPECIES", 5, 8], ["human", "SPECIES", 204, 209], ["Anti-RSV P protein", "TEST", 0, 18], ["monoclonal antibody", "TEST", 31, 50], ["Fixation", "TREATMENT", 102, 110], ["immunostainingshRNA reagents Lentiviral shRNA particles", "TREATMENT", 115, 170], ["human GAPDH", "TEST", 204, 215], ["a non-targeting control", "TREATMENT", 231, 254], ["three PKR SMARTvector shRNA constructs", "TREATMENT", 283, 321]]], ["HEp-2 cells were plated in 96-well plates and transduced with individual lentiviral constructs according to the manufacturer's protocol.", [["HEp-2 cells", "ANATOMY", 0, 11], ["HEp-2 cells", "CELL", 0, 11], ["lentiviral", "ORGANISM", 73, 83], ["HEp-2 cells", "CELL_LINE", 0, 11], ["HEp-2 cells", "TREATMENT", 0, 11], ["individual lentiviral constructs", "TREATMENT", 62, 94], ["the manufacturer's protocol", "TREATMENT", 108, 135]]], ["For selection of each target, cells containing integrated lentivirus sequences were selected using puromycin (5 \u03bcg/ mL) diluted in medium.", [["cells", "ANATOMY", 30, 35], ["puromycin", "CHEMICAL", 99, 108], ["puromycin", "CHEMICAL", 99, 108], ["cells", "CELL", 30, 35], ["lentivirus", "ORGANISM", 58, 68], ["puromycin", "SIMPLE_CHEMICAL", 99, 108], ["lentivirus sequences", "DNA", 58, 78], ["integrated lentivirus sequences", "TREATMENT", 47, 78], ["puromycin", "TREATMENT", 99, 108]]], ["Medium containing puromycin was replaced every 3 days until resistant colonies were observed.ImmunoblottingHEp-2 cells were grown in 6-well plates and harvested for protein.", [["colonies", "ANATOMY", 70, 78], ["ImmunoblottingHEp-2 cells", "ANATOMY", 93, 118], ["puromycin", "CHEMICAL", 18, 27], ["puromycin", "CHEMICAL", 18, 27], ["puromycin", "SIMPLE_CHEMICAL", 18, 27], ["ImmunoblottingHEp-2 cells", "CELL", 93, 118], ["ImmunoblottingHEp-2 cells", "CELL_LINE", 93, 118], ["Medium containing puromycin", "TREATMENT", 0, 27], ["resistant colonies", "PROBLEM", 60, 78], ["ImmunoblottingHEp", "TEST", 93, 110], ["puromycin", "OBSERVATION", 18, 27]]], ["Cells were lysed using lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, pH 8.0) containing 0.5% (v/v) of protease inhibitor cocktail (Sigma) and 1.0% (v/v) of phosphatase inhibitors (Sigma).", [["Cells", "ANATOMY", 0, 5], ["Tris-HCl", "CHEMICAL", 43, 51], ["NaCl", "CHEMICAL", 60, 64], ["Triton X-100", "CHEMICAL", 69, 81], ["Tris-HCl", "CHEMICAL", 43, 51], ["NaCl", "CHEMICAL", 60, 64], ["Cells", "CELL", 0, 5], ["Tris-HCl", "SIMPLE_CHEMICAL", 43, 51], ["Triton X-100", "SIMPLE_CHEMICAL", 69, 81], ["lysis buffer", "TREATMENT", 23, 35], ["NaCl", "TEST", 60, 64], ["pH", "TEST", 83, 85], ["protease inhibitor cocktail", "TREATMENT", 116, 143], ["phosphatase inhibitors", "TREATMENT", 170, 192]]], ["Lysates were separated in 4-12% NuPAGE Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membranes using an iBlot dryblotting system (Invitrogen).", [["Lysates", "ANATOMY", 0, 7], ["membranes", "ANATOMY", 100, 109], ["Bis-Tris", "CHEMICAL", 39, 47], ["NuPAGE Bis-Tris gels", "CHEMICAL", 32, 52], ["nitrocellulose", "CHEMICAL", 85, 99], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["Bis-Tris gels", "SIMPLE_CHEMICAL", 39, 52], ["Invitrogen", "SIMPLE_CHEMICAL", 54, 64], ["membranes", "CELLULAR_COMPONENT", 100, 109], ["Lysates", "TEST", 0, 7], ["12% NuPAGE Bis-Tris gels", "TREATMENT", 28, 52], ["nitrocellulose membranes", "TREATMENT", 85, 109], ["an iBlot dryblotting system", "TREATMENT", 116, 143]]], ["Membranes were blocked for 1 h using Odyssey blocking buffer (Li-Cor) diluted 1:1 in PBS.", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["Odyssey", "SIMPLE_CHEMICAL", 37, 44], ["Li-Cor", "SIMPLE_CHEMICAL", 62, 68], ["Odyssey blocking buffer (Li-Cor)", "TREATMENT", 37, 69]]], ["Primary antibodies were diluted in blocking buffer and incubated overnight at 4\u00b0C. Membranes then were washed four times in Tris buffered saline with 0.2% Tween (TBST) for 5 min each.", [["Membranes", "ANATOMY", 83, 92], ["Tween", "CHEMICAL", 155, 160], ["Membranes", "ORGANISM_SUBSTANCE", 83, 92], ["Tris buffered saline", "SIMPLE_CHEMICAL", 124, 144], ["Primary antibodies", "TREATMENT", 0, 18], ["blocking buffer", "TREATMENT", 35, 50], ["Tris buffered saline", "TREATMENT", 124, 144]]], ["Li-Cor IRDye 680CW or IRDye 800CW secondary antibodies were diluted 1:5000 in blocking buffer and added to each membrane for 1 h.", [["membrane", "ANATOMY", 112, 120], ["IRDye", "CHEMICAL", 22, 27], ["IRDye", "SIMPLE_CHEMICAL", 22, 27], ["membrane", "CELLULAR_COMPONENT", 112, 120], ["Li-Cor IRDye 680CW", "PROTEIN", 0, 18], ["IRDye 800CW secondary antibodies", "PROTEIN", 22, 54], ["IRDye", "TREATMENT", 22, 27], ["secondary antibodies", "PROBLEM", 34, 54], ["blocking buffer", "TREATMENT", 78, 93]]], ["Membranes were washed four times in TBST.", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9]]], ["Bands were imaged and quantified using the Odyssey Infrared Imaging System.", [["Bands", "TEST", 0, 5], ["the Odyssey Infrared Imaging System", "TEST", 39, 74]]], ["Total PKR or phosphorylated PKR were detected using monoclonal antibodies from Epitomics (1511-1 and 2283-1, respectively).", [["PKR", "GENE_OR_GENE_PRODUCT", 6, 9], ["PKR", "GENE_OR_GENE_PRODUCT", 28, 31], ["PKR", "PROTEIN", 6, 9], ["phosphorylated PKR", "PROTEIN", 13, 31], ["monoclonal antibodies", "PROTEIN", 52, 73], ["Total PKR", "TEST", 0, 9], ["phosphorylated PKR", "TEST", 13, 31], ["monoclonal antibodies", "TEST", 52, 73], ["Epitomics", "TEST", 79, 88]]], ["GAPDH was detected using a monoclonal antibody from Millipore (MAB374).", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH", "PROTEIN", 0, 5], ["monoclonal antibody", "PROTEIN", 27, 46], ["Millipore (MAB374)", "PROTEIN", 52, 70], ["GAPDH", "PROBLEM", 0, 5], ["a monoclonal antibody", "TEST", 25, 46]]]], "5c025d89fc6cf0a72ee801add30ca474f96a2fee": [["Antihormones in Health and DiseasePhilibert D., Costerousse G., Gaillardmoguilewsky M., Nedelec L., Nique F., Tournemine C. and Teutsch G. (1991) From RU-38486 towards dissociated antiglucocorticoid and antiprogesterone.", [["RU-38486", "CHEMICAL", 151, 159], ["antiglucocorticoid", "CHEMICAL", 180, 198], ["antiprogesterone", "CHEMICAL", 203, 219], ["RU-38486", "CHEMICAL", 151, 159], ["antiglucocorticoid", "CHEMICAL", 180, 198], ["antiprogesterone", "CHEMICAL", 203, 219], ["RU-38486", "SIMPLE_CHEMICAL", 151, 159], ["antiglucocorticoid", "SIMPLE_CHEMICAL", 180, 198], ["antiprogesterone", "SIMPLE_CHEMICAL", 203, 219], ["RU", "TEST", 151, 153], ["dissociated antiglucocorticoid", "TREATMENT", 168, 198], ["antiprogesterone", "TREATMENT", 203, 219]]], ["19, 1-17. progesterone-receptor; glucocorticoid antagonist; estrogen-receptor; chick oviduct; RU-486; RU486; cDNA; antiestrogen; binding; cloning.", [["oviduct", "ANATOMY", 85, 92], ["progesterone", "CHEMICAL", 10, 22], ["estrogen", "CHEMICAL", 60, 68], ["RU-486", "CHEMICAL", 94, 100], ["RU486", "CHEMICAL", 102, 107], ["antiestrogen", "CHEMICAL", 115, 127], ["progesterone", "CHEMICAL", 10, 22], ["estrogen", "CHEMICAL", 60, 68], ["RU-486", "CHEMICAL", 94, 100], ["RU486", "CHEMICAL", 102, 107], ["antiestrogen", "CHEMICAL", 115, 127], ["progesterone", "SIMPLE_CHEMICAL", 10, 22], ["glucocorticoid antagonist", "GENE_OR_GENE_PRODUCT", 33, 58], ["estrogen-receptor", "GENE_OR_GENE_PRODUCT", 60, 77], ["chick", "ORGANISM", 79, 84], ["oviduct", "ORGAN", 85, 92], ["RU-486", "SIMPLE_CHEMICAL", 94, 100], ["RU486", "SIMPLE_CHEMICAL", 102, 107], ["antiestrogen", "SIMPLE_CHEMICAL", 115, 127], ["progesterone-receptor", "PROTEIN", 10, 31], ["estrogen-receptor", "PROTEIN", 60, 77], ["cDNA", "DNA", 109, 113], ["progesterone", "TREATMENT", 10, 22], ["receptor", "TREATMENT", 23, 31], ["glucocorticoid antagonist", "TREATMENT", 33, 58], ["estrogen-receptor", "TREATMENT", 60, 77], ["RU", "TEST", 94, 96], ["antiestrogen", "TREATMENT", 115, 127]]], ["Gehring U. and Segnitz B. (1991) Mechanism of action of the antiglucocorticoid RU-38486 in S49-1 lymphoma cells.Antihormones Hlth Dis.", [["S49-1 lymphoma cells", "ANATOMY", 91, 111], ["RU-38486", "CHEMICAL", 79, 87], ["lymphoma", "DISEASE", 97, 105], ["RU-38486", "CHEMICAL", 79, 87], ["antiglucocorticoid RU-38486", "SIMPLE_CHEMICAL", 60, 87], ["S49-1 lymphoma cells", "CELL", 91, 111], ["S49-1 lymphoma cells", "CELL_LINE", 91, 111], ["the antiglucocorticoid RU", "TEST", 56, 81], ["S49", "TEST", 91, 94], ["lymphoma cells", "PROBLEM", 97, 111], ["lymphoma cells", "OBSERVATION", 97, 111]]], ["19, 18-35.mechanism; cells; heat-shock protein; liver glucocorticoid receptor; DNA-binding properties; monoclonal-antibodies; intact-cells; wild-type; activation; hormone; in &ro; transformation; lymphoma.", [["cells", "ANATOMY", 21, 26], ["liver", "ANATOMY", 48, 53], ["cells", "ANATOMY", 133, 138], ["lymphoma", "ANATOMY", 196, 204], ["lymphoma", "DISEASE", 196, 204], ["cells", "CELL", 21, 26], ["heat-shock protein", "GENE_OR_GENE_PRODUCT", 28, 46], ["liver", "ORGAN", 48, 53], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 54, 77], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["cells", "CELL", 133, 138], ["&ro", "GENE_OR_GENE_PRODUCT", 175, 178], ["lymphoma", "CANCER", 196, 204], ["heat-shock protein", "PROTEIN", 28, 46], ["liver glucocorticoid receptor", "PROTEIN", 48, 77], ["monoclonal-antibodies", "PROTEIN", 103, 124], ["cells", "PROBLEM", 21, 26], ["shock protein", "PROBLEM", 33, 46], ["liver glucocorticoid receptor", "TEST", 48, 77], ["DNA-binding properties", "TEST", 79, 101], ["monoclonal-antibodies", "TEST", 103, 124], ["transformation", "PROBLEM", 180, 194], ["lymphoma", "PROBLEM", 196, 204], ["liver", "ANATOMY", 48, 53], ["lymphoma", "OBSERVATION", 196, 204]]], ["Lazar G. and Agarwal M. K. (1991) Modification of shock by the antiglucocorticoid RU-38486.", [["shock", "DISEASE", 50, 55], ["antiglucocorticoid RU-38486", "CHEMICAL", 63, 90], ["RU-38486", "CHEMICAL", 82, 90], ["antiglucocorticoid RU-38486", "SIMPLE_CHEMICAL", 63, 90], ["shock", "PROBLEM", 50, 55], ["the antiglucocorticoid RU", "TEST", 59, 84], ["shock", "OBSERVATION", 50, 55]]], ["19, 36-44. tumor necrosis factor; septic shock; endotoxin; sepsis.", [["tumor", "DISEASE", 11, 16], ["necrosis", "DISEASE", 17, 25], ["septic shock", "DISEASE", 34, 46], ["endotoxin", "CHEMICAL", 48, 57], ["sepsis", "DISEASE", 59, 65], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 11, 32], ["tumor necrosis factor", "PROTEIN", 11, 32], ["tumor necrosis factor", "PROBLEM", 11, 32], ["septic shock", "PROBLEM", 34, 46], ["endotoxin", "PROBLEM", 48, 57], ["sepsis", "PROBLEM", 59, 65], ["necrosis", "OBSERVATION", 17, 25], ["septic shock", "OBSERVATION", 34, 46], ["endotoxin", "OBSERVATION_MODIFIER", 48, 57], ["sepsis", "OBSERVATION", 59, 65]]], ["Etgen A. M. and Vathy I. (1991) 127-167. antagonist; antiprogesterone steroid RU-486; trans-placental passage; early-pregnancy; menstrual-cycle; gonadotropinsecretion; rhesus monkey; intraocular-pressure; follicular phase; bonnet monkeys; chick oviduct.", [["placental", "ANATOMY", 92, 101], ["intraocular", "ANATOMY", 183, 194], ["follicular", "ANATOMY", 205, 215], ["oviduct", "ANATOMY", 245, 252], ["antiprogesterone steroid RU-486", "CHEMICAL", 53, 84], ["antiprogesterone", "CHEMICAL", 53, 69], ["RU-486", "CHEMICAL", 78, 84], ["antiprogesterone", "SIMPLE_CHEMICAL", 53, 69], ["RU-486", "SIMPLE_CHEMICAL", 78, 84], ["rhesus", "ORGANISM", 168, 174], ["monkey", "ORGANISM", 175, 181], ["monkeys", "ORGANISM", 230, 237], ["chick", "ORGANISM", 239, 244], ["oviduct", "ORGAN", 245, 252], ["rhesus monkey", "SPECIES", 168, 181], ["bonnet monkeys", "SPECIES", 223, 237], ["chick", "SPECIES", 239, 244], ["antagonist", "TREATMENT", 41, 51], ["antiprogesterone steroid RU", "TEST", 53, 80], ["placental passage", "PROBLEM", 92, 109], ["pregnancy", "PROBLEM", 117, 126], ["menstrual-cycle", "PROBLEM", 128, 143], ["gonadotropinsecretion", "TEST", 145, 166], ["intraocular-pressure", "TEST", 183, 203], ["chick oviduct", "PROBLEM", 239, 252]]], ["Moudgal N. R. and Ravindranath N. (1991) Use of gonadotropin and steroid hormone antibodies in studying specific hormone action in the monkey.", [["steroid", "CHEMICAL", 65, 72], ["steroid", "CHEMICAL", 65, 72], ["gonadotropin", "GENE_OR_GENE_PRODUCT", 48, 60], ["steroid hormone antibodies", "GENE_OR_GENE_PRODUCT", 65, 91], ["monkey", "ORGANISM", 135, 141], ["steroid hormone antibodies", "PROTEIN", 65, 91], ["monkey", "SPECIES", 135, 141], ["gonadotropin", "TREATMENT", 48, 60], ["steroid hormone antibodies", "TREATMENT", 65, 91]]], ["19, 168-175. hormone; antibodies; monkey; follicle-stimulating hormone; ovine luteinizing-hormone; Macoca radiara; earlypregnancy; chorionic-gonadotropin; beta-subunit; antiserum; FSH.Antihormones Hlth Dis.", [["monkey", "ORGANISM", 34, 40], ["follicle-stimulating hormone", "GENE_OR_GENE_PRODUCT", 42, 70], ["ovine", "ORGANISM", 72, 77], ["luteinizing-hormone", "GENE_OR_GENE_PRODUCT", 78, 97], ["chorionic-gonadotropin", "GENE_OR_GENE_PRODUCT", 131, 153], ["beta-subunit", "GENE_OR_GENE_PRODUCT", 155, 167], ["antiserum", "ORGANISM_SUBSTANCE", 169, 178], ["FSH", "GENE_OR_GENE_PRODUCT", 180, 183], ["antibodies", "PROTEIN", 22, 32], ["beta-subunit", "PROTEIN", 155, 167], ["FSH", "PROTEIN", 180, 183], ["monkey", "SPECIES", 34, 40], ["hormone", "TEST", 13, 20], ["antibodies", "TEST", 22, 32], ["monkey", "TEST", 34, 40], ["follicle", "TEST", 42, 50], ["stimulating hormone", "TEST", 51, 70], ["ovine luteinizing", "TEST", 72, 89], ["hormone", "TEST", 90, 97], ["Macoca radiara", "TREATMENT", 99, 113], ["earlypregnancy", "TREATMENT", 115, 129], ["chorionic-gonadotropin", "TREATMENT", 131, 153], ["beta-subunit", "TREATMENT", 155, 167], ["antiserum", "TREATMENT", 169, 178], ["FSH", "TREATMENT", 180, 183]]], ["19, 18-35.Houhen H. and Denef C. (1991) Bombesin receptor antagonists and their use in the evaluation of paracrine and autocrine intercellular communication.A&hormones Hlth Dis.", [["intercellular", "ANATOMY", 129, 142], ["Bombesin receptor antagonists", "GENE_OR_GENE_PRODUCT", 40, 69], ["Bombesin receptor antagonists", "TREATMENT", 40, 69], ["the evaluation", "TEST", 87, 101], ["paracrine and autocrine intercellular communication", "TREATMENT", 105, 156]]], ["19, 176-195.receptor; receptor antagonist; antagonist; gastrin-releasing peptide; Swiss 3t3 cells; central nervous-system; lung-cancer cells; pancreatic exocrine secretion; substance-P antagonists; acid secretion; rat; binding; growth.Biochemical JournalSugden P. H. and Fuller S. J. (1991) Regulation of protein turnover in skeletal and cardiac muscle.", [["Swiss 3t3 cells", "ANATOMY", 82, 97], ["central nervous-system", "ANATOMY", 99, 121], ["lung-cancer cells", "ANATOMY", 123, 140], ["pancreatic exocrine", "ANATOMY", 142, 161], ["skeletal", "ANATOMY", 325, 333], ["cardiac muscle", "ANATOMY", 338, 352], ["gastrin", "CHEMICAL", 55, 62], ["cancer", "DISEASE", 128, 134], ["gastrin-releasing peptide", "SIMPLE_CHEMICAL", 55, 80], ["Swiss 3t3 cells", "CELL", 82, 97], ["central nervous-system", "CELL", 99, 121], ["lung-cancer cells", "CELL", 123, 140], ["pancreatic exocrine", "MULTI-TISSUE_STRUCTURE", 142, 161], ["substance-P antagonists", "GENE_OR_GENE_PRODUCT", 173, 196], ["rat", "ORGANISM", 214, 217], ["skeletal", "TISSUE", 325, 333], ["cardiac muscle", "TISSUE", 338, 352], ["Swiss 3t3 cells", "CELL_LINE", 82, 97], ["lung-cancer cells", "CELL_TYPE", 123, 140], ["rat", "SPECIES", 214, 217], ["receptor; receptor antagonist", "TREATMENT", 12, 41], ["antagonist", "TREATMENT", 43, 53], ["gastrin-releasing peptide", "TREATMENT", 55, 80], ["lung-cancer cells", "PROBLEM", 123, 140], ["pancreatic exocrine secretion", "PROBLEM", 142, 171], ["antagonists", "TREATMENT", 185, 196], ["acid secretion", "PROBLEM", 198, 212], ["protein turnover in skeletal and cardiac muscle", "PROBLEM", 305, 352], ["central", "ANATOMY_MODIFIER", 99, 106], ["nervous", "ANATOMY", 107, 114], ["lung", "ANATOMY", 123, 127], ["cancer", "OBSERVATION", 128, 134], ["pancreatic", "ANATOMY", 142, 152], ["protein turnover", "OBSERVATION", 305, 321], ["skeletal", "ANATOMY", 325, 333], ["cardiac muscle", "ANATOMY", 338, 352]]], ["J. 273, 21-37.Biochemical Journalprotein; muscle; n-tau-methylhistidine; perfused rat-heart; branched-chain amino; myosin heavy-chain; nucleotide exchange factor; tumor necrosis factor; left-ventricular hypertrophy; initiation-factor eif-2; ribosomal-RNA synthesis; isolated rabbit muscle. expression; proteins; epidermal growth-factor; human-fetal lung; primary translation products; amino-acid sequence; respiratory-distress syndrome; human amniotic-fluid; ii epithelial-cells; K-dependent carboxylation; molecular-weight protein; hyaline-membrane disease.Biochemical JournalGeeves M. A. (1991) The dynamics of actin and myosin association and the crossbridge model of muscle contraction.Biochem.", [["muscle", "ANATOMY", 42, 48], ["heart", "ANATOMY", 86, 91], ["ventricular", "ANATOMY", 191, 202], ["muscle", "ANATOMY", 282, 288], ["fetal lung", "ANATOMY", 343, 353], ["amniotic-fluid", "ANATOMY", 443, 457], ["epithelial-cells", "ANATOMY", 462, 478], ["hyaline-membrane", "ANATOMY", 533, 549], ["muscle", "ANATOMY", 671, 677], ["n-tau-methylhistidine", "CHEMICAL", 50, 71], ["tumor necrosis", "DISEASE", 163, 177], ["amino-acid", "CHEMICAL", 385, 395], ["respiratory-distress syndrome", "DISEASE", 406, 435], ["muscle contraction", "DISEASE", 671, 689], ["n-tau-methylhistidine", "CHEMICAL", 50, 71], ["amino", "CHEMICAL", 108, 113], ["nucleotide", "CHEMICAL", 135, 145], ["amino-acid", "CHEMICAL", 385, 395], ["muscle", "ORGAN", 42, 48], ["n-tau-methylhistidine", "GENE_OR_GENE_PRODUCT", 50, 71], ["rat", "ORGANISM", 82, 85], ["heart", "ORGAN", 86, 91], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 163, 184], ["ventricular", "MULTI-TISSUE_STRUCTURE", 191, 202], ["eif-2", "GENE_OR_GENE_PRODUCT", 234, 239], ["ribosomal", "CELLULAR_COMPONENT", 241, 250], ["rabbit", "ORGANISM", 275, 281], ["muscle", "ORGAN", 282, 288], ["epidermal growth-factor", "GENE_OR_GENE_PRODUCT", 312, 335], ["human", "ORGANISM", 337, 342], ["lung", "ORGAN", 349, 353], ["amino-acid", "AMINO_ACID", 385, 395], ["human", "ORGANISM", 437, 442], ["ii epithelial-cells", "CELL", 459, 478], ["actin", "GENE_OR_GENE_PRODUCT", 613, 618], ["myosin", "GENE_OR_GENE_PRODUCT", 623, 629], ["muscle", "ORGAN", 671, 677], ["Biochemical Journalprotein; muscle; n-tau-methylhistidine; perfused rat-heart; branched-chain amino; myosin heavy-chain; nucleotide exchange factor", "PROTEIN", 14, 161], ["tumor necrosis factor", "PROTEIN", 163, 184], ["epidermal growth-factor", "PROTEIN", 312, 335], ["primary translation products", "PROTEIN", 355, 383], ["amino-acid sequence", "PROTEIN", 385, 404], ["epithelial-cells", "CELL_TYPE", 462, 478], ["K-dependent carboxylation; molecular-weight protein", "PROTEIN", 480, 531], ["actin", "PROTEIN", 613, 618], ["myosin", "PROTEIN", 623, 629], ["rat", "SPECIES", 82, 85], ["rabbit", "SPECIES", 275, 281], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 437, 442], ["rabbit", "SPECIES", 275, 281], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 437, 442], ["Biochemical Journalprotein", "TEST", 14, 40], ["n-tau", "TEST", 50, 55], ["methylhistidine", "TREATMENT", 56, 71], ["myosin heavy-chain", "TREATMENT", 115, 133], ["nucleotide exchange factor", "PROBLEM", 135, 161], ["tumor necrosis factor", "PROBLEM", 163, 184], ["left-ventricular hypertrophy", "PROBLEM", 186, 214], ["factor eif", "TEST", 227, 237], ["ribosomal-RNA synthesis", "PROBLEM", 241, 264], ["isolated rabbit muscle", "PROBLEM", 266, 288], ["epidermal growth", "TEST", 312, 328], ["primary translation products", "TREATMENT", 355, 383], ["amino-acid sequence", "TEST", 385, 404], ["respiratory-distress syndrome", "PROBLEM", 406, 435], ["human amniotic-fluid", "TEST", 437, 457], ["ii epithelial-cells", "PROBLEM", 459, 478], ["K-dependent carboxylation", "TEST", 480, 505], ["weight protein", "PROBLEM", 517, 531], ["hyaline-membrane disease", "PROBLEM", 533, 557], ["muscle", "ANATOMY", 42, 48], ["heart", "ANATOMY", 86, 91], ["left", "ANATOMY_MODIFIER", 186, 190], ["ventricular", "ANATOMY", 191, 202], ["hypertrophy", "OBSERVATION", 203, 214], ["rabbit muscle", "ANATOMY", 275, 288], ["lung", "ANATOMY", 349, 353], ["respiratory", "ANATOMY", 406, 417], ["hyaline", "OBSERVATION", 533, 540], ["membrane disease", "OBSERVATION", 541, 557], ["muscle contraction", "OBSERVATION", 671, 689]]], ["J. 274, l-14.actin; myosin; association; muscle; model; rabbit skeletal-muscle; actomyosin adenosine-triphosphatase; resonance energy-transfer;Biochem.", [["muscle", "ANATOMY", 41, 47], ["skeletal-muscle", "ANATOMY", 63, 78], ["adenosine", "CHEMICAL", 91, 100], ["adenosine", "CHEMICAL", 91, 100], ["actin", "GENE_OR_GENE_PRODUCT", 13, 18], ["myosin", "GENE_OR_GENE_PRODUCT", 20, 26], ["muscle", "ORGAN", 41, 47], ["rabbit", "ORGANISM", 56, 62], ["skeletal", "ORGAN", 63, 71], ["muscle", "ORGAN", 72, 78], ["actomyosin adenosine-triphosphatase", "GENE_OR_GENE_PRODUCT", 80, 115], ["actin", "PROTEIN", 13, 18], ["myosin", "PROTEIN", 20, 26], ["actomyosin adenosine-triphosphatase", "PROTEIN", 80, 115], ["rabbit", "SPECIES", 56, 62], ["actomyosin adenosine", "TREATMENT", 80, 100], ["muscle", "ANATOMY", 41, 47], ["skeletal", "ANATOMY", 63, 71], ["muscle", "ANATOMY", 72, 78]]], ["J. 274, l-14.sudden length change; f-actin; troponin-tropomyosin; cooperative binding; tension responses; heavymeromyosin; regulated actin.", [["troponin-tropomyosin", "GENE_OR_GENE_PRODUCT", 44, 64], ["heavymeromyosin", "GENE_OR_GENE_PRODUCT", 106, 121], ["actin", "GENE_OR_GENE_PRODUCT", 133, 138], ["f-actin", "PROTEIN", 35, 42], ["troponin", "PROTEIN", 44, 52], ["tropomyosin", "PROTEIN", 53, 64], ["heavymeromyosin", "PROTEIN", 106, 121], ["actin", "PROTEIN", 133, 138], ["sudden length change", "PROBLEM", 13, 33], ["f-actin", "TEST", 35, 42], ["troponin", "TEST", 44, 52], ["cooperative binding", "PROBLEM", 66, 85], ["tension responses", "PROBLEM", 87, 104], ["heavymeromyosin", "TREATMENT", 106, 121]]], ["Knowles P. F. and Marsh D. (1991) Magnetic resonance of membranes.Biochem.", [["membranes", "ANATOMY", 56, 65], ["membranes", "CELLULAR_COMPONENT", 56, 65]]], ["J. 274, 625-641. resonances; membranes; electron-spin-resonance; lipid-protein interactions; cytochrome-c oxidase; myelin basic-protein; state C-13 NMR; labeled sarcoplasmic-reticulum; photosynthetic reaction center; polymorphic phase-behavior; highresolution h-I-NMR; rhodopsin-dimyristoylphosphatidylcholine recombinants.Biochem.", [["membranes", "ANATOMY", 29, 38], ["sarcoplasmic-reticulum", "ANATOMY", 161, 183], ["274, 625-641", "CHEMICAL", 3, 15], ["rhodopsin-dimyristoylphosphatidylcholine", "CHEMICAL", 269, 309], ["dimyristoylphosphatidylcholine", "CHEMICAL", 279, 309], ["membranes", "CELLULAR_COMPONENT", 29, 38], ["electron", "SIMPLE_CHEMICAL", 40, 48], ["cytochrome-c oxidase", "GENE_OR_GENE_PRODUCT", 93, 113], ["rhodopsin-dimyristoylphosphatidylcholine recombinants", "SIMPLE_CHEMICAL", 269, 322], ["cytochrome-c oxidase", "PROTEIN", 93, 113], ["myelin basic-protein", "PROTEIN", 115, 135], ["rhodopsin", "PROTEIN", 269, 278], ["lipid", "TEST", 65, 70], ["cytochrome", "TEST", 93, 103], ["oxidase", "TEST", 106, 113], ["myelin basic", "TEST", 115, 127], ["state C", "TEST", 137, 144], ["NMR", "TEST", 148, 151], ["photosynthetic reaction", "PROBLEM", 185, 208], ["polymorphic phase", "TEST", 217, 234], ["highresolution h", "TEST", 245, 261], ["rhodopsin-dimyristoylphosphatidylcholine recombinants", "TREATMENT", 269, 322], ["reticulum", "ANATOMY", 174, 183]]], ["J. 274, l-14.Boulanger P. A. and Blair G. E. (1991) Expression and interactions of human adenovirus oncoproteins.Biochem.", [["human", "ORGANISM", 83, 88], ["adenovirus", "ORGANISM", 89, 99], ["human adenovirus oncoproteins", "PROTEIN", 83, 112], ["human", "SPECIES", 83, 88], ["human adenovirus", "SPECIES", 83, 99], ["human adenovirus oncoproteins", "TREATMENT", 83, 112]]], ["J. 275, 28 l-299.expression; humans; large-t-antigen; type-5 ela proteins; host-range mutants; class-i gene; sv40 large-t; retinoblastoma susceptibility gene; productively infected-cells; embryonal carcinoma-cells; early region-l proteins; cellular tumorantigen.", [["cells", "ANATOMY", 181, 186], ["embryonal carcinoma-cells", "ANATOMY", 188, 213], ["cellular", "ANATOMY", 240, 248], ["28 l-299", "CHEMICAL", 8, 16], ["retinoblastoma", "DISEASE", 123, 137], ["embryonal carcinoma", "DISEASE", 188, 207], ["humans", "ORGANISM", 29, 35], ["large-t-antigen", "GENE_OR_GENE_PRODUCT", 37, 52], ["ela", "GENE_OR_GENE_PRODUCT", 61, 64], ["class-i", "GENE_OR_GENE_PRODUCT", 95, 102], ["sv40", "GENE_OR_GENE_PRODUCT", 109, 113], ["retinoblastoma", "GENE_OR_GENE_PRODUCT", 123, 137], ["-cells", "CELL", 180, 186], ["embryonal carcinoma-cells", "CELL", 188, 213], ["early region-l proteins", "GENE_OR_GENE_PRODUCT", 215, 238], ["cellular", "CELL", 240, 248], ["ela proteins", "PROTEIN", 61, 73], ["host-range mutants", "DNA", 75, 93], ["class-i gene", "DNA", 95, 107], ["sv40 large-t; retinoblastoma susceptibility gene", "DNA", 109, 157], ["productively infected-cells", "CELL_TYPE", 159, 186], ["embryonal carcinoma-cells", "CELL_TYPE", 188, 213], ["early region-l proteins", "PROTEIN", 215, 238], ["cellular tumorantigen", "PROTEIN", 240, 261], ["humans", "SPECIES", 29, 35], ["humans", "SPECIES", 29, 35], ["ela proteins", "TEST", 61, 73], ["retinoblastoma susceptibility gene", "PROBLEM", 123, 157], ["productively infected-cells", "PROBLEM", 159, 186], ["embryonal carcinoma", "PROBLEM", 188, 207], ["early region-l proteins", "PROBLEM", 215, 238], ["cellular tumorantigen", "PROBLEM", 240, 261], ["retinoblastoma", "OBSERVATION", 123, 137], ["embryonal carcinoma", "OBSERVATION", 188, 207], ["l", "ANATOMY_MODIFIER", 228, 229], ["cellular tumorantigen", "OBSERVATION", 240, 261]]], ["Acta 1072, 9-31. model; chronic myelogenous leukemia; c-myc oncogene; bone-marrow cells; colony-stimulating factor; heavy-chain enhancer; 5~40 t-antigen; pre-b-cells; bcr-v-abl; p53 gene; a-myc. van de Vijver M. J. and Nusse R. (1991) The molecular biology of breast cancer.", [["chronic myelogenous leukemia", "ANATOMY", 24, 52], ["bone-marrow cells", "ANATOMY", 70, 87], ["pre-b-cells", "ANATOMY", 154, 165], ["breast cancer", "ANATOMY", 260, 273], ["Acta 1072, 9-31", "CHEMICAL", 0, 15], ["chronic myelogenous leukemia", "DISEASE", 24, 52], ["breast cancer", "DISEASE", 260, 273], ["chronic myelogenous leukemia", "CANCER", 24, 52], ["c-myc", "GENE_OR_GENE_PRODUCT", 54, 59], ["bone-marrow cells", "CELL", 70, 87], ["colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 89, 114], ["5~40 t-antigen", "GENE_OR_GENE_PRODUCT", 138, 152], ["pre-b", "GENE_OR_GENE_PRODUCT", 154, 159], ["bcr-v-abl", "GENE_OR_GENE_PRODUCT", 167, 176], ["p53", "GENE_OR_GENE_PRODUCT", 178, 181], ["breast cancer", "CANCER", 260, 273], ["c-myc oncogene", "DNA", 54, 68], ["bone-marrow cells", "CELL_TYPE", 70, 87], ["colony-stimulating factor; heavy-chain enhancer", "DNA", 89, 136], ["5~40 t-antigen; pre-b-cells", "DNA", 138, 165], ["bcr", "DNA", 167, 170], ["p53 gene", "DNA", 178, 186], ["chronic myelogenous leukemia", "PROBLEM", 24, 52], ["myc oncogene", "TEST", 56, 68], ["bone-marrow cells", "TEST", 70, 87], ["colony", "TEST", 89, 95], ["stimulating factor", "PROBLEM", 96, 114], ["bcr", "TEST", 167, 170], ["breast cancer", "PROBLEM", 260, 273], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["myelogenous leukemia", "OBSERVATION", 32, 52], ["bone", "ANATOMY", 70, 74], ["marrow cells", "ANATOMY", 75, 87], ["breast", "ANATOMY", 260, 266], ["cancer", "OBSERVATION", 267, 273]]], ["Acfa 1072, 33-50. cancer; epidermal-growth-factor; mammary-tumor virus; proto-oncogene int-I; retinoblastoma susceptibility gene; carcinoma cell-lines; factor-receptor gene; her-2 neu oncogene; i-related protein; ha-ras oncogene; c-myc gene; breast.", [["cancer", "ANATOMY", 18, 24], ["carcinoma cell-lines", "ANATOMY", 130, 150], ["breast", "ANATOMY", 242, 248], ["Acfa 1072, 33-50", "CHEMICAL", 0, 16], ["cancer", "DISEASE", 18, 24], ["mammary-tumor", "DISEASE", 51, 64], ["retinoblastoma", "DISEASE", 94, 108], ["carcinoma", "DISEASE", 130, 139], ["cancer", "CANCER", 18, 24], ["epidermal-growth-factor", "GENE_OR_GENE_PRODUCT", 26, 49], ["mammary-tumor", "CANCER", 51, 64], ["proto-oncogene int-I", "GENE_OR_GENE_PRODUCT", 72, 92], ["retinoblastoma", "GENE_OR_GENE_PRODUCT", 94, 108], ["carcinoma cell-lines; factor-receptor", "GENE_OR_GENE_PRODUCT", 130, 167], ["neu", "GENE_OR_GENE_PRODUCT", 180, 183], ["ha-ras", "GENE_OR_GENE_PRODUCT", 213, 219], ["c-myc", "GENE_OR_GENE_PRODUCT", 230, 235], ["breast", "ORGAN", 242, 248], ["epidermal-growth-factor", "PROTEIN", 26, 49], ["proto-oncogene int-I; retinoblastoma susceptibility gene", "DNA", 72, 128], ["carcinoma cell-lines; factor-receptor gene; her-2 neu oncogene", "DNA", 130, 192], ["i-related protein", "DNA", 194, 211], ["ha-ras oncogene", "DNA", 213, 228], ["c-myc gene", "DNA", 230, 240], ["Acfa", "TEST", 0, 4], ["cancer", "PROBLEM", 18, 24], ["tumor virus", "PROBLEM", 59, 70], ["proto-oncogene", "TREATMENT", 72, 86], ["retinoblastoma susceptibility gene", "PROBLEM", 94, 128], ["carcinoma cell-lines", "TREATMENT", 130, 150], ["factor-receptor gene", "TREATMENT", 152, 172], ["i-related protein", "PROBLEM", 194, 211], ["ha-ras oncogene", "TREATMENT", 213, 228], ["mammary", "ANATOMY", 51, 58], ["tumor", "OBSERVATION", 59, 64], ["retinoblastoma", "OBSERVATION", 94, 108], ["carcinoma cell", "OBSERVATION", 130, 144], ["breast", "ANATOMY", 242, 248]]], ["Bioessuys 13, 31-36. inhibition; resistance; agent; multidrug-resistance; angiostatic steroids; heparin fragment; p-glycoprotein: growth-factor: gene; proliferation; mechanism; progression; discovery.", [["steroids", "CHEMICAL", 86, 94], ["heparin", "CHEMICAL", 96, 103], ["steroids", "CHEMICAL", 86, 94], ["angiostatic steroids", "SIMPLE_CHEMICAL", 74, 94], ["heparin fragment", "SIMPLE_CHEMICAL", 96, 112], ["p-glycoprotein", "GENE_OR_GENE_PRODUCT", 114, 128], ["heparin fragment", "PROTEIN", 96, 112], ["p-glycoprotein", "PROTEIN", 114, 128], ["growth-factor", "PROTEIN", 130, 143], ["Bioessuys", "TEST", 0, 9], ["agent", "TREATMENT", 45, 50], ["multidrug-resistance", "TREATMENT", 52, 72], ["angiostatic steroids", "TREATMENT", 74, 94], ["heparin fragment", "TREATMENT", 96, 112], ["proliferation", "PROBLEM", 151, 164], ["proliferation", "OBSERVATION", 151, 164]]], ["Rattner J. B. (1991) The structure of the mamma~an centromere.", [["mamma~an centromere", "ANATOMY", 42, 61], ["mamma~an centromere", "CELLULAR_COMPONENT", 42, 61], ["mamma~an centromere", "DNA", 42, 61]]], ["Bioessays 13, 51-56. kinetochore structure; cells; proteins; autoantibodies; scleroderma; satellite; tub&n; mitosis; antigen; identification.", [["kinetochore", "ANATOMY", 21, 32], ["cells", "ANATOMY", 44, 49], ["scleroderma", "DISEASE", 77, 88], ["kinetochore", "CELLULAR_COMPONENT", 21, 32], ["cells", "CELL", 44, 49], ["autoantibodies", "PROTEIN", 61, 75], ["Bioessays", "TEST", 0, 9], ["proteins", "PROBLEM", 51, 59], ["autoantibodies", "PROBLEM", 61, 75], ["scleroderma", "PROBLEM", 77, 88], ["satellite", "PROBLEM", 90, 99], ["mitosis", "PROBLEM", 108, 115], ["scleroderma", "OBSERVATION", 77, 88]]], ["Andersen J. and Zieve G. W. (199f) Assembly and intracellular transport of snRNP particles.", [["intracellular", "ANATOMY", 48, 61], ["snRNP", "ANATOMY", 75, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 61], ["snRNP particles", "RNA", 75, 90], ["snRNP particles", "OBSERVATION", 75, 90]]], ["Bioessuys 13, 57-64. transport; particles; small nuclear-RNA; ribonucleoprotein particle; ul RNA; protein: sm; domain; ~4; ~6; identification: polypeptide.", [["Bioessuys 13, 57-64", "CHEMICAL", 0, 19], ["ribonucleoprotein particle", "PROTEIN", 62, 88], ["protein: sm; domain", "PROTEIN", 98, 117], ["Bioessuys", "TEST", 0, 9], ["ribonucleoprotein particle", "TEST", 62, 88], ["ul RNA", "TEST", 90, 96], ["protein", "TEST", 98, 105], ["polypeptide", "TREATMENT", 143, 154], ["small", "OBSERVATION_MODIFIER", 43, 48], ["sm", "ANATOMY", 107, 109]]], ["Smith P. J. S., Shepherd D. and Edwards J. S. (1991) Neural repair and glial proliferation-parallels with gliogenesis in insects.", [["glial", "ANATOMY", 71, 76], ["glial", "CELL", 71, 76], ["Neural repair", "TREATMENT", 53, 66], ["glial proliferation", "PROBLEM", 71, 90], ["gliogenesis", "PROBLEM", 106, 117], ["Neural", "ANATOMY", 53, 59], ["repair", "OBSERVATION", 60, 66], ["glial proliferation", "OBSERVATION", 71, 90]]], ["Bioessays 13, 65-72.Biochem.", [["Bioessays", "TEST", 0, 9]]], ["J. 275, 28 l-299.proliferation; central nervous-system; blood-brain-barrier; Drosophila melanogasfer; neurite growth; disruption; cells; neurons; culture; protein; injury.", [["central nervous-system", "ANATOMY", 32, 54], ["blood", "ANATOMY", 56, 61], ["brain", "ANATOMY", 62, 67], ["neurite", "ANATOMY", 102, 109], ["cells", "ANATOMY", 130, 135], ["neurons", "ANATOMY", 137, 144], ["28 l-299", "CHEMICAL", 8, 16], ["nervous", "ANATOMICAL_SYSTEM", 40, 47], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["brain-barrier", "TISSUE", 62, 75], ["cells", "CELL", 130, 135], ["neurons", "CELL", 137, 144], ["neurons", "CELL_TYPE", 137, 144], ["Drosophila", "SPECIES", 77, 87], ["proliferation", "PROBLEM", 17, 30], ["Drosophila melanogasfer", "PROBLEM", 77, 100], ["neurite growth", "PROBLEM", 102, 116], ["disruption; cells", "PROBLEM", 118, 135], ["culture", "TEST", 146, 153], ["injury", "PROBLEM", 164, 170], ["central", "ANATOMY_MODIFIER", 32, 39], ["nervous", "ANATOMY", 40, 47], ["brain", "ANATOMY", 62, 67], ["injury", "OBSERVATION", 164, 170]]], ["Allan G. F., Tsai S. Y., Omalley B. W. and Tsai M. J. (1991)Cancer, Genetics and CytogeneticsAuerbach A. D. and Allen R. G. (1991) Leukemia and preleukemia in Fanconi anemia patients-a review of the literature and report of the international Fanconi anemia registry.", [["Cancer", "DISEASE", 60, 66], ["Leukemia", "DISEASE", 131, 139], ["preleukemia", "DISEASE", 144, 155], ["Fanconi anemia", "DISEASE", 159, 173], ["Fanconi anemia", "DISEASE", 242, 256], ["Leukemia", "CANCER", 131, 139], ["preleukemia", "CANCER", 144, 155], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["Leukemia", "PROBLEM", 131, 139], ["preleukemia", "PROBLEM", 144, 155], ["Fanconi anemia", "PROBLEM", 159, 173], ["the international Fanconi anemia registry", "PROBLEM", 224, 265], ["Leukemia", "OBSERVATION", 131, 139], ["Fanconi anemia", "OBSERVATION", 159, 173], ["Fanconi anemia registry", "OBSERVATION", 242, 265]]], ["Cancer Gener.", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["Cancer", "CANCER", 0, 6]]], ["Cytogenet.", [["Cytogenet", "TEST", 0, 9]]], ["51, l-12. acute nonlymphocytic leukemia; severe aplastic-anemia; acute myelomonocytic leukemia; induced chromosomal breakage; bone-marrow; superoxide-dismutase; prenatal-diagnosis; mitomycin-c; 2 siblings; DNA-repair. mechanisms: stolonifer Clat~ularia oiridis; cell-cycle progression; human neuro-blastoma; simplex virus-replication: malignant-melanoma cells; myeloid-leukemia cells; growth-inhibition; heat-shock; cyclopentenone prostagiandins; synthetic analog.European Biophysics JournalChristensen H. and Pain R. H. (1991) Molten globule intermediates and protein folding.", [["acute nonlymphocytic leukemia", "ANATOMY", 10, 39], ["acute myelomonocytic leukemia", "ANATOMY", 65, 94], ["chromosomal", "ANATOMY", 104, 115], ["bone", "ANATOMY", 126, 130], ["marrow", "ANATOMY", 131, 137], ["cell", "ANATOMY", 262, 266], ["malignant-melanoma cells", "ANATOMY", 335, 359], ["myeloid-leukemia cells", "ANATOMY", 361, 383], ["acute nonlymphocytic leukemia", "DISEASE", 10, 39], ["aplastic-anemia", "DISEASE", 48, 63], ["acute myelomonocytic leukemia", "DISEASE", 65, 94], ["chromosomal breakage", "DISEASE", 104, 124], ["superoxide", "CHEMICAL", 139, 149], ["mitomycin", "CHEMICAL", 181, 190], ["neuro-blastoma", "DISEASE", 292, 306], ["malignant-melanoma", "DISEASE", 335, 353], ["myeloid-leukemia", "DISEASE", 361, 377], ["shock", "DISEASE", 409, 414], ["cyclopentenone", "CHEMICAL", 416, 430], ["Pain", "DISEASE", 510, 514], ["superoxide", "CHEMICAL", 139, 149], ["cyclopentenone prostagiandins", "CHEMICAL", 416, 445], ["acute nonlymphocytic leukemia", "CANCER", 10, 39], ["acute myelomonocytic leukemia", "CANCER", 65, 94], ["chromosomal", "CELLULAR_COMPONENT", 104, 115], ["bone", "TISSUE", 126, 130], ["marrow", "MULTI-TISSUE_STRUCTURE", 131, 137], ["superoxide-dismutase", "GENE_OR_GENE_PRODUCT", 139, 159], ["mitomycin-c", "GENE_OR_GENE_PRODUCT", 181, 192], ["DNA", "CELLULAR_COMPONENT", 206, 209], ["cell", "CELL", 262, 266], ["human", "ORGANISM", 286, 291], ["neuro-blastoma; simplex virus", "ORGANISM", 292, 321], ["malignant-melanoma cells", "CELL", 335, 359], ["myeloid-leukemia cells", "CELL", 361, 383], ["cyclopentenone prostagiandins", "SIMPLE_CHEMICAL", 416, 445], ["superoxide-dismutase", "PROTEIN", 139, 159], ["malignant-melanoma cells", "CELL_TYPE", 335, 359], ["myeloid-leukemia cells", "CELL_TYPE", 361, 383], ["Clat~ularia oiridis", "SPECIES", 241, 260], ["human", "SPECIES", 286, 291], ["Clat~ularia oiridis", "SPECIES", 241, 260], ["human", "SPECIES", 286, 291], ["acute nonlymphocytic leukemia", "PROBLEM", 10, 39], ["severe aplastic-anemia", "PROBLEM", 41, 63], ["acute myelomonocytic leukemia", "PROBLEM", 65, 94], ["induced chromosomal breakage", "PROBLEM", 96, 124], ["mitomycin", "TREATMENT", 181, 190], ["DNA", "PROBLEM", 206, 209], ["repair", "TREATMENT", 210, 216], ["stolonifer", "TEST", 230, 240], ["Clat", "TEST", 241, 245], ["cell-cycle progression", "PROBLEM", 262, 284], ["human neuro-blastoma", "PROBLEM", 286, 306], ["simplex virus", "PROBLEM", 308, 321], ["malignant-melanoma cells", "PROBLEM", 335, 359], ["myeloid-leukemia cells", "PROBLEM", 361, 383], ["shock", "PROBLEM", 409, 414], ["cyclopentenone prostagiandins", "TREATMENT", 416, 445], ["synthetic analog", "TREATMENT", 447, 463], ["Pain", "PROBLEM", 510, 514], ["nonlymphocytic leukemia", "OBSERVATION", 16, 39], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["aplastic", "OBSERVATION", 48, 56], ["anemia", "OBSERVATION", 57, 63], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["myelomonocytic leukemia", "OBSERVATION", 71, 94], ["chromosomal breakage", "OBSERVATION", 104, 124], ["bone", "ANATOMY", 126, 130], ["marrow", "ANATOMY", 131, 137], ["repair", "OBSERVATION", 210, 216], ["blastoma", "OBSERVATION", 298, 306], ["malignant", "OBSERVATION_MODIFIER", 335, 344], ["melanoma cells", "OBSERVATION", 345, 359], ["myeloid", "ANATOMY", 361, 368], ["leukemia cells", "OBSERVATION", 369, 383], ["protein folding", "OBSERVATION", 561, 576]]], ["J. 19, [221] [222] [223] [224] [225] [226] [227] [228] [229] protein; human alpha-lactalbumin; Sfoplry~~coccrrs US; beta-lactamase: compact state; mechanism; kinetics; NMR;European Biophysics Journalconformation; molecule; lysozyme.European Journal of BiochemistryHouslay M. D. (1991) Crosstalk-a pivotal role for protein kinase-C in modulating relationships between signal transduction pathways.", [["[221] [222] [223] [224] [225] [226", "SIMPLE_CHEMICAL", 7, 41], ["human", "ORGANISM", 70, 75], ["alpha-lactalbumin", "GENE_OR_GENE_PRODUCT", 76, 93], ["Sfoplry", "SIMPLE_CHEMICAL", 95, 102], ["beta-lactamase", "SIMPLE_CHEMICAL", 116, 130], ["lysozyme", "GENE_OR_GENE_PRODUCT", 223, 231], ["protein kinase-C", "GENE_OR_GENE_PRODUCT", 314, 330], ["lysozyme", "PROTEIN", 223, 231], ["protein kinase-C", "PROTEIN", 314, 330], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["protein", "TEST", 61, 68], ["human alpha-lactalbumin", "TEST", 70, 93], ["Sfoplry", "TEST", 95, 102], ["coccrrs US", "TEST", 104, 114], ["beta-lactamase", "TEST", 116, 130], ["NMR", "TEST", 168, 171], ["lysozyme", "TREATMENT", 223, 231], ["Crosstalk", "TEST", 285, 294], ["protein kinase", "TEST", 314, 328]]], ["195, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] protein; kinase-c; signal; signal transduction; pathways; protein kinase-c; epidermal growth-factor; adenylate-cyclase activity; cyclic-AMP phosphodiesterase: beta-adrenergic-receptor; nicotinic acetylcholine-receptor; phorbol-myristate acetate; GTP-binding-protein; inositol phospholipid-metabolism; isolated rat hepatocytes; vascular smooth-muscle. proteins; family; receptors; GTP-binding proteins; beta-adrenergic-receptor; platelet alpha-2-adrenergic receptor; human beta-2-adrenergic receptor; muscarinic acetylcholine-receptors; membrane-spanning domains; cardiac calcium channels; Iigand-binding; molecular characterization; affinity-chromatography; adenylyl cylase.European Journal of BiochemistryWeiss H., Friedrich T., Hofhaus G. and Preis D. (1991) The respiratory-chain NADH dehydrogenase (complex-I) of mitochondria.", [["hepatocytes", "ANATOMY", 413, 424], ["vascular smooth-muscle", "ANATOMY", 426, 448], ["membrane", "ANATOMY", 635, 643], ["cardiac", "ANATOMY", 662, 669], ["mitochondria", "ANATOMY", 916, 928], ["AMP", "CHEMICAL", 235, 238], ["acetylcholine", "CHEMICAL", 294, 307], ["phorbol-myristate acetate", "CHEMICAL", 318, 343], ["GTP", "CHEMICAL", 345, 348], ["inositol", "CHEMICAL", 366, 374], ["acetylcholine", "CHEMICAL", 610, 623], ["calcium", "CHEMICAL", 670, 677], ["NADH", "CHEMICAL", 882, 886], ["195, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26]", "CHEMICAL", 0, 93], ["adenylate", "CHEMICAL", 200, 209], ["cyclic-AMP", "CHEMICAL", 228, 238], ["acetylcholine", "CHEMICAL", 294, 307], ["phorbol-myristate acetate", "CHEMICAL", 318, 343], ["GTP", "CHEMICAL", 345, 348], ["inositol", "CHEMICAL", 366, 374], ["acetylcholine", "CHEMICAL", 610, 623], ["calcium", "CHEMICAL", 670, 677], ["adenylyl", "CHEMICAL", 757, 765], ["NADH", "CHEMICAL", 882, 886], ["[9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27", "SIMPLE_CHEMICAL", 5, 97], ["kinase-c", "GENE_OR_GENE_PRODUCT", 108, 116], ["protein kinase-c", "GENE_OR_GENE_PRODUCT", 157, 173], ["epidermal growth-factor", "GENE_OR_GENE_PRODUCT", 175, 198], ["adenylate-cyclase", "GENE_OR_GENE_PRODUCT", 200, 217], ["cyclic-AMP phosphodiesterase", "GENE_OR_GENE_PRODUCT", 228, 256], ["beta-adrenergic-receptor", "GENE_OR_GENE_PRODUCT", 258, 282], ["nicotinic acetylcholine", "SIMPLE_CHEMICAL", 284, 307], ["phorbol-myristate acetate", "SIMPLE_CHEMICAL", 318, 343], ["GTP", "SIMPLE_CHEMICAL", 345, 348], ["inositol phospholipid", "SIMPLE_CHEMICAL", 366, 387], ["rat", "ORGANISM", 409, 412], ["hepatocytes", "CELL", 413, 424], ["vascular smooth-muscle", "TISSUE", 426, 448], ["GTP-binding proteins", "GENE_OR_GENE_PRODUCT", 479, 499], ["beta-adrenergic-receptor", "GENE_OR_GENE_PRODUCT", 501, 525], ["platelet alpha-2-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 527, 563], ["human", "ORGANISM", 565, 570], ["beta-2-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 571, 597], ["calcium", "SIMPLE_CHEMICAL", 670, 677], ["Iigand", "SIMPLE_CHEMICAL", 688, 694], ["adenylyl cylase", "SIMPLE_CHEMICAL", 757, 772], ["respiratory-chain NADH dehydrogenase", "GENE_OR_GENE_PRODUCT", 864, 900], ["complex-I", "GENE_OR_GENE_PRODUCT", 902, 911], ["mitochondria", "CELLULAR_COMPONENT", 916, 928], ["kinase-c", "PROTEIN", 108, 116], ["protein kinase-c", "PROTEIN", 157, 173], ["epidermal growth-factor", "PROTEIN", 175, 198], ["adenylate-cyclase", "PROTEIN", 200, 217], ["GTP-binding-protein", "PROTEIN", 345, 364], ["isolated rat hepatocytes", "CELL_TYPE", 400, 424], ["GTP-binding proteins", "PROTEIN", 479, 499], ["beta-adrenergic-receptor", "PROTEIN", 501, 525], ["platelet alpha-2-adrenergic receptor", "PROTEIN", 527, 563], ["human beta-2-adrenergic receptor", "PROTEIN", 565, 597], ["muscarinic acetylcholine-receptors", "PROTEIN", 599, 633], ["membrane-spanning domains", "PROTEIN", 635, 660], ["cardiac calcium channels", "PROTEIN", 662, 686], ["Iigand", "PROTEIN", 688, 694], ["adenylyl cylase", "PROTEIN", 757, 772], ["respiratory-chain NADH dehydrogenase", "PROTEIN", 864, 900], ["complex-I", "PROTEIN", 902, 911], ["rat", "SPECIES", 409, 412], ["human", "SPECIES", 565, 570], ["protein", "TEST", 99, 106], ["kinase", "TEST", 108, 114], ["signal", "TEST", 118, 124], ["signal transduction", "TEST", 126, 145], ["pathways", "TEST", 147, 155], ["protein kinase", "TEST", 157, 171], ["c", "TEST", 172, 173], ["epidermal growth", "TEST", 175, 191], ["factor", "TEST", 192, 198], ["adenylate", "TEST", 200, 209], ["cyclase activity", "TEST", 210, 226], ["cyclic", "TEST", 228, 234], ["AMP phosphodiesterase", "TREATMENT", 235, 256], ["beta-adrenergic-receptor", "TREATMENT", 258, 282], ["nicotinic acetylcholine", "TREATMENT", 284, 307], ["receptor", "TREATMENT", 308, 316], ["phorbol", "TREATMENT", 318, 325], ["myristate acetate", "TREATMENT", 326, 343], ["GTP-binding-protein", "TEST", 345, 364], ["inositol phospholipid", "TEST", 366, 387], ["isolated rat hepatocytes", "PROBLEM", 400, 424], ["receptors", "TEST", 468, 477], ["GTP", "TEST", 479, 482], ["binding proteins", "TEST", 483, 499], ["beta-adrenergic", "TEST", 501, 516], ["receptor", "TEST", 517, 525], ["platelet alpha", "TEST", 527, 541], ["adrenergic receptor", "TEST", 544, 563], ["human beta-2", "TEST", 565, 577], ["adrenergic receptor", "TEST", 578, 597], ["muscarinic acetylcholine", "TREATMENT", 599, 623], ["spanning domains", "PROBLEM", 644, 660], ["cardiac calcium channels", "TEST", 662, 686], ["molecular characterization", "TEST", 704, 730], ["affinity-chromatography", "TEST", 732, 755], ["adenylyl cylase", "TREATMENT", 757, 772], ["mitochondria", "PROBLEM", 916, 928], ["rat hepatocytes", "ANATOMY", 409, 424], ["vascular smooth", "ANATOMY", 426, 441], ["muscle", "ANATOMY", 442, 448], ["cardiac", "ANATOMY", 662, 669], ["respiratory", "ANATOMY", 864, 875]]], ["197, [563] [564] [565] [566] [567] [568] [569] [570] [571] [572] [573] [574] [575] [576] respiratory-chain; dehydrogenase; mitochondria; NADH dehydrogenase; ubiquinone cxidoreductase complex; ironsulfur clusters; complete nucleotide-sequence; quinoprotein glucose-dehydro~enase: heart submitochondrial particles; Xetirospora ~Q-mitochondria; hereditary optic neuropathy; rat-liver mit~hondria; Kearns-Sayre syndrome; cytochrome-c oxidase.European Journal of Clinical Chemistry and Clinical Bioc~Cesnjaj M., Stavtjenic A. and Vukicevic S. (1991) Review--in vivo models in the study of osteopcnias. cells; glycoprotein; beta-galactoside alpha-2,6-sialytransferase; CMP-sialic acid; gal-beta-l-> 3(4)glcnac alpha-t > 3 sialytransferase; 2 brain sialytransferases; NH,-terminal signal anchor; N-linked oligosaccharides; rat-liver; Golgi-apparatus: enzymatic characterization; polysialosyl units.European Journal of Clinical Chemistry and Clinical Bioc~Hashimoto E. and Yamamura H. (1991) Protease-activated protein kinase-C in rat liver.", [["mitochondria", "ANATOMY", 123, 135], ["liver", "ANATOMY", 375, 380], ["cells", "ANATOMY", 597, 602], ["brain", "ANATOMY", 736, 741], ["liver", "ANATOMY", 820, 825], ["liver", "ANATOMY", 1027, 1032], ["NADH", "CHEMICAL", 137, 141], ["ubiquinone", "CHEMICAL", 157, 167], ["nucleotide", "CHEMICAL", 222, 232], ["glucose", "CHEMICAL", 256, 263], ["hereditary optic neuropathy", "DISEASE", 342, 369], ["liver mit~hondria", "DISEASE", 375, 392], ["Kearns-Sayre syndrome", "DISEASE", 394, 415], ["osteopcnias", "DISEASE", 584, 595], ["beta-galactoside alpha-2,6-sialytransferase", "CHEMICAL", 618, 661], ["CMP-sialic acid", "CHEMICAL", 663, 678], ["NADH", "CHEMICAL", 137, 141], ["ubiquinone", "CHEMICAL", 157, 167], ["ironsulfur", "CHEMICAL", 192, 202], ["nucleotide", "CHEMICAL", 222, 232], ["glucose", "CHEMICAL", 256, 263], ["CMP-sialic acid", "CHEMICAL", 663, 678], ["gal-beta-l->", "CHEMICAL", 680, 692], ["NH", "CHEMICAL", 761, 763], ["N", "CHEMICAL", 789, 790], ["polysialosyl", "CHEMICAL", 872, 884], ["dehydrogenase", "GENE_OR_GENE_PRODUCT", 108, 121], ["mitochondria", "CELLULAR_COMPONENT", 123, 135], ["NADH dehydrogenase", "GENE_OR_GENE_PRODUCT", 137, 155], ["ubiquinone cxidoreductase complex", "GENE_OR_GENE_PRODUCT", 157, 190], ["ironsulfur clusters", "SIMPLE_CHEMICAL", 192, 211], ["quinoprotein glucose-dehydro~enase", "SIMPLE_CHEMICAL", 243, 277], ["liver", "ORGAN", 375, 380], ["cytochrome-c oxidase", "GENE_OR_GENE_PRODUCT", 417, 437], ["cells", "CELL", 597, 602], ["beta-galactoside alpha-2,6-sialytransferase", "SIMPLE_CHEMICAL", 618, 661], ["CMP-sialic acid", "SIMPLE_CHEMICAL", 663, 678], ["gal-beta", "GENE_OR_GENE_PRODUCT", 680, 688], ["glcnac alpha-t > 3 sialytransferase", "SIMPLE_CHEMICAL", 697, 732], ["brain", "ORGAN", 736, 741], ["NH", "SIMPLE_CHEMICAL", 761, 763], ["N-linked oligosaccharides", "SIMPLE_CHEMICAL", 789, 814], ["rat", "ORGANISM", 816, 819], ["liver", "ORGAN", 820, 825], ["Golgi-apparatus", "SIMPLE_CHEMICAL", 827, 842], ["Protease-activated protein kinase-C", "GENE_OR_GENE_PRODUCT", 984, 1019], ["rat", "ORGANISM", 1023, 1026], ["liver", "ORGAN", 1027, 1032], ["dehydrogenase", "PROTEIN", 108, 121], ["NADH dehydrogenase", "PROTEIN", 137, 155], ["ubiquinone cxidoreductase complex", "PROTEIN", 157, 190], ["ironsulfur clusters", "PROTEIN", 192, 211], ["cytochrome-c oxidase", "PROTEIN", 417, 437], ["glycoprotein", "PROTEIN", 604, 616], ["beta-galactoside alpha", "PROTEIN", 618, 640], ["2,6", "PROTEIN", 641, 644], ["sialytransferase", "PROTEIN", 645, 661], ["CMP", "PROTEIN", 663, 666], ["glcnac alpha", "PROTEIN", 697, 709], ["brain sialytransferases", "PROTEIN", 736, 759], ["NH,-terminal signal anchor", "PROTEIN", 761, 787], ["N-linked oligosaccharides", "PROTEIN", 789, 814], ["Protease-activated protein kinase-C", "PROTEIN", 984, 1019], ["rat", "SPECIES", 816, 819], ["rat", "SPECIES", 1023, 1026], ["rat", "SPECIES", 1023, 1026], ["respiratory-chain", "TEST", 89, 106], ["dehydrogenase", "TEST", 108, 121], ["mitochondria", "PROBLEM", 123, 135], ["NADH dehydrogenase", "TEST", 137, 155], ["ubiquinone cxidoreductase complex", "PROBLEM", 157, 190], ["ironsulfur clusters", "PROBLEM", 192, 211], ["complete nucleotide-sequence", "TEST", 213, 241], ["quinoprotein", "TEST", 243, 255], ["glucose", "TEST", 256, 263], ["dehydro", "TEST", 264, 271], ["heart submitochondrial particles", "PROBLEM", 279, 311], ["Xetirospora", "TREATMENT", 313, 324], ["hereditary optic neuropathy", "PROBLEM", 342, 369], ["rat-liver mit~hondria", "TREATMENT", 371, 392], ["Sayre syndrome", "PROBLEM", 401, 415], ["cytochrome-c oxidase", "TREATMENT", 417, 437], ["Clinical Chemistry", "TEST", 458, 476], ["the study", "TEST", 571, 580], ["osteopcnias", "PROBLEM", 584, 595], ["cells", "TEST", 597, 602], ["glycoprotein", "TEST", 604, 616], ["beta-galactoside alpha", "TEST", 618, 640], ["sialytransferase", "TEST", 645, 661], ["CMP", "TEST", 663, 666], ["sialic acid", "TEST", 667, 678], ["gal", "TEST", 680, 683], ["beta", "TEST", 684, 688], ["glcnac alpha", "TEST", 697, 709], ["sialytransferase", "TEST", 716, 732], ["terminal signal anchor", "PROBLEM", 765, 787], ["polysialosyl units", "TREATMENT", 872, 890], ["Clinical Chemistry", "TEST", 911, 929], ["Protease", "TEST", 984, 992], ["activated protein kinase", "TEST", 993, 1017], ["heart", "ANATOMY", 279, 284], ["optic neuropathy", "OBSERVATION", 353, 369], ["liver", "ANATOMY", 375, 380], ["osteopcnias", "OBSERVATION", 584, 595], ["brain", "ANATOMY", 736, 741], ["liver", "ANATOMY", 820, 825], ["liver", "ANATOMY", 1027, 1032]]], ["23, [507] [508] [509] [510] [511] [512] protein; protein kinase-c; kinase-c; rat; liver; epidermal growth-factor; dependent proteolytic activation; synthetic peptide analog; trypsin-like protease; phorbol ester; ribosomal proteins6; stimulated phosphorylation; mammalian-tissues; Nat /H + exchange; plasma-membrane.", [["liver", "ANATOMY", 82, 87], ["tissues", "ANATOMY", 271, 278], ["plasma-membrane", "ANATOMY", 299, 314], ["phorbol ester", "CHEMICAL", 197, 210], ["phorbol ester", "CHEMICAL", 197, 210], ["H +", "CHEMICAL", 285, 288], ["protein kinase-c", "GENE_OR_GENE_PRODUCT", 49, 65], ["kinase-c", "GENE_OR_GENE_PRODUCT", 67, 75], ["rat", "ORGANISM", 77, 80], ["liver", "ORGAN", 82, 87], ["epidermal growth-factor", "GENE_OR_GENE_PRODUCT", 89, 112], ["trypsin-like protease", "GENE_OR_GENE_PRODUCT", 174, 195], ["phorbol ester", "SIMPLE_CHEMICAL", 197, 210], ["ribosomal proteins6", "GENE_OR_GENE_PRODUCT", 212, 231], ["tissues", "TISSUE", 271, 278], ["H +", "SIMPLE_CHEMICAL", 285, 288], ["plasma", "ORGANISM_SUBSTANCE", 299, 305], ["membrane", "CELLULAR_COMPONENT", 306, 314], ["protein kinase-c; kinase-c; rat; liver; epidermal growth-factor", "PROTEIN", 49, 112], ["trypsin", "PROTEIN", 174, 181], ["protease", "PROTEIN", 187, 195], ["ribosomal proteins6", "PROTEIN", 212, 231], ["rat", "SPECIES", 77, 80], ["protein", "TEST", 40, 47], ["protein kinase", "TEST", 49, 63], ["c", "TEST", 64, 65], ["kinase", "TEST", 67, 73], ["c", "TEST", 74, 75], ["rat", "TEST", 77, 80], ["liver", "TEST", 82, 87], ["epidermal growth", "TEST", 89, 105], ["dependent proteolytic activation", "PROBLEM", 114, 146], ["synthetic peptide analog", "TREATMENT", 148, 172], ["trypsin-like protease", "TREATMENT", 174, 195], ["phorbol ester", "TREATMENT", 197, 210], ["ribosomal proteins6", "TREATMENT", 212, 231], ["stimulated phosphorylation", "TREATMENT", 233, 259], ["Nat /H + exchange", "TREATMENT", 280, 297], ["plasma-membrane", "TREATMENT", 299, 314], ["liver", "ANATOMY", 82, 87], ["epidermal", "ANATOMY", 89, 98], ["tissues", "ANATOMY", 271, 278]]], ["Regan C. M. (1991) Regulation of neural cell adhesion molecule sialylation state.", [["neural cell", "ANATOMY", 33, 44], ["neural cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 33, 62], ["neural cell adhesion molecule", "PROTEIN", 33, 62], ["neural cell adhesion molecule sialylation state", "PROBLEM", 33, 80], ["neural cell adhesion", "OBSERVATION", 33, 53], ["molecule sialylation", "OBSERVATION", 54, 74]]], ["23, 513-523. cell; molecule; state; adhesion; gal-beta-l-> 3(4)glcnac alpha-2-> 3 sialytransferase; myelin-associated glycoprotein; temperature-induced alteration; heparan-sulfate proteoglycan; long oligosaccharide segment; immunoglobulin-like domains; embryonic chicken brain; N-CAM; monoclonal-antibody; polysialic acid.", [["cell", "ANATOMY", 13, 17], ["embryonic", "ANATOMY", 253, 262], ["brain", "ANATOMY", 271, 276], ["heparan-sulfate", "CHEMICAL", 164, 179], ["polysialic acid", "CHEMICAL", 306, 321], ["polysialic acid", "CHEMICAL", 306, 321], ["cell", "CELL", 13, 17], ["gal-beta", "GENE_OR_GENE_PRODUCT", 46, 54], ["sialytransferase", "GENE_OR_GENE_PRODUCT", 82, 98], ["myelin", "GENE_OR_GENE_PRODUCT", 100, 106], ["heparan-sulfate proteoglycan", "SIMPLE_CHEMICAL", 164, 192], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 224, 238], ["chicken", "ORGANISM", 263, 270], ["brain", "ORGAN", 271, 276], ["N-CAM", "GENE_OR_GENE_PRODUCT", 278, 283], ["polysialic acid", "SIMPLE_CHEMICAL", 306, 321], ["gal", "PROTEIN", 46, 49], ["glcnac alpha", "PROTEIN", 63, 75], ["sialytransferase", "PROTEIN", 82, 98], ["myelin-associated glycoprotein", "PROTEIN", 100, 130], ["heparan-sulfate proteoglycan", "PROTEIN", 164, 192], ["long oligosaccharide segment", "PROTEIN", 194, 222], ["immunoglobulin-like domains", "PROTEIN", 224, 251], ["embryonic chicken brain; N-CAM; monoclonal-antibody", "PROTEIN", 253, 304], ["chicken", "SPECIES", 263, 270], ["chicken", "SPECIES", 263, 270], ["adhesion", "TEST", 36, 44], ["gal", "TEST", 46, 49], ["beta", "TEST", 50, 54], ["glcnac alpha", "TEST", 63, 75], ["myelin", "TEST", 100, 106], ["associated glycoprotein", "PROBLEM", 107, 130], ["temperature", "TEST", 132, 143], ["induced alteration", "PROBLEM", 144, 162], ["heparan-sulfate proteoglycan", "TREATMENT", 164, 192], ["long oligosaccharide segment", "PROBLEM", 194, 222], ["immunoglobulin-like domains", "PROBLEM", 224, 251], ["embryonic chicken brain", "PROBLEM", 253, 276], ["CAM", "TEST", 280, 283], ["monoclonal-antibody", "TEST", 285, 304], ["polysialic acid", "PROBLEM", 306, 321], ["brain", "ANATOMY", 271, 276]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["266, -2008 proteins; oxidation: low-density hpoprotein; coli glutamine-synthetase; induced biological damage; active transitionmetals; mixed-function oxidation; site-specific mechanism; red blood-cells; Escherichia coli; denatured proteins; oxygen radicals. receptors; interleukm-2; interleukin-2 receptor; receptor; cell growth-factor; human t-cells; monoclonal-antibody; tat antigen; beta-chain: il.2 receptor; molecular-cloning; kinase activation; phorbol diester; protein-kinase.", [["red blood-cells", "ANATOMY", 186, 201], ["t-cells", "ANATOMY", 343, 350], ["glutamine", "CHEMICAL", 61, 70], ["oxygen", "CHEMICAL", 241, 247], ["phorbol diester", "CHEMICAL", 451, 466], ["glutamine", "CHEMICAL", 61, 70], ["oxygen", "CHEMICAL", 241, 247], ["phorbol diester", "CHEMICAL", 451, 466], ["glutamine-synthetase", "GENE_OR_GENE_PRODUCT", 61, 81], ["red blood-cells", "CELL", 186, 201], ["Escherichia coli", "ORGANISM", 203, 219], ["oxygen radicals", "SIMPLE_CHEMICAL", 241, 256], ["interleukm-2", "GENE_OR_GENE_PRODUCT", 269, 281], ["interleukin-2 receptor", "GENE_OR_GENE_PRODUCT", 283, 305], ["cell", "CELL", 317, 321], ["human", "ORGANISM", 337, 342], ["t-cells", "CELL", 343, 350], ["tat antigen", "GENE_OR_GENE_PRODUCT", 373, 384], ["beta-chain", "GENE_OR_GENE_PRODUCT", 386, 396], ["il.2 receptor", "GENE_OR_GENE_PRODUCT", 398, 411], ["phorbol diester", "SIMPLE_CHEMICAL", 451, 466], ["protein-kinase", "GENE_OR_GENE_PRODUCT", 468, 482], ["coli glutamine-synthetase", "PROTEIN", 56, 81], ["red blood-cells", "CELL_TYPE", 186, 201], ["denatured proteins", "PROTEIN", 221, 239], ["interleukm-2; interleukin-2 receptor; receptor; cell growth-factor", "PROTEIN", 269, 335], ["human t-cells", "CELL_TYPE", 337, 350], ["monoclonal-antibody", "PROTEIN", 352, 371], ["tat antigen", "PROTEIN", 373, 384], ["beta-chain", "PROTEIN", 386, 396], ["il.2 receptor", "PROTEIN", 398, 411], ["protein-kinase", "PROTEIN", 468, 482], ["Escherichia coli", "SPECIES", 203, 219], ["human", "SPECIES", 337, 342], ["Escherichia coli", "SPECIES", 203, 219], ["human", "SPECIES", 337, 342], ["oxidation", "TEST", 21, 30], ["coli glutamine", "TREATMENT", 56, 70], ["induced biological damage", "PROBLEM", 83, 108], ["active transitionmetals", "PROBLEM", 110, 133], ["mixed-function oxidation", "PROBLEM", 135, 159], ["red blood-cells", "TEST", 186, 201], ["Escherichia coli", "PROBLEM", 203, 219], ["denatured proteins", "PROBLEM", 221, 239], ["oxygen radicals", "TREATMENT", 241, 256], ["receptors", "TEST", 258, 267], ["interleukm", "TEST", 269, 279], ["interleukin", "TEST", 283, 294], ["cell growth", "TEST", 317, 328], ["human t-cells", "TEST", 337, 350], ["monoclonal-antibody", "TEST", 352, 371], ["tat antigen", "TEST", 373, 384], ["beta-chain", "TEST", 386, 396], ["kinase activation", "TEST", 432, 449], ["phorbol diester", "TEST", 451, 466], ["protein-kinase", "TEST", 468, 482], ["Escherichia coli", "OBSERVATION", 203, 219], ["oxygen radicals", "OBSERVATION", 241, 256]]], ["Tsomides T. J. and Eisen H. N. (1991) Antigenic structures recognized by cytotoxic lymphocytes-T.European Journal of Clinical Chemistry and Clinical Bioc~J. biol.", [["cytotoxic lymphocytes", "CELL", 73, 94], ["cytotoxic lymphocytes", "CELL_TYPE", 73, 94], ["Clinical Chemistry", "TEST", 117, 135], ["cytotoxic lymphocytes", "OBSERVATION", 73, 94]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["266, [3357] [3358] [3359] [3360] lymphocytes-t; hla-b antigens; i histocompatibility antigens; cell recognition; immunogenic peptides; influenza nucleoprotein; surface expression; beta-2-microglobulin; association; purification; molecules. enzymes; cytochrome-p-450; liver microsomal cytochrome-p-450; arachidonic-acid; rat-liver; chemical carcinogenesis; prosthetic heme; amino-acid; oxidation; mechanism; metabolism; reduction.Journal of Carbohydrate ChemistryRollin P. and KlafTke W. (1991) Enantiomerically pure insect pheromones--the carbohydrate synthetic approach.", [["lymphocytes", "ANATOMY", 33, 44], ["cell", "ANATOMY", 95, 99], ["surface", "ANATOMY", 160, 167], ["liver", "ANATOMY", 324, 329], ["cytochrome-p-450", "CHEMICAL", 249, 265], ["cytochrome-p-450", "CHEMICAL", 284, 300], ["arachidonic-acid", "CHEMICAL", 302, 318], ["carcinogenesis", "DISEASE", 340, 354], ["amino-acid", "CHEMICAL", 373, 383], ["arachidonic-acid", "CHEMICAL", 302, 318], ["heme", "CHEMICAL", 367, 371], ["amino-acid", "CHEMICAL", 373, 383], ["carbohydrate", "CHEMICAL", 539, 551], ["i histocompatibility antigens", "GENE_OR_GENE_PRODUCT", 64, 93], ["cell", "CELL", 95, 99], ["beta-2-microglobulin", "GENE_OR_GENE_PRODUCT", 180, 200], ["cytochrome-p-450", "GENE_OR_GENE_PRODUCT", 249, 265], ["liver", "ORGAN", 267, 272], ["cytochrome-p-450", "GENE_OR_GENE_PRODUCT", 284, 300], ["arachidonic-acid", "SIMPLE_CHEMICAL", 302, 318], ["liver", "ORGAN", 324, 329], ["amino-acid", "SIMPLE_CHEMICAL", 373, 383], ["hla-b antigens", "PROTEIN", 48, 62], ["histocompatibility antigens", "PROTEIN", 66, 93], ["influenza nucleoprotein", "PROTEIN", 135, 158], ["beta-2", "PROTEIN", 180, 186], ["microglobulin", "PROTEIN", 187, 200], ["cytochrome-p-450", "PROTEIN", 249, 265], ["lymphocytes", "TEST", 33, 44], ["t", "TEST", 45, 46], ["hla-b antigens", "TEST", 48, 62], ["histocompatibility antigens", "TEST", 66, 93], ["cell recognition", "TEST", 95, 111], ["immunogenic peptides", "TEST", 113, 133], ["influenza nucleoprotein", "PROBLEM", 135, 158], ["surface expression", "TEST", 160, 178], ["beta-2", "TEST", 180, 186], ["enzymes", "TEST", 240, 247], ["cytochrome", "TEST", 249, 259], ["liver microsomal cytochrome", "TEST", 267, 294], ["arachidonic-acid", "TEST", 302, 318], ["chemical carcinogenesis", "PROBLEM", 331, 354], ["prosthetic heme", "TREATMENT", 356, 371], ["amino-acid", "TREATMENT", 373, 383], ["Carbohydrate ChemistryRollin P.", "TREATMENT", 440, 471], ["Enantiomerically pure insect pheromones", "TREATMENT", 494, 533], ["the carbohydrate synthetic approach", "TREATMENT", 535, 570], ["liver", "ANATOMY", 267, 272], ["liver", "ANATOMY", 324, 329], ["chemical carcinogenesis", "OBSERVATION", 331, 354], ["prosthetic heme", "OBSERVATION", 356, 371]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["10, 115~157. carbohydrate; chiral building units; D-ghCOSe derivatives; optically-active pheromones; chain sugar dithioacetals; flyTruce E/em.", [["carbohydrate", "CHEMICAL", 13, 25], ["D-ghCOSe", "CHEMICAL", 50, 58], ["sugar", "CHEMICAL", 107, 112], ["flyTruce E", "CHEMICAL", 128, 138], ["carbohydrate", "SIMPLE_CHEMICAL", 13, 25], ["D-ghCOSe derivatives", "SIMPLE_CHEMICAL", 50, 70], ["optically-active pheromones; chain sugar dithioacetals", "SIMPLE_CHEMICAL", 72, 126], ["flyTruce E", "SIMPLE_CHEMICAL", 128, 138], ["carbohydrate", "TREATMENT", 13, 25], ["D-ghCOSe derivatives", "TREATMENT", 50, 70], ["optically-active pheromones", "TREATMENT", 72, 99]]], ["3, 177-185.intravenous magnesium; coronary-artery occlusion; isehemic heart-disease; heart-disease; serum magnesium; arrhythmias; potassium; lymphocyte; deficiency; mortality; infusion; sulfate.MatrixGathercole L. J. and Keller A. (1991) Crimp mo~hology in the jng collagens.", [["intravenous", "ANATOMY", 11, 22], ["coronary", "ANATOMY", 34, 42], ["artery", "ANATOMY", 43, 49], ["heart", "ANATOMY", 70, 75], ["heart", "ANATOMY", 85, 90], ["serum", "ANATOMY", 100, 105], ["lymphocyte", "ANATOMY", 141, 151], ["magnesium", "CHEMICAL", 23, 32], ["coronary-artery occlusion", "DISEASE", 34, 59], ["heart-disease", "DISEASE", 70, 83], ["heart-disease", "DISEASE", 85, 98], ["magnesium", "CHEMICAL", 106, 115], ["arrhythmias", "DISEASE", 117, 128], ["potassium", "CHEMICAL", 130, 139], ["magnesium", "CHEMICAL", 23, 32], ["magnesium", "CHEMICAL", 106, 115], ["potassium", "CHEMICAL", 130, 139], ["sulfate", "CHEMICAL", 186, 193], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 22], ["magnesium", "SIMPLE_CHEMICAL", 23, 32], ["coronary-artery", "MULTI-TISSUE_STRUCTURE", 34, 49], ["heart", "ORGAN", 70, 75], ["heart", "ORGAN", 85, 90], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["magnesium", "SIMPLE_CHEMICAL", 106, 115], ["potassium", "SIMPLE_CHEMICAL", 130, 139], ["lymphocyte", "CELL", 141, 151], ["sulfate", "SIMPLE_CHEMICAL", 186, 193], ["jng collagens", "GENE_OR_GENE_PRODUCT", 261, 274], ["jng collagens", "PROTEIN", 261, 274], ["intravenous magnesium", "TREATMENT", 11, 32], ["coronary-artery occlusion", "TREATMENT", 34, 59], ["isehemic heart-disease", "PROBLEM", 61, 83], ["heart-disease", "PROBLEM", 85, 98], ["serum magnesium", "PROBLEM", 100, 115], ["arrhythmias", "PROBLEM", 117, 128], ["potassium", "TEST", 130, 139], ["lymphocyte", "PROBLEM", 141, 151], ["deficiency", "PROBLEM", 153, 163], ["infusion", "TREATMENT", 176, 184], ["sulfate", "TREATMENT", 186, 193], ["coronary", "ANATOMY", 34, 42], ["artery", "ANATOMY", 43, 49], ["occlusion", "OBSERVATION", 50, 59], ["heart", "ANATOMY", 70, 75], ["disease", "OBSERVATION", 76, 83], ["heart", "ANATOMY", 85, 90], ["disease", "OBSERVATION", 91, 98]]], ["M&ix 11, 214-234.Matrixcollagen; rat tail tendon; mechanical-properties; ont~l-ligament; molecular packing; fibers; skin; organization; periodicity; microscopy; intestine.Molecular Biology-English TranslationPastushenkova I. A. (1990) Synthesis, transport, and assembly of chloroplast proteins-cooperation of two genomes.", [["tail tendon", "ANATOMY", 37, 48], ["fibers", "ANATOMY", 108, 114], ["skin", "ANATOMY", 116, 120], ["intestine", "ANATOMY", 161, 170], ["M&ix 11, 214-234", "CHEMICAL", 0, 16], ["Matrixcollagen", "SIMPLE_CHEMICAL", 17, 31], ["rat", "ORGANISM", 33, 36], ["tail tendon", "TISSUE", 37, 48], ["ligament", "TISSUE", 79, 87], ["skin", "ORGAN", 116, 120], ["intestine", "ORGAN", 161, 170], ["chloroplast", "CELLULAR_COMPONENT", 273, 284], ["chloroplast proteins", "PROTEIN", 273, 293], ["rat", "SPECIES", 33, 36], ["M&ix", "TEST", 0, 4], ["Matrixcollagen", "TEST", 17, 31], ["mechanical-properties", "TREATMENT", 50, 71], ["ont~l-ligament", "TREATMENT", 73, 87], ["molecular packing", "TREATMENT", 89, 106], ["microscopy", "TEST", 149, 159], ["chloroplast proteins", "TREATMENT", 273, 293], ["tail tendon", "ANATOMY", 37, 48], ["ligament", "ANATOMY", 79, 87], ["molecular packing", "OBSERVATION", 89, 106], ["skin", "ANATOMY", 116, 120], ["intestine", "ANATOMY", 161, 170]]], ["Shchelkunov S. N., Muravlev A. I., Netesova N. A., Mikryukov N. N., Gutorov V. V., Nikulin A. E., Kulichkov V. A. and Malygin E. G. (1990) Molecular biological study of the genome of Vuceiniu virus.", [["Vuceiniu virus", "ORGANISM", 183, 197], ["Vuceiniu virus", "SPECIES", 183, 197], ["Vuceiniu virus", "SPECIES", 183, 197], ["Molecular biological study", "TEST", 139, 165], ["Vuceiniu virus", "PROBLEM", 183, 197], ["Vuceiniu virus", "OBSERVATION", 183, 197]]], ["(2) Localization and determination of the nucleotide sequence of f/occinia virus genes coding for the protein-36K and protein-I2K.BioL-Engl.Transl.", [["nucleotide", "CHEMICAL", 42, 52], ["BioL-Engl", "CHEMICAL", 130, 139], ["Transl", "CHEMICAL", 140, 146], ["nucleotide", "CHEMICAL", 42, 52], ["f/occinia virus", "ORGANISM", 65, 80], ["protein-36K", "GENE_OR_GENE_PRODUCT", 102, 113], ["protein-I2K", "GENE_OR_GENE_PRODUCT", 118, 129], ["BioL-Engl", "GENE_OR_GENE_PRODUCT", 130, 139], ["f/occinia virus genes", "DNA", 65, 86], ["protein-36K and protein-I2K", "PROTEIN", 102, 129], ["BioL", "PROTEIN", 130, 134], ["Engl", "DNA", 135, 139], ["occinia virus", "SPECIES", 67, 80], ["the nucleotide sequence", "TEST", 38, 61], ["the protein", "TEST", 98, 109], ["K", "TEST", 112, 113], ["protein", "TEST", 118, 125]]], ["24, 780-786. genome; virus; localization; sequence; genes; thymidine kinase gene; functional-analysis; Hind iii; sites; DNA; translation; initiation; expression; prediction; mutations.", [["thymidine", "CHEMICAL", 59, 68], ["thymidine", "CHEMICAL", 59, 68], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 59, 75], ["Hind iii", "GENE_OR_GENE_PRODUCT", 103, 111], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["thymidine kinase gene", "DNA", 59, 80], ["Hind iii; sites", "DNA", 103, 118], ["virus", "PROBLEM", 21, 26], ["thymidine kinase gene", "TREATMENT", 59, 80], ["Hind iii", "PROBLEM", 103, 111], ["DNA", "PROBLEM", 120, 123], ["mutations", "PROBLEM", 174, 183], ["Hind", "ANATOMY", 103, 107]]], ["Ryazankina 0.", [["Ryazankina", "TREATMENT", 0, 10]]], ["I., Shchelkunov S. N., Muravlev A. I., Cheshenko N. V., Chikaev N. A. and Malygin E. G. (1990) carcinogenicity; foods; mutagenic compound; soybean globulin; f344 rats; 2-amino-3-methylimidazo-f>quinoline iq; tryptophan pyrolysate; broiled sardine; glutamic-acid; beef extract; fried beef: mouse skin.Nucleic Acid ResearchGiannelli F., Green P. M., High K. A., Sommer S., Lillicrap D. P., Ludwig M., Olek K., Reitsma P. H., Goossens M., Yoshioka A. and Brownlee G. G. (1991) Haemophilia-Bdatabase of point mutations and short additions and deletions -second edition.", [["extract", "ANATOMY", 268, 275], ["skin", "ANATOMY", 295, 299], ["2-amino-3-methylimidazo-f>quinoline iq", "CHEMICAL", 168, 206], ["tryptophan", "CHEMICAL", 208, 218], ["glutamic-acid", "CHEMICAL", 248, 261], ["2-amino-3-methylimidazo-f", "CHEMICAL", 168, 193], ["quinoline iq", "CHEMICAL", 194, 206], ["tryptophan pyrolysate", "CHEMICAL", 208, 229], ["glutamic-acid", "CHEMICAL", 248, 261], ["foods", "ORGANISM_SUBDIVISION", 112, 117], ["soybean globulin", "SIMPLE_CHEMICAL", 139, 155], ["f344 rats", "ORGANISM", 157, 166], ["2-amino-3-methylimidazo-f>quinoline iq", "SIMPLE_CHEMICAL", 168, 206], ["tryptophan pyrolysate", "SIMPLE_CHEMICAL", 208, 229], ["sardine", "SIMPLE_CHEMICAL", 239, 246], ["glutamic-acid", "SIMPLE_CHEMICAL", 248, 261], ["beef", "ORGANISM", 263, 267], ["beef", "ORGANISM_SUBDIVISION", 283, 287], ["mouse", "ORGANISM", 289, 294], ["skin", "ORGAN", 295, 299], ["soybean", "SPECIES", 139, 146], ["rats", "SPECIES", 162, 166], ["beef", "SPECIES", 263, 267], ["beef", "SPECIES", 283, 287], ["mouse", "SPECIES", 289, 294], ["beef", "SPECIES", 263, 267], ["mouse", "SPECIES", 289, 294], ["soybean globulin", "TEST", 139, 155], ["amino", "TEST", 170, 175], ["methylimidazo", "TREATMENT", 178, 191], ["tryptophan pyrolysate", "TREATMENT", 208, 229], ["broiled sardine", "TREATMENT", 231, 246], ["glutamic-acid", "TREATMENT", 248, 261], ["Haemophilia", "TEST", 474, 485], ["point mutations", "PROBLEM", 499, 514], ["skin", "ANATOMY", 295, 299]]], ["Nucl.", [["Nucl", "GENE_OR_GENE_PRODUCT", 0, 4], ["Nucl", "PROTEIN", 0, 4]]], ["Acid Res. 19, 219332219. mutations; deletion factor-ix gene; coagulation factor-ix; severe hemophilia-b; catalytic domain; molecular defect; cleavage site; abnormal activation; arginine residues; nonsense mutation; missense mutation.", [["hemophilia", "DISEASE", 91, 101], ["arginine", "CHEMICAL", 177, 185], ["arginine", "CHEMICAL", 177, 185], ["coagulation factor-ix", "GENE_OR_GENE_PRODUCT", 61, 82], ["hemophilia-b", "GENE_OR_GENE_PRODUCT", 91, 103], ["arginine", "AMINO_ACID", 177, 185], ["deletion factor-ix gene", "DNA", 36, 59], ["coagulation factor", "PROTEIN", 61, 79], ["catalytic domain", "PROTEIN", 105, 121], ["cleavage site", "PROTEIN", 141, 154], ["Acid Res.", "TEST", 0, 9], ["mutations", "PROBLEM", 25, 34], ["deletion factor", "TEST", 36, 51], ["ix gene", "TEST", 52, 59], ["coagulation factor", "TEST", 61, 79], ["severe hemophilia", "PROBLEM", 84, 101], ["catalytic domain", "PROBLEM", 105, 121], ["molecular defect", "PROBLEM", 123, 139], ["cleavage site", "PROBLEM", 141, 154], ["abnormal activation", "PROBLEM", 156, 175], ["arginine residues", "PROBLEM", 177, 194], ["nonsense mutation", "PROBLEM", 196, 213], ["missense mutation", "PROBLEM", 215, 232], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["hemophilia", "OBSERVATION", 91, 101], ["defect", "OBSERVATION", 133, 139]]]], "da8c2e0c808587382ebf25f8070a6b876cbcae0c": [["INTRODUCTIONAcute lower respiratory infection is a common cause of morbidity in infants and children, and at times, requires intensive care and mechanical ventilation.", [["respiratory infection", "DISEASE", 24, 45], ["infants", "ORGANISM", 80, 87], ["children", "ORGANISM", 92, 100], ["infants", "SPECIES", 80, 87], ["children", "SPECIES", 92, 100], ["INTRODUCTIONAcute lower respiratory infection", "PROBLEM", 0, 45], ["intensive care", "TREATMENT", 125, 139], ["mechanical ventilation", "TREATMENT", 144, 166], ["lower", "ANATOMY_MODIFIER", 18, 23], ["respiratory", "ANATOMY", 24, 35], ["infection", "OBSERVATION", 36, 45], ["morbidity", "OBSERVATION", 67, 76], ["mechanical ventilation", "OBSERVATION", 144, 166]]], ["Viral bronchiolitis and bacterial pneumonia account for the majority of lower respiratory tract infections that lead to respiratory insuffi ciency and pediatric intensive care admission.", [["lower respiratory tract", "ANATOMY", 72, 95], ["respiratory", "ANATOMY", 120, 131], ["bronchiolitis", "DISEASE", 6, 19], ["bacterial pneumonia", "DISEASE", 24, 43], ["respiratory tract infections", "DISEASE", 78, 106], ["respiratory insuffi ciency", "DISEASE", 120, 146], ["lower", "ORGANISM", 72, 77], ["respiratory tract", "ORGANISM_SUBDIVISION", 78, 95], ["Viral bronchiolitis", "PROBLEM", 0, 19], ["bacterial pneumonia", "PROBLEM", 24, 43], ["lower respiratory tract infections", "PROBLEM", 72, 106], ["bronchiolitis", "OBSERVATION", 6, 19], ["bacterial", "OBSERVATION_MODIFIER", 24, 33], ["pneumonia", "OBSERVATION", 34, 43], ["lower", "ANATOMY_MODIFIER", 72, 77], ["respiratory tract", "ANATOMY", 78, 95], ["infections", "OBSERVATION", 96, 106], ["respiratory insuffi", "OBSERVATION", 120, 139]]], ["Twenty-seven percent of children who require mechanical ventilation for at least 24 h in pediatric intensive care units are diagnosed with bronchiolitis and 16% have the diagnosis of pneumonia.", [["bronchiolitis", "DISEASE", 139, 152], ["pneumonia", "DISEASE", 183, 192], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["mechanical ventilation", "TREATMENT", 45, 67], ["bronchiolitis", "PROBLEM", 139, 152], ["pneumonia", "PROBLEM", 183, 192], ["mechanical ventilation", "OBSERVATION", 45, 67], ["bronchiolitis", "OBSERVATION", 139, 152], ["pneumonia", "OBSERVATION", 183, 192]]], ["The median length of time intubated for an acute pulmonary infection leading to respiratory failure is approximately 7 days.", [["pulmonary", "ANATOMY", 49, 58], ["respiratory", "ANATOMY", 80, 91], ["acute pulmonary infection", "DISEASE", 43, 68], ["respiratory failure", "DISEASE", 80, 99], ["pulmonary", "ORGAN", 49, 58], ["an acute pulmonary infection", "PROBLEM", 40, 68], ["respiratory failure", "PROBLEM", 80, 99], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["pulmonary", "ANATOMY", 49, 58], ["infection", "OBSERVATION", 59, 68], ["respiratory failure", "OBSERVATION", 80, 99]]], ["Viral bronchiolitis remains the leading cause for hospital admission in infancy and the most frequent cause of acute respiratory failure in children admitted to pediatric intensive care units in North America.", [["respiratory", "ANATOMY", 117, 128], ["Viral bronchiolitis", "DISEASE", 0, 19], ["acute respiratory failure", "DISEASE", 111, 136], ["children", "ORGANISM", 140, 148], ["children", "SPECIES", 140, 148], ["Viral bronchiolitis", "PROBLEM", 0, 19], ["acute respiratory failure", "PROBLEM", 111, 136], ["bronchiolitis", "OBSERVATION", 6, 19], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["respiratory failure", "OBSERVATION", 117, 136]]], ["Pneumonia in children younger than 5 years of age has an annual incidence KAREN S. POWERSC HAPTER 25 \u2022 AC UTE PU LMONARY I N FECTIONSof 34-40 cases per 1,000.", [["Pneumonia", "DISEASE", 0, 9], ["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21], ["Pneumonia", "PROBLEM", 0, 9]]], ["Community acquired pneumonia can also lead to severe respiratory compromise especially in children with pre-existing disease.", [["respiratory", "ANATOMY", 53, 64], ["pneumonia", "DISEASE", 19, 28], ["respiratory compromise", "DISEASE", 53, 75], ["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["Community acquired pneumonia", "PROBLEM", 0, 28], ["severe respiratory compromise", "PROBLEM", 46, 75], ["pre-existing disease", "PROBLEM", 104, 124], ["pneumonia", "OBSERVATION", 19, 28], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["respiratory compromise", "OBSERVATION", 53, 75], ["disease", "OBSERVATION", 117, 124]]], ["A detailed understanding of the diverse etiologies and distinct clinical courses of acute pulmonary infections is essential for the pediatric critical care practioner.", [["pulmonary", "ANATOMY", 90, 99], ["acute pulmonary infections", "DISEASE", 84, 110], ["pulmonary", "ORGAN", 90, 99], ["the diverse etiologies", "PROBLEM", 28, 50], ["acute pulmonary infections", "PROBLEM", 84, 110], ["distinct", "OBSERVATION_MODIFIER", 55, 63], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["pulmonary", "ANATOMY", 90, 99], ["infections", "OBSERVATION", 100, 110]]], ["This chapter will focus on bronchiolitis and pneumonia as the two leading causes of pulmonary infections leading to PICU admission.BRONCHIOLITIS EpidemiologyApproximately one third of children develop bronchiolitis during the fi rst 2 years of life.", [["pulmonary", "ANATOMY", 84, 93], ["bronchiolitis", "DISEASE", 27, 40], ["pneumonia", "DISEASE", 45, 54], ["pulmonary infections", "DISEASE", 84, 104], ["bronchiolitis", "DISEASE", 201, 214], ["pulmonary", "ORGAN", 84, 93], ["children", "ORGANISM", 184, 192], ["children", "SPECIES", 184, 192], ["bronchiolitis", "PROBLEM", 27, 40], ["pneumonia", "PROBLEM", 45, 54], ["pulmonary infections", "PROBLEM", 84, 104], ["BRONCHIOLITIS", "PROBLEM", 131, 144], ["bronchiolitis", "PROBLEM", 201, 214], ["bronchiolitis", "OBSERVATION", 27, 40], ["pneumonia", "OBSERVATION", 45, 54], ["pulmonary", "ANATOMY", 84, 93], ["infections", "OBSERVATION", 94, 104], ["one third", "OBSERVATION_MODIFIER", 171, 180], ["bronchiolitis", "OBSERVATION", 201, 214]]], ["Of these, only 1 in 10 (3% of all infants in the United States) will require hospitalization.", [["infants", "ORGANISM", 34, 41], ["infants", "SPECIES", 34, 41]]], ["Although hospitalization rates have increased over the last three decades, mortality remains low.", [["increased", "OBSERVATION_MODIFIER", 36, 45], ["low", "OBSERVATION_MODIFIER", 93, 96]]], ["Overall mortality rate is 1-2%, but as high as 5% in high risk infants.", [["infants", "ORGANISM", 63, 70], ["infants", "SPECIES", 63, 70], ["Overall mortality rate", "TEST", 0, 22]]], ["Most deaths occur in infants younger than 6 months of age with co-morbidities such as prematurity, congenital heart disease, congenital or acquired lung disease or immunodefi ciency.Etiology of Viral BronchiolitisRespiratory syncytial virus (RSV) was fi rst isolated in 1957 and still represents the major cause of bronchiolitis.", [["heart", "ANATOMY", 110, 115], ["lung", "ANATOMY", 148, 152], ["deaths", "DISEASE", 5, 11], ["prematurity", "DISEASE", 86, 97], ["congenital heart disease", "DISEASE", 99, 123], ["congenital or acquired lung disease", "DISEASE", 125, 160], ["Viral BronchiolitisRespiratory syncytial virus", "DISEASE", 194, 240], ["bronchiolitis", "DISEASE", 315, 328], ["infants", "ORGANISM", 21, 28], ["heart", "ORGAN", 110, 115], ["lung", "ORGAN", 148, 152], ["Viral BronchiolitisRespiratory syncytial virus", "ORGANISM", 194, 240], ["RSV", "ORGANISM", 242, 245], ["infants", "SPECIES", 21, 28], ["BronchiolitisRespiratory syncytial virus", "SPECIES", 200, 240], ["Viral BronchiolitisRespiratory syncytial virus", "SPECIES", 194, 240], ["RSV", "SPECIES", 242, 245], ["co-morbidities", "PROBLEM", 63, 77], ["prematurity", "PROBLEM", 86, 97], ["congenital heart disease", "PROBLEM", 99, 123], ["congenital or acquired lung disease", "PROBLEM", 125, 160], ["immunodefi ciency", "PROBLEM", 164, 181], ["Viral BronchiolitisRespiratory syncytial virus", "PROBLEM", 194, 240], ["bronchiolitis", "PROBLEM", 315, 328], ["prematurity", "OBSERVATION", 86, 97], ["heart", "ANATOMY", 110, 115], ["disease", "OBSERVATION", 116, 123], ["lung", "ANATOMY", 148, 152], ["disease", "OBSERVATION", 153, 160], ["Viral", "OBSERVATION_MODIFIER", 194, 199], ["BronchiolitisRespiratory syncytial virus", "OBSERVATION", 200, 240], ["bronchiolitis", "OBSERVATION", 315, 328]]], ["Other causative viruses include parainfl uenza, adenovirus, enterovirus, infl uenza and most recently human metapneumovirus and human bocavirus (HBoV).", [["parainfl uenza, adenovirus, enterovirus, infl uenza", "DISEASE", 32, 83], ["human metapneumovirus", "DISEASE", 102, 123], ["parainfl uenza", "ORGANISM", 32, 46], ["adenovirus", "ORGANISM", 48, 58], ["enterovirus", "ORGANISM", 60, 71], ["infl uenza", "ORGANISM", 73, 83], ["human", "ORGANISM", 102, 107], ["metapneumovirus", "ORGANISM", 108, 123], ["human", "ORGANISM", 128, 133], ["bocavirus", "ORGANISM", 134, 143], ["HBoV", "ORGANISM", 145, 149], ["human", "SPECIES", 102, 107], ["metapneumovirus", "SPECIES", 108, 123], ["human", "SPECIES", 128, 133], ["human metapneumovirus", "SPECIES", 102, 123], ["human bocavirus", "SPECIES", 128, 143], ["HBoV", "SPECIES", 145, 149], ["Other causative viruses", "PROBLEM", 0, 23], ["parainfl uenza", "PROBLEM", 32, 46], ["adenovirus", "PROBLEM", 48, 58], ["enterovirus", "PROBLEM", 60, 71], ["infl uenza", "PROBLEM", 73, 83], ["human metapneumovirus", "PROBLEM", 102, 123], ["human bocavirus", "PROBLEM", 128, 143], ["viruses", "OBSERVATION", 16, 23]]], ["In the northern hemisphere, RSV outbreaks occur from October to June.", [["RSV", "ORGANISM", 28, 31], ["RSV", "SPECIES", 28, 31], ["RSV outbreaks", "PROBLEM", 28, 41], ["northern", "ANATOMY_MODIFIER", 7, 15], ["hemisphere", "ANATOMY_MODIFIER", 16, 26], ["RSV", "OBSERVATION", 28, 31]]], ["Human metapneumovirus (hMPV) recently has been identifi ed as the causative agent in 3-19% of bronchiolitis cases, possibly surpassing parainfl uenza as the second most common etiology.", [["Human metapneumovirus (hMPV)", "DISEASE", 0, 28], ["bronchiolitis", "DISEASE", 94, 107], ["Human metapneumovirus", "ORGANISM", 0, 21], ["hMPV", "ORGANISM", 23, 27], ["Human", "SPECIES", 0, 5], ["metapneumovirus", "SPECIES", 6, 21], ["Human metapneumovirus", "SPECIES", 0, 21], ["hMPV", "SPECIES", 23, 27], ["Human metapneumovirus (hMPV", "PROBLEM", 0, 27], ["bronchiolitis cases", "PROBLEM", 94, 113], ["metapneumovirus", "OBSERVATION", 6, 21], ["bronchiolitis", "OBSERVATION", 94, 107]]], ["Its prevalence is slightly higher in the late winter and spring.", [["slightly", "OBSERVATION_MODIFIER", 18, 26], ["higher", "OBSERVATION_MODIFIER", 27, 33], ["late winter", "OBSERVATION_MODIFIER", 41, 52]]], ["Parainfl uenza infections peak at 10 months of age, representing approximately 7-10% of cases of bronchiolitis.", [["Parainfl uenza infections", "DISEASE", 0, 25], ["bronchiolitis", "DISEASE", 97, 110], ["Parainfl uenza infections", "PROBLEM", 0, 25], ["bronchiolitis", "PROBLEM", 97, 110], ["infections", "OBSERVATION", 15, 25], ["bronchiolitis", "OBSERVATION", 97, 110]]], ["Parainfl uenza (PIV-3) is endemic throughout the year, but especially common in the late spring.Etiology of Viral BronchiolitisMales are 1.5-2 times more likely to require hospitalization for bronchiolitis and are likely to have more severe disease.", [["Viral BronchiolitisMales", "DISEASE", 108, 132], ["bronchiolitis", "DISEASE", 192, 205], ["Parainfl uenza", "ORGANISM", 0, 14], ["PIV-3", "GENE_OR_GENE_PRODUCT", 16, 21], ["Parainfl uenza (PIV", "TREATMENT", 0, 19], ["endemic", "PROBLEM", 26, 33], ["Viral BronchiolitisMales", "PROBLEM", 108, 132], ["bronchiolitis", "PROBLEM", 192, 205], ["more severe disease", "PROBLEM", 229, 248], ["endemic", "OBSERVATION_MODIFIER", 26, 33], ["Viral", "OBSERVATION_MODIFIER", 108, 113], ["BronchiolitisMales", "OBSERVATION", 114, 132], ["bronchiolitis", "OBSERVATION", 192, 205], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["disease", "OBSERVATION", 241, 248]]], ["An X-linked genetic trait that results in a reduced tolerance to hypoxia has been postulated and would be consistent with the observation of increased mortality in newborn males with infant respiratory distress syndrome.", [["respiratory", "ANATOMY", 190, 201], ["hypoxia", "DISEASE", 65, 72], ["infant respiratory distress syndrome", "DISEASE", 183, 219], ["infant", "SPECIES", 183, 189], ["An X-linked genetic trait", "PROBLEM", 0, 25], ["a reduced tolerance to hypoxia", "PROBLEM", 42, 72], ["increased mortality", "PROBLEM", 141, 160], ["infant respiratory distress syndrome", "PROBLEM", 183, 219], ["consistent with", "UNCERTAINTY", 106, 121], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["mortality", "OBSERVATION", 151, 160], ["respiratory distress", "OBSERVATION", 190, 210], ["syndrome", "OBSERVATION", 211, 219]]], ["Virtually all children by the age of two will have been infected with RSV, all children by the age of fi ve will have been infected with hMPV, and all children by the age of nine will have been infected with HBoV.Etiology of Viral BronchiolitisThe remainder of the discussion on bronchiolitis will be divided into RSV and non-RSV bronchiolitis.", [["RSV", "DISEASE", 70, 73], ["hMPV", "DISEASE", 137, 141], ["HBoV", "DISEASE", 208, 212], ["Viral Bronchiolitis", "DISEASE", 225, 244], ["bronchiolitis", "DISEASE", 279, 292], ["RSV", "DISEASE", 314, 317], ["bronchiolitis", "DISEASE", 330, 343], ["children", "ORGANISM", 14, 22], ["RSV", "ORGANISM", 70, 73], ["children", "ORGANISM", 79, 87], ["hMPV", "ORGANISM", 137, 141], ["children", "ORGANISM", 151, 159], ["HBoV", "ORGANISM", 208, 212], ["RSV", "ORGANISM", 314, 317], ["children", "SPECIES", 14, 22], ["children", "SPECIES", 79, 87], ["children", "SPECIES", 151, 159], ["RSV", "SPECIES", 70, 73], ["hMPV", "SPECIES", 137, 141], ["HBoV", "SPECIES", 208, 212], ["RSV", "SPECIES", 314, 317], ["non-RSV", "SPECIES", 322, 329], ["HBoV", "PROBLEM", 208, 212], ["Viral Bronchiolitis", "PROBLEM", 225, 244], ["bronchiolitis", "PROBLEM", 279, 292], ["RSV", "PROBLEM", 314, 317], ["non-RSV bronchiolitis", "PROBLEM", 322, 343], ["infected", "OBSERVATION", 194, 202], ["Viral", "OBSERVATION_MODIFIER", 225, 230], ["Bronchiolitis", "OBSERVATION", 231, 244], ["remainder", "OBSERVATION_MODIFIER", 248, 257], ["bronchiolitis", "OBSERVATION", 279, 292], ["RSV", "OBSERVATION", 314, 317], ["bronchiolitis", "OBSERVATION", 330, 343]]], ["Although etiologic agents may differ, clinical courses are often similar.Respiratory Syncytial Virus (RSV)Respiratory syncytial virus (RSV) accounts for 50-80% of bronchiolitis, infecting one-half of all infants within the fi rst year of life and hospitalizing approximately 120,000 infants yearly (about 3% of affected infants).", [["Respiratory Syncytial Virus", "DISEASE", 73, 100], ["Respiratory syncytial virus", "DISEASE", 106, 133], ["RSV", "DISEASE", 135, 138], ["bronchiolitis", "DISEASE", 163, 176], ["Respiratory Syncytial Virus", "ORGANISM", 73, 100], ["RSV)", "ORGANISM", 102, 106], ["Respiratory syncytial virus", "ORGANISM", 106, 133], ["RSV", "ORGANISM", 135, 138], ["infants", "ORGANISM", 204, 211], ["infants", "ORGANISM", 283, 290], ["infants", "ORGANISM", 320, 327], ["Respiratory syncytial virus", "SPECIES", 106, 133], ["infants", "SPECIES", 204, 211], ["infants", "SPECIES", 283, 290], ["infants", "SPECIES", 320, 327], ["RSV", "SPECIES", 102, 105], ["Respiratory syncytial virus", "SPECIES", 106, 133], ["RSV", "SPECIES", 135, 138], ["Respiratory Syncytial Virus (RSV)", "PROBLEM", 73, 106], ["Respiratory syncytial virus", "PROBLEM", 106, 133], ["bronchiolitis", "PROBLEM", 163, 176], ["Syncytial Virus", "OBSERVATION", 85, 100], ["Respiratory syncytial virus", "OBSERVATION", 106, 133], ["bronchiolitis", "OBSERVATION", 163, 176]]], ["Approximately 10% of these infants require mechanical ventilation.", [["infants", "ORGANISM", 27, 34], ["infants", "SPECIES", 27, 34], ["mechanical ventilation", "TREATMENT", 43, 65], ["mechanical ventilation", "OBSERVATION", 43, 65]]], ["Co-infection with either hMPV or rhinovirus occurs in 10-30% of young children.Respiratory Syncytial Virus (RSV)Two types of RSV exist -types A and B. Type A is more common and is believed to cause more severe disease, although data is not conclusive.", [["Co-infection", "DISEASE", 0, 12], ["hMPV or rhinovirus", "DISEASE", 25, 43], ["Respiratory Syncytial Virus", "DISEASE", 79, 106], ["hMPV", "ORGANISM", 25, 29], ["rhinovirus", "ORGANISM", 33, 43], ["children", "ORGANISM", 70, 78], ["Respiratory Syncytial Virus", "ORGANISM", 79, 106], ["RSV", "ORGANISM", 108, 111], ["RSV", "ORGANISM", 125, 128], ["children", "SPECIES", 70, 78], ["hMPV", "SPECIES", 25, 29], ["RSV", "SPECIES", 108, 111], ["RSV", "SPECIES", 125, 128], ["Type A", "SPECIES", 151, 157], ["Co-infection", "PROBLEM", 0, 12], ["hMPV", "PROBLEM", 25, 29], ["rhinovirus", "PROBLEM", 33, 43], ["Respiratory Syncytial Virus (RSV)", "PROBLEM", 79, 112], ["RSV exist", "PROBLEM", 125, 134], ["more severe disease", "PROBLEM", 198, 217], ["hMPV", "OBSERVATION", 25, 29], ["rhinovirus", "OBSERVATION", 33, 43], ["Syncytial Virus", "OBSERVATION", 91, 106], ["RSV", "OBSERVATION", 125, 128], ["severe", "OBSERVATION_MODIFIER", 203, 209], ["disease", "OBSERVATION", 210, 217], ["not conclusive", "UNCERTAINTY", 236, 250]]], ["Infants less than 1 year will typically shed the virus for about 9 days.", [["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7]]], ["Children with immunodefi ciencies may shed the virus for months.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["immunodefi ciencies", "TREATMENT", 14, 33]]], ["The immune response varies with age and contributes to both termination of the disease and its pathologic features.Respiratory Syncytial Virus (RSV)The virus is transmitted from respiratory secretions by close contact with infected persons or by contact with contaminated objects or surfaces.", [["respiratory secretions", "ANATOMY", 178, 200], ["Respiratory Syncytial Virus", "DISEASE", 115, 142], ["Respiratory Syncytial Virus", "ORGANISM", 115, 142], ["RSV", "ORGANISM", 144, 147], ["secretions", "ORGANISM_SUBSTANCE", 190, 200], ["persons", "ORGANISM", 232, 239], ["persons", "SPECIES", 232, 239], ["RSV", "SPECIES", 144, 147], ["the disease", "PROBLEM", 75, 86], ["its pathologic features", "PROBLEM", 91, 114], ["Respiratory Syncytial Virus (RSV)", "PROBLEM", 115, 148], ["The virus", "PROBLEM", 148, 157], ["respiratory secretions", "PROBLEM", 178, 200], ["immune", "OBSERVATION", 4, 10], ["response varies", "OBSERVATION", 11, 26], ["disease", "OBSERVATION", 79, 86], ["Syncytial Virus", "OBSERVATION", 127, 142], ["respiratory secretions", "OBSERVATION", 178, 200]]], ["There is a 45% RSV transmission rate within families and about one-half of hospital workers will acquire RSV.", [["RSV", "DISEASE", 105, 108], ["RSV", "ORGANISM", 15, 18], ["workers", "ORGANISM", 84, 91], ["RSV", "ORGANISM", 105, 108], ["RSV", "SPECIES", 15, 18], ["RSV", "SPECIES", 105, 108], ["RSV", "PROBLEM", 105, 108]]], ["Therefore, hand washing and the wearing of gowns and gloves is of primary importance to attenuate transmission.Respiratory Syncytial Virus (RSV)Mortality from RSV bronchiolitis continues to decline with better intensive care and the use of preventive therapies.Respiratory Syncytial Virus (RSV)Male infants are more likely to require hospitalization and usually manifest more severe disease.Respiratory Syncytial Virus (RSV)About \u00bd of all infants will be infected with RSV bronchiolitis in their 1st year of life; 3% will be hospitalized; 10% of hospitalized infants will require mechanical ventilation.PathophysiologyAntibody-Mediated Immunity RSV introduced onto the nasal or conjunctival mucosal surface causes profuse rhinorrhea within a few days.", [["hand", "ANATOMY", 11, 15], ["nasal", "ANATOMY", 669, 674], ["conjunctival mucosal surface", "ANATOMY", 678, 706], ["Respiratory Syncytial Virus", "DISEASE", 111, 138], ["RSV bronchiolitis", "DISEASE", 159, 176], ["Respiratory Syncytial Virus", "DISEASE", 261, 288], ["Respiratory Syncytial Virus", "DISEASE", 391, 418], ["RSV bronchiolitis", "DISEASE", 469, 486], ["rhinorrhea", "DISEASE", 722, 732], ["Respiratory Syncytial Virus", "ORGANISM", 111, 138], ["RSV", "ORGANISM", 140, 143], ["RSV", "ORGANISM", 159, 162], ["Respiratory Syncytial Virus", "ORGANISM", 261, 288], ["RSV", "ORGANISM", 290, 293], ["Male infants", "ORGANISM", 294, 306], ["Respiratory Syncytial Virus", "ORGANISM", 391, 418], ["RSV", "ORGANISM", 420, 423], ["infants", "ORGANISM", 439, 446], ["RSV", "ORGANISM", 469, 472], ["infants", "ORGANISM", 559, 566], ["RSV", "ORGANISM", 645, 648], ["nasal", "ORGAN", 669, 674], ["conjunctival mucosal", "TISSUE", 678, 698], ["infants", "SPECIES", 299, 306], ["infants", "SPECIES", 439, 446], ["infants", "SPECIES", 559, 566], ["RSV", "SPECIES", 140, 143], ["RSV", "SPECIES", 159, 162], ["RSV", "SPECIES", 290, 293], ["RSV", "SPECIES", 420, 423], ["RSV", "SPECIES", 469, 472], ["RSV", "SPECIES", 645, 648], ["hand washing", "TREATMENT", 11, 23], ["gowns", "TREATMENT", 43, 48], ["gloves", "TREATMENT", 53, 59], ["Respiratory Syncytial Virus (RSV)", "PROBLEM", 111, 144], ["RSV bronchiolitis", "PROBLEM", 159, 176], ["preventive therapies", "TREATMENT", 240, 260], ["Respiratory Syncytial Virus", "PROBLEM", 261, 288], ["more severe disease", "PROBLEM", 371, 390], ["Respiratory Syncytial Virus", "PROBLEM", 391, 418], ["RSV bronchiolitis", "PROBLEM", 469, 486], ["mechanical ventilation", "TREATMENT", 580, 602], ["PathophysiologyAntibody", "TEST", 603, 626], ["Mediated Immunity RSV", "TREATMENT", 627, 648], ["profuse rhinorrhea", "PROBLEM", 714, 732], ["Syncytial Virus", "OBSERVATION", 123, 138], ["RSV bronchiolitis", "OBSERVATION", 159, 176], ["Syncytial Virus", "OBSERVATION", 273, 288], ["severe", "OBSERVATION_MODIFIER", 376, 382], ["disease", "OBSERVATION", 383, 390], ["Syncytial Virus", "OBSERVATION", 403, 418], ["infected", "OBSERVATION", 455, 463], ["RSV bronchiolitis", "OBSERVATION", 469, 486], ["mechanical ventilation", "OBSERVATION", 580, 602], ["Immunity RSV", "OBSERVATION", 636, 648], ["nasal", "ANATOMY", 669, 674], ["conjunctival mucosal", "ANATOMY", 678, 698], ["profuse", "OBSERVATION_MODIFIER", 714, 721], ["rhinorrhea", "OBSERVATION", 722, 732]]], ["During the fi rst 2 months of life, passively acquired maternal antibodies are protective.", [["maternal antibodies", "PROTEIN", 55, 74], ["passively acquired maternal antibodies", "PROBLEM", 36, 74]]], ["However, as maternal antibody titers gradually decrease, infants become susceptible to severe disease.", [["infants", "ORGANISM", 57, 64], ["infants", "SPECIES", 57, 64], ["maternal antibody titers", "TEST", 12, 36], ["severe disease", "PROBLEM", 87, 101], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["disease", "OBSERVATION", 94, 101]]], ["Cell-bound IgA may develop to help clear the virus.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["IgA", "GENE_OR_GENE_PRODUCT", 11, 14], ["IgA", "PROTEIN", 11, 14], ["Cell-bound IgA", "PROBLEM", 0, 14], ["the virus", "PROBLEM", 41, 50], ["virus", "OBSERVATION", 45, 50]]], ["Circulating IgG directed against the glycoprotein (G) and fusion (F) proteins (operative in syncytia formation) on the viral surface will develop several days later.", [["syncytia", "ANATOMY", 92, 100], ["surface", "ANATOMY", 125, 132], ["IgG directed against the glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 12, 53], ["fusion (F) proteins", "GENE_OR_GENE_PRODUCT", 58, 77], ["syncytia", "CELL", 92, 100], ["Circulating IgG", "PROTEIN", 0, 15], ["glycoprotein (G)", "PROTEIN", 37, 53], ["fusion (F) proteins", "PROTEIN", 58, 77], ["Circulating IgG", "TREATMENT", 0, 15], ["the glycoprotein (G) and fusion (F) proteins (operative in syncytia formation", "TREATMENT", 33, 110]]], ["Infants less than 3 months of age appear to induce a weaker antibody response likely due to the presence of maternal antibodies.", [["Infants", "ORGANISM", 0, 7], ["maternal antibodies", "PROTEIN", 108, 127], ["Infants", "SPECIES", 0, 7], ["a weaker antibody response", "PROBLEM", 51, 77], ["maternal antibodies", "PROBLEM", 108, 127]]], ["Virus-specifi c IgE in the respiratory tract is associated with disease severity.", [["respiratory tract", "ANATOMY", 27, 44], ["specifi c IgE", "GENE_OR_GENE_PRODUCT", 6, 19], ["respiratory tract", "ORGANISM_SUBDIVISION", 27, 44], ["Virus-specifi c IgE", "PROTEIN", 0, 19], ["Virus", "PROBLEM", 0, 5], ["specifi c IgE in the respiratory tract", "PROBLEM", 6, 44], ["disease severity", "PROBLEM", 64, 80], ["IgE", "OBSERVATION", 16, 19], ["respiratory tract", "ANATOMY", 27, 44], ["associated with", "UNCERTAINTY", 48, 63], ["disease", "OBSERVATION", 64, 71]]], ["Often, complete and effective immune responses are not induced, thus re-infections are possible even during the same season.Cell-Mediated ImmunityEpithelial cells and alveolar macrophages are key activators of cellular immunity.", [["Cell", "ANATOMY", 124, 128], ["ImmunityEpithelial cells", "ANATOMY", 138, 162], ["alveolar macrophages", "ANATOMY", 167, 187], ["cellular", "ANATOMY", 210, 218], ["Cell", "CELL", 124, 128], ["ImmunityEpithelial cells", "CELL", 138, 162], ["alveolar macrophages", "CELL", 167, 187], ["cellular", "CELL", 210, 218], ["Mediated ImmunityEpithelial cells", "CELL_TYPE", 129, 162], ["alveolar macrophages", "CELL_TYPE", 167, 187], ["Cell", "TEST", 124, 128], ["ImmunityEpithelial cells", "PROBLEM", 138, 162], ["alveolar macrophages", "PROBLEM", 167, 187], ["ImmunityEpithelial cells", "OBSERVATION", 138, 162], ["alveolar macrophages", "OBSERVATION", 167, 187], ["cellular immunity", "OBSERVATION", 210, 227]]], ["Although these cells enhance viral clearing, they also contribute to airway infl ammation through the release of cytokines and chemokines.", [["cells", "ANATOMY", 15, 20], ["airway", "ANATOMY", 69, 75], ["cells", "CELL", 15, 20], ["cytokines", "PROTEIN", 113, 122], ["chemokines", "PROTEIN", 127, 137], ["these cells", "PROBLEM", 9, 20], ["cytokines and chemokines", "TREATMENT", 113, 137], ["viral clearing", "OBSERVATION", 29, 43], ["airway", "ANATOMY", 69, 75]]], ["These include interleukin (IL)-1, tumor necrosis factor-alpha, IL-6, IL-8, macrophage-infl ammatory protein (MIP)-1-alpha and RANTES (regulated upon activation, normal T cell expressed and secreted).", [["T cell", "ANATOMY", 168, 174], ["necrosis", "DISEASE", 40, 48], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 14, 32], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 34, 61], ["IL-6", "GENE_OR_GENE_PRODUCT", 63, 67], ["IL-8", "GENE_OR_GENE_PRODUCT", 69, 73], ["macrophage-infl ammatory protein (MIP)-1-alpha", "GENE_OR_GENE_PRODUCT", 75, 121], ["RANTES", "GENE_OR_GENE_PRODUCT", 126, 132], ["T cell", "CELL", 168, 174], ["interleukin (IL)-1", "PROTEIN", 14, 32], ["tumor necrosis factor-alpha, IL-6, IL-8", "PROTEIN", 34, 73], ["macrophage-infl ammatory protein (MIP)-1-alpha", "PROTEIN", 75, 121], ["RANTES", "PROTEIN", 126, 132], ["interleukin (IL)", "TEST", 14, 30], ["tumor necrosis factor", "PROBLEM", 34, 55], ["alpha", "TEST", 56, 61], ["IL", "TEST", 63, 65], ["IL", "TEST", 69, 71], ["macrophage", "TEST", 75, 85], ["ammatory protein", "TEST", 91, 107], ["MIP", "TEST", 109, 112], ["RANTES", "TEST", 126, 132], ["tumor", "OBSERVATION_MODIFIER", 34, 39], ["necrosis", "OBSERVATION", 40, 48], ["alpha", "ANATOMY", 56, 61], ["macrophage", "ANATOMY", 75, 85]]], ["Release of these cytokines and chemokines are believed to be partially responsible for airway infl ammation and hyperreactivity.", [["airway", "ANATOMY", 87, 93], ["hyperreactivity", "DISEASE", 112, 127], ["cytokines", "PROTEIN", 17, 26], ["chemokines", "PROTEIN", 31, 41], ["these cytokines", "TREATMENT", 11, 26], ["chemokines", "TREATMENT", 31, 41], ["airway infl ammation", "PROBLEM", 87, 107], ["hyperreactivity", "PROBLEM", 112, 127], ["cytokines", "OBSERVATION", 17, 26], ["believed to be partially responsible for", "UNCERTAINTY", 46, 86], ["airway", "ANATOMY", 87, 93], ["hyperreactivity", "OBSERVATION", 112, 127]]], ["The effects of these mediators persist beyond the acute infection and contribute to prolonged pulmonary dysfunction.Cell-Mediated ImmunityChildren who require mechanical ventilation have lower peripheral T cell counts compared to hospitalized infants not requiring mechanical ventilation.", [["pulmonary", "ANATOMY", 94, 103], ["Cell", "ANATOMY", 116, 120], ["peripheral T cell", "ANATOMY", 193, 210], ["infection", "DISEASE", 56, 65], ["pulmonary dysfunction", "DISEASE", 94, 115], ["pulmonary", "ORGAN", 94, 103], ["Cell", "CELL", 116, 120], ["peripheral T cell", "CELL", 193, 210], ["infants", "ORGANISM", 243, 250], ["Children", "SPECIES", 138, 146], ["infants", "SPECIES", 243, 250], ["the acute infection", "PROBLEM", 46, 65], ["prolonged pulmonary dysfunction", "PROBLEM", 84, 115], ["mechanical ventilation", "TREATMENT", 159, 181], ["lower peripheral T cell counts", "PROBLEM", 187, 217], ["mechanical ventilation", "TREATMENT", 265, 287], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["infection", "OBSERVATION", 56, 65], ["prolonged", "OBSERVATION_MODIFIER", 84, 93], ["pulmonary", "ANATOMY", 94, 103], ["dysfunction", "OBSERVATION", 104, 115], ["peripheral", "ANATOMY_MODIFIER", 193, 203], ["T cell counts", "OBSERVATION", 204, 217], ["mechanical ventilation", "OBSERVATION", 265, 287]]], ["These infants demonstrate low T cell proliferative responses and interferon (IFN-g ) production.", [["T cell", "ANATOMY", 30, 36], ["infants", "ORGANISM", 6, 13], ["T cell", "CELL", 30, 36], ["interferon", "GENE_OR_GENE_PRODUCT", 65, 75], ["IFN-g", "GENE_OR_GENE_PRODUCT", 77, 82], ["interferon", "PROTEIN", 65, 75], ["IFN", "PROTEIN", 77, 80], ["infants", "SPECIES", 6, 13], ["low T cell proliferative responses", "PROBLEM", 26, 60], ["interferon (IFN", "TREATMENT", 65, 80], ["low T cell proliferative responses", "OBSERVATION", 26, 60]]], ["IL-12 is required for the initiation of cellular immunity.", [["cellular", "ANATOMY", 40, 48], ["IL-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 40, 48], ["IL-12", "PROTEIN", 0, 5], ["IL", "TREATMENT", 0, 2], ["cellular immunity", "TREATMENT", 40, 57]]], ["The length of time requiring mechanical ventilation has been found to be inversely related to IL-12 production.", [["IL-12", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL", "PROTEIN", 94, 96], ["mechanical ventilation", "TREATMENT", 29, 51], ["length", "OBSERVATION_MODIFIER", 4, 10], ["mechanical ventilation", "OBSERVATION", 29, 51]]], ["The role of Th1/Th2-like cytokine profi les, expressed as IFN-g /IL-4 ratios, is controversial.", [["Th1", "GENE_OR_GENE_PRODUCT", 12, 15], ["Th2", "GENE_OR_GENE_PRODUCT", 16, 19], ["IFN-g", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-4", "GENE_OR_GENE_PRODUCT", 65, 69], ["cytokine", "PROTEIN", 25, 33], ["IFN", "PROTEIN", 58, 61], ["IFN", "TEST", 58, 61], ["g /IL", "TEST", 62, 67], ["Th1", "ANATOMY", 12, 15]]], ["In some studies, these ratios decreased after polyclonal stimulation in hospitalized infants with RSV.", [["RSV", "DISEASE", 98, 101], ["infants", "ORGANISM", 85, 92], ["RSV", "ORGANISM", 98, 101], ["infants", "SPECIES", 85, 92], ["RSV", "SPECIES", 98, 101], ["some studies", "TEST", 3, 15], ["these ratios", "TEST", 17, 29], ["polyclonal stimulation", "TREATMENT", 46, 68], ["RSV", "PROBLEM", 98, 101], ["ratios", "OBSERVATION_MODIFIER", 23, 29], ["decreased", "OBSERVATION_MODIFIER", 30, 39], ["polyclonal stimulation", "OBSERVATION", 46, 68]]], ["However, more recent studies have shown normal ratios following polyclonal stimulation.Cell-Mediated ImmunityNeutrophils are the predominant cell found in the airways of infants with RSV bronchiolitis.", [["Cell", "ANATOMY", 87, 91], ["Neutrophils", "ANATOMY", 109, 120], ["cell", "ANATOMY", 141, 145], ["airways", "ANATOMY", 159, 166], ["RSV bronchiolitis", "DISEASE", 183, 200], ["Cell", "CELL", 87, 91], ["Neutrophils", "CELL", 109, 120], ["cell", "CELL", 141, 145], ["airways", "MULTI-TISSUE_STRUCTURE", 159, 166], ["infants", "ORGANISM", 170, 177], ["RSV", "ORGANISM", 183, 186], ["Neutrophils", "CELL_TYPE", 109, 120], ["infants", "SPECIES", 170, 177], ["RSV", "SPECIES", 183, 186], ["RSV", "SPECIES", 183, 186], ["polyclonal stimulation", "TREATMENT", 64, 86], ["Cell", "TEST", 87, 91], ["RSV bronchiolitis", "PROBLEM", 183, 200], ["normal", "OBSERVATION", 40, 46], ["polyclonal stimulation", "OBSERVATION", 64, 86], ["ImmunityNeutrophils", "OBSERVATION", 101, 120], ["predominant cell", "OBSERVATION", 129, 145], ["airways", "ANATOMY", 159, 166], ["RSV bronchiolitis", "OBSERVATION", 183, 200]]], ["Elevated levels of IL-8 are found in high concentrations in the nasal secretions of infected children and act as a neutrophil chemoattractant.", [["nasal secretions", "ANATOMY", 64, 80], ["neutrophil", "ANATOMY", 115, 125], ["IL-8", "GENE_OR_GENE_PRODUCT", 19, 23], ["nasal secretions", "ORGAN", 64, 80], ["children", "ORGANISM", 93, 101], ["neutrophil", "CELL", 115, 125], ["IL-8", "PROTEIN", 19, 23], ["neutrophil chemoattractant", "PROTEIN", 115, 141], ["children", "SPECIES", 93, 101], ["Elevated levels of IL", "PROBLEM", 0, 21], ["high concentrations in the nasal secretions", "PROBLEM", 37, 80], ["a neutrophil chemoattractant", "TREATMENT", 113, 141], ["high concentrations", "OBSERVATION_MODIFIER", 37, 56], ["nasal", "ANATOMY", 64, 69], ["secretions", "OBSERVATION", 70, 80], ["infected", "OBSERVATION", 84, 92]]], ["Further evidence of cellular induced injury is seen in post-mortem examination where peribronchial lymphocyte infi ltration with bronchial epithelial necrosis is typically present.Clinical Presentation and CourseInfants typically present with tachypnea, rhinorrhea, cough, low-grade fever, irritability, poor feeding and vomiting.", [["cellular", "ANATOMY", 20, 28], ["peribronchial lymphocyte", "ANATOMY", 85, 109], ["bronchial epithelial", "ANATOMY", 129, 149], ["bronchial epithelial necrosis", "DISEASE", 129, 158], ["tachypnea", "DISEASE", 243, 252], ["rhinorrhea", "DISEASE", 254, 264], ["cough", "DISEASE", 266, 271], ["low-grade fever", "DISEASE", 273, 288], ["irritability", "DISEASE", 290, 302], ["vomiting", "DISEASE", 321, 329], ["cellular", "CELL", 20, 28], ["peribronchial lymphocyte", "CELL", 85, 109], ["bronchial epithelial", "TISSUE", 129, 149], ["cellular induced injury", "PROBLEM", 20, 43], ["post-mortem examination", "TEST", 55, 78], ["peribronchial lymphocyte infi ltration", "PROBLEM", 85, 123], ["bronchial epithelial necrosis", "PROBLEM", 129, 158], ["tachypnea", "PROBLEM", 243, 252], ["rhinorrhea", "PROBLEM", 254, 264], ["cough", "PROBLEM", 266, 271], ["low-grade fever", "PROBLEM", 273, 288], ["irritability", "PROBLEM", 290, 302], ["poor feeding", "PROBLEM", 304, 316], ["vomiting", "PROBLEM", 321, 329], ["evidence of", "UNCERTAINTY", 8, 19], ["cellular induced", "OBSERVATION", 20, 36], ["injury", "OBSERVATION", 37, 43], ["peribronchial", "ANATOMY", 85, 98], ["lymphocyte infi", "OBSERVATION", 99, 114], ["bronchial", "ANATOMY", 129, 138], ["epithelial", "ANATOMY_MODIFIER", 139, 149], ["necrosis", "OBSERVATION", 150, 158], ["rhinorrhea", "OBSERVATION", 254, 264], ["cough", "OBSERVATION", 266, 271], ["low-grade", "OBSERVATION_MODIFIER", 273, 282], ["fever", "OBSERVATION", 283, 288]]], ["Respiratory rates greater than 60 breaths per minute are often associated with room air saturations of less than 96%.", [["Respiratory rates", "TEST", 0, 17], ["room air saturations", "TEST", 79, 99], ["greater", "OBSERVATION_MODIFIER", 18, 25]]], ["Infants may also have tachycardia, mild conjunctivitis, otitis media, or pharyngitis.", [["tachycardia", "DISEASE", 22, 33], ["conjunctivitis", "DISEASE", 40, 54], ["otitis media", "DISEASE", 56, 68], ["pharyngitis", "DISEASE", 73, 84], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["tachycardia", "PROBLEM", 22, 33], ["mild conjunctivitis", "PROBLEM", 35, 54], ["otitis media", "PROBLEM", 56, 68], ["pharyngitis", "PROBLEM", 73, 84], ["tachycardia", "OBSERVATION", 22, 33], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["conjunctivitis", "OBSERVATION", 40, 54], ["otitis", "OBSERVATION", 56, 62], ["pharyngitis", "OBSERVATION", 73, 84]]], ["Low-grade fever usually persists for 1-3 days.", [["fever", "DISEASE", 10, 15], ["Low-grade fever", "PROBLEM", 0, 15], ["-grade", "OBSERVATION_MODIFIER", 3, 9], ["fever", "OBSERVATION", 10, 15]]], ["In addition, infants may develop a metabolic acidosis from poor caloric and fl uid intake.Clinical Presentation and CourseApnea often is the fi rst presenting symptom of RSV bronchiolitis in small infants.", [["metabolic acidosis", "DISEASE", 35, 53], ["CourseApnea", "DISEASE", 116, 127], ["bronchiolitis", "DISEASE", 174, 187], ["infants", "ORGANISM", 13, 20], ["RSV", "ORGANISM", 170, 173], ["infants", "ORGANISM", 197, 204], ["infants", "SPECIES", 13, 20], ["infants", "SPECIES", 197, 204], ["RSV", "SPECIES", 170, 173], ["a metabolic acidosis", "PROBLEM", 33, 53], ["RSV bronchiolitis in small infants", "PROBLEM", 170, 204], ["metabolic acidosis", "OBSERVATION", 35, 53], ["RSV bronchiolitis", "OBSERVATION", 170, 187], ["small", "OBSERVATION_MODIFIER", 191, 196]]], ["The etiology of apnea remains unknown; however, is likely related to the immaturity of the respiratory control center in the brainstem.", [["respiratory", "ANATOMY", 91, 102], ["brainstem", "ANATOMY", 125, 134], ["apnea", "DISEASE", 16, 21], ["brainstem", "ORGAN", 125, 134], ["apnea", "PROBLEM", 16, 21], ["the immaturity of the respiratory control center in the brainstem", "PROBLEM", 69, 134], ["apnea", "OBSERVATION", 16, 21], ["likely related to", "UNCERTAINTY", 51, 68], ["immaturity", "OBSERVATION", 73, 83], ["respiratory control", "OBSERVATION", 91, 110], ["brainstem", "ANATOMY", 125, 134]]], ["The incidence of apnea in infants with bronchiolitis is approximately 16-20%.Clinical Presentation and CourseThe heterogeneous nature of RSV induced lung disease can cause atelectasis in some areas and overdistension in others.", [["lung", "ANATOMY", 149, 153], ["apnea", "DISEASE", 17, 22], ["bronchiolitis", "DISEASE", 39, 52], ["RSV", "DISEASE", 137, 140], ["lung disease", "DISEASE", 149, 161], ["atelectasis", "DISEASE", 172, 183], ["overdistension", "DISEASE", 202, 216], ["infants", "ORGANISM", 26, 33], ["RSV", "ORGANISM", 137, 140], ["lung", "ORGAN", 149, 153], ["infants", "SPECIES", 26, 33], ["RSV", "SPECIES", 137, 140], ["apnea", "PROBLEM", 17, 22], ["bronchiolitis", "PROBLEM", 39, 52], ["RSV induced lung disease", "PROBLEM", 137, 161], ["atelectasis", "PROBLEM", 172, 183], ["overdistension in others", "PROBLEM", 202, 226], ["apnea", "OBSERVATION", 17, 22], ["bronchiolitis", "OBSERVATION", 39, 52], ["heterogeneous", "OBSERVATION_MODIFIER", 113, 126], ["RSV", "OBSERVATION", 137, 140], ["lung", "ANATOMY", 149, 153], ["disease", "OBSERVATION", 154, 161], ["atelectasis", "OBSERVATION", 172, 183], ["some", "OBSERVATION_MODIFIER", 187, 191], ["areas", "OBSERVATION_MODIFIER", 192, 197], ["overdistension", "OBSERVATION", 202, 216]]], ["Chest roentgenograms often show hyperinfl ation with fl attening of the diaphragms and patchy or peribronchial infi ltrates.", [["diaphragms", "ANATOMY", 72, 82], ["diaphragms", "MULTI-TISSUE_STRUCTURE", 72, 82], ["Chest roentgenograms", "TEST", 0, 20], ["hyperinfl ation", "PROBLEM", 32, 47], ["fl attening of the diaphragms", "PROBLEM", 53, 82], ["patchy or peribronchial infi ltrates", "PROBLEM", 87, 123], ["hyperinfl ation", "OBSERVATION", 32, 47], ["diaphragms", "ANATOMY", 72, 82], ["patchy", "OBSERVATION_MODIFIER", 87, 93], ["peribronchial", "ANATOMY_MODIFIER", 97, 110]]], ["Atelectasis, especially of the right upper lobe, is often seen.", [["right upper lobe", "ANATOMY", 31, 47], ["Atelectasis", "DISEASE", 0, 11], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 37, 47], ["Atelectasis", "PROBLEM", 0, 11], ["right upper lobe", "ANATOMY", 31, 47]]], ["Infants may have high lung volumes with the functional residual capacity often being twice normal.", [["lung", "ANATOMY", 22, 26], ["Infants", "ORGANISM", 0, 7], ["lung", "ORGAN", 22, 26], ["Infants", "SPECIES", 0, 7], ["high lung volumes", "PROBLEM", 17, 34], ["the functional residual capacity", "PROBLEM", 40, 72], ["high", "OBSERVATION_MODIFIER", 17, 21], ["lung", "ANATOMY", 22, 26], ["volumes", "OBSERVATION", 27, 34], ["residual capacity", "OBSERVATION", 55, 72]]], ["The decrease in dynamic compliance and increase Up regulation of the infl ammatory cascade with release of chemokines and cytokines are contributory to the airway infl ammation and hyperreactivity.", [["airway", "ANATOMY", 156, 162], ["hyperreactivity", "DISEASE", 181, 196], ["infl", "GENE_OR_GENE_PRODUCT", 69, 73], ["chemokines", "PROTEIN", 107, 117], ["cytokines", "PROTEIN", 122, 131], ["The decrease in dynamic compliance", "PROBLEM", 0, 34], ["the infl ammatory cascade", "TREATMENT", 65, 90], ["chemokines and cytokines", "TREATMENT", 107, 131], ["hyperreactivity", "PROBLEM", 181, 196], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["dynamic compliance", "OBSERVATION", 16, 34], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["airway", "ANATOMY", 156, 162], ["hyperreactivity", "OBSERVATION", 181, 196]]], ["C HAPTER 25 \u2022 AC UTE PU LMONARY I N FECTIONS in airway resistance leads to marked increase in work of breathing, often worse during expiration from lower airway obstruction.", [["airway", "ANATOMY", 48, 54], ["lower airway", "ANATOMY", 148, 160], ["airway obstruction", "DISEASE", 154, 172], ["airway", "MULTI-TISSUE_STRUCTURE", 48, 54], ["lower airway", "ORGANISM_SUBDIVISION", 148, 160], ["obstruction", "PATHOLOGICAL_FORMATION", 161, 172], ["airway resistance leads", "PROBLEM", 48, 71], ["marked increase in work of breathing", "PROBLEM", 75, 111], ["lower airway obstruction", "PROBLEM", 148, 172], ["airway", "ANATOMY", 48, 54], ["resistance", "OBSERVATION", 55, 65], ["marked", "OBSERVATION_MODIFIER", 75, 81], ["increase", "OBSERVATION_MODIFIER", 82, 90], ["work of breathing", "OBSERVATION", 94, 111], ["lower", "ANATOMY_MODIFIER", 148, 153], ["airway", "ANATOMY", 154, 160], ["obstruction", "OBSERVATION", 161, 172]]], ["Alterations in gas exchange and hypoxemia are secondary to a ventilation-perfusion mismatch.Clinical Presentation and CourseThe anatomical differences between young infants and older children contribute to the severity of the disease in the young.", [["hypoxemia", "DISEASE", 32, 41], ["infants", "ORGANISM", 165, 172], ["children", "ORGANISM", 183, 191], ["infants", "SPECIES", 165, 172], ["children", "SPECIES", 183, 191], ["Alterations in gas exchange", "PROBLEM", 0, 27], ["hypoxemia", "PROBLEM", 32, 41], ["a ventilation", "TEST", 59, 72], ["the disease", "PROBLEM", 222, 233], ["gas exchange", "OBSERVATION", 15, 27], ["perfusion mismatch", "OBSERVATION", 73, 91], ["anatomical", "OBSERVATION_MODIFIER", 128, 138], ["differences", "OBSERVATION_MODIFIER", 139, 150], ["disease", "OBSERVATION", 226, 233]]], ["Due to the highly compliant cartilaginous chest wall and poor thoracic musculature, the infant's chest wall has diffi culty countering the lung's inherent tendency towards collapse.", [["cartilaginous chest wall", "ANATOMY", 28, 52], ["thoracic musculature", "ANATOMY", 62, 82], ["chest wall", "ANATOMY", 97, 107], ["lung", "ANATOMY", 139, 143], ["chest wall", "MULTI-TISSUE_STRUCTURE", 42, 52], ["thoracic musculature", "MULTI-TISSUE_STRUCTURE", 62, 82], ["chest wall", "MULTI-TISSUE_STRUCTURE", 97, 107], ["lung", "ORGAN", 139, 143], ["infant", "SPECIES", 88, 94], ["the highly compliant cartilaginous chest wall and poor thoracic musculature", "PROBLEM", 7, 82], ["collapse", "PROBLEM", 172, 180], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["compliant", "OBSERVATION", 18, 27], ["cartilaginous", "ANATOMY_MODIFIER", 28, 41], ["chest", "ANATOMY", 42, 47], ["wall", "ANATOMY_MODIFIER", 48, 52], ["poor", "OBSERVATION", 57, 61], ["thoracic musculature", "ANATOMY", 62, 82], ["chest", "ANATOMY", 97, 102], ["wall", "ANATOMY_MODIFIER", 103, 107], ["lung", "ANATOMY", 139, 143], ["collapse", "OBSERVATION", 172, 180]]], ["This leads to a greater propensity of small infants towards atelectasis compared with older children.", [["atelectasis", "DISEASE", 60, 71], ["infants", "ORGANISM", 44, 51], ["children", "ORGANISM", 92, 100], ["infants", "SPECIES", 44, 51], ["children", "SPECIES", 92, 100], ["atelectasis", "PROBLEM", 60, 71], ["greater", "OBSERVATION_MODIFIER", 16, 23], ["propensity", "OBSERVATION_MODIFIER", 24, 34], ["small", "OBSERVATION_MODIFIER", 38, 43], ["atelectasis", "OBSERVATION", 60, 71]]], ["The absence of effective collateral ventilation in infants also contributes to the development of atelectasis and impaired gas exchange.", [["collateral", "ANATOMY", 25, 35], ["atelectasis", "DISEASE", 98, 109], ["collateral", "MULTI-TISSUE_STRUCTURE", 25, 35], ["infants", "ORGANISM", 51, 58], ["infants", "SPECIES", 51, 58], ["effective collateral ventilation", "TREATMENT", 15, 47], ["atelectasis", "PROBLEM", 98, 109], ["impaired gas exchange", "PROBLEM", 114, 135], ["effective", "OBSERVATION_MODIFIER", 15, 24], ["collateral ventilation", "OBSERVATION", 25, 47], ["atelectasis", "OBSERVATION", 98, 109], ["impaired", "OBSERVATION_MODIFIER", 114, 122], ["gas exchange", "OBSERVATION", 123, 135]]], ["Cellular debris in small airways and peribronchial edema increase airways resistance leading to wheezing as the predominant symptom in some infants.Clinical Presentation and CourseDespite the potential for severe impairment in lung function, most hospitalized infants improve within 3-5 days.", [["Cellular debris", "ANATOMY", 0, 15], ["small airways", "ANATOMY", 19, 32], ["peribronchial edema", "ANATOMY", 37, 56], ["airways", "ANATOMY", 66, 73], ["lung", "ANATOMY", 227, 231], ["edema", "DISEASE", 51, 56], ["wheezing", "DISEASE", 96, 104], ["impairment in lung function", "DISEASE", 213, 240], ["airways", "MULTI-TISSUE_STRUCTURE", 25, 32], ["peribronchial edema", "PATHOLOGICAL_FORMATION", 37, 56], ["airways", "MULTI-TISSUE_STRUCTURE", 66, 73], ["infants", "ORGANISM", 140, 147], ["lung", "ORGAN", 227, 231], ["infants", "ORGANISM", 260, 267], ["infants", "SPECIES", 140, 147], ["infants", "SPECIES", 260, 267], ["Cellular debris in small airways", "PROBLEM", 0, 32], ["peribronchial edema", "PROBLEM", 37, 56], ["airways resistance", "PROBLEM", 66, 84], ["wheezing", "PROBLEM", 96, 104], ["the predominant symptom", "PROBLEM", 108, 131], ["severe impairment in lung function", "PROBLEM", 206, 240], ["debris", "OBSERVATION", 9, 15], ["small", "OBSERVATION_MODIFIER", 19, 24], ["airways", "ANATOMY", 25, 32], ["peribronchial", "ANATOMY_MODIFIER", 37, 50], ["edema", "OBSERVATION", 51, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["airways resistance", "OBSERVATION", 66, 84], ["wheezing", "OBSERVATION", 96, 104], ["predominant", "OBSERVATION_MODIFIER", 112, 123], ["symptom", "OBSERVATION_MODIFIER", 124, 131], ["potential for", "UNCERTAINTY", 192, 205], ["severe", "OBSERVATION_MODIFIER", 206, 212], ["impairment", "OBSERVATION", 213, 223], ["lung", "ANATOMY", 227, 231], ["function", "OBSERVATION", 232, 240]]], ["Typically, by 2 weeks, they have normal respiratory rates, oxygenation, and ventilation.", [["respiratory", "ANATOMY", 40, 51], ["ventilation", "TREATMENT", 76, 87], ["respiratory rates", "OBSERVATION", 40, 57]]], ["Chest radiographs usually normalize by day 9.", [["Chest radiographs", "TEST", 0, 17]]], ["However, about 20% of infants will have a protracted course, with some mild respiratory symptoms persisting for months.", [["respiratory", "ANATOMY", 76, 87], ["respiratory symptoms", "DISEASE", 76, 96], ["infants", "ORGANISM", 22, 29], ["infants", "SPECIES", 22, 29], ["a protracted course", "TREATMENT", 40, 59], ["some mild respiratory symptoms", "PROBLEM", 66, 96], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["respiratory symptoms", "OBSERVATION", 76, 96]]], ["Viral respiratory infections have been linked to the development of asthma later in childhood.", [["respiratory", "ANATOMY", 6, 17], ["Viral respiratory infections", "DISEASE", 0, 28], ["asthma", "DISEASE", 68, 74], ["Viral respiratory infections", "PROBLEM", 0, 28], ["asthma", "PROBLEM", 68, 74], ["respiratory", "ANATOMY", 6, 17], ["infections", "OBSERVATION", 18, 28], ["asthma", "OBSERVATION", 68, 74]]], ["The Tucson Children's Respiratory Study group prospectively followed for 13 years, 880 infants who had bronchiolitis and found an increased risk for subsequent wheezing episodes.High Risk PopulationsSome infants are at an increased risk for severe RSV disease such as those with chronic lung disease due to prematurity (bronchopulmonary dysplasia), cystic fi brosis, congenital heart disease, and immunodefi ciencies.", [["lung", "ANATOMY", 287, 291], ["bronchopulmonary dysplasia", "ANATOMY", 320, 346], ["cystic", "ANATOMY", 349, 355], ["heart", "ANATOMY", 378, 383], ["bronchiolitis", "DISEASE", 103, 116], ["wheezing", "DISEASE", 160, 168], ["RSV disease", "DISEASE", 248, 259], ["chronic lung disease", "DISEASE", 279, 299], ["prematurity", "DISEASE", 307, 318], ["bronchopulmonary dysplasia", "DISEASE", 320, 346], ["cystic fi brosis", "DISEASE", 349, 365], ["congenital heart disease", "DISEASE", 367, 391], ["infants", "ORGANISM", 87, 94], ["infants", "ORGANISM", 204, 211], ["RSV", "ORGANISM", 248, 251], ["lung", "ORGAN", 287, 291], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 320, 346], ["heart", "ORGAN", 378, 383], ["Children", "SPECIES", 11, 19], ["infants", "SPECIES", 87, 94], ["infants", "SPECIES", 204, 211], ["RSV", "SPECIES", 248, 251], ["bronchiolitis", "PROBLEM", 103, 116], ["subsequent wheezing episodes", "PROBLEM", 149, 177], ["High Risk Populations", "PROBLEM", 178, 199], ["severe RSV disease", "PROBLEM", 241, 259], ["chronic lung disease", "PROBLEM", 279, 299], ["prematurity", "PROBLEM", 307, 318], ["bronchopulmonary dysplasia", "PROBLEM", 320, 346], ["cystic fi brosis", "PROBLEM", 349, 365], ["congenital heart disease", "PROBLEM", 367, 391], ["immunodefi ciencies", "PROBLEM", 397, 416], ["bronchiolitis", "OBSERVATION", 103, 116], ["increased", "OBSERVATION_MODIFIER", 130, 139], ["wheezing", "OBSERVATION", 160, 168], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["RSV", "OBSERVATION", 248, 251], ["chronic", "OBSERVATION_MODIFIER", 279, 286], ["lung", "ANATOMY", 287, 291], ["disease", "OBSERVATION", 292, 299], ["prematurity", "OBSERVATION", 307, 318], ["bronchopulmonary", "ANATOMY", 320, 336], ["dysplasia", "OBSERVATION", 337, 346], ["cystic", "OBSERVATION_MODIFIER", 349, 355], ["fi brosis", "OBSERVATION", 356, 365], ["congenital", "OBSERVATION_MODIFIER", 367, 377], ["heart", "ANATOMY", 378, 383], ["disease", "OBSERVATION", 384, 391]]], ["In children with cystic fi brosis, RSV accounted for 18% of symptomatic infections, 33% of hospitalizations for infants less than 1 year, and 43% of infants requiring mechanical ventilation.", [["cystic fi brosis", "DISEASE", 17, 33], ["RSV", "DISEASE", 35, 38], ["infections", "DISEASE", 72, 82], ["children", "ORGANISM", 3, 11], ["RSV", "ORGANISM", 35, 38], ["infants", "ORGANISM", 112, 119], ["infants", "ORGANISM", 149, 156], ["children", "SPECIES", 3, 11], ["infants", "SPECIES", 112, 119], ["infants", "SPECIES", 149, 156], ["RSV", "SPECIES", 35, 38], ["cystic fi brosis", "PROBLEM", 17, 33], ["RSV", "PROBLEM", 35, 38], ["symptomatic infections", "PROBLEM", 60, 82], ["mechanical ventilation", "TREATMENT", 167, 189], ["cystic", "OBSERVATION", 17, 23], ["brosis", "OBSERVATION", 27, 33], ["symptomatic", "OBSERVATION_MODIFIER", 60, 71], ["infections", "OBSERVATION", 72, 82], ["mechanical ventilation", "OBSERVATION", 167, 189]]], ["In a study of hospitalized infants with congenital heart disease infected with RSV, 33% required intensive care, 19% received mechanical ventilation, and 3.4% died.", [["heart", "ANATOMY", 51, 56], ["congenital heart disease infected", "DISEASE", 40, 73], ["RSV", "DISEASE", 79, 82], ["infants", "ORGANISM", 27, 34], ["heart", "ORGAN", 51, 56], ["RSV", "ORGANISM", 79, 82], ["infants", "SPECIES", 27, 34], ["RSV", "SPECIES", 79, 82], ["congenital heart disease", "PROBLEM", 40, 64], ["RSV", "PROBLEM", 79, 82], ["mechanical ventilation", "TREATMENT", 126, 148], ["heart", "ANATOMY", 51, 56], ["disease", "OBSERVATION", 57, 64]]], ["Children having undergone hematopoietic stem cell transplants who develop RSV infections have an extremely high mortality of 60-80% despite mechanical ventilation and antiviral therapy.", [["hematopoietic stem cell", "ANATOMY", 26, 49], ["RSV infections", "DISEASE", 74, 88], ["Children", "ORGANISM", 0, 8], ["hematopoietic stem cell", "CELL", 26, 49], ["RSV", "ORGANISM", 74, 77], ["Children", "SPECIES", 0, 8], ["RSV", "SPECIES", 74, 77], ["hematopoietic stem cell transplants", "TREATMENT", 26, 61], ["RSV infections", "PROBLEM", 74, 88], ["mechanical ventilation", "TREATMENT", 140, 162], ["antiviral therapy", "TREATMENT", 167, 184], ["hematopoietic stem cell transplants", "OBSERVATION", 26, 61], ["RSV infections", "OBSERVATION", 74, 88], ["extremely", "OBSERVATION_MODIFIER", 97, 106], ["high", "OBSERVATION_MODIFIER", 107, 111], ["mechanical ventilation", "OBSERVATION", 140, 162], ["antiviral therapy", "OBSERVATION", 167, 184]]], ["Environmental factors such as crowding, passive exposure to tobacco smoke, and lack of breast-feeding are associated with the development of severe disease.", [["breast", "ANATOMY", 87, 93], ["smoke", "CHEMICAL", 68, 73], ["tobacco", "ORGANISM", 60, 67], ["breast", "ORGANISM_SUBDIVISION", 87, 93], ["tobacco", "SPECIES", 60, 67], ["Environmental factors", "PROBLEM", 0, 21], ["severe disease", "PROBLEM", 141, 155], ["breast", "ANATOMY", 87, 93], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["disease", "OBSERVATION", 148, 155]]], ["Compared to national averages, Native American and Alaskan children younger than 1 year of age have higher rates of infections.Parainfl uenzaThere are three subtypes of human parainfl uenza viruses.", [["infections", "DISEASE", 116, 126], ["children", "ORGANISM", 59, 67], ["human", "ORGANISM", 169, 174], ["parainfl uenza viruses", "ORGANISM", 175, 197], ["children", "SPECIES", 59, 67], ["human", "SPECIES", 169, 174], ["human parainfl uenza viruses", "SPECIES", 169, 197], ["higher rates of infections", "PROBLEM", 100, 126], ["human parainfl uenza viruses", "PROBLEM", 169, 197], ["infections", "OBSERVATION", 116, 126], ["three subtypes", "OBSERVATION_MODIFIER", 151, 165], ["parainfl uenza viruses", "OBSERVATION", 175, 197]]], ["HPIV-3 is most frequently isolated from children with bronchiolitis, while PIV-1 and PIV-2 most commonly cause croup.", [["bronchiolitis", "DISEASE", 54, 67], ["croup", "DISEASE", 111, 116], ["HPIV-3", "GENE_OR_GENE_PRODUCT", 0, 6], ["children", "ORGANISM", 40, 48], ["PIV-1", "ORGANISM", 75, 80], ["PIV-2", "ORGANISM", 85, 90], ["children", "SPECIES", 40, 48], ["HPIV-3", "SPECIES", 0, 6], ["PIV-1", "SPECIES", 75, 80], ["bronchiolitis", "PROBLEM", 54, 67], ["PIV", "TREATMENT", 75, 78], ["PIV", "TREATMENT", 85, 88], ["croup", "PROBLEM", 111, 116], ["bronchiolitis", "OBSERVATION", 54, 67], ["croup", "OBSERVATION", 111, 116]]], ["Similar to RSV, both cell-mediated hyper-responsiveness to viral antigen and virus-specifi c IgE responses are observed in children with parainfl uenza bronchiolitis.", [["cell", "ANATOMY", 21, 25], ["bronchiolitis", "DISEASE", 152, 165], ["RSV", "ORGANISM", 11, 14], ["cell", "CELL", 21, 25], ["specifi c IgE", "GENE_OR_GENE_PRODUCT", 83, 96], ["children", "ORGANISM", 123, 131], ["viral antigen", "PROTEIN", 59, 72], ["IgE", "PROTEIN", 93, 96], ["children", "SPECIES", 123, 131], ["RSV", "SPECIES", 11, 14], ["RSV", "PROBLEM", 11, 14], ["hyper-responsiveness", "PROBLEM", 35, 55], ["viral antigen", "TEST", 59, 72], ["virus", "PROBLEM", 77, 82], ["parainfl uenza bronchiolitis", "PROBLEM", 137, 165], ["RSV", "OBSERVATION", 11, 14], ["hyper", "OBSERVATION", 35, 40], ["uenza", "ANATOMY", 146, 151], ["bronchiolitis", "OBSERVATION", 152, 165]]], ["Upper airway edema with concomitant obstructive symptoms may be present.", [["airway", "ANATOMY", 6, 12], ["airway edema", "DISEASE", 6, 18], ["airway edema", "PATHOLOGICAL_FORMATION", 6, 18], ["Upper airway edema", "PROBLEM", 0, 18], ["concomitant obstructive symptoms", "PROBLEM", 24, 56], ["airway", "ANATOMY", 6, 12], ["edema", "OBSERVATION", 13, 18], ["concomitant", "OBSERVATION_MODIFIER", 24, 35], ["obstructive", "OBSERVATION", 36, 47], ["may be", "UNCERTAINTY", 57, 63]]], ["Children that are infected with parainfl uenza have a signifi cant likelihood of developing asthma later in life.MetapneumovirusesThe human metapneumoviruses (hMPV) are a group of RNA viruses of the Paramyxoviridae family identifi ed in humans in 2001. hMPV appears to be the second most common cause of bronchiolitis in children throughout the world.", [["asthma", "DISEASE", 92, 98], ["hMPV", "DISEASE", 253, 257], ["bronchiolitis", "DISEASE", 304, 317], ["Children", "ORGANISM", 0, 8], ["Metapneumoviruses", "GENE_OR_GENE_PRODUCT", 113, 130], ["human", "ORGANISM", 134, 139], ["metapneumoviruses", "GENE_OR_GENE_PRODUCT", 140, 157], ["hMPV", "ORGANISM", 159, 163], ["humans", "ORGANISM", 237, 243], ["hMPV", "ORGANISM", 253, 257], ["children", "ORGANISM", 321, 329], ["Children", "SPECIES", 0, 8], ["human", "SPECIES", 134, 139], ["humans", "SPECIES", 237, 243], ["children", "SPECIES", 321, 329], ["human", "SPECIES", 134, 139], ["hMPV", "SPECIES", 159, 163], ["humans", "SPECIES", 237, 243], ["hMPV", "SPECIES", 253, 257], ["developing asthma", "PROBLEM", 81, 98], ["hMPV", "PROBLEM", 253, 257], ["bronchiolitis", "PROBLEM", 304, 317], ["infected", "OBSERVATION", 18, 26], ["asthma", "OBSERVATION", 92, 98], ["bronchiolitis", "OBSERVATION", 304, 317]]], ["The majority of children are born with maternal hMPV specifi c IgG which wanes to around 25% by 6-12 months of age.", [["children", "ORGANISM", 16, 24], ["hMPV", "ORGANISM", 48, 52], ["specifi c IgG", "GENE_OR_GENE_PRODUCT", 53, 66], ["maternal hMPV specifi c IgG", "PROTEIN", 39, 66], ["children", "SPECIES", 16, 24], ["hMPV", "SPECIES", 48, 52], ["hMPV", "SPECIES", 48, 52], ["maternal hMPV specifi c IgG", "TREATMENT", 39, 66]]], ["By age fi ve, essentially 100% of children have been exposed to hMPV and will have neutralizing antibody to hMPV.", [["hMPV", "DISEASE", 64, 68], ["hMPV", "DISEASE", 108, 112], ["children", "ORGANISM", 34, 42], ["hMPV", "ORGANISM", 64, 68], ["hMPV", "ORGANISM", 108, 112], ["neutralizing antibody", "PROTEIN", 83, 104], ["children", "SPECIES", 34, 42], ["hMPV", "SPECIES", 64, 68], ["hMPV", "SPECIES", 108, 112], ["hMPV", "PROBLEM", 64, 68], ["neutralizing antibody", "TREATMENT", 83, 104], ["hMPV", "PROBLEM", 108, 112]]], ["There are two subgroups, A and B, with group A having more severe clinical symptoms.", [["more severe clinical symptoms", "PROBLEM", 54, 83], ["two", "OBSERVATION_MODIFIER", 10, 13], ["subgroups", "OBSERVATION_MODIFIER", 14, 23]]], ["Clinical presentation of children with this virus is similar to RSV.", [["RSV", "DISEASE", 64, 67], ["children", "ORGANISM", 25, 33], ["RSV", "ORGANISM", 64, 67], ["children", "SPECIES", 25, 33], ["RSV", "SPECIES", 64, 67], ["this virus", "PROBLEM", 39, 49], ["RSV", "PROBLEM", 64, 67]]], ["The pulmonary infl ammation generally peaks on day 5 which includes interstitial edema and infl ammatory cell infi ltrates of the bronchioles and alveoli.", [["pulmonary", "ANATOMY", 4, 13], ["interstitial edema", "ANATOMY", 68, 86], ["infl ammatory cell", "ANATOMY", 91, 109], ["bronchioles", "ANATOMY", 130, 141], ["alveoli", "ANATOMY", 146, 153], ["interstitial edema", "DISEASE", 68, 86], ["pulmonary", "ORGAN", 4, 13], ["interstitial edema", "PATHOLOGICAL_FORMATION", 68, 86], ["infl ammatory cell", "CELL", 91, 109], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 130, 141], ["alveoli", "MULTI-TISSUE_STRUCTURE", 146, 153], ["The pulmonary infl ammation", "TEST", 0, 27], ["interstitial edema", "PROBLEM", 68, 86], ["infl ammatory cell", "PROBLEM", 91, 109], ["pulmonary", "ANATOMY", 4, 13], ["peaks", "OBSERVATION_MODIFIER", 38, 43], ["interstitial", "ANATOMY_MODIFIER", 68, 80], ["edema", "OBSERVATION", 81, 86], ["ammatory cell infi", "OBSERVATION", 96, 114], ["bronchioles", "ANATOMY", 130, 141], ["alveoli", "ANATOMY_MODIFIER", 146, 153]]], ["These infl ammatory changes can persist for up to 21 days.", [["These infl ammatory changes", "PROBLEM", 0, 27]]], ["About half of infected children are 0-12 months of age, and infection is primarily in the winter months.Human BocavirusHuman bocavirus (HBoV) was recently discovered in 2003.", [["infection", "DISEASE", 60, 69], ["children", "ORGANISM", 23, 31], ["Human", "ORGANISM", 104, 109], ["BocavirusHuman bocavirus", "ORGANISM", 110, 134], ["HBoV", "ORGANISM", 136, 140], ["children", "SPECIES", 23, 31], ["Human", "SPECIES", 104, 109], ["Human BocavirusHuman bocavirus", "SPECIES", 104, 134], ["HBoV", "SPECIES", 136, 140], ["infection", "PROBLEM", 60, 69], ["Human BocavirusHuman bocavirus (HBoV", "PROBLEM", 104, 140], ["infected", "OBSERVATION", 14, 22], ["infection", "OBSERVATION", 60, 69]]], ["With amino acid sequencing, this new member of the Parvoviridae family was found to be closely related to the bovine parvovirus and the canine minute virus, hence the name bocavirus (BO for Bovine and CA for Canine).", [["amino acid", "CHEMICAL", 5, 15], ["amino acid", "CHEMICAL", 5, 15], ["amino acid", "AMINO_ACID", 5, 15], ["Parvoviridae", "GENE_OR_GENE_PRODUCT", 51, 63], ["bovine", "ORGANISM", 110, 116], ["parvovirus", "ORGANISM", 117, 127], ["canine minute virus", "ORGANISM", 136, 155], ["Bovine", "ORGANISM", 190, 196], ["Canine", "ORGANISM", 208, 214], ["Parvoviridae family", "PROTEIN", 51, 70], ["bovine", "SPECIES", 110, 116], ["canine", "SPECIES", 136, 142], ["Bovine", "SPECIES", 190, 196], ["bovine parvovirus", "SPECIES", 110, 127], ["canine minute virus", "SPECIES", 136, 155], ["Bovine", "SPECIES", 190, 196], ["amino acid sequencing", "TREATMENT", 5, 26], ["the bovine parvovirus", "PROBLEM", 106, 127], ["the canine minute virus", "PROBLEM", 132, 155], ["Bovine and CA for Canine)", "TREATMENT", 190, 215]]], ["Detection of the HBoV from the respiratory tract in symptomatic children and its absence of detection in non-symptomatic controls strongly suggest the virus to have a role in respiratory infections in children.", [["respiratory tract", "ANATOMY", 31, 48], ["respiratory", "ANATOMY", 175, 186], ["HBoV from the respiratory tract", "DISEASE", 17, 48], ["respiratory infections", "DISEASE", 175, 197], ["HBoV", "ORGANISM", 17, 21], ["respiratory tract", "ORGANISM_SUBDIVISION", 31, 48], ["children", "ORGANISM", 64, 72], ["children", "ORGANISM", 201, 209], ["children", "SPECIES", 64, 72], ["children", "SPECIES", 201, 209], ["HBoV", "SPECIES", 17, 21], ["the HBoV", "PROBLEM", 13, 21], ["the respiratory tract", "PROBLEM", 27, 48], ["non-symptomatic controls", "PROBLEM", 105, 129], ["the virus", "PROBLEM", 147, 156], ["respiratory infections", "PROBLEM", 175, 197], ["HBoV", "OBSERVATION", 17, 21], ["respiratory tract", "ANATOMY", 31, 48], ["respiratory", "ANATOMY", 175, 186], ["infections", "OBSERVATION", 187, 197]]], ["Co-infection is commonly described in up to 60% of samples.", [["samples", "ANATOMY", 51, 58], ["Co-infection", "DISEASE", 0, 12], ["samples", "CANCER", 51, 58], ["Co-infection", "PROBLEM", 0, 12]]], ["It remains unclear if HBoV is a primary pathogen or acts to exacerbate other viral illnesses.", [["viral illnesses", "DISEASE", 77, 92], ["HBoV", "ORGANISM", 22, 26], ["HBoV", "SPECIES", 22, 26], ["HBoV", "PROBLEM", 22, 26], ["a primary pathogen", "PROBLEM", 30, 48], ["other viral illnesses", "PROBLEM", 71, 92]]], ["The pathogenesis of HBoV has not been well described, but with the high occurrence of wheezing and lower respiratory tract symptoms in children infected with the virus, it is speculated that this virus may be a signifi cant contributor to asthma exacerbations.", [["lower respiratory tract", "ANATOMY", 99, 122], ["HBoV", "DISEASE", 20, 24], ["wheezing", "DISEASE", 86, 94], ["respiratory tract symptoms", "DISEASE", 105, 131], ["asthma", "DISEASE", 239, 245], ["HBoV", "ORGANISM", 20, 24], ["lower", "ORGANISM_SUBDIVISION", 99, 104], ["respiratory tract", "ORGANISM_SUBDIVISION", 105, 122], ["children", "ORGANISM", 135, 143], ["children", "SPECIES", 135, 143], ["HBoV", "SPECIES", 20, 24], ["HBoV", "PROBLEM", 20, 24], ["wheezing", "PROBLEM", 86, 94], ["lower respiratory tract symptoms", "PROBLEM", 99, 131], ["the virus", "PROBLEM", 158, 167], ["this virus", "PROBLEM", 191, 201], ["asthma exacerbations", "PROBLEM", 239, 259], ["HBoV", "OBSERVATION", 20, 24], ["wheezing", "OBSERVATION", 86, 94], ["lower", "ANATOMY_MODIFIER", 99, 104], ["respiratory tract", "ANATOMY", 105, 122], ["asthma", "OBSERVATION", 239, 245]]], ["The majority of infected children have rhinorrhea, cough, and wheezing, however, diarrhea has been reported in up to 25% of these children.", [["rhinorrhea", "DISEASE", 39, 49], ["cough", "DISEASE", 51, 56], ["wheezing", "DISEASE", 62, 70], ["diarrhea", "DISEASE", 81, 89], ["children", "ORGANISM", 25, 33], ["children", "ORGANISM", 130, 138], ["children", "SPECIES", 25, 33], ["children", "SPECIES", 130, 138], ["rhinorrhea", "PROBLEM", 39, 49], ["cough", "PROBLEM", 51, 56], ["wheezing", "PROBLEM", 62, 70], ["diarrhea", "PROBLEM", 81, 89], ["infected", "OBSERVATION_MODIFIER", 16, 24], ["rhinorrhea", "OBSERVATION", 39, 49], ["cough", "OBSERVATION", 51, 56], ["wheezing", "OBSERVATION", 62, 70]]], ["In children with high viral loads, HBoV has been detected in the serum suggesting the potential for disease beyond the respiratory tract.Infl uenza A and BBoth infl uenza A, including novel infl uenza strains such as H1N1, and infl uenza B can cause a clinical picture consistent with bronchiolitis in the small infant.", [["serum", "ANATOMY", 65, 70], ["respiratory tract", "ANATOMY", 119, 136], ["bronchiolitis", "DISEASE", 285, 298], ["children", "ORGANISM", 3, 11], ["HBoV", "ORGANISM", 35, 39], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["respiratory tract", "ORGANISM_SUBDIVISION", 119, 136], ["BBoth infl uenza A", "CANCER", 154, 172], ["infl uenza strains", "ORGANISM", 190, 208], ["infl uenza B", "CELL", 227, 239], ["infant", "ORGANISM", 312, 318], ["children", "SPECIES", 3, 11], ["infant", "SPECIES", 312, 318], ["HBoV", "SPECIES", 35, 39], ["BBoth infl uenza A", "SPECIES", 154, 172], ["infl uenza B", "SPECIES", 227, 239], ["high viral loads", "PROBLEM", 17, 33], ["HBoV", "PROBLEM", 35, 39], ["disease beyond the respiratory tract", "PROBLEM", 100, 136], ["novel infl uenza strains", "PROBLEM", 184, 208], ["H1N1", "PROBLEM", 217, 221], ["a clinical picture", "PROBLEM", 250, 268], ["bronchiolitis in the small infant", "PROBLEM", 285, 318], ["viral loads", "OBSERVATION", 22, 33], ["HBoV", "OBSERVATION", 35, 39], ["suggesting the potential for", "UNCERTAINTY", 71, 99], ["disease", "OBSERVATION", 100, 107], ["respiratory tract", "ANATOMY", 119, 136], ["consistent with", "UNCERTAINTY", 269, 284], ["bronchiolitis", "OBSERVATION", 285, 298], ["small", "OBSERVATION_MODIFIER", 306, 311]]], ["These viruses may cause severe multisystem disease and are discussed in greater detail in the viral pneumonia section.DiagnosisRapid diagnostic assays are available for early detection of many viruses.", [["multisystem disease", "DISEASE", 31, 50], ["pneumonia", "DISEASE", 100, 109], ["These viruses", "PROBLEM", 0, 13], ["severe multisystem disease", "PROBLEM", 24, 50], ["the viral pneumonia section", "PROBLEM", 90, 117], ["DiagnosisRapid diagnostic assays", "TEST", 118, 150], ["many viruses", "PROBLEM", 188, 200], ["viruses", "OBSERVATION", 6, 13], ["may cause", "UNCERTAINTY", 14, 23], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["multisystem", "OBSERVATION_MODIFIER", 31, 42], ["disease", "OBSERVATION", 43, 50], ["viral", "OBSERVATION_MODIFIER", 94, 99], ["pneumonia", "OBSERVATION", 100, 109], ["viruses", "OBSERVATION", 193, 200]]], ["The older assays are antigen-based and include indirect immunofl uorescence/direct immunofl uorescence (IFA/ DFA), enzyme immunoassay (EIA), optical immunoassay (OIA), and neuraminidase activity assays.", [["neuraminidase", "PROTEIN", 172, 185], ["The older assays", "TEST", 0, 16], ["IFA/ DFA", "TEST", 104, 112], ["enzyme immunoassay", "TEST", 115, 133], ["EIA", "TEST", 135, 138], ["optical immunoassay", "TEST", 141, 160], ["neuraminidase activity assays", "TEST", 172, 201]]], ["Molecular assays are becoming the new \"gold standard\" for respiratory virus detection -replacing tissue culture that may take days.", [["tissue culture", "ANATOMY", 97, 111], ["tissue", "TISSUE", 97, 103], ["Molecular assays", "TEST", 0, 16], ["respiratory virus detection", "PROBLEM", 58, 85], ["tissue culture", "TEST", 97, 111]]], ["The published sensitivities and specifi cities approach 100% when compared to tissue culture or antigen assay.", [["tissue", "ANATOMY", 78, 84], ["tissue", "TISSUE", 78, 84], ["The published sensitivities", "TEST", 0, 27], ["specifi cities approach", "TREATMENT", 32, 55], ["tissue culture", "TEST", 78, 92], ["antigen assay", "TEST", 96, 109]]], ["These assays generally use polymerase chain reaction (PCR) amplifi cation.", [["These assays", "TEST", 0, 12], ["polymerase chain reaction (PCR) amplifi cation", "TREATMENT", 27, 73]]], ["Signifi cant advancements in these assays are being made to simplify the performance of the assay and decrease the required time.", [["these assays", "TEST", 29, 41], ["the assay", "TEST", 88, 97]]], ["The most important cause of false negative test results remains poor specimen handling or inadequate sample collection.", [["specimen", "ANATOMY", 69, 77], ["sample", "ANATOMY", 101, 107], ["false negative test", "PROBLEM", 28, 47], ["poor specimen handling", "PROBLEM", 64, 86], ["inadequate sample collection", "PROBLEM", 90, 118]]], ["Other than aiding with cohorting of hospitalized patients, serologic detection of respiratory viruses is rarely clinically useful.TreatmentRegardless of the viral etiology of bronchiolitis, supportive care remains the mainstay of treatment.", [["respiratory viruses", "DISEASE", 82, 101], ["bronchiolitis", "DISEASE", 175, 188], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["serologic detection", "TEST", 59, 78], ["respiratory viruses", "PROBLEM", 82, 101], ["Treatment", "TREATMENT", 130, 139], ["bronchiolitis", "PROBLEM", 175, 188], ["supportive care", "TREATMENT", 190, 205], ["treatment", "TREATMENT", 230, 239], ["respiratory viruses", "OBSERVATION", 82, 101], ["viral", "OBSERVATION_MODIFIER", 157, 162], ["bronchiolitis", "OBSERVATION", 175, 188]]], ["Supplemental humidifi ed oxygen is frequently needed.", [["humidifi", "CHEMICAL", 13, 21], ["oxygen", "CHEMICAL", 25, 31], ["humidifi", "CHEMICAL", 13, 21], ["oxygen", "CHEMICAL", 25, 31], ["humidifi ed oxygen", "SIMPLE_CHEMICAL", 13, 31], ["Supplemental humidifi ed oxygen", "TREATMENT", 0, 31]]], ["Due to many infants being obligate nasal breathers, frequent nasal suctioning may be benefi cial to maintain an unobstructed upper airway.", [["nasal", "ANATOMY", 35, 40], ["nasal", "ANATOMY", 61, 66], ["upper airway", "ANATOMY", 125, 137], ["infants", "ORGANISM", 12, 19], ["nasal", "ORGANISM_SUBDIVISION", 35, 40], ["nasal", "ORGANISM_SUBDIVISION", 61, 66], ["upper airway", "MULTI-TISSUE_STRUCTURE", 125, 137], ["infants", "SPECIES", 12, 19], ["obligate nasal breathers", "PROBLEM", 26, 50], ["frequent nasal suctioning", "TREATMENT", 52, 77], ["benefi cial", "TREATMENT", 85, 96], ["unobstructed", "OBSERVATION", 112, 124], ["upper", "ANATOMY_MODIFIER", 125, 130], ["airway", "ANATOMY", 131, 137]]], ["The affected infant or child is often unable to take adequate fl uids complicated by increased insensible losses from the respiratory tract; hence, intravenous fl uids may be required.", [["respiratory tract", "ANATOMY", 122, 139], ["intravenous", "ANATOMY", 148, 159], ["infant", "ORGANISM", 13, 19], ["child", "ORGANISM", 23, 28], ["respiratory tract", "ORGANISM_SUBDIVISION", 122, 139], ["intravenous fl uids", "SIMPLE_CHEMICAL", 148, 167], ["infant", "SPECIES", 13, 19], ["child", "SPECIES", 23, 28], ["increased insensible losses from the respiratory tract", "PROBLEM", 85, 139], ["intravenous fl uids", "TREATMENT", 148, 167], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["insensible losses", "OBSERVATION", 95, 112], ["respiratory tract", "ANATOMY", 122, 139]]], ["Infants and children with severe respiratory distress should be kept NPO in the event respiratory failure ensues and endotracheal intubation is required.", [["respiratory", "ANATOMY", 33, 44], ["respiratory", "ANATOMY", 86, 97], ["endotracheal", "ANATOMY", 117, 129], ["respiratory distress", "DISEASE", 33, 53], ["respiratory failure", "DISEASE", 86, 105], ["Infants", "ORGANISM", 0, 7], ["children", "ORGANISM", 12, 20], ["Infants", "SPECIES", 0, 7], ["children", "SPECIES", 12, 20], ["severe respiratory distress", "PROBLEM", 26, 53], ["NPO", "TREATMENT", 69, 72], ["respiratory failure", "PROBLEM", 86, 105], ["endotracheal intubation", "TREATMENT", 117, 140], ["respiratory", "ANATOMY", 33, 44], ["distress", "OBSERVATION", 45, 53], ["respiratory", "ANATOMY", 86, 97], ["failure", "OBSERVATION", 98, 105]]], ["Antibiotics are not routinely indicated in previously healthy children infected with RSV.", [["RSV", "DISEASE", 85, 88], ["children", "ORGANISM", 62, 70], ["RSV", "ORGANISM", 85, 88], ["children", "SPECIES", 62, 70], ["RSV", "SPECIES", 85, 88], ["Antibiotics", "TREATMENT", 0, 11], ["RSV", "PROBLEM", 85, 88]]], ["Progressive disease, leukocytosis, persistent fever, consolidation on radiograph or systemic toxicity should prompt an evaluation of bacterial co-infection and the use of empiric antibiotics.TreatmentHigh risk patients often require close monitoring and care in an intensive care unit.", [["leukocytosis", "DISEASE", 21, 33], ["fever", "DISEASE", 46, 51], ["toxicity", "DISEASE", 93, 101], ["bacterial co-infection", "DISEASE", 133, 155], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 210, 218], ["Progressive disease", "PROBLEM", 0, 19], ["leukocytosis", "PROBLEM", 21, 33], ["persistent fever", "PROBLEM", 35, 51], ["consolidation", "PROBLEM", 53, 66], ["radiograph", "TEST", 70, 80], ["systemic toxicity", "PROBLEM", 84, 101], ["an evaluation", "TEST", 116, 129], ["bacterial co-infection", "PROBLEM", 133, 155], ["empiric antibiotics", "TREATMENT", 171, 190], ["close monitoring", "TEST", 233, 249], ["disease", "OBSERVATION", 12, 19], ["leukocytosis", "OBSERVATION_MODIFIER", 21, 33], ["persistent", "OBSERVATION_MODIFIER", 35, 45], ["fever", "OBSERVATION", 46, 51], ["consolidation", "OBSERVATION", 53, 66], ["bacterial", "OBSERVATION_MODIFIER", 133, 142], ["co-infection", "OBSERVATION", 143, 155]]], ["These include infants less than 6 weeks of age or infants with a history of prematurity, congenital heart disease, bronchopulmonary dysplasia, immunodefi ciency or neurologic disease.", [["heart", "ANATOMY", 100, 105], ["bronchopulmonary dysplasia", "ANATOMY", 115, 141], ["neurologic", "ANATOMY", 164, 174], ["prematurity", "DISEASE", 76, 87], ["congenital heart disease", "DISEASE", 89, 113], ["bronchopulmonary dysplasia", "DISEASE", 115, 141], ["immunodefi ciency", "DISEASE", 143, 160], ["neurologic disease", "DISEASE", 164, 182], ["infants", "ORGANISM", 14, 21], ["infants", "ORGANISM", 50, 57], ["heart", "ORGAN", 100, 105], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 115, 141], ["infants", "SPECIES", 14, 21], ["infants", "SPECIES", 50, 57], ["prematurity", "PROBLEM", 76, 87], ["congenital heart disease", "PROBLEM", 89, 113], ["bronchopulmonary dysplasia", "PROBLEM", 115, 141], ["immunodefi ciency", "PROBLEM", 143, 160], ["neurologic disease", "PROBLEM", 164, 182], ["prematurity", "OBSERVATION", 76, 87], ["heart", "ANATOMY", 100, 105], ["disease", "OBSERVATION", 106, 113], ["bronchopulmonary", "ANATOMY", 115, 131], ["dysplasia", "OBSERVATION", 132, 141], ["neurologic disease", "OBSERVATION", 164, 182]]], ["Infants with RSV bronchiolitis typically have a combination of hyperinfl ation, pulmonary infi ltrates, Supportive therapy is the mainstay of treatment for bronchiolitis.", [["pulmonary", "ANATOMY", 80, 89], ["RSV bronchiolitis", "DISEASE", 13, 30], ["bronchiolitis", "DISEASE", 156, 169], ["Infants", "ORGANISM", 0, 7], ["RSV", "ORGANISM", 13, 16], ["pulmonary", "ORGAN", 80, 89], ["Infants", "SPECIES", 0, 7], ["RSV", "SPECIES", 13, 16], ["RSV", "SPECIES", 13, 16], ["RSV bronchiolitis", "PROBLEM", 13, 30], ["hyperinfl ation", "TREATMENT", 63, 78], ["pulmonary infi ltrates", "TREATMENT", 80, 102], ["Supportive therapy", "TREATMENT", 104, 122], ["treatment", "TREATMENT", 142, 151], ["bronchiolitis", "PROBLEM", 156, 169], ["RSV bronchiolitis", "OBSERVATION", 13, 30], ["hyperinfl ation", "OBSERVATION", 63, 78], ["pulmonary", "ANATOMY", 80, 89], ["bronchiolitis", "OBSERVATION", 156, 169]]], ["Ribavirin, bronchodilators, and corticosteroids have not shown to be of benefi t.", [["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "CHEMICAL", 0, 9], ["corticosteroids", "CHEMICAL", 32, 47], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["Ribavirin", "TREATMENT", 0, 9], ["bronchodilators", "TREATMENT", 11, 26], ["corticosteroids", "TREATMENT", 32, 47]]], ["Secondary bacterial infections are rare. and atelectasis.", [["bacterial infections", "DISEASE", 10, 30], ["atelectasis", "DISEASE", 45, 56], ["Secondary bacterial infections", "PROBLEM", 0, 30], ["atelectasis", "PROBLEM", 45, 56], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["infections", "OBSERVATION", 20, 30], ["atelectasis", "OBSERVATION", 45, 56]]], ["Therefore, no one mode of ventilation can be recommended for all infants.", [["infants", "ORGANISM", 65, 72], ["infants", "SPECIES", 65, 72], ["ventilation", "TREATMENT", 26, 37]]], ["Non-invasive positive pressure (NIIPP) modes (CPAP or BiPAP) may be attempted in infants where their primary respiratory embarrassment is secondary to atelectasis.", [["respiratory", "ANATOMY", 109, 120], ["respiratory embarrassment", "DISEASE", 109, 134], ["atelectasis", "DISEASE", 151, 162], ["infants", "ORGANISM", 81, 88], ["infants", "SPECIES", 81, 88], ["Non-invasive positive pressure (NIIPP) modes (CPAP", "TREATMENT", 0, 50], ["BiPAP", "TREATMENT", 54, 59], ["their primary respiratory embarrassment", "PROBLEM", 95, 134], ["atelectasis", "PROBLEM", 151, 162], ["positive", "OBSERVATION", 13, 21], ["pressure", "OBSERVATION_MODIFIER", 22, 30], ["atelectasis", "OBSERVATION", 151, 162]]], ["However, this may not be suitable if the disease process appears severe or protracted as prolonged use of NIPP may make feeding diffi cult, cause breakdown of facial tissue, or be diffi cult to maintain without signifi cant sedation that further compromises ventilation.", [["facial tissue", "ANATOMY", 159, 172], ["NIPP", "CHEMICAL", 106, 110], ["NIPP", "SIMPLE_CHEMICAL", 106, 110], ["facial tissue", "TISSUE", 159, 172], ["the disease process", "PROBLEM", 37, 56], ["NIPP", "TREATMENT", 106, 110], ["feeding diffi cult", "TEST", 120, 138], ["breakdown of facial tissue", "PROBLEM", 146, 172], ["diffi cult", "PROBLEM", 180, 190], ["signifi cant sedation", "TREATMENT", 211, 232], ["further compromises ventilation", "TREATMENT", 238, 269], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["facial tissue", "ANATOMY", 159, 172]]], ["If an infant requires endotracheal intubation, the mode of mechanical ventilation should be tailored to the predominant lung pathology present (i.e. atelectasis versus hyperinfl ation).", [["endotracheal", "ANATOMY", 22, 34], ["lung", "ANATOMY", 120, 124], ["atelectasis", "DISEASE", 149, 160], ["lung", "ORGAN", 120, 124], ["infant", "SPECIES", 6, 12], ["endotracheal intubation", "TREATMENT", 22, 45], ["mechanical ventilation", "TREATMENT", 59, 81], ["atelectasis", "PROBLEM", 149, 160], ["hyperinfl ation", "TREATMENT", 168, 183], ["endotracheal intubation", "OBSERVATION", 22, 45], ["mechanical ventilation", "OBSERVATION", 59, 81], ["predominant", "OBSERVATION_MODIFIER", 108, 119], ["lung", "ANATOMY", 120, 124], ["pathology", "OBSERVATION", 125, 134], ["atelectasis", "OBSERVATION", 149, 160]]], ["Children with signifi cant air trapping may need mechanical ventilation similar to a child with asthma, providing low respiratory rates and longer inspiration and exhalation times.", [["respiratory", "ANATOMY", 118, 129], ["asthma", "DISEASE", 96, 102], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["signifi cant air trapping", "PROBLEM", 14, 39], ["mechanical ventilation", "TREATMENT", 49, 71], ["asthma", "PROBLEM", 96, 102], ["low respiratory rates", "PROBLEM", 114, 135], ["air trapping", "OBSERVATION", 27, 39], ["mechanical ventilation", "OBSERVATION", 49, 71], ["asthma", "OBSERVATION", 96, 102]]], ["The more typical infant will lose functional residual capacity (FRC) because of atelectasis and alveolar infi ltrates.", [["alveolar", "ANATOMY", 96, 104], ["atelectasis", "DISEASE", 80, 91], ["infant", "SPECIES", 17, 23], ["functional residual capacity", "PROBLEM", 34, 62], ["atelectasis", "PROBLEM", 80, 91], ["alveolar infi ltrates", "PROBLEM", 96, 117], ["atelectasis", "OBSERVATION", 80, 91], ["alveolar", "ANATOMY_MODIFIER", 96, 104]]], ["Therefore, despite having some air trapping, these infants often need PEEP to be adjusted to recruit alveoli and return FRC to normal.", [["alveoli", "ANATOMY", 101, 108], ["infants", "ORGANISM", 51, 58], ["alveoli", "MULTI-TISSUE_STRUCTURE", 101, 108], ["FRC", "GENE_OR_GENE_PRODUCT", 120, 123], ["infants", "SPECIES", 51, 58], ["some air trapping", "PROBLEM", 26, 43], ["PEEP", "TREATMENT", 70, 74], ["alveoli", "PROBLEM", 101, 108], ["air trapping", "OBSERVATION", 31, 43], ["normal", "OBSERVATION", 127, 133]]], ["In the setting of elevated pulmonary vascular resistance (PVR) which may occur in infants with congenital heart disease or bronchopulmonary dysplasia, lowering PVR by traditional methods such as maintaining oxygenation, deep sedation, muscle relaxation and even nitric oxide may be indicated.TreatmentRibavirin is the only FDA-approved antiviral drug for RSV.", [["pulmonary vascular", "ANATOMY", 27, 45], ["heart", "ANATOMY", 106, 111], ["bronchopulmonary dysplasia", "ANATOMY", 123, 149], ["muscle", "ANATOMY", 235, 241], ["elevated pulmonary vascular resistance", "DISEASE", 18, 56], ["congenital heart disease", "DISEASE", 95, 119], ["bronchopulmonary dysplasia", "DISEASE", 123, 149], ["nitric oxide", "CHEMICAL", 262, 274], ["TreatmentRibavirin", "CHEMICAL", 292, 310], ["RSV", "DISEASE", 355, 358], ["nitric oxide", "CHEMICAL", 262, 274], ["TreatmentRibavirin", "CHEMICAL", 292, 310], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 27, 45], ["infants", "ORGANISM", 82, 89], ["heart", "ORGAN", 106, 111], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 123, 149], ["muscle", "ORGAN", 235, 241], ["nitric oxide", "SIMPLE_CHEMICAL", 262, 274], ["TreatmentRibavirin", "SIMPLE_CHEMICAL", 292, 310], ["RSV", "ORGANISM", 355, 358], ["infants", "SPECIES", 82, 89], ["RSV", "SPECIES", 355, 358], ["elevated pulmonary vascular resistance", "PROBLEM", 18, 56], ["congenital heart disease", "PROBLEM", 95, 119], ["bronchopulmonary dysplasia", "PROBLEM", 123, 149], ["lowering PVR", "TREATMENT", 151, 163], ["traditional methods", "TREATMENT", 167, 186], ["deep sedation", "TREATMENT", 220, 233], ["muscle relaxation", "TREATMENT", 235, 252], ["even nitric oxide", "TREATMENT", 257, 274], ["TreatmentRibavirin", "TREATMENT", 292, 310], ["antiviral drug", "TREATMENT", 336, 350], ["RSV", "PROBLEM", 355, 358], ["elevated", "OBSERVATION", 18, 26], ["pulmonary vascular", "ANATOMY", 27, 45], ["resistance", "OBSERVATION", 46, 56], ["PVR", "OBSERVATION", 58, 61], ["heart", "ANATOMY", 106, 111], ["disease", "OBSERVATION", 112, 119], ["bronchopulmonary", "ANATOMY", 123, 139], ["dysplasia", "OBSERVATION", 140, 149], ["lowering", "OBSERVATION_MODIFIER", 151, 159], ["PVR", "OBSERVATION", 160, 163], ["deep", "ANATOMY_MODIFIER", 220, 224]]], ["Ribavirin inhibits viral replication and is active against RSV, infl uenza A and B, adenoviruses, and hepatitis viruses.", [["Ribavirin", "CHEMICAL", 0, 9], ["hepatitis viruses", "DISEASE", 102, 119], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["RSV", "ORGANISM", 59, 62], ["infl uenza A", "ORGANISM", 64, 76], ["B", "GENE_OR_GENE_PRODUCT", 81, 82], ["adenoviruses", "ORGANISM", 84, 96], ["hepatitis viruses", "ORGANISM", 102, 119], ["RSV", "SPECIES", 59, 62], ["infl uenza A", "SPECIES", 64, 76], ["hepatitis viruses", "SPECIES", 102, 119], ["Ribavirin", "TREATMENT", 0, 9], ["viral replication", "TREATMENT", 19, 36], ["RSV", "PROBLEM", 59, 62], ["adenoviruses", "PROBLEM", 84, 96], ["hepatitis viruses", "PROBLEM", 102, 119], ["viral replication", "OBSERVATION", 19, 36], ["hepatitis viruses", "OBSERVATION", 102, 119]]], ["For lower respiratory tract diseases, ribavirin is typically administered via aerosolization.", [["lower respiratory tract", "ANATOMY", 4, 27], ["respiratory tract diseases", "DISEASE", 10, 36], ["ribavirin", "CHEMICAL", 38, 47], ["ribavirin", "CHEMICAL", 38, 47], ["tract", "ORGANISM_SUBDIVISION", 22, 27], ["ribavirin", "SIMPLE_CHEMICAL", 38, 47], ["lower respiratory tract diseases", "PROBLEM", 4, 36], ["ribavirin", "TREATMENT", 38, 47], ["lower", "ANATOMY_MODIFIER", 4, 9], ["respiratory tract", "ANATOMY", 10, 27], ["ribavirin", "OBSERVATION", 38, 47]]], ["In 1996, a meta-analysis of studies involving ribavirin was discouraging and was consistent with the common clinical experience that ribavirin did not improve clinical outcomes.", [["ribavirin", "CHEMICAL", 46, 55], ["ribavirin", "CHEMICAL", 133, 142], ["ribavirin", "CHEMICAL", 46, 55], ["ribavirin", "CHEMICAL", 133, 142], ["ribavirin", "SIMPLE_CHEMICAL", 46, 55], ["ribavirin", "SIMPLE_CHEMICAL", 133, 142], ["studies", "TEST", 28, 35], ["ribavirin", "TREATMENT", 46, 55], ["ribavirin", "TREATMENT", 133, 142], ["ribavirin", "OBSERVATION", 46, 55], ["consistent with", "UNCERTAINTY", 81, 96]]], ["Therapy targeted at attenuating the virus-induced infl ammatory cascade has also been disappointing.", [["infl", "GENE_OR_GENE_PRODUCT", 50, 54], ["Therapy", "TREATMENT", 0, 7], ["the virus", "TREATMENT", 32, 41], ["infl ammatory cascade", "TREATMENT", 50, 71]]], ["Corticosteroid administration was not associated with reduction in clinical scores, the need for hospitalization, or the length of hospitalization.", [["Corticosteroid", "SIMPLE_CHEMICAL", 0, 14], ["Corticosteroid administration", "TREATMENT", 0, 29], ["hospitalization", "TREATMENT", 97, 112]]], ["Routine use of any corticosteroid given via any route (intravenous, enteral or aerosolized) is not indicated, except in patients with pre-existing chronic lung disease.TreatmentBronchodilators have not shown a clear benefi t in patients with acute RSV bronchiolitis.", [["intravenous", "ANATOMY", 55, 66], ["lung", "ANATOMY", 155, 159], ["chronic lung disease", "DISEASE", 147, 167], ["bronchiolitis", "DISEASE", 252, 265], ["corticosteroid", "SIMPLE_CHEMICAL", 19, 33], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 66], ["patients", "ORGANISM", 120, 128], ["lung", "ORGAN", 155, 159], ["patients", "ORGANISM", 228, 236], ["RSV", "ORGANISM", 248, 251], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 228, 236], ["RSV", "SPECIES", 248, 251], ["any corticosteroid", "TREATMENT", 15, 33], ["any route (intravenous, enteral or aerosolized)", "TREATMENT", 44, 91], ["pre-existing chronic lung disease", "PROBLEM", 134, 167], ["TreatmentBronchodilators", "TREATMENT", 168, 192], ["acute RSV bronchiolitis", "PROBLEM", 242, 265], ["chronic", "OBSERVATION_MODIFIER", 147, 154], ["lung", "ANATOMY", 155, 159], ["disease", "OBSERVATION", 160, 167], ["acute", "OBSERVATION_MODIFIER", 242, 247], ["RSV bronchiolitis", "OBSERVATION", 248, 265]]], ["In 12 randomized control trials, involving 843 infants, evaluating the effect of salbutamol or albuterol on bronchiolitis, 9 (75%) showed no effect.", [["salbutamol", "CHEMICAL", 81, 91], ["albuterol", "CHEMICAL", 95, 104], ["bronchiolitis", "DISEASE", 108, 121], ["salbutamol", "CHEMICAL", 81, 91], ["albuterol", "CHEMICAL", 95, 104], ["infants", "ORGANISM", 47, 54], ["salbutamol", "SIMPLE_CHEMICAL", 81, 91], ["albuterol", "SIMPLE_CHEMICAL", 95, 104], ["infants", "SPECIES", 47, 54], ["salbutamol", "TREATMENT", 81, 91], ["albuterol", "TREATMENT", 95, 104], ["bronchiolitis", "PROBLEM", 108, 121], ["bronchiolitis", "OBSERVATION", 108, 121]]], ["The remaining three studies demonstrated only a small transient improvement in the acute clinical score.", [["The remaining three studies", "TEST", 0, 27], ["a small transient improvement", "PROBLEM", 46, 75], ["the acute clinical score", "PROBLEM", 79, 103], ["small", "OBSERVATION_MODIFIER", 48, 53], ["transient", "OBSERVATION_MODIFIER", 54, 63], ["improvement", "OBSERVATION_MODIFIER", 64, 75], ["acute", "OBSERVATION_MODIFIER", 83, 88]]], ["Although the routine use of bronchodilator therapy cannot be recommended, it has become acceptable practice to attempt to see if individual infants are beta agonist responsive or not.", [["infants", "ORGANISM", 140, 147], ["beta agonist", "GENE_OR_GENE_PRODUCT", 152, 164], ["infants", "SPECIES", 140, 147], ["bronchodilator therapy", "TREATMENT", 28, 50]]], ["If no clinical response is seen after a trial of a beta agonist, its use should be discontinued.TreatmentIn the 1990s, fi ve randomized trials involving 225 infants, evaluating the effect of nebulized adrenaline (epinephrine) on bronchiolitis showed clinical improvement, with reductions in oxygen requirement, respiratory rate, wheezing, and decrease in pulmonary vascular resistance.", [["respiratory", "ANATOMY", 311, 322], ["pulmonary vascular", "ANATOMY", 355, 373], ["adrenaline", "CHEMICAL", 201, 211], ["epinephrine", "CHEMICAL", 213, 224], ["bronchiolitis", "DISEASE", 229, 242], ["oxygen", "CHEMICAL", 291, 297], ["wheezing", "DISEASE", 329, 337], ["adrenaline", "CHEMICAL", 201, 211], ["epinephrine", "CHEMICAL", 213, 224], ["oxygen", "CHEMICAL", 291, 297], ["beta", "GENE_OR_GENE_PRODUCT", 51, 55], ["infants", "ORGANISM", 157, 164], ["adrenaline", "SIMPLE_CHEMICAL", 201, 211], ["epinephrine", "SIMPLE_CHEMICAL", 213, 224], ["oxygen", "SIMPLE_CHEMICAL", 291, 297], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 355, 373], ["infants", "SPECIES", 157, 164], ["a beta agonist", "TREATMENT", 49, 63], ["TreatmentIn", "TREATMENT", 96, 107], ["fi ve randomized trials", "TREATMENT", 119, 142], ["nebulized adrenaline (epinephrine", "TREATMENT", 191, 224], ["bronchiolitis", "PROBLEM", 229, 242], ["reductions in oxygen requirement", "PROBLEM", 277, 309], ["respiratory rate", "TEST", 311, 327], ["wheezing", "PROBLEM", 329, 337], ["decrease in pulmonary vascular resistance", "PROBLEM", 343, 384], ["bronchiolitis", "OBSERVATION", 229, 242], ["reductions", "OBSERVATION_MODIFIER", 277, 287], ["oxygen requirement", "OBSERVATION", 291, 309], ["respiratory rate", "OBSERVATION", 311, 327], ["wheezing", "OBSERVATION", 329, 337], ["decrease", "OBSERVATION_MODIFIER", 343, 351], ["pulmonary vascular", "ANATOMY", 355, 373], ["resistance", "OBSERVATION", 374, 384]]], ["Two of these studies showed lower hospital admission rates and earlier discharge.", [["these studies", "TEST", 7, 20], ["lower", "OBSERVATION_MODIFIER", 28, 33]]], ["A 2004 Cochrane systematic review suggested a potential benefi t with epinephrine administration.", [["epinephrine", "CHEMICAL", 70, 81], ["epinephrine", "CHEMICAL", 70, 81], ["epinephrine", "SIMPLE_CHEMICAL", 70, 81], ["epinephrine administration", "TREATMENT", 70, 96]]], ["However, subsequent studies have not supported its routine use.", [["subsequent studies", "TEST", 9, 27]]], ["As with albuterol, a clinical trial in selected infants seems reasonable.TreatmentNebulized hypertonic saline has been used for treating hospitalized, as well as ambulatory, children with viral bronchiolitis with variable success.", [["albuterol", "CHEMICAL", 8, 17], ["bronchiolitis", "DISEASE", 194, 207], ["albuterol", "CHEMICAL", 8, 17], ["albuterol", "SIMPLE_CHEMICAL", 8, 17], ["infants", "ORGANISM", 48, 55], ["children", "ORGANISM", 174, 182], ["infants", "SPECIES", 48, 55], ["children", "SPECIES", 174, 182], ["albuterol", "TREATMENT", 8, 17], ["a clinical trial", "TREATMENT", 19, 35], ["TreatmentNebulized hypertonic saline", "TREATMENT", 73, 109], ["viral bronchiolitis", "PROBLEM", 188, 207], ["bronchiolitis", "OBSERVATION", 194, 207]]], ["A recent Cochrane meta-analysis of nebulized hypertonic saline has shown an improvement in clinical scores and decrease in hospital duration.TreatmentSeveral studies have evaluated the benefi t of surfactant and nitric oxide for severe respiratory distress.", [["respiratory", "ANATOMY", 236, 247], ["nitric oxide", "CHEMICAL", 212, 224], ["respiratory distress", "DISEASE", 236, 256], ["nitric oxide", "CHEMICAL", 212, 224], ["surfactant", "SIMPLE_CHEMICAL", 197, 207], ["nitric oxide", "SIMPLE_CHEMICAL", 212, 224], ["nebulized hypertonic saline", "TREATMENT", 35, 62], ["Several studies", "TEST", 150, 165], ["surfactant", "TREATMENT", 197, 207], ["nitric oxide", "TREATMENT", 212, 224], ["severe respiratory distress", "PROBLEM", 229, 256], ["improvement", "OBSERVATION_MODIFIER", 76, 87], ["decrease", "OBSERVATION_MODIFIER", 111, 119], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["respiratory distress", "OBSERVATION", 236, 256]]], ["Heliox, a mixture of oxygen (20-30%) and helium (70-80%) with lower viscosity than air has been used successfully in cases of airway obstruction, croup, airway surgery, and asthma to reduce respiratory effort during the period of airway compromise.", [["airway", "ANATOMY", 126, 132], ["airway", "ANATOMY", 153, 159], ["respiratory", "ANATOMY", 190, 201], ["airway", "ANATOMY", 230, 236], ["Heliox", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 21, 27], ["helium", "CHEMICAL", 41, 47], ["airway obstruction", "DISEASE", 126, 144], ["croup", "DISEASE", 146, 151], ["asthma", "DISEASE", 173, 179], ["oxygen", "CHEMICAL", 21, 27], ["helium", "CHEMICAL", 41, 47], ["Heliox", "SIMPLE_CHEMICAL", 0, 6], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["airway", "MULTI-TISSUE_STRUCTURE", 126, 132], ["airway", "MULTI-TISSUE_STRUCTURE", 153, 159], ["airway", "MULTI-TISSUE_STRUCTURE", 230, 236], ["Heliox", "TREATMENT", 0, 6], ["a mixture of oxygen", "TREATMENT", 8, 27], ["helium", "TREATMENT", 41, 47], ["airway obstruction", "PROBLEM", 126, 144], ["croup", "PROBLEM", 146, 151], ["airway surgery", "TREATMENT", 153, 167], ["asthma", "PROBLEM", 173, 179], ["respiratory effort", "PROBLEM", 190, 208], ["airway compromise", "PROBLEM", 230, 247], ["airway", "ANATOMY", 126, 132], ["obstruction", "OBSERVATION", 133, 144], ["airway", "ANATOMY", 153, 159], ["surgery", "OBSERVATION", 160, 167], ["asthma", "OBSERVATION", 173, 179], ["respiratory effort", "OBSERVATION", 190, 208], ["airway", "ANATOMY", 230, 236], ["compromise", "OBSERVATION", 237, 247]]], ["Several studies have shown improved respiratory distress scores in patients on heliox with continuous positive airway pressure obviating the need for intubation and mechanical ventilation.PreventionPalivizumab is a neutralizing humanized mouse monoclonal antibody directed against the RSV-F glycoprotein.", [["respiratory", "ANATOMY", 36, 47], ["airway", "ANATOMY", 111, 117], ["respiratory distress", "DISEASE", 36, 56], ["Palivizumab", "CHEMICAL", 198, 209], ["heliox", "CHEMICAL", 79, 85], ["Palivizumab", "CHEMICAL", 198, 209], ["patients", "ORGANISM", 67, 75], ["airway", "MULTI-TISSUE_STRUCTURE", 111, 117], ["Palivizumab", "SIMPLE_CHEMICAL", 198, 209], ["mouse", "ORGANISM", 238, 243], ["RSV-F glycoprotein", "GENE_OR_GENE_PRODUCT", 285, 303], ["neutralizing humanized mouse monoclonal antibody", "PROTEIN", 215, 263], ["RSV-F glycoprotein", "PROTEIN", 285, 303], ["patients", "SPECIES", 67, 75], ["mouse", "SPECIES", 238, 243], ["mouse", "SPECIES", 238, 243], ["RSV", "SPECIES", 285, 288], ["Several studies", "TEST", 0, 15], ["improved respiratory distress scores", "PROBLEM", 27, 63], ["heliox", "TREATMENT", 79, 85], ["continuous positive airway pressure", "TREATMENT", 91, 126], ["intubation", "TREATMENT", 150, 160], ["mechanical ventilation", "TREATMENT", 165, 187], ["Palivizumab", "TREATMENT", 198, 209], ["a neutralizing humanized mouse monoclonal antibody", "TREATMENT", 213, 263], ["improved", "OBSERVATION_MODIFIER", 27, 35], ["respiratory distress", "OBSERVATION", 36, 56], ["airway pressure", "OBSERVATION", 111, 126], ["mechanical ventilation", "OBSERVATION", 165, 187]]], ["It was licensed by the Food and Drug Administration (FDA) in 1998 for premature infants and infants with bronchopulmonary dysplasia.", [["bronchopulmonary dysplasia", "ANATOMY", 105, 131], ["bronchopulmonary dysplasia", "DISEASE", 105, 131], ["infants", "ORGANISM", 80, 87], ["infants", "ORGANISM", 92, 99], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 105, 131], ["infants", "SPECIES", 80, 87], ["infants", "SPECIES", 92, 99], ["Drug Administration", "TREATMENT", 32, 51], ["premature infants", "PROBLEM", 70, 87], ["bronchopulmonary dysplasia", "PROBLEM", 105, 131], ["bronchopulmonary", "ANATOMY", 105, 121], ["dysplasia", "OBSERVATION", 122, 131]]], ["The randomized, double blind, placebo controlled IMpact-RSV trial involving 1,502 high risk infants found a signifi cant reduction of 55% in hospitalizations.", [["infants", "ORGANISM", 92, 99], ["infants", "SPECIES", 92, 99], ["RSV", "SPECIES", 56, 59], ["double blind", "PROBLEM", 16, 28], ["RSV trial", "TREATMENT", 56, 65], ["a signifi cant reduction", "TREATMENT", 106, 130]]], ["With the exception of very rare anaphylaxis, no signifi cant adverse effects have been observed.", [["anaphylaxis", "DISEASE", 32, 43], ["very rare anaphylaxis", "PROBLEM", 22, 43], ["signifi cant adverse effects", "PROBLEM", 48, 76], ["very", "OBSERVATION_MODIFIER", 22, 26], ["rare", "OBSERVATION_MODIFIER", 27, 31], ["anaphylaxis", "OBSERVATION", 32, 43], ["no", "UNCERTAINTY", 45, 47]]], ["Palivizumab has been approved for use in infants with congenital heart disease.", [["heart", "ANATOMY", 65, 70], ["Palivizumab", "CHEMICAL", 0, 11], ["congenital heart disease", "DISEASE", 54, 78], ["Palivizumab", "CHEMICAL", 0, 11], ["Palivizumab", "SIMPLE_CHEMICAL", 0, 11], ["infants", "ORGANISM", 41, 48], ["heart", "ORGAN", 65, 70], ["infants", "SPECIES", 41, 48], ["Palivizumab", "TREATMENT", 0, 11], ["congenital heart disease", "PROBLEM", 54, 78], ["heart", "ANATOMY", 65, 70], ["disease", "OBSERVATION", 71, 78]]], ["The cardiac synagis study group included 1,287 children with congenital heart disease in a randomized, double blind, placebo controlled trial; it found a 45% relative reduction in RSV associated hospitalizations with no deaths attributable to the palivizumab.", [["cardiac", "ANATOMY", 4, 11], ["heart", "ANATOMY", 72, 77], ["congenital heart disease", "DISEASE", 61, 85], ["RSV", "DISEASE", 180, 183], ["deaths", "DISEASE", 220, 226], ["palivizumab", "CHEMICAL", 247, 258], ["children", "ORGANISM", 47, 55], ["heart", "ORGAN", 72, 77], ["RSV", "ORGANISM", 180, 183], ["children", "SPECIES", 47, 55], ["RSV", "SPECIES", 180, 183], ["The cardiac synagis study", "TEST", 0, 25], ["congenital heart disease", "PROBLEM", 61, 85], ["double blind", "PROBLEM", 103, 115], ["placebo controlled trial", "TREATMENT", 117, 141], ["a 45% relative reduction", "PROBLEM", 152, 176], ["deaths", "PROBLEM", 220, 226], ["the palivizumab", "TREATMENT", 243, 258], ["cardiac", "ANATOMY", 4, 11], ["heart", "ANATOMY", 72, 77], ["disease", "OBSERVATION", 78, 85], ["reduction", "OBSERVATION_MODIFIER", 167, 176], ["RSV", "OBSERVATION", 180, 183]]], ["Since cardiopulmonary bypass can decrease serum drug concentrations by about 58%, it is recommended that an additional dose be given following surgery, if continued protection is desired.PreventionPalivizumab should be administered intramuscularly as 15 mg/kg every 30 days for a total of fi ve doses during RSV season, which is generally from November through March, to high risk infants.", [["cardiopulmonary", "ANATOMY", 6, 21], ["serum", "ANATOMY", 42, 47], ["Palivizumab", "CHEMICAL", 197, 208], ["Palivizumab", "CHEMICAL", 197, 208], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["Palivizumab", "SIMPLE_CHEMICAL", 197, 208], ["RSV", "ORGANISM", 308, 311], ["infants", "ORGANISM", 381, 388], ["infants", "SPECIES", 381, 388], ["RSV", "SPECIES", 308, 311], ["cardiopulmonary bypass", "TREATMENT", 6, 28], ["serum drug concentrations", "TEST", 42, 67], ["surgery", "TREATMENT", 143, 150], ["Palivizumab", "TREATMENT", 197, 208], ["a total of fi ve doses", "TREATMENT", 278, 300], ["cardiopulmonary", "ANATOMY", 6, 21], ["bypass", "OBSERVATION", 22, 28]]], ["Infants or children that develop an RSV infection should continue to receive prophylaxis following recovery because the naturally acquired antibodies are not fully protective.", [["RSV infection", "DISEASE", 36, 49], ["Infants", "ORGANISM", 0, 7], ["children", "ORGANISM", 11, 19], ["RSV", "ORGANISM", 36, 39], ["Infants", "SPECIES", 0, 7], ["children", "SPECIES", 11, 19], ["RSV", "SPECIES", 36, 39], ["an RSV infection", "PROBLEM", 33, 49], ["prophylaxis", "TREATMENT", 77, 88], ["the naturally acquired antibodies", "PROBLEM", 116, 149], ["RSV", "ANATOMY", 36, 39], ["infection", "OBSERVATION", 40, 49]]], ["Motavizumab, a new, enhanced potency, humanized RSV monoclonal antibody has demonstrated 50-100 times greater neutralizing activity against RSV.", [["Motavizumab", "CHEMICAL", 0, 11], ["Motavizumab", "CHEMICAL", 0, 11], ["Motavizumab", "SIMPLE_CHEMICAL", 0, 11], ["RSV", "ORGANISM", 48, 51], ["RSV", "ORGANISM", 140, 143], ["humanized RSV monoclonal antibody", "PROTEIN", 38, 71], ["RSV", "SPECIES", 48, 51], ["RSV", "SPECIES", 140, 143], ["Motavizumab", "TREATMENT", 0, 11], ["humanized RSV monoclonal antibody", "TEST", 38, 71], ["RSV", "PROBLEM", 140, 143]]], ["In completion of a phase III trial, motavizumab was found equal to palivizumab for the prevention of RSV hospitalization and superior to palivizumab for reduction of RSV-specifi c outpatient medically attended lower respiratory tract infections (MALRIs).PNEUMONIAPneumonia describes any infl ammatory condition of the lung in which the alveoli are compromised by aspirated foreign matter, infl ammatory fl uid, or cellular debris.", [["lower respiratory tract", "ANATOMY", 210, 233], ["lung", "ANATOMY", 318, 322], ["alveoli", "ANATOMY", 336, 343], ["cellular debris", "ANATOMY", 414, 429], ["motavizumab", "CHEMICAL", 36, 47], ["palivizumab", "CHEMICAL", 67, 78], ["RSV", "DISEASE", 101, 104], ["palivizumab", "CHEMICAL", 137, 148], ["lower respiratory tract infections", "DISEASE", 210, 244], ["MALRIs", "DISEASE", 246, 252], ["motavizumab", "CHEMICAL", 36, 47], ["motavizumab", "SIMPLE_CHEMICAL", 36, 47], ["RSV", "ORGANISM", 101, 104], ["RSV", "ORGANISM", 166, 169], ["lower", "ORGANISM_SUBDIVISION", 210, 215], ["respiratory tract", "ORGANISM_SUBDIVISION", 216, 233], ["lung", "ORGAN", 318, 322], ["alveoli", "MULTI-TISSUE_STRUCTURE", 336, 343], ["cellular", "CELL", 414, 422], ["RSV", "SPECIES", 101, 104], ["RSV", "SPECIES", 166, 169], ["a phase III trial", "TREATMENT", 17, 34], ["motavizumab", "TREATMENT", 36, 47], ["palivizumab", "TREATMENT", 67, 78], ["RSV hospitalization", "TREATMENT", 101, 120], ["palivizumab", "TREATMENT", 137, 148], ["RSV", "PROBLEM", 166, 169], ["lower respiratory tract infections", "PROBLEM", 210, 244], ["PNEUMONIAPneumonia", "PROBLEM", 254, 272], ["any infl ammatory condition of the lung", "PROBLEM", 283, 322], ["aspirated foreign matter", "PROBLEM", 363, 387], ["cellular debris", "PROBLEM", 414, 429], ["RSV", "OBSERVATION", 166, 169], ["respiratory tract", "ANATOMY", 216, 233], ["lung", "ANATOMY", 318, 322], ["alveoli", "ANATOMY", 336, 343], ["aspirated", "OBSERVATION_MODIFIER", 363, 372], ["foreign matter", "OBSERVATION", 373, 387], ["cellular debris", "OBSERVATION", 414, 429]]], ["Infection is the primary cause of parenchymal injury to the lung.", [["parenchymal", "ANATOMY", 34, 45], ["lung", "ANATOMY", 60, 64], ["Infection", "DISEASE", 0, 9], ["parenchymal injury to the lung", "DISEASE", 34, 64], ["parenchymal", "TISSUE", 34, 45], ["lung", "ORGAN", 60, 64], ["Infection", "PROBLEM", 0, 9], ["parenchymal injury to the lung", "PROBLEM", 34, 64], ["parenchymal", "ANATOMY_MODIFIER", 34, 45], ["injury", "OBSERVATION", 46, 52], ["lung", "ANATOMY", 60, 64]]], ["Pathogens include viruses, bacteria and fungi.Clinical PresentationSigns and symptoms of pneumonia are non-specifi c and may be occult in the young infant.", [["pneumonia", "DISEASE", 89, 98], ["infant", "ORGANISM", 148, 154], ["infant", "SPECIES", 148, 154], ["Pathogens", "PROBLEM", 0, 9], ["viruses", "PROBLEM", 18, 25], ["bacteria", "PROBLEM", 27, 35], ["fungi", "PROBLEM", 40, 45], ["Clinical PresentationSigns", "PROBLEM", 46, 72], ["symptoms", "PROBLEM", 77, 85], ["pneumonia", "PROBLEM", 89, 98], ["viruses", "OBSERVATION", 18, 25], ["bacteria", "OBSERVATION_MODIFIER", 27, 35], ["fungi", "OBSERVATION", 40, 45], ["pneumonia", "OBSERVATION", 89, 98], ["may be", "UNCERTAINTY", 121, 127]]], ["Children often have fever, chills, headache, malaise, restlessness, and irritability.", [["fever", "DISEASE", 20, 25], ["chills", "DISEASE", 27, 33], ["headache", "DISEASE", 35, 43], ["restlessness", "DISEASE", 54, 66], ["irritability", "DISEASE", 72, 84], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["fever", "PROBLEM", 20, 25], ["chills", "PROBLEM", 27, 33], ["headache", "PROBLEM", 35, 43], ["malaise", "PROBLEM", 45, 52], ["restlessness", "PROBLEM", 54, 66], ["irritability", "PROBLEM", 72, 84], ["fever", "OBSERVATION", 20, 25], ["chills", "OBSERVATION", 27, 33], ["malaise", "OBSERVATION", 45, 52]]], ["Gastrointestinal complaints such as abdominal pain, distention, or emesis may also be present in young children.", [["Gastrointestinal", "ANATOMY", 0, 16], ["abdominal", "ANATOMY", 36, 45], ["Gastrointestinal complaints", "DISEASE", 0, 27], ["abdominal pain", "DISEASE", 36, 50], ["distention", "DISEASE", 52, 62], ["emesis", "DISEASE", 67, 73], ["abdominal", "ORGANISM_SUBDIVISION", 36, 45], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["Gastrointestinal complaints", "PROBLEM", 0, 27], ["abdominal pain", "PROBLEM", 36, 50], ["distention", "PROBLEM", 52, 62], ["emesis", "PROBLEM", 67, 73], ["abdominal", "ANATOMY", 36, 45], ["distention", "OBSERVATION", 52, 62]]], ["The symptoms are often preceded by minor upper respiratory tract infections characterized by low-grade fever and rhinorrhea.", [["upper respiratory tract", "ANATOMY", 41, 64], ["respiratory tract infections", "DISEASE", 47, 75], ["fever", "DISEASE", 103, 108], ["rhinorrhea", "DISEASE", 113, 123], ["upper respiratory", "ORGANISM_SUBDIVISION", 41, 58], ["tract", "ORGANISM_SUBDIVISION", 59, 64], ["The symptoms", "PROBLEM", 0, 12], ["minor upper respiratory tract infections", "PROBLEM", 35, 75], ["low-grade fever", "PROBLEM", 93, 108], ["rhinorrhea", "PROBLEM", 113, 123], ["upper", "ANATOMY_MODIFIER", 41, 46], ["respiratory tract", "ANATOMY", 47, 64], ["infections", "OBSERVATION", 65, 75], ["low-grade", "OBSERVATION_MODIFIER", 93, 102], ["fever", "OBSERVATION", 103, 108], ["rhinorrhea", "OBSERVATION", 113, 123]]], ["With more signifi cant involvement of the lower respiratory tract, tachypnea, dyspnea, cough, nasal fl aring, grunting, or retractions may be seen.", [["lower respiratory tract", "ANATOMY", 42, 65], ["nasal", "ANATOMY", 94, 99], ["tachypnea", "DISEASE", 67, 76], ["dyspnea", "DISEASE", 78, 85], ["cough", "DISEASE", 87, 92], ["grunting", "DISEASE", 110, 118], ["lower", "ORGANISM_SUBDIVISION", 42, 47], ["respiratory tract", "ORGANISM_SUBDIVISION", 48, 65], ["the lower respiratory tract", "PROBLEM", 38, 65], ["tachypnea", "PROBLEM", 67, 76], ["dyspnea", "PROBLEM", 78, 85], ["cough", "PROBLEM", 87, 92], ["nasal fl aring", "PROBLEM", 94, 108], ["grunting", "PROBLEM", 110, 118], ["retractions", "PROBLEM", 123, 134], ["lower", "ANATOMY_MODIFIER", 42, 47], ["respiratory tract", "ANATOMY", 48, 65], ["tachypnea", "OBSERVATION", 67, 76], ["cough", "OBSERVATION", 87, 92], ["nasal", "ANATOMY", 94, 99], ["fl aring", "OBSERVATION", 100, 108], ["grunting", "OBSERVATION", 110, 118], ["retractions", "OBSERVATION", 123, 134]]], ["The older child may demonstrate productive sputum and complain of pleuritic chest pain.", [["sputum", "ANATOMY", 43, 49], ["chest", "ANATOMY", 76, 81], ["chest pain", "DISEASE", 76, 86], ["child", "ORGANISM", 10, 15], ["sputum", "ORGANISM_SUBSTANCE", 43, 49], ["chest", "ORGANISM_SUBDIVISION", 76, 81], ["child", "SPECIES", 10, 15], ["productive sputum", "PROBLEM", 32, 49], ["pleuritic chest pain", "PROBLEM", 66, 86], ["productive", "OBSERVATION_MODIFIER", 32, 42], ["sputum", "OBSERVATION", 43, 49], ["chest", "ANATOMY", 76, 81]]], ["On auscultation of the chest, rales and/or decreased breath sounds might be heard over areas of consolidation or pleural effusions.", [["chest", "ANATOMY", 23, 28], ["pleural effusions", "ANATOMY", 113, 130], ["pleural effusions", "DISEASE", 113, 130], ["chest", "ORGANISM_SUBDIVISION", 23, 28], ["pleural effusions", "PATHOLOGICAL_FORMATION", 113, 130], ["auscultation of the chest", "TEST", 3, 28], ["rales", "PROBLEM", 30, 35], ["decreased breath sounds", "PROBLEM", 43, 66], ["consolidation", "PROBLEM", 96, 109], ["pleural effusions", "PROBLEM", 113, 130], ["auscultation", "OBSERVATION", 3, 15], ["chest", "ANATOMY", 23, 28], ["rales", "OBSERVATION", 30, 35], ["decreased", "OBSERVATION_MODIFIER", 43, 52], ["breath sounds", "OBSERVATION", 53, 66], ["consolidation", "OBSERVATION", 96, 109], ["pleural", "ANATOMY", 113, 120], ["effusions", "OBSERVATION", 121, 130]]], ["However, due the short path for transmission of breath sounds and the small chest size in infants, breath sounds may not be decreased, even in the presence of effusions.", [["chest", "ANATOMY", 76, 81], ["effusions", "ANATOMY", 159, 168], ["effusions", "DISEASE", 159, 168], ["chest", "ORGANISM_SUBDIVISION", 76, 81], ["infants", "ORGANISM", 90, 97], ["infants", "SPECIES", 90, 97], ["breath sounds", "TEST", 48, 61], ["the small chest size in infants", "PROBLEM", 66, 97], ["breath sounds", "TEST", 99, 112], ["effusions", "PROBLEM", 159, 168], ["breath sounds", "OBSERVATION", 48, 61], ["small", "OBSERVATION_MODIFIER", 70, 75], ["chest", "ANATOMY", 76, 81], ["size", "OBSERVATION_MODIFIER", 82, 86], ["may not be", "UNCERTAINTY", 113, 123], ["decreased", "OBSERVATION_MODIFIER", 124, 133], ["effusions", "OBSERVATION", 159, 168]]], ["Children with pleural irritation might prefer to lie on the affected side with legs fl exed and may complain of radiating pain to the neck and shoulder or into the abdomen.EpidemiologyCommunity acquired pneumonia (CAP) is a common, and at times, a serious infection in children.", [["pleural", "ANATOMY", 14, 21], ["legs", "ANATOMY", 79, 83], ["neck", "ANATOMY", 134, 138], ["shoulder", "ANATOMY", 143, 151], ["abdomen", "ANATOMY", 164, 171], ["pleural irritation", "DISEASE", 14, 32], ["pain", "DISEASE", 122, 126], ["pneumonia", "DISEASE", 203, 212], ["CAP", "DISEASE", 214, 217], ["infection", "DISEASE", 256, 265], ["Children", "ORGANISM", 0, 8], ["pleural", "ORGAN", 14, 21], ["legs", "ORGANISM_SUBDIVISION", 79, 83], ["neck", "ORGANISM_SUBDIVISION", 134, 138], ["shoulder", "ORGANISM_SUBDIVISION", 143, 151], ["abdomen", "ORGAN", 164, 171], ["children", "ORGANISM", 269, 277], ["Children", "SPECIES", 0, 8], ["children", "SPECIES", 269, 277], ["pleural irritation", "PROBLEM", 14, 32], ["radiating pain to the neck and shoulder", "PROBLEM", 112, 151], ["EpidemiologyCommunity acquired pneumonia (CAP)", "PROBLEM", 172, 218], ["a serious infection in children", "PROBLEM", 246, 277], ["pleural", "ANATOMY", 14, 21], ["irritation", "OBSERVATION", 22, 32], ["legs", "ANATOMY", 79, 83], ["neck", "ANATOMY", 134, 138], ["shoulder", "ANATOMY", 143, 151], ["abdomen", "ANATOMY", 164, 171], ["pneumonia", "OBSERVATION", 203, 212], ["CAP", "OBSERVATION_MODIFIER", 214, 217], ["serious", "OBSERVATION_MODIFIER", 248, 255], ["infection", "OBSERVATION", 256, 265]]], ["The incidence of CAP is 35-40 cases per 1,000 children less than 5 years of age and 11-16 cases per 1,000 children 5-14 years of age.", [["CAP", "DISEASE", 17, 20], ["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54], ["children", "SPECIES", 106, 114], ["CAP", "OBSERVATION_MODIFIER", 17, 20]]], ["The exact prevalence of the etiologic agents causing pediatric pneumonia is diffi cult to ascertain.", [["pneumonia", "DISEASE", 63, 72], ["pediatric pneumonia", "PROBLEM", 53, 72], ["pneumonia", "OBSERVATION", 63, 72]]], ["It is often diffi cult to differentiate viral from bacterial pneumonia based solely on clinical examination.", [["pneumonia", "DISEASE", 61, 70], ["viral", "PROBLEM", 40, 45], ["bacterial pneumonia", "PROBLEM", 51, 70], ["clinical examination", "TEST", 87, 107], ["bacterial", "OBSERVATION_MODIFIER", 51, 60], ["pneumonia", "OBSERVATION", 61, 70]]], ["Specifi c pathogens causing CAP can be determined in only approximately one-third of children using commonly available cultures, antigen detection, or serologic techniques.", [["CAP", "DISEASE", 28, 31], ["Specifi c pathogens", "ORGANISM", 0, 19], ["children", "ORGANISM", 85, 93], ["children", "SPECIES", 85, 93], ["pathogens", "PROBLEM", 10, 19], ["CAP", "PROBLEM", 28, 31], ["cultures", "TEST", 119, 127], ["antigen detection", "TEST", 129, 146], ["serologic techniques", "TEST", 151, 171]]], ["Blood cultures yield pathogens in only about 10-15% of infants and children with bacterial CAP and many children do not undergo viral testing as it is often unnecessary.", [["Blood cultures", "ANATOMY", 0, 14], ["CAP", "DISEASE", 91, 94], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["infants", "ORGANISM", 55, 62], ["children", "ORGANISM", 67, 75], ["children", "ORGANISM", 104, 112], ["infants", "SPECIES", 55, 62], ["children", "SPECIES", 67, 75], ["children", "SPECIES", 104, 112], ["Blood cultures", "TEST", 0, 14], ["pathogens", "PROBLEM", 21, 30], ["bacterial CAP", "PROBLEM", 81, 94], ["viral testing", "TEST", 128, 141]]], ["With these inherent limitations, it is generally thought that viruses account for approximately 80% of CAP in children under the age of 2 years and approximately 50% of CAP in preschool children ages 2-5 years.EpidemiologyPalivizumab should be used as preventive therapy in infants with chronic lung disease and congenital heart disease.", [["lung", "ANATOMY", 295, 299], ["heart", "ANATOMY", 323, 328], ["CAP", "DISEASE", 103, 106], ["CAP", "DISEASE", 169, 172], ["Palivizumab", "CHEMICAL", 222, 233], ["chronic lung disease", "DISEASE", 287, 307], ["congenital heart disease", "DISEASE", 312, 336], ["Palivizumab", "CHEMICAL", 222, 233], ["children", "ORGANISM", 110, 118], ["children", "ORGANISM", 186, 194], ["Palivizumab", "SIMPLE_CHEMICAL", 222, 233], ["infants", "ORGANISM", 274, 281], ["lung", "ORGAN", 295, 299], ["heart", "ORGAN", 323, 328], ["children", "SPECIES", 110, 118], ["children", "SPECIES", 186, 194], ["infants", "SPECIES", 274, 281], ["viruses", "PROBLEM", 62, 69], ["EpidemiologyPalivizumab", "TREATMENT", 210, 233], ["preventive therapy", "TREATMENT", 252, 270], ["chronic lung disease", "PROBLEM", 287, 307], ["congenital heart disease", "PROBLEM", 312, 336], ["viruses", "OBSERVATION", 62, 69], ["chronic", "OBSERVATION_MODIFIER", 287, 294], ["lung", "ANATOMY", 295, 299], ["disease", "OBSERVATION", 300, 307], ["congenital", "OBSERVATION_MODIFIER", 312, 322], ["heart", "ANATOMY", 323, 328], ["disease", "OBSERVATION", 329, 336]]], ["Cardiopulmonary bypass signifi cantly lowers the serum level of palivizumab, so it should be redosed following surgery if continued protection desired.C HAPTER 25 \u2022 AC UTE PU LMONARY I N FECTIONSViral causes decline in the school age and adolescent child and bacterial causes such as Streptococcus pneumoniae and Mycoplasma become important pathogens ( Fig. 25-1 ) .C HAPTER 25 \u2022 AC UTE PU LMONARY I N FECTIONSOverall, bacteria account for 20-30% of community-acquired pneumonias.", [["Cardiopulmonary", "ANATOMY", 0, 15], ["serum", "ANATOMY", 49, 54], ["palivizumab", "CHEMICAL", 64, 75], ["Streptococcus pneumoniae", "DISEASE", 284, 308], ["pneumonias", "DISEASE", 469, 479], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["palivizumab", "SIMPLE_CHEMICAL", 64, 75], ["Streptococcus pneumoniae", "ORGANISM", 284, 308], ["Streptococcus pneumoniae", "SPECIES", 284, 308], ["Streptococcus pneumoniae", "SPECIES", 284, 308], ["Cardiopulmonary bypass", "TREATMENT", 0, 22], ["the serum level", "TEST", 45, 60], ["palivizumab", "TREATMENT", 64, 75], ["surgery", "TREATMENT", 111, 118], ["adolescent child", "PROBLEM", 238, 254], ["bacterial causes", "PROBLEM", 259, 275], ["Streptococcus pneumoniae", "PROBLEM", 284, 308], ["Mycoplasma", "PROBLEM", 313, 323], ["bacteria", "PROBLEM", 419, 427], ["community-acquired pneumonias", "PROBLEM", 450, 479], ["bypass", "OBSERVATION", 16, 22], ["pneumonias", "OBSERVATION", 469, 479]]], ["The likelihood of infection with different bacteria varies by age.", [["infection", "DISEASE", 18, 27], ["infection", "PROBLEM", 18, 27], ["different bacteria", "PROBLEM", 33, 51], ["likelihood of", "UNCERTAINTY", 4, 17], ["infection", "OBSERVATION", 18, 27], ["different", "OBSERVATION_MODIFIER", 33, 42], ["bacteria", "OBSERVATION", 43, 51]]], ["In the newborn period, organisms from the maternal genital tract are likely causes and include Group B Streptococcus , Escherichia coli , enteric Gram-negative bacilli, Listeria , and Chlamydia .", [["genital tract", "ANATOMY", 51, 64], ["Chlamydia", "DISEASE", 184, 193], ["maternal", "ORGANISM_SUBDIVISION", 42, 50], ["genital tract", "ORGANISM_SUBDIVISION", 51, 64], ["Group B Streptococcus", "ORGANISM", 95, 116], ["Escherichia coli", "ORGANISM", 119, 135], ["enteric Gram-negative bacilli", "GENE_OR_GENE_PRODUCT", 138, 167], ["Escherichia coli", "SPECIES", 119, 135], ["Escherichia coli", "SPECIES", 119, 135], ["organisms", "PROBLEM", 23, 32], ["the maternal genital tract", "PROBLEM", 38, 64], ["Group B Streptococcus", "PROBLEM", 95, 116], ["Escherichia coli", "PROBLEM", 119, 135], ["enteric Gram", "TEST", 138, 150], ["Listeria", "PROBLEM", 169, 177], ["Chlamydia", "PROBLEM", 184, 193], ["genital tract", "ANATOMY", 51, 64], ["Escherichia coli", "OBSERVATION", 119, 135], ["negative bacilli", "OBSERVATION", 151, 167], ["Chlamydia", "OBSERVATION", 184, 193]]], ["In older infants, Streptococcus pneumoniae becomes a signifi cant cause and remains so until 6 years of age.", [["Streptococcus pneumoniae", "DISEASE", 18, 42], ["infants", "ORGANISM", 9, 16], ["Streptococcus pneumoniae", "ORGANISM", 18, 42], ["infants", "SPECIES", 9, 16], ["Streptococcus pneumoniae", "SPECIES", 18, 42], ["Streptococcus pneumoniae", "SPECIES", 18, 42], ["Streptococcus pneumoniae", "PROBLEM", 18, 42], ["Streptococcus pneumoniae", "OBSERVATION", 18, 42]]], ["Group A Streptococcus and Staphylococcus aureus are uncommon causes.", [["Staphylococcus aureus", "DISEASE", 26, 47], ["Group A Streptococcus", "ORGANISM", 0, 21], ["Staphylococcus aureus", "ORGANISM", 26, 47], ["Staphylococcus aureus", "SPECIES", 26, 47], ["Staphylococcus aureus", "SPECIES", 26, 47], ["Group A Streptococcus", "TEST", 0, 21], ["Staphylococcus aureus", "PROBLEM", 26, 47], ["Streptococcus", "OBSERVATION", 8, 21], ["Staphylococcus aureus", "OBSERVATION", 26, 47]]], ["Moraxella catarralis is a common cause of upper respiratory tract disease, but rarely causes pneumonia.", [["upper respiratory tract", "ANATOMY", 42, 65], ["Moraxella catarralis", "DISEASE", 0, 20], ["respiratory tract disease", "DISEASE", 48, 73], ["pneumonia", "DISEASE", 93, 102], ["Moraxella catarralis", "ORGANISM", 0, 20], ["upper", "ORGANISM_SUBDIVISION", 42, 47], ["respiratory tract", "ORGANISM_SUBDIVISION", 48, 65], ["Moraxella catarralis", "SPECIES", 0, 20], ["Moraxella catarralis", "SPECIES", 0, 20], ["Moraxella catarralis", "PROBLEM", 0, 20], ["upper respiratory tract disease", "PROBLEM", 42, 73], ["pneumonia", "PROBLEM", 93, 102], ["upper", "ANATOMY_MODIFIER", 42, 47], ["respiratory tract", "ANATOMY", 48, 65], ["disease", "OBSERVATION", 66, 73], ["pneumonia", "OBSERVATION", 93, 102]]], ["About 20% of infants with pertussis will have bacterial co-infection.", [["pertussis", "DISEASE", 26, 35], ["bacterial co-infection", "DISEASE", 46, 68], ["infants", "ORGANISM", 13, 20], ["infants", "SPECIES", 13, 20], ["pertussis", "PROBLEM", 26, 35], ["bacterial co-infection", "PROBLEM", 46, 68], ["bacterial", "OBSERVATION_MODIFIER", 46, 55], ["co-infection", "OBSERVATION", 56, 68]]], ["In children older than 6 years of age, Streptococcus pneumoniae remains the most common cause.", [["Streptococcus pneumoniae", "DISEASE", 39, 63], ["children", "ORGANISM", 3, 11], ["Streptococcus pneumoniae", "ORGANISM", 39, 63], ["children", "SPECIES", 3, 11], ["Streptococcus pneumoniae", "SPECIES", 39, 63], ["Streptococcus pneumoniae", "SPECIES", 39, 63], ["Streptococcus pneumoniae", "PROBLEM", 39, 63], ["Streptococcus pneumoniae", "OBSERVATION", 39, 63], ["most common", "OBSERVATION_MODIFIER", 76, 87]]], ["Hemophilus infl uenzae type B (HIB), and most recently Streptococcus pneumoniae , have decreased signifi cantly as causes of CAP due to the widespread use of effective vaccines.C HAPTER 25 \u2022 AC UTE PU LMONARY I N FECTIONSIn the older child and young adolescent, the atypical pneumonias, Mycoplasma and Chlamydia , become more prevalent and viral causes less common.", [["Hemophilus infl uenzae type B", "DISEASE", 0, 29], ["Streptococcus pneumoniae", "DISEASE", 55, 79], ["CAP", "DISEASE", 125, 128], ["pneumonias", "DISEASE", 275, 285], ["Mycoplasma and Chlamydia", "DISEASE", 287, 311], ["Hemophilus infl uenzae type B", "ORGANISM", 0, 29], ["HIB", "CANCER", 31, 34], ["Streptococcus pneumoniae", "ORGANISM", 55, 79], ["Hemophilus infl uenzae", "SPECIES", 0, 22], ["Streptococcus pneumoniae", "SPECIES", 55, 79], ["child", "SPECIES", 234, 239], ["Hemophilus infl uenzae type B", "SPECIES", 0, 29], ["HIB", "SPECIES", 31, 34], ["Streptococcus pneumoniae", "SPECIES", 55, 79], ["Hemophilus", "PROBLEM", 0, 10], ["type B (HIB)", "PROBLEM", 23, 35], ["Streptococcus pneumoniae", "PROBLEM", 55, 79], ["CAP", "PROBLEM", 125, 128], ["effective vaccines", "TREATMENT", 158, 176], ["the atypical pneumonias", "PROBLEM", 262, 285], ["Mycoplasma", "PROBLEM", 287, 297], ["Chlamydia", "PROBLEM", 302, 311], ["Streptococcus pneumoniae", "OBSERVATION", 55, 79], ["atypical", "OBSERVATION_MODIFIER", 266, 274], ["pneumonias", "OBSERVATION", 275, 285], ["Mycoplasma", "OBSERVATION", 287, 297]]], ["Rare bacterial pneumonias can occur with animal contact and include: Francisella tularensis (rabbits); Chlamydia psittaci (parrots and birds); Coxiella burnetii (sheep); and Salmonella choleraesuis (pigs).", [["pneumonias", "DISEASE", 15, 25], ["Chlamydia psittaci", "DISEASE", 103, 121], ["Coxiella burnetii", "DISEASE", 143, 160], ["Francisella tularensis", "ORGANISM", 69, 91], ["rabbits", "ORGANISM", 93, 100], ["Chlamydia psittaci", "ORGANISM", 103, 121], ["parrots", "ORGANISM_SUBDIVISION", 123, 130], ["birds", "ORGANISM", 135, 140], ["Coxiella burnetii", "ORGANISM", 143, 160], ["sheep", "ORGANISM", 162, 167], ["Salmonella choleraesuis", "ORGANISM", 174, 197], ["pigs", "ORGANISM", 199, 203], ["Francisella tularensis", "SPECIES", 69, 91], ["rabbits", "SPECIES", 93, 100], ["Chlamydia psittaci", "SPECIES", 103, 121], ["Coxiella burnetii", "SPECIES", 143, 160], ["sheep", "SPECIES", 162, 167], ["Salmonella choleraesuis", "SPECIES", 174, 197], ["pigs", "SPECIES", 199, 203], ["Francisella tularensis", "SPECIES", 69, 91], ["rabbits", "SPECIES", 93, 100], ["Chlamydia psittaci", "SPECIES", 103, 121], ["Coxiella burnetii", "SPECIES", 143, 160], ["sheep", "SPECIES", 162, 167], ["Salmonella choleraesuis", "SPECIES", 174, 197], ["Rare bacterial pneumonias", "PROBLEM", 0, 25], ["Francisella tularensis (rabbits)", "PROBLEM", 69, 101], ["Chlamydia psittaci", "PROBLEM", 103, 121], ["Coxiella burnetii (sheep)", "PROBLEM", 143, 168], ["Salmonella choleraesuis", "PROBLEM", 174, 197], ["bacterial", "OBSERVATION_MODIFIER", 5, 14], ["pneumonias", "OBSERVATION", 15, 25]]], ["Children with congenital anatomical defects, immunodefi ciencies, and genetic disorders are at increased risk for bacterial, viral and fungal pneumonia.Normal Host Defense MechanismsThe airways are normally sterile below the sublaryngeal area to the lung parenchyma.", [["airways", "ANATOMY", 186, 193], ["sublaryngeal area", "ANATOMY", 225, 242], ["lung parenchyma", "ANATOMY", 250, 265], ["congenital anatomical defects", "DISEASE", 14, 43], ["immunodefi ciencies", "DISEASE", 45, 64], ["genetic disorders", "DISEASE", 70, 87], ["bacterial, viral and fungal pneumonia", "DISEASE", 114, 151], ["Children", "ORGANISM", 0, 8], ["airways", "MULTI-TISSUE_STRUCTURE", 186, 193], ["sublaryngeal area", "MULTI-TISSUE_STRUCTURE", 225, 242], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 250, 265], ["Children", "SPECIES", 0, 8], ["congenital anatomical defects", "PROBLEM", 14, 43], ["immunodefi ciencies", "PROBLEM", 45, 64], ["genetic disorders", "PROBLEM", 70, 87], ["bacterial, viral and fungal pneumonia", "PROBLEM", 114, 151], ["anatomical defects", "OBSERVATION", 25, 43], ["bacterial", "OBSERVATION_MODIFIER", 114, 123], ["viral", "OBSERVATION", 125, 130], ["fungal", "OBSERVATION_MODIFIER", 135, 141], ["pneumonia", "OBSERVATION", 142, 151], ["Host Defense", "OBSERVATION", 159, 171], ["airways", "ANATOMY", 186, 193], ["normally", "OBSERVATION", 198, 206], ["sublaryngeal", "ANATOMY_MODIFIER", 225, 237], ["area", "ANATOMY_MODIFIER", 238, 242], ["lung", "ANATOMY", 250, 254], ["parenchyma", "ANATOMY_MODIFIER", 255, 265]]], ["There are several protective mechanisms that include anatomic and mechanical factors, local immune defenses, and the systemic immune response.", [["anatomic and mechanical factors", "PROBLEM", 53, 84], ["local immune defenses", "PROBLEM", 86, 107], ["the systemic immune response", "PROBLEM", 113, 141], ["immune response", "OBSERVATION", 126, 141]]], ["Microbes are fi ltered by nasal hairs or are expelled from the airways by the epiglottic refl ex, cough refl ex, and mucociliary apparatus.", [["nasal hairs", "ANATOMY", 26, 37], ["airways", "ANATOMY", 63, 70], ["mucociliary", "ANATOMY", 117, 128], ["nasal hairs", "MULTI-TISSUE_STRUCTURE", 26, 37], ["airways", "MULTI-TISSUE_STRUCTURE", 63, 70], ["mucociliary apparatus", "MULTI-TISSUE_STRUCTURE", 117, 138], ["nasal hairs", "PROBLEM", 26, 37], ["cough refl ex", "PROBLEM", 98, 111], ["mucociliary apparatus", "PROBLEM", 117, 138], ["nasal hairs", "ANATOMY", 26, 37], ["airways", "ANATOMY", 63, 70], ["epiglottic", "ANATOMY", 78, 88], ["mucociliary apparatus", "OBSERVATION", 117, 138]]], ["Immunoglobulin A (IgA) is the predominant immunoglobulin present in the upper respiratory tract.", [["upper respiratory tract", "ANATOMY", 72, 95], ["Immunoglobulin A", "GENE_OR_GENE_PRODUCT", 0, 16], ["IgA", "GENE_OR_GENE_PRODUCT", 18, 21], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 42, 56], ["upper respiratory", "ORGANISM_SUBDIVISION", 72, 89], ["tract", "ORGANISM_SUBDIVISION", 90, 95], ["Immunoglobulin A", "PROTEIN", 0, 16], ["IgA", "PROTEIN", 18, 21], ["immunoglobulin", "PROTEIN", 42, 56], ["Immunoglobulin A (IgA", "TEST", 0, 21], ["the predominant immunoglobulin", "PROBLEM", 26, 56], ["predominant", "OBSERVATION_MODIFIER", 30, 41], ["immunoglobulin", "OBSERVATION", 42, 56], ["upper", "ANATOMY_MODIFIER", 72, 77], ["respiratory tract", "ANATOMY", 78, 95]]], ["IgA is able to bind two antigens simultaneously, forming large antigen-antibody complexes.", [["IgA", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgA", "PROTEIN", 0, 3], ["antigens", "PROTEIN", 24, 32], ["antigen-antibody complexes", "PROTEIN", 63, 89]]], ["In this manner, the microbes are neutralized and removed by ciliary clearance, thus preventing microbial binding to the epithelium.", [["ciliary", "ANATOMY", 60, 67], ["epithelium", "ANATOMY", 120, 130], ["ciliary", "MULTI-TISSUE_STRUCTURE", 60, 67], ["epithelium", "TISSUE", 120, 130], ["ciliary clearance", "TEST", 60, 77], ["microbial binding to the epithelium", "PROBLEM", 95, 130], ["epithelium", "ANATOMY_MODIFIER", 120, 130]]], ["In the lower tract, immunoglobulin G (IgG) provides humoral protection by opsonizing microbes for phagocytosis by neutrophils and macrophages, activating the complement cascade, and by neutralizing bacterial It is diffi cult to determine the etiologic agent causing pneumonia, but when microbial agents are identifi ed, bacteria are isolated in 20-30%.", [["lower tract", "ANATOMY", 7, 18], ["neutrophils", "ANATOMY", 114, 125], ["macrophages", "ANATOMY", 130, 141], ["pneumonia", "DISEASE", 266, 275], ["lower tract", "ORGANISM_SUBDIVISION", 7, 18], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 20, 36], ["IgG", "GENE_OR_GENE_PRODUCT", 38, 41], ["neutrophils", "CELL", 114, 125], ["macrophages", "CELL", 130, 141], ["immunoglobulin G", "PROTEIN", 20, 36], ["IgG", "PROTEIN", 38, 41], ["neutrophils", "CELL_TYPE", 114, 125], ["macrophages", "CELL_TYPE", 130, 141], ["immunoglobulin G (IgG)", "TREATMENT", 20, 42], ["humoral protection", "TREATMENT", 52, 70], ["phagocytosis", "PROBLEM", 98, 110], ["neutrophils", "TEST", 114, 125], ["macrophages", "PROBLEM", 130, 141], ["the complement cascade", "TREATMENT", 154, 176], ["neutralizing bacterial", "TREATMENT", 185, 207], ["pneumonia", "PROBLEM", 266, 275], ["microbial agents", "TREATMENT", 286, 302], ["bacteria", "PROBLEM", 320, 328], ["lower tract", "ANATOMY", 7, 18], ["pneumonia", "OBSERVATION", 266, 275]]], ["Etiology of community acquired pneumonia based on age endotoxin.", [["pneumonia", "DISEASE", 31, 40], ["endotoxin", "CHEMICAL", 54, 63], ["community acquired pneumonia", "PROBLEM", 12, 40], ["community acquired", "OBSERVATION", 12, 30], ["pneumonia", "OBSERVATION", 31, 40]]], ["Alveolar macrophages produce superoxide anions, hydrogen peroxide, and hydroxyl radicals that serve an important role in the host defense; however, uncontrolled production can lead to lung injury.", [["Alveolar macrophages", "ANATOMY", 0, 20], ["lung", "ANATOMY", 184, 188], ["superoxide", "CHEMICAL", 29, 39], ["hydrogen peroxide", "CHEMICAL", 48, 65], ["hydroxyl", "CHEMICAL", 71, 79], ["lung injury", "DISEASE", 184, 195], ["superoxide", "CHEMICAL", 29, 39], ["hydrogen peroxide", "CHEMICAL", 48, 65], ["hydroxyl", "CHEMICAL", 71, 79], ["Alveolar macrophages", "CELL", 0, 20], ["superoxide anions", "SIMPLE_CHEMICAL", 29, 46], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 48, 65], ["hydroxyl radicals", "SIMPLE_CHEMICAL", 71, 88], ["lung", "ORGAN", 184, 188], ["Alveolar macrophages", "CELL_TYPE", 0, 20], ["Alveolar macrophages", "PROBLEM", 0, 20], ["superoxide anions", "TREATMENT", 29, 46], ["hydrogen peroxide", "TREATMENT", 48, 65], ["hydroxyl radicals", "TREATMENT", 71, 88], ["uncontrolled production", "PROBLEM", 148, 171], ["lung injury", "PROBLEM", 184, 195], ["superoxide anions", "OBSERVATION", 29, 46], ["lung", "ANATOMY", 184, 188], ["injury", "OBSERVATION", 189, 195]]], ["In addition to oxygen radicals, a number of cytokines are produced by the alveolar macrophages.", [["alveolar macrophages", "ANATOMY", 74, 94], ["oxygen", "CHEMICAL", 15, 21], ["oxygen", "CHEMICAL", 15, 21], ["oxygen radicals", "SIMPLE_CHEMICAL", 15, 30], ["alveolar macrophages", "CELL", 74, 94], ["cytokines", "PROTEIN", 44, 53], ["alveolar macrophages", "CELL_TYPE", 74, 94], ["oxygen radicals", "TREATMENT", 15, 30], ["oxygen radicals", "OBSERVATION", 15, 30], ["alveolar macrophages", "OBSERVATION", 74, 94]]], ["These include IL-1, IL-6, TNF, transforming growth factor-\u03b2 (TGF-b ), chemotactic factors, platelet derived growth factor, and M-CSF.", [["IL-1", "GENE_OR_GENE_PRODUCT", 14, 18], ["IL-6", "GENE_OR_GENE_PRODUCT", 20, 24], ["TNF", "GENE_OR_GENE_PRODUCT", 26, 29], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 31, 59], ["TGF-b", "GENE_OR_GENE_PRODUCT", 61, 66], ["platelet derived growth factor", "GENE_OR_GENE_PRODUCT", 91, 121], ["M-CSF", "GENE_OR_GENE_PRODUCT", 127, 132], ["IL-1, IL-6", "PROTEIN", 14, 24], ["TNF", "PROTEIN", 26, 29], ["transforming growth factor-\u03b2", "PROTEIN", 31, 59], ["TGF-b", "PROTEIN", 61, 66], ["chemotactic factors", "PROTEIN", 70, 89], ["platelet derived growth factor", "PROTEIN", 91, 121], ["M-CSF", "PROTEIN", 127, 132], ["IL", "TEST", 14, 16], ["IL", "TEST", 20, 22], ["TNF", "PROBLEM", 26, 29], ["transforming growth factor", "TEST", 31, 57], ["TGF", "TEST", 61, 64], ["chemotactic factors", "PROBLEM", 70, 89], ["platelet derived growth factor", "TEST", 91, 121], ["M-CSF", "TEST", 127, 132]]], ["These cytokines play a central role in phagocytic recruitment and activation.", [["cytokines", "PROTEIN", 6, 15], ["phagocytic recruitment", "TREATMENT", 39, 61], ["central", "OBSERVATION_MODIFIER", 23, 30], ["phagocytic recruitment", "OBSERVATION", 39, 61]]], ["Infection occurs when one or more of the defense mechanisms is altered or if the inoculum is too large.", [["Infection", "PROBLEM", 0, 9], ["the inoculum", "PROBLEM", 77, 89], ["altered", "OBSERVATION_MODIFIER", 63, 70], ["inoculum", "OBSERVATION", 81, 89], ["too large", "OBSERVATION_MODIFIER", 93, 102]]], ["Pathogens typically gain entry through inhalation of aerosolized material or through aspiration of resistant organisms inhabiting the upper airways.", [["upper airways", "ANATOMY", 134, 147], ["upper airways", "MULTI-TISSUE_STRUCTURE", 134, 147], ["Pathogens", "PROBLEM", 0, 9], ["aerosolized material", "PROBLEM", 53, 73], ["resistant organisms inhabiting the upper airways", "PROBLEM", 99, 147], ["upper", "ANATOMY_MODIFIER", 134, 139], ["airways", "ANATOMY", 140, 147]]], ["Less frequently, pneumonia can occur via hematogenous spread.Normal Host Defense MechanismsIn children with bacterial pneumonia, a signifi cant portion will have a concurrent or preceding viral infection.", [["pneumonia", "DISEASE", 17, 26], ["bacterial pneumonia", "DISEASE", 108, 127], ["viral infection", "DISEASE", 188, 203], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102], ["pneumonia", "PROBLEM", 17, 26], ["hematogenous spread", "PROBLEM", 41, 60], ["bacterial pneumonia", "PROBLEM", 108, 127], ["a signifi cant portion", "PROBLEM", 129, 151], ["preceding viral infection", "PROBLEM", 178, 203], ["pneumonia", "OBSERVATION", 17, 26], ["hematogenous", "OBSERVATION_MODIFIER", 41, 53], ["Host Defense", "OBSERVATION_MODIFIER", 68, 80], ["bacterial", "OBSERVATION_MODIFIER", 108, 117], ["pneumonia", "OBSERVATION", 118, 127], ["viral", "OBSERVATION_MODIFIER", 188, 193], ["infection", "OBSERVATION", 194, 203]]], ["Viral infection may predispose to bacterial superinfection by reducing clearance mechanisms and by weakening the host immune response.PathophysiologyPathogens entering the lower airways evoke an exudative consolidation of pulmonary tissues.", [["lower airways", "ANATOMY", 172, 185], ["pulmonary tissues", "ANATOMY", 222, 239], ["Viral infection", "DISEASE", 0, 15], ["superinfection", "DISEASE", 44, 58], ["Viral", "ORGANISM", 0, 5], ["lower", "ORGANISM_SUBDIVISION", 172, 177], ["airways", "MULTI-TISSUE_STRUCTURE", 178, 185], ["pulmonary tissues", "TISSUE", 222, 239], ["Viral infection", "PROBLEM", 0, 15], ["bacterial superinfection", "PROBLEM", 34, 58], ["reducing clearance mechanisms", "PROBLEM", 62, 91], ["PathophysiologyPathogens", "PROBLEM", 134, 158], ["an exudative consolidation of pulmonary tissues", "PROBLEM", 192, 239], ["infection", "OBSERVATION", 6, 15], ["bacterial", "OBSERVATION_MODIFIER", 34, 43], ["superinfection", "OBSERVATION", 44, 58], ["Pathogens", "OBSERVATION", 149, 158], ["lower", "ANATOMY_MODIFIER", 172, 177], ["airways", "ANATOMY", 178, 185], ["exudative", "OBSERVATION_MODIFIER", 195, 204], ["consolidation", "OBSERVATION", 205, 218], ["pulmonary tissues", "ANATOMY", 222, 239]]], ["Initially, there is hyperemia of lung parenchyma due to vascular engorgement and capillary leak causing exudation and intra-alveolar fl uid accumulation.", [["lung parenchyma", "ANATOMY", 33, 48], ["vascular", "ANATOMY", 56, 64], ["capillary", "ANATOMY", 81, 90], ["intra-alveolar", "ANATOMY", 118, 132], ["hyperemia", "DISEASE", 20, 29], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 33, 48], ["vascular", "MULTI-TISSUE_STRUCTURE", 56, 64], ["capillary", "TISSUE", 81, 90], ["hyperemia of lung parenchyma", "PROBLEM", 20, 48], ["vascular engorgement", "PROBLEM", 56, 76], ["capillary leak", "PROBLEM", 81, 95], ["exudation", "PROBLEM", 104, 113], ["intra-alveolar fl uid accumulation", "PROBLEM", 118, 152], ["hyperemia", "OBSERVATION", 20, 29], ["lung", "ANATOMY", 33, 37], ["parenchyma", "ANATOMY_MODIFIER", 38, 48], ["vascular", "ANATOMY", 56, 64], ["engorgement", "OBSERVATION", 65, 76], ["capillary leak", "OBSERVATION", 81, 95], ["exudation", "OBSERVATION_MODIFIER", 104, 113], ["intra-alveolar fl uid accumulation", "OBSERVATION", 118, 152]]], ["Fibrin is then deposited and the airways are infi ltrated with neutrophils.", [["airways", "ANATOMY", 33, 40], ["neutrophils", "ANATOMY", 63, 74], ["Fibrin", "GENE_OR_GENE_PRODUCT", 0, 6], ["airways", "MULTI-TISSUE_STRUCTURE", 33, 40], ["neutrophils", "CELL", 63, 74], ["neutrophils", "CELL_TYPE", 63, 74], ["Fibrin", "TREATMENT", 0, 6], ["neutrophils", "TEST", 63, 74], ["airways", "ANATOMY", 33, 40], ["neutrophils", "OBSERVATION", 63, 74]]], ["Consolidation causes a decrease in lung compliance and vital capacity and a total reduction in the surface area available for gas exchange.", [["lung", "ANATOMY", 35, 39], ["surface area", "ANATOMY", 99, 111], ["lung", "ORGAN", 35, 39], ["Consolidation", "PROBLEM", 0, 13], ["a decrease in lung compliance", "PROBLEM", 21, 50], ["vital capacity", "TEST", 55, 69], ["a total reduction", "TREATMENT", 74, 91], ["the surface area", "TREATMENT", 95, 111], ["gas exchange", "TEST", 126, 138], ["decrease", "OBSERVATION_MODIFIER", 23, 31], ["lung", "ANATOMY", 35, 39], ["compliance", "OBSERVATION", 40, 50], ["total", "OBSERVATION_MODIFIER", 76, 81], ["reduction", "OBSERVATION_MODIFIER", 82, 91], ["surface", "OBSERVATION_MODIFIER", 99, 106], ["gas exchange", "OBSERVATION", 126, 138]]], ["A physiologic shunt (V/Q mismatch) occurs as there is increased blood fl ow through poorly ventilated segments of lung, resulting in hypoxia.", [["blood", "ANATOMY", 64, 69], ["lung", "ANATOMY", 114, 118], ["hypoxia", "DISEASE", 133, 140], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["lung", "ORGAN", 114, 118], ["A physiologic shunt (V/Q mismatch)", "TREATMENT", 0, 34], ["increased blood fl ow through poorly ventilated segments of lung", "PROBLEM", 54, 118], ["hypoxia", "PROBLEM", 133, 140], ["physiologic", "OBSERVATION_MODIFIER", 2, 13], ["shunt", "OBSERVATION", 14, 19], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["blood fl", "OBSERVATION", 64, 72], ["ventilated", "OBSERVATION", 91, 101], ["segments", "ANATOMY_MODIFIER", 102, 110], ["lung", "ANATOMY", 114, 118], ["hypoxia", "OBSERVATION", 133, 140]]], ["Compensatory hypoxic vasoconstriction may occur in an attempt to reduce V/Q mismatch and hypoxia, especially in localized areas of consolidation.PathophysiologyWith treatment, resolution of consolidation will occur in 8-10 days.", [["hypoxia", "DISEASE", 89, 96], ["Compensatory hypoxic vasoconstriction", "PROBLEM", 0, 37], ["V/Q mismatch", "PROBLEM", 72, 84], ["hypoxia", "PROBLEM", 89, 96], ["consolidation", "PROBLEM", 131, 144], ["PathophysiologyWith treatment", "TREATMENT", 145, 174], ["consolidation", "PROBLEM", 190, 203], ["hypoxic", "OBSERVATION_MODIFIER", 13, 20], ["vasoconstriction", "OBSERVATION", 21, 37], ["hypoxia", "OBSERVATION", 89, 96], ["localized", "OBSERVATION_MODIFIER", 112, 121], ["areas", "OBSERVATION_MODIFIER", 122, 127], ["consolidation", "OBSERVATION", 131, 144], ["resolution", "OBSERVATION_MODIFIER", 176, 186], ["consolidation", "OBSERVATION", 190, 203]]], ["The exudate undergoes enzymatic digestion and is either reabsorbed or removed by coughing.", [["exudate", "ANATOMY", 4, 11], ["exudate", "ORGANISM_SUBSTANCE", 4, 11], ["The exudate", "PROBLEM", 0, 11], ["enzymatic digestion", "PROBLEM", 22, 41], ["coughing", "PROBLEM", 81, 89], ["exudate", "OBSERVATION", 4, 11], ["enzymatic digestion", "OBSERVATION", 22, 41]]], ["If the bacterial infection extends into the pleural cavity, an empyema may result.Bacterial Pneumonia Streptococcus PneumoniaeStreptococcus pneumoniae is a Gram-positive diplococcus that is frequently found in the upper respiratory tract.", [["pleural cavity", "ANATOMY", 44, 58], ["empyema", "ANATOMY", 63, 70], ["upper respiratory tract", "ANATOMY", 214, 237], ["bacterial infection", "DISEASE", 7, 26], ["empyema", "DISEASE", 63, 70], ["pleural cavity", "MULTI-TISSUE_STRUCTURE", 44, 58], ["Bacterial Pneumonia Streptococcus PneumoniaeStreptococcus pneumoniae", "ORGANISM", 82, 150], ["Gram-", "GENE_OR_GENE_PRODUCT", 156, 161], ["upper respiratory", "ORGANISM_SUBDIVISION", 214, 231], ["tract", "ORGANISM_SUBDIVISION", 232, 237], ["Pneumonia", "SPECIES", 92, 101], ["Streptococcus PneumoniaeStreptococcus pneumoniae", "SPECIES", 102, 150], ["Streptococcus PneumoniaeStreptococcus pneumoniae", "SPECIES", 102, 150], ["the bacterial infection", "PROBLEM", 3, 26], ["an empyema", "PROBLEM", 60, 70], ["Bacterial Pneumonia Streptococcus PneumoniaeStreptococcus pneumoniae", "PROBLEM", 82, 150], ["a Gram-positive diplococcus", "PROBLEM", 154, 181], ["bacterial", "OBSERVATION_MODIFIER", 7, 16], ["infection", "OBSERVATION", 17, 26], ["pleural", "ANATOMY", 44, 51], ["cavity", "ANATOMY_MODIFIER", 52, 58], ["empyema", "OBSERVATION", 63, 70], ["Pneumonia", "OBSERVATION", 92, 101], ["positive diplococcus", "OBSERVATION", 161, 181], ["upper", "ANATOMY_MODIFIER", 214, 219], ["respiratory tract", "ANATOMY", 220, 237]]], ["There are over 80 capsular serotypes with 80% of infections caused by 14 serotypes.", [["infections", "DISEASE", 49, 59], ["80 capsular serotypes", "TREATMENT", 15, 36], ["infections", "PROBLEM", 49, 59]]], ["It is the most common bacterial cause for pneumonia occurring at a peak age of 13-18 months.", [["pneumonia", "DISEASE", 42, 51], ["pneumonia", "PROBLEM", 42, 51], ["most common", "OBSERVATION_MODIFIER", 10, 21], ["pneumonia", "OBSERVATION", 42, 51]]], ["Typically, it causes a lobar or segmental consolidation, but it may manifest as patchy infi ltrates in infants.", [["lobar", "ANATOMY", 23, 28], ["infants", "ORGANISM", 103, 110], ["infants", "SPECIES", 103, 110], ["a lobar or segmental consolidation", "PROBLEM", 21, 55], ["patchy infi ltrates in infants", "PROBLEM", 80, 110], ["lobar", "OBSERVATION_MODIFIER", 23, 28], ["segmental", "OBSERVATION_MODIFIER", 32, 41], ["consolidation", "OBSERVATION", 42, 55], ["may manifest", "UNCERTAINTY", 64, 76], ["patchy", "OBSERVATION_MODIFIER", 80, 86]]], ["Pleural effusions occur in up to 20% of children that require hospitalization (Fig. 25-2 ) .", [["Pleural effusions", "ANATOMY", 0, 17], ["Pleural effusions", "DISEASE", 0, 17], ["Pleural effusions", "PATHOLOGICAL_FORMATION", 0, 17], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["Pleural effusions", "PROBLEM", 0, 17], ["effusions", "OBSERVATION", 8, 17]]], ["Pneumatocoele formation is rare.", [["Pneumatocoele", "ANATOMY", 0, 13], ["Pneumatocoele", "DISEASE", 0, 13], ["Pneumatocoele", "SIMPLE_CHEMICAL", 0, 13], ["Pneumatocoele formation", "PROBLEM", 0, 23], ["rare", "OBSERVATION_MODIFIER", 27, 31]]], ["Hemolytic uremic syndrome is associated with neuraminidase-producing strains.Bacterial Pneumonia Streptococcus PneumoniaeTreatment is typically with a penicillin or cephalosporin.", [["Hemolytic uremic syndrome", "DISEASE", 0, 25], ["Pneumonia Streptococcus PneumoniaeTreatment", "DISEASE", 87, 130], ["penicillin", "CHEMICAL", 151, 161], ["cephalosporin", "CHEMICAL", 165, 178], ["penicillin", "CHEMICAL", 151, 161], ["cephalosporin", "CHEMICAL", 165, 178], ["penicillin", "SIMPLE_CHEMICAL", 151, 161], ["cephalosporin", "SIMPLE_CHEMICAL", 165, 178], ["neuraminidase", "PROTEIN", 45, 58], ["Hemolytic uremic syndrome", "PROBLEM", 0, 25], ["neuraminidase", "PROBLEM", 45, 58], ["strains", "PROBLEM", 69, 76], ["Bacterial Pneumonia Streptococcus PneumoniaeTreatment", "PROBLEM", 77, 130], ["a penicillin", "TREATMENT", 149, 161], ["cephalosporin", "TREATMENT", 165, 178], ["uremic syndrome", "OBSERVATION", 10, 25], ["Pneumonia", "OBSERVATION", 87, 96]]], ["Emerging resistance may require initial therapy with vancomycin.", [["vancomycin", "CHEMICAL", 53, 63], ["vancomycin", "CHEMICAL", 53, 63], ["vancomycin", "SIMPLE_CHEMICAL", 53, 63], ["initial therapy", "TREATMENT", 32, 47], ["vancomycin", "TREATMENT", 53, 63]]], ["In hospitalized patients, parenteral therapy is generally needed for 48-72 h after fever resolves, followed by completion of 7-10 days of enteral therapy.Bacterial Pneumonia Streptococcus PneumoniaePneumococcal conjugate vaccines (PCV) have been developed that confer immunity against 7 and 13 serotypes.", [["parenteral", "ANATOMY", 26, 36], ["fever", "DISEASE", 83, 88], ["patients", "ORGANISM", 16, 24], ["Bacterial Pneumonia Streptococcus PneumoniaePneumococcal conjugate vaccines", "ORGANISM", 154, 229], ["patients", "SPECIES", 16, 24], ["Pneumonia Streptococcus PneumoniaePneumococcal", "SPECIES", 164, 210], ["PCV", "SPECIES", 231, 234], ["parenteral therapy", "TREATMENT", 26, 44], ["fever", "PROBLEM", 83, 88], ["enteral therapy", "TREATMENT", 138, 153], ["Bacterial Pneumonia", "PROBLEM", 154, 173], ["Streptococcus PneumoniaePneumococcal conjugate vaccines", "TREATMENT", 174, 229], ["Pneumonia", "OBSERVATION", 164, 173], ["conjugate vaccines", "OBSERVATION", 211, 229]]], ["The 7-valent PCV (Prevnar) was licensed for use in the United States in 2000.", [["Prevnar", "CHEMICAL", 18, 25], ["The 7-valent PCV", "TREATMENT", 0, 16]]], ["A 13-valent PCV has been recently introduced and will replace the 7-valent PCV.", [["A 13-valent PCV", "TREATMENT", 0, 15], ["the 7-valent PCV", "TREATMENT", 62, 78]]], ["The PCVs have been highly effective at reducing hospitalizations among children younger than 2 years for pneumococcal pneumonia.Bacterial Pneumonia Streptococcus PneumoniaePCV is now recommended universally for children younger than 24 months of age and older children at high risk due to underlying diseases.", [["pneumonia", "DISEASE", 118, 127], ["Pneumonia Streptococcus", "DISEASE", 138, 161], ["children", "ORGANISM", 71, 79], ["children", "ORGANISM", 211, 219], ["children", "ORGANISM", 260, 268], ["children", "SPECIES", 71, 79], ["children", "SPECIES", 211, 219], ["children", "SPECIES", 260, 268], ["pneumococcal", "SPECIES", 105, 117], ["The PCVs", "TREATMENT", 0, 8], ["pneumococcal pneumonia", "PROBLEM", 105, 127], ["Bacterial Pneumonia Streptococcus PneumoniaePCV", "PROBLEM", 128, 175], ["underlying diseases", "PROBLEM", 289, 308], ["highly", "OBSERVATION_MODIFIER", 19, 25], ["effective", "OBSERVATION_MODIFIER", 26, 35], ["pneumonia", "OBSERVATION", 118, 127], ["Pneumonia", "OBSERVATION", 138, 147], ["diseases", "OBSERVATION", 300, 308]]], ["High risk children include those with sickle cell disease and other types of functional asplenia, human immunodefi ciency syndrome, primary immunodefi ciency, children receiving immunosuppressive therapy, and children with chronic pulmonary or cardiac disease.", [["sickle cell", "ANATOMY", 38, 49], ["pulmonary", "ANATOMY", 231, 240], ["cardiac", "ANATOMY", 244, 251], ["sickle cell disease", "DISEASE", 38, 57], ["asplenia", "DISEASE", 88, 96], ["immunodefi ciency syndrome", "DISEASE", 104, 130], ["primary immunodefi ciency", "DISEASE", 132, 157], ["chronic pulmonary or cardiac disease", "DISEASE", 223, 259], ["children", "ORGANISM", 10, 18], ["sickle cell", "CELL", 38, 49], ["human", "ORGANISM", 98, 103], ["children", "ORGANISM", 159, 167], ["children", "ORGANISM", 209, 217], ["pulmonary", "ORGAN", 231, 240], ["cardiac", "ORGAN", 244, 251], ["children", "SPECIES", 10, 18], ["human", "SPECIES", 98, 103], ["children", "SPECIES", 159, 167], ["children", "SPECIES", 209, 217], ["human", "SPECIES", 98, 103], ["sickle cell disease", "PROBLEM", 38, 57], ["functional asplenia", "PROBLEM", 77, 96], ["human immunodefi ciency syndrome", "PROBLEM", 98, 130], ["primary immunodefi ciency", "PROBLEM", 132, 157], ["immunosuppressive therapy", "TREATMENT", 178, 203], ["chronic pulmonary or cardiac disease", "PROBLEM", 223, 259], ["sickle cell disease", "OBSERVATION", 38, 57], ["functional asplenia", "OBSERVATION", 77, 96], ["chronic", "OBSERVATION_MODIFIER", 223, 230], ["pulmonary", "ANATOMY", 231, 240], ["cardiac", "ANATOMY", 244, 251], ["disease", "OBSERVATION", 252, 259]]], ["A 23-valent PCV is available for Pneumonia occurs when one or more of the host defense mechanisms are altered.", [["Pneumonia", "DISEASE", 33, 42], ["PCV", "ORGANISM", 12, 15], ["A 23-valent PCV", "TREATMENT", 0, 15], ["Pneumonia", "PROBLEM", 33, 42], ["Pneumonia", "OBSERVATION", 33, 42], ["altered", "OBSERVATION_MODIFIER", 102, 109]]], ["Viruses enhance the host susceptibility to bacterial pathogens by affecting clearing mechanisms and by weakening the host immune response.Bacterial Pneumonia Streptococcus PneumoniaeStreptococcus pneumoniae is the most common bacterial cause for pneumonia.", [["pneumonia", "DISEASE", 246, 255], ["Bacterial Pneumonia Streptococcus PneumoniaeStreptococcus pneumoniae", "ORGANISM", 138, 206], ["Pneumonia", "SPECIES", 148, 157], ["Streptococcus PneumoniaeStreptococcus pneumoniae", "SPECIES", 158, 206], ["Streptococcus PneumoniaeStreptococcus pneumoniae", "SPECIES", 158, 206], ["Viruses", "PROBLEM", 0, 7], ["bacterial pathogens", "PROBLEM", 43, 62], ["Bacterial Pneumonia Streptococcus PneumoniaeStreptococcus pneumoniae", "PROBLEM", 138, 206], ["pneumonia", "PROBLEM", 246, 255], ["host susceptibility", "OBSERVATION_MODIFIER", 20, 39], ["bacterial", "OBSERVATION_MODIFIER", 43, 52], ["pathogens", "OBSERVATION", 53, 62], ["host immune response", "OBSERVATION", 117, 137], ["Pneumonia", "OBSERVATION", 148, 157], ["pneumoniae", "OBSERVATION", 196, 206], ["most common", "OBSERVATION_MODIFIER", 214, 225], ["pneumonia", "OBSERVATION", 246, 255]]], ["C HAPTER 25 \u2022 AC UTE PU LMONARY I N FECTIONS high risk children who need expanded serotype coverage.", [["children", "ORGANISM", 55, 63], ["children", "SPECIES", 55, 63], ["expanded serotype coverage", "TREATMENT", 73, 99]]], ["Children with sickle cell disease or functional asplenia should continue to receive antibiotic prophylaxis regardless of whether or not they have received pneumococcal vaccines.Chlamydia TrachomatisApproximately 50-75% of infants born to Chlamydia trachomatis -infected mothers will become infected at one or more anatomical site, including conjunctiva, nasopharynx, rectum, and vagina.", [["sickle cell", "ANATOMY", 14, 25], ["site", "ANATOMY", 325, 329], ["conjunctiva", "ANATOMY", 341, 352], ["nasopharynx", "ANATOMY", 354, 365], ["rectum", "ANATOMY", 367, 373], ["vagina", "ANATOMY", 379, 385], ["sickle cell disease", "DISEASE", 14, 33], ["functional asplenia", "DISEASE", 37, 56], ["Chlamydia TrachomatisApproximately", "DISEASE", 177, 211], ["Chlamydia trachomatis -infected", "DISEASE", 238, 269], ["Children", "ORGANISM", 0, 8], ["sickle cell", "CELL", 14, 25], ["infants", "ORGANISM", 222, 229], ["Chlamydia trachomatis", "ORGANISM", 238, 259], ["mothers", "ORGANISM", 270, 277], ["conjunctiva", "ORGAN", 341, 352], ["nasopharynx", "ORGAN", 354, 365], ["rectum", "ORGAN", 367, 373], ["vagina", "ORGAN", 379, 385], ["Children", "SPECIES", 0, 8], ["infants", "SPECIES", 222, 229], ["Chlamydia trachomatis", "SPECIES", 238, 259], ["pneumococcal", "SPECIES", 155, 167], ["Chlamydia trachomatis", "SPECIES", 238, 259], ["sickle cell disease", "PROBLEM", 14, 33], ["functional asplenia", "PROBLEM", 37, 56], ["antibiotic prophylaxis", "TREATMENT", 84, 106], ["pneumococcal vaccines", "TREATMENT", 155, 176], ["Chlamydia", "TEST", 177, 186], ["Chlamydia trachomatis", "PROBLEM", 238, 259], ["conjunctiva, nasopharynx, rectum, and vagina", "PROBLEM", 341, 385], ["sickle cell disease", "OBSERVATION", 14, 33], ["asplenia", "OBSERVATION", 48, 56], ["infected", "OBSERVATION", 290, 298], ["conjunctiva", "ANATOMY", 341, 352], ["nasopharynx", "ANATOMY", 354, 365], ["rectum", "ANATOMY", 367, 373], ["vagina", "ANATOMY", 379, 385]]], ["About 30% of infants with nasopharyngeal infections will develop pneumonia.", [["nasopharyngeal", "ANATOMY", 26, 40], ["nasopharyngeal infections", "DISEASE", 26, 51], ["pneumonia", "DISEASE", 65, 74], ["infants", "ORGANISM", 13, 20], ["nasopharyngeal", "CANCER", 26, 40], ["infants", "SPECIES", 13, 20], ["nasopharyngeal infections", "PROBLEM", 26, 51], ["pneumonia", "PROBLEM", 65, 74], ["nasopharyngeal", "ANATOMY", 26, 40], ["infections", "OBSERVATION", 41, 51], ["pneumonia", "OBSERVATION", 65, 74]]], ["The infants usually present at about 4-12 weeks of age with cough and congestion, but an absence of fever.", [["cough", "DISEASE", 60, 65], ["congestion", "DISEASE", 70, 80], ["fever", "DISEASE", 100, 105], ["infants", "ORGANISM", 4, 11], ["infants", "SPECIES", 4, 11], ["cough", "PROBLEM", 60, 65], ["congestion", "PROBLEM", 70, 80], ["fever", "PROBLEM", 100, 105], ["cough", "OBSERVATION", 60, 65], ["congestion", "OBSERVATION", 70, 80], ["fever", "OBSERVATION", 100, 105]]], ["The cough often interferes with the ability to feed.", [["cough", "DISEASE", 4, 9], ["The cough", "PROBLEM", 0, 9], ["cough", "OBSERVATION", 4, 9]]], ["Infants generally have tachypnea and rales on examination and chest x-ray frequently shows hyperinfl ation.", [["tachypnea", "DISEASE", 23, 32], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["tachypnea", "PROBLEM", 23, 32], ["rales", "PROBLEM", 37, 42], ["examination", "TEST", 46, 57], ["chest x-ray", "TEST", 62, 73], ["hyperinfl ation", "PROBLEM", 91, 106], ["tachypnea", "OBSERVATION", 23, 32], ["rales", "OBSERVATION", 37, 42], ["chest", "ANATOMY", 62, 67]]], ["A peripheral eosinophilia may be present.", [["peripheral eosinophilia", "DISEASE", 2, 25], ["A peripheral eosinophilia", "PROBLEM", 0, 25], ["peripheral", "ANATOMY_MODIFIER", 2, 12], ["eosinophilia", "OBSERVATION", 13, 25], ["may be", "UNCERTAINTY", 26, 32]]], ["C . trachomatis is susceptible to macrolides, tetracyclines, quinolones, and sulfonamides.", [["trachomatis", "DISEASE", 4, 15], ["macrolides", "CHEMICAL", 34, 44], ["tetracyclines", "CHEMICAL", 46, 59], ["quinolones", "CHEMICAL", 61, 71], ["sulfonamides", "CHEMICAL", 77, 89], ["macrolides", "CHEMICAL", 34, 44], ["tetracyclines", "CHEMICAL", 46, 59], ["quinolones", "CHEMICAL", 61, 71], ["sulfonamides", "CHEMICAL", 77, 89], ["C", "GENE_OR_GENE_PRODUCT", 0, 1], ["trachomatis", "ORGANISM", 4, 15], ["macrolides", "SIMPLE_CHEMICAL", 34, 44], ["tetracyclines", "SIMPLE_CHEMICAL", 46, 59], ["quinolones", "SIMPLE_CHEMICAL", 61, 71], ["sulfonamides", "SIMPLE_CHEMICAL", 77, 89], ["trachomatis", "SPECIES", 4, 15], ["trachomatis", "SPECIES", 4, 15], ["trachomatis", "PROBLEM", 4, 15], ["macrolides", "TREATMENT", 34, 44], ["tetracyclines", "TREATMENT", 46, 59], ["quinolones", "TREATMENT", 61, 71], ["sulfonamides", "TREATMENT", 77, 89]]], ["Erythromycin for 2-3 weeks is the treatment of choice for neonatal pneumonia.Chlamydia pneumoniae and Mycoplasma PneumoniaeMycoplasma pneumoniae and Chlamydia pneumoniae play a greater role in causing respiratory tract disease in children then previously thought.", [["respiratory tract", "ANATOMY", 201, 218], ["Erythromycin", "CHEMICAL", 0, 12], ["pneumonia", "DISEASE", 67, 76], ["Chlamydia pneumoniae", "DISEASE", 77, 97], ["Mycoplasma PneumoniaeMycoplasma pneumoniae", "DISEASE", 102, 144], ["Chlamydia pneumoniae", "DISEASE", 149, 169], ["respiratory tract disease", "DISEASE", 201, 226], ["Erythromycin", "CHEMICAL", 0, 12], ["Erythromycin", "SIMPLE_CHEMICAL", 0, 12], ["Chlamydia pneumoniae", "ORGANISM", 77, 97], ["Mycoplasma PneumoniaeMycoplasma pneumoniae", "ORGANISM", 102, 144], ["Chlamydia pneumoniae", "ORGANISM", 149, 169], ["respiratory tract", "ORGANISM_SUBDIVISION", 201, 218], ["children", "ORGANISM", 230, 238], ["Chlamydia pneumoniae", "SPECIES", 77, 97], ["Mycoplasma PneumoniaeMycoplasma pneumoniae", "SPECIES", 102, 144], ["Chlamydia pneumoniae", "SPECIES", 149, 169], ["children", "SPECIES", 230, 238], ["Chlamydia pneumoniae", "SPECIES", 77, 97], ["Mycoplasma PneumoniaeMycoplasma pneumoniae", "SPECIES", 102, 144], ["Chlamydia pneumoniae", "SPECIES", 149, 169], ["Erythromycin", "TREATMENT", 0, 12], ["neonatal pneumonia", "PROBLEM", 58, 76], ["Chlamydia pneumoniae", "PROBLEM", 77, 97], ["Mycoplasma PneumoniaeMycoplasma pneumoniae", "PROBLEM", 102, 144], ["Chlamydia pneumoniae", "PROBLEM", 149, 169], ["respiratory tract disease", "PROBLEM", 201, 226], ["pneumonia", "OBSERVATION", 67, 76], ["pneumoniae", "OBSERVATION", 87, 97], ["Mycoplasma PneumoniaeMycoplasma pneumoniae", "OBSERVATION", 102, 144], ["Chlamydia pneumoniae", "OBSERVATION", 149, 169], ["greater", "OBSERVATION_MODIFIER", 177, 184], ["respiratory tract", "ANATOMY", 201, 218]]], ["An indolent course that develops over 5-7 days manifested by low-grade fever, scratchy sore throat, aches, and headaches characterizes both pathogens.", [["throat", "ANATOMY", 92, 98], ["fever", "DISEASE", 71, 76], ["scratchy sore throat", "DISEASE", 78, 98], ["aches", "DISEASE", 100, 105], ["headaches", "DISEASE", 111, 120], ["aches", "ORGANISM_SUBDIVISION", 100, 105], ["low-grade fever", "PROBLEM", 61, 76], ["scratchy sore throat", "PROBLEM", 78, 98], ["aches", "PROBLEM", 100, 105], ["headaches", "PROBLEM", 111, 120], ["both pathogens", "PROBLEM", 135, 149], ["indolent", "OBSERVATION_MODIFIER", 3, 11], ["low-grade", "OBSERVATION_MODIFIER", 61, 70], ["fever", "OBSERVATION", 71, 76], ["sore throat", "ANATOMY", 87, 98], ["aches", "ANATOMY", 100, 105], ["both", "OBSERVATION_MODIFIER", 135, 139], ["pathogens", "OBSERVATION", 140, 149]]], ["After a few days, rales may be heard, particularly in the bases where the infi ltrates tend to occur.", [["rales", "PROBLEM", 18, 23], ["rales", "OBSERVATION", 18, 23], ["bases", "ANATOMY_MODIFIER", 58, 63]]], ["These organisms have been associated with the initiation, promotion, and exacerbation of asthma in children.", [["asthma", "DISEASE", 89, 95], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["asthma", "PROBLEM", 89, 95], ["exacerbation", "OBSERVATION_MODIFIER", 73, 85], ["asthma", "OBSERVATION", 89, 95]]], ["In addition, a pertussis-like illness with acute bronchitis has been described.", [["pertussis-like illness", "DISEASE", 15, 37], ["bronchitis", "DISEASE", 49, 59], ["a pertussis-like illness", "PROBLEM", 13, 37], ["acute bronchitis", "PROBLEM", 43, 59], ["pertussis", "OBSERVATION", 15, 24], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["bronchitis", "OBSERVATION", 49, 59]]], ["A recent study has shown that nearly half of the cases of community-acquired pneumonia in children aged 2-14 years were associated with M . pneumoniae or C . pneumoniae .", [["pneumonia", "DISEASE", 77, 86], ["children", "ORGANISM", 90, 98], ["M . pneumoniae", "ORGANISM", 136, 150], ["C . pneumoniae", "ORGANISM", 154, 168], ["children", "SPECIES", 90, 98], ["M . pneumoniae", "SPECIES", 136, 150], ["C . pneumoniae", "SPECIES", 154, 168], ["M . pneumoniae", "SPECIES", 136, 150], ["C . pneumoniae", "SPECIES", 154, 168], ["A recent study", "TEST", 0, 14], ["community-acquired pneumonia", "PROBLEM", 58, 86], ["M", "PROBLEM", 136, 137], ["pneumoniae", "PROBLEM", 140, 150], ["C", "PROBLEM", 154, 155], ["pneumoniae", "PROBLEM", 158, 168], ["pneumonia", "OBSERVATION", 77, 86], ["pneumoniae", "OBSERVATION", 140, 150], ["pneumoniae", "OBSERVATION", 158, 168]]], ["Classic atypical pneumonias caused by these organisms are usually mild and self-limited.", [["pneumonias", "DISEASE", 17, 27], ["Classic atypical pneumonias", "PROBLEM", 0, 27], ["these organisms", "PROBLEM", 38, 53], ["atypical", "OBSERVATION_MODIFIER", 8, 16], ["pneumonias", "OBSERVATION", 17, 27], ["mild", "OBSERVATION_MODIFIER", 66, 70]]], ["However, a number of studies have suggested that severe pulmonary infection may occur in otherwise healthy children.", [["pulmonary", "ANATOMY", 56, 65], ["pulmonary infection", "DISEASE", 56, 75], ["pulmonary", "ORGAN", 56, 65], ["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["studies", "TEST", 21, 28], ["severe pulmonary infection", "PROBLEM", 49, 75], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["pulmonary", "ANATOMY", 56, 65], ["infection", "OBSERVATION", 66, 75]]], ["Pleural effusions, pneumatocoeles, lung abscesses, pneumothoraces, bronchiectasis, chronic interstitial fi brosis, and acute respiratory distress syndrome although rare complications, have all been reported.", [["Pleural effusions", "ANATOMY", 0, 17], ["pneumatocoeles", "ANATOMY", 19, 33], ["lung abscesses", "ANATOMY", 35, 49], ["pneumothoraces", "ANATOMY", 51, 65], ["interstitial", "ANATOMY", 91, 103], ["respiratory", "ANATOMY", 125, 136], ["Pleural effusions", "DISEASE", 0, 17], ["pneumatocoeles", "DISEASE", 19, 33], ["lung abscesses", "DISEASE", 35, 49], ["pneumothoraces", "DISEASE", 51, 65], ["bronchiectasis", "DISEASE", 67, 81], ["interstitial fi brosis", "DISEASE", 91, 113], ["acute respiratory distress syndrome", "DISEASE", 119, 154], ["Pleural effusions", "PATHOLOGICAL_FORMATION", 0, 17], ["lung", "ORGAN", 35, 39], ["Pleural effusions", "PROBLEM", 0, 17], ["pneumatocoeles", "PROBLEM", 19, 33], ["lung abscesses", "PROBLEM", 35, 49], ["pneumothoraces", "PROBLEM", 51, 65], ["bronchiectasis", "PROBLEM", 67, 81], ["chronic interstitial fi brosis", "PROBLEM", 83, 113], ["acute respiratory distress syndrome", "PROBLEM", 119, 154], ["rare complications", "PROBLEM", 164, 182], ["effusions", "OBSERVATION", 8, 17], ["lung", "ANATOMY", 35, 39], ["abscesses", "OBSERVATION", 40, 49], ["pneumothoraces", "OBSERVATION", 51, 65], ["bronchiectasis", "OBSERVATION", 67, 81], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["interstitial", "ANATOMY_MODIFIER", 91, 103], ["fi brosis", "OBSERVATION", 104, 113], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["respiratory distress syndrome", "OBSERVATION", 125, 154], ["rare", "OBSERVATION_MODIFIER", 164, 168], ["complications", "OBSERVATION", 169, 182]]], ["Serological testing is the most common means of diagnosis, but this is often retrospective.", [["Serological testing", "TEST", 0, 19]]], ["Cultures obtained from swabbing the nasopharynx may take several days to grow.", [["nasopharynx", "ANATOMY", 36, 47], ["nasopharynx", "ORGAN", 36, 47], ["Cultures", "TEST", 0, 8], ["swabbing the nasopharynx", "PROBLEM", 23, 47], ["nasopharynx", "ANATOMY", 36, 47]]], ["PCR techniques are currently being refi ned and standardized.", [["PCR techniques", "TEST", 0, 14]]], ["Treatment with antibiotics reduces the rate of recurrent wheezing episodes, decreases morbidity, and shortens the duration of symptoms.", [["wheezing", "DISEASE", 57, 65], ["antibiotics", "TREATMENT", 15, 26], ["recurrent wheezing episodes", "PROBLEM", 47, 74], ["symptoms", "PROBLEM", 126, 134], ["recurrent", "OBSERVATION_MODIFIER", 47, 56], ["wheezing", "OBSERVATION", 57, 65]]], ["The organisms are susceptible to tetracyclines, macrolides, and quinolones.", [["tetracyclines", "CHEMICAL", 33, 46], ["macrolides", "CHEMICAL", 48, 58], ["quinolones", "CHEMICAL", 64, 74], ["tetracyclines", "CHEMICAL", 33, 46], ["macrolides", "CHEMICAL", 48, 58], ["quinolones", "CHEMICAL", 64, 74], ["tetracyclines", "SIMPLE_CHEMICAL", 33, 46], ["macrolides", "SIMPLE_CHEMICAL", 48, 58], ["quinolones", "SIMPLE_CHEMICAL", 64, 74], ["The organisms", "PROBLEM", 0, 13], ["tetracyclines", "TREATMENT", 33, 46], ["macrolides", "TREATMENT", 48, 58], ["quinolones", "TREATMENT", 64, 74]]], ["The optimal doses and duration of treatment is unclear; however, some data suggest that prolonged treatment for greater than 2 weeks may be more desirable to decrease symptoms and eradicate the organism from the nasopharynx.Mycoplasma pneumoniae andChlamydia pneumoniae have an increased prevalence in older children.FIGURE 25-2Chest radiograph of 3 year old female with Streptococcus pneumoniae pneumonia.", [["nasopharynx", "ANATOMY", 212, 223], ["Mycoplasma pneumoniae", "DISEASE", 224, 245], ["Chlamydia pneumoniae", "DISEASE", 249, 269], ["Streptococcus pneumoniae pneumonia", "DISEASE", 371, 405], ["nasopharynx", "ORGAN", 212, 223], ["Mycoplasma pneumoniae", "ORGANISM", 224, 245], ["Chlamydia pneumoniae", "ORGANISM", 249, 269], ["children", "ORGANISM", 308, 316], ["female", "ORGANISM", 359, 365], ["Streptococcus pneumoniae", "ORGANISM", 371, 395], ["Mycoplasma pneumoniae", "SPECIES", 224, 245], ["Chlamydia pneumoniae", "SPECIES", 249, 269], ["children", "SPECIES", 308, 316], ["Streptococcus pneumoniae", "SPECIES", 371, 395], ["Mycoplasma pneumoniae", "SPECIES", 224, 245], ["Chlamydia pneumoniae", "SPECIES", 249, 269], ["Streptococcus pneumoniae", "SPECIES", 371, 395], ["treatment", "TREATMENT", 34, 43], ["prolonged treatment", "TREATMENT", 88, 107], ["decrease symptoms", "PROBLEM", 158, 175], ["the organism from the nasopharynx", "PROBLEM", 190, 223], ["Mycoplasma pneumoniae", "PROBLEM", 224, 245], ["Chlamydia pneumoniae", "PROBLEM", 249, 269], ["FIGURE", "TEST", 317, 323], ["2Chest radiograph", "TEST", 327, 344], ["Streptococcus pneumoniae pneumonia", "PROBLEM", 371, 405], ["nasopharynx", "ANATOMY", 212, 223], ["pneumoniae", "OBSERVATION", 235, 245], ["Chlamydia pneumoniae", "OBSERVATION", 249, 269], ["increased", "OBSERVATION_MODIFIER", 278, 287], ["prevalence", "OBSERVATION_MODIFIER", 288, 298], ["Streptococcus pneumoniae", "OBSERVATION", 371, 395], ["pneumonia", "OBSERVATION", 396, 405]]], ["Note the combination of consolidation and effusion affecting the right lung.", [["right lung", "ANATOMY", 65, 75], ["effusion", "DISEASE", 42, 50], ["lung", "ORGAN", 71, 75], ["consolidation", "PROBLEM", 24, 37], ["effusion affecting the right lung", "PROBLEM", 42, 75], ["consolidation", "OBSERVATION", 24, 37], ["effusion", "OBSERVATION", 42, 50], ["right", "ANATOMY_MODIFIER", 65, 70], ["lung", "ANATOMY", 71, 75]]], ["(Image provided courtesy of FA Maffei)Staphylococcus AureusStaphylococcus aureus is a Gram-positive organism that can be found on the skin, nasal mucosa, and other mucus membranes.", [["skin", "ANATOMY", 134, 138], ["nasal mucosa", "ANATOMY", 140, 152], ["mucus membranes", "ANATOMY", 164, 179], ["Staphylococcus AureusStaphylococcus aureus", "ORGANISM", 38, 80], ["skin", "ORGAN", 134, 138], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 140, 152], ["mucus membranes", "CELLULAR_COMPONENT", 164, 179], ["Staphylococcus", "SPECIES", 38, 52], ["AureusStaphylococcus aureus", "SPECIES", 53, 80], ["Staphylococcus AureusStaphylococcus aureus", "SPECIES", 38, 80], ["FA Maffei", "TEST", 28, 37], ["Staphylococcus AureusStaphylococcus aureus", "PROBLEM", 38, 80], ["a Gram-positive organism", "PROBLEM", 84, 108], ["other mucus membranes", "PROBLEM", 158, 179], ["skin", "ANATOMY", 134, 138], ["nasal mucosa", "ANATOMY", 140, 152], ["mucus membranes", "OBSERVATION", 164, 179]]], ["About 20-30% of children are carriers.", [["children", "ORGANISM", 16, 24], ["children", "SPECIES", 16, 24]]], ["S . aureus is an unusual cause of lower airway disease in otherwise healthy children.", [["lower airway", "ANATOMY", 34, 46], ["lower airway disease", "DISEASE", 34, 54], ["S . aureus", "ORGANISM", 0, 10], ["lower airway", "ORGANISM_SUBDIVISION", 34, 46], ["children", "ORGANISM", 76, 84], ["S . aureus", "SPECIES", 0, 10], ["children", "SPECIES", 76, 84], ["S . aureus", "SPECIES", 0, 10], ["aureus", "PROBLEM", 4, 10], ["lower airway disease", "PROBLEM", 34, 54], ["aureus", "OBSERVATION", 4, 10], ["lower", "ANATOMY_MODIFIER", 34, 39], ["airway", "ANATOMY", 40, 46], ["disease", "OBSERVATION", 47, 54]]], ["It is more typically isolated from infants and young children with debilitating conditions.", [["infants", "ORGANISM", 35, 42], ["children", "ORGANISM", 53, 61], ["infants", "SPECIES", 35, 42], ["children", "SPECIES", 53, 61], ["debilitating conditions", "PROBLEM", 67, 90], ["more typically", "OBSERVATION_MODIFIER", 6, 20]]], ["Primary S . aureus pneumonia presents in the winter or early spring with a short febrile prodrome and a rapid onset of pulmonary symptoms.", [["pulmonary", "ANATOMY", 119, 128], ["pneumonia", "DISEASE", 19, 28], ["febrile prodrome", "DISEASE", 81, 97], ["pulmonary symptoms", "DISEASE", 119, 137], ["S . aureus", "ORGANISM", 8, 18], ["pulmonary", "ORGAN", 119, 128], ["S . aureus", "SPECIES", 8, 18], ["S . aureus", "SPECIES", 8, 18], ["aureus pneumonia", "PROBLEM", 12, 28], ["a short febrile prodrome", "PROBLEM", 73, 97], ["pulmonary symptoms", "PROBLEM", 119, 137], ["aureus", "OBSERVATION_MODIFIER", 12, 18], ["pneumonia", "OBSERVATION", 19, 28], ["pulmonary", "ANATOMY", 119, 128], ["symptoms", "OBSERVATION", 129, 137]]], ["Blood cultures are positive in 20-30% of patients.", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Blood cultures", "TEST", 0, 14]]], ["Secondary staphylococcal pneumonia will have a more prolonged prodrome with no seasonal predilection, but is often seen after infl uenza infections.", [["staphylococcal pneumonia", "DISEASE", 10, 34], ["infections", "DISEASE", 137, 147], ["Secondary staphylococcal pneumonia", "PROBLEM", 0, 34], ["a more prolonged prodrome", "PROBLEM", 45, 70], ["seasonal predilection", "PROBLEM", 79, 100], ["infl uenza infections", "PROBLEM", 126, 147], ["staphylococcal", "OBSERVATION_MODIFIER", 10, 24], ["pneumonia", "OBSERVATION", 25, 34], ["more prolonged", "OBSERVATION_MODIFIER", 47, 61], ["no", "UNCERTAINTY", 76, 78], ["seasonal", "OBSERVATION_MODIFIER", 79, 87], ["predilection", "OBSERVATION", 88, 100]]], ["As this secondary pneumonia is usually a result of hematogenous spread, blood cultures are positive in about 90% of patients.", [["blood cultures", "ANATOMY", 72, 86], ["pneumonia", "DISEASE", 18, 27], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["this secondary pneumonia", "PROBLEM", 3, 27], ["hematogenous spread", "PROBLEM", 51, 70], ["blood cultures", "TEST", 72, 86], ["pneumonia", "OBSERVATION", 18, 27], ["hematogenous", "OBSERVATION_MODIFIER", 51, 63]]], ["Unilateral lobar disease is more typical with primary disease, while diffuse bilateral infi ltrates are more frequent with secondary pneumonia.", [["lobar", "ANATOMY", 11, 16], ["lobar disease", "DISEASE", 11, 24], ["pneumonia", "DISEASE", 133, 142], ["Unilateral lobar disease", "PROBLEM", 0, 24], ["primary disease", "PROBLEM", 46, 61], ["diffuse bilateral infi ltrates", "PROBLEM", 69, 99], ["secondary pneumonia", "PROBLEM", 123, 142], ["lobar", "OBSERVATION_MODIFIER", 11, 16], ["disease", "OBSERVATION", 17, 24], ["more typical", "OBSERVATION_MODIFIER", 28, 40], ["diffuse", "OBSERVATION_MODIFIER", 69, 76], ["bilateral", "ANATOMY_MODIFIER", 77, 86], ["infi ltrates", "OBSERVATION", 87, 99], ["secondary", "OBSERVATION_MODIFIER", 123, 132], ["pneumonia", "OBSERVATION", 133, 142]]], ["Effusions can be diagnosed in about 15% of children at presentation, but ultimately will develop in about 75% of cases.", [["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["Effusions", "PROBLEM", 0, 9]]], ["Pneumatocoeles occur in up to 45-65% of children.", [["Pneumatocoeles", "ANATOMY", 0, 14], ["Pneumatocoeles", "DISEASE", 0, 14], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["Pneumatocoeles", "TEST", 0, 14]]], ["Treatment is with nafcillin or oxacillin, but more organisms are becoming resistant and require therapy for serious or invasive disease with vancomycin, linezolid, daptomycin, or quinupristin-dalfopristin.Staphylococcus AureusMethicillin resistant Staphylococcus aureus (MRSA) was once considered to be restricted to hospitals and long-term care facilities.", [["nafcillin", "CHEMICAL", 18, 27], ["oxacillin", "CHEMICAL", 31, 40], ["vancomycin", "CHEMICAL", 141, 151], ["linezolid", "CHEMICAL", 153, 162], ["daptomycin", "CHEMICAL", 164, 174], ["quinupristin-dalfopristin", "CHEMICAL", 179, 204], ["Staphylococcus AureusMethicillin", "CHEMICAL", 205, 237], ["Staphylococcus aureus", "DISEASE", 248, 269], ["nafcillin", "CHEMICAL", 18, 27], ["oxacillin", "CHEMICAL", 31, 40], ["vancomycin", "CHEMICAL", 141, 151], ["linezolid", "CHEMICAL", 153, 162], ["daptomycin", "CHEMICAL", 164, 174], ["quinupristin", "CHEMICAL", 179, 191], ["dalfopristin", "CHEMICAL", 192, 204], ["nafcillin", "SIMPLE_CHEMICAL", 18, 27], ["oxacillin", "SIMPLE_CHEMICAL", 31, 40], ["vancomycin", "SIMPLE_CHEMICAL", 141, 151], ["linezolid", "SIMPLE_CHEMICAL", 153, 162], ["daptomycin", "SIMPLE_CHEMICAL", 164, 174], ["quinupristin-dalfopristin", "SIMPLE_CHEMICAL", 179, 204], ["Staphylococcus AureusMethicillin resistant Staphylococcus aureus", "ORGANISM", 205, 269], ["MRSA", "CANCER", 271, 275], ["Staphylococcus", "SPECIES", 205, 219], ["Staphylococcus aureus", "SPECIES", 248, 269], ["MRSA", "SPECIES", 271, 275], ["Staphylococcus aureus", "SPECIES", 248, 269], ["MRSA", "SPECIES", 271, 275], ["nafcillin", "TREATMENT", 18, 27], ["oxacillin", "TREATMENT", 31, 40], ["therapy", "TREATMENT", 96, 103], ["serious or invasive disease", "PROBLEM", 108, 135], ["vancomycin", "TREATMENT", 141, 151], ["linezolid", "TREATMENT", 153, 162], ["daptomycin", "TREATMENT", 164, 174], ["quinupristin", "TREATMENT", 179, 191], ["dalfopristin", "TREATMENT", 192, 204], ["Staphylococcus AureusMethicillin resistant Staphylococcus aureus", "PROBLEM", 205, 269], ["MRSA", "PROBLEM", 271, 275], ["invasive", "OBSERVATION_MODIFIER", 119, 127], ["resistant", "OBSERVATION_MODIFIER", 238, 247], ["Staphylococcus aureus", "OBSERVATION", 248, 269]]], ["However, community acquired MRSA (CA-MRSA) is now a signifi cant cause of a variety of infections (including pneumonia) in children without prior health care facility exposure.", [["MRSA (CA-MRSA", "DISEASE", 28, 41], ["infections", "DISEASE", 87, 97], ["pneumonia", "DISEASE", 109, 118], ["CA-MRSA", "ORGANISM", 34, 41], ["children", "ORGANISM", 123, 131], ["MRSA", "SPECIES", 28, 32], ["MRSA", "SPECIES", 37, 41], ["children", "SPECIES", 123, 131], ["MRSA", "SPECIES", 28, 32], ["MRSA", "SPECIES", 37, 41], ["community acquired MRSA (CA-MRSA", "PROBLEM", 9, 41], ["infections", "PROBLEM", 87, 97], ["pneumonia", "PROBLEM", 109, 118], ["MRSA", "OBSERVATION", 28, 32], ["variety", "OBSERVATION_MODIFIER", 76, 83], ["infections", "OBSERVATION", 87, 97], ["pneumonia", "OBSERVATION", 109, 118]]], ["The majority of community acquired MRSA infections involve minor skin and soft tissue infections, but invasive and sometimes fatal infections can occur in otherwise healthy individuals.", [["skin", "ANATOMY", 65, 69], ["soft tissue", "ANATOMY", 74, 85], ["MRSA infections", "DISEASE", 35, 50], ["soft tissue infections", "DISEASE", 74, 96], ["infections", "DISEASE", 131, 141], ["skin", "ORGAN", 65, 69], ["soft tissue", "TISSUE", 74, 85], ["MRSA", "SPECIES", 35, 39], ["community acquired MRSA infections", "PROBLEM", 16, 50], ["minor skin", "PROBLEM", 59, 69], ["soft tissue infections", "PROBLEM", 74, 96], ["invasive and sometimes fatal infections", "PROBLEM", 102, 141], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["community", "OBSERVATION_MODIFIER", 16, 25], ["MRSA", "OBSERVATION_MODIFIER", 35, 39], ["infections", "OBSERVATION", 40, 50], ["minor", "OBSERVATION_MODIFIER", 59, 64], ["skin", "ANATOMY", 65, 69], ["soft tissue", "OBSERVATION_MODIFIER", 74, 85], ["infections", "OBSERVATION", 86, 96], ["invasive", "OBSERVATION_MODIFIER", 102, 110], ["fatal", "OBSERVATION_MODIFIER", 125, 130], ["infections", "OBSERVATION", 131, 141]]], ["CA-MRSA and healthcare-associated MRSA (HA-MRSA) can be distinguished by several important features.", [["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["MRSA", "SPECIES", 3, 7], ["MRSA", "SPECIES", 34, 38], ["MRSA", "SPECIES", 43, 47], ["MRSA", "SPECIES", 34, 38], ["CA", "TEST", 0, 2], ["MRSA", "PROBLEM", 3, 7], ["MRSA", "PROBLEM", 34, 38], ["HA", "PROBLEM", 40, 42], ["MRSA", "PROBLEM", 43, 47], ["MRSA", "OBSERVATION", 3, 7], ["MRSA", "OBSERVATION", 34, 38]]], ["Patients with CA-MRSA by defi nition have not had recent hospitalization (acute or chronic care), prolonged antibiotic use or chronic underlying disease.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["MRSA", "SPECIES", 17, 21], ["CA", "PROBLEM", 14, 16], ["MRSA", "PROBLEM", 17, 21], ["chronic care", "TREATMENT", 83, 95], ["prolonged antibiotic use", "TREATMENT", 98, 122], ["chronic underlying disease", "PROBLEM", 126, 152], ["MRSA", "OBSERVATION", 17, 21], ["chronic", "OBSERVATION_MODIFIER", 126, 133], ["disease", "OBSERVATION", 145, 152]]], ["Toxin production also distinguishes CA-MRSA from HA-MRSA.", [["Toxin", "GENE_OR_GENE_PRODUCT", 0, 5], ["CA-MRSA", "GENE_OR_GENE_PRODUCT", 36, 43], ["HA-MRSA", "ORGANISM", 49, 56], ["MRSA", "SPECIES", 39, 43], ["MRSA", "SPECIES", 52, 56], ["Toxin production", "TEST", 0, 16], ["CA", "TEST", 36, 38], ["MRSA", "PROBLEM", 39, 43], ["HA", "PROBLEM", 49, 51], ["MRSA", "PROBLEM", 52, 56], ["MRSA", "OBSERVATION", 39, 43], ["MRSA", "OBSERVATION", 52, 56]]], ["Panton valentine leukocidin (PVL) is a toxin which is present in most CA-MRSA isolates, but rarely in HA-MRSA isolates.", [["Panton valentine leukocidin", "CHEMICAL", 0, 27], ["PVL", "CHEMICAL", 29, 32], ["Panton valentine leukocidin", "GENE_OR_GENE_PRODUCT", 0, 27], ["PVL", "GENE_OR_GENE_PRODUCT", 29, 32], ["CA", "GENE_OR_GENE_PRODUCT", 70, 72], ["HA-MRSA isolates", "ORGANISM", 102, 118], ["MRSA", "SPECIES", 73, 77], ["MRSA", "SPECIES", 105, 109], ["Panton valentine leukocidin", "TREATMENT", 0, 27], ["a toxin", "PROBLEM", 37, 44], ["MRSA isolates", "PROBLEM", 73, 86], ["HA", "PROBLEM", 102, 104], ["MRSA isolates", "PROBLEM", 105, 118]]], ["PVL toxin lyses white blood cells leading to leukopenia and a decreased ability to kill S . aureus .", [["white blood cells", "ANATOMY", 16, 33], ["leukopenia", "DISEASE", 45, 55], ["PVL toxin", "GENE_OR_GENE_PRODUCT", 0, 9], ["white blood cells", "CELL", 16, 33], ["S . aureus", "ORGANISM", 88, 98], ["PVL toxin", "PROTEIN", 0, 9], ["white blood cells", "CELL_TYPE", 16, 33], ["S . aureus", "SPECIES", 88, 98], ["S . aureus", "SPECIES", 88, 98], ["PVL toxin lyses white blood cells", "PROBLEM", 0, 33], ["leukopenia", "PROBLEM", 45, 55], ["a decreased ability", "PROBLEM", 60, 79], ["aureus", "PROBLEM", 92, 98], ["leukopenia", "OBSERVATION", 45, 55], ["decreased", "OBSERVATION_MODIFIER", 62, 71], ["aureus", "OBSERVATION", 92, 98]]], ["Its production has been implicated as a contributor to the development of CA-MRSA necrotizing pneumonia.", [["pneumonia", "DISEASE", 94, 103], ["CA", "GENE_OR_GENE_PRODUCT", 74, 76], ["MRSA", "SPECIES", 77, 81], ["CA", "PROBLEM", 74, 76], ["MRSA necrotizing pneumonia", "PROBLEM", 77, 103], ["CA", "OBSERVATION", 74, 76], ["MRSA", "OBSERVATION_MODIFIER", 77, 81], ["necrotizing", "OBSERVATION_MODIFIER", 82, 93], ["pneumonia", "OBSERVATION", 94, 103]]], ["CA-MRSA isolates, unlike HA-MRSA, lack multi-drug resistance.", [["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["HA-MRSA", "ORGANISM", 25, 32], ["MRSA", "SPECIES", 3, 7], ["MRSA", "SPECIES", 28, 32], ["CA", "TEST", 0, 2], ["MRSA isolates", "TEST", 3, 16], ["HA", "PROBLEM", 25, 27], ["MRSA", "PROBLEM", 28, 32], ["lack multi-drug resistance", "PROBLEM", 34, 60], ["MRSA", "OBSERVATION", 28, 32], ["drug resistance", "OBSERVATION", 45, 60]]], ["CA-MRSA is generally more susceptible to clindamycin, trimethoprim-sulfamethoxazole and doxycycline than HA-MRSA, probably because HA-MRSA has developed resistance to survive in the healthcare setting.Group A Beta-Hemolytic StreptococcusGroup A betahemolytic Streptococcus (GABHS) is a Gram-positive organism responsible for about 15% of pharyngitis and tonsillitis in children.", [["clindamycin", "CHEMICAL", 41, 52], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 54, 83], ["doxycycline", "CHEMICAL", 88, 99], ["HA-MRSA", "CHEMICAL", 105, 112], ["HA-MRSA", "CHEMICAL", 131, 138], ["GABHS", "DISEASE", 274, 279], ["pharyngitis", "DISEASE", 338, 349], ["tonsillitis", "DISEASE", 354, 365], ["clindamycin", "CHEMICAL", 41, 52], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 54, 83], ["doxycycline", "CHEMICAL", 88, 99], ["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["clindamycin", "SIMPLE_CHEMICAL", 41, 52], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 54, 83], ["doxycycline", "SIMPLE_CHEMICAL", 88, 99], ["HA-MRSA", "SIMPLE_CHEMICAL", 105, 112], ["HA-MRSA", "ORGANISM", 131, 138], ["Beta-Hemolytic StreptococcusGroup A betahemolytic Streptococcus", "ORGANISM", 209, 272], ["children", "ORGANISM", 369, 377], ["MRSA", "SPECIES", 3, 7], ["MRSA", "SPECIES", 108, 112], ["MRSA", "SPECIES", 134, 138], ["children", "SPECIES", 369, 377], ["CA", "TEST", 0, 2], ["MRSA", "PROBLEM", 3, 7], ["clindamycin", "TREATMENT", 41, 52], ["trimethoprim", "TREATMENT", 54, 66], ["sulfamethoxazole", "TREATMENT", 67, 83], ["doxycycline", "TREATMENT", 88, 99], ["HA", "PROBLEM", 105, 107], ["MRSA", "PROBLEM", 108, 112], ["HA", "PROBLEM", 131, 133], ["MRSA", "PROBLEM", 134, 138], ["Group A Beta-Hemolytic StreptococcusGroup", "TEST", 201, 242], ["A betahemolytic Streptococcus (GABHS", "PROBLEM", 243, 279], ["a Gram-positive organism", "PROBLEM", 284, 308], ["pharyngitis", "PROBLEM", 338, 349], ["tonsillitis", "PROBLEM", 354, 365], ["MRSA", "OBSERVATION", 3, 7], ["MRSA", "OBSERVATION", 108, 112], ["MRSA", "OBSERVATION", 134, 138], ["Beta-Hemolytic", "OBSERVATION_MODIFIER", 209, 223], ["betahemolytic Streptococcus", "OBSERVATION", 245, 272], ["Gram-positive organism", "OBSERVATION", 286, 308], ["pharyngitis", "OBSERVATION", 338, 349], ["tonsillitis", "OBSERVATION", 354, 365]]], ["It is rare as a primary cause of pneumonia.", [["pneumonia", "DISEASE", 33, 42], ["pneumonia", "PROBLEM", 33, 42], ["pneumonia", "OBSERVATION", 33, 42]]], ["When it does occur, the children generally have high fever and appear toxic.", [["fever", "DISEASE", 53, 58], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["high fever", "PROBLEM", 48, 58], ["toxic", "OBSERVATION_MODIFIER", 70, 75]]], ["The pneumonia is typically lobar.", [["lobar", "ANATOMY", 27, 32], ["pneumonia", "DISEASE", 4, 13], ["The pneumonia", "PROBLEM", 0, 13], ["pneumonia", "OBSERVATION", 4, 13], ["typically", "OBSERVATION_MODIFIER", 17, 26], ["lobar", "OBSERVATION", 27, 32]]], ["Associated empyemas are common and pneumatocoeles may develop.", [["empyemas", "ANATOMY", 11, 19], ["pneumatocoeles", "ANATOMY", 35, 49], ["empyemas", "DISEASE", 11, 19], ["pneumatocoeles", "DISEASE", 35, 49], ["empyemas", "CANCER", 11, 19], ["pneumatocoeles", "CANCER", 35, 49], ["empyemas", "PROBLEM", 11, 19], ["empyemas", "OBSERVATION", 11, 19]]], ["There are several virulent toxin-producing GABHS M-serotypes that are associated with toxic shock syndrome.", [["toxic shock syndrome", "DISEASE", 86, 106], ["several virulent toxin", "PROBLEM", 10, 32], ["GABHS M-serotypes", "PROBLEM", 43, 60], ["toxic shock syndrome", "PROBLEM", 86, 106], ["several", "OBSERVATION_MODIFIER", 10, 17], ["virulent", "OBSERVATION_MODIFIER", 18, 26], ["associated with", "UNCERTAINTY", 70, 85], ["toxic", "OBSERVATION_MODIFIER", 86, 91], ["shock syndrome", "OBSERVATION", 92, 106]]], ["Pre-existing varicella disease with disruption of skin and soft tissue as the port of entry is reported approximately 40-50% of the time.", [["skin", "ANATOMY", 50, 54], ["soft tissue", "ANATOMY", 59, 70], ["varicella disease", "DISEASE", 13, 30], ["skin", "ORGAN", 50, 54], ["soft tissue", "TISSUE", 59, 70], ["Pre-existing varicella disease", "PROBLEM", 0, 30], ["disruption of skin and soft tissue", "PROBLEM", 36, 70], ["varicella disease", "OBSERVATION", 13, 30], ["disruption", "OBSERVATION", 36, 46], ["skin", "ANATOMY", 50, 54], ["soft tissue", "ANATOMY", 59, 70], ["entry", "OBSERVATION_MODIFIER", 86, 91]]], ["An associated pneumonia occurs in 10-20% of children with toxic shock syndrome.", [["pneumonia", "DISEASE", 14, 23], ["toxic shock syndrome", "DISEASE", 58, 78], ["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52], ["An associated pneumonia", "PROBLEM", 0, 23], ["toxic shock syndrome", "PROBLEM", 58, 78], ["pneumonia", "OBSERVATION", 14, 23], ["10-20", "OBSERVATION_MODIFIER", 34, 39], ["toxic", "OBSERVATION_MODIFIER", 58, 63], ["shock syndrome", "OBSERVATION", 64, 78]]], ["GABHS are highly susceptible to penicillins and cephalosporins.", [["GABHS", "DISEASE", 0, 5], ["penicillins", "CHEMICAL", 32, 43], ["cephalosporins", "CHEMICAL", 48, 62], ["penicillins", "CHEMICAL", 32, 43], ["cephalosporins", "CHEMICAL", 48, 62], ["penicillins", "SIMPLE_CHEMICAL", 32, 43], ["cephalosporins", "SIMPLE_CHEMICAL", 48, 62], ["GABHS", "PROBLEM", 0, 5], ["penicillins", "TREATMENT", 32, 43], ["cephalosporins", "TREATMENT", 48, 62]]], ["In cases of toxic shock, clindamycin is often added to inhibit the production of streptococcal pyrogenic exotoxins A (SPE-A) and B (SPE-B).Group B StreptococcusAbout 30-40% of infants with perinatally acquired Group B Streptococcus (GBS) infections will have pneumonia.", [["shock", "DISEASE", 18, 23], ["clindamycin", "CHEMICAL", 25, 36], ["SPE-B", "CHEMICAL", 132, 137], ["Group B Streptococcus", "DISEASE", 210, 231], ["GBS) infections", "DISEASE", 233, 248], ["pneumonia", "DISEASE", 259, 268], ["clindamycin", "CHEMICAL", 25, 36], ["clindamycin", "SIMPLE_CHEMICAL", 25, 36], ["pyrogenic exotoxins A", "SIMPLE_CHEMICAL", 95, 116], ["SPE-A", "SIMPLE_CHEMICAL", 118, 123], ["B", "CELL", 129, 130], ["SPE-B", "GENE_OR_GENE_PRODUCT", 132, 137], ["Group B StreptococcusAbout", "ORGANISM", 139, 165], ["infants", "ORGANISM", 176, 183], ["Group B Streptococcus", "ORGANISM", 210, 231], ["B", "PROTEIN", 129, 130], ["SPE", "PROTEIN", 132, 135], ["infants", "SPECIES", 176, 183], ["B Streptococcus", "SPECIES", 216, 231], ["toxic shock", "PROBLEM", 12, 23], ["clindamycin", "TREATMENT", 25, 36], ["streptococcal pyrogenic exotoxins", "PROBLEM", 81, 114], ["Group B StreptococcusAbout", "TEST", 139, 165], ["perinatally acquired Group B Streptococcus (GBS) infections", "PROBLEM", 189, 248], ["pneumonia", "PROBLEM", 259, 268], ["toxic shock", "OBSERVATION", 12, 23], ["pneumonia", "OBSERVATION", 259, 268]]], ["The infant usually has systemic disease and blood cultures are frequently positive.", [["blood cultures", "ANATOMY", 44, 58], ["infant", "ORGANISM", 4, 10], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["infant", "SPECIES", 4, 10], ["systemic disease", "PROBLEM", 23, 39], ["blood cultures", "TEST", 44, 58], ["systemic", "OBSERVATION_MODIFIER", 23, 31], ["disease", "OBSERVATION", 32, 39]]], ["Late-onset GBS is predominantly caused by the type III serotype.", [["GBS", "DISEASE", 11, 14], ["Late-onset GBS", "PROBLEM", 0, 14], ["the type III serotype", "PROBLEM", 42, 63], ["onset", "OBSERVATION_MODIFIER", 5, 10], ["GBS", "OBSERVATION", 11, 14], ["predominantly", "OBSERVATION_MODIFIER", 18, 31], ["type III", "OBSERVATION_MODIFIER", 46, 54], ["serotype", "OBSERVATION", 55, 63]]], ["In these infants, the infection is usually manifest as bacteremia without a focus or with meningitis.", [["infection", "DISEASE", 22, 31], ["bacteremia", "DISEASE", 55, 65], ["meningitis", "DISEASE", 90, 100], ["infants", "ORGANISM", 9, 16], ["infants", "SPECIES", 9, 16], ["the infection", "PROBLEM", 18, 31], ["bacteremia", "PROBLEM", 55, 65], ["meningitis", "PROBLEM", 90, 100], ["infection", "OBSERVATION", 22, 31], ["bacteremia", "OBSERVATION", 55, 65], ["meningitis", "OBSERVATION", 90, 100]]], ["Pneumonia is rare in late-onset disease.", [["Pneumonia", "DISEASE", 0, 9], ["Pneumonia", "PROBLEM", 0, 9], ["late-onset disease", "PROBLEM", 21, 39], ["rare", "OBSERVATION_MODIFIER", 13, 17], ["late-onset", "OBSERVATION_MODIFIER", 21, 31], ["disease", "OBSERVATION", 32, 39]]], ["GBS is uniformly sensitive to penicillin.Group B StreptococcusWhile Staphylococcus aureus pneumonia is uncommon, effusions ultimately develop in about 75% of cases and pneumatocoeles occur in 45-60%.PertussisPertussis, or \"whooping cough\" is a highly contagious respiratory tract infection caused by the Gram-negative pleomorphic bacillus Bordetella pertussis and less commonly Bordetella parapertussis .", [["effusions", "ANATOMY", 113, 122], ["pneumatocoeles", "ANATOMY", 168, 182], ["respiratory tract", "ANATOMY", 262, 279], ["GBS", "DISEASE", 0, 3], ["penicillin", "CHEMICAL", 30, 40], ["Staphylococcus aureus pneumonia", "DISEASE", 68, 99], ["effusions", "DISEASE", 113, 122], ["pneumatocoeles", "DISEASE", 168, 182], ["PertussisPertussis", "CHEMICAL", 199, 217], ["whooping cough", "DISEASE", 223, 237], ["respiratory tract infection", "DISEASE", 262, 289], ["Bordetella pertussis", "DISEASE", 339, 359], ["Bordetella parapertussis", "DISEASE", 378, 402], ["penicillin", "CHEMICAL", 30, 40], ["penicillin", "SIMPLE_CHEMICAL", 30, 40], ["Group B StreptococcusWhile Staphylococcus aureus", "ORGANISM", 41, 89], ["pneumatocoeles", "CANCER", 168, 182], ["respiratory tract", "ORGANISM_SUBDIVISION", 262, 279], ["Gram-", "GENE_OR_GENE_PRODUCT", 304, 309], ["Bordetella pertussis", "ORGANISM", 339, 359], ["Bordetella parapertussis", "ORGANISM", 378, 402], ["Staphylococcus aureus", "SPECIES", 68, 89], ["bacillus", "SPECIES", 330, 338], ["Bordetella pertussis", "SPECIES", 339, 359], ["Bordetella parapertussis", "SPECIES", 378, 402], ["Staphylococcus aureus", "SPECIES", 68, 89], ["Bordetella pertussis", "SPECIES", 339, 359], ["Bordetella parapertussis", "SPECIES", 378, 402], ["GBS", "PROBLEM", 0, 3], ["penicillin", "TREATMENT", 30, 40], ["Group B StreptococcusWhile Staphylococcus aureus pneumonia", "PROBLEM", 41, 99], ["effusions", "PROBLEM", 113, 122], ["pneumatocoeles", "TEST", 168, 182], ["PertussisPertussis", "PROBLEM", 199, 217], ["\"whooping cough", "PROBLEM", 222, 237], ["a highly contagious respiratory tract infection", "PROBLEM", 242, 289], ["the Gram-negative pleomorphic bacillus Bordetella pertussis", "PROBLEM", 300, 359], ["commonly Bordetella parapertussis", "PROBLEM", 369, 402], ["Staphylococcus aureus", "OBSERVATION", 68, 89], ["pneumonia", "OBSERVATION", 90, 99], ["effusions", "OBSERVATION", 113, 122], ["highly", "OBSERVATION_MODIFIER", 244, 250], ["contagious", "OBSERVATION_MODIFIER", 251, 261], ["respiratory tract", "ANATOMY", 262, 279], ["infection", "OBSERVATION", 280, 289], ["pleomorphic", "OBSERVATION_MODIFIER", 318, 329], ["bacillus Bordetella pertussis", "OBSERVATION", 330, 359]]], ["With the development and widespread use of a vaccine in the 1940s, a significant and sustained decrease in incidence has occurred.", [["a vaccine", "TREATMENT", 43, 52], ["widespread", "OBSERVATION_MODIFIER", 25, 35], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["sustained", "OBSERVATION_MODIFIER", 85, 94], ["decrease", "OBSERVATION_MODIFIER", 95, 103]]], ["However, despite immunization rates greater than 80%, cyclical recurrences of the disease have occurred every 3-4 years since the 1980s.", [["immunization rates", "TEST", 17, 35], ["cyclical recurrences of the disease", "PROBLEM", 54, 89], ["disease", "OBSERVATION", 82, 89]]], ["This is likely secondary to the waning of immunity in adolescents and young adults.", [["adolescents", "SPECIES", 54, 65], ["likely secondary to", "UNCERTAINTY", 8, 27]]], ["Under-immunized or unimmunized infants are the most vulnerable.", [["infants", "ORGANISM", 31, 38], ["infants", "SPECIES", 31, 38], ["most vulnerable", "OBSERVATION_MODIFIER", 47, 62]]], ["Nearly all deaths reported from pertussis occur in infants younger than 3 months of age.PertussisPertussis is often divided into catarrahal (fever, rhinnorhea and initiation of cough), paroxysmal (severe coughing episodes, lymphocytosis, potential for complications) and convalescent stages (slow waning of cough over weeks to months).", [["deaths", "DISEASE", 11, 17], ["pertussis", "DISEASE", 32, 41], ["fever", "DISEASE", 141, 146], ["rhinnorhea", "DISEASE", 148, 158], ["cough", "DISEASE", 177, 182], ["paroxysmal", "DISEASE", 185, 195], ["coughing", "DISEASE", 204, 212], ["lymphocytosis", "DISEASE", 223, 236], ["cough", "DISEASE", 307, 312], ["infants", "ORGANISM", 51, 58], ["infants", "SPECIES", 51, 58], ["pertussis", "PROBLEM", 32, 41], ["fever", "PROBLEM", 141, 146], ["rhinnorhea", "PROBLEM", 148, 158], ["cough", "PROBLEM", 177, 182], ["paroxysmal (severe coughing episodes", "PROBLEM", 185, 221], ["lymphocytosis", "PROBLEM", 223, 236], ["complications", "PROBLEM", 252, 265], ["convalescent stages", "PROBLEM", 271, 290], ["slow waning of cough", "PROBLEM", 292, 312], ["severe", "OBSERVATION_MODIFIER", 197, 203]]], ["Complications include secondary bacterial or viral pneumonia, apnea, malnutrition, pulmonary hypertension and neurologic involvement including seizures and encephalopathy.", [["pulmonary", "ANATOMY", 83, 92], ["neurologic", "ANATOMY", 110, 120], ["pneumonia", "DISEASE", 51, 60], ["apnea", "DISEASE", 62, 67], ["malnutrition", "DISEASE", 69, 81], ["pulmonary hypertension", "DISEASE", 83, 105], ["seizures", "DISEASE", 143, 151], ["encephalopathy", "DISEASE", 156, 170], ["pulmonary", "ORGAN", 83, 92], ["secondary bacterial or viral pneumonia", "PROBLEM", 22, 60], ["apnea", "PROBLEM", 62, 67], ["malnutrition", "PROBLEM", 69, 81], ["pulmonary hypertension", "PROBLEM", 83, 105], ["neurologic involvement", "PROBLEM", 110, 132], ["seizures", "PROBLEM", 143, 151], ["encephalopathy", "PROBLEM", 156, 170], ["secondary", "OBSERVATION_MODIFIER", 22, 31], ["bacterial", "OBSERVATION_MODIFIER", 32, 41], ["viral", "OBSERVATION_MODIFIER", 45, 50], ["pneumonia", "OBSERVATION", 51, 60], ["apnea", "OBSERVATION", 62, 67], ["malnutrition", "OBSERVATION", 69, 81], ["pulmonary", "ANATOMY", 83, 92], ["hypertension", "OBSERVATION", 93, 105], ["encephalopathy", "OBSERVATION", 156, 170]]], ["Infants less than 6 months of age are at highest risk for complications and mortality.", [["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["complications", "PROBLEM", 58, 71]]], ["Characteristic paroxysms of cough with an end inspiratory whoop occur in children.", [["paroxysms", "DISEASE", 15, 24], ["cough", "DISEASE", 28, 33], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["Characteristic paroxysms of cough", "PROBLEM", 0, 33], ["cough", "OBSERVATION", 28, 33]]], ["Infants may present with a nonspecifi c cough with associated apnea and cyanosis, without a whoop.", [["cough", "DISEASE", 40, 45], ["apnea", "DISEASE", 62, 67], ["cyanosis", "DISEASE", 72, 80], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["a nonspecifi c cough", "PROBLEM", 25, 45], ["associated apnea", "PROBLEM", 51, 67], ["cyanosis", "PROBLEM", 72, 80], ["a whoop", "PROBLEM", 90, 97], ["apnea", "OBSERVATION", 62, 67], ["cyanosis", "OBSERVATION", 72, 80]]], ["Adolescents may be asymptomatic or have only a mild prolonged cough.", [["cough", "DISEASE", 62, 67], ["Adolescents", "SPECIES", 0, 11], ["asymptomatic", "PROBLEM", 19, 31], ["a mild prolonged cough", "PROBLEM", 45, 67], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["prolonged", "OBSERVATION_MODIFIER", 52, 61], ["cough", "OBSERVATION", 62, 67]]], ["An increased white blood count up to 100,000 with a lymphocytosis is characteristic early in the course of the disease.", [["white blood", "ANATOMY", 13, 24], ["lymphocytosis", "DISEASE", 52, 65], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["An increased white blood count", "TEST", 0, 30], ["a lymphocytosis", "PROBLEM", 50, 65], ["the disease", "PROBLEM", 107, 118], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["white blood count", "OBSERVATION", 13, 30], ["lymphocytosis", "OBSERVATION", 52, 65], ["characteristic", "OBSERVATION_MODIFIER", 69, 83], ["early", "OBSERVATION_MODIFIER", 84, 89], ["disease", "OBSERVATION", 111, 118]]], ["The preferred test for laboratory confi rmation is the detection of B. pertussis DNA by PCR assay.", [["B. pertussis", "ORGANISM", 68, 80], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["B. pertussis", "SPECIES", 68, 80], ["B. pertussis", "SPECIES", 68, 80], ["laboratory confi rmation", "TEST", 23, 47], ["B. pertussis DNA", "PROBLEM", 68, 84], ["PCR assay", "TEST", 88, 97]]], ["Bacteriologic culture provides a defi nitive diagnosis.PertussisIf administered during the early stages of the disease (fi rst 7-10 days of illness), erythromycin for 14 days may decrease symptoms and reduce the risk of spread.", [["PertussisIf", "CHEMICAL", 55, 66], ["erythromycin", "CHEMICAL", 150, 162], ["erythromycin", "CHEMICAL", 150, 162], ["erythromycin", "SIMPLE_CHEMICAL", 150, 162], ["Bacteriologic culture", "TEST", 0, 21], ["PertussisIf", "TREATMENT", 55, 66], ["the disease", "PROBLEM", 107, 118], ["illness", "PROBLEM", 140, 147], ["erythromycin", "TREATMENT", 150, 162], ["decrease symptoms", "PROBLEM", 179, 196], ["disease", "OBSERVATION", 111, 118], ["spread", "OBSERVATION_MODIFIER", 220, 226]]], ["A 5 day course of azithromycin or a 7-10 day course of clarithromycin has been found to be as effective with less gastrointestinal symptoms.", [["gastrointestinal", "ANATOMY", 114, 130], ["azithromycin", "CHEMICAL", 18, 30], ["clarithromycin", "CHEMICAL", 55, 69], ["azithromycin", "CHEMICAL", 18, 30], ["clarithromycin", "CHEMICAL", 55, 69], ["azithromycin", "SIMPLE_CHEMICAL", 18, 30], ["clarithromycin", "SIMPLE_CHEMICAL", 55, 69], ["gastrointestinal", "ORGANISM_SUBDIVISION", 114, 130], ["azithromycin", "TREATMENT", 18, 30], ["clarithromycin", "TREATMENT", 55, 69], ["less gastrointestinal symptoms", "PROBLEM", 109, 139]]], ["Corticosteroids, bronchodilators, or intravenous immunoglobulins have not demonstrated effi cacy.", [["intravenous", "ANATOMY", 37, 48], ["Corticosteroids", "TREATMENT", 0, 15], ["bronchodilators", "TREATMENT", 17, 32], ["intravenous immunoglobulins", "TREATMENT", 37, 64]]], ["Supportive care with supplemental oxygen, mechanical ventilation, intravenous fl uids, maintenance of adequate caloric intake, and treatment of secondary bacterial infections are the mainstay of therapy.", [["intravenous", "ANATOMY", 66, 77], ["oxygen", "CHEMICAL", 34, 40], ["bacterial infections", "DISEASE", 154, 174], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["Supportive care", "TREATMENT", 0, 15], ["supplemental oxygen", "TREATMENT", 21, 40], ["mechanical ventilation", "TREATMENT", 42, 64], ["intravenous fl uids", "TREATMENT", 66, 85], ["treatment", "TREATMENT", 131, 140], ["secondary bacterial infections", "PROBLEM", 144, 174], ["therapy", "TREATMENT", 195, 202], ["mechanical ventilation", "OBSERVATION", 42, 64], ["secondary", "OBSERVATION_MODIFIER", 144, 153], ["bacterial infections", "OBSERVATION", 154, 174]]], ["The use of extracorporeal membrane oxygenation in infants with hypoxemia, pulmonary hypertension and right heart failure refractory to conventional mechanical ventilation has resulted in poorer outcomes than expected.", [["extracorporeal membrane", "ANATOMY", 11, 34], ["pulmonary", "ANATOMY", 74, 83], ["right heart", "ANATOMY", 101, 112], ["hypoxemia", "DISEASE", 63, 72], ["pulmonary hypertension", "DISEASE", 74, 96], ["heart failure", "DISEASE", 107, 120], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 11, 34], ["infants", "ORGANISM", 50, 57], ["pulmonary", "ORGAN", 74, 83], ["heart", "ORGAN", 107, 112], ["infants", "SPECIES", 50, 57], ["extracorporeal membrane oxygenation", "TREATMENT", 11, 46], ["hypoxemia", "PROBLEM", 63, 72], ["pulmonary hypertension", "PROBLEM", 74, 96], ["right heart failure", "PROBLEM", 101, 120], ["conventional mechanical ventilation", "TREATMENT", 135, 170], ["extracorporeal membrane oxygenation", "OBSERVATION", 11, 46], ["hypoxemia", "OBSERVATION", 63, 72], ["pulmonary", "ANATOMY", 74, 83], ["hypertension", "OBSERVATION", 84, 96], ["right", "ANATOMY_MODIFIER", 101, 106], ["heart", "ANATOMY", 107, 112], ["failure", "OBSERVATION", 113, 120], ["mechanical ventilation", "OBSERVATION", 148, 170]]], ["Vaccination in infancy with booster doses in adolescence is preventative.Viral PneumoniaAbout 80-85% of pneumonias in children are caused by viruses.", [["pneumonias", "DISEASE", 104, 114], ["children", "ORGANISM", 118, 126], ["children", "SPECIES", 118, 126], ["Vaccination", "TREATMENT", 0, 11], ["Viral PneumoniaAbout", "TEST", 73, 93], ["pneumonias", "PROBLEM", 104, 114], ["viruses", "PROBLEM", 141, 148], ["pneumonias", "OBSERVATION", 104, 114], ["viruses", "OBSERVATION", 141, 148]]], ["There is considerable evidence that viral infections often precede bacterial pneumonias and cause weakening of the host defenses.", [["viral infections", "DISEASE", 36, 52], ["pneumonias", "DISEASE", 77, 87], ["viral infections", "PROBLEM", 36, 52], ["bacterial pneumonias", "PROBLEM", 67, 87], ["considerable evidence that", "UNCERTAINTY", 9, 35], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["infections", "OBSERVATION", 42, 52], ["bacterial", "OBSERVATION_MODIFIER", 67, 76], ["pneumonias", "OBSERVATION", 77, 87], ["host defenses", "OBSERVATION", 115, 128]]], ["Viral pneumonias with RSV and parainfl uenza are discussed in more detail in the bronchiolitis section.Infl uenzaInfl uenza is the main viral cause of pneumonia in school-aged children requiring hospitalization.", [["pneumonias", "DISEASE", 6, 16], ["RSV", "DISEASE", 22, 25], ["bronchiolitis", "DISEASE", 81, 94], ["pneumonia", "DISEASE", 151, 160], ["Viral", "ORGANISM", 0, 5], ["RSV", "ORGANISM", 22, 25], ["children", "ORGANISM", 176, 184], ["RSV", "SPECIES", 22, 25], ["children", "SPECIES", 176, 184], ["RSV", "SPECIES", 22, 25], ["Infl uenzaInfl uenza", "SPECIES", 103, 123], ["Viral pneumonias", "PROBLEM", 0, 16], ["RSV", "PROBLEM", 22, 25], ["parainfl uenza", "PROBLEM", 30, 44], ["the bronchiolitis section", "TREATMENT", 77, 102], ["pneumonia", "PROBLEM", 151, 160], ["pneumonias", "OBSERVATION", 6, 16], ["RSV", "OBSERVATION", 22, 25], ["parainfl uenza", "OBSERVATION", 30, 44], ["bronchiolitis", "OBSERVATION", 81, 94], ["main", "OBSERVATION_MODIFIER", 131, 135], ["viral", "OBSERVATION_MODIFIER", 136, 141], ["pneumonia", "OBSERVATION", 151, 160]]], ["There are three serotypes, A, B, and C which are further divided into subtypes based on the hemagglutinin and neuraminidase genes.", [["B", "GENE_OR_GENE_PRODUCT", 30, 31], ["C", "GENE_OR_GENE_PRODUCT", 37, 38], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 92, 105], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 110, 123], ["hemagglutinin and neuraminidase genes", "DNA", 92, 129], ["three serotypes", "PROBLEM", 10, 25], ["the hemagglutinin and neuraminidase genes", "TREATMENT", 88, 129], ["three", "OBSERVATION_MODIFIER", 10, 15], ["serotypes", "OBSERVATION", 16, 25]]], ["Hemagglutinin 1, 2, and 3 and neuraminidase 1 and 2 typically infect humans.", [["Hemagglutinin 1", "GENE_OR_GENE_PRODUCT", 0, 15], ["2", "GENE_OR_GENE_PRODUCT", 17, 18], ["3", "GENE_OR_GENE_PRODUCT", 24, 25], ["neuraminidase 1", "GENE_OR_GENE_PRODUCT", 30, 45], ["2", "GENE_OR_GENE_PRODUCT", 50, 51], ["humans", "ORGANISM", 69, 75], ["Hemagglutinin 1, 2, and 3", "PROTEIN", 0, 25], ["neuraminidase 1 and 2", "PROTEIN", 30, 51], ["humans", "SPECIES", 69, 75], ["humans", "SPECIES", 69, 75], ["Hemagglutinin", "TEST", 0, 13], ["neuraminidase", "TREATMENT", 30, 43]]], ["The gene segments for the surface glycoproteins are unstable, so mutations, called antigenic shift, occur regularly.", [["surface", "ANATOMY", 26, 33], ["surface glycoproteins", "PROTEIN", 26, 47], ["the surface glycoproteins", "TREATMENT", 22, 47], ["segments", "ANATOMY_MODIFIER", 9, 17], ["unstable", "OBSERVATION_MODIFIER", 52, 60]]], ["Epidemics occur annually during the winter months with a short, 1-3 day incubation period.", [["Epidemics", "PROBLEM", 0, 9]]], ["The virus causes destruction of the ciliated respiratory epithelium within 1 day of symptoms.", [["respiratory epithelium", "ANATOMY", 45, 67], ["ciliated respiratory epithelium", "TISSUE", 36, 67], ["The virus", "PROBLEM", 0, 9], ["destruction", "PROBLEM", 17, 28], ["the ciliated respiratory epithelium", "PROBLEM", 32, 67], ["symptoms", "PROBLEM", 84, 92], ["virus", "OBSERVATION", 4, 9], ["destruction", "OBSERVATION", 17, 28], ["ciliated", "ANATOMY_MODIFIER", 36, 44], ["respiratory epithelium", "OBSERVATION", 45, 67]]], ["Airway edema and infi ltration with infl ammatory cells into the airway mucosa and epithelium follows.", [["Airway", "ANATOMY", 0, 6], ["infl ammatory cells", "ANATOMY", 36, 55], ["airway mucosa", "ANATOMY", 65, 78], ["epithelium", "ANATOMY", 83, 93], ["edema", "DISEASE", 7, 12], ["Airway edema", "PATHOLOGICAL_FORMATION", 0, 12], ["infl ammatory cells", "CELL", 36, 55], ["airway mucosa", "MULTI-TISSUE_STRUCTURE", 65, 78], ["epithelium", "TISSUE", 83, 93], ["infl ammatory cells", "CELL_TYPE", 36, 55], ["Airway edema", "PROBLEM", 0, 12], ["infi ltration", "TREATMENT", 17, 30], ["infl ammatory cells", "TREATMENT", 36, 55], ["edema", "OBSERVATION", 7, 12], ["airway mucosa", "ANATOMY", 65, 78], ["epithelium", "ANATOMY_MODIFIER", 83, 93]]], ["Slow repair occurs over 2-4 weeks.", [["Slow repair", "TREATMENT", 0, 11], ["repair", "OBSERVATION", 5, 11]]], ["A severe fulminating pneumonia may result in hemorrhagic exudates that contain many polymorphonuclear and mononuclear cells.", [["polymorphonuclear", "ANATOMY", 84, 101], ["mononuclear cells", "ANATOMY", 106, 123], ["pneumonia", "DISEASE", 21, 30], ["hemorrhagic", "DISEASE", 45, 56], ["polymorphonuclear", "CELL", 84, 101], ["mononuclear cells", "CELL", 106, 123], ["polymorphonuclear and mononuclear cells", "CELL_TYPE", 84, 123], ["A severe fulminating pneumonia", "PROBLEM", 0, 30], ["hemorrhagic exudates", "PROBLEM", 45, 65], ["many polymorphonuclear and mononuclear cells", "PROBLEM", 79, 123], ["severe", "OBSERVATION_MODIFIER", 2, 8], ["fulminating", "OBSERVATION_MODIFIER", 9, 20], ["pneumonia", "OBSERVATION", 21, 30], ["hemorrhagic", "OBSERVATION_MODIFIER", 45, 56], ["exudates", "OBSERVATION", 57, 65], ["many", "OBSERVATION_MODIFIER", 79, 83], ["polymorphonuclear", "OBSERVATION_MODIFIER", 84, 101], ["mononuclear cells", "OBSERVATION", 106, 123]]], ["Destruction of the respiratory epithelium often leads to secondary bacterial infections.Infl uenzaDuring the 2003-2004 infl uenza season, 143 infl uenza-related deaths occurred in children; of these, 41% were less than 2 years of age.", [["respiratory epithelium", "ANATOMY", 19, 41], ["bacterial infections", "DISEASE", 67, 87], ["deaths", "DISEASE", 161, 167], ["respiratory epithelium", "TISSUE", 19, 41], ["children", "ORGANISM", 180, 188], ["children", "SPECIES", 180, 188], ["Destruction of the respiratory epithelium", "PROBLEM", 0, 41], ["secondary bacterial infections", "PROBLEM", 57, 87], ["respiratory epithelium", "ANATOMY", 19, 41], ["secondary", "OBSERVATION_MODIFIER", 57, 66], ["bacterial", "OBSERVATION_MODIFIER", 67, 76], ["infections", "OBSERVATION", 77, 87]]], ["Forty-fi ve percent of the older children (2-17 years of age) did not have an underlying medical condition.", [["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["an underlying medical condition", "PROBLEM", 75, 106]]], ["Rare complications of Although death from infl uenza pneumonia is uncommon, a signifi cant number of the children that died were previously healthy.K. S. POWERSinfl uenza include acute myositis, rhabdomyolysis, myocarditis, pericarditis, Reye syndrome, encephalitis, transverse myelitis, and Guillain-Barr\u00e9 syndrome.K. S. POWERSChildren may present with an abrupt clinical course manifested by high fever, myalgias, headaches, scratchy sore throats, and dry cough.", [["death", "DISEASE", 31, 36], ["pneumonia", "DISEASE", 53, 62], ["acute myositis", "DISEASE", 179, 193], ["rhabdomyolysis", "DISEASE", 195, 209], ["myocarditis", "DISEASE", 211, 222], ["pericarditis", "DISEASE", 224, 236], ["Reye syndrome", "DISEASE", 238, 251], ["encephalitis", "DISEASE", 253, 265], ["transverse myelitis", "DISEASE", 267, 286], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 292, 315], ["fever", "DISEASE", 399, 404], ["myalgias", "DISEASE", 406, 414], ["headaches", "DISEASE", 416, 425], ["scratchy sore throats", "DISEASE", 427, 448], ["dry cough", "DISEASE", 454, 463], ["children", "ORGANISM", 105, 113], ["children", "SPECIES", 105, 113], ["K.", "SPECIES", 148, 150], ["S. POWERSinfl uenza", "SPECIES", 151, 170], ["Rare complications", "PROBLEM", 0, 18], ["death", "PROBLEM", 31, 36], ["infl uenza pneumonia", "PROBLEM", 42, 62], ["acute myositis", "PROBLEM", 179, 193], ["rhabdomyolysis", "PROBLEM", 195, 209], ["myocarditis", "PROBLEM", 211, 222], ["pericarditis", "PROBLEM", 224, 236], ["Reye syndrome", "PROBLEM", 238, 251], ["encephalitis", "PROBLEM", 253, 265], ["transverse myelitis", "PROBLEM", 267, 286], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 292, 315], ["high fever", "PROBLEM", 394, 404], ["myalgias", "PROBLEM", 406, 414], ["headaches", "PROBLEM", 416, 425], ["scratchy sore throats", "PROBLEM", 427, 448], ["dry cough", "PROBLEM", 454, 463], ["complications", "OBSERVATION", 5, 18], ["pneumonia", "OBSERVATION", 53, 62], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["myositis", "OBSERVATION", 185, 193], ["rhabdomyolysis", "OBSERVATION", 195, 209], ["myocarditis", "OBSERVATION", 211, 222], ["pericarditis", "OBSERVATION", 224, 236], ["Reye syndrome", "OBSERVATION", 238, 251], ["encephalitis", "OBSERVATION", 253, 265], ["transverse myelitis", "OBSERVATION", 267, 286], ["Barr\u00e9 syndrome", "OBSERVATION", 301, 315], ["high", "OBSERVATION_MODIFIER", 394, 398], ["fever", "OBSERVATION", 399, 404], ["sore throats", "ANATOMY", 436, 448], ["dry", "OBSERVATION_MODIFIER", 454, 457], ["cough", "OBSERVATION", 458, 463]]], ["Peripheral white blood counts are usually less than 5,000.", [["Peripheral white blood", "ANATOMY", 0, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["Peripheral white blood counts", "TEST", 0, 29], ["white", "OBSERVATION_MODIFIER", 11, 16]]], ["Pulmonary infi ltrates often involve multiple lobes.", [["Pulmonary", "ANATOMY", 0, 9], ["lobes", "ANATOMY", 46, 51], ["lobes", "ORGAN", 46, 51], ["Pulmonary infi ltrates", "TEST", 0, 22], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["lobes", "ANATOMY_MODIFIER", 46, 51]]], ["Bacterial co-infection, especially with MRSA, increases morbidity and mortality signifi cantly.K. S. POWERSRimantidine and amantadine can shorten the course for infl uenza type A disease by limiting viral replication, but only if given within the fi rst 48 h of the disease.", [["co-infection", "DISEASE", 10, 22], ["MRSA", "CHEMICAL", 40, 44], ["POWERSRimantidine", "CHEMICAL", 101, 118], ["amantadine", "CHEMICAL", 123, 133], ["amantadine", "CHEMICAL", 123, 133], ["amantadine", "SIMPLE_CHEMICAL", 123, 133], ["infl uenza type A", "CANCER", 161, 178], ["MRSA", "SPECIES", 40, 44], ["MRSA", "SPECIES", 40, 44], ["infl uenza type A", "SPECIES", 161, 178], ["Bacterial co-infection", "PROBLEM", 0, 22], ["MRSA", "PROBLEM", 40, 44], ["increases morbidity", "PROBLEM", 46, 65], ["POWERSRimantidine", "TREATMENT", 101, 118], ["amantadine", "TREATMENT", 123, 133], ["infl uenza type A disease", "PROBLEM", 161, 186], ["viral replication", "TREATMENT", 199, 216], ["the disease", "PROBLEM", 262, 273], ["co-infection", "OBSERVATION", 10, 22], ["MRSA", "OBSERVATION", 40, 44], ["disease", "OBSERVATION", 179, 186], ["viral replication", "OBSERVATION", 199, 216], ["disease", "OBSERVATION", 266, 273]]], ["Prophylactic dosing is 70-90% effective and does not interfere with antibody production from the vaccine.", [["Prophylactic dosing", "TREATMENT", 0, 19], ["antibody production", "TREATMENT", 68, 87], ["the vaccine", "TREATMENT", 93, 104]]], ["Both drugs have central nervous system and gastrointestinal side effects, including an increase in the incidence of seizures.", [["central nervous system", "ANATOMY", 16, 38], ["gastrointestinal", "ANATOMY", 43, 59], ["seizures", "DISEASE", 116, 124], ["nervous system", "ANATOMICAL_SYSTEM", 24, 38], ["gastrointestinal", "ANATOMICAL_SYSTEM", 43, 59], ["central nervous system", "PROBLEM", 16, 38], ["gastrointestinal side effects", "PROBLEM", 43, 72], ["seizures", "PROBLEM", 116, 124], ["drugs", "OBSERVATION", 5, 10], ["central", "ANATOMY_MODIFIER", 16, 23], ["nervous system", "ANATOMY", 24, 38], ["gastrointestinal", "ANATOMY", 43, 59], ["increase", "OBSERVATION_MODIFIER", 87, 95]]], ["Oseltamivir and zanamivir have recently been approved for the treatment of infl uenza infections in children.", [["Oseltamivir", "CHEMICAL", 0, 11], ["zanamivir", "CHEMICAL", 16, 25], ["infl uenza infections", "DISEASE", 75, 96], ["Oseltamivir", "CHEMICAL", 0, 11], ["zanamivir", "CHEMICAL", 16, 25], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["zanamivir", "SIMPLE_CHEMICAL", 16, 25], ["infl uenza", "ORGANISM", 75, 85], ["children", "ORGANISM", 100, 108], ["children", "SPECIES", 100, 108], ["Oseltamivir", "TREATMENT", 0, 11], ["zanamivir", "TREATMENT", 16, 25], ["infl uenza infections", "PROBLEM", 75, 96]]], ["They inhibit neuraminidase, an enzyme produced by infl uenza A and B. The course of disease in healthy adults can be reduced by 1-2 days, if started within 48 h of the onset of symptoms.", [["neuraminidase", "GENE_OR_GENE_PRODUCT", 13, 26], ["infl uenza A", "ORGANISM", 50, 62], ["neuraminidase", "PROTEIN", 13, 26], ["neuraminidase", "PROBLEM", 13, 26], ["an enzyme", "TEST", 28, 37], ["symptoms", "PROBLEM", 177, 185]]], ["Zanamivir is a dry powder aerosol that must be delivered by a special breath-activated device.", [["Zanamivir", "CHEMICAL", 0, 9], ["Zanamivir", "CHEMICAL", 0, 9], ["Zanamivir", "SIMPLE_CHEMICAL", 0, 9], ["Zanamivir", "TREATMENT", 0, 9], ["a dry powder aerosol", "TREATMENT", 13, 33], ["a special breath-activated device", "TREATMENT", 60, 93]]], ["Bronchospasm in patients with asthma has been reported.", [["Bronchospasm", "DISEASE", 0, 12], ["asthma", "DISEASE", 30, 36], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["Bronchospasm", "PROBLEM", 0, 12], ["asthma", "PROBLEM", 30, 36], ["asthma", "OBSERVATION", 30, 36]]], ["Aspirin or aspirin-containing products should be avoided due to the risk of Reye syndrome.K. S. POWERSImmunoprophylaxis is the most effective strategy for the prevention of infl uenza infection.", [["Aspirin", "CHEMICAL", 0, 7], ["aspirin", "CHEMICAL", 11, 18], ["Reye syndrome", "DISEASE", 76, 89], ["infl uenza infection", "DISEASE", 173, 193], ["Aspirin", "CHEMICAL", 0, 7], ["aspirin", "CHEMICAL", 11, 18], ["Aspirin", "SIMPLE_CHEMICAL", 0, 7], ["aspirin", "SIMPLE_CHEMICAL", 11, 18], ["infl uenza", "ORGANISM", 173, 183], ["Aspirin", "TREATMENT", 0, 7], ["aspirin", "TREATMENT", 11, 18], ["products", "TREATMENT", 30, 38], ["Reye syndrome", "PROBLEM", 76, 89], ["POWERSImmunoprophylaxis", "TREATMENT", 96, 119], ["infl uenza infection", "PROBLEM", 173, 193], ["Reye syndrome", "OBSERVATION", 76, 89], ["infection", "OBSERVATION", 184, 193]]], ["Inactivated vaccines have effi cacy rates from 70% to 90%.", [["Inactivated vaccines", "TREATMENT", 0, 20], ["effi cacy rates", "TEST", 26, 41]]], ["Currently, the inactivated vaccine is recommended for all children older than 6 months of age with high risk conditions including chronic pulmonary or cardiac disease, immunosuppressive disorders, sickle cell disease and other hemoglobinopathies, diseases requiring long-term aspirin therapy, chronic metabolic and renal diseases; healthy children aged 6-23 months; and household contacts over the age of 6 months of high risk persons.", [["pulmonary", "ANATOMY", 138, 147], ["cardiac", "ANATOMY", 151, 158], ["sickle cell", "ANATOMY", 197, 208], ["renal", "ANATOMY", 315, 320], ["chronic pulmonary or cardiac disease", "DISEASE", 130, 166], ["immunosuppressive disorders", "DISEASE", 168, 195], ["sickle cell disease", "DISEASE", 197, 216], ["hemoglobinopathies", "DISEASE", 227, 245], ["aspirin", "CHEMICAL", 276, 283], ["chronic metabolic and renal diseases", "DISEASE", 293, 329], ["aspirin", "CHEMICAL", 276, 283], ["children", "ORGANISM", 58, 66], ["pulmonary", "ORGAN", 138, 147], ["cardiac", "ORGAN", 151, 158], ["sickle cell", "CELL", 197, 208], ["aspirin", "SIMPLE_CHEMICAL", 276, 283], ["renal", "ORGAN", 315, 320], ["persons", "ORGANISM", 427, 434], ["children", "SPECIES", 58, 66], ["children", "SPECIES", 339, 347], ["persons", "SPECIES", 427, 434], ["the inactivated vaccine", "TREATMENT", 11, 34], ["high risk conditions", "PROBLEM", 99, 119], ["chronic pulmonary or cardiac disease", "PROBLEM", 130, 166], ["immunosuppressive disorders", "PROBLEM", 168, 195], ["sickle cell disease", "PROBLEM", 197, 216], ["other hemoglobinopathies", "PROBLEM", 221, 245], ["diseases", "PROBLEM", 247, 255], ["long-term aspirin therapy", "TREATMENT", 266, 291], ["chronic metabolic and renal diseases", "PROBLEM", 293, 329], ["chronic", "OBSERVATION_MODIFIER", 130, 137], ["pulmonary", "ANATOMY", 138, 147], ["cardiac", "ANATOMY", 151, 158], ["disease", "OBSERVATION", 159, 166], ["sickle cell disease", "OBSERVATION", 197, 216], ["hemoglobinopathies", "OBSERVATION", 227, 245], ["long-term", "OBSERVATION_MODIFIER", 266, 275], ["chronic", "OBSERVATION_MODIFIER", 293, 300], ["metabolic", "OBSERVATION_MODIFIER", 301, 310], ["renal", "ANATOMY", 315, 320], ["diseases", "OBSERVATION", 321, 329]]], ["A live, attenuated infl uenza vaccine was licensed in 2003.", [["infl uenza", "ORGANISM", 19, 29], ["attenuated infl uenza vaccine", "TREATMENT", 8, 37]]], ["It is administered by the intranasal route and is approved for healthy children aged 5-17 years.Avian Infl uenzaAvian infl uenza viruses do not normally infect species other than birds and pigs.", [["children", "ORGANISM", 71, 79], ["Avian", "ORGANISM", 96, 101], ["Infl uenzaAvian infl uenza viruses", "ORGANISM", 102, 136], ["pigs", "ORGANISM", 189, 193], ["children", "SPECIES", 71, 79], ["Avian", "SPECIES", 96, 101], ["pigs", "SPECIES", 189, 193], ["Avian Infl uenzaAvian infl uenza viruses", "SPECIES", 96, 136], ["uenza viruses", "PROBLEM", 123, 136]]], ["However, in 1997, the fi rst human death from avian infl uenza occurred in Hong Kong in a 3 year old with Reye syndrome.", [["death", "DISEASE", 35, 40], ["avian infl uenza", "DISEASE", 46, 62], ["Reye syndrome", "DISEASE", 106, 119], ["human", "ORGANISM", 29, 34], ["avian", "ORGANISM", 46, 51], ["infl uenza", "ORGANISM", 52, 62], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["Reye syndrome", "PROBLEM", 106, 119], ["Reye syndrome", "OBSERVATION", 106, 119]]], ["Subsequently, an epidemic occurred among humans in Hong Kong with close contact to live, infected poultry.", [["humans", "ORGANISM", 41, 47], ["humans", "SPECIES", 41, 47], ["humans", "SPECIES", 41, 47], ["epidemic", "OBSERVATION", 17, 25], ["infected", "OBSERVATION", 89, 97]]], ["The subtype H5N1 appears to be the most ominous due to its ability to rapidly mutate and infect new species.", [["H5N1", "DISEASE", 12, 16], ["H5N1", "ORGANISM", 12, 16], ["The subtype H5N1", "PROBLEM", 0, 16], ["infect new species", "PROBLEM", 89, 107], ["subtype", "OBSERVATION_MODIFIER", 4, 11], ["H5N1", "OBSERVATION", 12, 16]]], ["The overall mortality rate is greater than 70%.", [["The overall mortality rate", "TEST", 0, 26], ["greater", "OBSERVATION_MODIFIER", 30, 37]]], ["The avian viruses are not believed to be transmissible from person-to-person, but some recent cases are being investigated for this possibility.", [["avian viruses", "ORGANISM", 4, 17], ["person", "SPECIES", 60, 66], ["person", "SPECIES", 70, 76], ["viruses", "OBSERVATION", 10, 17], ["not believed to be", "UNCERTAINTY", 22, 40]]], ["Children uniformly present with fever and cough.", [["fever", "DISEASE", 32, 37], ["cough", "DISEASE", 42, 47], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["fever", "PROBLEM", 32, 37], ["cough", "PROBLEM", 42, 47], ["fever", "OBSERVATION", 32, 37], ["cough", "OBSERVATION", 42, 47]]], ["Symptoms range from typical infl uenza-like symptoms to conjunctivitis to respiratory disease and failure.", [["respiratory", "ANATOMY", 74, 85], ["conjunctivitis", "DISEASE", 56, 70], ["respiratory disease", "DISEASE", 74, 93], ["Symptoms", "PROBLEM", 0, 8], ["typical infl uenza", "PROBLEM", 20, 38], ["symptoms", "PROBLEM", 44, 52], ["conjunctivitis", "PROBLEM", 56, 70], ["respiratory disease", "PROBLEM", 74, 93], ["failure", "PROBLEM", 98, 105], ["conjunctivitis", "OBSERVATION", 56, 70], ["respiratory disease", "OBSERVATION", 74, 93], ["failure", "OBSERVATION", 98, 105]]], ["Signifi cant laboratory data include leukopenia and thrombocytopenia.", [["leukopenia", "DISEASE", 37, 47], ["thrombocytopenia", "DISEASE", 52, 68], ["Signifi cant laboratory data", "TEST", 0, 28], ["leukopenia", "PROBLEM", 37, 47], ["thrombocytopenia", "PROBLEM", 52, 68], ["leukopenia", "OBSERVATION", 37, 47], ["thrombocytopenia", "OBSERVATION", 52, 68]]], ["All children who developed pneumonia and progressed to ARDS died.", [["pneumonia", "DISEASE", 27, 36], ["ARDS", "DISEASE", 55, 59], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["pneumonia", "PROBLEM", 27, 36], ["ARDS", "PROBLEM", 55, 59], ["pneumonia", "OBSERVATION", 27, 36], ["ARDS", "OBSERVATION", 55, 59]]], ["Diagnosis remains diffi cult, as no tests are widely available.", [["diffi cult", "TEST", 18, 28], ["tests", "TEST", 36, 41]]], ["Of the antiviral drugs available for infl uenza A, the most recent H5N1 strains in Southeast Asia are resistant to rimantadine and amantadine.", [["rimantadine", "CHEMICAL", 115, 126], ["amantadine", "CHEMICAL", 131, 141], ["rimantadine", "CHEMICAL", 115, 126], ["amantadine", "CHEMICAL", 131, 141], ["infl uenza A", "ORGANISM", 37, 49], ["H5N1", "ORGANISM", 67, 71], ["rimantadine", "SIMPLE_CHEMICAL", 115, 126], ["amantadine", "SIMPLE_CHEMICAL", 131, 141], ["infl uenza A", "SPECIES", 37, 49], ["the antiviral drugs", "TREATMENT", 3, 22], ["rimantadine", "TREATMENT", 115, 126], ["amantadine", "TREATMENT", 131, 141], ["H5N1", "OBSERVATION", 67, 71]]], ["Therefore, treatment is mainly supportive.", [["treatment", "TREATMENT", 11, 20]]], ["A prototype H5N1 vaccine was made available to manufacturers in April 2004, but production is diffi cult because the standard means of producing infl uenza vaccines from specially grown chicken eggs is not feasible.", [["H5N1", "ORGANISM", 12, 16], ["infl uenza", "ORGANISM", 145, 155], ["chicken", "ORGANISM", 186, 193], ["chicken", "SPECIES", 186, 193], ["chicken", "SPECIES", 186, 193], ["A prototype H5N1 vaccine", "TREATMENT", 0, 24], ["infl uenza vaccines", "TREATMENT", 145, 164]]], ["H5N1 kills the embryo before enough viruses can be harvested for vaccine production.Novel H1N1 Infl uenza AIn April, 2009, The Centers for Disease Control confi rmed the emergence of a novel infl uenza A (H1N1) virus with genes from swine viruses of the Eurasian lineage and genes from avian infl uenza viruses.", [["embryo", "ANATOMY", 15, 21], ["H5N1", "ORGANISM", 0, 4], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 15, 21], ["infl uenza A (H1N1) virus", "ORGANISM", 191, 216], ["swine viruses", "ORGANISM", 233, 246], ["Eurasian lineage", "CELL", 254, 270], ["avian", "ORGANISM", 286, 291], ["infl uenza viruses", "ORGANISM", 292, 310], ["H5N1", "SPECIES", 0, 4], ["H1N1) virus", "SPECIES", 205, 216], ["swine", "SPECIES", 233, 238], ["H5N1", "SPECIES", 0, 4], ["H1N1", "SPECIES", 90, 94], ["infl uenza A (H1N1) virus", "SPECIES", 191, 216], ["swine viruses", "SPECIES", 233, 246], ["infl uenza viruses", "SPECIES", 292, 310], ["H5N1", "PROBLEM", 0, 4], ["enough viruses", "PROBLEM", 29, 43], ["vaccine production", "TREATMENT", 65, 83], ["Novel H1N1", "PROBLEM", 84, 94], ["Disease Control confi", "PROBLEM", 139, 160], ["A (H1N1) virus", "PROBLEM", 202, 216], ["H1N1", "OBSERVATION", 90, 94], ["Eurasian lineage", "OBSERVATION", 254, 270]]], ["In comparison to illnesses with seasonal infl uenza, the majority of cases occurred in individuals younger than 65 years of age, with nearly half of the cases occurring in children under 18 years of age .Novel H1N1 Infl uenza AThe clinical symptoms can be typical for infl uenza; fever, sore throat, cough, and muscle aches with the addition of vomiting and diarrhea in children.", [["sore throat", "ANATOMY", 287, 298], ["muscle", "ANATOMY", 311, 317], ["fever", "DISEASE", 280, 285], ["sore throat", "DISEASE", 287, 298], ["cough", "DISEASE", 300, 305], ["muscle aches", "DISEASE", 311, 323], ["vomiting", "DISEASE", 345, 353], ["diarrhea", "DISEASE", 358, 366], ["children", "ORGANISM", 172, 180], ["throat", "ORGANISM_SUBDIVISION", 292, 298], ["muscle", "ORGAN", 311, 317], ["children", "ORGANISM", 370, 378], ["children", "SPECIES", 172, 180], ["children", "SPECIES", 370, 378], ["H1N1", "SPECIES", 210, 214], ["seasonal infl uenza", "PROBLEM", 32, 51], ["Novel H1N1", "PROBLEM", 204, 214], ["clinical symptoms", "PROBLEM", 231, 248], ["infl uenza", "PROBLEM", 268, 278], ["fever", "PROBLEM", 280, 285], ["sore throat", "PROBLEM", 287, 298], ["cough", "PROBLEM", 300, 305], ["muscle aches", "PROBLEM", 311, 323], ["vomiting", "PROBLEM", 345, 353], ["diarrhea", "PROBLEM", 358, 366], ["H1N1", "OBSERVATION", 210, 214], ["fever", "OBSERVATION", 280, 285], ["sore throat", "ANATOMY", 287, 298], ["cough", "OBSERVATION", 300, 305], ["muscle", "ANATOMY", 311, 317]]], ["A wide range of complications Although antiviral medications may attenuate the course of infl uenza when given early, immunoprophylaxis with vaccines is the most effective strategy for the control of infl uenza infections.Novel H1N1 Infl uenza AAvian Infl uenza has occurred in epidemics among persons with close contact to live, infected poultry.", [["infections", "DISEASE", 211, 221], ["uenza", "CHEMICAL", 256, 261], ["infl uenza", "ORGANISM", 89, 99], ["infl uenza", "ORGANISM", 200, 210], ["persons", "ORGANISM", 294, 301], ["persons", "SPECIES", 294, 301], ["infl uenza", "SPECIES", 200, 210], ["H1N1", "SPECIES", 228, 232], ["A wide range of complications", "PROBLEM", 0, 29], ["antiviral medications", "TREATMENT", 39, 60], ["infl uenza", "TREATMENT", 89, 99], ["immunoprophylaxis", "TREATMENT", 118, 135], ["vaccines", "TREATMENT", 141, 149], ["infl uenza infections", "PROBLEM", 200, 221], ["Novel H1N1", "PROBLEM", 222, 232], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["H1N1", "OBSERVATION", 228, 232], ["infected", "OBSERVATION", 330, 338]]], ["All children with pneumonia that progressed to ARDS succumbed to the disease.Novel H1N1 Infl uenza Ahave been reported that include mild-to-moderate (otitis media, sinusitis, myositis, and febrile seizures) to more severe complications such as myocarditis, rhabdomyolysis or encephalitis.", [["pneumonia", "DISEASE", 18, 27], ["ARDS", "DISEASE", 47, 51], ["otitis media", "DISEASE", 150, 162], ["sinusitis", "DISEASE", 164, 173], ["myositis", "DISEASE", 175, 183], ["febrile seizures", "DISEASE", 189, 205], ["myocarditis", "DISEASE", 244, 255], ["rhabdomyolysis", "DISEASE", 257, 271], ["encephalitis", "DISEASE", 275, 287], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["H1N1", "SPECIES", 83, 87], ["Infl uenza", "SPECIES", 88, 98], ["pneumonia", "PROBLEM", 18, 27], ["ARDS", "PROBLEM", 47, 51], ["the disease", "PROBLEM", 65, 76], ["Novel H1N1", "PROBLEM", 77, 87], ["mild-to-moderate (otitis media", "PROBLEM", 132, 162], ["sinusitis", "PROBLEM", 164, 173], ["myositis", "PROBLEM", 175, 183], ["febrile seizures", "PROBLEM", 189, 205], ["more severe complications", "PROBLEM", 210, 235], ["myocarditis", "PROBLEM", 244, 255], ["rhabdomyolysis", "PROBLEM", 257, 271], ["encephalitis", "PROBLEM", 275, 287], ["pneumonia", "OBSERVATION", 18, 27], ["ARDS", "OBSERVATION", 47, 51], ["disease", "OBSERVATION", 69, 76], ["H1N1", "OBSERVATION", 83, 87], ["mild", "OBSERVATION_MODIFIER", 132, 136], ["-to-moderate", "OBSERVATION_MODIFIER", 136, 148], ["otitis", "OBSERVATION", 150, 156], ["sinusitis", "OBSERVATION", 164, 173], ["myositis", "OBSERVATION", 175, 183], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["complications", "OBSERVATION", 222, 235], ["myocarditis", "OBSERVATION", 244, 255], ["rhabdomyolysis", "OBSERVATION", 257, 271], ["encephalitis", "OBSERVATION", 275, 287]]], ["Severe complications may frequently involve invasive bacterial co-infection (i.e. MRSA) and/or exacerbation of underlying medical conditions in particular asthma.", [["bacterial co-infection", "DISEASE", 53, 75], ["MRSA", "DISEASE", 82, 86], ["asthma", "DISEASE", 155, 161], ["MRSA", "SPECIES", 82, 86], ["MRSA", "SPECIES", 82, 86], ["Severe complications", "PROBLEM", 0, 20], ["invasive bacterial co-infection", "PROBLEM", 44, 75], ["MRSA", "PROBLEM", 82, 86], ["exacerbation", "PROBLEM", 95, 107], ["underlying medical conditions", "PROBLEM", 111, 140], ["asthma", "PROBLEM", 155, 161], ["invasive", "OBSERVATION_MODIFIER", 44, 52], ["bacterial", "OBSERVATION_MODIFIER", 53, 62], ["co-infection", "OBSERVATION", 63, 75], ["MRSA", "OBSERVATION", 82, 86], ["asthma", "OBSERVATION", 155, 161]]], ["Children who present initially with uncomplicated infl uenza may have rapidly progressive hypoxemic respiratory failure and multiorgan system dysfunction that is refractory to all therapies ( Fig. 25-3 ) .Novel H1N1 Infl uenza AOf reported H1N1 deaths, approximately 20% were in children.", [["respiratory", "ANATOMY", 100, 111], ["multiorgan system", "ANATOMY", 124, 141], ["hypoxemic respiratory failure", "DISEASE", 90, 119], ["multiorgan system dysfunction", "DISEASE", 124, 153], ["deaths", "DISEASE", 245, 251], ["Children", "ORGANISM", 0, 8], ["H1N1", "ORGANISM", 211, 215], ["Infl uenza AOf", "ORGANISM", 216, 230], ["children", "ORGANISM", 279, 287], ["Children", "SPECIES", 0, 8], ["children", "SPECIES", 279, 287], ["rapidly progressive hypoxemic respiratory failure", "PROBLEM", 70, 119], ["multiorgan system dysfunction", "PROBLEM", 124, 153], ["all therapies", "TREATMENT", 176, 189], ["progressive", "OBSERVATION_MODIFIER", 78, 89], ["hypoxemic", "OBSERVATION_MODIFIER", 90, 99], ["respiratory failure", "OBSERVATION", 100, 119], ["multiorgan system dysfunction", "OBSERVATION", 124, 153], ["refractory", "OBSERVATION_MODIFIER", 162, 172], ["H1N1", "OBSERVATION", 211, 215]]], ["The majority of these children had comorbid asthma, neuro-developmental conditions, or obesity.", [["asthma", "DISEASE", 44, 50], ["neuro-developmental conditions", "DISEASE", 52, 82], ["obesity", "DISEASE", 87, 94], ["children", "ORGANISM", 22, 30], ["children", "SPECIES", 22, 30], ["comorbid asthma", "PROBLEM", 35, 50], ["developmental conditions", "PROBLEM", 58, 82], ["obesity", "PROBLEM", 87, 94], ["asthma", "OBSERVATION", 44, 50], ["obesity", "OBSERVATION", 87, 94]]], ["An American Academy of Pediatrics Work Group identifi ed children at greatest risk for life-threatening H1N1 infl uenza disease (Table 25-1 ) .Novel H1N1 Infl uenza AThe Centers for Disease Control has recommended prompt empiric antiviral therapy for infants, children, and adolescents of any age presenting with suspected or confi rmed H1N1 infl uenza and any of the following conditions:Novel H1N1 Infl uenza AIllness requiring hospitalization \u25a0 Progressive, severe, or complicated illness, regardless of previous health \u25a0 Presence of signifi cant risk factors (see Table \u25a0 25-1 )Novel H1N1 Infl uenza AThe H1N1 strain has been found to be resistant to amantadine and rimantadine, but is usually sensitive to neuraminidase inhibitors, specifi cally oseltamivir or zanamir.", [["H1N1 infl uenza disease", "DISEASE", 104, 127], ["amantadine", "CHEMICAL", 655, 665], ["rimantadine", "CHEMICAL", 670, 681], ["oseltamivir", "CHEMICAL", 751, 762], ["zanamir", "CHEMICAL", 766, 773], ["amantadine", "CHEMICAL", 655, 665], ["rimantadine", "CHEMICAL", 670, 681], ["oseltamivir", "CHEMICAL", 751, 762], ["zanamir", "CHEMICAL", 766, 773], ["children", "ORGANISM", 57, 65], ["infants", "ORGANISM", 251, 258], ["children", "ORGANISM", 260, 268], ["Infl uenza AThe H1N1", "ORGANISM", 593, 613], ["amantadine", "SIMPLE_CHEMICAL", 655, 665], ["rimantadine", "SIMPLE_CHEMICAL", 670, 681], ["neuraminidase inhibitors", "SIMPLE_CHEMICAL", 711, 735], ["specifi cally oseltamivir", "SIMPLE_CHEMICAL", 737, 762], ["zanamir", "SIMPLE_CHEMICAL", 766, 773], ["children", "SPECIES", 57, 65], ["infants", "SPECIES", 251, 258], ["children", "SPECIES", 260, 268], ["adolescents", "SPECIES", 274, 285], ["H1N1", "SPECIES", 149, 153], ["H1N1", "SPECIES", 395, 399], ["Infl uenza AThe H1N1 strain", "SPECIES", 593, 620], ["life-threatening H1N1 infl uenza disease", "PROBLEM", 87, 127], ["Novel H1N1", "PROBLEM", 143, 153], ["Disease Control", "TREATMENT", 182, 197], ["prompt empiric antiviral therapy", "TREATMENT", 214, 246], ["Novel H1N1", "PROBLEM", 389, 399], ["complicated illness", "PROBLEM", 472, 491], ["signifi cant risk factors", "PROBLEM", 537, 562], ["H1N1 strain", "PROBLEM", 609, 620], ["amantadine", "TREATMENT", 655, 665], ["rimantadine", "TREATMENT", 670, 681], ["neuraminidase inhibitors", "TREATMENT", 711, 735], ["specifi cally oseltamivir", "TREATMENT", 737, 762], ["zanamir", "TREATMENT", 766, 773], ["H1N1", "OBSERVATION", 149, 153], ["H1N1", "OBSERVATION", 395, 399], ["Progressive", "OBSERVATION_MODIFIER", 448, 459], ["severe", "OBSERVATION_MODIFIER", 461, 467], ["H1N1", "OBSERVATION", 588, 592]]], ["In 2009, oseltamivir was emergently approved for treatment in children less than 12 months of age.", [["oseltamivir", "CHEMICAL", 9, 20], ["oseltamivir", "CHEMICAL", 9, 20], ["oseltamivir", "SIMPLE_CHEMICAL", 9, 20], ["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70], ["oseltamivir", "TREATMENT", 9, 20], ["treatment", "TREATMENT", 49, 58]]], ["Resistance to oseltamivir has been reported and is thought due to the H275Y mutation.", [["oseltamivir", "CHEMICAL", 14, 25], ["oseltamivir", "CHEMICAL", 14, 25], ["oseltamivir", "SIMPLE_CHEMICAL", 14, 25], ["H275Y", "GENE_OR_GENE_PRODUCT", 70, 75], ["oseltamivir", "TREATMENT", 14, 25], ["the H275Y mutation", "PROBLEM", 66, 84], ["oseltamivir", "OBSERVATION", 14, 25], ["thought due to", "UNCERTAINTY", 51, 65]]], ["Interestingly, the mutation confers resistance to oseltamivir, but not to zanamivir.", [["oseltamivir", "CHEMICAL", 50, 61], ["zanamivir", "CHEMICAL", 74, 83], ["oseltamivir", "CHEMICAL", 50, 61], ["zanamivir", "CHEMICAL", 74, 83], ["oseltamivir", "SIMPLE_CHEMICAL", 50, 61], ["zanamivir", "SIMPLE_CHEMICAL", 74, 83], ["the mutation", "PROBLEM", 15, 27], ["oseltamivir", "TREATMENT", 50, 61], ["zanamivir", "TREATMENT", 74, 83]]], ["Peramivir, a neuraminidase inhibitor, an unapproved (investigational) antiviral available in an intravenous formulation received an emergency use authorization permit from the FDA for use in children with confi rmed severe refractory H1N1 infl uenza.", [["intravenous", "ANATOMY", 96, 107], ["Peramivir", "CHEMICAL", 0, 9], ["H1N1 infl uenza", "DISEASE", 234, 249], ["Peramivir", "CHEMICAL", 0, 9], ["Peramivir", "SIMPLE_CHEMICAL", 0, 9], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 107], ["children", "ORGANISM", 191, 199], ["children", "SPECIES", 191, 199], ["H1N1 infl uenza", "SPECIES", 234, 249], ["Peramivir", "TREATMENT", 0, 9], ["a neuraminidase inhibitor", "TREATMENT", 11, 36], ["antiviral", "TREATMENT", 70, 79], ["an intravenous formulation", "TREATMENT", 93, 119], ["severe refractory H1N1 infl uenza", "PROBLEM", 216, 249], ["refractory", "OBSERVATION_MODIFIER", 223, 233], ["H1N1", "OBSERVATION", 234, 238]]], ["Its use should be restricted to children that are not responding to either oral or inhaled antiviral drugs or if the parenteral route is the only dependable method of drug delivery.", [["oral", "ANATOMY", 75, 79], ["children", "ORGANISM", 32, 40], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["children", "SPECIES", 32, 40], ["inhaled antiviral drugs", "TREATMENT", 83, 106], ["the parenteral route", "TREATMENT", 113, 133], ["drug delivery", "TREATMENT", 167, 180]]], ["A vaccine was manufactured and licensed using the same standards as seasonal infl uenza by late 2009.", [["A vaccine", "TREATMENT", 0, 9]]], ["A single dose was found to provide adequate protection in children older than 10 years of age, younger children requiring two doses separated by at least 21 days.AdenovirusAdenoviruses have been implicated in 4-10% of pneumonias in children.", [["pneumonias", "DISEASE", 218, 228], ["children", "ORGANISM", 58, 66], ["children", "ORGANISM", 103, 111], ["AdenovirusAdenoviruses", "GENE_OR_GENE_PRODUCT", 162, 184], ["children", "ORGANISM", 232, 240], ["children", "SPECIES", 58, 66], ["children", "SPECIES", 103, 111], ["children", "SPECIES", 232, 240], ["AdenovirusAdenoviruses", "TREATMENT", 162, 184], ["pneumonias", "PROBLEM", 218, 228], ["pneumonias", "OBSERVATION", 218, 228]]], ["Adenoviruses are classifi ed into 49 serotypes with types 3, 7, 7a, 11, and 21 being the most common etiologic agents of lower respiratory disease and causing a severe necrotizing pneumonitis.", [["respiratory", "ANATOMY", 127, 138], ["lower respiratory disease", "DISEASE", 121, 146], ["pneumonitis", "DISEASE", 180, 191], ["Adenoviruses", "PROBLEM", 0, 12], ["lower respiratory disease", "PROBLEM", 121, 146], ["a severe necrotizing pneumonitis", "PROBLEM", 159, 191], ["lower", "OBSERVATION_MODIFIER", 121, 126], ["respiratory disease", "OBSERVATION", 127, 146], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["necrotizing", "OBSERVATION_MODIFIER", 168, 179], ["pneumonitis", "OBSERVATION", 180, 191]]], ["These serotypes are associated with serious pulmonary sequelae, such as bronchiectasis, bronchiolitis obliterans, unilateral hyperlucent lung, and persistently abnormal pulmonary function tests.", [["pulmonary", "ANATOMY", 44, 53], ["hyperlucent lung", "ANATOMY", 125, 141], ["pulmonary", "ANATOMY", 169, 178], ["pulmonary sequelae", "DISEASE", 44, 62], ["bronchiectasis", "DISEASE", 72, 86], ["bronchiolitis obliterans", "DISEASE", 88, 112], ["abnormal pulmonary function", "DISEASE", 160, 187], ["pulmonary", "ORGAN", 44, 53], ["lung", "ORGAN", 137, 141], ["pulmonary", "ORGAN", 169, 178], ["These serotypes", "PROBLEM", 0, 15], ["serious pulmonary sequelae", "PROBLEM", 36, 62], ["bronchiectasis", "PROBLEM", 72, 86], ["bronchiolitis obliterans", "PROBLEM", 88, 112], ["unilateral hyperlucent lung", "PROBLEM", 114, 141], ["persistently abnormal pulmonary function tests", "PROBLEM", 147, 193], ["serotypes", "OBSERVATION", 6, 15], ["associated with", "UNCERTAINTY", 20, 35], ["serious", "OBSERVATION_MODIFIER", 36, 43], ["pulmonary", "ANATOMY", 44, 53], ["sequelae", "OBSERVATION", 54, 62], ["bronchiectasis", "OBSERVATION", 72, 86], ["bronchiolitis obliterans", "OBSERVATION", 88, 112], ["unilateral", "ANATOMY_MODIFIER", 114, 124], ["hyperlucent", "ANATOMY_MODIFIER", 125, 136], ["lung", "ANATOMY", 137, 141], ["persistently", "OBSERVATION_MODIFIER", 147, 159], ["abnormal", "OBSERVATION_MODIFIER", 160, 168], ["pulmonary function", "OBSERVATION", 169, 187]]], ["Adenovirus infections peak between 6 months and 5 years of age.", [["Adenovirus infections", "DISEASE", 0, 21], ["Adenovirus", "ORGANISM", 0, 10], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus infections", "PROBLEM", 0, 21], ["infections", "OBSERVATION", 11, 21]]], ["Mortality from severe respiratory infections can be high, because the disease often involves multiple organ systems.", [["respiratory", "ANATOMY", 22, 33], ["organ", "ANATOMY", 102, 107], ["respiratory infections", "DISEASE", 22, 44], ["organ", "ORGAN", 102, 107], ["severe respiratory infections", "PROBLEM", 15, 44], ["the disease", "PROBLEM", 66, 77], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["respiratory", "ANATOMY", 22, 33], ["infections", "OBSERVATION", 34, 44], ["disease", "OBSERVATION", 70, 77]]], ["Survivors may have permanent lung injury often in the form of bronchiolitis obliterans.", [["lung", "ANATOMY", 29, 33], ["lung injury", "DISEASE", 29, 40], ["bronchiolitis obliterans", "DISEASE", 62, 86], ["lung", "ORGAN", 29, 33], ["permanent lung injury", "PROBLEM", 19, 40], ["bronchiolitis obliterans", "PROBLEM", 62, 86], ["lung", "ANATOMY", 29, 33], ["injury", "OBSERVATION", 34, 40], ["bronchiolitis", "OBSERVATION", 62, 75], ["obliterans", "OBSERVATION", 76, 86]]], ["In the immunocompromised host, mortality rates are as high as 50-80%.", [["mortality rates", "TEST", 31, 46], ["immunocompromised host", "OBSERVATION", 7, 29]]], ["Cidofovir has in vitro activity against adenovirus, but proof of effi cacy is limited.", [["Cidofovir", "CHEMICAL", 0, 9], ["Cidofovir", "CHEMICAL", 0, 9], ["Cidofovir", "SIMPLE_CHEMICAL", 0, 9], ["adenovirus", "ORGANISM", 40, 50], ["adenovirus", "SPECIES", 40, 50], ["Cidofovir", "TREATMENT", 0, 9], ["adenovirus", "PROBLEM", 40, 50]]], ["Therapy is supportive.Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV)Severe acute respiratory syndrome is a newly described pulmonary infection caused by a novel SARS-associated coronavirus.", [["pulmonary", "ANATOMY", 144, 153], ["Acute Respiratory Syndrome-Associated Coronavirus", "DISEASE", 29, 78], ["SARS-CoV", "DISEASE", 80, 88], ["acute respiratory syndrome", "DISEASE", 96, 122], ["pulmonary infection", "DISEASE", 144, 163], ["SARS-associated coronavirus", "DISEASE", 182, 209], ["pulmonary", "ORGAN", 144, 153], ["coronavirus", "ORGANISM", 198, 209], ["Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV", "SPECIES", 22, 88], ["Therapy", "TREATMENT", 0, 7], ["Severe Acute Respiratory Syndrome", "PROBLEM", 22, 55], ["Associated Coronavirus (SARS-CoV)", "PROBLEM", 56, 89], ["Severe acute respiratory syndrome", "PROBLEM", 89, 122], ["pulmonary infection", "PROBLEM", 144, 163], ["a novel SARS", "PROBLEM", 174, 186], ["coronavirus", "PROBLEM", 198, 209], ["Acute", "OBSERVATION_MODIFIER", 29, 34], ["Respiratory Syndrome", "OBSERVATION", 35, 55], ["Coronavirus", "OBSERVATION", 67, 78], ["Severe", "OBSERVATION_MODIFIER", 89, 95], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory syndrome", "OBSERVATION", 102, 122], ["pulmonary", "ANATOMY", 144, 153], ["infection", "OBSERVATION", 154, 163], ["coronavirus", "OBSERVATION", 198, 209]]], ["SARS-CoV is highly contagious and was coined \"the fi rst plague of the twenty-fi rst century\".", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["highly", "OBSERVATION_MODIFIER", 12, 18], ["contagious", "OBSERVATION_MODIFIER", 19, 29]]], ["The disease rapidly spreads among household contacts and healthcare personnel.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["Children less than 18 years of age account for only approximately 5% of those affected, with a mean age of 12 years.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["No deaths were reported among children in the 2003 outbreak.", [["deaths", "DISEASE", 3, 9], ["children", "ORGANISM", 30, 38], ["children", "SPECIES", 30, 38]]], ["Children and adults present with fever, malaise, cough, coryza, chills or rigor, sputum production, headache, myalgia, leukopenia, lymphopenia, thrombocytopenia, mildly elevated activated partial thromboplastin times, and elevated levels of lactate dehydrogenase.", [["sputum", "ANATOMY", 81, 87], ["fever", "DISEASE", 33, 38], ["cough", "DISEASE", 49, 54], ["coryza", "DISEASE", 56, 62], ["chills", "DISEASE", 64, 70], ["sputum production", "DISEASE", 81, 98], ["headache", "DISEASE", 100, 108], ["myalgia", "DISEASE", 110, 117], ["leukopenia", "DISEASE", 119, 129], ["lymphopenia", "DISEASE", 131, 142], ["thrombocytopenia", "DISEASE", 144, 160], ["elevated activated partial thromboplastin times", "DISEASE", 169, 216], ["lactate", "CHEMICAL", 241, 248], ["lactate", "CHEMICAL", 241, 248], ["Children", "ORGANISM", 0, 8], ["adults", "ORGANISM", 13, 19], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 196, 210], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 241, 262], ["lactate dehydrogenase", "PROTEIN", 241, 262], ["Children", "SPECIES", 0, 8], ["fever", "PROBLEM", 33, 38], ["malaise", "PROBLEM", 40, 47], ["cough", "PROBLEM", 49, 54], ["coryza", "PROBLEM", 56, 62], ["chills", "PROBLEM", 64, 70], ["rigor", "PROBLEM", 74, 79], ["sputum production", "PROBLEM", 81, 98], ["headache", "PROBLEM", 100, 108], ["myalgia", "PROBLEM", 110, 117], ["leukopenia", "PROBLEM", 119, 129], ["lymphopenia", "PROBLEM", 131, 142], ["thrombocytopenia", "PROBLEM", 144, 160], ["mildly elevated activated partial thromboplastin times", "PROBLEM", 162, 216], ["elevated levels of lactate dehydrogenase", "PROBLEM", 222, 262], ["chills", "OBSERVATION", 64, 70], ["myalgia", "OBSERVATION", 110, 117], ["leukopenia", "OBSERVATION", 119, 129], ["lymphopenia", "OBSERVATION", 131, 142], ["thrombocytopenia", "OBSERVATION", 144, 160], ["mildly", "OBSERVATION_MODIFIER", 162, 168], ["elevated", "OBSERVATION_MODIFIER", 169, 177], ["partial", "OBSERVATION_MODIFIER", 188, 195], ["thromboplastin times", "OBSERVATION", 196, 216], ["lactate dehydrogenase", "OBSERVATION", 241, 262]]], ["Radiographs of the chest show non-specifi c infi ltrates.", [["chest", "ANATOMY", 19, 24], ["chest", "ORGANISM_SUBDIVISION", 19, 24], ["Radiographs of the chest", "TEST", 0, 24], ["non-specifi c infi ltrates", "PROBLEM", 30, 56], ["chest", "ANATOMY", 19, 24]]], ["Apart from diarrhea, patients have minimal extrapulmonary symptoms.", [["extrapulmonary", "ANATOMY", 43, 57], ["diarrhea", "DISEASE", 11, 19], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["diarrhea", "PROBLEM", 11, 19], ["minimal extrapulmonary symptoms", "PROBLEM", 35, 66], ["diarrhea", "OBSERVATION", 11, 19], ["minimal", "OBSERVATION_MODIFIER", 35, 42], ["extrapulmonary", "ANATOMY", 43, 57], ["symptoms", "OBSERVATION", 58, 66]]], ["Early diagnosis by reverse transcription-polymerase chain reaction (RT-PCR) can be made with 80% sensitivity on nasopharyngeal aspirates within the fi rst 3 days of the illness.", [["nasopharyngeal aspirates", "ANATOMY", 112, 136], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 112, 136], ["reverse transcription-polymerase chain reaction", "PROBLEM", 19, 66], ["RT-PCR", "TEST", 68, 74], ["nasopharyngeal aspirates", "TEST", 112, 136], ["the illness", "PROBLEM", 165, 176], ["nasopharyngeal", "ANATOMY", 112, 126], ["aspirates", "OBSERVATION", 127, 136]]], ["There is an incubation period of 2-10 days with a prodrome of high fever, chills, malaise, headache, and myalgias.", [["fever", "DISEASE", 67, 72], ["chills", "DISEASE", 74, 80], ["headache", "DISEASE", 91, 99], ["myalgias", "DISEASE", 105, 113], ["high fever", "PROBLEM", 62, 72], ["chills", "PROBLEM", 74, 80], ["malaise", "PROBLEM", 82, 89], ["headache", "PROBLEM", 91, 99], ["myalgias", "PROBLEM", 105, 113], ["incubation", "OBSERVATION_MODIFIER", 12, 22], ["myalgias", "OBSERVATION", 105, 113]]], ["Diarrhea occurs in up to 20% of adults.", [["Diarrhea", "DISEASE", 0, 8], ["adults", "ORGANISM", 32, 38], ["Diarrhea", "PROBLEM", 0, 8]]], ["After 2-7 days, the disease progresses to involve the lower airways with a dry non-productive cough and dyspnea.", [["lower airways", "ANATOMY", 54, 67], ["cough", "DISEASE", 94, 99], ["dyspnea", "DISEASE", 104, 111], ["lower airways", "ORGANISM_SUBDIVISION", 54, 67], ["the disease", "PROBLEM", 16, 27], ["a dry non-productive cough", "PROBLEM", 73, 99], ["dyspnea", "PROBLEM", 104, 111], ["disease", "OBSERVATION", 20, 27], ["lower", "ANATOMY_MODIFIER", 54, 59], ["airways", "ANATOMY", 60, 67], ["dry", "OBSERVATION_MODIFIER", 75, 78], ["non-productive", "OBSERVATION_MODIFIER", 79, 93], ["cough", "OBSERVATION", 94, 99], ["dyspnea", "OBSERVATION", 104, 111]]], ["In 10-20% of cases, acute respiratory distress syndrome (ARDS) follows and often patients require mechanical ventilation.", [["respiratory", "ANATOMY", 26, 37], ["acute respiratory distress syndrome", "DISEASE", 20, 55], ["ARDS", "DISEASE", 57, 61], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["acute respiratory distress syndrome", "PROBLEM", 20, 55], ["ARDS", "PROBLEM", 57, 61], ["mechanical ventilation", "TREATMENT", 98, 120], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory distress", "OBSERVATION", 26, 46], ["mechanical ventilation", "OBSERVATION", 98, 120]]], ["Deaths occur from respiratory failure.", [["respiratory", "ANATOMY", 18, 29], ["respiratory failure", "DISEASE", 18, 37], ["respiratory failure", "PROBLEM", 18, 37], ["respiratory failure", "OBSERVATION", 18, 37]]], ["Young children run a milder and shorter biphasic clinical course.", [["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14], ["a milder and shorter biphasic clinical course", "PROBLEM", 19, 64]]], ["Cough is found in approximately half the children, and crackles are rarely heard despite radiographic evidence of infi ltrates.", [["Cough", "DISEASE", 0, 5], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["Cough", "PROBLEM", 0, 5], ["crackles", "PROBLEM", 55, 63], ["infi ltrates", "PROBLEM", 114, 126], ["crackles", "OBSERVATION", 55, 63]]], ["A regimen of antibiotics, ribavirin, and corticosteroids was proposed based on initial anecdotal success.", [["ribavirin", "CHEMICAL", 26, 35], ["ribavirin", "CHEMICAL", 26, 35], ["corticosteroids", "CHEMICAL", 41, 56], ["ribavirin", "SIMPLE_CHEMICAL", 26, 35], ["antibiotics", "TREATMENT", 13, 24], ["ribavirin", "TREATMENT", 26, 35], ["corticosteroids", "TREATMENT", 41, 56]]], ["However, ribavirin has demonstrated minimal activity against SARS-CoV isolates in vitro .", [["ribavirin", "CHEMICAL", 9, 18], ["SARS", "DISEASE", 61, 65], ["ribavirin", "CHEMICAL", 9, 18], ["ribavirin", "SIMPLE_CHEMICAL", 9, 18], ["SARS-CoV", "ORGANISM", 61, 69], ["SARS-CoV", "SPECIES", 61, 69], ["ribavirin", "TREATMENT", 9, 18], ["SARS", "PROBLEM", 61, 65], ["CoV isolates", "TREATMENT", 66, 78], ["ribavirin", "OBSERVATION", 9, 18], ["minimal", "OBSERVATION_MODIFIER", 36, 43], ["activity", "OBSERVATION_MODIFIER", 44, 52]]], ["Non-randomized studies of corticosteroids have reported favorable outcomes.", [["corticosteroids", "CHEMICAL", 26, 41], ["Non-randomized studies", "TEST", 0, 22], ["corticosteroids", "TREATMENT", 26, 41]]], ["A pediatric series of 44 children with confi rmed SARS treated with ribavirin and corticosteroids showed no adverse effects and all survived.Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV)Mortality from adenovirus infections remains high because of multiple organ system involvement.Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV)SARS rarely affects children, and when it does, morbidity is less, with no reported mortalities.Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV)1.", [["organ system", "ANATOMY", 278, 290], ["SARS", "DISEASE", 50, 54], ["ribavirin", "CHEMICAL", 68, 77], ["Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV)", "DISEASE", 148, 208], ["adenovirus infections", "DISEASE", 223, 244], ["Acute Respiratory Syndrome-Associated Coronavirus", "DISEASE", 310, 359], ["SARS-CoV)", "DISEASE", 361, 370], ["SARS", "DISEASE", 370, 374], ["Acute Respiratory Syndrome-Associated Coronavirus", "DISEASE", 473, 522], ["ribavirin", "CHEMICAL", 68, 77], ["corticosteroids", "CHEMICAL", 82, 97], ["children", "ORGANISM", 25, 33], ["ribavirin", "SIMPLE_CHEMICAL", 68, 77], ["adenovirus", "ORGANISM", 223, 233], ["organ", "ORGAN", 278, 283], ["children", "ORGANISM", 390, 398], ["children", "SPECIES", 25, 33], ["children", "SPECIES", 390, 398], ["Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV", "SPECIES", 141, 207], ["Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV", "SPECIES", 303, 369], ["Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV", "SPECIES", 466, 532], ["ribavirin", "TREATMENT", 68, 77], ["corticosteroids", "TREATMENT", 82, 97], ["adverse effects", "PROBLEM", 108, 123], ["Severe Acute Respiratory Syndrome", "PROBLEM", 141, 174], ["Associated Coronavirus (SARS", "PROBLEM", 175, 203], ["Mortality", "PROBLEM", 208, 217], ["adenovirus infections", "PROBLEM", 223, 244], ["multiple organ system involvement", "PROBLEM", 269, 302], ["Severe Acute Respiratory Syndrome", "PROBLEM", 303, 336], ["Associated Coronavirus", "PROBLEM", 337, 359], ["Severe Acute Respiratory Syndrome", "PROBLEM", 466, 499], ["Associated Coronavirus (SARS", "PROBLEM", 500, 528], ["no", "UNCERTAINTY", 105, 107], ["Acute", "OBSERVATION_MODIFIER", 148, 153], ["Respiratory Syndrome", "OBSERVATION", 154, 174], ["Coronavirus", "OBSERVATION", 186, 197], ["organ system", "ANATOMY", 278, 290], ["involvement", "OBSERVATION", 291, 302], ["Acute", "OBSERVATION_MODIFIER", 310, 315], ["Respiratory Syndrome", "OBSERVATION", 316, 336], ["Coronavirus", "OBSERVATION", 348, 359], ["Acute", "OBSERVATION_MODIFIER", 473, 478], ["Respiratory Syndrome", "OBSERVATION", 479, 499], ["Coronavirus", "OBSERVATION", 511, 522]]], ["Neurological disorders, such as epilepsy, cerebral palsy, developmental delay and neuromuscular disorders 2.", [["cerebral", "ANATOMY", 42, 50], ["neuromuscular", "ANATOMY", 82, 95], ["Neurological disorders", "DISEASE", 0, 22], ["epilepsy", "DISEASE", 32, 40], ["cerebral palsy", "DISEASE", 42, 56], ["developmental delay", "DISEASE", 58, 77], ["neuromuscular disorders", "DISEASE", 82, 105], ["cerebral", "ORGAN", 42, 50], ["Neurological disorders", "PROBLEM", 0, 22], ["epilepsy", "PROBLEM", 32, 40], ["cerebral palsy", "PROBLEM", 42, 56], ["developmental delay", "PROBLEM", 58, 77], ["neuromuscular disorders 2", "PROBLEM", 82, 107], ["cerebral", "ANATOMY", 42, 50], ["palsy", "OBSERVATION", 51, 56], ["neuromuscular", "ANATOMY", 82, 95]]], ["Chronic respiratory diseases associated with impaired pulmonary function and/or diffi culty handling lung secretions, moderate and especially severe persistent asthma, technology-dependent children (e.g., those requiring oxygen, tracheostomy, or a ventilator) 3.", [["respiratory", "ANATOMY", 8, 19], ["pulmonary", "ANATOMY", 54, 63], ["lung", "ANATOMY", 101, 105], ["respiratory diseases", "DISEASE", 8, 28], ["impaired pulmonary function", "DISEASE", 45, 72], ["lung secretions", "DISEASE", 101, 116], ["asthma", "DISEASE", 160, 166], ["oxygen", "CHEMICAL", 221, 227], ["oxygen", "CHEMICAL", 221, 227], ["pulmonary", "ORGAN", 54, 63], ["lung", "ORGAN", 101, 105], ["children", "ORGANISM", 189, 197], ["oxygen", "SIMPLE_CHEMICAL", 221, 227], ["children", "SPECIES", 189, 197], ["Chronic respiratory diseases", "PROBLEM", 0, 28], ["impaired pulmonary function", "PROBLEM", 45, 72], ["diffi culty handling lung secretions", "PROBLEM", 80, 116], ["moderate and especially severe persistent asthma", "PROBLEM", 118, 166], ["oxygen", "TREATMENT", 221, 227], ["tracheostomy", "TREATMENT", 229, 241], ["respiratory", "ANATOMY", 8, 19], ["diseases", "OBSERVATION", 20, 28], ["impaired", "OBSERVATION_MODIFIER", 45, 53], ["pulmonary function", "OBSERVATION", 54, 72], ["lung", "ANATOMY", 101, 105], ["secretions", "OBSERVATION", 106, 116], ["moderate", "OBSERVATION_MODIFIER", 118, 126], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["persistent", "OBSERVATION_MODIFIER", 149, 159], ["asthma", "OBSERVATION", 160, 166], ["tracheostomy", "OBSERVATION", 229, 241]]], ["Primary immunodefi ciencies or conditions that require medications or treatments that result in secondary immunodefi ciencies 5.", [["Primary immunodefi ciencies", "TREATMENT", 0, 27], ["medications", "TREATMENT", 55, 66], ["treatments", "TREATMENT", 70, 80], ["secondary immunodefi ciencies", "PROBLEM", 96, 125]]], ["Congenital heart disease 6.", [["heart", "ANATOMY", 11, 16], ["Congenital heart disease", "DISEASE", 0, 24], ["heart", "ORGAN", 11, 16], ["Congenital heart disease", "PROBLEM", 0, 24], ["heart", "ANATOMY", 11, 16], ["disease", "OBSERVATION", 17, 24]]], ["Metabolic (e.g., mitochondrial) or endocrine disorders, especially if cardiopulmonary function is impaired Adapted from http://www.aap.org/new/swinefl u.htmHantavirus Cardiopulmonary Syndrome (HCPS)Hantavirus Cardiopulmonary Syndrome is a viral zoonotic disease that affects healthy children and adolescents who are exposed to aerosols of rodent excreta.", [["mitochondrial", "ANATOMY", 17, 30], ["endocrine", "ANATOMY", 35, 44], ["endocrine disorders", "DISEASE", 35, 54], ["Hantavirus Cardiopulmonary Syndrome", "DISEASE", 198, 233], ["viral zoonotic disease", "DISEASE", 239, 261], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["children", "ORGANISM", 283, 291], ["rodent", "ORGANISM", 339, 345], ["excreta", "ORGANISM_SUBDIVISION", 346, 353], ["children", "SPECIES", 283, 291], ["adolescents", "SPECIES", 296, 307], ["rodent", "SPECIES", 339, 345], ["Metabolic (e.g., mitochondrial)", "PROBLEM", 0, 31], ["endocrine disorders", "PROBLEM", 35, 54], ["cardiopulmonary function", "PROBLEM", 70, 94], ["Cardiopulmonary Syndrome", "PROBLEM", 167, 191], ["Hantavirus Cardiopulmonary Syndrome", "PROBLEM", 198, 233], ["a viral zoonotic disease", "PROBLEM", 237, 261], ["Cardiopulmonary", "ANATOMY", 167, 182], ["Syndrome", "OBSERVATION", 183, 191], ["Cardiopulmonary", "ANATOMY", 209, 224], ["Syndrome", "OBSERVATION", 225, 233], ["viral", "OBSERVATION_MODIFIER", 239, 244], ["zoonotic", "OBSERVATION_MODIFIER", 245, 253]]], ["The deer mouse is the main rodent reservoir.", [["deer", "ORGANISM", 4, 8], ["mouse", "ORGANISM", 9, 14], ["rodent", "ORGANISM", 27, 33], ["deer", "SPECIES", 4, 8], ["mouse", "SPECIES", 9, 14], ["rodent", "SPECIES", 27, 33], ["mouse", "SPECIES", 9, 14], ["main", "OBSERVATION_MODIFIER", 22, 26], ["rodent", "OBSERVATION_MODIFIER", 27, 33], ["reservoir", "OBSERVATION_MODIFIER", 34, 43]]], ["HCPS presents with a prodrome of fever, chills, myalgia, headache, and gastrointestinal symptoms.", [["gastrointestinal", "ANATOMY", 71, 87], ["HCPS", "DISEASE", 0, 4], ["fever", "DISEASE", 33, 38], ["chills", "DISEASE", 40, 46], ["myalgia", "DISEASE", 48, 55], ["headache", "DISEASE", 57, 65], ["gastrointestinal symptoms", "DISEASE", 71, 96], ["gastrointestinal", "ORGANISM_SUBDIVISION", 71, 87], ["fever", "PROBLEM", 33, 38], ["chills", "PROBLEM", 40, 46], ["myalgia", "PROBLEM", 48, 55], ["headache", "PROBLEM", 57, 65], ["gastrointestinal symptoms", "PROBLEM", 71, 96], ["myalgia", "OBSERVATION", 48, 55], ["gastrointestinal", "ANATOMY", 71, 87]]], ["Respiratory compromise requiring supplemental oxygen generally occurs within 72 h.", [["Respiratory", "ANATOMY", 0, 11], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["Respiratory compromise", "PROBLEM", 0, 22], ["supplemental oxygen", "TREATMENT", 33, 52], ["compromise", "OBSERVATION", 12, 22], ["supplemental oxygen", "OBSERVATION", 33, 52]]], ["The disease can progress to respiratory distress and ARDS.", [["respiratory", "ANATOMY", 28, 39], ["respiratory distress", "DISEASE", 28, 48], ["ARDS", "DISEASE", 53, 57], ["The disease", "PROBLEM", 0, 11], ["respiratory distress", "PROBLEM", 28, 48], ["ARDS", "PROBLEM", 53, 57], ["disease", "OBSERVATION", 4, 11], ["respiratory distress", "OBSERVATION", 28, 48], ["ARDS", "OBSERVATION", 53, 57]]], ["The majority of deaths result from hypoxemia and cardiac dysfunction with marked hypotension and ventricular arrhythmias.", [["cardiac", "ANATOMY", 49, 56], ["ventricular", "ANATOMY", 97, 108], ["deaths", "DISEASE", 16, 22], ["hypoxemia", "DISEASE", 35, 44], ["cardiac dysfunction", "DISEASE", 49, 68], ["hypotension", "DISEASE", 81, 92], ["ventricular arrhythmias", "DISEASE", 97, 120], ["cardiac", "ORGAN", 49, 56], ["ventricular", "ORGAN", 97, 108], ["hypoxemia", "PROBLEM", 35, 44], ["cardiac dysfunction", "PROBLEM", 49, 68], ["marked hypotension", "PROBLEM", 74, 92], ["ventricular arrhythmias", "PROBLEM", 97, 120], ["hypoxemia", "OBSERVATION", 35, 44], ["cardiac", "ANATOMY", 49, 56], ["dysfunction", "OBSERVATION", 57, 68], ["marked", "OBSERVATION_MODIFIER", 74, 80], ["hypotension", "OBSERVATION", 81, 92], ["ventricular", "ANATOMY", 97, 108], ["arrhythmias", "OBSERVATION", 109, 120]]], ["In adults, the case fatality rate is approximately 38%.", [["the case fatality rate", "TEST", 11, 33]]], ["A recent case series of 13 children aged 10-16 years, revealed that 92% of infected children developed HCPS, 33% died, and 67% were critically ill and required mechanical ventilation.", [["HCPS", "DISEASE", 103, 107], ["critically ill", "DISEASE", 132, 146], ["children", "ORGANISM", 27, 35], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 27, 35], ["children", "SPECIES", 84, 92], ["critically ill", "PROBLEM", 132, 146], ["mechanical ventilation", "TREATMENT", 160, 182], ["mechanical ventilation", "OBSERVATION", 160, 182]]], ["Treatment is supportive as ribavirin has not been proven to reduce mortality.", [["ribavirin", "CHEMICAL", 27, 36], ["ribavirin", "CHEMICAL", 27, 36], ["ribavirin", "SIMPLE_CHEMICAL", 27, 36], ["ribavirin", "TREATMENT", 27, 36]]], ["Extracorporeal membrane oxygenation was used on two patients, one of which survived.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["Extracorporeal membrane oxygenation", "TREATMENT", 0, 35], ["membrane oxygenation", "OBSERVATION", 15, 35]]], ["Laboratory evaluation reveals thrombocytopenia, leukocytosis, and circulating immunoblasts.", [["immunoblasts", "ANATOMY", 78, 90], ["thrombocytopenia", "DISEASE", 30, 46], ["leukocytosis", "DISEASE", 48, 60], ["Laboratory evaluation", "TEST", 0, 21], ["thrombocytopenia", "PROBLEM", 30, 46], ["leukocytosis", "PROBLEM", 48, 60], ["circulating immunoblasts", "PROBLEM", 66, 90], ["thrombocytopenia", "OBSERVATION", 30, 46], ["leukocytosis", "OBSERVATION", 48, 60], ["circulating immunoblasts", "OBSERVATION", 66, 90]]], ["An elevated prothrombin time of \u00b3 14 s is predictive of severe disease.", [["prothrombin", "GENE_OR_GENE_PRODUCT", 12, 23], ["prothrombin", "PROTEIN", 12, 23], ["An elevated prothrombin time", "TEST", 0, 28], ["severe disease", "PROBLEM", 56, 70], ["elevated", "OBSERVATION_MODIFIER", 3, 11], ["prothrombin", "OBSERVATION", 12, 23], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["disease", "OBSERVATION", 63, 70]]], ["No deaths were reported in children younger than 14 years of age.", [["deaths", "DISEASE", 3, 9], ["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35], ["deaths", "PROBLEM", 3, 9], ["deaths", "OBSERVATION", 3, 9]]], ["Diagnosis can be made by detection of hantavirus-specifi c immunoglobulin M, hantavirus-specifi c RNA by polymerase chain reaction, or hantavirus antigen by immunohistochemistry.Pneumonia in the Immunocompromised HostRespiratory infections in children with primary or acquired immunodefi ciencies requiring intensive care are not uncommon.", [["Pneumonia", "DISEASE", 178, 187], ["HostRespiratory infections", "DISEASE", 213, 239], ["specifi c immunoglobulin M", "GENE_OR_GENE_PRODUCT", 49, 75], ["hantavirus-specifi c", "GENE_OR_GENE_PRODUCT", 77, 97], ["hantavirus antigen", "GENE_OR_GENE_PRODUCT", 135, 153], ["children", "ORGANISM", 243, 251], ["hantavirus-specifi c RNA", "RNA", 77, 101], ["hantavirus antigen", "PROTEIN", 135, 153], ["hantavirus-specifi", "SPECIES", 77, 95], ["children", "SPECIES", 243, 251], ["hantavirus", "TEST", 38, 48], ["immunoglobulin M", "TREATMENT", 59, 75], ["hantavirus", "TREATMENT", 77, 87], ["polymerase chain reaction", "PROBLEM", 105, 130], ["hantavirus antigen", "PROBLEM", 135, 153], ["Pneumonia", "PROBLEM", 178, 187], ["the Immunocompromised HostRespiratory infections", "PROBLEM", 191, 239], ["acquired immunodefi ciencies", "PROBLEM", 268, 296], ["intensive care", "TREATMENT", 307, 321], ["Immunocompromised", "OBSERVATION_MODIFIER", 195, 212], ["HostRespiratory", "OBSERVATION_MODIFIER", 213, 228], ["infections", "OBSERVATION", 229, 239]]], ["These infants and children are susceptible to many organisms that are rarely pathogenic in a normal host.", [["infants", "ORGANISM", 6, 13], ["children", "ORGANISM", 18, 26], ["infants", "SPECIES", 6, 13], ["children", "SPECIES", 18, 26], ["many organisms", "PROBLEM", 46, 60], ["normal host", "OBSERVATION_MODIFIER", 93, 104]]], ["Primary immunodefciencies include abnormalities or defi ciencies in immunoglobulins and antibodies, T and B cells, phagocytes, natural killer cells, and complement.", [["B cells", "ANATOMY", 106, 113], ["phagocytes", "ANATOMY", 115, 125], ["natural killer cells", "ANATOMY", 127, 147], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 68, 83], ["T", "CELL", 100, 101], ["B cells", "CELL", 106, 113], ["phagocytes", "CELL", 115, 125], ["natural killer cells", "CELL", 127, 147], ["immunoglobulins", "PROTEIN", 68, 83], ["antibodies", "PROTEIN", 88, 98], ["T and B cells", "CELL_TYPE", 100, 113], ["phagocytes", "CELL_TYPE", 115, 125], ["natural killer cells", "CELL_TYPE", 127, 147], ["Primary immunodefciencies", "PROBLEM", 0, 25], ["abnormalities", "PROBLEM", 34, 47], ["defi ciencies", "PROBLEM", 51, 64], ["immunoglobulins", "TEST", 68, 83], ["antibodies", "TEST", 88, 98], ["phagocytes", "TEST", 115, 125], ["natural killer cells", "OBSERVATION", 127, 147]]], ["Acquired immunodefi ciencies include asplenia, human immunodefi ciency virus (HIV), corticosteroid therapy, and immunosuppresion used for marrow or solid organ transplants.", [["marrow", "ANATOMY", 138, 144], ["solid organ", "ANATOMY", 148, 159], ["asplenia", "DISEASE", 37, 45], ["immunodefi ciency virus (HIV)", "DISEASE", 53, 82], ["human", "ORGANISM", 47, 52], ["immunodefi ciency virus", "ORGANISM", 53, 76], ["HIV", "ORGANISM", 78, 81], ["marrow", "TISSUE", 138, 144], ["solid", "CANCER", 148, 153], ["organ", "ORGAN", 154, 159], ["human", "SPECIES", 47, 52], ["immunodefi ciency virus", "SPECIES", 53, 76], ["HIV", "SPECIES", 78, 81], ["human immunodefi ciency virus", "SPECIES", 47, 76], ["HIV", "SPECIES", 78, 81], ["Acquired immunodefi ciencies", "PROBLEM", 0, 28], ["asplenia", "PROBLEM", 37, 45], ["human immunodefi ciency virus", "TREATMENT", 47, 76], ["corticosteroid therapy", "TREATMENT", 84, 106], ["immunosuppresion", "TREATMENT", 112, 128], ["marrow or solid organ transplants", "TREATMENT", 138, 171], ["asplenia", "OBSERVATION", 37, 45], ["transplants", "OBSERVATION", 160, 171]]], ["Immunocompromised children can present with attenuated signs and symptoms of respiratory infections.", [["respiratory", "ANATOMY", 77, 88], ["respiratory infections", "DISEASE", 77, 99], ["children", "ORGANISM", 18, 26], ["children", "SPECIES", 18, 26], ["attenuated signs and symptoms", "PROBLEM", 44, 73], ["respiratory infections", "PROBLEM", 77, 99], ["respiratory", "ANATOMY", 77, 88], ["infections", "OBSERVATION", 89, 99]]], ["In addition to physical examination and chest roentgenograms, these children often require chest computed tomography to better delineate the extent of disease.", [["children", "ORGANISM", 68, 76], ["children", "SPECIES", 68, 76], ["physical examination", "TEST", 15, 35], ["chest roentgenograms", "TEST", 40, 60], ["chest computed tomography", "TEST", 91, 116], ["disease", "PROBLEM", 151, 158], ["chest", "ANATOMY", 40, 45], ["chest", "ANATOMY", 91, 96], ["disease", "OBSERVATION", 151, 158]]], ["Bronchoalveolar lavage, needle aspiration, or lung biopsies might be required to make a defi nitive diagnosis.", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["lung", "ANATOMY", 46, 50], ["Bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 0, 22], ["lung biopsies", "MULTI-TISSUE_STRUCTURE", 46, 59], ["Bronchoalveolar lavage", "TEST", 0, 22], ["needle aspiration", "TEST", 24, 41], ["lung biopsies", "TEST", 46, 59], ["lavage", "OBSERVATION", 16, 22], ["lung", "ANATOMY", 46, 50], ["biopsies", "OBSERVATION", 51, 59]]], ["Pulmonary specimens should be tested for common bacteria as well as for Pneumocystis Carinii, acid-fast bacilli, Nocardia, Legionella, Crytococcus, Aspergillus, Candida, Histoplasma, Coccidioides, and Blastomyces.", [["Pulmonary specimens", "ANATOMY", 0, 19], ["Pneumocystis Carinii", "DISEASE", 72, 92], ["Histoplasma, Coccidioides, and Blastomyces", "DISEASE", 170, 212], ["Pulmonary specimens", "CANCER", 0, 19], ["Pneumocystis Carinii", "ORGANISM", 72, 92], ["acid-fast bacilli", "SIMPLE_CHEMICAL", 94, 111], ["Crytococcus", "ORGANISM", 135, 146], ["Aspergillus, Candida", "ORGANISM", 148, 168], ["Histoplasma, Coccidioides", "ORGANISM", 170, 195], ["Pneumocystis Carinii", "SPECIES", 72, 92], ["Pneumocystis Carinii", "SPECIES", 72, 92], ["Pulmonary specimens", "TEST", 0, 19], ["common bacteria", "PROBLEM", 41, 56], ["Pneumocystis Carinii", "PROBLEM", 72, 92], ["acid-fast bacilli", "TEST", 94, 111], ["Nocardia", "PROBLEM", 113, 121], ["Legionella", "PROBLEM", 123, 133], ["Crytococcus", "TEST", 135, 146], ["Aspergillus", "PROBLEM", 148, 159], ["Candida", "PROBLEM", 161, 168], ["Histoplasma", "PROBLEM", 170, 181], ["Coccidioides", "PROBLEM", 183, 195], ["Blastomyces", "PROBLEM", 201, 212]]], ["Viruses such as cytomegalovirus, varicella, herpes virus, and measles should be considered.Pneumocystis carinii Pneumonia (PCP)Pneumocystis carinii (now known Pneumocystis jiroveci ) is an opportunistic pulmonary pathogen in infants and children with human immunodefi ciency virus (HIV) and other primary immunodefi ciencies, malnutrition, hematological malignancies, solid organ and bone marrow transplant recipients, and patients on high dose corticosteroid therapy for infl ammatory and collagen-vascular diseases.", [["pulmonary", "ANATOMY", 203, 212], ["hematological malignancies", "ANATOMY", 340, 366], ["solid organ", "ANATOMY", 368, 379], ["bone marrow", "ANATOMY", 384, 395], ["vascular", "ANATOMY", 499, 507], ["cytomegalovirus, varicella, herpes virus", "DISEASE", 16, 56], ["measles", "DISEASE", 62, 69], ["Pneumocystis carinii Pneumonia", "DISEASE", 91, 121], ["PCP", "DISEASE", 123, 126], ["Pneumocystis carinii", "DISEASE", 127, 147], ["Pneumocystis jiroveci", "DISEASE", 159, 180], ["opportunistic pulmonary pathogen", "DISEASE", 189, 221], ["immunodefi ciency virus (HIV)", "DISEASE", 257, 286], ["primary immunodefi ciencies", "DISEASE", 297, 324], ["malnutrition", "DISEASE", 326, 338], ["hematological malignancies", "DISEASE", 340, 366], ["collagen-vascular diseases", "DISEASE", 490, 516], ["cytomegalovirus", "ORGANISM", 16, 31], ["varicella", "ORGANISM", 33, 42], ["herpes virus", "ORGANISM", 44, 56], ["Pneumocystis carinii", "ORGANISM", 91, 111], ["Pneumocystis carinii", "ORGANISM", 127, 147], ["Pneumocystis jiroveci", "ORGANISM", 159, 180], ["pulmonary", "ORGAN", 203, 212], ["infants", "ORGANISM", 225, 232], ["children", "ORGANISM", 237, 245], ["human immunodefi ciency virus", "ORGANISM", 251, 280], ["HIV", "ORGANISM", 282, 285], ["malignancies", "CANCER", 354, 366], ["organ", "ORGAN", 374, 379], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 384, 395], ["patients", "ORGANISM", 423, 431], ["collagen", "GENE_OR_GENE_PRODUCT", 490, 498], ["vascular", "MULTI-TISSUE_STRUCTURE", 499, 507], ["collagen", "PROTEIN", 490, 498], ["varicella, herpes virus", "SPECIES", 33, 56], ["Pneumocystis carinii", "SPECIES", 91, 111], ["Pneumocystis carinii", "SPECIES", 127, 147], ["Pneumocystis jiroveci", "SPECIES", 159, 180], ["infants", "SPECIES", 225, 232], ["children", "SPECIES", 237, 245], ["human", "SPECIES", 251, 256], ["immunodefi ciency virus", "SPECIES", 257, 280], ["HIV", "SPECIES", 282, 285], ["patients", "SPECIES", 423, 431], ["herpes virus", "SPECIES", 44, 56], ["Pneumocystis carinii", "SPECIES", 91, 111], ["Pneumocystis carinii", "SPECIES", 127, 147], ["Pneumocystis jiroveci", "SPECIES", 159, 180], ["human immunodefi ciency virus", "SPECIES", 251, 280], ["HIV", "SPECIES", 282, 285], ["Viruses", "PROBLEM", 0, 7], ["cytomegalovirus", "PROBLEM", 16, 31], ["varicella", "PROBLEM", 33, 42], ["herpes virus", "PROBLEM", 44, 56], ["measles", "PROBLEM", 62, 69], ["Pneumocystis carinii Pneumonia", "PROBLEM", 91, 121], ["Pneumocystis carinii", "PROBLEM", 127, 147], ["Pneumocystis jiroveci", "PROBLEM", 159, 180], ["an opportunistic pulmonary pathogen", "PROBLEM", 186, 221], ["human immunodefi ciency virus", "PROBLEM", 251, 280], ["HIV", "PROBLEM", 282, 285], ["other primary immunodefi ciencies", "PROBLEM", 291, 324], ["malnutrition", "PROBLEM", 326, 338], ["hematological malignancies", "PROBLEM", 340, 366], ["solid organ", "PROBLEM", 368, 379], ["bone marrow transplant recipients", "TREATMENT", 384, 417], ["high dose corticosteroid therapy", "TREATMENT", 435, 467], ["infl ammatory", "PROBLEM", 472, 485], ["collagen-vascular diseases", "PROBLEM", 490, 516], ["cytomegalovirus", "OBSERVATION", 16, 31], ["varicella", "OBSERVATION", 33, 42], ["herpes virus", "OBSERVATION", 44, 56], ["carinii", "OBSERVATION_MODIFIER", 104, 111], ["Pneumonia", "OBSERVATION", 112, 121], ["Pneumocystis carinii", "OBSERVATION", 127, 147], ["Pneumocystis jiroveci", "OBSERVATION", 159, 180], ["opportunistic", "OBSERVATION_MODIFIER", 189, 202], ["pulmonary", "ANATOMY", 203, 212], ["pathogen", "OBSERVATION", 213, 221], ["hematological malignancies", "OBSERVATION", 340, 366], ["solid organ", "ANATOMY", 368, 379], ["bone", "ANATOMY", 384, 388], ["marrow transplant", "OBSERVATION", 389, 406], ["collagen", "OBSERVATION", 490, 498], ["vascular", "ANATOMY", 499, 507], ["diseases", "OBSERVATION", 508, 516]]], ["It is a unicellular organism that exists as a cyst (the diagnostic form).", [["cyst", "ANATOMY", 46, 50], ["cyst", "CANCER", 46, 50], ["a unicellular organism", "PROBLEM", 6, 28], ["a cyst", "PROBLEM", 44, 50], ["unicellular organism", "OBSERVATION", 8, 28], ["cyst", "OBSERVATION", 46, 50]]], ["The organism attaches to the type I alveolar cells resulting in an alveolitis characterized by ventilation-perfusion mismatch and decreased pulmonary compliance.", [["alveolar cells", "ANATOMY", 36, 50], ["pulmonary", "ANATOMY", 140, 149], ["alveolitis", "DISEASE", 67, 77], ["alveolar cells", "CELL", 36, 50], ["pulmonary", "ORGAN", 140, 149], ["type I alveolar cells", "CELL_TYPE", 29, 50], ["The organism", "PROBLEM", 0, 12], ["an alveolitis", "PROBLEM", 64, 77], ["decreased pulmonary compliance", "PROBLEM", 130, 160], ["alveolar cells", "OBSERVATION", 36, 50], ["alveolitis", "OBSERVATION", 67, 77], ["ventilation", "OBSERVATION", 95, 106], ["perfusion mismatch", "OBSERVATION", 107, 125], ["decreased", "OBSERVATION_MODIFIER", 130, 139], ["pulmonary compliance", "OBSERVATION", 140, 160]]], ["If untreated, PCP carries a mortality rate of 25-50%, and nearly 100% in the HIV-seropositive child.", [["PCP", "DISEASE", 14, 17], ["HIV-seropositive", "DISEASE", 77, 93], ["PCP", "CHEMICAL", 14, 17], ["HIV", "ORGANISM", 77, 80], ["child", "ORGANISM", 94, 99], ["HIV", "SPECIES", 77, 80], ["child", "SPECIES", 94, 99], ["HIV", "SPECIES", 77, 80], ["a mortality rate", "TEST", 26, 42]]], ["Fortunately, the incidence has markedly decreased with the administration of chemoprophylactic agents to high risk patients.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["chemoprophylactic agents", "TREATMENT", 77, 101], ["markedly", "OBSERVATION_MODIFIER", 31, 39], ["decreased", "OBSERVATION_MODIFIER", 40, 49]]], ["Children typically present with fever, tachypnea, non-productive cough, and hypoxia with an absence of rales on auscultation of the chest.", [["chest", "ANATOMY", 132, 137], ["fever", "DISEASE", 32, 37], ["tachypnea", "DISEASE", 39, 48], ["cough", "DISEASE", 65, 70], ["hypoxia", "DISEASE", 76, 83], ["Children", "ORGANISM", 0, 8], ["chest", "ORGANISM_SUBDIVISION", 132, 137], ["Children", "SPECIES", 0, 8], ["fever", "PROBLEM", 32, 37], ["tachypnea", "PROBLEM", 39, 48], ["non-productive cough", "PROBLEM", 50, 70], ["hypoxia", "PROBLEM", 76, 83], ["rales", "PROBLEM", 103, 108], ["auscultation of the chest", "TEST", 112, 137], ["fever", "OBSERVATION", 32, 37], ["non-productive", "OBSERVATION_MODIFIER", 50, 64], ["cough", "OBSERVATION", 65, 70], ["hypoxia", "OBSERVATION", 76, 83], ["rales", "OBSERVATION", 103, 108], ["chest", "ANATOMY", 132, 137]]], ["Initially, they may have an elevated pH and low carbon dioxide levels.", [["carbon dioxide", "CHEMICAL", 48, 62], ["carbon dioxide", "CHEMICAL", 48, 62], ["carbon dioxide", "SIMPLE_CHEMICAL", 48, 62], ["an elevated pH", "PROBLEM", 25, 39], ["low carbon dioxide levels", "PROBLEM", 44, 69], ["elevated", "OBSERVATION", 28, 36]]], ["Lactate dehydrogenase levels are generally elevated.", [["Lactate", "CHEMICAL", 0, 7], ["Lactate", "CHEMICAL", 0, 7], ["Lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 21], ["Lactate dehydrogenase", "PROTEIN", 0, 21], ["Lactate dehydrogenase levels", "TEST", 0, 28], ["generally elevated", "PROBLEM", 33, 51], ["generally", "OBSERVATION_MODIFIER", 33, 42], ["elevated", "OBSERVATION_MODIFIER", 43, 51]]], ["Bilateral diffuse alveolar infi ltrates are seen with initial hilar involvement subsequently spreading to the periphery (Fig. 25-4 ) .", [["alveolar", "ANATOMY", 18, 26], ["hilar", "ANATOMY", 62, 67], ["Bilateral diffuse alveolar infi ltrates", "PROBLEM", 0, 39], ["initial hilar involvement", "PROBLEM", 54, 79], ["diffuse", "OBSERVATION_MODIFIER", 10, 17], ["alveolar", "ANATOMY_MODIFIER", 18, 26], ["infi ltrates", "OBSERVATION", 27, 39], ["hilar", "ANATOMY", 62, 67], ["involvement", "OBSERVATION", 68, 79], ["periphery", "ANATOMY_MODIFIER", 110, 119]]], ["Diagnosis is made by demonstrating the organism with the methenamine silver nitrate stain on pulmonary tissue, respiratory secretions, or lung fl uid.", [["pulmonary tissue", "ANATOMY", 93, 109], ["respiratory secretions", "ANATOMY", 111, 133], ["lung", "ANATOMY", 138, 142], ["methenamine", "CHEMICAL", 57, 68], ["silver nitrate", "CHEMICAL", 69, 83], ["methenamine silver nitrate", "CHEMICAL", 57, 83], ["methenamine", "SIMPLE_CHEMICAL", 57, 68], ["silver", "SIMPLE_CHEMICAL", 69, 75], ["pulmonary tissue", "TISSUE", 93, 109], ["secretions", "ORGANISM_SUBSTANCE", 123, 133], ["lung", "ORGAN", 138, 142], ["the organism", "PROBLEM", 35, 47], ["the methenamine silver nitrate", "TREATMENT", 53, 83], ["pulmonary tissue", "PROBLEM", 93, 109], ["respiratory secretions", "PROBLEM", 111, 133], ["lung fl uid", "PROBLEM", 138, 149], ["pulmonary tissue", "ANATOMY", 93, 109], ["respiratory", "ANATOMY", 111, 122], ["secretions", "OBSERVATION", 123, 133], ["lung", "ANATOMY", 138, 142], ["fl uid", "OBSERVATION", 143, 149]]], ["Bronchoalveolar lavage is the most widely used technique to obtain lung fl uid for diagnosis.", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["lung", "ANATOMY", 67, 71], ["lung", "ORGAN", 67, 71], ["Bronchoalveolar lavage", "TEST", 0, 22], ["lavage", "OBSERVATION", 16, 22], ["lung", "ANATOMY", 67, 71], ["fl", "OBSERVATION", 72, 74]]], ["Treatment consists of supportive therapy Hantavirus is rare in infants and school-aged children.", [["Hantavirus", "DISEASE", 41, 51], ["infants", "ORGANISM", 63, 70], ["children", "ORGANISM", 87, 95], ["infants", "SPECIES", 63, 70], ["children", "SPECIES", 87, 95], ["supportive therapy", "TREATMENT", 22, 40], ["supportive therapy", "OBSERVATION", 22, 40]]], ["No deaths have been reported in children less than 14 years of age.K. S. POWERSwith supplemental oxygen; ultimately continuous positive airway pressure or mechanical ventilation may be necessary if respiratory failure occurs.", [["airway", "ANATOMY", 136, 142], ["respiratory", "ANATOMY", 198, 209], ["deaths", "DISEASE", 3, 9], ["oxygen", "CHEMICAL", 97, 103], ["respiratory failure", "DISEASE", 198, 217], ["oxygen", "CHEMICAL", 97, 103], ["children", "ORGANISM", 32, 40], ["oxygen", "SIMPLE_CHEMICAL", 97, 103], ["airway", "MULTI-TISSUE_STRUCTURE", 136, 142], ["children", "SPECIES", 32, 40], ["K.", "SPECIES", 67, 69], ["deaths", "PROBLEM", 3, 9], ["supplemental oxygen", "TREATMENT", 84, 103], ["ultimately continuous positive airway pressure", "TREATMENT", 105, 151], ["mechanical ventilation", "TREATMENT", 155, 177], ["respiratory failure", "PROBLEM", 198, 217], ["airway pressure", "OBSERVATION", 136, 151], ["failure", "OBSERVATION", 210, 217]]], ["Trimethoprim-sulfamethoxazole (TMP-SMX) is the recommended initial treatment.", [["Trimethoprim-sulfamethoxazole", "CHEMICAL", 0, 29], ["TMP-SMX", "CHEMICAL", 31, 38], ["Trimethoprim-sulfamethoxazole", "CHEMICAL", 0, 29], ["TMP-SMX", "CHEMICAL", 31, 38], ["Trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 0, 29], ["TMP-SMX", "SIMPLE_CHEMICAL", 31, 38], ["Trimethoprim", "TREATMENT", 0, 12], ["sulfamethoxazole (TMP-SMX)", "TREATMENT", 13, 39], ["initial treatment", "TREATMENT", 59, 76]]], ["In patients that cannot tolerate TMP-SMX, then pentamidine isoethionate should be used.", [["TMP-SMX", "CHEMICAL", 33, 40], ["pentamidine isoethionate", "CHEMICAL", 47, 71], ["TMP-SMX", "CHEMICAL", 33, 40], ["pentamidine isoethionate", "CHEMICAL", 47, 71], ["patients", "ORGANISM", 3, 11], ["TMP-SMX", "SIMPLE_CHEMICAL", 33, 40], ["pentamidine isoethionate", "SIMPLE_CHEMICAL", 47, 71], ["patients", "SPECIES", 3, 11], ["TMP-SMX", "TREATMENT", 33, 40], ["pentamidine isoethionate", "TREATMENT", 47, 71]]], ["Corticosteroids in anti-infl ammatory doses as an adjunct to antimicrobial therapy have improved clinical outcomes.", [["anti-infl ammatory", "SIMPLE_CHEMICAL", 19, 37], ["Corticosteroids", "TREATMENT", 0, 15], ["anti-infl ammatory doses", "TREATMENT", 19, 43], ["antimicrobial therapy", "TREATMENT", 61, 82]]], ["Concurrent pulmonary infections were found in 35% of patients, most frequently bacterial or cytomegalovirus pneumonia.DIAGNOSIS OF PNEUMONIADetermination of the etiologic agent in pneumonia is diffi cult.", [["pulmonary", "ANATOMY", 11, 20], ["pulmonary infections", "DISEASE", 11, 31], ["cytomegalovirus pneumonia", "DISEASE", 92, 117], ["pneumonia", "DISEASE", 180, 189], ["pulmonary", "ORGAN", 11, 20], ["patients", "ORGANISM", 53, 61], ["cytomegalovirus", "ORGANISM", 92, 107], ["patients", "SPECIES", 53, 61], ["Concurrent pulmonary infections", "PROBLEM", 0, 31], ["cytomegalovirus pneumonia", "PROBLEM", 92, 117], ["PNEUMONIADetermination", "PROBLEM", 131, 153], ["the etiologic agent", "PROBLEM", 157, 176], ["pneumonia", "PROBLEM", 180, 189], ["cult", "TEST", 199, 203], ["pulmonary", "ANATOMY", 11, 20], ["infections", "OBSERVATION", 21, 31], ["most frequently", "OBSERVATION_MODIFIER", 63, 78], ["bacterial", "OBSERVATION_MODIFIER", 79, 88], ["cytomegalovirus", "OBSERVATION_MODIFIER", 92, 107], ["pneumonia", "OBSERVATION", 108, 117], ["pneumonia", "OBSERVATION", 180, 189]]], ["Fortunately, in most community-acquired pneumonias, identifi cation of the specifi c causative organism is not critical.", [["pneumonias", "DISEASE", 40, 50], ["specifi c", "GENE_OR_GENE_PRODUCT", 75, 84], ["acquired pneumonias", "PROBLEM", 31, 50], ["the specifi c causative organism", "PROBLEM", 71, 103], ["pneumonias", "OBSERVATION", 40, 50]]], ["However, in children with a complicated course that fails to respond to standard therapies, defi nitive diagnosis of the etiologic agent is essential.", [["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["standard therapies", "TREATMENT", 72, 90]]], ["Complete blood counts, infl ammatory markers, and chest radiographs do not differentiate the causative agents for pneumonia.", [["blood", "ANATOMY", 9, 14], ["chest", "ANATOMY", 50, 55], ["pneumonia", "DISEASE", 114, 123], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["infl ammatory markers", "PROTEIN", 23, 44], ["Complete blood counts", "TEST", 0, 21], ["infl ammatory markers", "TEST", 23, 44], ["chest radiographs", "TEST", 50, 67], ["pneumonia", "PROBLEM", 114, 123], ["chest", "ANATOMY", 50, 55], ["pneumonia", "OBSERVATION", 114, 123]]], ["Blood cultures are rarely positive outside of the neonatal period.", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood cultures", "TEST", 0, 14]]], ["Rapid antigen tests are available for RSV, parainfl uenza, infl uenza, and adenovirus.", [["RSV", "ORGANISM", 38, 41], ["parainfl uenza", "ORGANISM", 43, 57], ["infl uenza", "ORGANISM", 59, 69], ["adenovirus", "ORGANISM", 75, 85], ["RSV", "SPECIES", 38, 41], ["adenovirus", "SPECIES", 75, 85], ["Rapid antigen tests", "TEST", 0, 19], ["RSV", "PROBLEM", 38, 41], ["parainfl uenza", "TEST", 43, 57], ["adenovirus", "PROBLEM", 75, 85]]], ["Nasopharyngeal swabs for viral cultures generally take 7-8 days to become positive, and in one study, 86% of the patients had been discharged prior to the positive results.", [["Nasopharyngeal swabs", "ANATOMY", 0, 20], ["Nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 0, 20], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Nasopharyngeal swabs", "TEST", 0, 20], ["viral cultures", "TEST", 25, 39], ["one study", "TEST", 91, 100]]], ["Older children and adolescents might be able to produce sputum for Gram stain and culture.", [["sputum", "ANATOMY", 56, 62], ["children", "ORGANISM", 6, 14], ["adolescents", "ORGANISM", 19, 30], ["sputum", "ORGANISM_SUBSTANCE", 56, 62], ["children", "SPECIES", 6, 14], ["adolescents", "SPECIES", 19, 30], ["Gram stain", "TEST", 67, 77], ["culture", "TEST", 82, 89]]], ["An adequate specimen should contain more the 25 leukocytes and fewer than 25 squamous epithelial cells per low-power fi eld.", [["specimen", "ANATOMY", 12, 20], ["leukocytes", "ANATOMY", 48, 58], ["squamous epithelial cells", "ANATOMY", 77, 102], ["leukocytes", "CELL", 48, 58], ["squamous epithelial cells", "CELL", 77, 102], ["leukocytes", "CELL_TYPE", 48, 58], ["squamous epithelial cells", "CELL_TYPE", 77, 102], ["An adequate specimen", "TEST", 0, 20], ["the 25 leukocytes", "TEST", 41, 58], ["squamous epithelial cells", "TEST", 77, 102], ["epithelial cells", "OBSERVATION", 86, 102]]], ["In the intubated patient, sputum can be more easily acquired.", [["sputum", "ANATOMY", 26, 32], ["patient", "ORGANISM", 17, 24], ["sputum", "ORGANISM_SUBSTANCE", 26, 32], ["patient", "SPECIES", 17, 24], ["sputum", "TEST", 26, 32]]], ["However, interpretation of the results of Gram stains and cultures is at times diffi cult in differentiating colonizing from pathologic organisms.", [["Gram stains", "TEST", 42, 53], ["cultures", "TEST", 58, 66], ["cult", "TEST", 85, 89], ["pathologic organisms", "PROBLEM", 125, 145]]], ["Colonization of the endotracheal tube may occur as early as 12 h, but most frequently between 60 and 96 h.", [["endotracheal tube", "ANATOMY", 20, 37], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 20, 37], ["Colonization of the endotracheal tube", "TREATMENT", 0, 37], ["endotracheal tube", "OBSERVATION", 20, 37]]], ["The oropharynx becomes colonized within 36 h, the stomach at 36-60 h, and the lower respiratory tract between 60 and 84 h.", [["oropharynx", "ANATOMY", 4, 14], ["stomach", "ANATOMY", 50, 57], ["lower respiratory tract", "ANATOMY", 78, 101], ["oropharynx", "ORGAN", 4, 14], ["stomach", "ORGAN", 50, 57], ["lower", "ORGANISM_SUBDIVISION", 78, 83], ["respiratory tract", "ORGANISM_SUBDIVISION", 84, 101], ["the lower respiratory tract", "PROBLEM", 74, 101], ["oropharynx", "ANATOMY", 4, 14], ["colonized", "OBSERVATION", 23, 32], ["stomach", "ANATOMY", 50, 57], ["lower", "ANATOMY_MODIFIER", 78, 83], ["respiratory tract", "ANATOMY", 84, 101]]], ["In addition, a comparison of infectious agents isolated by both tracheal aspirates and bronchoalveolar lavage found only 36% concordance.DIAGNOSIS OF PNEUMONIABronchoalveolar lavage (BAL) can be safely used to obtain secretions from the lower airways for Gram stain and culture.", [["tracheal aspirates", "ANATOMY", 64, 82], ["bronchoalveolar lavage", "ANATOMY", 87, 109], ["secretions", "ANATOMY", 217, 227], ["lower airways", "ANATOMY", 237, 250], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 64, 82], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 87, 109], ["lower airways", "ORGANISM_SUBDIVISION", 237, 250], ["infectious agents", "TREATMENT", 29, 46], ["both tracheal aspirates", "TEST", 59, 82], ["bronchoalveolar lavage", "TEST", 87, 109], ["PNEUMONIABronchoalveolar lavage (BAL)", "TREATMENT", 150, 187], ["secretions from the lower airways", "TEST", 217, 250], ["Gram stain", "TEST", 255, 265], ["culture", "TEST", 270, 277], ["infectious", "OBSERVATION", 29, 39], ["tracheal", "ANATOMY", 64, 72], ["aspirates", "OBSERVATION", 73, 82], ["bronchoalveolar lavage", "OBSERVATION", 87, 109], ["PNEUMONIABronchoalveolar lavage", "OBSERVATION", 150, 181], ["lower", "ANATOMY_MODIFIER", 237, 242], ["airways", "ANATOMY", 243, 250]]], ["It is especially useful in the diagnosis of pneumonia in the immunocompromised child.", [["pneumonia", "DISEASE", 44, 53], ["child", "ORGANISM", 79, 84], ["pneumonia", "PROBLEM", 44, 53], ["pneumonia", "OBSERVATION", 44, 53], ["immunocompromised child", "OBSERVATION", 61, 84]]], ["However, BAL performed directly through the bronchoscope carries a risk of contamination.", [["BAL", "ANATOMY", 9, 12], ["BAL", "TEST", 9, 12], ["the bronchoscope", "TREATMENT", 40, 56], ["contamination", "PROBLEM", 75, 88], ["contamination", "OBSERVATION", 75, 88]]], ["The smallest bronchoscope that can accommodate a protected specimen brush is 4.8 mm and requires a 6.5 mm endotracheal tube for passage.", [["specimen brush", "ANATOMY", 59, 73], ["specimen brush", "MULTI-TISSUE_STRUCTURE", 59, 73], ["The smallest bronchoscope", "TREATMENT", 0, 25], ["a protected specimen brush", "TREATMENT", 47, 73], ["a 6.5 mm endotracheal tube", "TREATMENT", 97, 123], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["bronchoscope", "OBSERVATION", 13, 25], ["4.8 mm", "OBSERVATION_MODIFIER", 77, 83], ["6.5 mm", "OBSERVATION_MODIFIER", 99, 105], ["endotracheal tube", "OBSERVATION", 106, 123]]], ["The smallest fl exible fi beroptic bronchoscope with a suction channel has an external Chest radiograph of severe Pneumocystis carinii pneumonia in a 13 month old male with combined immunodefi ciency.", [["Pneumocystis carinii pneumonia", "DISEASE", 114, 144], ["carinii", "ORGANISM", 127, 134], ["Pneumocystis carinii", "SPECIES", 114, 134], ["Pneumocystis carinii", "SPECIES", 114, 134], ["The smallest fl exible fi beroptic bronchoscope", "TREATMENT", 0, 47], ["a suction channel", "TREATMENT", 53, 70], ["an external Chest radiograph", "TEST", 75, 103], ["severe Pneumocystis carinii pneumonia", "PROBLEM", 107, 144], ["combined immunodefi ciency", "TREATMENT", 173, 199], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["fl", "OBSERVATION_MODIFIER", 13, 15], ["beroptic bronchoscope", "OBSERVATION", 26, 47], ["Chest", "ANATOMY", 87, 92], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["Pneumocystis", "OBSERVATION", 114, 126], ["carinii pneumonia", "OBSERVATION", 127, 144]]], ["Note the diffuse alveolar involvement and air bronchograms.", [["alveolar", "ANATOMY", 17, 25], ["alveolar", "MULTI-TISSUE_STRUCTURE", 17, 25], ["the diffuse alveolar involvement", "PROBLEM", 5, 37], ["air bronchograms", "PROBLEM", 42, 58], ["diffuse", "OBSERVATION_MODIFIER", 9, 16], ["alveolar", "ANATOMY_MODIFIER", 17, 25], ["involvement", "OBSERVATION", 26, 37], ["air bronchograms", "OBSERVATION", 42, 58]]], ["(Image provided courtesy of FA Maffei) diameter of 2.8 mm and is too small to admit a double-sheathed brush.", [["brush", "ANATOMY", 102, 107], ["brush", "TISSUE", 102, 107], ["a double-sheathed brush", "TREATMENT", 84, 107], ["2.8 mm", "OBSERVATION_MODIFIER", 51, 57], ["too small to", "OBSERVATION_MODIFIER", 65, 77]]], ["Non-bronchoscopic double-lumen plugged catheters can be inserted blindly through the endotracheal tube to obtain a non-contaminated specimen.", [["lumen", "ANATOMY", 25, 30], ["endotracheal tube", "ANATOMY", 85, 102], ["specimen", "ANATOMY", 132, 140], ["endotracheal tube", "TISSUE", 85, 102], ["Non-bronchoscopic double-lumen plugged catheters", "TREATMENT", 0, 48], ["the endotracheal tube", "TREATMENT", 81, 102], ["a non-contaminated specimen", "TEST", 113, 140], ["lumen", "ANATOMY_MODIFIER", 25, 30], ["plugged catheters", "OBSERVATION", 31, 48], ["endotracheal tube", "OBSERVATION", 85, 102]]], ["The sensitivity and specifi city of these samples are similar to those obtained by a bronchoscopic guided protected specimen.", [["samples", "ANATOMY", 42, 49], ["specimen", "ANATOMY", 116, 124], ["samples", "CANCER", 42, 49], ["The sensitivity", "TEST", 0, 15], ["a bronchoscopic guided protected specimen", "TEST", 83, 124]]], ["Transthoracic needle aspirations are performed in some centers with good results.", [["Transthoracic needle aspirations", "TEST", 0, 32]]], ["One study reported a diagnostic success rate in 59% of patients.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["One study", "TEST", 0, 9]]], ["The incidence of pneumothorax was approximately 20%, but none required subsequent placement of a pleural drainage catheter.", [["pleural", "ANATOMY", 97, 104], ["pneumothorax", "DISEASE", 17, 29], ["pneumothorax", "PROBLEM", 17, 29], ["a pleural drainage catheter", "TREATMENT", 95, 122], ["pneumothorax", "OBSERVATION", 17, 29], ["approximately", "OBSERVATION_MODIFIER", 34, 47], ["20%", "OBSERVATION_MODIFIER", 48, 51], ["pleural", "ANATOMY", 97, 104], ["drainage catheter", "OBSERVATION", 105, 122]]], ["A lung biopsy is rarely needed to make a defi nitive diagnosis.TREATMENTSupportive treatment with oxygen and intravenous fl uids are often standard therapies.", [["lung", "ANATOMY", 2, 6], ["intravenous", "ANATOMY", 109, 120], ["oxygen", "CHEMICAL", 98, 104], ["oxygen", "CHEMICAL", 98, 104], ["lung", "ORGAN", 2, 6], ["oxygen", "SIMPLE_CHEMICAL", 98, 104], ["intravenous fl uids", "SIMPLE_CHEMICAL", 109, 128], ["A lung biopsy", "TEST", 0, 13], ["TREATMENTSupportive treatment", "TREATMENT", 63, 92], ["oxygen", "TREATMENT", 98, 104], ["intravenous fl uids", "TREATMENT", 109, 128], ["standard therapies", "TREATMENT", 139, 157], ["lung", "ANATOMY", 2, 6], ["biopsy", "OBSERVATION", 7, 13]]], ["As both pneumonia and mechanical ventilation can cause an elevation in anti-diuretic hormone levels, careful fl uid monitoring is essential to avoid overhydration, excessive lung water and hyponatremia.", [["lung", "ANATOMY", 174, 178], ["pneumonia", "DISEASE", 8, 17], ["overhydration", "DISEASE", 149, 162], ["hyponatremia", "DISEASE", 189, 201], ["anti-diuretic hormone", "GENE_OR_GENE_PRODUCT", 71, 92], ["lung", "ORGAN", 174, 178], ["pneumonia", "PROBLEM", 8, 17], ["mechanical ventilation", "TREATMENT", 22, 44], ["an elevation in anti-diuretic hormone levels", "PROBLEM", 55, 99], ["careful fl uid monitoring", "TEST", 101, 126], ["overhydration", "PROBLEM", 149, 162], ["excessive lung water", "PROBLEM", 164, 184], ["hyponatremia", "PROBLEM", 189, 201], ["pneumonia", "OBSERVATION", 8, 17], ["mechanical ventilation", "OBSERVATION", 22, 44], ["elevation", "OBSERVATION_MODIFIER", 58, 67], ["excessive", "OBSERVATION_MODIFIER", 164, 173], ["lung", "ANATOMY", 174, 178], ["water", "OBSERVATION", 179, 184], ["hyponatremia", "OBSERVATION", 189, 201]]], ["Initial antibiotic choices should be empiric and based upon the likely organisms for each age group, because of the diffi culty in identifying the causative agent.TREATMENTThe child's respiratory status including respiratory rate, work of breathing, pulse oximetry, and central nervous system response should be closely monitored.", [["respiratory", "ANATOMY", 184, 195], ["respiratory", "ANATOMY", 213, 224], ["central nervous system", "ANATOMY", 270, 292], ["central nervous system", "ANATOMICAL_SYSTEM", 270, 292], ["child", "SPECIES", 176, 181], ["Initial antibiotic choices", "TREATMENT", 0, 26], ["TREATMENT", "TREATMENT", 163, 172], ["respiratory rate", "TEST", 213, 229], ["work of breathing", "PROBLEM", 231, 248], ["pulse oximetry", "TEST", 250, 264], ["respiratory rate", "OBSERVATION", 213, 229], ["central", "ANATOMY_MODIFIER", 270, 277]]], ["Non-invasive bi-level positive airway pressure (BiPAP) has been effective for use in children with mild to moderate respiratory insuffi ciency, defi ned as an A-a gradient >100 and <250 or PaO 2 /FiO 2 ratio <200 but >100 mm Hg.", [["airway", "ANATOMY", 31, 37], ["respiratory", "ANATOMY", 116, 127], ["BiPAP", "CHEMICAL", 48, 53], ["Hg", "CHEMICAL", 225, 227], ["airway", "MULTI-TISSUE_STRUCTURE", 31, 37], ["children", "ORGANISM", 85, 93], ["children", "SPECIES", 85, 93], ["Non-invasive bi-level positive airway pressure (BiPAP", "TREATMENT", 0, 53], ["mild to moderate respiratory insuffi ciency", "PROBLEM", 99, 142], ["a gradient", "TEST", 161, 171], ["PaO", "TEST", 189, 192], ["FiO 2 ratio", "TEST", 196, 207], ["airway pressure", "OBSERVATION", 31, 46], ["moderate", "OBSERVATION_MODIFIER", 107, 115], ["respiratory insuffi", "OBSERVATION", 116, 135]]], ["Serial evaluation of mask-face contact areas is essential to avoid skin breakdown.TREATMENTChildren with moderate or severe respiratory insuffi ciency often require intubation and mechanical ventilation.", [["skin", "ANATOMY", 67, 71], ["respiratory", "ANATOMY", 124, 135], ["skin", "ORGAN", 67, 71], ["Serial evaluation", "TEST", 0, 17], ["mask", "TREATMENT", 21, 25], ["face contact areas", "PROBLEM", 26, 44], ["skin breakdown", "PROBLEM", 67, 81], ["moderate or severe respiratory insuffi ciency", "PROBLEM", 105, 150], ["intubation", "TREATMENT", 165, 175], ["mechanical ventilation", "TREATMENT", 180, 202], ["skin", "ANATOMY", 67, 71], ["breakdown", "OBSERVATION", 72, 81], ["moderate", "OBSERVATION_MODIFIER", 105, 113], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["respiratory insuffi", "OBSERVATION", 124, 143], ["mechanical ventilation", "OBSERVATION", 180, 202]]], ["Children with respiratory failure secondary to pneumonia often require increased positive end expiratory pressure (PEEP), increased inspiratory time, and aggressive pulmonary toilet to recruit alveoli.", [["respiratory", "ANATOMY", 14, 25], ["pulmonary", "ANATOMY", 165, 174], ["alveoli", "ANATOMY", 193, 200], ["respiratory failure", "DISEASE", 14, 33], ["pneumonia", "DISEASE", 47, 56], ["Children", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 165, 174], ["alveoli", "MULTI-TISSUE_STRUCTURE", 193, 200], ["Children", "SPECIES", 0, 8], ["respiratory failure", "PROBLEM", 14, 33], ["pneumonia", "PROBLEM", 47, 56], ["increased positive end expiratory pressure", "TREATMENT", 71, 113], ["PEEP", "TREATMENT", 115, 119], ["increased inspiratory time", "PROBLEM", 122, 148], ["aggressive pulmonary toilet", "TREATMENT", 154, 181], ["alveoli", "PROBLEM", 193, 200], ["respiratory", "ANATOMY", 14, 25], ["failure", "OBSERVATION", 26, 33], ["pneumonia", "OBSERVATION", 47, 56], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["positive", "OBSERVATION_MODIFIER", 81, 89], ["end", "OBSERVATION_MODIFIER", 90, 93], ["expiratory pressure", "OBSERVATION", 94, 113], ["inspiratory time", "OBSERVATION", 132, 148], ["aggressive", "OBSERVATION_MODIFIER", 154, 164], ["pulmonary", "ANATOMY", 165, 174], ["toilet", "OBSERVATION", 175, 181]]], ["For patients requiring high levels of PEEP, adequate sedation is often required to prevent patient/ventilator asynchrony and barotrauma.", [["barotrauma", "DISEASE", 125, 135], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 91, 98], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 91, 98], ["PEEP", "TREATMENT", 38, 42], ["adequate sedation", "TREATMENT", 44, 61], ["patient/ventilator asynchrony", "PROBLEM", 91, 120], ["barotrauma", "PROBLEM", 125, 135], ["ventilator asynchrony", "OBSERVATION", 99, 120], ["barotrauma", "OBSERVATION", 125, 135]]], ["Spontaneous respirations should be encouraged while on mechanical ventilation.", [["Spontaneous respirations", "PROBLEM", 0, 24], ["mechanical ventilation", "TREATMENT", 55, 77], ["respirations", "OBSERVATION", 12, 24]]], ["Rarely, the use of neuromuscular blockade is required to allow mechanical ventilation.", [["neuromuscular", "ANATOMY", 19, 32], ["neuromuscular blockade", "DISEASE", 19, 41], ["neuromuscular", "MULTI-TISSUE_STRUCTURE", 19, 32], ["neuromuscular blockade", "TREATMENT", 19, 41], ["mechanical ventilation", "TREATMENT", 63, 85], ["mechanical ventilation", "OBSERVATION", 63, 85]]], ["Prone positioning may improve ventilation/perfusion (V/Q) mismatching in dependent lung regions.", [["lung", "ANATOMY", 83, 87], ["lung", "ORGAN", 83, 87], ["Prone positioning", "TREATMENT", 0, 17], ["ventilation", "TEST", 30, 41], ["perfusion (V/Q) mismatching in dependent lung regions", "PROBLEM", 42, 95], ["mismatching", "OBSERVATION", 58, 69], ["dependent", "ANATOMY_MODIFIER", 73, 82], ["lung", "ANATOMY", 83, 87], ["regions", "ANATOMY_MODIFIER", 88, 95]]], ["Lung protective strategies allowing permissive hypercapnea with small lung volumes to ventilate and appropriate PEEP to maintain alveolar recruitment is recommended for children with pneumonia.", [["Lung", "ANATOMY", 0, 4], ["lung", "ANATOMY", 70, 74], ["alveolar", "ANATOMY", 129, 137], ["hypercapnea", "DISEASE", 47, 58], ["pneumonia", "DISEASE", 183, 192], ["Lung", "ORGAN", 0, 4], ["lung", "ORGAN", 70, 74], ["alveolar", "MULTI-TISSUE_STRUCTURE", 129, 137], ["children", "ORGANISM", 169, 177], ["children", "SPECIES", 169, 177], ["Lung protective strategies", "TREATMENT", 0, 26], ["permissive hypercapnea", "PROBLEM", 36, 58], ["small lung volumes", "PROBLEM", 64, 82], ["appropriate PEEP", "TREATMENT", 100, 116], ["alveolar recruitment", "TREATMENT", 129, 149], ["pneumonia", "PROBLEM", 183, 192], ["permissive", "OBSERVATION_MODIFIER", 36, 46], ["hypercapnea", "OBSERVATION", 47, 58], ["small", "OBSERVATION_MODIFIER", 64, 69], ["lung", "ANATOMY", 70, 74], ["volumes", "OBSERVATION", 75, 82], ["alveolar recruitment", "OBSERVATION", 129, 149], ["pneumonia", "OBSERVATION", 183, 192]]], ["High frequency oscillatory ventilation can also be utilized to maintain mean airway pressure and alveolar recruitment.", [["airway", "ANATOMY", 77, 83], ["alveolar", "ANATOMY", 97, 105], ["airway", "MULTI-TISSUE_STRUCTURE", 77, 83], ["alveolar", "MULTI-TISSUE_STRUCTURE", 97, 105], ["High frequency oscillatory ventilation", "TREATMENT", 0, 38], ["mean airway pressure", "TEST", 72, 92], ["alveolar recruitment", "PROBLEM", 97, 117], ["oscillatory ventilation", "OBSERVATION", 15, 38], ["airway pressure", "OBSERVATION", 77, 92], ["alveolar recruitment", "OBSERVATION", 97, 117]]], ["Airway pressure release ventilation (APRV) provides recruitment of alveoli while allowing spontaneous respirations.", [["Airway", "ANATOMY", 0, 6], ["alveoli", "ANATOMY", 67, 74], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["alveoli", "MULTI-TISSUE_STRUCTURE", 67, 74], ["Airway pressure release ventilation", "TREATMENT", 0, 35], ["APRV", "TREATMENT", 37, 41], ["recruitment of alveoli", "TREATMENT", 52, 74], ["pressure", "OBSERVATION_MODIFIER", 7, 15], ["alveoli", "ANATOMY_MODIFIER", 67, 74]]], ["In children with severe respiratory distress syndrome, treatment with bovine surfactant may improve oxygenation.", [["respiratory", "ANATOMY", 24, 35], ["respiratory distress syndrome", "DISEASE", 24, 53], ["children", "ORGANISM", 3, 11], ["bovine", "ORGANISM", 70, 76], ["children", "SPECIES", 3, 11], ["bovine", "SPECIES", 70, 76], ["bovine", "SPECIES", 70, 76], ["severe respiratory distress syndrome", "PROBLEM", 17, 53], ["bovine surfactant", "TREATMENT", 70, 87], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["respiratory distress", "OBSERVATION", 24, 44]]], ["Extracorporeal life support continues to have a role in children with reversible severe acute hypoxemic respiratory failure refractory to mechanical ventilation.TREATMENTPneumonias can often be complicated by the development of pleural effusions and empyemas.", [["respiratory", "ANATOMY", 104, 115], ["pleural effusions", "ANATOMY", 228, 245], ["hypoxemic respiratory failure", "DISEASE", 94, 123], ["TREATMENTPneumonias", "DISEASE", 161, 180], ["pleural effusions", "DISEASE", 228, 245], ["empyemas", "DISEASE", 250, 258], ["children", "ORGANISM", 56, 64], ["pleural effusions", "PATHOLOGICAL_FORMATION", 228, 245], ["empyemas", "CANCER", 250, 258], ["children", "SPECIES", 56, 64], ["Extracorporeal life support", "TREATMENT", 0, 27], ["reversible severe acute hypoxemic respiratory failure", "PROBLEM", 70, 123], ["mechanical ventilation", "TREATMENT", 138, 160], ["TREATMENTPneumonias", "TREATMENT", 161, 180], ["pleural effusions", "PROBLEM", 228, 245], ["empyemas", "PROBLEM", 250, 258], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["hypoxemic", "OBSERVATION_MODIFIER", 94, 103], ["respiratory failure", "OBSERVATION", 104, 123], ["mechanical ventilation", "OBSERVATION", 138, 160], ["pleural", "ANATOMY", 228, 235], ["effusions", "OBSERVATION", 236, 245], ["empyemas", "OBSERVATION", 250, 258]]], ["These occur when the fl uid production by the interstitial lung tissue exceeds the maximum pleural lymphatic fl ow.", [["interstitial lung tissue", "ANATOMY", 46, 70], ["pleural lymphatic", "ANATOMY", 91, 108], ["fl uid", "GENE_OR_GENE_PRODUCT", 21, 27], ["interstitial lung tissue", "TISSUE", 46, 70], ["the fl uid production", "TREATMENT", 17, 38], ["the interstitial lung tissue", "PROBLEM", 42, 70], ["interstitial", "ANATOMY_MODIFIER", 46, 58], ["lung", "ANATOMY", 59, 63], ["tissue", "OBSERVATION", 64, 70], ["maximum", "OBSERVATION_MODIFIER", 83, 90], ["pleural", "ANATOMY", 91, 98], ["lymphatic fl", "OBSERVATION", 99, 111]]], ["Parapneumonic effusions often occur from pneumonia as white blood cells and other debris of infection block the lymphatics resulting in elevation of protein in the pleural space, increase in colloid osmotic pressure, and consequent failure of fl uid reabsorption.", [["Parapneumonic effusions", "ANATOMY", 0, 23], ["white blood cells", "ANATOMY", 54, 71], ["lymphatics", "ANATOMY", 112, 122], ["pleural space", "ANATOMY", 164, 177], ["Parapneumonic effusions", "DISEASE", 0, 23], ["pneumonia", "DISEASE", 41, 50], ["infection", "DISEASE", 92, 101], ["blood cells", "CELL", 60, 71], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 112, 122], ["pleural space", "MULTI-TISSUE_STRUCTURE", 164, 177], ["fl uid", "SIMPLE_CHEMICAL", 243, 249], ["white blood cells", "CELL_TYPE", 54, 71], ["Parapneumonic effusions", "PROBLEM", 0, 23], ["pneumonia", "PROBLEM", 41, 50], ["white blood cells", "TEST", 54, 71], ["other debris", "PROBLEM", 76, 88], ["infection block the lymphatics", "PROBLEM", 92, 122], ["elevation of protein in the pleural space", "PROBLEM", 136, 177], ["colloid osmotic pressure", "TEST", 191, 215], ["consequent failure", "PROBLEM", 221, 239], ["fl uid reabsorption", "TREATMENT", 243, 262], ["effusions", "OBSERVATION", 14, 23], ["pneumonia", "OBSERVATION", 41, 50], ["debris", "OBSERVATION_MODIFIER", 82, 88], ["infection", "OBSERVATION", 92, 101], ["lymphatics", "ANATOMY", 112, 122], ["elevation", "OBSERVATION_MODIFIER", 136, 145], ["protein", "OBSERVATION", 149, 156], ["pleural", "ANATOMY", 164, 171], ["increase", "OBSERVATION_MODIFIER", 179, 187], ["colloid osmotic pressure", "OBSERVATION", 191, 215], ["failure", "OBSERVATION_MODIFIER", 232, 239], ["fl uid reabsorption", "OBSERVATION", 243, 262]]], ["On physical exam, the child will have decreased breath sounds over the effusion.", [["effusion", "DISEASE", 71, 79], ["child", "ORGANISM", 22, 27], ["physical exam", "TEST", 3, 16], ["decreased breath sounds over the effusion", "PROBLEM", 38, 79], ["decreased", "OBSERVATION_MODIFIER", 38, 47], ["breath sounds", "OBSERVATION", 48, 61], ["effusion", "OBSERVATION", 71, 79]]], ["In older children, auscultatory percussion changes might be appreciated.", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["auscultatory percussion changes", "TEST", 19, 50], ["percussion", "OBSERVATION", 32, 42]]], ["Plain chest radiographs can reveal most clinically signifi cant effusions.", [["chest", "ANATOMY", 6, 11], ["effusions", "DISEASE", 64, 73], ["cant effusions", "CANCER", 59, 73], ["Plain chest radiographs", "TEST", 0, 23], ["most clinically signifi cant effusions", "PROBLEM", 35, 73], ["chest", "ANATOMY", 6, 11], ["effusions", "OBSERVATION", 64, 73]]], ["Ultrasound and chest computed tomograms are useful in determining the volume and quality of the fl uid and the presence of loculations.", [["Ultrasound", "TEST", 0, 10], ["chest computed tomograms", "TEST", 15, 39], ["the fl uid", "TEST", 92, 102], ["loculations", "PROBLEM", 123, 134], ["chest", "ANATOMY", 15, 20], ["loculations", "OBSERVATION", 123, 134]]], ["Simple parapneumonic effusions or transudates can also be differentiated from exudates by using the criteria of Light et al. (Table 25 -2 ).", [["parapneumonic effusions", "ANATOMY", 7, 30], ["exudates", "ANATOMY", 78, 86], ["parapneumonic effusions", "DISEASE", 7, 30], ["Simple parapneumonic effusions", "PROBLEM", 0, 30], ["transudates", "PROBLEM", 34, 45], ["exudates", "PROBLEM", 78, 86], ["parapneumonic", "OBSERVATION_MODIFIER", 7, 20], ["effusions", "OBSERVATION", 21, 30], ["transudates", "OBSERVATION", 34, 45], ["exudates", "OBSERVATION", 78, 86]]], ["A pleural fl uid pH less than 7.2 indicates a complicated effusion that is likely exudative and requires drainage whereas a pleural fl uid pH more than 7.3 suggests that the effusion may be managed with systemic antibiotics alone.TREATMENTComplicated parapneumonic effusions or empyemas occur when the fl uid becomes purulent.", [["pleural", "ANATOMY", 124, 131], ["parapneumonic effusions", "ANATOMY", 251, 274], ["empyemas", "ANATOMY", 278, 286], ["effusion", "DISEASE", 58, 66], ["effusion", "DISEASE", 174, 182], ["parapneumonic effusions", "DISEASE", 251, 274], ["empyemas", "DISEASE", 278, 286], ["A pleural fl uid pH", "TEST", 0, 19], ["a complicated effusion", "PROBLEM", 44, 66], ["exudative", "PROBLEM", 82, 91], ["drainage", "TREATMENT", 105, 113], ["a pleural fl uid pH", "TEST", 122, 141], ["the effusion", "PROBLEM", 170, 182], ["systemic antibiotics", "TREATMENT", 203, 223], ["parapneumonic effusions", "PROBLEM", 251, 274], ["empyemas", "PROBLEM", 278, 286], ["purulent", "PROBLEM", 317, 325], ["pleural", "ANATOMY", 2, 9], ["complicated", "OBSERVATION_MODIFIER", 46, 57], ["effusion", "OBSERVATION", 58, 66], ["is likely", "UNCERTAINTY", 72, 81], ["exudative", "OBSERVATION_MODIFIER", 82, 91], ["drainage", "OBSERVATION", 105, 113], ["pleural", "ANATOMY", 124, 131], ["effusion", "OBSERVATION", 174, 182], ["parapneumonic", "OBSERVATION_MODIFIER", 251, 264], ["effusions", "OBSERVATION", 265, 274], ["empyemas", "OBSERVATION", 278, 286], ["purulent", "OBSERVATION", 317, 325]]], ["During this stage, the effusions undergo a fi brinopurulent stage with many polymorphonuclear leukocytes, bacteria, and cellular debris entering the fl uid.", [["effusions", "ANATOMY", 23, 32], ["polymorphonuclear leukocytes", "ANATOMY", 76, 104], ["cellular debris", "ANATOMY", 120, 135], ["effusions", "DISEASE", 23, 32], ["polymorphonuclear leukocytes", "CELL", 76, 104], ["cellular debris", "CELLULAR_COMPONENT", 120, 135], ["polymorphonuclear leukocytes", "CELL_TYPE", 76, 104], ["the effusions", "PROBLEM", 19, 32], ["a fi brinopurulent stage", "PROBLEM", 41, 65], ["many polymorphonuclear leukocytes", "PROBLEM", 71, 104], ["bacteria", "PROBLEM", 106, 114], ["cellular debris", "PROBLEM", 120, 135], ["effusions", "OBSERVATION", 23, 32], ["many", "OBSERVATION_MODIFIER", 71, 75], ["polymorphonuclear leukocytes", "OBSERVATION", 76, 104], ["bacteria", "OBSERVATION_MODIFIER", 106, 114], ["cellular debris", "OBSERVATION", 120, 135], ["fl uid", "OBSERVATION", 149, 155]]], ["Fibrin is deposited over the pleural surfaces and loculations begin to form.", [["pleural surfaces", "ANATOMY", 29, 45], ["Fibrin", "GENE_OR_GENE_PRODUCT", 0, 6], ["pleural surfaces", "MULTI-TISSUE_STRUCTURE", 29, 45], ["Fibrin", "TREATMENT", 0, 6], ["loculations", "PROBLEM", 50, 61], ["deposited", "OBSERVATION_MODIFIER", 10, 19], ["pleural", "ANATOMY", 29, 36], ["surfaces", "ANATOMY_MODIFIER", 37, 45], ["loculations", "OBSERVATION", 50, 61]]], ["The pH and glucose levels fall as the LDH levels rise.", [["glucose", "CHEMICAL", 11, 18], ["glucose", "CHEMICAL", 11, 18], ["glucose", "SIMPLE_CHEMICAL", 11, 18], ["LDH", "SIMPLE_CHEMICAL", 38, 41], ["LDH", "PROTEIN", 38, 41], ["The pH", "TEST", 0, 6], ["glucose levels", "TEST", 11, 25], ["the LDH levels", "TEST", 34, 48]]], ["If untreated, they often progress to a third organizing stage in which the exudate Non-invasive BiPAP ventilation can be effective for children with moderate respiratory insuffi ciency.TREATMENTdevelops into an inelastic, fi brotic peel that restricts the lung.", [["exudate", "ANATOMY", 75, 82], ["respiratory", "ANATOMY", 158, 169], ["peel", "ANATOMY", 232, 236], ["lung", "ANATOMY", 256, 260], ["respiratory insuffi ciency", "DISEASE", 158, 184], ["children", "ORGANISM", 135, 143], ["peel", "TISSUE", 232, 236], ["lung", "ORGAN", 256, 260], ["children", "SPECIES", 135, 143], ["a third organizing stage", "PROBLEM", 37, 61], ["the exudate", "PROBLEM", 71, 82], ["Non-invasive BiPAP ventilation", "TREATMENT", 83, 113], ["moderate respiratory insuffi ciency", "PROBLEM", 149, 184], ["TREATMENTdevelops", "TREATMENT", 185, 202], ["an inelastic, fi brotic peel", "TREATMENT", 208, 236], ["exudate", "OBSERVATION_MODIFIER", 75, 82], ["moderate", "OBSERVATION_MODIFIER", 149, 157], ["respiratory insuffi", "OBSERVATION", 158, 177], ["inelastic", "OBSERVATION", 211, 220], ["brotic peel", "OBSERVATION", 225, 236], ["lung", "ANATOMY", 256, 260]]], ["Simple parapneumonic effusions usually resolve with thoracentesis or tube thoracostomy and antibiotic treatment of the pneumonia.", [["parapneumonic effusions", "ANATOMY", 7, 30], ["tube", "ANATOMY", 69, 73], ["parapneumonic effusions", "DISEASE", 7, 30], ["pneumonia", "DISEASE", 119, 128], ["tube", "TISSUE", 69, 73], ["Simple parapneumonic effusions", "PROBLEM", 0, 30], ["thoracentesis", "TREATMENT", 52, 65], ["tube thoracostomy", "TREATMENT", 69, 86], ["antibiotic treatment", "TREATMENT", 91, 111], ["the pneumonia", "PROBLEM", 115, 128], ["parapneumonic", "OBSERVATION_MODIFIER", 7, 20], ["effusions", "OBSERVATION", 21, 30], ["thoracentesis", "OBSERVATION", 52, 65], ["tube thoracostomy", "OBSERVATION", 69, 86], ["pneumonia", "OBSERVATION", 119, 128]]], ["More complicated parapneumonic effusions have been successfully treated with thoracotomy tubes and fi brinolytics.", [["parapneumonic effusions", "ANATOMY", 17, 40], ["parapneumonic effusions", "DISEASE", 17, 40], ["parapneumonic effusions", "CANCER", 17, 40], ["More complicated parapneumonic effusions", "PROBLEM", 0, 40], ["thoracotomy tubes", "TREATMENT", 77, 94], ["fi brinolytics", "TREATMENT", 99, 113], ["complicated", "OBSERVATION_MODIFIER", 5, 16], ["parapneumonic", "OBSERVATION_MODIFIER", 17, 30], ["effusions", "OBSERVATION", 31, 40], ["thoracotomy tubes", "OBSERVATION", 77, 94]]], ["However, although risks for bleeding are reportedly low, this therapy requires close monitoring of chest tube drainage and instillation of expensive medications with intermittent clamping of the chest tube.", [["chest tube", "ANATOMY", 99, 109], ["chest tube", "ANATOMY", 195, 205], ["bleeding", "DISEASE", 28, 36], ["chest tube", "MULTI-TISSUE_STRUCTURE", 99, 109], ["chest tube", "MULTI-TISSUE_STRUCTURE", 195, 205], ["bleeding", "PROBLEM", 28, 36], ["this therapy", "TREATMENT", 57, 69], ["close monitoring", "TEST", 79, 95], ["chest tube drainage", "TREATMENT", 99, 118], ["instillation of expensive medications", "TREATMENT", 123, 160], ["intermittent clamping of the chest tube", "TREATMENT", 166, 205], ["chest", "ANATOMY", 99, 104], ["tube drainage", "OBSERVATION", 105, 118], ["chest", "ANATOMY", 195, 200], ["tube", "OBSERVATION", 201, 205]]], ["No single recommendation for the choice of fi brinolytic agent or dosage has been established.", [["fi brinolytic", "SIMPLE_CHEMICAL", 43, 56], ["fi brinolytic agent", "TREATMENT", 43, 62]]], ["Also, if tried late in the organizing phase, this is often unsuccessful due to loculations and the high viscosity of the purulent fl uid.", [["loculations", "PROBLEM", 79, 90], ["the high viscosity of the purulent fl uid", "PROBLEM", 95, 136], ["loculations", "OBSERVATION", 79, 90], ["high viscosity", "OBSERVATION_MODIFIER", 99, 113], ["purulent fl", "OBSERVATION", 121, 132]]], ["Surgical debridement either by open procedure or by video-assisted thorascopic surgery (VATS) is often needed for organizing, complicated parapneumonic effusions.", [["parapneumonic effusions", "ANATOMY", 138, 161], ["parapneumonic effusions", "DISEASE", 138, 161], ["Surgical debridement", "TREATMENT", 0, 20], ["open procedure", "TREATMENT", 31, 45], ["video-assisted thorascopic surgery", "TREATMENT", 52, 86], ["VATS", "TREATMENT", 88, 92], ["complicated parapneumonic effusions", "PROBLEM", 126, 161], ["debridement", "OBSERVATION", 9, 20], ["complicated", "OBSERVATION_MODIFIER", 126, 137], ["parapneumonic", "OBSERVATION_MODIFIER", 138, 151], ["effusions", "OBSERVATION", 152, 161]]], ["Multiple studies have reported that early VATS or thoracotomy for empyema leads to a shorter hospital stay.", [["empyema", "DISEASE", 66, 73], ["Multiple studies", "TEST", 0, 16], ["early VATS", "TREATMENT", 36, 46], ["thoracotomy", "TREATMENT", 50, 61], ["empyema", "PROBLEM", 66, 73], ["early", "OBSERVATION_MODIFIER", 36, 41], ["VATS", "OBSERVATION", 42, 46], ["thoracotomy", "OBSERVATION", 50, 61], ["empyema", "OBSERVATION", 66, 73]]], ["The treatment modality is best determined by the temporal stage and nature of the effusion.CONCLUSIONAcute pulmonary infections are common diagnoses that require admission to the pediatric intensive care units.", [["pulmonary", "ANATOMY", 107, 116], ["effusion", "DISEASE", 82, 90], ["pulmonary infections", "DISEASE", 107, 127], ["pulmonary", "ORGAN", 107, 116], ["The treatment modality", "TREATMENT", 0, 22], ["the effusion", "PROBLEM", 78, 90], ["CONCLUSIONAcute pulmonary infections", "PROBLEM", 91, 127], ["temporal stage", "OBSERVATION_MODIFIER", 49, 63], ["effusion", "OBSERVATION", 82, 90], ["pulmonary", "ANATOMY", 107, 116], ["infections", "OBSERVATION", 117, 127]]], ["Understanding the pathophysiology of lower respiratory infections enables the intensivist to tailor therapy to the individual child and pathogen.", [["lower respiratory", "ANATOMY", 37, 54], ["lower respiratory infections", "DISEASE", 37, 65], ["lower respiratory infections", "PROBLEM", 37, 65], ["tailor therapy", "TREATMENT", 93, 107], ["pathogen", "PROBLEM", 136, 144], ["lower", "ANATOMY_MODIFIER", 37, 42], ["respiratory", "ANATOMY", 43, 54], ["infections", "OBSERVATION", 55, 65]]], ["Early establishment of a specifi c etiology and the selection of the correct treatment plan directly impacts clinical outcome.CONCLUSIONVideo-assisted thorascopic surgery (VATS) for the treatment of empyemas has been associated with shorter hospital stay.A 3 month old, former 27 week premature infant with bronchopulmonary dysplasia presents with clinical signs of bronchiolitis.", [["bronchopulmonary dysplasia", "ANATOMY", 307, 333], ["empyemas", "DISEASE", 199, 207], ["bronchopulmonary dysplasia", "DISEASE", 307, 333], ["bronchiolitis", "DISEASE", 366, 379], ["empyemas", "CANCER", 199, 207], ["infant", "ORGANISM", 295, 301], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 307, 333], ["infant", "SPECIES", 295, 301], ["CONCLUSIONVideo-assisted thorascopic surgery", "TREATMENT", 126, 170], ["VATS", "TREATMENT", 172, 176], ["empyemas", "PROBLEM", 199, 207], ["bronchopulmonary dysplasia", "PROBLEM", 307, 333], ["bronchiolitis", "PROBLEM", 366, 379], ["empyemas", "OBSERVATION", 199, 207], ["bronchopulmonary", "ANATOMY", 307, 323], ["dysplasia", "OBSERVATION", 324, 333], ["bronchiolitis", "OBSERVATION", 366, 379]]], ["Analysis of nasopharyngeal secretions by polymerase chain reaction testing identifi es respiratory syncitial virus.Which of the following therapies have been proven to be a consistent benefi t for RSV bronchiolitis?", [["nasopharyngeal secretions", "ANATOMY", 12, 37], ["bronchiolitis", "DISEASE", 201, 214], ["nasopharyngeal secretions", "ORGAN", 12, 37], ["respiratory syncitial virus", "ORGANISM", 87, 114], ["RSV", "ORGANISM", 197, 200], ["RSV", "SPECIES", 197, 200], ["nasopharyngeal secretions", "PROBLEM", 12, 37], ["polymerase chain reaction testing", "TEST", 41, 74], ["respiratory syncitial virus", "PROBLEM", 87, 114], ["RSV bronchiolitis", "PROBLEM", 197, 214], ["nasopharyngeal", "ANATOMY", 12, 26], ["secretions", "OBSERVATION", 27, 37], ["syncitial virus", "OBSERVATION", 99, 114], ["bronchiolitis", "OBSERVATION", 201, 214]]], ["A. Aminophylline B. Bronchodilators C. Corticosteroids D. Ribavirin E. Supportive care 2.", [["Ribavirin", "CHEMICAL", 58, 67], ["Aminophylline B.", "TREATMENT", 3, 19], ["Bronchodilators C. Corticosteroids", "TREATMENT", 20, 54], ["Ribavirin E. Supportive care", "TREATMENT", 58, 86]]], ["Palivizumab is indicated for which of the following children?", [["Palivizumab", "CHEMICAL", 0, 11], ["Palivizumab", "CHEMICAL", 0, 11], ["Palivizumab", "SIMPLE_CHEMICAL", 0, 11], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["Palivizumab", "TREATMENT", 0, 11]]], ["A. A 5 month old, former 27 week premature infant who just underwent surgical repair of a large ventricular septal defect who received palivizumab 2 weeks ago B. A 9 month old, former 28 week premature infant with mild bronchopulmonary dysplasia who received palivizumab 2 weeks ago C. A 1 month old, former 36 week premature infant with peripheral pulmonic stenosis who has never received palivizumab D. A 2 month old full term infant with a urea cycle defect who has never received palivizumab E. An 8 month old, former 25 week premature infant with bronchopulmonary dysplasia who received his fi fth dose of palivizumab a month agoREVIEW QUESTIONSPleural fl uid may be classifi ed as exudative, if one or more of the following criteria are met: \u25a0 Pleural fl uid protein divided by serum protein >0.5 (Sensitivity 98%, Specifi city 83%) \u25a0 Pleural fl uid lactate dehydrogenase (LDH) divided by serum LDH > 0.6 (Sensitivity 86%, Specifi city 84%) \u25a0 Pleural fl uid LDH is more than two-thirds of the upper limit of normal for serum LDH (Sensitivity 82%, Specifi city 89%)REVIEW QUESTIONSAdapted from Light (2002)", [["ventricular septal", "ANATOMY", 96, 114], ["bronchopulmonary dysplasia", "ANATOMY", 219, 245], ["peripheral pulmonic", "ANATOMY", 338, 357], ["bronchopulmonary dysplasia", "ANATOMY", 552, 578], ["serum", "ANATOMY", 784, 789], ["serum", "ANATOMY", 895, 900], ["serum", "ANATOMY", 1025, 1030], ["ventricular septal defect", "DISEASE", 96, 121], ["palivizumab", "CHEMICAL", 135, 146], ["bronchopulmonary dysplasia", "DISEASE", 219, 245], ["palivizumab", "CHEMICAL", 259, 270], ["peripheral pulmonic stenosis", "DISEASE", 338, 366], ["urea", "CHEMICAL", 443, 447], ["palivizumab", "CHEMICAL", 484, 495], ["bronchopulmonary dysplasia", "DISEASE", 552, 578], ["palivizumab", "CHEMICAL", 611, 622], ["exudative", "DISEASE", 687, 696], ["lactate", "CHEMICAL", 856, 863], ["urea", "CHEMICAL", 443, 447], ["lactate", "CHEMICAL", 856, 863], ["infant", "ORGANISM", 43, 49], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 96, 114], ["infant", "ORGANISM", 202, 208], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 219, 245], ["infant", "ORGANISM", 326, 332], ["peripheral pulmonic", "MULTI-TISSUE_STRUCTURE", 338, 357], ["infant", "ORGANISM", 429, 435], ["infant", "ORGANISM", 540, 546], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 552, 578], ["palivizumab", "ORGANISM", 611, 622], ["serum", "ORGANISM_SUBSTANCE", 784, 789], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 856, 877], ["LDH", "GENE_OR_GENE_PRODUCT", 879, 882], ["serum", "ORGANISM_SUBSTANCE", 895, 900], ["LDH", "SIMPLE_CHEMICAL", 901, 904], ["serum", "ORGANISM_SUBSTANCE", 1025, 1030], ["LDH", "SIMPLE_CHEMICAL", 1031, 1034], ["Pleural fl uid protein", "PROTEIN", 750, 772], ["serum protein", "PROTEIN", 784, 797], ["Pleural fl uid lactate dehydrogenase", "PROTEIN", 841, 877], ["LDH", "PROTEIN", 879, 882], ["infant", "SPECIES", 43, 49], ["infant", "SPECIES", 202, 208], ["infant", "SPECIES", 326, 332], ["infant", "SPECIES", 429, 435], ["infant", "SPECIES", 540, 546], ["surgical repair", "TREATMENT", 69, 84], ["a large ventricular septal defect", "PROBLEM", 88, 121], ["palivizumab", "TREATMENT", 135, 146], ["mild bronchopulmonary dysplasia", "PROBLEM", 214, 245], ["palivizumab", "TREATMENT", 259, 270], ["peripheral pulmonic stenosis", "PROBLEM", 338, 366], ["a urea cycle defect", "PROBLEM", 441, 460], ["palivizumab E.", "TREATMENT", 484, 498], ["bronchopulmonary dysplasia", "PROBLEM", 552, 578], ["palivizumab", "TREATMENT", 611, 622], ["Pleural fl uid protein", "TEST", 750, 772], ["serum protein", "TEST", 784, 797], ["Sensitivity", "TEST", 804, 815], ["Pleural fl uid lactate dehydrogenase", "TEST", 841, 877], ["LDH)", "TEST", 879, 883], ["serum LDH", "TEST", 895, 904], ["Sensitivity", "TEST", 912, 923], ["Pleural fl uid LDH", "TEST", 949, 967], ["serum LDH", "TEST", 1025, 1034], ["Sensitivity", "TEST", 1036, 1047], ["surgical repair", "OBSERVATION", 69, 84], ["large", "OBSERVATION_MODIFIER", 90, 95], ["ventricular septal", "ANATOMY", 96, 114], ["defect", "OBSERVATION", 115, 121], ["mild", "OBSERVATION_MODIFIER", 214, 218], ["bronchopulmonary", "ANATOMY", 219, 235], ["dysplasia", "OBSERVATION", 236, 245], ["peripheral pulmonic", "ANATOMY", 338, 357], ["stenosis", "OBSERVATION", 358, 366], ["bronchopulmonary", "ANATOMY", 552, 568], ["dysplasia", "OBSERVATION", 569, 578], ["Pleural", "ANATOMY", 750, 757], ["fl", "ANATOMY", 849, 851], ["fl", "OBSERVATION", 957, 959], ["LDH", "OBSERVATION", 964, 967], ["upper limit", "OBSERVATION_MODIFIER", 999, 1010], ["normal", "OBSERVATION", 1014, 1020]]]]}